<SEC-DOCUMENT>0000785161-22-000021.txt : 20220503
<SEC-HEADER>0000785161-22-000021.hdr.sgml : 20220503
<ACCEPTANCE-DATETIME>20220503171812
ACCESSION NUMBER:		0000785161-22-000021
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		69
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220503
DATE AS OF CHANGE:		20220503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Encompass Health Corp
		CENTRAL INDEX KEY:			0000785161
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				630860407
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-10315
		FILM NUMBER:		22888340

	BUSINESS ADDRESS:	
		STREET 1:		9001 LIBERTY PARKWAY
		CITY:			BIRMINGHAM
		STATE:			AL
		ZIP:			35242
		BUSINESS PHONE:		205-967-7116

	MAIL ADDRESS:	
		STREET 1:		9001 LIBERTY PARKWAY
		CITY:			BIRMINGHAM
		STATE:			AL
		ZIP:			35242

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTHSOUTH CORP
		DATE OF NAME CHANGE:	19950113

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTHSOUTH REHABILITATION CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ehc-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:69533f56-540a-48e1-b4ee-a7401038559f,g:2f1c880e-7b65-4846-aaa6-f9cb86c4b8d3,d:a58a0d4539bf462e8f4621edacd97f5a--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ehc="http://www.encompasshealth.com/20220331" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ehc-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80L2ZyYWc6N2RiZWE3MTliMmQ5NGVhODlhMDk4ODQ3NjdlZDM1MDcvdGFibGU6NTI5NmM5NWE2MzljNDI1Yjg1MmEyNTI2MDIyYjlkYzkvdGFibGVyYW5nZTo1Mjk2Yzk1YTYzOWM0MjViODUyYTI1MjYwMjJiOWRjOV8zLTEtMS0xLTEyOTYwMQ_0d412d1e-7347-41a7-9ce5-3589c7aab45f">0000785161</ix:nonNumeric><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80L2ZyYWc6N2RiZWE3MTliMmQ5NGVhODlhMDk4ODQ3NjdlZDM1MDcvdGFibGU6NTI5NmM5NWE2MzljNDI1Yjg1MmEyNTI2MDIyYjlkYzkvdGFibGVyYW5nZTo1Mjk2Yzk1YTYzOWM0MjViODUyYTI1MjYwMjJiOWRjOV80LTEtMS0xLTEyOTYwMQ_e4344d6e-7d9d-4874-b8c9-2ff954692c4c">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80L2ZyYWc6N2RiZWE3MTliMmQ5NGVhODlhMDk4ODQ3NjdlZDM1MDcvdGFibGU6NTI5NmM5NWE2MzljNDI1Yjg1MmEyNTI2MDIyYjlkYzkvdGFibGVyYW5nZTo1Mjk2Yzk1YTYzOWM0MjViODUyYTI1MjYwMjJiOWRjOV81LTEtMS0xLTEyOTYwMQ_895dc436-2077-4901-9fd6-6d997e02deca">2022</ix:nonNumeric><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80L2ZyYWc6N2RiZWE3MTliMmQ5NGVhODlhMDk4ODQ3NjdlZDM1MDcvdGFibGU6NTI5NmM5NWE2MzljNDI1Yjg1MmEyNTI2MDIyYjlkYzkvdGFibGVyYW5nZTo1Mjk2Yzk1YTYzOWM0MjViODUyYTI1MjYwMjJiOWRjOV82LTEtMS0xLTEyOTYwMQ_978dc247-7c11-41dc-b9ef-8c977d44d53f">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80L2ZyYWc6N2RiZWE3MTliMmQ5NGVhODlhMDk4ODQ3NjdlZDM1MDcvdGFibGU6NTI5NmM5NWE2MzljNDI1Yjg1MmEyNTI2MDIyYjlkYzkvdGFibGVyYW5nZTo1Mjk2Yzk1YTYzOWM0MjViODUyYTI1MjYwMjJiOWRjOV83LTEtMS0xLTEyOTYwMQ_c96ccb0a-9d36-44a5-9ee3-e7b1d20cad46">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ehc-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i3531353b480a49df89986d34e925eca7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28ab1ceed8dd4ef4ada8933e4e54a5ff_I20220421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i91231db0dbac4520908543814857793e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if5385614e8bd4b7081a64d6cba8c9291_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i557a32613c404e579eedda986be748b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i027580bf78e446f9a1be1690bafd5055_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05a3cf2b8383461c94f1b27d662f994c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14493ec43a054a37a265fe545acfae34_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb8ac1140bb546ffbe29c3297dfca0ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5eaecfe3f96400b8f59e7967a61104c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd0a16468f25461eaa2eada251e33da7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0db82f105f774106945877e84af0cc3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i576c769a2bf3490093c90b7f2fd1d565_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33aac6e817b84b2fbedbc7be7dd1d4e1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70ffad11b2f64e0dafb9e8f6c59e3600_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia54089ca96194a95b6a9346ce2f33fc1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74ec993229934505b223d7e527442ba7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c072fe2fb1348d68775f83549979f34_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf0cae1f6a4a43f293213bf2aea45abd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4efb9bf256844561b1d2a7fbb842421e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i288ad08f50a44c848d9ae9b15441d2dc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2bafe8e3cac4147865d701ae99d921c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1beec8de6cfd45d8b5f89af034ba4093_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78cf1e166e974c539ccf23447cde940b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b3a08ff093f420c99340aa4e1150824_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36bea0bf3d9144caa0f8df9028b1dc79_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief9203a9500e4500971e238696312597_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f5b35fb51614954816b817c495b5d51_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c1ae97e068e4cff900ec3092c7f4f04_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i036534c3f4a5413e8de12b55fc657fe1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i622188ef7ebe41c680e18a9991186c28_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i117392f9d15f489cbe838f6b1ce3da6b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cd1f1cb74084bb3b9abaf864a2e064b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i013c277808804f42827dd89d591b0f7c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i972509dbc5b6416a9dd899dc87ebd08b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia12ac2a64d1641ba80099f0e2982b794_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d9c8cd1de2c4f13933b82337c8517f4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9121edbdc21a47948aa5552e7f4240fb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c6a42e404cd4326b6c8697c3add3bf6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>ehc:state</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>ehc:segment</xbrli:measure></xbrli:unit><xbrli:context id="i8aff770be2384e718613ee73e75c9d8c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20db95e52d4340b89253015dadddfce8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22e38d1a9d8c492983b5fe7bbc4a8114_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ed9eb823c2440d48088c6f6ef06b87d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d2de80a9ea142658a08aff95c64af19_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a399017e33d42b2bf858dd4d6a9c0e1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i915084ab4bdd4e1689693609d0ef6b82_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c8d685705124a67ba3a91dabc43a282_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ef7afb70a7f4b27a6a3cefbe6320e01_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1745bec828ac49b1818f4f9a5135a42c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcc4e89df88e43cfbef7da1f99240779_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39f739399fa44a149e9c4093be040820_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84bb98c1d43644a39513c7d343c7ffec_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75ecf985b4164bff9fa7316be1a7474a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d2d7e560f1441bca94bad9f8a814402_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibab4a62b6ba444c883fdc49380be38fb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79fb50ea872e4a0ca7a8afe1c90123b2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d5c49ba6ba94af8960ab5d485207093_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0b8349513794a3294fb7992b1d132ab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacc1a722e4414822b283443f547fa10b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2903b136be2a4ee89a98bcd8d1360b19_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad23a50207a142ab9c646522e8434d32_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc33a324f2c0445d95695eba2ca8ef8a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i599a045bbb1143038e76b94639d195fe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i817f1c2f30674f89942c2d872a2ba105_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4efd11aa331481487fdb712ec4c0ac2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aafa9f641b84852af3d2fb5f01099e5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia19311f0969f4d318270fc2cc5ed5d0a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i816cdecfdda244c89818aaa109f9acec_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b5fd3df85ec4c319b4bc0219d463e49_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f172a6226384fecb27f5515fca37ab0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9457af3cee914d029434093eeae9c559_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34d269849de54ca9aef661bdd4496c95_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdc9747447a24dfdb2bc0d42c7649f61_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5a3de3efd3d4a48ad46ff05596eb38e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58a18ced43b9420abf4802064fa8951d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib164992f54584ed39d8de9248794b352_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i886e59e872c246ddb347cb38ec9a1160_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1416420c060b4050821f6eee0ac9a457_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7135e07b877d4f569de8504b4686a6ee_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibded32670d67459ca73c7300d578990b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id491747513c74175b42ca0a5e71438c0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i852f28e7df1d406994d8a3bd00d23115_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16d0b325d18e4ddd9457d92019914f3a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id807874539934f0e9ed224fbc31c78b6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3313d74b1254472598b291ece765395d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33b51c955001459e8173f274705cb785_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i293d6fb19adf46f18fb8ccfda949db85_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if99233a02a77455db55959da352fbfb2_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i29d56a10f17343bcaab0acd8dbcc3b4e_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b102d83166e4bc490cf1528eaade88d_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i629dd79718e44513b2d60bcae0d6f51a_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida96cd2b0e2746e39759c8c22c9bf7a5_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c4b218e644546e8963de5f7bb2c0e6c_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53b09e480b6142de9d92527b0b5b9375_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93824ec251c546cbb304b0de1adc1bc2_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica57130d0db94872b9b3a94cd9e7c39b_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bcefb1b301b491f9f6a61d393edcd39_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6861efcf5c8e4791b4cf9947c83117e8_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i944fc8295c154979b4c5e2ae485eb03b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i090568ccb08b421a8703daa2d9b4d2c9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1e6082c727c4be9853cda9efc66e5bd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="entity"><xbrli:measure>ehc:entity</xbrli:measure></xbrli:unit><xbrli:context id="i0b4d6eb8f1624f5780188f869aa798da_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice6f42f88a4d40f2bb746a1622dc9ab6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice148ce40d284c87b5c5abf7edb0c698_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2382ba129c3486f990cf1eea014c79c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a79fe1564694ed59ea5acbff6dafa13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibff53e67228d4423a59336248f7e8a19_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idace690b6bd742fbb796490135ea208a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05147760daea434eab785f9bb77eed18_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i518ef403619b45068725459a3694675c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40e9e244d5e64ca7bf0040d18e4fa154_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54ff49d44cd5451da021a1dcfdd01a1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b70c8bc77434fcf8e8e9acd22c58c45_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6856f14b9e514819a81cb49c920770ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cbef4d679154efc951e5c1786ca6bae_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfab5bb13d1544f8b92a234bde75f0a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d86755ee8bc4045b33ab465c664b7a9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia263377add53435796d020a9fae4da89_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb23149d81b145d683c4131122e0613c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i135485ea2e124322b3cb9b6b28d207bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2432d02ccbce4152a2ebbc620946b0eb_I20211209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib87798305a954bd68f594d703bee708a_I20211209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3dee57d45ef4967a06bff2bb1519d67_I20211209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c40d9c98c634e8d9e33b00ff58b2939_I20211209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37b439614a834d5fa4da55874df55dc4_I20211209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i825551a2736a4a0cbed667eb8cc2cca2_D20211201-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i368ed4d7ad354f0cab721ebb36d47844_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id320e21f82b8400fadbbfe37b609516d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39fdefb343d340ef94ee64a4ec92f2ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b46f0824cfc44a390637375c885461c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6ea604dd0d04859a2c8cc03396c69bb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80c5200a89154eb89d8ae5eb77290c4e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc945c722fc841aa95f6763fdd77a02c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61423539f4b4453f9ea5b7bbc38883be_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icddbe6c9e899402ab0cd9e710f9d31ea_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfc43ca1f96d45b5a0cf5b2d38ae5a60_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8d214445f7041df915d431f92d7a70e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a7dc7ae27134c52a55c357b78dd3cff_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ac35e30b3384503867b9b29c33fcd12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39472c9a755a464e8a2cc3ca1799e165_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3e4ffea3ce24cf29b0a92241c3ecd15_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia606fb5d54a34f2fbc455e7223986acc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79fc6be415b54a58b5d2c217fab0f29b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59d953168b134eaba7885b47f0cda8fd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if034be9bc98b47cf8c97bf47ab9ea038_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a7b858f19554add8379afca7b705865_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b444a6f37fa4de1992c65a1698b0b20_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64624582638a400485740c96311c1394_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if83c0d9db5394bde9d8b0c44800f9c9b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91e7df9c82b3434983f969e537117392_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i831cf2390be0435eaadf768914370cbe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i248a1de457614c1c9d9c3795a5c5c6c2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d4f1aa977184bbbbfe5144289d41e12_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78e41d6d12974156b84238a2892182c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id07fee3147fe47a5868dde0e75b961bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47572d62b06342fe93e19a7e55a4943a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73e315035b554c8aa1875547b4630339_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c9476be5bf24acb9f60b2167f82eb5e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02839eb8521947c8b4c9744e0ac23d7a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fb81c7757df47a7872a6c2daef100ce_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e88c315ef4c4d62ade591e994da366d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dbc9fad2e274e4eb37fa988811ee2a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94daa3156e1a45adbf33553663dd83fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfcf9427557d461fbbebdf16a3b33843_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74ea71ca5cf549bf8c8f2f8fc6a335b2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic05d7792773941d2b4f0ae2bfd35090b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e473304e17c4251a584a305f441fc45_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic402c5736b164f289ef558cc5bdc16b3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c080a5046b140e19a17e88f98ac2e72_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5708fcd82894c208dadd2fea50fa007_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc43445772fb4f7cafc73de38ead4bd0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab66f41dc66040f2856dd6db44d58787_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41ff03c5cba2460d8cadd19e31f7ce2a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idedd404a57704848af9e8d99770a3e84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ccf6303eceb4c8882cde606d6046e98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib55408ef11da47b9a9ab25b915d6f44a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie932836488174026b6c0bb470e9937e1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dcc02c84fae47a2a3f1e83d9186a6a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8628daca39564875a3d296261d4ddd8a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic22004d0542449c28c0dbfbf72a7738f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9905941e5e914330a739320a89ef96fa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23319d48cfb542baa5100da894e4efd7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11f4eda008a3429e868ab8b5af645b77_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic01094ffa7604c71a90a6271b77d95ef_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3198110221a45879053dbae18100b29_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc081404cf0e4077909986bdf740a73b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3075bca9de3b4ee89c80a477c6851ee1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53bdf1d6ecf041d7af98f062aa3d7212_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="hospital"><xbrli:measure>ehc:hospital</xbrli:measure></xbrli:unit><xbrli:context id="i96474acd4c0142dda31b7d96f99582f1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79515ce75bf44070a97a38241f1e7d61_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f992e9347194664b26f07fbc9a93d86_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="location"><xbrli:measure>ehc:location</xbrli:measure></xbrli:unit><xbrli:context id="iefcb7a67042b48cfb0c73139f067b3df_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9f95cf921114fbfb5398dadad725123_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibabc6d389eb7499992b42a9d1f4b3120_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i407e8fe2e2364e5d91792421c5019898_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia036ff2cbdc34388aff7771c98304af2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie391de2d22ab44fda7310331622d23d1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77fc9042b9d744ba9d2f6c315981cd86_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c857df9e79e4435ab0c5961811291c6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f9a417ef1c843ab8b66fc1f0fe8a378_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:InpatientMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee63741659464a8288af029c2e936705_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:InpatientMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77101558c6ed4f6da49ce1c65da87750_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:OutpatientandotherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee418860b1b04eaabf4f28548bafff1c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:OutpatientandotherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06506ef5bc914c559c598b5f9589d0b3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib65ddfd24dd24997b9a0d223f2e38f80_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4931e9bee9c14ae88ae967c8efd7c1da_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00989e00d19949b0b76add02ac72e8dc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTUtMy0xLTEtMTI5NjAx_0f538598-45b6-4f09-a95f-5f81800fa896 id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzUtMy0xLTEtMTI5NjAx_b8465d0d-15b4-4e6b-8fca-465d4f86d90d id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTUtMS0xLTEtMTI5NjAx_7f8cccaa-f1ba-40bc-ad42-fcd4ee98eeb5 id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzUtMS0xLTEtMTI5NjAx_376f026e-0a45-4eb7-8571-082b11d62254" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RleHRyZWdpb246ZWIxMjhmOWM2ZmJlNDE2ZDk3NTZjOWMyZTQ5NTU5YmVfMzUz_4d3515ba-93b0-4f03-8b82-aa0c4c4c406d" order="1"></ix:relationship></ix:resources></ix:header></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">______________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTgx_8a8662e9-b2a0-436c-b061-56adc95e8093">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6MmE3YWI3NDFkMDQ2NDQzNmFhZTFlOTkzMzljOTVjNTQvdGFibGVyYW5nZToyYTdhYjc0MWQwNDY0NDM2YWFlMWU5OTMzOWM5NWM1NF8wLTAtMS0xLTEyOTYwMQ_d7337f9d-78a7-4f52-898f-c9f167b8f17f">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xNTE_99e3a940-02ad-481b-b310-d2a9ed3ade96">March&#160;31, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6MmNjNDUzM2VlMjY0NDI0NGFhYWM0OTkxODBlOTBhZGIvdGFibGVyYW5nZToyY2M0NTMzZWUyNjQ0MjQ0YWFhYzQ5OTE4MGU5MGFkYl8wLTAtMS0xLTEyOTYwMQ_65f5258f-7756-4ad6-982f-4cfd352736ff">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTgy_955c408d-739b-4a4a-aaad-cb8fbaa7b9c3">001-10315</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">______________________________</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTg4_4436db63-6e4f-421b-af5c-a34f084608fc">Encompass Health Corporation</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its Charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"></td><td style="width:57.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6MmE4NDNhYmMzZTRjNGIyYmIwNDY2YjdiNTA4NDM5M2IvdGFibGVyYW5nZToyYTg0M2FiYzNlNGM0YjJiYjA0NjZiN2I1MDg0MzkzYl8wLTAtMS0xLTEyOTYwMQ_ec40fa6d-1b3f-46c6-85a3-4e2abd333f7a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6MmE4NDNhYmMzZTRjNGIyYmIwNDY2YjdiNTA4NDM5M2IvdGFibGVyYW5nZToyYTg0M2FiYzNlNGM0YjJiYjA0NjZiN2I1MDg0MzkzYl8wLTEtMS0xLTEyOTYwMQ_f90fc723-be22-409e-bba3-952dc7b728e5">63-0860407</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTg5_f935c5ac-7891-4ea6-a9aa-d946ed302661">9001 Liberty Parkway</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTc5_41cdf28e-1402-4bc7-8cc5-83676319f17c">Birmingham</ix:nonNumeric>, <ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTkw_46c315a4-176f-428f-b0f0-2a638d592cc2">Alabama</ix:nonNumeric> <ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTgw_8388b9fd-172c-4ebc-b91f-070bbaedcd2f">35242</ix:nonNumeric> </span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTg0_da582875-1f42-48eb-a4a9-d43aa390c41c">205</ix:nonNumeric>) <ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTg1_4945a640-e203-4bcd-9023-72fc48e80e59">967-7116</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number)</span></div><div style="margin-top:9pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"></td><td style="width:37.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6NThlMWQyOWJhZmRiNDVjNWExODFjZWU4MTY5NWZkYzcvdGFibGVyYW5nZTo1OGUxZDI5YmFmZGI0NWM1YTE4MWNlZTgxNjk1ZmRjN18xLTAtMS0xLTEyOTYwMQ_bee71ddc-612a-4c0a-b38f-07aa4e3b1b14">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6NThlMWQyOWJhZmRiNDVjNWExODFjZWU4MTY5NWZkYzcvdGFibGVyYW5nZTo1OGUxZDI5YmFmZGI0NWM1YTE4MWNlZTgxNjk1ZmRjN18xLTEtMS0xLTEyOTYwMQ_9d81e442-42af-4caa-bd93-958e22d73b24">EHC</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6NThlMWQyOWJhZmRiNDVjNWExODFjZWU4MTY5NWZkYzcvdGFibGVyYW5nZTo1OGUxZDI5YmFmZGI0NWM1YTE4MWNlZTgxNjk1ZmRjN18xLTItMS0xLTEyOTYwMQ_8056410e-1447-48a0-acc8-6d50f238ae01">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;<ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTg2_31fe2786-5d94-4bd9-b819-a949dd52c029">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTg3_e6172e6d-d82b-4390-8e37-723fb0d5cfea">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.912%"><tr><td style="width:1.0%"></td><td style="width:26.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6Y2I5ODZkYTMyNzJkNDQ0MjgxYzdhNjMxNWE5NmVmNjIvdGFibGVyYW5nZTpjYjk4NmRhMzI3MmQ0NDQyODFjN2E2MzE1YTk2ZWY2Ml8wLTAtMS0xLTEyOTYwMQ_6b5dcbd3-8361-4a8e-bb43-5e097710571b">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6Y2I5ODZkYTMyNzJkNDQ0MjgxYzdhNjMxNWE5NmVmNjIvdGFibGVyYW5nZTpjYjk4NmRhMzI3MmQ0NDQyODFjN2E2MzE1YTk2ZWY2Ml8xLTEtMS0xLTEyOTYwMQ_2a894111-af92-4e66-b294-76b5ac67d7c7">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6Y2I5ODZkYTMyNzJkNDQ0MjgxYzdhNjMxNWE5NmVmNjIvdGFibGVyYW5nZTpjYjk4NmRhMzI3MmQ0NDQyODFjN2E2MzE1YTk2ZWY2Ml8xLTMtMS0xLTEyOTYwMQ_12694c60-8c26-4aad-b9cc-5fbd625f00dc">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2). Yes&#160;<ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTgz_0a6671af-cd88-47e3-93bd-57229ebc2011">&#9744;</ix:nonNumeric>&#160;No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant had <ix:nonFraction unitRef="shares" contextRef="i28ab1ceed8dd4ef4ada8933e4e54a5ff_I20220421" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTA4_15756c3c-6534-40e1-bae8-ec727f4a910b">99,802,649</ix:nonFraction> shares of common stock outstanding, net of treasury shares, as of April 21, 2022.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.331%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_13">PART&#160;I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_13">Financial Information</a></span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_16">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_100">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_100">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_100">16</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_115">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_115">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_115">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_118">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_118">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_118">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_121">PART&#160;II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_121">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_124">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_124">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_124">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_127">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_127">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_127">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_130">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_130">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_130">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_133">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_133">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia58a0d4539bf462e8f4621edacd97f5a_133">35</a></span></div></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE TO READERS</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this report, the terms &#8220;Encompass Health,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; refer to Encompass Health Corporation and its consolidated subsidiaries, unless otherwise stated or indicated by context. This drafting style is suggested by the Securities and Exchange Commission and is not meant to imply that Encompass Health Corporation, the publicly traded parent company, owns or operates any specific asset, business, or property. The hospitals, operations, and businesses described in this filing are primarily owned and operated by subsidiaries of the parent company. In addition, we use the term &#8220;Encompass Health Corporation&#8221; to refer to Encompass Health Corporation alone wherever a distinction between Encompass Health Corporation and its subsidiaries is required or aids in the understanding of this filing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report contains historical information, as well as forward-looking statements that involve known and unknown risks and relate to, among other things, future events, the spread and impact of the COVID-19 pandemic, changes to Medicare reimbursement and other healthcare laws and regulations from time to time, our business strategy and ongoing strategic review, including the planned separation of our home health and hospice business, our dividend and stock repurchase strategies, our financial plans, our growth plans, our future financial performance, our projected business results, or our projected capital expenditures. In some cases, the reader can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;targets,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Any forward-looking statement is based on information current as of the date of this report and speaks only as of the date on which such statement is made. Actual events or results may differ materially from the results anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, the factors described below could cause, and in the case of the COVID-19 pandemic has already caused, actual results to differ materially from those estimated by us.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Each of the factors discussed in Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of our Annual Report on Form 10-K for the year ended December&#160;31, 2021, as well as uncertainties and factors, if any, discussed elsewhere in this Form 10-Q, including in the &#8220;Executive Overview&#8212;Key Challenges&#8221; section of Part I, Item 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in our other filings from time to time with the SEC, or in materials incorporated therein by reference.</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ongoing strategic review and planned spin off of our home health and hospice business exposes us to a number of risks and uncertainties, including diversion of management&#8217;s time to the process; the incurrence of significant expenses associated with the review and pursuit of the planned separation or transaction; increased difficulties in attracting, retaining or motivating key management personnel; exposure to potential litigation; and inability to complete or realize anticipated benefits from the planned separation or other strategic alternative involving our home health and hospice business, any of which could adversely affect our business, financial results or condition, or stock price.</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the spin off is completed, both the remaining company and the new company will be highly concentrated in their respective primary lines of business, particularly with respect to Medicare regulations and reimbursement, and each will be a less diversified company than we currently are.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the spin off is completed, there may be changes in our stockholder base, which may cause volatility in the price of our common stock. </span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A pandemic, epidemic, or other widespread outbreak of an infectious disease or other public health crisis could decrease our patient volumes, pricing, and revenues, lead to staffing and supply shortages and associated cost increases, otherwise interrupt operations, or lead to increased litigation risk and, in the case of the COVID-19 pandemic, has already done so in many instances.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Governmental actions in response to the COVID-19 pandemic, such as limitations on elective procedures, vaccine mandates, shelter-in-place orders, new workplace regulations, facility closures and quarantines, could reduce volumes, lead to staffing shortages, increase staffing costs, and otherwise impair our ability to operate and provide care and in many instances already have done so.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to maintain infectious disease prevention and control efforts that are required and effectively minimize the spread of COVID-19 among patients and employees could decrease our patient volumes and revenues, lead to staffing shortages or otherwise interrupt operations, or lead to increased litigation risk.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reductions or delays in, or suspension of, reimbursement for our services by governmental or private payors, including our inability to obtain and retain favorable arrangements with third-party payors, could decrease our revenues and adversely affect other operating results.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictive interpretations of the regulations governing the claims that are reimbursable by Medicare could decrease our revenues and adversely affect other operating results.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">New or changing Medicare quality reporting requirements could adversely affect our operating costs or Medicare reimbursement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reimbursement claims are subject to various audits from time to time and such audits may lead to assertions that we have been overpaid or have submitted improper claims, and such assertions may require us to incur additional costs to respond to requests for records and defend the validity of payments and claims and may ultimately require us to refund any amounts determined to have been overpaid.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The use by governmental agencies and contractors of statistical sampling and extrapolation may substantially expand claims of overpayment or noncompliance.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delays and other substantive and procedural deficiencies in the administrative appeals process associated with denied Medicare reimbursement claims, including from various Medicare audit programs, could delay or reduce our reimbursement for services previously provided, including through recoupment from other claims due to us from Medicare.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Efforts to reduce payments to healthcare providers undertaken by third-party payors, conveners, and referral sources could adversely affect our revenues or profitability.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in our payor mix or the acuity of our patients could reduce our revenues or profitability.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in the rules and regulations of the healthcare industry at either or both of the federal and state levels, including those contemplated now and in the future as part of national healthcare reform and deficit reduction (such as the re-basing of payment systems, the introduction of site neutral payments or case-mix weightings across post-acute settings, and other payment system reforms) could decrease revenues and increase the costs of complying with the rules and regulations.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ongoing evolution of the healthcare delivery system, including alternative payment models and value-based purchasing initiatives, could decrease our reimbursement rate or increase costs associated with our operations.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compliance with the extensive and frequently changing laws and regulations applicable to healthcare providers, including those related to data privacy and security, anti-trust, and employment practices, requires substantial time, effort and expense, and if we fail to comply, we could incur penalties and significant costs of investigating and defending asserted claims, whether meritorious or not, or be required to make significant changes to our operations.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to maintain proper local, state and federal licensing, including compliance with the Medicare conditions of participation and provider enrollment requirements, such as the CMS vaccine mandate, could decrease our revenues.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Incidents affecting the proper operation, availability, or security of our or our vendors&#8217; or partners&#8217; information systems, including the patient information stored there, could cause substantial losses and adversely affect our operations and governmental mandates to increase use of electronic records and interoperability exacerbate that risk.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings, including disclosed and undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suits could be difficult to predict and could adversely affect our financial results or condition or our operations, and we could experience increased costs of defending and insuring against alleged professional liability and other claims.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with our growth strategy, including realization of anticipated revenues, cost savings, productivity improvements arising from the related operations and avoidance of unanticipated difficulties, costs or liabilities that could arise from acquisitions or integrations could adversely affect our financial results or condition.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages and potential union activity could increase staffing costs and adversely affect other financial and operating results.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competitive pressures in the healthcare industry, including from other providers that may be participating in integrated delivery payment arrangements in which we do not participate, and our response to those pressures could adversely affect our revenues or other financial results.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to provide a consistently high quality of care, including as represented in metrics publish by Medicare, could decrease our revenues.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to maintain or develop relationships with patient referral sources could decrease our revenues.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our debt and the associated restrictive covenants could have negative consequences for our business and limit our ability to execute aspects of our business plan successfully.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The price of our common stock could adversely affect our willingness and ability to repurchase shares.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable or unwilling to continue to declare and pay dividends on our common stock.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General conditions in the economy and capital markets, including any disruption, instability, or uncertainty related to armed conflict or an act of terrorism, a governmental impasse over approval of the United States federal budget or an increase to the debt ceiling, an international trade war, or a sovereign debt crisis could adversely affect our financial results or condition, including access to the capital markets.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cautionary statements referred to in this section also should be considered in connection with any subsequent written or oral forward-looking statements that may be issued by us or persons acting on our behalf. We undertake no duty to update these forward-looking statements, even though our situation may change in the future. Furthermore, we cannot guarantee future results, events, levels of activity, performance, or achievements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I. FINANCIAL INFORMATION</span></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_16"></div><div style="margin-bottom:7pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Financial Statements (Unaudited)</span></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Income</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Per Share Data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMy01LTEtMS0xMjk2MDE_1cc480da-cb14-4f4d-9ad4-1119fa22016e">1,333.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMy03LTEtMS0xMjk2MDE_70a7235b-0201-4911-9461-7ac7c5d3b533">1,230.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNS01LTEtMS0xMjk2MDE_242d3901-3d09-4d0e-95db-8371b6322109">776.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNS03LTEtMS0xMjk2MDE_95a0f1d2-8073-4b3e-9ec2-cb6c475bf12e">687.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNi01LTEtMS0xMjk2MDE_a862fd7b-79d7-42ec-a413-f25b86080da4">182.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNi03LTEtMS0xMjk2MDE_612aec22-271d-4397-a3b6-1e2004419ab4">162.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNy01LTEtMS0xMjk2MDE_12540313-c8ec-4f69-9dd7-afa4a5197581">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNy03LTEtMS0xMjk2MDE_cc44249b-df3a-4ef9-9619-5c1dcc335cfe">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfOC01LTEtMS0xMjk2MDE_e8b7f540-6277-488b-91ad-5c3dc12a9368">56.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfOC03LTEtMS0xMjk2MDE_5c8ab23f-5e6c-4ace-8e7b-0a78aba36d13">51.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfOS01LTEtMS0xMjk2MDE_7e039b86-ab55-4a13-8fe8-547b817afb8f">48.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfOS03LTEtMS0xMjk2MDE_9b113b7b-04f6-464b-b587-302d7e94b02c">38.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTAtNS0xLTEtMTI5NjAx_1020e3ad-20d2-4370-aecd-d08b2d7bb683">66.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTAtNy0xLTEtMTI5NjAx_7e2a729b-bf4e-4010-ac4a-3d0842100b77">62.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTMtNS0xLTEtMTI5NjAx_b635c72f-ce25-42ca-a013-1906567e84e3">1,149.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTMtNy0xLTEtMTI5NjAx_37fd6ead-b185-4efe-a128-2c759249a354">1,022.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTQtNS0xLTEtMTI5NjAx_54fd02dd-6e4e-4abd-be80-6de3ac877484">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTQtNy0xLTEtMTI5NjAx_7efcc42b-3c13-4ac6-bab8-663908281984">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTUtNS0xLTEtMTI5NjAx_8fbded54-eb41-4a85-a15a-2a21ca2f3265">39.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTUtNy0xLTEtMTI5NjAx_8c60e4cb-ed22-4218-9f7b-c5086d5b7982">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTYtNS0xLTEtMTI5NjAx_c58708bf-f0b5-4a78-af98-573f16256783">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTYtNy0xLTEtMTI5NjAx_0a15f2a8-fe8e-4238-ae85-2d1df5022e12">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTctNS0xLTEtMTI5NjAx_080b7711-2688-467e-922a-e342dd9b2c36">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTctNy0xLTEtMTI5NjAx_cf67ca7d-d8fa-418b-9a64-2df6261f24d8">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTgtNS0xLTEtMTI5NjAx_6c3738a3-4a3c-46b4-926b-aa7de7d17497">141.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTgtNy0xLTEtMTI5NjAx_82a2b056-e635-41fe-a508-c71bab9f1eae">167.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTktNS0xLTEtMTI5NjAx_b2cb674c-1330-4ed2-bece-3475266c25df">31.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTktNy0xLTEtMTI5NjAx_13e847ea-0d05-470c-86d0-635f7c0f60e6">34.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjAtNS0xLTEtMTI5NjAx_bfc47e69-7c5a-4ee5-9d10-a81053e47d09">110.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjAtNy0xLTEtMTI5NjAx_c337e573-d378-4f77-ac3c-62631bee4f38">132.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjEtNS0xLTEtMTI5NjAx_7adb4485-93db-49ab-a662-80b88905ef1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjEtNy0xLTEtMTI5NjAx_e735989c-5bc6-48ee-977d-19a76281b848">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net and comprehensive income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjItNS0xLTEtMTI5NjAx_1d1fffb1-53e9-4b62-a310-dc33a7c36760"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjItNS0xLTEtMTI5NjAx_aa438da0-3dae-4574-91f7-a3488beed7ad">110.1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjItNy0xLTEtMTI5NjAx_21917c71-ce44-4b02-8afc-b68745c24ca0"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjItNy0xLTEtMTI5NjAx_e4a44361-5fbf-4adc-805a-e4ffe0d73b44">132.8</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net and comprehensive income attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjMtNS0xLTEtMTI5NjAx_59b575b3-d981-4df7-b8bd-01e739ab2830"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjMtNS0xLTEtMTI5NjAx_7a2c4a6a-1d73-467e-9572-e682e1234723">22.6</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjMtNy0xLTEtMTI5NjAx_5a8aa03a-22d8-402e-93b7-ea61249110b1"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjMtNy0xLTEtMTI5NjAx_a4dff9b7-c2f1-4b46-ab13-6b72ea1f3861">25.5</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net and comprehensive income attributable to Encompass Health</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjQtNS0xLTEtMTI5NjAx_ed0fc66c-3993-46b4-8e43-429d81cbaed6"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjQtNS0xLTEtMTI5NjAx_fbf15bbd-f3cb-470e-9ee9-940a5d71dad7">87.5</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjQtNy0xLTEtMTI5NjAx_1a72859a-384e-4027-94bc-fc9c67f2d30a"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjQtNy0xLTEtMTI5NjAx_75451e88-30c5-4016-ae26-4bb241f3ebab">107.3</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average common shares outstanding:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjktNS0xLTEtMTI5NjAx_332ee1ac-9e91-4d0e-873f-72d9af286329">99.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjktNy0xLTEtMTI5NjAx_5ed23d5b-7a48-4815-9f10-fbf300ecbb03">99.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzAtNS0xLTEtMTI5NjAx_3c64b99c-8018-460e-bc5e-9ffd18b1a9c7">100.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzAtNy0xLTEtMTI5NjAx_85ca85b7-2dcc-468f-92fe-e19bc9b888b1">100.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per common share:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzMtNS0xLTEtMTI5NjAx_65032a8d-dbbf-45ea-bcfa-19343724c254">0.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzMtNy0xLTEtMTI5NjAx_71647d60-55a2-47b2-ab17-de07ede1dd05">1.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzQtNS0xLTEtMTI5NjAx_a5ee8106-d931-46dc-b8c2-4ca160a574c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzQtNy0xLTEtMTI5NjAx_658bff30-5261-4dcf-8859-828d7840f5ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzUtNS0xLTEtMTI5NjAx_99930b2f-0388-410f-86e1-66bf31b97e36">0.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzUtNy0xLTEtMTI5NjAx_7e99a04e-3c17-413d-b238-6b51e7b143c3">1.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzctNS0xLTEtMTI5NjAx_edd4849c-6e31-4ad5-bf81-d10911f45960">0.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzctNy0xLTEtMTI5NjAx_10cbf231-6366-4781-99f8-66546798bc0e">1.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzgtNS0xLTEtMTI5NjAx_4e9b2e40-a065-4d51-a111-07e113900cfe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzgtNy0xLTEtMTI5NjAx_ff05c29d-a683-460b-804f-83b92d0e5515">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzktNS0xLTEtMTI5NjAx_d0e269c1-d349-47a8-aec1-4e10f8cecff1">0.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzktNy0xLTEtMTI5NjAx_896a436a-9920-47a8-b884-c9d9ece09c7c">1.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNDItNS0xLTEtMTI5NjAx_3139e4ad-7f77-48a9-b395-4e06d6fd2fe0">87.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNDItNy0xLTEtMTI5NjAx_7d24d382-7494-4f9f-8df9-c0c83aa337ef">107.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNDMtNS0xLTEtMTI5NjAx_9c39c348-7509-40a7-ba6d-6e45ef78ee87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNDMtNy0xLTEtMTI5NjAx_5016b20f-208d-4ee5-8f8c-0b2854ebc492">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNDQtNS0xLTEtMTI5NjAx_a7c4a5b7-20fe-4ec5-a49f-8d1a165c8fb1">87.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNDQtNy0xLTEtMTI5NjAx_75a1e431-3561-4cca-8891-79001c8c4767">107.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfNC0xLTEtMS0xMjk2MDE_25cf0e48-4dfd-43ef-a905-70bb4bb1c4a2">94.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfNC0zLTEtMS0xMjk2MDE_5ef4cbcc-adc1-4f1f-a268-f2e43e5b0d90">54.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfNS0xLTEtMS0xMjk2MDE_45dd6e83-e1cb-4f17-98da-96bf339c4985">61.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfNS0zLTEtMS0xMjk2MDE_2f164129-a4ab-4403-afb6-e53333f34e61">65.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfNi0xLTEtMS0xMjk2MDE_d10aa4d8-ebaa-49e4-a489-a39fdddb73b9">683.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfNi0zLTEtMS0xMjk2MDE_603efe03-f72a-4029-b7bc-9e1fc5442c58">680.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfNy0xLTEtMS0xMjk2MDE_24b1ed1b-b319-44c8-a1e6-a693663f9ffe">111.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfNy0zLTEtMS0xMjk2MDE_e365b3b4-ad8f-40b3-85a4-9a848229f267">121.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfOC0xLTEtMS0xMjk2MDE_98f8696c-3be0-480a-a9d4-dce8d1622228">949.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfOC0zLTEtMS0xMjk2MDE_314ad60a-214d-4206-92b6-089b8f95ecb3">921.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfOS0xLTEtMS0xMjk2MDE_bc6a1a02-6589-4231-b5ca-9fbe360f47ad">2,667.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfOS0zLTEtMS0xMjk2MDE_24eb4f5d-e41d-4539-bae2-62a0b2259a52">2,601.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTAtMS0xLTEtMTI5NjAx_12efd679-d821-4bec-b397-58933a80d77d">236.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTAtMy0xLTEtMTI5NjAx_8f5fd09e-4af5-4b1d-bbaa-275732be0097">242.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTEtMS0xLTEtMTI5NjAx_3a3d3b24-5ded-4c91-a819-b4d7fcd7385f">2,456.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTEtMy0xLTEtMTI5NjAx_3f195f29-92f3-452f-a042-0221e8b12154">2,427.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTItMS0xLTEtMTI5NjAx_495c6620-8436-4bed-99a8-f051590b4e2c">410.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTItMy0xLTEtMTI5NjAx_631e6500-c5b8-4ad7-aeee-a14a1c3093d0">417.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTQtMS0xLTEtMTI5NjAx_861d7b3b-0150-41fc-b7c7-7baafc736522">223.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTQtMy0xLTEtMTI5NjAx_c815d6da-b808-4cde-8c06-59615f41bb79">254.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTUtMS0xLTEtMTI5NjAx_7f8cccaa-f1ba-40bc-ad42-fcd4ee98eeb5">6,944.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTUtMy0xLTEtMTI5NjAx_0f538598-45b6-4f09-a95f-5f81800fa896">6,864.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTgtMS0xLTEtMTI5NjAx_033896b7-01dd-4c9c-87af-a6146c8a2c39">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTgtMy0xLTEtMTI5NjAx_47f8b27e-dffb-42e9-bc3e-ac5fa3908651">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTktMS0xLTEtMTI5NjAx_7394c8ad-3c2e-477b-bf3a-af579a630026">38.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTktMy0xLTEtMTI5NjAx_bd3b9cf0-5d40-4de4-870b-4cd1ee008dac">38.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjAtMS0xLTEtMTI5NjAx_827de33c-12b3-42e1-ad83-01c8410b4d7b">147.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjAtMy0xLTEtMTI5NjAx_65d146ea-11b6-4959-b4ba-b14fcae04add">137.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjEtMS0xLTEtMTI5NjAx_017aeaa6-ff88-45e4-a4ec-959b596b3215">526.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjEtMy0xLTEtMTI5NjAx_d42fd917-eaa9-4d2d-80ca-073d29f444fa">530.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjItMS0xLTEtMTI5NjAx_70f59388-93ed-481e-b3a1-75e306f6bdda">754.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjItMy0xLTEtMTI5NjAx_2290604b-e574-4699-8297-de594924d6c5">748.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjMtMS0xLTEtMTI5NjAx_afa52b39-88cd-4025-8f3e-5d5e252b016c">3,221.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjMtMy0xLTEtMTI5NjAx_1dc3cb3b-f773-4ce3-a801-36e30b0fb843">3,243.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjQtMS0xLTEtMTI5NjAx_1515784e-7a71-4f2b-bf6c-f991c8040e2c">208.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjQtMy0xLTEtMTI5NjAx_07cee54d-beff-41aa-abb5-2a50977fc9af">213.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjUtMS0xLTEtMTI5NjAx_3252cfee-0aa5-407a-939a-1bbd3b6e80d6">89.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjUtMy0xLTEtMTI5NjAx_cf573116-ad60-4200-8f01-a6d36f50a0eb">86.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjYtMS0xLTEtMTI5NjAx_668a520e-5ea1-4c51-a045-34cf49c5f886">178.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjYtMy0xLTEtMTI5NjAx_7480d374-27a1-4ff2-abb5-6a8b7f15b963">173.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjctMS0xLTEtMTI5NjAx_2cb1ea28-7786-4c0c-a4a7-5bfc9b59bd7d">4,452.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjctMy0xLTEtMTI5NjAx_14071f8b-05d6-4fcc-89d3-c899f2583088">4,465.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjgtMS0xLTEtMTI5NjAx_91a86abc-3432-4742-b61f-f6ef7a2f9baa"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjgtMy0xLTEtMTI5NjAx_49e4a846-7f1c-4a9a-9273-3b4f75f9f1e2"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzAtMS0xLTEtMTI5NjAx_76243aca-7fc2-4eec-9573-664a24382c2e">43.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzAtMy0xLTEtMTI5NjAx_24a3a4bd-7aad-49eb-a4f9-b17a38b32e75">42.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzItMS0xLTEtMTI5NjAx_03fe291a-ae8b-4fff-897d-002132e5e41c">1,973.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzItMy0xLTEtMTI5NjAx_015413bc-8a5c-45a0-bf5e-106fadcbb73c">1,911.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzMtMS0xLTEtMTI5NjAx_fc2fedf2-d059-4e24-b5fc-0c02d43892ee">474.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzMtMy0xLTEtMTI5NjAx_6c6c6d7e-e54a-42db-b8fd-31ffa781003d">445.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzQtMS0xLTEtMTI5NjAx_324a4b36-89e6-4f13-bf1c-8efc662bfd5f">2,448.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzQtMy0xLTEtMTI5NjAx_f02f1253-7df9-4393-a53b-46276311a712">2,357.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">and shareholders&#8217; equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzUtMS0xLTEtMTI5NjAx_376f026e-0a45-4eb7-8571-082b11d62254">6,944.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzUtMy0xLTEtMTI5NjAx_b8465d0d-15b4-4e6b-8fca-465d4f86d90d">6,864.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RleHRyZWdpb246ZWIxMjhmOWM2ZmJlNDE2ZDk3NTZjOWMyZTQ5NTU5YmVfMzUz_4d3515ba-93b0-4f03-8b82-aa0c4c4c406d" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of March&#160;31, 2022 and December&#160;31, 2021 include total assets of variable interest entities of $<ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RleHRyZWdpb246ZWIxMjhmOWM2ZmJlNDE2ZDk3NTZjOWMyZTQ5NTU5YmVfMTAy_4a063b0b-baa6-4382-b2e6-f656101b3d98">228.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RleHRyZWdpb246ZWIxMjhmOWM2ZmJlNDE2ZDk3NTZjOWMyZTQ5NTU5YmVfMTA5_d46c722c-6214-44cc-bf36-aeec3eac4572">226.2</ix:nonFraction> million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of March&#160;31, 2022 and December&#160;31, 2021 include total liabilities of the variable interest entities of $<ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RleHRyZWdpb246ZWIxMjhmOWM2ZmJlNDE2ZDk3NTZjOWMyZTQ5NTU5YmVfMzA3_a644d747-94a2-4529-9240-da095d33f4b7">40.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RleHRyZWdpb246ZWIxMjhmOWM2ZmJlNDE2ZDk3NTZjOWMyZTQ5NTU5YmVfMzE0_c5b38950-c29a-4bce-8144-6b67fc28b456">38.2</ix:nonFraction> million, respectively. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></ix:footnote></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div><div><span><br/></span></div></div></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_37"></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.404%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:5.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Encompass Health Common Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Common <br/>Shares Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital in Excess of <br/>Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling <br/>Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14493ec43a054a37a265fe545acfae34_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNC0xLTEtMS0xMjk2MDE_c03ef9fc-b1f3-4b44-9f0b-dfbea51f2baf">99.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14493ec43a054a37a265fe545acfae34_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNC0zLTEtMS0xMjk2MDE_17501c0f-dee6-473d-8c4a-69f1f9e11819">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8ac1140bb546ffbe29c3297dfca0ff_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNC01LTEtMS0xMjk2MDE_a5324491-0ce6-4395-8ac2-6452b9320fbc">2,289.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5eaecfe3f96400b8f59e7967a61104c_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNC03LTEtMS0xMjk2MDE_1bfcbee0-aee2-4fba-8ed7-52ad670f54cf">141.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd0a16468f25461eaa2eada251e33da7_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNC0xMS0xLTEtMTI5NjAx_a0fb951f-304b-431d-9ee3-77c750d7c84c">521.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db82f105f774106945877e84af0cc3e_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNC0xMy0xLTEtMTI5NjAx_867c455e-2a6c-4938-928d-c236f2974470">445.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNC0xNS0xLTEtMTI5NjAx_fc5acc5e-0ae8-45d7-bc7e-a0e5d31c0a83">2,357.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i576c769a2bf3490093c90b7f2fd1d565_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNS03LTEtMS0xMjk2MDE_7b563fd7-70f6-4c07-8e6e-4cbe26fe70c9">87.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33aac6e817b84b2fbedbc7be7dd1d4e1_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNS0xMy0xLTEtMTI5NjAx_5acd748e-312e-4862-99f4-aa33548c83bc">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNS0xNS0xLTEtMTI5NjAx_3fb766e9-ab40-4c68-b8d0-31e080d808f2">108.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receipt of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i70ffad11b2f64e0dafb9e8f6c59e3600_D20220101-20220331" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNi0xLTEtMS0xMjk2MDE_62d94b28-710e-4479-958a-108b9e9c426f">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia54089ca96194a95b6a9346ce2f33fc1_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNi0xMS0xLTEtMTI5NjAx_69e17644-148f-4c52-a79a-626186ebba27">7.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNi0xNS0xLTEtMTI5NjAx_83890d9c-904c-4b30-a59f-a26992bd7e0b">7.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNy0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjo0MjQxNzI3NmI5NzA0NTcwYTU5NTE3MGIzMjVkMmYzY18yNA_65906638-f3d4-4986-8ae0-b084b1c21869">0.28</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i576c769a2bf3490093c90b7f2fd1d565_D20220101-20220331" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNy03LTEtMS0xMjk2MDE_5efc94fe-4fae-4da7-9103-6d40de794a3d">28.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNy0xNS0xLTEtMTI5NjAx_648d6bd7-1326-43f5-b347-28aa319f26b9">28.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ec993229934505b223d7e527442ba7_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfOS01LTEtMS0xMjk2MDE_4cbcf6c8-c3ca-4660-81e0-bd3a26d1e036">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfOS0xNS0xLTEtMTI5NjAx_d0455003-431f-4bcb-b94b-11608500a883">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33aac6e817b84b2fbedbc7be7dd1d4e1_D20220101-20220331" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTItMTMtMS0xLTEyOTYwMQ_c2c0f117-6a44-4589-9725-c6b5d70236bd">24.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTItMTUtMS0xLTEyOTYwMQ_e1c1c8b6-a087-4548-9feb-09fa73d5c6fe">24.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contributions from consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33aac6e817b84b2fbedbc7be7dd1d4e1_D20220101-20220331" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTMtMTMtMS0xLTEyOTYwMQ_a5ad3cd8-11cf-4962-9c46-78f4d131ebfc">21.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTMtMTUtMS0xLTEyOTYwMQ_a766faf4-8d20-416d-8537-e4c03533840c">21.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i70ffad11b2f64e0dafb9e8f6c59e3600_D20220101-20220331" decimals="-5" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTgtMS0xLTEtMTI5NjAx_eba57f50-c9d2-41f3-80e9-8bfbd6ab1ff2">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ec993229934505b223d7e527442ba7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTgtNS0xLTEtMTI5NjAx_65b63c67-eea6-4077-8fae-82aeb8d2869c">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia54089ca96194a95b6a9346ce2f33fc1_D20220101-20220331" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTgtMTEtMS0xLTEyOTYwMQ_00163e03-d82b-4ee8-88c8-ee720a2e48c9">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33aac6e817b84b2fbedbc7be7dd1d4e1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTgtMTMtMS0xLTEyOTYwMQ_f85cc06a-d071-4133-9a7e-aaa610350096">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTgtMTUtMS0xLTEyOTYwMQ_4f14aacd-a36a-4219-b58d-bda372f5e958">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c072fe2fb1348d68775f83549979f34_I20220331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTktMS0xLTEtMTI5NjAx_e6fdbf78-fcbe-41b2-9aae-f84aee4d09ab">99.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c072fe2fb1348d68775f83549979f34_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTktMy0xLTEtMTI5NjAx_2e0a8bc0-03bc-47c3-886e-cc9d568a8288">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0cae1f6a4a43f293213bf2aea45abd_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTktNS0xLTEtMTI5NjAx_c4f0bda5-59e0-4d5f-9d77-a212cb3b9490">2,301.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4efb9bf256844561b1d2a7fbb842421e_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTktNy0xLTEtMTI5NjAx_aa68e3a4-bd73-4620-ac78-c25ca9795fa0">201.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i288ad08f50a44c848d9ae9b15441d2dc_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTktMTEtMS0xLTEyOTYwMQ_2de2c936-605c-4f45-94c7-77b3a66020a2">529.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2bafe8e3cac4147865d701ae99d921c_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTktMTMtMS0xLTEyOTYwMQ_f8b8acb1-9af8-4605-ae82-92dcad10ac01">474.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTktMTUtMS0xLTEyOTYwMQ_7dc0c14c-6b8b-43e0-a1bc-a219bdfb22f2">2,448.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.404%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:5.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Encompass Health Common Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Common Shares Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1beec8de6cfd45d8b5f89af034ba4093_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNC0xLTEtMS0xMjk2MDE_221b928c-9eda-4989-b5fd-1423bd8671ab">99.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1beec8de6cfd45d8b5f89af034ba4093_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNC0zLTEtMS0xMjk2MDE_fd6bb73f-9ad8-43ec-ae65-31ecfc57f002">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78cf1e166e974c539ccf23447cde940b_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNC01LTEtMS0xMjk2MDE_f8847068-9e97-4332-895c-d7b4ab145528">2,326.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3a08ff093f420c99340aa4e1150824_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNC03LTEtMS0xMjk2MDE_eaf17013-2e78-4b3e-a198-873cf4af64b5">242.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36bea0bf3d9144caa0f8df9028b1dc79_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNC0xMS0xLTEtMTI5NjAx_c91f449a-c16c-461e-b9a1-b596b72f65c6">497.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9203a9500e4500971e238696312597_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNC0xMy0xLTEtMTI5NjAx_e215412e-5d2d-489b-b0dc-7503588dc136">382.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f5b35fb51614954816b817c495b5d51_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNC0xNS0xLTEtMTI5NjAx_80b4521c-fe1c-4e8a-90d5-a9bba33be37d">1,970.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c1ae97e068e4cff900ec3092c7f4f04_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNS03LTEtMS0xMjk2MDE_145ef965-db1c-4106-bb29-18b18bfc4afa">107.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i036534c3f4a5413e8de12b55fc657fe1_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNS0xMy0xLTEtMTI5NjAx_d6ae9141-5731-47bd-a04d-1421e0780532">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNS0xNS0xLTEtMTI5NjAx_69387bab-0574-4499-b892-83f4a0766f0d">130.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receipt of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i622188ef7ebe41c680e18a9991186c28_D20210101-20210331" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNy0xLTEtMS0xMjk2MDE_36a08065-d0aa-47e8-aa20-a44a4a22c45a">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i117392f9d15f489cbe838f6b1ce3da6b_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNy0xMS0xLTEtMTI5NjAx_99438676-da7a-403a-bec5-52e804e9e10f">15.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNy0xNS0xLTEtMTI5NjAx_a08f5813-4316-426a-89cd-3e33bba31560">15.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfOC0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjpiMTkxNGRiZWI4OGU0MGVkYWIxNWMzYWI0N2M5MmZkOV8yNA_e5e2ff3c-fe27-4710-9164-b5268af4fe51">0.28</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cd1f1cb74084bb3b9abaf864a2e064b_D20210101-20210331" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfOC01LTEtMS0xMjk2MDE_3cdd459c-102d-4a29-89ee-254fa416e8bf">27.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfOC0xNS0xLTEtMTI5NjAx_fffafd5b-17c4-4b56-8330-e16d0c362b70">27.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd1f1cb74084bb3b9abaf864a2e064b_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTAtNS0xLTEtMTI5NjAx_99384d6c-db7a-4aae-9ca9-c401e758ef05">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTAtMTUtMS0xLTEyOTYwMQ_aee534e4-6786-42c0-9f03-19cf2cfccaae">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i036534c3f4a5413e8de12b55fc657fe1_D20210101-20210331" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTMtMTMtMS0xLTEyOTYwMQ_2fc8018f-44b6-4234-ae91-2f4856c74e52">22.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTMtMTUtMS0xLTEyOTYwMQ_5c33ec4e-f0a2-4595-bdd7-42eb39b44ba4">22.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contributions from consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i036534c3f4a5413e8de12b55fc657fe1_D20210101-20210331" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTQtMTMtMS0xLTEyOTYwMQ_ca04062f-f1ea-4ca7-9d0d-014891ad4e63">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTQtMTUtMS0xLTEyOTYwMQ_bb428162-31be-4d6a-94be-cd531dbe27c2">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i622188ef7ebe41c680e18a9991186c28_D20210101-20210331" decimals="-5" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTktMS0xLTEtMTI5NjAx_594a131f-d4b5-4fa6-a19b-a05653b0126e">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd1f1cb74084bb3b9abaf864a2e064b_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTktNS0xLTEtMTI5NjAx_a85d53d8-da43-457f-8eaf-e8cd0bda9b7e">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i117392f9d15f489cbe838f6b1ce3da6b_D20210101-20210331" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTktMTEtMS0xLTEyOTYwMQ_5dfb64ef-b3ef-404e-9664-3a80ab935fd8">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i036534c3f4a5413e8de12b55fc657fe1_D20210101-20210331" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTktMTMtMS0xLTEyOTYwMQ_21600dca-5b07-4178-9439-b44d80b66074">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTktMTUtMS0xLTEyOTYwMQ_6d95df15-ae9a-4ae9-8e35-fbb0440ee0de">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i013c277808804f42827dd89d591b0f7c_I20210331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMjAtMS0xLTEtMTI5NjAx_5676b82e-ef30-4317-8892-712e3979f1e7">99.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i013c277808804f42827dd89d591b0f7c_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMjAtMy0xLTEtMTI5NjAx_3d026b78-8b07-44c0-8e33-83847eb59e41">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972509dbc5b6416a9dd899dc87ebd08b_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMjAtNS0xLTEtMTI5NjAx_d35d4a8e-71cc-4d1b-88f9-f8e47697d35f">2,302.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia12ac2a64d1641ba80099f0e2982b794_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMjAtNy0xLTEtMTI5NjAx_6fb1b1f2-84da-4cf0-8618-7d40b8451cf4">135.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d9c8cd1de2c4f13933b82337c8517f4_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMjAtMTEtMS0xLTEyOTYwMQ_3511a324-8e8c-4f20-a91d-01e712337ba1">513.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9121edbdc21a47948aa5552e7f4240fb_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMjAtMTMtMS0xLTEyOTYwMQ_b4306742-ece2-4263-b47a-6259e0970880">387.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6a42e404cd4326b6c8697c3add3bf6_I20210331" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMjAtMTUtMS0xLTEyOTYwMQ_bc1a98a6-998c-41d3-b586-6c675134ac6f">2,043.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div><div><span><br/></span></div></div></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:10pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNC0xLTEtMS0xMjk2MDE_0148d8e2-1efd-46fc-9bdd-9c501ffb7a86">110.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNC0zLTEtMS0xMjk2MDE_65b1e6c2-4589-41a4-9595-e3f512bd2853">132.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfOC0xLTEtMS0xMjk2MDE_baa3fc1d-8630-4543-b819-48ef102a2fa6">66.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfOC0zLTEtMS0xMjk2MDE_9ecf6f1e-1d47-4e5f-a9c5-d353248c665c">62.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTItMS0xLTEtMTI5NjAx_4dc384e1-6179-432e-980e-192a72c7003e">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTItMy0xLTEtMTI5NjAx_aa583faa-5d01-4db3-ac01-c441976d175b">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTMtMS0xLTEtMTI5NjAx_a36b2b5e-aa8b-4fdb-9ac8-d42a5f271809">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTMtMy0xLTEtMTI5NjAx_5f10ef50-d4e5-4437-b87e-752fe3bf90e2">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTUtMS0xLTEtMTI5NjAx_5167f50c-1a71-407f-a2fc-138cdbd009d8">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTUtMy0xLTEtMTI5NjAx_3ef6b382-962b-4600-8b76-9003117ced83">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in assets and liabilities, net of acquisitions&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTctMS0xLTEtMTI5NjAx_e700c1c8-39d5-4a63-af7c-c90709e33b3a">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTctMy0xLTEtMTI5NjAx_e8e21f30-bc18-48b1-8af7-e006dda9f74d">55.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTgtMS0xLTEtMTI5NjAx_f29f25cd-c8db-4fac-ac0d-c1dc6dce382a">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTgtMy0xLTEtMTI5NjAx_07bf286e-62db-402b-b14d-b0d540aac976">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedSalaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjAtMS0xLTEtMTI5NjAx_00e95ba2-225f-4d6d-b4a1-cefda917fe82">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedSalaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjAtMy0xLTEtMTI5NjAx_c60065d9-075a-4070-8377-6ed6e000fd47">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjItMS0xLTEtMTI5NjAx_617843c6-ca4a-4b79-9da8-e1b7223d8f95">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjItMy0xLTEtMTI5NjAx_fa1132da-d8e4-4b54-b0a5-1f3bf3422542">2.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjMtMS0xLTEtMTI5NjAx_8e31f82f-e336-4109-9c24-dc8798b87635">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjMtMy0xLTEtMTI5NjAx_4c702eca-5190-4b26-b5a5-533cc1f25f7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjQtMS0xLTEtMTI5NjAx_a2126790-ba05-422d-92ca-a7a43b82d1c9">108.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjQtMy0xLTEtMTI5NjAx_7cafe668-9f9a-42ad-9199-ed113596f88b">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjUtMS0xLTEtMTI5NjAx_69b876a6-6f2e-4a1e-8e35-2db4c1fc3367">218.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjUtMy0xLTEtMTI5NjAx_e302520d-8d9d-4e81-b656-5cb1b37e1e4e">158.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjgtMS0xLTEtMTI5NjAx_5d3c049b-1b46-4856-a914-ad093f018f97">115.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjgtMy0xLTEtMTI5NjAx_7b6cfd7a-efbd-45cc-9e1b-739183133a69">98.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMzItMS0xLTEtMTI5NjAx_3cc201d4-bf5d-4cba-b950-6a8cd5422cfc">7.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMzItMy0xLTEtMTI5NjAx_159f5b23-451e-4431-95d4-cb0c35ee7977">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMzMtMS0xLTEtMTI5NjAx_3ce07b76-1cc7-4845-b14c-cca9fee1e0f6">123.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMzMtMy0xLTEtMTI5NjAx_9c7470a2-9d94-423e-8d60-ee8664d947c2">95.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments on debt, including pre-payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDAtMS0xLTEtMTI5NjAx_6f1c549d-1d2b-4812-bdf6-262601c12225">103.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDAtMy0xLTEtMTI5NjAx_88772cd8-a5ee-4236-a9f1-f5d81ac69106">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDEtMS0xLTEtMTI5NjAx_76032e4f-f236-49c1-a009-a0af6938b861">130.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDEtMy0xLTEtMTI5NjAx_cf21e471-06e3-463c-a6c6-4f5ca3148829">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on revolving credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDItMS0xLTEtMTI5NjAx_aefbfff7-499e-4afc-9b83-4b81726e797f">25.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDItMy0xLTEtMTI5NjAx_8218b00f-76b8-42d3-b8e0-bb2fd6704565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt amendment costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsOfDebtRestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDQtMS0xLTEtMTI5NjAx_61faf674-27ea-4797-b3ec-93bd6128d6a1">20.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsOfDebtRestructuringCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDQtMy0xLTEtMTI5NjAx_9d7f3e3e-d652-4066-9611-09151cb5cba3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid on behalf of employees for shares withheld</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDUtMS0xLTEtMTI5NjAx_8cec6529-dff4-4b8c-8504-ed3e7edd0fe2">7.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDUtMy0xLTEtMTI5NjAx_0e338ad0-e604-40b7-a86f-613c68aba1d3">15.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions from consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDYtMS0xLTEtMTI5NjAx_73753b80-7dd3-4d6d-b60c-66d0e91e28a4">21.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDYtMy0xLTEtMTI5NjAx_1dc6bc4d-02a9-4048-accb-d39e015c8dba">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid on common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDctMS0xLTEtMTI5NjAx_4f32008e-c8ac-49f3-9d04-8b7001d0b6f0">28.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDctMy0xLTEtMTI5NjAx_ca40c2b2-9639-4296-a113-d41bba19a04a">29.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions paid to noncontrolling interests of consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDgtMS0xLTEtMTI5NjAx_66b211f7-f963-4181-887a-28d5fb78a2c1">21.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDgtMy0xLTEtMTI5NjAx_de1734ac-9ff8-4769-b42d-872b588d5d88">27.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTEtMS0xLTEtMTI5NjAx_86deeca5-cbe3-4a61-bb6c-2b37044e3cfa">6.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTEtMy0xLTEtMTI5NjAx_a41e5a17-7ad7-402c-a7d5-9992026a41cb">5.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTItMS0xLTEtMTI5NjAx_6aeceda3-1741-4f16-913a-fe23f3408ee0">60.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTItMy0xLTEtMTI5NjAx_b9c1f812-3df6-4cf4-a307-9005b13873de">77.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTMtMS0xLTEtMTI5NjAx_d0f196d0-eeb7-42f7-9716-361e517ad05f">34.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTMtMy0xLTEtMTI5NjAx_bb80869b-b5d2-4a64-a5be-b1342194a74f">14.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTQtMS0xLTEtMTI5NjAx_6f8d27ad-3bb5-4310-bdbf-bfb84c69b6d5">120.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f5b35fb51614954816b817c495b5d51_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTQtMy0xLTEtMTI5NjAx_092058c8-bcdc-4960-8e70-a16b2717f53c">310.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTUtMS0xLTEtMTI5NjAx_14e4e778-7879-41b2-b1a1-6d3b2f0c9325">155.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6a42e404cd4326b6c8697c3add3bf6_I20210331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTUtMy0xLTEtMTI5NjAx_4b9c5e6d-02f3-455c-969f-5e991c41f964">296.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTgtMS0xLTEtMTI5NjAx_ff1010e0-9438-4270-bc67-084c803e37cb">54.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f5b35fb51614954816b817c495b5d51_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTgtMy0xLTEtMTI5NjAx_ca213391-cfbb-4c08-8d2d-03b8afbea00f">224.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash at beginning of period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTktMS0xLTEtMTI5NjAx_d6169312-30b3-468c-98dc-f238aaf3a6d8">65.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f5b35fb51614954816b817c495b5d51_I20201231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTktMy0xLTEtMTI5NjAx_bb55151a-2ade-4295-990c-fbac7a483765">65.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other long-term assets at beginning of period</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjAtMS0xLTEtMTI5NjAx_0a6ecd07-4a50-42ce-b12c-b921043e1d46">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f5b35fb51614954816b817c495b5d51_I20201231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjAtMy0xLTEtMTI5NjAx_6e1e5b34-0e44-4e23-80d9-1f61d76d882d">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjEtMS0xLTEtMTI5NjAx_4f48908d-e165-4f7d-9597-69aabb84ab67">120.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f5b35fb51614954816b817c495b5d51_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjEtMy0xLTEtMTI5NjAx_46d3b760-2093-4228-aa68-7cf4e5ba4365">310.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjMtMS0xLTEtMTI5NjAx_89d6142e-06c0-4043-9af9-3e78ef0c0620">94.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6a42e404cd4326b6c8697c3add3bf6_I20210331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjMtMy0xLTEtMTI5NjAx_8f434bba-85f9-43fb-8ef8-0c639e81cfd5">223.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash at end of period</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjQtMS0xLTEtMTI5NjAx_5c34f575-bcf8-4fa2-8f7d-fb18a38adecb">61.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6a42e404cd4326b6c8697c3add3bf6_I20210331" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjQtMy0xLTEtMTI5NjAx_bf9885c5-ed30-401e-a583-ec61830e0cf7">62.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other long-term assets at end of period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjUtMS0xLTEtMTI5NjAx_5bbcbe3f-9c6d-4fe8-80de-eca63dae29ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6a42e404cd4326b6c8697c3add3bf6_I20210331" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjUtMy0xLTEtMTI5NjAx_74b51532-df4c-47e9-999b-9b9ffaefb1d2">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjYtMS0xLTEtMTI5NjAx_82a55c81-dde7-4f9e-9aad-137799cdf807">155.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6a42e404cd4326b6c8697c3add3bf6_I20210331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjYtMy0xLTEtMTI5NjAx_77e4af01-1375-46bd-a2b9-67f0ad03bd44">296.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental schedule of noncash operating, investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment additions through finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjktMS0xLTEtMTI5NjAx_4335cc31-13f3-4a64-9472-1064428267ab">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjktMy0xLTEtMTI5NjAx_ef200405-d0c1-4e59-b0b7-8173437fce02">19.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNzEtMS0xLTEtMTI5NjAx_8def29b5-5c02-45ae-9a29-0c03fa4da8e4">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNzEtMy0xLTEtMTI5NjAx_ff003522-3bc0-4b68-97c6-15fb5f0d9da2">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div><div><span><br/></span></div></div></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_43"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><div style="text-align:center"><span><br/></span></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_46"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80Ni9mcmFnOjUyOTk3YWZjOWVhNTRhYTZiMjZiY2RkZmRlYWRmYzUxL3RleHRyZWdpb246NTI5OTdhZmM5ZWE1NGFhNmIyNmJjZGRmZGVhZGZjNTFfMjE1OQ_becb5e28-446b-4cbf-a9ba-f1840dee6bc2" continuedAt="i71b2d84b3db7459a846d39cec6792a16" escape="true">Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i71b2d84b3db7459a846d39cec6792a16" continuedAt="i83c18c7ba1804fc58d53700dc085b514"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health Corporation, incorporated in Delaware in 1984, including its subsidiaries, is a leading provider of post-acute healthcare services, offering both facility-based and home-based patient services in <ix:nonFraction unitRef="state" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80Ni9mcmFnOjUyOTk3YWZjOWVhNTRhYTZiMjZiY2RkZmRlYWRmYzUxL3RleHRyZWdpb246NTI5OTdhZmM5ZWE1NGFhNmIyNmJjZGRmZGVhZGZjNTFfMjQx_44f14cb9-7761-4cde-a1d2-04b2dc63b3f5">42</ix:nonFraction> states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. We manage our operations and disclose financial information using <ix:nonFraction unitRef="segment" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80Ni9mcmFnOjUyOTk3YWZjOWVhNTRhYTZiMjZiY2RkZmRlYWRmYzUxL3RleHRyZWdpb246NTI5OTdhZmM5ZWE1NGFhNmIyNmJjZGRmZGVhZGZjNTFfNDM2_69c93ae5-d0df-4bc0-aca7-d84d85e3609f">two</ix:nonFraction> reportable segments: (1) inpatient rehabilitation and (2) home health and hospice. See also Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2020, we announced a formal process to explore strategic alternatives for our home health and hospice business. As a result of this process, we expect to spin off our home health and hospice business to form an independent, publicly traded company on July 1, 2022, subject to customary conditions, including the effectiveness of a Form&#160;10 registration statement, regulatory approvals and receipt of a favorable IRS private letter ruling. On January 19, 2022, we announced the home health and hospice business would be rebranded and operate under the name Enhabit Home Health &amp; Hospice. The rebranding of agency locations began in mid-April 2022 and is expected to be largely completed by the effective date of the spin off.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Encompass Health Corporation and Subsidiaries should be read in conjunction with the consolidated financial statements and accompanying notes contained in Encompass Health&#8217;s Annual Report on Form&#160;10-K filed with the United States Securities and Exchange Commission on February&#160;25, 2022 (the &#8220;2021 Form 10&#8209;K&#8221;). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC applicable to interim financial information. Certain information and note disclosures included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been omitted in these interim statements, as allowed by such SEC rules and regulations. The condensed consolidated balance sheet as of December&#160;31, 2021 has been derived from audited financial statements, but it does not include all disclosures required by GAAP. However, we believe the disclosures are adequate to make the information presented not misleading.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited results of operations for the interim periods shown in these financial statements are not necessarily indicative of operating results for the entire year. In our opinion, the accompanying condensed consolidated financial statements recognize all adjustments of a normal recurring nature considered necessary to fairly state the financial position, results of operations, and cash flows for each interim period presented. Certain prior-year amounts have been reclassified to conform to the current year presentation.</span></div></ix:continuation><div id="ia58a0d4539bf462e8f4621edacd97f5a_49"></div><ix:continuation id="i83c18c7ba1804fc58d53700dc085b514" continuedAt="iadddde13c53d48b08899d606a5c34f38"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Operating Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RleHRyZWdpb246NzdmNWFhMWVhZDY1NGIzOWE4NWNmM2IxMWVhYWEwNGZfMjc1_2378bfa6-1a8a-4701-970b-e83b348a19d3" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by payor source and segment are as follows (in millions):</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:35.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.097%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aff770be2384e718613ee73e75c9d8c_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMy0xLTEtMS0xMjk2MDE_1ecaf57c-0854-4b0f-b11d-a56cb62d0c95">689.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20db95e52d4340b89253015dadddfce8_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMy0zLTEtMS0xMjk2MDE_0e026599-9d54-4dba-b852-599eb8945cfd">614.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e38d1a9d8c492983b5fe7bbc4a8114_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMy01LTEtMS0xMjk2MDE_8d34ea69-d98b-40da-8a42-48a0d892ab2f">217.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ed9eb823c2440d48088c6f6ef06b87d_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMy03LTEtMS0xMjk2MDE_16716ed9-2535-43f9-b9bf-9c8362ec6051">223.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d2de80a9ea142658a08aff95c64af19_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMy05LTEtMS0xMjk2MDE_1558677d-b994-4f34-afa1-145e37e103de">907.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a399017e33d42b2bf858dd4d6a9c0e1_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMy0xMS0xLTEtMTI5NjAx_0317eda1-abcc-467b-bac5-7688a08fb28f">838.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i915084ab4bdd4e1689693609d0ef6b82_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNC0xLTEtMS0xMjk2MDE_65a4bfdf-ef40-48ce-907b-b52dad768cb8">156.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c8d685705124a67ba3a91dabc43a282_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNC0zLTEtMS0xMjk2MDE_6f2e1329-3992-447e-9037-72d65f3fc18f">158.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ef7afb70a7f4b27a6a3cefbe6320e01_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNC01LTEtMS0xMjk2MDE_b9c2fea4-7df1-45df-994b-48b13a2a5a62">34.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1745bec828ac49b1818f4f9a5135a42c_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNC03LTEtMS0xMjk2MDE_8293c6ab-12de-413a-b3a7-e9e78deb744f">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcc4e89df88e43cfbef7da1f99240779_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNC05LTEtMS0xMjk2MDE_ea160eab-34bc-45ab-8015-4c64f1c30b76">190.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39f739399fa44a149e9c4093be040820_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNC0xMS0xLTEtMTI5NjAx_9f152abd-f5ef-4076-87cd-1953bdb3e747">186.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84bb98c1d43644a39513c7d343c7ffec_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNS0xLTEtMS0xMjk2MDE_c4a5dc58-0a34-4605-b544-65ef3fa906b8">131.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75ecf985b4164bff9fa7316be1a7474a_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNS0zLTEtMS0xMjk2MDE_8a55a073-52d1-461c-a207-1349fc00e9b2">112.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d2d7e560f1441bca94bad9f8a814402_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNS01LTEtMS0xMjk2MDE_72c24127-e06f-4d12-a059-6162ab68f94d">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibab4a62b6ba444c883fdc49380be38fb_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNS03LTEtMS0xMjk2MDE_8d6ded88-cc00-4c4b-a239-eb240f667586">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79fb50ea872e4a0ca7a8afe1c90123b2_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNS05LTEtMS0xMjk2MDE_511900e2-c9f6-4084-ba6e-f4aac6db094d">150.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c49ba6ba94af8960ab5d485207093_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNS0xMS0xLTEtMTI5NjAx_0ac16664-385e-4728-8371-217e31068934">126.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0b8349513794a3294fb7992b1d132ab_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNi0xLTEtMS0xMjk2MDE_364c5879-d12f-4f07-839e-0503509e4bc2">41.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacc1a722e4414822b283443f547fa10b_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNi0zLTEtMS0xMjk2MDE_a8433498-901e-4524-a51e-a2c6efa62422">39.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2903b136be2a4ee89a98bcd8d1360b19_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNi01LTEtMS0xMjk2MDE_527b1137-62a9-43c5-89d7-c47b9beee457">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad23a50207a142ab9c646522e8434d32_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNi03LTEtMS0xMjk2MDE_8e29d155-ec08-471d-b963-256d06f9a64a">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc33a324f2c0445d95695eba2ca8ef8a_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNi05LTEtMS0xMjk2MDE_7e0d3864-05b3-4e14-a875-9d4fe6810bcf">45.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i599a045bbb1143038e76b94639d195fe_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNi0xMS0xLTEtMTI5NjAx_6da0b453-abc7-4361-b794-71dccbc363cd">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i817f1c2f30674f89942c2d872a2ba105_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNy0xLTEtMS0xMjk2MDE_498fa479-7168-4269-880d-76df03a46c2e">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4efd11aa331481487fdb712ec4c0ac2_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNy0zLTEtMS0xMjk2MDE_eb5a1600-e9a7-42c8-a75d-4ec6e7094cad">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aafa9f641b84852af3d2fb5f01099e5_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNy01LTEtMS0xMjk2MDE_e64fc2ae-3af1-4d92-9c16-4044f1c1f857">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia19311f0969f4d318270fc2cc5ed5d0a_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNy03LTEtMS0xMjk2MDE_8464ee59-8ae2-4ef1-934f-7e1033ea340f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816cdecfdda244c89818aaa109f9acec_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNy05LTEtMS0xMjk2MDE_87a576ce-176b-4348-b759-503122e69830">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5fd3df85ec4c319b4bc0219d463e49_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNy0xMS0xLTEtMTI5NjAx_1b176ed5-c8e9-48ec-b04a-3f0571d439ab">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f172a6226384fecb27f5515fca37ab0_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOC0xLTEtMS0xMjk2MDE_8401ab54-1264-46f6-8d78-034c918fa179">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9457af3cee914d029434093eeae9c559_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOC0zLTEtMS0xMjk2MDE_b7b658f4-df31-4f62-98f6-9b1c8117604c">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d269849de54ca9aef661bdd4496c95_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOC01LTEtMS0xMjk2MDE_e42aa293-e2f3-4e5b-aaec-6f691deab3c0">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc9747447a24dfdb2bc0d42c7649f61_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOC03LTEtMS0xMjk2MDE_30ee2f53-2ee1-46ae-ad09-b4a924c0f76f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5a3de3efd3d4a48ad46ff05596eb38e_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOC05LTEtMS0xMjk2MDE_4f21c7e4-c769-4f98-8295-7def791628fc">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58a18ced43b9420abf4802064fa8951d_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOC0xMS0xLTEtMTI5NjAx_49217339-677a-4537-acb0-9e84c4b4c050">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib164992f54584ed39d8de9248794b352_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOS0xLTEtMS0xMjk2MDE_8308a4e9-b5bd-42a0-86ad-026a532139cf">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i886e59e872c246ddb347cb38ec9a1160_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOS0zLTEtMS0xMjk2MDE_10ffdb4b-0ccb-4359-91db-483d85cc4dd1">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1416420c060b4050821f6eee0ac9a457_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOS01LTEtMS0xMjk2MDE_ad77654b-11ab-4e05-b8a0-a6c39a6f0d4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7135e07b877d4f569de8504b4686a6ee_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOS03LTEtMS0xMjk2MDE_56664834-acea-4b4b-abd0-05071c864b22">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibded32670d67459ca73c7300d578990b_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOS05LTEtMS0xMjk2MDE_36dea482-7cc9-474d-9afb-784ab3850b2a">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id491747513c74175b42ca0a5e71438c0_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOS0xMS0xLTEtMTI5NjAx_19e6267c-51d4-45e2-be0b-7d6448caedb7">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852f28e7df1d406994d8a3bd00d23115_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTAtMS0xLTEtMTI5NjAx_a19c4a03-de0f-463d-9fa1-a425ff615aed">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d0b325d18e4ddd9457d92019914f3a_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTAtMy0xLTEtMTI5NjAx_e753d049-1bd5-480c-8ab0-81ea36a3e860">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id807874539934f0e9ed224fbc31c78b6_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTAtNS0xLTEtMTI5NjAx_7d739071-a7ef-455c-90f9-347ffb38377b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3313d74b1254472598b291ece765395d_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTAtNy0xLTEtMTI5NjAx_3dde1d6f-594b-4254-9621-b17503d63c11">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b51c955001459e8173f274705cb785_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTAtOS0xLTEtMTI5NjAx_03216d3b-5157-47fc-b3f8-778bd6c0b000">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293d6fb19adf46f18fb8ccfda949db85_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTAtMTEtMS0xLTEyOTYwMQ_803e0c80-5f25-41bc-9080-dde1c1bdbfd1">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTEtMS0xLTEtMTI5NjAx_8ff287a1-5764-4f2e-b79b-2387e76a128c">1,059.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTEtMy0xLTEtMTI5NjAx_1beb5c2e-ea8c-491a-a3a4-9b05b695d1e4">959.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTEtNS0xLTEtMTI5NjAx_9fb29f54-248c-49f3-ad0a-8e39bb077f5f">274.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTEtNy0xLTEtMTI5NjAx_f67b1b76-b2ea-4451-8ada-7f3254e35248">270.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTEtOS0xLTEtMTI5NjAx_df71c74e-0405-4e3e-abe8-21e282c1e2ee">1,333.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTEtMTEtMS0xLTEyOTYwMQ_d1d24dc5-1072-469f-b2b6-1ff79f052ad3">1,230.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2021 Form 10-K for our policy related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_55"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="iadddde13c53d48b08899d606a5c34f38"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81NS9mcmFnOjVmMzg0YWQ2ZTc3YjQ2MjhiNDRmM2U1MjFmNjViMjAwL3RleHRyZWdpb246NWYzODRhZDZlNzdiNDYyOGI0NGYzZTUyMWY2NWIyMDBfODQ2_5007f9b3-bead-42b9-b434-06f1b8470445" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe any recently issued, but not yet effective, accounting standards will have a material effect on our condensed consolidated financial position, results of operations, or cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="ia58a0d4539bf462e8f4621edacd97f5a_58"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RleHRyZWdpb246OWQ3MzQwYjJkZGYzNDljOWJjZWY5MjcxYjU5NDBkNWFfNjQ0OQ_b0de0bb4-af06-4aa5-8a88-b7c2c7544038" continuedAt="i81985f1a8efb4eb29c2236584c625958" escape="true">Business Combinations</ix:nonNumeric></span></div><ix:continuation id="i81985f1a8efb4eb29c2236584c625958" continuedAt="ia9f34437a84c436d8b2fc545fd3fbcd3"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health and Hospice</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we acquired a <ix:nonFraction unitRef="number" contextRef="if99233a02a77455db55959da352fbfb2_I20220101" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RleHRyZWdpb246OWQ3MzQwYjJkZGYzNDljOWJjZWY5MjcxYjU5NDBkNWFfMTA5OTUxMTYzODMwNQ_7bf0e388-ccd1-4413-9962-4c28c10afd91">50</ix:nonFraction>% equity interest from Frontier Home Health and Hospice, LLC in a joint venture with Saint Alphonsus System (&#8220;Saint Alphonsus&#8221;) which operates home health and hospice locations in Boise, Idaho. The total purchase price was $<ix:nonFraction unitRef="usd" contextRef="i29d56a10f17343bcaab0acd8dbcc3b4e_D20220101-20220101" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RleHRyZWdpb246OWQ3MzQwYjJkZGYzNDljOWJjZWY5MjcxYjU5NDBkNWFfMTA5OTUxMTYzODMyNA_f88f403f-23aa-4a7e-b8f1-46fe330d90a0">15.9</ix:nonFraction>&#160;million and was funded on December 31, 2021. This acquisition was made to enhance our existing joint venture relationship with Saint Alphonsus and expand our footprint in this geographic area. This transaction was not material to our financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for this transaction under the acquisition method of accounting and reported the results of operations of the acquired locations from the date of acquisition. Assets acquired, liabilities assumed, and noncontrolling interests were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including: an income approach using primarily discounted cash flow techniques for the noncompete and license intangible assets; and an income approach utilizing the relief-from-royalty method for the trade name intangible asset. The aforementioned income methods utilize management&#8217;s estimates of future operating results and cash flows discounted using a weighted average cost of capital that reflects market participant assumptions. For all other assets and liabilities, the fair value was assumed to represent carrying value due to their short maturities. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. All goodwill recorded reflects our expectations of favorable growth opportunities in the home health and hospice markets based on positive demographic trends. At least $<ix:nonFraction unitRef="usd" contextRef="if99233a02a77455db55959da352fbfb2_I20220101" decimals="-5" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RleHRyZWdpb246OWQ3MzQwYjJkZGYzNDljOWJjZWY5MjcxYjU5NDBkNWFfNDkyMw_cab5a35d-a165-427a-b500-ca5cbc4f7974">14.4</ix:nonFraction> million of the goodwill recorded as a result of this transaction is deductible for federal income tax purposes.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values recorded were based upon a preliminary valuation. Estimates and assumptions used in such valuation are subject to change, which could be significant, within the measurement period (up to one year from the acquisition date). We expect to continue to obtain information to assist us in determining the fair value of the net assets acquired at the acquisition date during the measurement period.</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="ia9f34437a84c436d8b2fc545fd3fbcd3" continuedAt="i7f3bfb77ee7045a3ae7940f1607dcdb0"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RleHRyZWdpb246OWQ3MzQwYjJkZGYzNDljOWJjZWY5MjcxYjU5NDBkNWFfNjQzNA_0047a85b-fd00-4058-b34a-b94cf7220269" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMC0xLTEtMS0xMjk2MDE_1e051c75-e874-491f-b510-350bbd4f5a7e">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMS0xLTEtMS0xMjk2MDE_b82ea2cc-015a-4f98-bc04-8f67adb0cfeb">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use-assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101" decimals="-5" name="ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfNC0xLTEtMS0xMjk2MDE_66a08d9e-386c-4faa-be57-66860afef97b">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreement (useful life of <ix:nonNumeric contextRef="i629dd79718e44513b2d60bcae0d6f51a_D20220101-20220101" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfNi0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjo2NjdkYTYwYjMwZTU0NDRhOWE4ODU5YWM2YjE1YTBhMl80MQ_9e96ce13-c59d-4685-af83-710f7730fb21">5</ix:nonNumeric> years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida96cd2b0e2746e39759c8c22c9bf7a5_I20220101" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfNi0xLTEtMS0xMjk2MDE_c4c7e69b-f1bc-45b0-b5b4-26e8f892ece7">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of <ix:nonNumeric contextRef="i6c4b218e644546e8963de5f7bb2c0e6c_D20220101-20220101" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfNy0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjo4YjUyZDk2NzgwODU0N2ZmYjdiMTY1NDZlYzlkNTA4Y18zMQ_e564bba3-668b-4c18-8dd0-2c03ffe392aa">6</ix:nonNumeric> months)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b09e480b6142de9d92527b0b5b9375_I20220101" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfNy0xLTEtMS0xMjk2MDE_5c0693aa-de3b-4c67-a912-05c667b8b418">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses (useful lives of <ix:nonNumeric contextRef="i93824ec251c546cbb304b0de1adc1bc2_D20220101-20220101" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfOS0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjpjM2NjYjBiNjFhMTI0YWFhYWQyMTE3NDZlZmM3MTBmN18zMA_a36772aa-88ba-4376-9d3f-642df4151ec1">10</ix:nonNumeric> years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica57130d0db94872b9b3a94cd9e7c39b_I20220101" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfOS0xLTEtMS0xMjk2MDE_44f81791-6990-4057-8303-d8031d5febba">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software (useful life of <ix:nonNumeric contextRef="i9bcefb1b301b491f9f6a61d393edcd39_D20220101-20220101" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMTAtMC0xLTEtMTY1MTEwL3RleHRyZWdpb246OTQzY2FhMzJlMmY0NDk4OWE4ZTEwYTkwMDE5YjEyYmVfMTA5OTUxMTYyNzgzOQ_61938928-a99c-4ec0-a39f-85dbcbeb3a43">3</ix:nonNumeric> years)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6861efcf5c8e4791b4cf9947c83117e8_I20220101" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMTAtMS0xLTEtMTYxNDE5_488da3a2-272a-4364-805b-cea6d0277038">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMTAtMS0xLTEtMTI5NjAx_efcac328-d292-46ad-82fb-7504449fbef4">28.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101" decimals="-5" name="ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMTItMS0xLTEtMTI5NjAx_50c0b976-05c0-46a8-89d0-d751b2549c41">32.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101" decimals="-5" name="ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMTQtMS0xLTEtMTI5NjAx_648d9134-eb8d-4027-a9e6-a431c0a86ea0">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMTUtMS0xLTEtMTI5NjAx_6c9a88a4-ae37-4fb2-9290-1255aa612c2f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101" decimals="-5" name="ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMTYtMS0xLTEtMTI5NjAx_41f955d9-d3e9-4dad-b963-5bf27a4ce824">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMTctMS0xLTEtMTI5NjAx_856881b6-6516-43d7-9c61-b775647e2fae">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMTgtMS0xLTEtMTI5NjAx_cc09a4b0-07e8-4789-98e6-ab0b66140f02">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMjAtMS0xLTEtMTI5NjAx_cdb751f9-5cca-4360-9a10-f08171401418">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMjEtMS0xLTEtMTI5NjAx_7ae1bf4e-99ed-42bb-a528-2d390a7b7bb8">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMjItMS0xLTEtMTI5NjAx_e90adc0c-ab51-4f38-821b-2036a80bac29">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RleHRyZWdpb246OWQ3MzQwYjJkZGYzNDljOWJjZWY5MjcxYjU5NDBkNWFfNjQ0MA_c16260db-d3cb-4b7d-a2c9-f31999706e57" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the cash paid for the acquisition during each period presented is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.683%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i944fc8295c154979b4c5e2ae485eb03b_D20220101-20220331" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfMi01LTEtMS0xMjk2MDE_85d5ccc2-8da6-4333-b79b-bfdddd71cd99">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090568ccb08b421a8703daa2d9b4d2c9_D20210101-20210331" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfMi03LTEtMS0xMjk2MDE_ca6abdfb-5a94-4850-9f18-60bc07e06942">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i944fc8295c154979b4c5e2ae485eb03b_D20220101-20220331" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfMy01LTEtMS0xMjk2MDE_060161f2-4f65-43f5-809d-0ba8be54d181">28.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090568ccb08b421a8703daa2d9b4d2c9_D20210101-20210331" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfMy03LTEtMS0xMjk2MDE_29a0f3b5-9957-4096-9b60-2b280af71dae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i944fc8295c154979b4c5e2ae485eb03b_D20220101-20220331" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfNC01LTEtMS0xMjk2MDE_dea95930-c2f9-4cc8-b5ee-0a27f53946a0">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090568ccb08b421a8703daa2d9b4d2c9_D20210101-20210331" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfNC03LTEtMS0xMjk2MDE_69c5a309-6f3e-4eb3-bd9f-6fd2e3af7f93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i944fc8295c154979b4c5e2ae485eb03b_D20220101-20220331" decimals="-5" name="ehc:BusinessCombinationNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfNS01LTEtMS0xMjk2MDE_2574b252-4fe7-45c1-8913-f3b5f7aa381f">15.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090568ccb08b421a8703daa2d9b4d2c9_D20210101-20210331" decimals="-5" name="ehc:BusinessCombinationNoncontrollingInterestFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfNS03LTEtMS0xMjk2MDE_74330eb9-1cd2-4555-8990-b93b6102ebdd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisition</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i944fc8295c154979b4c5e2ae485eb03b_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfNy01LTEtMS0xMjk2MDE_c825d756-e1c6-463c-83bc-42681147e85d">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090568ccb08b421a8703daa2d9b4d2c9_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfNy03LTEtMS0xMjk2MDE_b9f0b9f0-7846-4b4f-9cbe-9f063e6c729b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro Forma Results of Operations</span></div><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RleHRyZWdpb246OWQ3MzQwYjJkZGYzNDljOWJjZWY5MjcxYjU5NDBkNWFfNjQ1OQ_5eff808d-2cc3-4884-a920-cd516f709ae9" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above mentioned acquisition from the date of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisition been January&#160;1, 2021 (in millions): </span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.030%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health and Hospice</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjBlMTNhYWFiMjJjODQ1YWQ4NmY2ZDU3OWRkNWQyMWM5L3RhYmxlcmFuZ2U6MGUxM2FhYWIyMmM4NDVhZDg2ZjZkNTc5ZGQ1ZDIxYzlfNC0xLTEtMS0xMjk2MDE_846ca744-9b08-4a3a-92a4-a359cb52d837">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjBlMTNhYWFiMjJjODQ1YWQ4NmY2ZDU3OWRkNWQyMWM5L3RhYmxlcmFuZ2U6MGUxM2FhYWIyMmM4NDVhZDg2ZjZkNTc5ZGQ1ZDIxYzlfNC0zLTEtMS0xMjk2MDE_cbf3c074-5871-4174-84d1-2b5b4d9fa411">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2022-03/31/2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjBlMTNhYWFiMjJjODQ1YWQ4NmY2ZDU3OWRkNWQyMWM5L3RhYmxlcmFuZ2U6MGUxM2FhYWIyMmM4NDVhZDg2ZjZkNTc5ZGQ1ZDIxYzlfNS0xLTEtMS0xMjk2MDE_faedfe6c-5b47-4414-af36-2f3bfc67a389">1,333.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjBlMTNhYWFiMjJjODQ1YWQ4NmY2ZDU3OWRkNWQyMWM5L3RhYmxlcmFuZ2U6MGUxM2FhYWIyMmM4NDVhZDg2ZjZkNTc5ZGQ1ZDIxYzlfNS0zLTEtMS0xMjk2MDE_b8f9d7e1-a8dc-4e30-90b3-5cd915a86d49">87.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2021-03/31/2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjBlMTNhYWFiMjJjODQ1YWQ4NmY2ZDU3OWRkNWQyMWM5L3RhYmxlcmFuZ2U6MGUxM2FhYWIyMmM4NDVhZDg2ZjZkNTc5ZGQ1ZDIxYzlfNi0xLTEtMS0xMjk2MDE_6fcefac6-fa00-41a7-9362-7828ac181ec4">1,232.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjBlMTNhYWFiMjJjODQ1YWQ4NmY2ZDU3OWRkNWQyMWM5L3RhYmxlcmFuZ2U6MGUxM2FhYWIyMmM4NDVhZDg2ZjZkNTc5ZGQ1ZDIxYzlfNi0zLTEtMS0xMjk2MDE_87e14345-9e85-42a4-85c2-aa3a6c28a70f">107.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisition had occurred as of the beginning of our 2021 reporting period. See Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><div style="margin-bottom:10pt"><ix:continuation id="i7f3bfb77ee7045a3ae7940f1607dcdb0"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2021 Form 10&#8209;K for information regarding acquisitions completed in 2021.</span></ix:continuation></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_64"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RleHRyZWdpb246NzhkMDgzZmIyMTQwNDE3Njk2ODVjZGI5NjM3YWJmNThfMTMzMA_e4ebc6d2-b6c1-4abf-a2cc-f12c2905f730" continuedAt="i19c798b462564c7eaf139042e5d83bf3" escape="true">Variable Interest Entities</ix:nonNumeric></span></div><ix:continuation id="i19c798b462564c7eaf139042e5d83bf3"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, we consolidated <ix:nonFraction unitRef="entity" contextRef="ie1e6082c727c4be9853cda9efc66e5bd_D20220101-20220331" decimals="INF" name="ehc:VariableInterestEntityNumberofEntitiesConsolidated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RleHRyZWdpb246NzhkMDgzZmIyMTQwNDE3Njk2ODVjZGI5NjM3YWJmNThfNjY_49ea043d-d4b5-452b-8c35-13caf1c41e9d"><ix:nonFraction unitRef="entity" contextRef="i0b4d6eb8f1624f5780188f869aa798da_D20210101-20211231" decimals="INF" name="ehc:VariableInterestEntityNumberofEntitiesConsolidated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RleHRyZWdpb246NzhkMDgzZmIyMTQwNDE3Njk2ODVjZGI5NjM3YWJmNThfNjY_5bee5a2a-fee3-4f1e-b649-e4b671a6a607">ten</ix:nonFraction></ix:nonFraction> limited partnership-like entities that are variable interest entities (&#8220;VIEs&#8221;) and of which we are the primary beneficiary. Our ownership percentages in these entities range from <ix:nonFraction unitRef="number" contextRef="ice6f42f88a4d40f2bb746a1622dc9ab6_D20220101-20220331" decimals="3" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RleHRyZWdpb246NzhkMDgzZmIyMTQwNDE3Njk2ODVjZGI5NjM3YWJmNThfMjcw_bb51f43c-52fd-4051-b8f7-0dc9cedfc96e">50.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ice148ce40d284c87b5c5abf7edb0c698_D20220101-20220331" decimals="3" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RleHRyZWdpb246NzhkMDgzZmIyMTQwNDE3Njk2ODVjZGI5NjM3YWJmNThfMjc2_a4bea4a7-4833-4a50-8ea8-f95b52e702c0">90.0</ix:nonFraction>% as of March&#160;31, 2022. Through partnership and management agreements with or governing each of these entities, we manage all of these entities and handle all day-to-day operating decisions. Accordingly, we have the decision making power over the activities that most significantly impact the economic performance of our VIEs and an obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections, and creation and maintenance of medical records. The terms of the agreements governing each of our VIEs prohibit us from using the assets of each VIE to satisfy the obligations of other entities.</span></div><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RleHRyZWdpb246NzhkMDgzZmIyMTQwNDE3Njk2ODVjZGI5NjM3YWJmNThfMTMyNg_d6bbfd8f-b081-4000-91f3-7d9e4d236c7c" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and classifications of the consolidated VIEs&#8217; assets and liabilities, which are included in our condensed consolidated balance sheet, are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMy0xLTEtMS0xMjk2MDE_c5af0e4b-ae22-48dc-b99c-bb1b512f8821">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMy0zLTEtMS0xMjk2MDE_5e2c8b0e-73f8-4c89-9413-98116df7b3ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfNC0xLTEtMS0xMjk2MDE_71812d4e-7b4f-41e7-883e-5c3bd39da94d">34.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfNC0zLTEtMS0xMjk2MDE_728f38ae-60dc-4170-887b-0060cea4bd95">36.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfNS0xLTEtMS0xMjk2MDE_81c47a36-a081-4ac8-8eac-bdeb378d0ed5">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfNS0zLTEtMS0xMjk2MDE_f85a7b85-a482-4669-a0b8-e671759c3443">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfNi0xLTEtMS0xMjk2MDE_f7cc5c14-628e-4dfc-baa7-323342ec84bb">46.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfNi0zLTEtMS0xMjk2MDE_9c9fc240-3930-4d38-aed5-7276645dcf2c">44.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfNy0xLTEtMS0xMjk2MDE_17e36e86-99df-4b63-be7c-5d31b40ff995">115.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfNy0zLTEtMS0xMjk2MDE_eeabdd0a-62c4-4a84-92fe-dddbe513bb65">116.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfOC0xLTEtMS0xMjk2MDE_f870fb3e-a50e-4a34-b284-1aa1c6b1a8c4">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfOC0zLTEtMS0xMjk2MDE_2c099159-8f1d-409a-8b9c-d7345bb282d7">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfOS0xLTEtMS0xMjk2MDE_d6e2d5a9-3ad4-480c-b573-880726bd55ff">28.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfOS0zLTEtMS0xMjk2MDE_e181aaf4-9f6c-499e-be63-a3526b7229ce">28.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTAtMS0xLTEtMTI5NjAx_6c1a227d-0907-48a8-a772-58e1efcfce41">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTAtMy0xLTEtMTI5NjAx_167d476a-79ea-4c0b-8fa0-1eea2f8b930e">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTEtMS0xLTEtMTI5NjAx_928bdb57-c6cf-437f-995f-fc6df3f894b9">31.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTEtMy0xLTEtMTI5NjAx_03e75314-7f0a-4645-9907-1baadeb4e040">31.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTItMS0xLTEtMTI5NjAx_e16e1600-d1d0-4505-bfb2-09233739bdb2">228.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTItMy0xLTEtMTI5NjAx_112f0ed3-4aa4-40c5-bbd8-a4d402f3e5d2">226.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTUtMS0xLTEtMTI5NjAx_212ecd7c-576e-435f-8cdd-1fce769d2152">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTUtMy0xLTEtMTI5NjAx_ac53fb78-ea5b-4a65-9ec5-71f3e4e5ce87">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTYtMS0xLTEtMTI5NjAx_d3587324-c93e-43d4-b730-fbc04c5ce97e">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTYtMy0xLTEtMTI5NjAx_3321f068-5493-4b3e-83b4-9de4a561ff0e">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTctMS0xLTEtMTI5NjAx_cf9cf6ef-a653-4d12-a011-7220c2962f34">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTctMy0xLTEtMTI5NjAx_44c35ba1-8c6f-412b-817f-0c8be84475bf">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTgtMS0xLTEtMTI5NjAx_76323138-1977-4851-971e-2cbcbe88ea78">22.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTgtMy0xLTEtMTI5NjAx_8439f1bf-2723-44c0-9f6b-4e0c6cbcb992">19.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTktMS0xLTEtMTI5NjAx_6acafd13-c9cf-43d3-8b20-c49802c5f375">30.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTktMy0xLTEtMTI5NjAx_f4978ac5-ae09-4e83-bead-a091b19986b1">27.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMjAtMS0xLTEtMTI5NjAx_025c1400-283f-4b80-be2e-325798d61523">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMjAtMy0xLTEtMTI5NjAx_f3536c22-47f5-404c-8d0c-b87b60fe823f">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMjEtMS0xLTEtMTI5NjAx_59d5b669-755d-4874-b3dd-5645372ddc94">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMjEtMy0xLTEtMTI5NjAx_074aa2a9-3727-4991-a2f4-8aad21927095">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMjMtMS0xLTEtMTI5NjAx_524ca8c3-5de7-4cdd-ad28-76f8cbeefccb">40.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMjMtMy0xLTEtMTI5NjAx_50757705-f7ea-4344-a0ed-2662e1b342bc">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_76"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfNTUy_2eb0e67a-0177-4d54-a668-cf90e8afd3eb" continuedAt="i63c7b9a41c9041538ae8893f4c223bbb" escape="true">Long-term Debt</ix:nonNumeric></span></div><ix:continuation id="i63c7b9a41c9041538ae8893f4c223bbb"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfNTU1_b8902419-9738-4484-8982-13d65635b04f" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term debt outstanding consists of the following (in&#160;millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"><tr><td style="width:1.0%"></td><td style="width:59.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2382ba129c3486f990cf1eea014c79c_I20220331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMi0xLTEtMS0xMjk2MDE_0c2f0432-6dff-47a1-987a-dbee5878e615">305.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a79fe1564694ed59ea5acbff6dafa13_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMi0zLTEtMS0xMjk2MDE_e399d8d5-09f5-4110-bcd6-04068f2c3a52">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibff53e67228d4423a59336248f7e8a19_I20220331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMy0xLTEtMS0xMjk2MDE_6a337378-73ec-47a0-9a2e-fce8c6a02fb5">235.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idace690b6bd742fbb796490135ea208a_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMy0zLTEtMS0xMjk2MDE_fbaaae00-d0ad-461f-a960-de3f0c823205">238.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonds payable&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i05147760daea434eab785f9bb77eed18_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfNS0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjpkN2VjOGQxMGY2NWI0YmZhYTc4YTI5NTJiYTcwNTM2Y180_fd1a326f-0c44-405c-9e4a-ab3d0f7bc918">5.125</ix:nonFraction>% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05147760daea434eab785f9bb77eed18_I20220331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfNS0xLTEtMS0xMjk2MDE_49bc954c-b1f1-4d11-b459-56f7bc125bcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i518ef403619b45068725459a3694675c_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfNS0zLTEtMS0xMjk2MDE_a96a536a-0113-498c-a0c3-81635f1fd428">99.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i40e9e244d5e64ca7bf0040d18e4fa154_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfNi0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjphMDkwZDg1YTY2NGQ0MjNlYmRkNzQ0YjNmYTM2ZTg0MF80_3402c9c5-4882-4230-87d6-7b033034fd5a">5.75</ix:nonFraction>% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e9e244d5e64ca7bf0040d18e4fa154_I20220331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfNi0xLTEtMS0xMjk2MDE_3cab2d85-a11d-42fb-ab6e-9963db78ae69">347.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54ff49d44cd5451da021a1dcfdd01a1c_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfNi0zLTEtMS0xMjk2MDE_ad6f30c7-3aa2-43fe-8a81-06b28081d159">347.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b70c8bc77434fcf8e8e9acd22c58c45_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfNy0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjo1YTlmNDU2Mzk5ZjQ0YjIwYWE2ODgzZDg2MTNkYzQ5Nl80_48fd3f56-01a0-4362-accf-bdad2220338a">4.50</ix:nonFraction>% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b70c8bc77434fcf8e8e9acd22c58c45_I20220331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfNy0xLTEtMS0xMjk2MDE_77b3efe7-ff54-4425-9043-fef6ef651866">779.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6856f14b9e514819a81cb49c920770ac_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfNy0zLTEtMS0xMjk2MDE_5750ef36-cee7-4f92-a7e9-7a8287fc6ab5">786.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2cbef4d679154efc951e5c1786ca6bae_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfOC0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjphMTM4YTI0M2I4NjI0OGI5OTRhYTRjMmIyN2M2MWZjNF80_99e2fb40-87d2-44e2-8cdc-cdf5f99a78bb">4.75</ix:nonFraction>% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cbef4d679154efc951e5c1786ca6bae_I20220331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfOC0xLTEtMS0xMjk2MDE_6ebb7f27-ca75-441f-bcf5-f51103e67e55">777.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfab5bb13d1544f8b92a234bde75f0a9_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfOC0zLTEtMS0xMjk2MDE_36de1bb2-bb12-4a29-b2d6-7838b985556f">784.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d86755ee8bc4045b33ab465c664b7a9_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfOS0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjphZjE2YzQxNTZiNGI0Yzk0YjBhMGE3YjI5YzU3YzliOF80_9857f756-60b0-4933-b8f3-f4afa1d4a010">4.625</ix:nonFraction>% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d86755ee8bc4045b33ab465c664b7a9_I20220331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfOS0xLTEtMS0xMjk2MDE_f04b81de-4b2c-4051-ac10-6038ea6b643f">389.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia263377add53435796d020a9fae4da89_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfOS0zLTEtMS0xMjk2MDE_88c5755b-94e0-4746-b71e-98a4b514d492">393.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb23149d81b145d683c4131122e0613c_I20220331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTAtMS0xLTEtMTI5NjAx_a7157f32-d3ed-4e97-9656-6f05608b746f">49.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135485ea2e124322b3cb9b6b28d207bc_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTAtMy0xLTEtMTI5NjAx_4ced35f4-119e-4926-9362-34a79ada9eac">49.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTEtMS0xLTEtMTI5NjAx_33e86cab-d803-458a-8489-a14b0af9a1da">381.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTEtMy0xLTEtMTI5NjAx_9dbe4275-600b-45f0-9df2-f23978d0f90c">386.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:DebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTItMS0xLTEtMTI5NjAx_bf807792-b7c0-441e-8cb7-25aec5307107">3,264.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:DebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTItMy0xLTEtMTI5NjAx_75f7430d-6694-4754-85ac-46c517888f6b">3,286.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTMtMS0xLTEtMTI5NjAx_cb78bfc6-1139-405d-9ad6-7ab8eabb6140">42.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTMtMy0xLTEtMTI5NjAx_2db1acaa-f80f-428d-b9e2-6c7b233a264f">42.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTQtMS0xLTEtMTI5NjAx_1c9a9d75-5b84-4441-8a92-5344e434d924">3,221.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTQtMy0xLTEtMTI5NjAx_5afa447b-7dd6-4607-ab72-be77fab160aa">3,243.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2021, we announced the commencement of a consent solicitation of holders of our <ix:nonFraction unitRef="number" contextRef="i2432d02ccbce4152a2ebbc620946b0eb_I20211209" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfNDk0NzgwMjMyODkwNQ_0a2a0478-8dc4-405f-95de-f7dd2033c0f6">5.75</ix:nonFraction>% Senior Notes due 2025, <ix:nonFraction unitRef="number" contextRef="ib87798305a954bd68f594d703bee708a_I20211209" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfNDk0NzgwMjMyODg4Mw_30e7fa58-8774-482d-a2fc-43b0b4a2942a">4.50</ix:nonFraction>% Senior Notes due 2028, <ix:nonFraction unitRef="number" contextRef="if3dee57d45ef4967a06bff2bb1519d67_I20211209" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfNDk0NzgwMjMyODg5MA_d9980e80-74dd-4386-b5fc-01897c24cd73">4.75</ix:nonFraction>% Senior Notes due 2030, and <ix:nonFraction unitRef="number" contextRef="i9c40d9c98c634e8d9e33b00ff58b2939_I20211209" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfNDk0NzgwMjMyODg5Nw_57a1335d-0965-426a-b1e1-0085e471262a">4.625</ix:nonFraction>% Senior Notes due 2031 (collectively the &#8220;Senior Notes&#8221;) for the adoption of certain amendments to an indenture (the &#8220;Base Indenture&#8221;) dated as of December&#160;1,&#160;2009, as supplemented by each Senior Notes&#8217; respective supplemental indenture (together with the Base Indenture, the &#8220;Indenture&#8221;), which will provide us with greater flexibility in effecting the spin off discussed in Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Each Indenture contains restrictive covenants that, among other things, limit our ability and the ability of certain of our subsidiaries to make certain asset dispositions, investments, and distributions to holders of our capital stock. The amendments to the Indentures permit us, subject to the leverage ratio condition set forth below, to distribute to our equity holders in one or more transactions (a &#8220;Distribution&#8221;) some or all of the common stock of a subsidiary that holds substantially all of the assets of our home health and hospice business. We may make any such distribution so long as the Leverage Ratio (as defined in each Indenture) is no more than <ix:nonFraction unitRef="number" contextRef="i37b439614a834d5fa4da55874df55dc4_I20211209" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfMTA5OTUxMTYzMDY2Nw_1a77c80e-9b88-43b0-a0d1-51b1074861c9">3.5</ix:nonFraction> to 1.0 on a pro forma basis after giving effect thereto. The amendments also reduce the capacity under our restricted payments builder basket under each existing Indenture by $<ix:nonFraction unitRef="usd" contextRef="i37b439614a834d5fa4da55874df55dc4_I20211209" decimals="-6" name="ehc:DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfMTA5OTUxMTYzMDY4NQ_a4577b46-842d-4f3b-936c-2a7aa0e9caef">200</ix:nonFraction>&#160;million and amends the definition of &#8220;Consolidated Net Income&#8221; to allow us to exclude from Consolidated Net Income (a component of the Leverage Ratio) any fees, expenses or charges related to any Distribution and the solicitation of consents from the holders of the Senior Notes. In December 2021 and January 2022, we received the requisite consents for the adoption of these amendments. Under the terms of the amendments, we agreed to pay the holders of the Senior Notes a total of $<ix:nonFraction unitRef="usd" contextRef="i825551a2736a4a0cbed667eb8cc2cca2_D20211201-20220131" decimals="-5" name="ehc:DebtInstrumentAmendmentAgreementAmountToBePaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfMTA5OTUxMTYzMDcxMw_4625e480-cba6-485b-a4dc-b5eff9a66174">40.5</ix:nonFraction>&#160;million, excluding fees. We paid $<ix:nonFraction unitRef="usd" contextRef="i368ed4d7ad354f0cab721ebb36d47844_D20220101-20220131" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfMTA5OTUxMTYzMDc0MA_c567820e-fc35-4eaf-91dd-df80b17ca2fb">20</ix:nonFraction>&#160;million of this amount in January 2022. The remaining payment is contingent upon the execution of a Distribution and will be paid at such time.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we redeemed the remaining $<ix:nonFraction unitRef="usd" contextRef="i05147760daea434eab785f9bb77eed18_I20220331" decimals="-6" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfMTM2_d2e30d68-8d7f-4de6-b81a-5399131816fc">100</ix:nonFraction>&#160;million in outstanding principal amount of the <ix:nonFraction unitRef="number" contextRef="i05147760daea434eab785f9bb77eed18_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfMTc4_987d3bf0-f14f-467d-9899-d829e1d70b6c">5.125</ix:nonFraction>% Senior Notes due 2023 (the &#8220;2023 Notes&#8221;) using capacity under our revolving credit facility. Pursuant to the terms of the 2023 Notes, this optional redemption was made at a price of par. As a result of this redemption, we recorded an aggregate $<ix:nonFraction unitRef="usd" contextRef="id320e21f82b8400fadbbfe37b609516d_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfNDQ3_0234506f-352e-4a4e-ae5c-d2aa40260eb6">0.3</ix:nonFraction>&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the three months ended March 31, 2022.</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_79"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:MinorityInterestDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RleHRyZWdpb246YmY2YzU4Yzc1ZDBkNGVlZmJmNTI4YWYyMDUzN2JkZTlfMzU4OQ_fc3cb7ee-ea8c-41fc-a6e3-5abda778c38f" continuedAt="ic97f88c342eb43c49a95a98a9de232dc" escape="true">Redeemable Noncontrolling Interests</ix:nonNumeric></span></div><ix:continuation id="ic97f88c342eb43c49a95a98a9de232dc"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:RedeemableNoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RleHRyZWdpb246YmY2YzU4Yzc1ZDBkNGVlZmJmNTI4YWYyMDUzN2JkZTlfMzU4MA_32fca21a-8dc4-4ecd-96bd-378e9166fb8d" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the activity related to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39fdefb343d340ef94ee64a4ec92f2ae_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjUxN2YyOGRhMTUwYzQzOWE5ZmQ0YjViMzRmNDBiYWQ2L3RhYmxlcmFuZ2U6NTE3ZjI4ZGExNTBjNDM5YTlmZDRiNWIzNGY0MGJhZDZfMi0xLTEtMS0xMjk2MDE_35e02172-fc67-41fc-90c1-9f4af26d31ad">42.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b46f0824cfc44a390637375c885461c_I20201231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjUxN2YyOGRhMTUwYzQzOWE5ZmQ0YjViMzRmNDBiYWQ2L3RhYmxlcmFuZ2U6NTE3ZjI4ZGExNTBjNDM5YTlmZDRiNWIzNGY0MGJhZDZfMi0zLTEtMS0xMjk2MDE_5825905d-ab29-40b0-9542-3414b2cf9f6b">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6ea604dd0d04859a2c8cc03396c69bb_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjUxN2YyOGRhMTUwYzQzOWE5ZmQ0YjViMzRmNDBiYWQ2L3RhYmxlcmFuZ2U6NTE3ZjI4ZGExNTBjNDM5YTlmZDRiNWIzNGY0MGJhZDZfMy0xLTEtMS0xMjk2MDE_92adb122-fb70-4ba6-b239-49479193c05e">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80c5200a89154eb89d8ae5eb77290c4e_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjUxN2YyOGRhMTUwYzQzOWE5ZmQ0YjViMzRmNDBiYWQ2L3RhYmxlcmFuZ2U6NTE3ZjI4ZGExNTBjNDM5YTlmZDRiNWIzNGY0MGJhZDZfMy0zLTEtMS0xMjk2MDE_ced20bee-2e74-4fe9-8aca-da95db81f2cb">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6ea604dd0d04859a2c8cc03396c69bb_D20220101-20220331" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjUxN2YyOGRhMTUwYzQzOWE5ZmQ0YjViMzRmNDBiYWQ2L3RhYmxlcmFuZ2U6NTE3ZjI4ZGExNTBjNDM5YTlmZDRiNWIzNGY0MGJhZDZfNC0xLTEtMS0xMjk2MDE_e2dcf30e-6009-41fe-9358-e90eaf5e611e">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80c5200a89154eb89d8ae5eb77290c4e_D20210101-20210331" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjUxN2YyOGRhMTUwYzQzOWE5ZmQ0YjViMzRmNDBiYWQ2L3RhYmxlcmFuZ2U6NTE3ZjI4ZGExNTBjNDM5YTlmZDRiNWIzNGY0MGJhZDZfNC0zLTEtMS0xMjk2MDE_86dd96f3-f2ae-4d93-add7-cb4971587e46">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc945c722fc841aa95f6763fdd77a02c_I20220331" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjUxN2YyOGRhMTUwYzQzOWE5ZmQ0YjViMzRmNDBiYWQ2L3RhYmxlcmFuZ2U6NTE3ZjI4ZGExNTBjNDM5YTlmZDRiNWIzNGY0MGJhZDZfMTEtMS0xLTEtMTI5NjAx_ae062584-4409-43d1-b261-4ccf9e3d264a">43.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61423539f4b4453f9ea5b7bbc38883be_I20210331" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjUxN2YyOGRhMTUwYzQzOWE5ZmQ0YjViMzRmNDBiYWQ2L3RhYmxlcmFuZ2U6NTE3ZjI4ZGExNTBjNDM5YTlmZDRiNWIzNGY0MGJhZDZfMTEtMy0xLTEtMTI5NjAx_a90e193c-9d1e-4490-96a1-ca6bc6b7b153">31.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="ehc:ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RleHRyZWdpb246YmY2YzU4Yzc1ZDBkNGVlZmJmNTI4YWYyMDUzN2JkZTlfMzU4NA_745680a8-21eb-4a15-ad19-bfb85787413f" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the net income attributable to nonredeemable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the shareholders&#8217; equity section of the condensed consolidated balance sheets, and the net income attributable to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the mezzanine section of the condensed consolidated balance sheets, to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net and comprehensive income attributable to noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> presented in the condensed consolidated statements of comprehensive income (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to nonredeemable noncontrolling interests</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjdhYTg1ZTQ3NThiNjQyMmJhN2QxNmU2NmNmZWI2ODlhL3RhYmxlcmFuZ2U6N2FhODVlNDc1OGI2NDIyYmE3ZDE2ZTY2Y2ZlYjY4OWFfMi0xLTEtMS0xMjk2MDE_55fb82a3-e3b8-4aae-afcc-4a80ed9eafb2">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjdhYTg1ZTQ3NThiNjQyMmJhN2QxNmU2NmNmZWI2ODlhL3RhYmxlcmFuZ2U6N2FhODVlNDc1OGI2NDIyYmE3ZDE2ZTY2Y2ZlYjY4OWFfMi0zLTEtMS0xMjk2MDE_25b9c8c5-1286-40ab-a066-50a51ad3a446">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to redeemable noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjdhYTg1ZTQ3NThiNjQyMmJhN2QxNmU2NmNmZWI2ODlhL3RhYmxlcmFuZ2U6N2FhODVlNDc1OGI2NDIyYmE3ZDE2ZTY2Y2ZlYjY4OWFfMy0xLTEtMS0xMjk2MDE_70d31390-3992-4f22-9b54-3efae22f694f">1.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjdhYTg1ZTQ3NThiNjQyMmJhN2QxNmU2NmNmZWI2ODlhL3RhYmxlcmFuZ2U6N2FhODVlNDc1OGI2NDIyYmE3ZDE2ZTY2Y2ZlYjY4OWFfMy0zLTEtMS0xMjk2MDE_96ef004e-d5f2-4063-92e5-2f3eb9d1305c">2.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjdhYTg1ZTQ3NThiNjQyMmJhN2QxNmU2NmNmZWI2ODlhL3RhYmxlcmFuZ2U6N2FhODVlNDc1OGI2NDIyYmE3ZDE2ZTY2Y2ZlYjY4OWFfNC0xLTEtMS0xMjk2MDE_c05d8af1-a0b8-4afe-8917-f6bc11bda2d0">22.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjdhYTg1ZTQ3NThiNjQyMmJhN2QxNmU2NmNmZWI2ODlhL3RhYmxlcmFuZ2U6N2FhODVlNDc1OGI2NDIyYmE3ZDE2ZTY2Y2ZlYjY4OWFfNC0zLTEtMS0xMjk2MDE_a5c6f7ed-f9ee-4dad-8170-9a3c239cea12">25.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="ia58a0d4539bf462e8f4621edacd97f5a_82"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RleHRyZWdpb246YmUxYzA4YjVjMzNlNGI4NmE1MGNmOWZlNGRkMjUyMGRfMTQxMQ_9c1c207e-9258-4605-bf37-2ab26fb8ebf3" continuedAt="i55fb3005d54441b39d70295e40a2836a" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i55fb3005d54441b39d70295e40a2836a" continuedAt="idd13b7d72b1145b3bc023503c1bf7a8b"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RleHRyZWdpb246YmUxYzA4YjVjMzNlNGI4NmE1MGNmOWZlNGRkMjUyMGRfMTQyNQ_9f921633-2a4f-4c76-8a8b-cfec731cd97a" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): </span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of March 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddbe6c9e899402ab0cd9e710f9d31ea_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfMy0xLTEtMS0xMjk2MDE_c8bd7a3a-6721-4790-b984-5566ead20c12">80.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc43ca1f96d45b5a0cf5b2d38ae5a60_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfMy0zLTEtMS0xMjk2MDE_281c6027-f6e3-4ce5-a033-71565b51a8db">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8d214445f7041df915d431f92d7a70e_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfMy01LTEtMS0xMjk2MDE_9fa7de5c-0d6a-4ece-8e11-50c82109979c">76.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7dc7ae27134c52a55c357b78dd3cff_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfMy03LTEtMS0xMjk2MDE_6eb5b97c-af4b-448e-bf7c-677ca1185966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddbe6c9e899402ab0cd9e710f9d31ea_I20220331" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfNS0xLTEtMS0xMjk2MDE_ce0d8ef1-074e-4026-9fb1-10ef9acbe8c7">43.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc43ca1f96d45b5a0cf5b2d38ae5a60_I20220331" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfNS0zLTEtMS0xMjk2MDE_75535aea-1bb9-4f96-b5f3-38332c3b34d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8d214445f7041df915d431f92d7a70e_I20220331" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfNS01LTEtMS0xMjk2MDE_865fa668-cb28-4235-8b9e-deef5e80a5ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7dc7ae27134c52a55c357b78dd3cff_I20220331" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfNS03LTEtMS0xMjk2MDE_77d03d24-2c34-4371-a2f2-172d1f6c0c26">43.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ac35e30b3384503867b9b29c33fcd12_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfOC0xLTEtMS0xMjk2MDE_4ef067b9-8865-4839-9a5b-b724d58e0aec">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39472c9a755a464e8a2cc3ca1799e165_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfOC0zLTEtMS0xMjk2MDE_c105d734-81fb-4a96-aefc-8f0aad401adf">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3e4ffea3ce24cf29b0a92241c3ecd15_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfOC01LTEtMS0xMjk2MDE_73a63044-8b01-46a6-bcd3-073ee795743e">78.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia606fb5d54a34f2fbc455e7223986acc_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfOC03LTEtMS0xMjk2MDE_e312d507-6d17-41d4-9bff-cc5a10f78c1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ac35e30b3384503867b9b29c33fcd12_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfMTAtMS0xLTEtMTI5NjAx_181ec135-e2b9-45a5-9e29-05b4c919c717">42.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39472c9a755a464e8a2cc3ca1799e165_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfMTAtMy0xLTEtMTI5NjAx_a8e05cdc-a796-4c79-b2a4-ab259902655f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3e4ffea3ce24cf29b0a92241c3ecd15_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfMTAtNS0xLTEtMTI5NjAx_2ac4f127-5e51-44d1-8e96-b80dfdddbce3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia606fb5d54a34f2fbc455e7223986acc_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfMTAtNy0xLTEtMTI5NjAx_70de9cb3-cf5d-4591-bdb0-891aab7d74bf">42.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr></table></div><div style="margin-bottom:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).</span></div><div style="margin-bottom:10pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  As of March&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i79fc6be415b54a58b5d2c217fab0f29b_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RleHRyZWdpb246YmUxYzA4YjVjMzNlNGI4NmE1MGNmOWZlNGRkMjUyMGRfMTY0OTI2NzQ0NDMyOA_2670b7a5-24f2-44a8-9d59-be88e2f8a0a2">4.8</ix:nonFraction>&#160;million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="i59d953168b134eaba7885b47f0cda8fd_I20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RleHRyZWdpb246YmUxYzA4YjVjMzNlNGI4NmE1MGNmOWZlNGRkMjUyMGRfMTY0OTI2NzQ0NDM0Mg_93487c71-3cc4-43ca-a965-13185af72de5">75.6</ix:nonFraction>&#160;million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other long-term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> assets in the condensed consolidated balance sheet. As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="if034be9bc98b47cf8c97bf47ab9ea038_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RleHRyZWdpb246YmUxYzA4YjVjMzNlNGI4NmE1MGNmOWZlNGRkMjUyMGRfMTY0OTI2NzQ0NDM1Nw_aeeb5d4d-e5a8-4927-9186-ccc97d2eda1d">82.2</ix:nonFraction>&#160;million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other long-term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> assets in the condensed consolidated balance sheet.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are assets and liabilities that are not required to be measured at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. During the three months ended March&#160;31, 2022 and 2021, we did <ix:nonFraction unitRef="usd" contextRef="i4a7b858f19554add8379afca7b705865_D20210101-20210331" decimals="INF" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RleHRyZWdpb246YmUxYzA4YjVjMzNlNGI4NmE1MGNmOWZlNGRkMjUyMGRfNjU5NzA2OTc2ODEwMQ_1e5e0869-e32d-451d-956d-9462bc5ec35b"><ix:nonFraction unitRef="usd" contextRef="i7b444a6f37fa4de1992c65a1698b0b20_D20220101-20220331" decimals="INF" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RleHRyZWdpb246YmUxYzA4YjVjMzNlNGI4NmE1MGNmOWZlNGRkMjUyMGRfNjU5NzA2OTc2ODEwMQ_5cc0b15f-602d-4fa7-a3ca-9051e8b91e15">not</ix:nonFraction></ix:nonFraction> record any material gains or losses related to these assets.</span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="idd13b7d72b1145b3bc023503c1bf7a8b"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Fair Value Measurements,&#8221; to the consolidated financial statements accompanying the 2021 Form 10&#8209;K, the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our condensed consolidated balance sheets. <ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RleHRyZWdpb246YmUxYzA4YjVjMzNlNGI4NmE1MGNmOWZlNGRkMjUyMGRfMTQxNQ_af660af2-d529-49a8-bdae-95b5d1645f76" continuedAt="i663b241e15284cbca103564ca03bbcca" escape="true">The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:10pt;margin-top:5pt"><ix:continuation id="i663b241e15284cbca103564ca03bbcca"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64624582638a400485740c96311c1394_I20220331" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMy0xLTEtMS0xMjk2MDE_20b04a74-1b45-4c5d-9911-122c5b4faa3c">305.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if83c0d9db5394bde9d8b0c44800f9c9b_I20220331" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMy0zLTEtMS0xMjk2MDE_93bd5300-bc6d-4721-8822-1fd4b1df1fdd">305.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e7df9c82b3434983f969e537117392_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMy01LTEtMS0xMjk2MDE_8a46cbf3-71af-4451-8768-e4df5c8acb14">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i831cf2390be0435eaadf768914370cbe_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMy03LTEtMS0xMjk2MDE_04e3ddce-4785-4bc7-a4ab-636145ad960c">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248a1de457614c1c9d9c3795a5c5c6c2_I20220331" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNC0xLTEtMS0xMjk2MDE_2b0c9041-36d5-4e40-aecb-497e32081986">235.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4f1aa977184bbbbfe5144289d41e12_I20220331" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNC0zLTEtMS0xMjk2MDE_22f5e2b0-624b-4966-8755-7805234f03d0">236.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e41d6d12974156b84238a2892182c6_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNC01LTEtMS0xMjk2MDE_29f51405-46fe-403a-8525-b3f073e3c87b">238.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id07fee3147fe47a5868dde0e75b961bd_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNC03LTEtMS0xMjk2MDE_63aecc51-0a26-474e-ac76-739359d27404">239.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i05147760daea434eab785f9bb77eed18_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNS0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjpmNzcxMWJkMzM1ZWM0MzdlODM1ZDVlNTQwYzdiMTBhNl80_50d97453-903f-43eb-bef6-feb4ec83b07d">5.125</ix:nonFraction>% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47572d62b06342fe93e19a7e55a4943a_I20220331" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNS0xLTEtMS0xMjk2MDE_885e091f-3bb6-467e-bc3b-56b5bfdb4d4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e315035b554c8aa1875547b4630339_I20220331" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNS0zLTEtMS0xMjk2MDE_cd89a716-6143-45a2-a410-9d1ba4a98235">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9476be5bf24acb9f60b2167f82eb5e_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNS01LTEtMS0xMjk2MDE_35a04022-0afb-4629-bb25-575707729dc7">99.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02839eb8521947c8b4c9744e0ac23d7a_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNS03LTEtMS0xMjk2MDE_9fdc4185-1813-481a-a656-ef1419f1d190">100.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i40e9e244d5e64ca7bf0040d18e4fa154_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNi0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjowYmZjYWU3ZGU1MjQ0MTdlOTJlZGZlNzQ4MDA2NzRiNV80_1031dd48-4c14-4db9-a01c-871d0bcb46b5">5.75</ix:nonFraction>% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fb81c7757df47a7872a6c2daef100ce_I20220331" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNi0xLTEtMS0xMjk2MDE_b55691ec-3593-426a-86df-e1a910eb5a3f">347.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e88c315ef4c4d62ade591e994da366d_I20220331" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNi0zLTEtMS0xMjk2MDE_de846fe0-6b37-4cca-b043-d74c9b90b641">356.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbc9fad2e274e4eb37fa988811ee2a9_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNi01LTEtMS0xMjk2MDE_12edb45e-eb41-4b14-b9f6-95360f73c5a7">347.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94daa3156e1a45adbf33553663dd83fe_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNi03LTEtMS0xMjk2MDE_e04c0456-cf84-40ed-8e57-97b25cee3584">357.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b70c8bc77434fcf8e8e9acd22c58c45_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNy0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjpjODliMWU2ZjAwZGQ0YWJjODU1MmQ1OTIwN2M5NGVlMF80_02450122-06a1-4536-a47b-d9ae39dc17fa">4.50</ix:nonFraction>% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfcf9427557d461fbbebdf16a3b33843_I20220331" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNy0xLTEtMS0xMjk2MDE_caa0048f-1966-4989-80ca-1417e3e74c10">779.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ea71ca5cf549bf8c8f2f8fc6a335b2_I20220331" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNy0zLTEtMS0xMjk2MDE_44f97ce7-73cc-499b-9b10-f08539fd697a">790.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05d7792773941d2b4f0ae2bfd35090b_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNy01LTEtMS0xMjk2MDE_e04debe9-e026-4109-9e37-38c1b9609576">786.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e473304e17c4251a584a305f441fc45_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNy03LTEtMS0xMjk2MDE_26ff98eb-1df3-4c70-a8ee-e116685c2f8c">823.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2cbef4d679154efc951e5c1786ca6bae_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOC0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjpmNjQ0ZTkxMjY2NmM0YTk4YjlhMzZjZmQyYjcxNmY0Nl80_67ccb168-7c99-4f1c-b885-746dc3651beb">4.75</ix:nonFraction>% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic402c5736b164f289ef558cc5bdc16b3_I20220331" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOC0xLTEtMS0xMjk2MDE_84c9e28f-d66d-4a6a-bb50-8566a402850a">777.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c080a5046b140e19a17e88f98ac2e72_I20220331" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOC0zLTEtMS0xMjk2MDE_21ccbcba-0c9e-45f1-b224-1524fb4030a1">768.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5708fcd82894c208dadd2fea50fa007_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOC01LTEtMS0xMjk2MDE_4f15635f-9e33-42a7-a5bd-697b5d85b42a">784.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc43445772fb4f7cafc73de38ead4bd0_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOC03LTEtMS0xMjk2MDE_d6c24f4b-5e11-4c3b-a41e-40ca40d457d1">824.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d86755ee8bc4045b33ab465c664b7a9_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOS0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjphNDBjNWJlYjY5N2U0MWI5YjU4MGFhMGMyNjdjNTJmMl80_65d38af5-bbb6-4c75-bcf9-30c61609545d">4.625</ix:nonFraction>% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab66f41dc66040f2856dd6db44d58787_I20220331" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOS0xLTEtMS0xMjk2MDE_7bc42725-8ecc-4111-a038-42ebd62381f8">389.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ff03c5cba2460d8cadd19e31f7ce2a_I20220331" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOS0zLTEtMS0xMjk2MDE_cbc81087-71b3-4cf2-9521-5be096924f71">374.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedd404a57704848af9e8d99770a3e84_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOS01LTEtMS0xMjk2MDE_0ff1933c-e934-43d3-bff0-a800fe78ac04">393.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ccf6303eceb4c8882cde606d6046e98_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOS03LTEtMS0xMjk2MDE_8f2dbe20-60cd-4487-87e2-6eadba9db6b0">407.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55408ef11da47b9a9ab25b915d6f44a_I20220331" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMTAtMS0xLTEtMTI5NjAx_985faeb4-ee82-466b-bb01-9c04300d6cb7">49.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie932836488174026b6c0bb470e9937e1_I20220331" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMTAtMy0xLTEtMTI5NjAx_946499ab-3aeb-49dc-9dc5-28cba6d1a3cc">49.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dcc02c84fae47a2a3f1e83d9186a6a2_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMTAtNS0xLTEtMTI5NjAx_24d68923-44d9-4d87-84bc-43adddec6de2">49.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8628daca39564875a3d296261d4ddd8a_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMTAtNy0xLTEtMTI5NjAx_940a4100-078a-4488-855b-8c3759ecb4e8">49.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial commitments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letters of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22004d0542449c28c0dbfbf72a7738f_I20220331" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMTItMS0xLTEtMTI5NjAx_9cf123b2-90c5-4024-9de6-7c9c3e44a3a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9905941e5e914330a739320a89ef96fa_I20220331" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMTItMy0xLTEtMTI5NjAx_ab192e24-2afc-4cf2-9880-de6ba81c7830">37.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23319d48cfb542baa5100da894e4efd7_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMTItNS0xLTEtMTI5NjAx_7fd49b15-0480-4e1e-9b37-20e4bac98a86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f4eda008a3429e868ab8b5af645b77_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMTItNy0xLTEtMTI5NjAx_9fb1dbda-4024-421a-a766-e92881d2fe56">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inputs within the fair value hierarchy. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Fair Value Measurements,&#8221; to the consolidated financial statements accompanying the 2021 Form 10&#8209;K.</span></div></ix:continuation><div id="ia58a0d4539bf462e8f4621edacd97f5a_85"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84NS9mcmFnOmE1NzQ5ZDcyYThjOTQzZjk4MzM2ODU2ZDcyMDRiNDQ2L3RleHRyZWdpb246YTU3NDlkNzJhOGM5NDNmOTgzMzY4NTZkNzIwNGI0NDZfMTI0Nw_ae93d47d-cdcd-4974-bb58-67246813de15" continuedAt="ia8ad3381515a4ef89425700ec206e5dc" escape="true">Share-Based Payments</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-indent:36pt"><ix:continuation id="ia8ad3381515a4ef89425700ec206e5dc"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, we issued a total of <ix:nonFraction unitRef="shares" contextRef="ic01094ffa7604c71a90a6271b77d95ef_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84NS9mcmFnOmE1NzQ5ZDcyYThjOTQzZjk4MzM2ODU2ZDcyMDRiNDQ2L3RleHRyZWdpb246YTU3NDlkNzJhOGM5NDNmOTgzMzY4NTZkNzIwNGI0NDZfNzk_82b58146-884c-4f1f-800a-5baa2bcf8a4b">0.6</ix:nonFraction> million restricted stock awards to members of our management team and our board of directors. Approximately <ix:nonFraction unitRef="shares" contextRef="if3198110221a45879053dbae18100b29_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84NS9mcmFnOmE1NzQ5ZDcyYThjOTQzZjk4MzM2ODU2ZDcyMDRiNDQ2L3RleHRyZWdpb246YTU3NDlkNzJhOGM5NDNmOTgzMzY4NTZkNzIwNGI0NDZfMTgy_d4285833-edcd-4a8e-a637-4b66973dcc0e">0.2</ix:nonFraction> million of these awards contain only a service condition, while the remainder contain both a service and a performance condition. For the awards that include a performance condition, the number of shares that will ultimately be granted to employees may vary based on the Company&#8217;s performance during the applicable <ix:nonNumeric contextRef="idc081404cf0e4077909986bdf740a73b_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84NS9mcmFnOmE1NzQ5ZDcyYThjOTQzZjk4MzM2ODU2ZDcyMDRiNDQ2L3RleHRyZWdpb246YTU3NDlkNzJhOGM5NDNmOTgzMzY4NTZkNzIwNGI0NDZfMTI0Mw_0624671a-2455-40e1-b083-87b06ec28e2a">two year</ix:nonNumeric> performance measurement period. Additionally, we granted <ix:nonFraction unitRef="shares" contextRef="i3075bca9de3b4ee89c80a477c6851ee1_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84NS9mcmFnOmE1NzQ5ZDcyYThjOTQzZjk4MzM2ODU2ZDcyMDRiNDQ2L3RleHRyZWdpb246YTU3NDlkNzJhOGM5NDNmOTgzMzY4NTZkNzIwNGI0NDZfNTU3_3bcfc8f3-277d-4877-9958-0738cc3c429d">0.1</ix:nonFraction> million stock options to members of our management team. The fair value of these awards and options was determined using the policies described in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note&#160;14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2021 Form 10&#8209;K.</span></ix:continuation></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_88"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84OC9mcmFnOjRiZGMxMTJhNjEzYTRkYzlhZGU3MzMxYjMyZjRjMjM0L3RleHRyZWdpb246NGJkYzExMmE2MTNhNGRjOWFkZTczMzFiMzJmNGMyMzRfNjg1_3410f6be-80af-44e8-bfd8-8a78d1a7fdfe" continuedAt="iafef10d70dbd467badcf952b96a5e70f" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-indent:36pt"><ix:continuation id="iafef10d70dbd467badcf952b96a5e70f"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84OC9mcmFnOjRiZGMxMTJhNjEzYTRkYzlhZGU3MzMxYjMyZjRjMjM0L3RleHRyZWdpb246NGJkYzExMmE2MTNhNGRjOWFkZTczMzFiMzJmNGMyMzRfNTk_53a69111-d7c1-4267-9d03-0a87de76a529">31.2</ix:nonFraction> million for the three months ended March&#160;31, 2022 primarily resulted from the application of our estimated effective blended federal and state income tax rate. Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84OC9mcmFnOjRiZGMxMTJhNjEzYTRkYzlhZGU3MzMxYjMyZjRjMjM0L3RleHRyZWdpb246NGJkYzExMmE2MTNhNGRjOWFkZTczMzFiMzJmNGMyMzRfNjY_25c1b012-0c19-4c06-bd62-a148d5aeb4ea">34.5</ix:nonFraction> million for the three months ended March 31, 2021 primarily resulted from the application of our estimated effective blended federal and state income tax rate offset by tax benefits resulting from share-based compensation windfalls.</span></ix:continuation></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_91"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RleHRyZWdpb246ZTMzNGRlZjI4ZTI2NDZiMDliMjE2NWQ2ZDQyMjNlMzVfNDk5_0a70fe03-3891-4c85-8504-e86bf318db86" continuedAt="i1a7e259e5dcf4b899a517b8cb7cbb018" escape="true">Earnings per Common Share</ix:nonNumeric></span></div><ix:continuation id="i1a7e259e5dcf4b899a517b8cb7cbb018" continuedAt="i2b159bb510034bd997b6641abd3df2ef"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RleHRyZWdpb246ZTMzNGRlZjI4ZTI2NDZiMDliMjE2NWQ2ZDQyMjNlMzVfNTAz_d310ed3e-90a3-48ae-941b-de5f144272bd" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfNC0xLTEtMS0xMjk2MDE_bd9da633-9c5a-4996-92d6-a7b8c2c336f7">110.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfNC0zLTEtMS0xMjk2MDE_a7d60cac-5805-472e-a2c0-9bc9ee344298">132.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfNS0xLTEtMS0xMjk2MDE_7f13184c-0d84-45c3-ac02-078a5d1a1af4">22.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfNS0zLTEtMS0xMjk2MDE_f5ded1bf-a731-4068-8dd5-e4d9cf40d4fc">25.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income allocated to participating securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfNi0xLTEtMS0xMjk2MDE_102ad7ba-003b-4f8f-9bb0-6068656cdd44">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfNi0zLTEtMS0xMjk2MDE_e73c3832-c1ca-4241-82b6-f58c04bf7787">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfOC0xLTEtMS0xMjk2MDE_cf4f09df-ab33-4d8c-9ba7-54752eeb88c3">87.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfOC0zLTEtMS0xMjk2MDE_876abaee-9fa8-454b-839a-f88baa92355d">106.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfOS0xLTEtMS0xMjk2MDE_f8959763-0833-4d87-9ac7-65cdd512bf3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfOS0zLTEtMS0xMjk2MDE_87a98d98-95f6-4113-a271-fa18d3027310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="ehc:NetIncomeLossAvailabletoCommonStockholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTEtMS0xLTEtMTI5NjAx_1615ecba-ecea-4fa4-97f4-28498eb4b00b">87.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="ehc:NetIncomeLossAvailabletoCommonStockholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTEtMy0xLTEtMTI5NjAx_e7bb0b7c-7207-4924-9c8a-db906843f412">106.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTMtMS0xLTEtMTI5NjAx_fd312cbd-d41e-435c-9c29-55a31321f98c">99.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTMtMy0xLTEtMTI5NjAx_71401687-8ad0-4ed1-ba20-ffdcb4c6afc6">99.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTUtMS0xLTEtMTI5NjAx_528025eb-f1e0-4669-b223-176f68c4ab48">0.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTUtMy0xLTEtMTI5NjAx_89b8c877-8a78-4423-9d21-e8dc8693d63f">1.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTYtMS0xLTEtMTI5NjAx_5a25557e-4aca-4bbc-8b5d-9a14d4973151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTYtMy0xLTEtMTI5NjAx_5a04d692-1c98-4219-adff-59e593b52a36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTctMS0xLTEtMTI5NjAx_646cac16-ddd5-49ac-b529-8d24bbfd5542">0.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTctMy0xLTEtMTI5NjAx_c15fdb43-bd21-44d7-b961-a6e1b3e2e52a">1.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjEtMS0xLTEtMTI5NjAx_bd9da633-9c5a-4996-92d6-a7b8c2c336f7">110.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjEtMy0xLTEtMTI5NjAx_a7d60cac-5805-472e-a2c0-9bc9ee344298">132.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjItMS0xLTEtMTI5NjAx_7f13184c-0d84-45c3-ac02-078a5d1a1af4">22.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjItMy0xLTEtMTI5NjAx_f5ded1bf-a731-4068-8dd5-e4d9cf40d4fc">25.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjUtMS0xLTEtMTI5NjAx_4eaa03ed-0914-4ba5-be4f-e908c43611df">87.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjUtMy0xLTEtMTI5NjAx_c25575a1-ad1f-417c-a6da-5431ad623e4b">107.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjYtMS0xLTEtMTI5NjAx_f8959763-0833-4d87-9ac7-65cdd512bf3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjYtMy0xLTEtMTI5NjAx_87a98d98-95f6-4113-a271-fa18d3027310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjctMS0xLTEtMTI5NjAx_ae8c4988-e997-4ce5-881a-873f97f793c1">87.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjctMy0xLTEtMTI5NjAx_29842694-9e1b-482c-a373-57004e767142">107.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjktMS0xLTEtMTI5NjAx_d625537a-5f3d-4f88-824c-4f2d4ddc4215">100.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjktMy0xLTEtMTI5NjAx_552b2bac-0450-4246-a322-5be18be1a44a">100.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMzEtMS0xLTEtMTI5NjAx_75cc2edb-67d4-49f9-8a05-ca340ad6aa5c">0.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMzEtMy0xLTEtMTI5NjAx_981c87cb-aba3-46af-97bb-0465220f5809">1.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMzItMS0xLTEtMTI5NjAx_1df8982c-264c-4fb4-a558-82d6530e9a70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMzItMy0xLTEtMTI5NjAx_c0d1ed92-b6d8-453c-84e2-8cd079c0badd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMzMtMS0xLTEtMTI5NjAx_7fc5d7cf-d5ac-41ec-a476-33ec6bac89b3">0.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMzMtMy0xLTEtMTI5NjAx_86aa6b58-a91f-4f1c-9c65-bbb83e5f064f">1.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="i2b159bb510034bd997b6641abd3df2ef" continuedAt="i53859dd3f8dc437ab3b1d96aec81db1b"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RleHRyZWdpb246ZTMzNGRlZjI4ZTI2NDZiMDliMjE2NWQ2ZDQyMjNlMzVfNDg4_47ca7853-b119-4fc2-a945-7d5c3f31a811" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjU5YTdjNWUwZGQyMDRjZmM5YTk0MWNlMzk1NDMwM2FkL3RhYmxlcmFuZ2U6NTlhN2M1ZTBkZDIwNGNmYzlhOTQxY2UzOTU0MzAzYWRfMi0xLTEtMS0xMjk2MDE_fd312cbd-d41e-435c-9c29-55a31321f98c">99.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjU5YTdjNWUwZGQyMDRjZmM5YTk0MWNlMzk1NDMwM2FkL3RhYmxlcmFuZ2U6NTlhN2M1ZTBkZDIwNGNmYzlhOTQxY2UzOTU0MzAzYWRfMi0zLTEtMS0xMjk2MDE_71401687-8ad0-4ed1-ba20-ffdcb4c6afc6">99.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards, dilutive stock options, and restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjU5YTdjNWUwZGQyMDRjZmM5YTk0MWNlMzk1NDMwM2FkL3RhYmxlcmFuZ2U6NTlhN2M1ZTBkZDIwNGNmYzlhOTQxY2UzOTU0MzAzYWRfNS0xLTEtMS0xMjk2MDE_619198d0-68a4-4f9f-b173-fe50c5c04a8f">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjU5YTdjNWUwZGQyMDRjZmM5YTk0MWNlMzk1NDMwM2FkL3RhYmxlcmFuZ2U6NTlhN2M1ZTBkZDIwNGNmYzlhOTQxY2UzOTU0MzAzYWRfNS0zLTEtMS0xMjk2MDE_b46a9150-5dd0-4db6-b357-d96741b92c69">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjU5YTdjNWUwZGQyMDRjZmM5YTk0MWNlMzk1NDMwM2FkL3RhYmxlcmFuZ2U6NTlhN2M1ZTBkZDIwNGNmYzlhOTQxY2UzOTU0MzAzYWRfNi0xLTEtMS0xMjk2MDE_61432f07-086d-49b0-a75a-6fdbfeb7511e">100.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjU5YTdjNWUwZGQyMDRjZmM5YTk0MWNlMzk1NDMwM2FkL3RhYmxlcmFuZ2U6NTlhN2M1ZTBkZDIwNGNmYzlhOTQxY2UzOTU0MzAzYWRfNi0zLTEtMS0xMjk2MDE_98e9ac00-02f2-497e-95d3-2b505d4ca859">100.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><ix:continuation id="i53859dd3f8dc437ab3b1d96aec81db1b" continuedAt="i4633239b83994323885b568cf62c2545"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Common Share</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4633239b83994323885b568cf62c2545">, to the consolidated financial statements accompanying the 2021 Form 10&#8209;K for additional information related to our common stock.</ix:continuation> </span></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_94"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:LossContingencyDisclosures" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85NC9mcmFnOjQ5ODcxZjVhNmZhMTRlYWRiMzcxNmVjMDhlOTZjNTM1L3RleHRyZWdpb246NDk4NzFmNWE2ZmExNGVhZGIzNzE2ZWMwOGU5NmM1MzVfMzY3MQ_02a6a036-1bb4-4d1b-8310-cb05c3babeee" continuedAt="if67b0102e0e24c6ba36c9252682ebfda" escape="true">Contingencies and Other Commitments</ix:nonNumeric></span></div><ix:continuation id="if67b0102e0e24c6ba36c9252682ebfda"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The False Claims Act allows private citizens, called &#8220;relators,&#8221; to institute civil proceedings on behalf of the United States alleging violations of the False Claims Act. These lawsuits, also known as &#8220;whistleblower&#8221; or &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; actions, can involve significant monetary damages, fines, attorneys&#8217; fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases are sealed at the time of filing, which means knowledge of the information contained in the complaint typically is limited to the relator, the federal government, and the presiding court. The defendant in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action may remain unaware of the existence of a sealed complaint for years. While the complaint is under seal, the government reviews the merits of the case and may conduct a broad investigation and seek discovery from the defendant and other parties before deciding whether to intervene in the case and take the lead on litigating the claims. The court lifts the seal when the government makes its decision on whether to intervene. If the government decides not to intervene, the relator may elect to continue to pursue the lawsuit individually on behalf of the government. It is possible that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases brought pursuant to the False Claims Act.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the United States Department of Health and Human Services Office of Inspector General and the Centers for Medicare &amp; Medicaid Services relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, Encompass Health refunding amounts to Medicare or other federal healthcare programs.</span></div></ix:continuation><div id="ia58a0d4539bf462e8f4621edacd97f5a_97"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMzI2Mw_76478167-1e1d-46c3-b386-d168a0a9650f" continuedAt="i89b2efe4809c47f0a72ac9368f10e8ce" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="i89b2efe4809c47f0a72ac9368f10e8ce" continuedAt="i062e8c72f83e478ca4568f53cff26a94"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal financial reporting and management structure is focused on the major types of services provided by Encompass Health. We manage our operations using <ix:nonFraction unitRef="segment" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMTg1_ecab0597-40a0-430f-bc72-8f48b1e2b220">two</ix:nonFraction> operating segments which are also our reportable segments: (1)&#160;inpatient rehabilitation and (2)&#160;home health and hospice. These reportable operating segments are consistent with information used by our chief executive officer, who is our chief operating decision maker, to assess performance and allocate resources. The following is a brief description of our reportable segments:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inpatient Rehabilitation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our national network of inpatient rehabilitation hospitals stretches across <ix:nonFraction unitRef="state" contextRef="i53bdf1d6ecf041d7af98f062aa3d7212_I20220331" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfNjcy_f1a715af-7386-4575-a5eb-d27fc4acb16f">35</ix:nonFraction> states and Puerto Rico, with a concentration of hospitals in the eastern half of the United States and Texas. As of March&#160;31, 2022, we operate <ix:nonFraction unitRef="hospital" contextRef="i53bdf1d6ecf041d7af98f062aa3d7212_I20220331" decimals="INF" name="ehc:NumberOfInpatientRehabilitationHospitals" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfODA2_2d169de0-0bdf-4d1b-8b63-2d9eec65278c">147</ix:nonFraction> inpatient rehabilitation hospitals. We are the sole owner of <ix:nonFraction unitRef="hospital" contextRef="i53bdf1d6ecf041d7af98f062aa3d7212_I20220331" decimals="INF" name="ehc:Numberofsolelyownedinpatientrehabilitationhospitals" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfODcw_18178a02-1aaf-47b5-b3db-87873b409db0">93</ix:nonFraction> of these hospitals. We retain <ix:nonFraction unitRef="number" contextRef="i96474acd4c0142dda31b7d96f99582f1_I20220331" decimals="3" name="ehc:Jointventureownershippercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfOTAz_26e00931-b6f0-420d-ae4c-ec1e167053a9">50.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i79515ce75bf44070a97a38241f1e7d61_I20220331" decimals="3" name="ehc:Jointventureownershippercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfOTA5_12e316bd-09fe-40e4-88f2-2a3d67d0b3bd">97.5</ix:nonFraction>% ownership in the remaining <ix:nonFraction unitRef="hospital" contextRef="i53bdf1d6ecf041d7af98f062aa3d7212_I20220331" decimals="INF" name="ehc:Numberofjointlyownedinpatientrehabilitationhospitals" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfOTM5_0879f0de-566b-49a6-8719-c4f75e78c126">54</ix:nonFraction> jointly owned hospitals. In addition, we manage <ix:nonFraction unitRef="hospital" contextRef="i53bdf1d6ecf041d7af98f062aa3d7212_I20220331" decimals="INF" name="ehc:NumberOfInpatientRehabilitationUnitsUnderManagementContracts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfOTkw_9a158385-628e-429d-8e8a-40e3edadfde8">two</ix:nonFraction> inpatient rehabilitation units through management contracts. We provide specialized rehabilitative treatment on both an inpatient and outpatient basis. Our inpatient rehabilitation hospitals provide a higher level of rehabilitative care to </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="i062e8c72f83e478ca4568f53cff26a94" continuedAt="id395fa6a808047d89255bdc0968e3ee8"><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Home Health and Hospice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- As of March&#160;31, 2022, we provide home health services in <ix:nonFraction unitRef="location" contextRef="i4f992e9347194664b26f07fbc9a93d86_I20220331" decimals="INF" name="ehc:Numberofhomehealthlocations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMTUxMQ_64b2fe6d-1e7c-494f-b4ea-62a6bb32a8ed">252</ix:nonFraction> locations and hospice services in <ix:nonFraction unitRef="location" contextRef="i4f992e9347194664b26f07fbc9a93d86_I20220331" decimals="INF" name="ehc:Numberofhospicelocations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMTU0OA_7f20bdac-1caf-41f7-b6a1-34b1def5d903">99</ix:nonFraction> locations across <ix:nonFraction unitRef="state" contextRef="i4f992e9347194664b26f07fbc9a93d86_I20220331" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMTU2OA_99d3b02e-f6ec-4986-b1ce-69d9bbb40bb3">34</ix:nonFraction> states with concentrations in the southern half of the United States. We are the sole owner of <ix:nonFraction unitRef="location" contextRef="i4f992e9347194664b26f07fbc9a93d86_I20220331" decimals="INF" name="ehc:Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMTgwMQ_bcea5c00-d038-4704-827f-639efe74e6c2">335</ix:nonFraction> of these locations. We retain <ix:nonFraction unitRef="number" contextRef="iefcb7a67042b48cfb0c73139f067b3df_I20220331" decimals="3" name="ehc:Jointventureownershippercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMTgzNA_c36a0ca7-ca63-4fa5-bd37-f701ed47d6da">50.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ia9f95cf921114fbfb5398dadad725123_I20220331" decimals="3" name="ehc:Jointventureownershippercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMTg0MA_c902996d-0296-47b3-b8b7-0c4092868924">90.0</ix:nonFraction>% ownership in the remaining <ix:nonFraction unitRef="location" contextRef="i4f992e9347194664b26f07fbc9a93d86_I20220331" decimals="INF" name="ehc:Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMTg3MA_88342b99-825b-4035-97cb-f3fce8e94e37">16</ix:nonFraction> jointly owned locations. Our home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. Hospice care focuses on the quality of life for patients who are experiencing an advanced, life limiting illness while treating the person and symptoms of the disease, rather than the disease itself. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of our reportable segments are the same as those described in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2021 Form 10&#8209;K. All revenues for our services are generated through external customers. See Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues,&#8221; for the disaggregation of our revenues. No corporate overhead is allocated to either of our reportable segments. Our chief operating decision maker evaluates the performance of our segments and allocates resources to them based on adjusted earnings before interest, taxes, depreciation, and amortization (&#8220;Segment Adjusted EBITDA&#8221;).</span></div><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMzI2Ng_669e2edd-6cae-4446-a7d8-f9f61ea37d21" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected financial information for our reportable segments is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMy0xLTEtMS0xMjk2MDE_20edfffb-ff31-4860-8c9d-6281cd93fcc0">1,059.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMy0zLTEtMS0xMjk2MDE_d697a0a9-5da8-4ba8-b8c1-fb179eb7ae8d">959.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMy05LTEtMS0xMjk2MDE_73c2d8d7-c0f9-4e8c-b6a2-82eb76bdbc65">274.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMy0xMS0xLTEtMTI5NjAx_fdeb8ec9-16a6-48b1-959b-e6fecebf784f">270.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfNi0xLTEtMS0xMjk2MDE_2eeb1f91-d3e8-4097-b4c6-18acf656b9ab">587.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfNi0zLTEtMS0xMjk2MDE_a55d8cd6-cd6b-40da-82f9-e2e4e8ba12d0">501.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331" decimals="-5" name="us-gaap:LaborAndRelatedExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfNi05LTEtMS0xMjk2MDE_91c3bb7e-0307-45bf-9dd4-a0391f0f75b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331" decimals="-5" name="us-gaap:LaborAndRelatedExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfNi0xMS0xLTEtMTI5NjAx_38f14d66-9216-4b4b-a7e6-46c1d5af0fe9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfNy0xLTEtMS0xMjk2MDE_3f948120-71a2-47b0-88f1-981ea5538429">158.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfNy0zLTEtMS0xMjk2MDE_c2445f3b-637a-4fde-94ce-00aad89802ea">140.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfNy05LTEtMS0xMjk2MDE_eea575ec-eefb-4e52-bb51-be2614b6f6b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfNy0xMS0xLTEtMTI5NjAx_bdd11661-f16b-48ae-8bf3-e444bdd96dfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfOC0xLTEtMS0xMjk2MDE_5c474aa5-3026-4b5b-9b05-cf94350d1858">49.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfOC0zLTEtMS0xMjk2MDE_c15a4c60-ab71-43cf-9fa8-000ff5c8f5ff">45.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331" decimals="-5" name="us-gaap:SuppliesExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfOC05LTEtMS0xMjk2MDE_2abafbf9-d88c-4ad1-aaf3-f713537d3c9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331" decimals="-5" name="us-gaap:SuppliesExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfOC0xMS0xLTEtMTI5NjAx_40dfb3dd-3cd8-40f7-9cc0-e3185897f7c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfOS0xLTEtMS0xMjk2MDE_e8c5238d-8a5c-423a-b6d5-b908de885607">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfOS0zLTEtMS0xMjk2MDE_4e79a4a5-9bf7-4a89-92af-9592d3cf73fa">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331" decimals="-5" name="ehc:OccupancyCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfOS05LTEtMS0xMjk2MDE_c0f5ac74-b9d5-42a2-a64c-0c09e3b8560a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331" decimals="-5" name="ehc:OccupancyCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfOS0xMS0xLTEtMTI5NjAx_33ebf9e4-1a03-47e7-8edc-fad4e52009ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health and hospice:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service (excluding depreciation and amortization)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331" decimals="-5" name="ehc:CostofServicesExcludingDepreciationandAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTEtMS0xLTEtMTI5NjAx_3e65273f-c108-44d1-8af1-a8117daa6ec6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331" decimals="-5" name="ehc:CostofServicesExcludingDepreciationandAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTEtMy0xLTEtMTI5NjAx_133a0d06-6102-4c8e-a311-3da6ce436e82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331" decimals="-5" name="ehc:CostofServicesExcludingDepreciationandAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTEtOS0xLTEtMTI5NjAx_29a8e5b2-8d4b-4f20-9386-f1b2ba1b63da">124.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331" decimals="-5" name="ehc:CostofServicesExcludingDepreciationandAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTEtMTEtMS0xLTEyOTYwMQ_8b643967-40db-47a1-889d-b52aa5fd8d2a">118.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Support and overhead costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldOverhead" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTItMS0xLTEtMTI5NjAx_bc4c9c7b-7752-470d-ba75-e0ddc0e95753">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldOverhead" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTItMy0xLTEtMTI5NjAx_983eb8b8-f7d4-4d4b-8100-d4d898692454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldOverhead" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTItOS0xLTEtMTI5NjAx_7318d079-a1df-472a-bc30-534d38b3975b">99.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldOverhead" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTItMTEtMS0xLTEyOTYwMQ_e19813b6-f059-4b30-82ad-344c6e2e5ce1">101.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTMtMS0xLTEtMTI5NjAx_812c3b05-c2a2-44dc-b3ce-095b9184982b">810.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTMtMy0xLTEtMTI5NjAx_e2b61197-55e3-4000-b812-3d333feac6e5">702.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTMtOS0xLTEtMTI5NjAx_dd080b8c-4909-467c-a081-8d525839d6e6">223.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTMtMTEtMS0xLTEyOTYwMQ_b4e8ebc5-c8d4-4f07-889a-be7d68255202">219.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTQtMS0xLTEtMTI5NjAx_aeeb1aa3-2d73-47cb-b5fd-663738d32a18">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTQtMy0xLTEtMTI5NjAx_0daf733a-d431-4f5e-ab80-f1dfa5df3f58">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTQtOS0xLTEtMTI5NjAx_36fe407d-7395-4888-af8e-5b1e9e9d7cd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTQtMTEtMS0xLTEyOTYwMQ_3ac6517f-e36c-4ad6-a0f1-8d7cc253ee36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTUtMS0xLTEtMTI5NjAx_f6cae5d3-d558-4364-9bbb-fd622e7a16b0">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTUtMy0xLTEtMTI5NjAx_4f3c8261-2abb-4601-a6d6-b7eff6f94402">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTUtOS0xLTEtMTI5NjAx_ef373bac-b3ee-4414-bf61-39da47bf5306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTUtMTEtMS0xLTEyOTYwMQ_10e5c72e-4605-4c13-9bb3-e0e9f15f6b2a">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTYtMS0xLTEtMTI5NjAx_6fd37ee2-27b8-44bd-87d2-2399c27fee49">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTYtMy0xLTEtMTI5NjAx_cbea3438-bb48-4ed6-a82a-863339296a6c">25.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTYtOS0xLTEtMTI5NjAx_927a745b-8b5b-4499-9187-c8c3ee701a41">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTYtMTEtMS0xLTEyOTYwMQ_2327d641-820d-4dd9-ac2f-95d537a26f51">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Adjusted EBITDA</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTctMS0xLTEtMTI5NjAx_ddc3e539-bc1c-433a-8495-e5e411935019">226.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTctMy0xLTEtMTI5NjAx_661948d6-b170-4b95-a369-393d5f09a313">234.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTctOS0xLTEtMTI5NjAx_d0f4e8ff-1f0c-4609-bd87-71904f6cd6e6">50.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTctMTEtMS0xLTEyOTYwMQ_570f8fb3-9fa2-4edb-a933-fb9653fbf774">50.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTktMS0xLTEtMTI5NjAx_c4dcc116-33e7-460c-a91a-6d85e8fc34fe">117.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTktMy0xLTEtMTI5NjAx_b46a92a7-2a32-4780-b859-5104e248534d">99.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTktOS0xLTEtMTI5NjAx_dac50874-8d8e-4b81-9083-b07c5bd6403c">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTktMTEtMS0xLTEyOTYwMQ_504e59ba-1296-41e3-980e-09eb88d0c33c">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="id395fa6a808047d89255bdc0968e3ee8"><div style="margin-bottom:10pt"><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfNDk0NzgwMjMyODI3Mg_e1d7aee8-c937-49d4-8238-877a98b93d45" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:51.477%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.219%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53bdf1d6ecf041d7af98f062aa3d7212_I20220331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfMi0xLTEtMS0xMzE5ODY_a894270d-2a4f-4055-9a47-5e34183bf127">5,199.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f992e9347194664b26f07fbc9a93d86_I20220331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfMi0zLTEtMS0xMzE5ODY_733d6309-0002-4cbe-9ebf-c8b6e68d23a4">1,745.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfMi01LTEtMS0xMzE5ODY_777e8c01-0fb5-4637-a255-0fddea49e4ef">6,944.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to nonconsolidated affiliates</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53bdf1d6ecf041d7af98f062aa3d7212_I20220331" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfMy0xLTEtMS0xNDQ4MTc_ac10b872-ca3c-4160-b8f8-b4570fb40021">2.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f992e9347194664b26f07fbc9a93d86_I20220331" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfMy0zLTEtMS0xMzE5OTM_a4457891-a37f-490d-b2fa-42aadd5a5e8a">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfMy01LTEtMS0xMzE5OTM_867ac8c4-c3c4-4513-8d61-d45ca87f90e1">3.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibabc6d389eb7499992b42a9d1f4b3120_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfNS0xLTEtMS0xMzIwMDE_86298b17-4282-42f5-901d-1e872877bcdc">5,143.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i407e8fe2e2364e5d91792421c5019898_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfNS0zLTEtMS0xMzIwMDE_3ce7faf4-1fe9-4604-9fce-63ac95bdd9e9">1,721.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfNS01LTEtMS0xMzIwMDE_08256c54-4501-4646-acfd-1445fa4445a4">6,864.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibabc6d389eb7499992b42a9d1f4b3120_I20211231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfNi0xLTEtMS0xNDQ4MTc_c948081e-323f-4893-a876-b18f2dd46bb5">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i407e8fe2e2364e5d91792421c5019898_I20211231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfNi0zLTEtMS0xMzIwMDk_437b6fe4-dd29-466b-a217-c7a8fb02936e">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557a32613c404e579eedda986be748b3_I20211231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfNi01LTEtMS0xMzIwMDk_483ab810-8763-4e35-ac8e-78d6860a4efa">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="ehc:ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMzI2Nw_ae311556-83a8-4368-a303-bf45fb7942a5" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment reconciliations (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia036ff2cbdc34388aff7771c98304af2_D20220101-20220331" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMi0xLTEtMS0xMjk2MDE_726b92ab-2727-4a05-a293-887b6c1b6f34">276.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie391de2d22ab44fda7310331622d23d1_D20210101-20210331" decimals="-5" name="ehc:AdjustedEBITDA" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMi0zLTEtMS0xMjk2MDE_bd817751-fec7-4af0-a6ba-3574fd6fa7bc">285.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77fc9042b9d744ba9d2f6c315981cd86_D20220101-20220331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMy0xLTEtMS0xMjk2MDE_4f1b2d63-3701-4c8d-b1be-621353224c7c">48.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c857df9e79e4435ab0c5961811291c6_D20210101-20210331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMy0zLTEtMS0xMjk2MDE_5862c172-dc66-4eb4-9c4c-87798f6fc7a3">38.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77fc9042b9d744ba9d2f6c315981cd86_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfNC0xLTEtMS0xMjk2MDE_942377fd-8eb9-49f7-8d73-d2a37b9515e1">66.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c857df9e79e4435ab0c5961811291c6_D20210101-20210331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfNC0zLTEtMS0xMjk2MDE_864a5805-c6fd-4331-bd09-a725ff6a21be">62.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on disposal or impairment of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77fc9042b9d744ba9d2f6c315981cd86_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfNS0xLTEtMS0xMjk2MDE_25242d5b-b925-45d3-8660-81b9cd514608">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c857df9e79e4435ab0c5961811291c6_D20210101-20210331" decimals="-5" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfNS0zLTEtMS0xMjk2MDE_2502d3f4-00d7-4d76-87cc-bb5222e5f672">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77fc9042b9d744ba9d2f6c315981cd86_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfOC0xLTEtMS0xMjk2MDE_2d67b365-d6e8-485a-b4e8-679f267e3e1e">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c857df9e79e4435ab0c5961811291c6_D20210101-20210331" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfOC0zLTEtMS0xMjk2MDE_1f9408a9-4a0e-45c4-a13d-7c95903bc2b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77fc9042b9d744ba9d2f6c315981cd86_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfOS0xLTEtMS0xMjk2MDE_f8120897-578d-4d7f-b4a7-6fa3fb8a4928">39.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c857df9e79e4435ab0c5961811291c6_D20210101-20210331" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfOS0zLTEtMS0xMjk2MDE_0508165d-6db1-4bd6-b875-d8c8afd893d5">42.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77fc9042b9d744ba9d2f6c315981cd86_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMTEtMS0xLTEtMTI5NjAx_ed6c52bb-1f58-4149-af56-23dcbef7ac6b">22.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c857df9e79e4435ab0c5961811291c6_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMTEtMy0xLTEtMTI5NjAx_25735b6a-e93b-43ae-b76a-28d80c267db7">25.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77fc9042b9d744ba9d2f6c315981cd86_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:MarketableSecuritiesGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMTMtMS0xLTEtMTI5NjAx_568e5eda-0bf0-42d8-8838-2017275797cb">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c857df9e79e4435ab0c5961811291c6_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:MarketableSecuritiesGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMTMtMy0xLTEtMTI5NjAx_b9dc5d0b-231b-4cbd-b841-afb6c20da655">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from continuing operations before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMTctMS0xLTEtMTI5NjAx_d319af4d-05a6-4995-ae53-8084d337cfb5">141.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMTctMy0xLTEtMTI5NjAx_49394571-52b7-45ca-95fe-c973f581e7d1">167.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMzI3Mw_fbb851cf-7425-4607-8902-52268f43f065" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional detail regarding the revenues of our operating segments by service line follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f9a417ef1c843ab8b66fc1f0fe8a378_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfMy0xLTEtMS0xMjk2MDE_a5bef492-bc1b-4200-92a0-b9b779323b29">1,036.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee63741659464a8288af029c2e936705_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfMy0zLTEtMS0xMjk2MDE_236e5b35-a709-441b-940b-88dfc16abeb8">942.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77101558c6ed4f6da49ce1c65da87750_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfNC0xLTEtMS0xMjk2MDE_6df06e70-00ae-4f67-946b-b7ab32876754">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee418860b1b04eaabf4f28548bafff1c_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfNC0zLTEtMS0xMjk2MDE_44f39188-0b9b-4b7c-86b0-bc82feecd5b4">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inpatient rehabilitation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfNS0xLTEtMS0xMjk2MDE_66bb1412-1757-4502-92e3-35af6a070f36">1,059.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfNS0zLTEtMS0xMjk2MDE_591d2c42-4242-4f3a-a910-feeaf86eb625">959.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health and hospice:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06506ef5bc914c559c598b5f9589d0b3_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfNy0xLTEtMS0xMjk2MDE_f7e71d05-03f0-498e-9147-dea7ed3d9284">224.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib65ddfd24dd24997b9a0d223f2e38f80_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfNy0zLTEtMS0xMjk2MDE_1ea3890e-d82f-4b45-9bbc-dc6dbbf305fe">219.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4931e9bee9c14ae88ae967c8efd7c1da_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfOC0xLTEtMS0xMjk2MDE_9da34d46-aac7-4f12-b654-eebfdc9c2e57">49.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00989e00d19949b0b76add02ac72e8dc_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfOC0zLTEtMS0xMjk2MDE_19059f91-d445-49eb-851f-af451b194b1a">50.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total home health and hospice</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfOS0xLTEtMS0xMjk2MDE_5288a572-1382-408e-a3b3-90fcf15336ff">274.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfOS0zLTEtMS0xMjk2MDE_c3ff216d-ea7e-4ab5-8c9f-f52d4aa6c4ed">270.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net operating revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfMTAtMS0xLTEtMTI5NjAx_37b5ac2f-4fde-4677-a7df-b8f9d7088712">1,333.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfMTAtMy0xLTEtMTI5NjAx_1abb0d58-4b15-4423-a9ff-23cade1c5d0f">1,230.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_100"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) relates to Encompass Health Corporation and its subsidiaries and should be read in conjunction with our condensed consolidated financial statements included under Part&#160;I, Item&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report. In addition, the following MD&amp;A should be read in conjunction with our audited consolidated financial statements for the year ended December&#160;31, 2021, Part II, Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part&#160;I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed on February&#160;25, 2022 (collectively, the &#8220;2021 Form 10&#8209;K&#8221;).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This MD&amp;A is designed to provide the reader with information that will assist in understanding our condensed consolidated financial statements, the changes in certain key items in those financial statements from period to period, and the primary factors that accounted for those changes, as well as how certain accounting principles affect our condensed consolidated financial statements. See &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; on page ii of this report for a description of important factors that could cause actual results to differ from expected results. See also Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report and to the 2021 Form 10&#8209;K.</span></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_103"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Overview</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Business</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a national leader in integrated healthcare services, offering both facility-based and home-based patient care through our network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. As of March&#160;31, 2022, our national footprint includes 42 states and Puerto Rico. As discussed in this Item, &#8220;Segment Results of Operations,&#8221; we currently manage our operations in two operating segments which are also our reportable segments: (1)&#160;inpatient rehabilitation and (2)&#160;home health and hospice. For additional information about our business, see Item&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the 2021 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2020, we announced a formal process to explore strategic alternatives for our home health and hospice business. As a result of this process, we expect to spin off our home health and hospice business to form an independent, publicly traded company on July 1, 2022, subject to customary conditions, including the effectiveness of a Form&#160;10 registration statement, regulatory approvals and receipt of a favorable IRS private letter ruling. On January 19, 2022, we announced the home health and hospice business would be rebranded and operate under the name Enhabit Home Health &amp; Hospice. The rebranding of agency locations began in mid-April 2022 and is expected to be largely completed by the effective date of the spin off.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The onset of the COVID-19 Pandemic (the &#8220;pandemic&#8221;) in the United States resulted in significant changes to our operating environment. For discussion of the financial and operational impacts we have experienced as a result of the pandemic, see Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;Results of Operations&#8221; and &#8220;Segment Results of Operations&#8221; of the 2021 Form 10-K.  For discussion of the financial and operational impacts we are experiencing in 2022 as a result of the pandemic, see &#8220;Key Challenges&#8221; below and the &#8220;Results of Operations&#8221; and &#8220;Segment Results of Operations&#8221; sections of this Item.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inpatient Rehabilitation</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the nation&#8217;s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals. We provide specialized rehabilitative treatment on predominantly an inpatient basis. We operate hospitals in 35 states and Puerto Rico, with concentrations in the eastern half of the United States and Texas. As of March&#160;31, 2022, we operate 147 inpatient rehabilitation hospitals and manage two inpatient rehabilitation units through management contracts. Our inpatient rehabilitation segment represents approximately 79% of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March&#160;31, 2022. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health and Hospice</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our home health business is the nation&#8217;s fourth largest provider of Medicare-certified skilled home health services in terms of revenues. Our home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. Our hospice business is the nation&#8217;s twelfth largest provider of Medicare-certified hospice services in terms of revenues. Hospice care focuses on the quality of life for patients who are experiencing an advanced, life limiting illness while treating the person and symptoms of the disease, rather than the disease itself. As of March&#160;31, 2022, we provide home health services in 252 locations and hospice services in 99 locations across 34 states, with concentrations in the </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">southern half of the United States. Our home health and hospice segment represents approximately 21% of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March&#160;31, 2022.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Overview</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased 8.4% over the same period of 2021 due primarily to volume and pricing growth in our inpatient rehabilitation segment. See &#8220;Results of Operations&#8221; and the &#8220;Segment Results of Operations&#8221; sections of this Item for additional volume and pricing information. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continued our development and expansion efforts in 2022. In our inpatient rehabilitation segment we:</span></div><div style="margin-bottom:7pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 40-bed inpatient rehabilitation hospital in Shiloh, Illinois with our joint venture partner BJC HealthCare in February 2022;</span></div><div style="margin-bottom:7pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 40-bed inpatient rehabilitation hospital in St. Augustine, Florida in March 2022;</span></div><div style="margin-bottom:7pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 60-bed inpatient rehabilitation hospital in Libertyville, Illinois in March 2022;</span></div><div style="margin-bottom:7pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued our capacity expansions by adding 29 new beds to existing hospitals; and</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announced or continued the development of the following hospitals:</span></div><div style="margin-bottom:3pt;margin-top:5pt;padding-left:11.25pt;padding-right:11.25pt;text-align:center;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.877%"><tr><td style="width:1.0%"></td><td style="width:52.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.509%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of New Beds  </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Expected Opening</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lakeland, Florida</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cape Coral, Florida</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Jacksonville, Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Moline, Illinois</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Naples, Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Grand Forks, North Dakota</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Eau Claire, Wisconsin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">36</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Owasso, Oklahoma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clermont, Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Knoxville, Tennessee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">73</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Bowie, Maryland</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prosper, Texas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Columbus, Georgia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Strongville, Ohio</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Fitchburg, Wisconsin</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Louisville, Kentucky</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Kissimmee, Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Fort Mill, South Carolina</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">39</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amarillo, Texas</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Atlanta, Georgia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lake Worth, Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Fort Myers, Florida</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">60</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Palm Beach Gardens, Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td></tr></table></div><div style="margin-bottom:10pt;margin-top:2pt;padding-left:22.5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected joint venture</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also continued our expansion efforts in our home health and hospice segment. In January 2022, we acquired one home health location and one hospice location in Boise, Idaho and began accepting patients at our new hospice locations in Williamsburg, Virginia (January 2022) and Marble Falls, Texas (March 2022).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continued our shareholder distributions during the three months ended March&#160;31, 2022 by paying a quarterly cash dividend of $0.28 per share on our common stock in January and April. For additional information see the &#8220;Liquidity and Capital Resources&#8221; section of this Item.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Outlook</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the current impacts from the pandemic, we remain optimistic regarding the intermediate and long-term prospects for our business. Demographic trends, such as population aging, should continue to increase long-term demand for the services we provide. While we treat patients of all ages, most of our patients are 65 and older, and the number of Medicare enrollees is expected to grow approximately 3% per year for the foreseeable future, reaching approximately 73 million people over the age of 65 by 2030. Even more specifically, the average age of our patients is approximately 76, and the population group ranging in ages from 75 to 79 is expected to grow at approximately 5% per year through 2026. We believe the demand for the services we provide will continue to increase as the U.S. population ages. We believe these factors align with our strengths in, and focus on, post-acute services. In addition, we believe we can address the demand for facility-based and home-based post-acute care services in markets where we currently do not have a presence by constructing or acquiring new hospitals and by acquiring or opening home health and hospice agencies in those fragmented industries.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leading provider of post-acute healthcare services, offering both facility-based and home-based patient care through our network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. We are committed to delivering high-quality, cost-effective, integrated patient care. As the nation&#8217;s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals, we believe we differentiate ourselves from our competitors based on the quality of our clinical outcomes, our cost-effectiveness, our financial strength, and our extensive application of technology. As the fourth largest provider of Medicare-certified skilled home health services in terms of revenues, we believe we differentiate ourselves from our competitors by the application of a highly integrated technology platform, our ability to manage a variety of care pathways, and a proven track record of consummating and integrating acquisitions.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the healthcare industry is currently engaged in addressing the healthcare crisis caused by the pandemic, the industry also faces the prospect of ongoing efforts to transform the healthcare system to coordinated care delivery and payment models. The nature, timing and extent of that transformation remains uncertain, as the development and implementation of new care delivery and payment systems will require significant time and resources. Our short-term goal is to serve our communities and provide the best care possible during the pandemic. Our long-term goal is to position the Company in a prudent manner to be responsive to industry shifts. We have invested in our core business and created an infrastructure that enables us to provide high-quality care on a cost-effective basis. We have been disciplined in creating a capital structure that is flexible with no significant debt maturities prior to 2024. We continue to have a strong, well-capitalized balance sheet, including a substantial portfolio of owned real estate and significant availability under our revolving credit facility. For these and other reasons, we believe we will be able to adapt to changes in reimbursement, sustain our business model, and grow through acquisition and consolidation opportunities as they arise. See also Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Competitive Strengths&#8221; and &#8220;Strategy and 2022 Strategic Priorities&#8221; of the 2021 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Key Challenges</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare is a highly regulated industry facing many well-publicized regulatory and reimbursement challenges. The Medicare reimbursement systems for both inpatient rehabilitation and home health have recently undergone significant changes. The future of many aspects of healthcare regulation remains uncertain. Successful healthcare providers are those able to adapt to changes in the regulatory and operating environments, build strategic relationships across the healthcare continuum, and consistently provide high-quality, cost-effective care. We believe we have the necessary capabilities&#8212;change agility, strategic relationships, quality of patient outcomes, cost effectiveness, and ability to capitalize on growth opportunities&#8212;to adapt to and succeed in a dynamic, highly regulated industry, and we have a proven track record of doing so. For a detailed discussion of the challenges we face, see Item&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Executive Overview&#8212;Key Challenges&#8221; of the 2021 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to execute our business plan, the following are some of the challenges we face.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Operating in a Highly Regulated Industry</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. More specifically, because Medicare comprises a significant portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, failure to comply with the laws and regulations governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us. These rules and regulations have affected, or could in the future affect, our business activities by having an impact on the reimbursement we receive for services provided or the costs of compliance, mandating new documentation standards, requiring additional licensure or certification, regulating our relationships with physicians and other referral sources, regulating the use of our properties, and limiting our ability to enter new markets or add new capacity to existing hospitals and agencies. Ensuring continuous compliance with extensive </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">laws and regulations is an operating requirement for all healthcare providers. See Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Regulation,&#8221; Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Executive Overview&#8212;Key Challenges,&#8221; of the 2021 Form 10&#8209;K for detailed discussions of the most important regulations we face and our programs intended to ensure we comply with those regulations.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Changes to Our Operating Environment Resulting from the pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In response to the public health emergency associated with the pandemic, Congress and the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) adopted several statutory and regulatory measures intended to provide relief to healthcare providers in order to ensure patients would continue to have adequate access to care. On March 27, 2020, former President Trump signed into law the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the &#8220;CARES Act&#8221;), which suspended sequestration, an automatic 2% reduction of Medicare program payments for all healthcare providers, for the period of May 1 through December&#160;31, 2020. The sequestration suspension was extended a number of times. Sequestration resumed as of April 1, 2022, but is only a 1% payment reduction through June 30, 2022. Thereafter, the full 2% Medicare payment reduction will resume. During the three months ended March 31, 2022, the sequestration suspension provided additional revenues in our inpatient rehabilitation segment and home health and hospice segment of approximately $16 million and $5 million, respectively. The CARES Act and CMS regulatory actions include a number of other provisions affecting our reimbursement and operations in both segments. These provisions are discussed in Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Sources of Revenue,&#8221; Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Results of Operations&#8221; of the 2021 Form 10-K.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Changes to Our Operating Environment Resulting from Federal Regulatory and Legislative Actions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On March&#160;31, 2022, CMS released its notice of proposed rulemaking for fiscal year 2023 for inpatient rehabilitation facilities under the inpatient rehabilitation facility prospective payment system (the &#8220;2023 Proposed IRF Rule&#8221;). The 2023 Proposed IRF Rule would implement a net 2.8% market basket increase (market basket update of 3.2% reduced by a productivity adjustment of 0.4%) effective for discharges between October 1, 2022 and September&#160;30, 2023. The 2023 Proposed IRF Rule also includes changes that impact our hospital-by-hospital base rate for Medicare reimbursement. Such changes include, but are not limited to, revisions to the wage index and labor-related share values, updates to outlier payments and updates to the case-mix group relative weights and average lengths of stay values. Based on our analysis that utilizes, among other things, the acuity of our patients annualized over a twelve-month period ended February 28, 2022, our experience with outlier payments over this same time frame, and other factors, we believe the 2023 Proposed IRF Rule will result in a net increase to our Medicare payment rates of approximately 2.9% effective October 1, 2022.</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Proposed IRF Rule also included a request for comment on a potential change in inpatient rehabilitation facility (&#8220;IRF&#8221;) reimbursement that could be included in future rulemaking. Based on a recent United States Department of Health and Human Services Office of Inspector General (&#8220;HHS-OIG&#8221;) report, CMS is considering whether to modify the IRF &#8220;transfer&#8221; payment policy to reduce reimbursement for early discharges to home health, similar to how early home health discharges are paid for under the Acute Care Prospective Payment System. HHS-OIG estimated that its recommended change to the policy could reduce total IRF industry reimbursements by approximately 6% based on 2017 and 2018 data.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Maintaining Strong Volume Growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As described in our 2021 Form 10&#8209;K, we believe a number of conditions related to the pandemic negatively impacted volumes in 2021. While we continue to see our volumes recover, as discussed in the &#8220;Results of Operations&#8221; and &#8220;Segment Results of Operations&#8221; sections of this Item, a current or future resurgence of COVID-19 infections could cause disruptions to our volume growth in both segments.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Recruiting and Retaining High-Quality Personnel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the 2021 Form 10&#8209;K for a discussion of competition for staffing, shortages of qualified personnel, and other factors that may increase our labor costs and constrain our ability to take new patients. Additionally, our operations have been affected and may in the future be affected by staffing shortages where employees must self-quarantine due to exposure to COVID-19, where employees are unavailable due to a lack of childcare or care for elderly family, or due to competition within the local market. These factors have resulted in increased labor costs and increased use of contract labor as discussed in the &#8220;Results of Operations&#8221; and &#8220;Segment Results of Operations&#8221; sections of this Item.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain confident in the prospects of our business based on the increasing demands for the services we provide to an aging population. This confidence is further supported by our strong financial foundation and the substantial investments we have made in our businesses. We have a proven track record of working through difficult situations, and we believe in our ability to overcome current and future challenges.</span></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_106"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payor Mix</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derived consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the following payor sources:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding our payors by segment, see the &#8220;Segment Results of Operations&#8221; section of this Item. For additional information regarding our payors, see the &#8220;Sources of Revenues&#8221; section of Item&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the 2021 Form 10&#8209;K.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Results</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated results of operations were as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Percentage Change)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income tax expense </span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Encompass Health</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses as a % of Net Operating Revenues</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the discussion that follows, we use &#8220;same-store&#8221; comparisons to explain the changes in certain performance metrics and line items within our financial statements. We calculate same-store comparisons based on hospitals and home health and hospice locations open throughout both the full current periods and prior periods presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on our results of operations. </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Operating Revenues</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased during the three months ended March 31, 2022 compared to the same period of 2021 primarily from volume and pricing growth in our inpatient rehabilitation segment. See additional discussion in the &#8220;Segment Results of Operations&#8221; section of this Item.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Salaries and Benefits</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased during the three months ended March 31, 2022 compared to the same period of 2021 primarily due to salary increases for our employees and increased contract labor to meet higher patient volumes. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a percent of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased during the three months ended March 31, 2022 compared to the same period of 2021 primarily due to increases in contract labor and clinician compensation, including sign-on and shift bonuses, to meet higher patient volumes. See additional discussion in the &#8220;Segment Results of Operations&#8221; section of this Item.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased in terms of dollars and as a percent of revenue during the three months ended March&#160;31, 2022 compared to the same period of 2021 primarily due to increased provider taxes and higher costs associated with travel, recruiting, and legal services. See additional discussion in the &#8220;Segment Results of Operations&#8221; section of this Item.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General and Administrative Expenses</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased in terms of dollars and as a percent of revenue during the three months ended March&#160;31, 2022 compared to the same period of 2021 primarily due to higher costs associated with the spin off of our home health and hospice business. Costs associated with the strategic alternatives review for the home health and hospice business were $9.6 million during the three months ended March&#160;31, 2022 compared to $0.9 million in the same period of 2021. See the &#8220;Executive Overview&#8221; section of this Item for additional information on the strategic alternatives review.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Depreciation and Amortization</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased during the three months ended March&#160;31, 2022 compared to the same period of 2021 due to our capital investments. We expect </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to increase going forward as a result of our recent and ongoing capital investments.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income from Continuing Operations Before Income Tax Expense</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pre-tax income from continuing operations decreased during the three months ended March&#160;31, 2022 compared to the same period of 2021 primarily due to the increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as discussed above.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Provision for Income Tax Expense</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreased during the three months ended March&#160;31, 2022 compared to the same period of 2021 primarily due to lower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income from continuing operations before income tax expense.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently estimate our cash payments for income taxes to be approximately $80 million to $100 million, net of refunds, for 2022. These payments are expected to primarily result from federal and state income tax expenses based on estimates of taxable income for 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain jurisdictions, we do not expect to generate sufficient income to use all of the available state net operating losses and other credits prior to their expiration. This determination is based on our evaluation of all available evidence in these jurisdictions including results of operations during the preceding three years, our forecast of future earnings, and prudent tax planning strategies. It is possible we may be required to increase or decrease our valuation allowance at some future time if our forecast of future earnings varies from actual results on a consolidated basis or in the applicable tax jurisdiction, if the timing of future tax deductions differs from our expectations, or pursuant to changes in state tax laws and rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report and Note&#160;16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2021 Form 10&#8209;K.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Income Attributable to Noncontrolling Interests</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the three months ended March&#160;31, 2022 compared to the same period of 2021 resulted from the ramp up of new joint venture de novo locations and decreased profitability from certain existing joint venture hospitals.</span></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_109"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Results of Operations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal financial reporting and management structure is focused on the major types of services provided by Encompass Health. We manage our operations using two operating segments which are also our reportable segments: (1)&#160;inpatient rehabilitation and (2)&#160;home health and hospice. For additional information regarding our business segments, including a detailed description of the services we provide, financial data for each segment, and a reconciliation of total segment Adjusted EBITDA to income from continuing operations before income tax expense, see Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inpatient Rehabilitation</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inpatient rehabilitation segment derived its</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the following payor sources:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding our inpatient rehabilitation segment&#8217;s operating results is as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Percentage Change)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient and other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient rehabilitation segment revenues</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Adjusted EBITDA</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Actual Amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discharges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,771</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,187</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net patient revenue per discharge</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,409</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,969</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient visits</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,229</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,194</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average length of stay (days)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy %</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.1&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.4&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"># of licensed beds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full-time equivalents*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,313</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,383</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees per occupied bed</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Full-time equivalents included in the above table represent our employees who participate in or support the operations of our hospitals and exclude an estimate of full-time equivalents related to contract labor.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively manage the productive portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> utilizing certain metrics, including employees per occupied bed, or &#8220;EPOB.&#8221; This metric is determined by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by our occupancy percentage.</span></div><div style="margin-bottom:10pt;padding-left:22.5pt;padding-right:22.5pt;text-align:center;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses as a % of Net Operating Revenues</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Operating Revenues</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inpatient revenue increased during the three months ended March 31, 2022 compared to the same period of 2021 primarily due to increased volumes and favorable pricing. Discharge growth included a 3.8% increase in same-store discharges. Discharge growth from new stores during the three months ended March 31, 2022 compared to the same period of 2021 resulted from our joint ventures in San Angelo, Texas (March 2021), Henry County, Georgia (October 2021), and Shiloh, Illinois (February 2022), as well as wholly owned hospitals in North Tampa, Florida (April 2021), Cumming, Georgia (June 2021), Waco, Texas (August 2021), Shreveport, Louisiana (August 2021), Greenville, South Carolina (August 2021), and Pensacola, Florida (September 2021). Growth in net patient revenue per discharge during the three months ended March 31, 2022 compared to the same period of 2021 primarily resulted from an increase in reimbursement rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in outpatient and other revenue during the three months ended March 31, 2022 included an increase of $5.8 million in provider tax revenues (offset by $2.7 million of provider tax expenses included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjusted EBITDA</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Adjusted EBITDA during the three months ended March 31, 2022 compared to the same period of 2021 primarily resulted from the increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a percent of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased during the three months ended March 31, 2022 compared to the same period of 2021 primarily due to increases in contract labor and clinician compensation, including sign-on and shift bonuses, to meet higher patient volumes (approximately $63 million during the three months ended March 31, 2022 compared to approximately $21 million in the same period of 2021).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health and Hospice</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our home health and hospice segment derived its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the following payor sources:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding our home health and hospice segment&#8217;s operating results is as follows:</span></div><div style="margin-bottom:2pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Percentage Change)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home health and hospice segment revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services (excluding depreciation and amortization)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Support and overhead costs</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Adjusted EBITDA</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Actual Amounts)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home health:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Episodic admissions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recertifications</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Episodic recertifications</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Episodes</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total starts of care</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per episode</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visits per episode</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total visits</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost per visit</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospice:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Admissions</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient days</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per day</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:22.5pt;text-indent:-9pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:22.5pt;padding-right:22.5pt;text-align:center;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses as a % of Net Operating Revenues</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services (excluding depreciation and amortization)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Support and overhead costs</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Operating Revenues</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Home health revenue growth during the three months ended March 31, 2022 compared to the same period of 2021 was driven by increased volumes and pricing. Total starts of care increased during the three months ended March 31, 2022 compared to the same period of 2021 primarily due to the acquisition of Frontier on June 1, 2021 and increased non-episodic admissions and recertifications as a result of our national contract with United Healthcare. Revenue per episode growth during the three months ended March 31, 2022 compared to the same period of 2021 was driven primarily by an increase in Medicare reimbursement rates.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjusted EBITDA</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Adjusted EBITDA during the three months ended March 31, 2022 compared to the same period of 2021 resulted from higher </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as a percent of revenues related to higher labor costs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased as a percent of revenues for the three months ended March 31, 2022 compared to the same period of 2021 primarily due to higher cost per visit resulting from higher labor costs.</span></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_112"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are cash on hand, cash flows from operations, and borrowings under our revolving credit facility.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objectives of our capital structure strategy are to ensure we maintain adequate liquidity and flexibility. Pursuing and achieving those objectives allow us to support the execution of our operating and strategic plans and weather temporary disruptions in the capital markets and general business environment. Maintaining adequate liquidity is a function of our unrestricted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our available borrowing capacity. Maintaining flexibility in our capital structure is a function of, among other things, the amount of debt maturities in any given year, the options for debt prepayments without onerous penalties, and limiting restrictive terms and maintenance covenants in our debt agreements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with these objectives, in March 2022, we redeemed the remaining $100&#160;million in outstanding principal amount of the 5.125% Senior Notes due 2023 (the &#8220;2023 Notes&#8221;) using capacity under our revolving credit facility. Pursuant to the terms of the 2023 Notes, this optional redemption was made at a price of par. As a result of this redemption, we recorded an aggregate $0.3&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the three months ended March&#160;31, 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been disciplined in creating a capital structure that is flexible with no significant debt maturities prior to 2024. We continue to have a strong, well-capitalized balance sheet, including a substantial portfolio of owned real estate, and we have significant availability under our revolving credit facility. We continue to generate strong cash flows from operations and we have significant flexibility with how we choose to invest our cash and return capital to shareholders.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report, and Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements accompanying the 2021 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current Liquidity</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had $94.2 million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;This amount excludes $61.0&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $80.4 million of restricted marketable securities ($4.8 million included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $75.6 million included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our condensed consolidated balance sheet). Our restricted assets pertain primarily to obligations associated with our captive insurance company, as well as obligations we have under agreements with joint venture partners. See Note&#160;4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Marketable Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2021 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as of March&#160;31, 2022, we had approximately $658 m</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">illion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> available to us under our revolving credit facility. Our credit agreement governs the substantial majority of our senior secured borrowing capacity and contains a leverage ratio and an interest coverage ratio as financial covenants. Our leverage ratio is defined in our credit agreement as the ratio of consolidated total debt (less up to $300 million of cash on hand) to Adjusted EBITDA for the trailing four quarters. In calculating the leverage ratio under our credit agreement, we are permitted to use pro forma Adjusted EBITDA, the calculation of which includes historical income statement items and pro forma adjustments resulting from (1) the dispositions and repayments or incurrence of debt and (2) the investments, acquisitions, mergers, amalgamations, consolidations and operational changes from acquisitions to the extent such items or effects are not yet reflected in our trailing </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">four-quarter financial statements. Our interest coverage ratio is defined in our credit agreement as the ratio of Adjusted EBITDA to consolidated interest expense, excluding the amortization of financing fees, for the trailing four quarters. As of March&#160;31, 2022, the maximum leverage ratio requirement per our credit agreement was 4.25x and the minimum interest coverage ratio requirement was 3.0x, and we were in compliance with these covenants. Based on Adjusted EBITDA for the trailing four quarters and the interest rate in effect under our credit agreement during the three-month period ended March&#160;31, 2022, if we had drawn on the first day and maintained the maximum amount of outstanding draws under our revolving credit facility for that entire period, we would still be in compliance with the maximum leverage ratio and minimum interest coverage ratio requirements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2021, we announced the commencement of a consent solicitation of holders of our 5.75% Senior Notes due 2025, 4.50% Senior Notes due 2028, 4.75% Senior Notes due 2030, and 4.625% Senior Notes due 2031 (collectively the &#8220;Notes&#8221;) for the adoption of certain amendments to an indenture (the &#8220;Base Indenture&#8221;) dated as of December&#160;1,&#160;2009, as supplemented by each Notes&#8217; respective supplemental indenture (together with the Base Indenture, the &#8220;Indenture&#8221;), which will provide us with greater flexibility in effecting the spin off discussed in the &#8220;Executive Overview&#8221; section of this Item. Each Indenture contains restrictive covenants that, among other things, limit our ability and the ability of certain of our subsidiaries to make certain asset dispositions, investments, and distributions to holders of our capital stock. The amendments to the Indentures permit us, subject to the leverage ratio condition set forth below, to distribute to our equity holders in one or more transactions (a &#8220;Distribution&#8221;) some or all of the common stock of a subsidiary that holds substantially all of the assets of our home health and hospice business. We may make any such distribution so long as the Leverage Ratio (as defined in each Indenture) is no more than 3.5 to 1.0 on a pro forma basis after giving effect thereto. The amendments also reduce the capacity under our restricted payments builder basket under each existing Indenture by $200&#160;million and amends the definition of &#8220;Consolidated Net Income&#8221; to allow us to exclude from Consolidated Net Income (a component of the Leverage Ratio) any fees, expenses or charges related to any Distribution and the solicitation of consents from the holders of the Notes. In December 2021 and January 2022, we received the requisite consents for the adoption of these amendments. Under the terms of the amendments, we agreed to pay the holders of the Notes a total of $40.5 million, excluding fees. We paid $20 million of this amount in January 2022. The remaining payment is contingent upon the execution of a Distribution and will be paid at such time.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not face near-term refinancing risk, as the amounts outstanding under our credit agreement do not mature </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">until 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and our bonds all mature in 2025 and beyond. See the &#8220;Contractual Obligations&#8221; section below for information related to our contractual obligations as of March&#160;31, 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of risks and uncertainties facing us see Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under Part II, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report and Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the 2021 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sources and Uses of Cash </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the cash flows provided by or used in operating, investing, and financing activities (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.665%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March&#160;31, 2022 compared to the same period of 2021 primarily resulted from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">improved collection of accounts receivable</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">crease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in investing activities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the three months ended March&#160;31, 2022 compared to the same period of 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily resulted from the increase in cash used for capital expenditures.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The decrease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in financing activities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three months ended March&#160;31, 2022 compa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">red to the same period of 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily resulted from higher contributions received from and lower distributions paid to noncontrolling interests of consolidated affiliates offset by debt amendment costs in 2022. For additional information on </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the debt amendment costs, see Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Obligations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated contractual obligations as of March&#160;31, 2022 are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 1 through December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 and<br/> thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, excluding revolving credit facility and finance lease obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,578.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,562.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,711.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,481.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Included in long-term debt are amounts owed on our bonds payable and other notes payable. These borrowings are further explained in Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, accompanying the condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report, and Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements accompanying the 2021 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Interest on our fixed rate debt is presented using the stated interest rate. Interest expense on our variable rate debt is estimated using the rate in effect as of March&#160;31, 2022. Interest pertaining to our credit agreement and bonds is included to their respective ultimate maturity dates. Interest related to finance lease obligations is excluded from this line. Amounts exclude amortization of debt discounts, amortization of loan fees, or fees for lines of credit that would be included in interest expense in our condensed consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Amounts include interest portion of future minimum finance lease payments.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our inpatient rehabilitation segment leases approximately 10% of its hospitals as well as other property and equipment under operating leases in the normal course of business. Our home health and hospice segment leases relatively small office spaces in the localities it serves, space for its corporate office, and other equipment under operating leases in the normal course of business. Amounts include interest portion of future minimum operating lease payments. For more information, see Note&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements accompanying the 2021 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding on Encompass Health and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable without penalty. Our purchase obligations primarily relate to software licensing and support and medical equipment. Purchase obligations are not recognized in our condensed consolidated balance sheet.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital expenditures include costs associated with our hospital refresh program, de novo projects, capacity expansions, technology initiatives, and building and equipment upgrades and purchases. During the three months ended March&#160;31, 2022, we made capital expenditures of approximately $120 million for property and equipment, capitalized software, and other intangible assets. During 2022, we expect to spend approximately $570 million to $660 million for capital expenditures using cash on hand and borrowings under our revolving credit facility. Approximately $200 million to $250 million of this budgeted amount is considered nondiscretionary expenditures, which we may refer to in other filings as &#8220;maintenance&#8221; expenditures. In addition, we expect to spend approximately $50 million to $100 million on home health and hospice acquisitions during 2022. Actual amounts spent will be dependent upon the timing of development projects and acquisition opportunities for our home health and hospice business.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Authorizations for Returning Capital to Stakeholders</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021 and February 2022, our board of directors declared cash dividends of $0.28 per share that were paid in January 2022 and April 2022, respectively. We expect quarterly dividends to be paid in January, April, July, and October. However, the actual declaration of any future cash dividends, and the setting of record and payment dates as well as the per share amounts, will be at the discretion of our board of directors after consideration of various factors, including our capital position and alternative uses of funds. Cash dividends are expected to be funded using cash flows from operations, cash on hand, and availability under our revolving credit facility.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 24, 2018, our board approved resetting the aggregate common stock repurchase authorization to $250 million. As of March&#160;31, 2022, approximately $198 million remained under this authorization. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. Subject to certain terms and conditions, including a maximum price per share and compliance with federal and state securities and other laws, the repurchases may be made from time to time in open market transactions, privately negotiated transactions, or other transactions, including trades under a plan established in accordance with Rule&#160;10b5-1 under the Securities Exchange Act of 1934, as amended. For additional information, see Part II, Item 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of this report</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental Guarantor Financial Information</span></div><div style="margin-bottom:10pt;padding-left:2.25pt;padding-right:6.75pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness under our credit agreement and the Notes are guaranteed by certain consolidated subsidiaries. These guarantees are full and unconditional and joint and several, subject to certain customary conditions for release. The Notes are guaranteed on a senior, unsecured basis by all of our existing and future subsidiaries that guarantee borrowings under our credit agreement and other capital markets debt. The other subsidiaries of Encompass Health do not guarantee the Notes (such subsidiaries are referred to as the &#8220;non-guarantor subsidiaries&#8221;).</span></div><div style="margin-bottom:10pt;padding-left:2.25pt;padding-right:6.75pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of our credit agreement allow us to declare and pay cash dividends on our common stock so long as: (1) we are not in default under our credit agreement, and (2) either (a) our senior secured leverage ratio (as defined in our credit agreement) remains less than or equal to 2x and our leverage ratio (as defined in our credit agreement) remains less than or equal to 4.50x or (b) there is capacity under the Available Amount as defined in the credit agreement. The terms of our Notes indenture allow us to declare and pay cash dividends on our common stock so long as (1) we are not in default, (2) the consolidated coverage ratio (as defined in the indenture) exceeds 2x or we are otherwise allowed under the indenture to incur debt, and (3) we have capacity under the indenture&#8217;s restricted payments covenant to declare and pay dividends. See Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report, and Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2021 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt;padding-left:2.25pt;padding-right:4.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information is presented below for Encompass Health, the parent company, and the subsidiary guarantors on a combined basis after elimination of intercompany transactions and balances among Encompass Health and the subsidiary guarantors and does not include investments in and equity in the earnings of non-guarantor subsidiaries. Amounts for prior periods have been revised to reflect the status of guarantors and non-guarantors as of March&#160;31, 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intercompany revenues generated from non-guarantor subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intercompany expenses incurred in transactions with non-guarantor subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of<br/>&#160;March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,942.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,896.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,081.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intercompany receivable due from non-guarantor subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,809.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,778.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,173.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,194.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjusted EBITDA</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes Adjusted EBITDA as defined in our credit agreement is a measure of our ability to service our debt and our ability to make capital expenditures. We reconcile Adjusted EBITDA to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use Adjusted EBITDA on a consolidated basis as a liquidity measure. We believe this financial measure on a consolidated basis is important in analyzing our liquidity because it is the key component of certain material covenants contained within our credit agreement, which is discussed in more detail in Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2021 Form 10&#8209;K. These covenants are material terms of the credit agreement. Noncompliance with these financial covenants under our credit agreement&#8212;our interest coverage ratio and our leverage ratio&#8212;could result in our lenders requiring us to immediately repay all amounts borrowed. If we anticipated a potential covenant violation, we would seek relief from our lenders, which would have some cost to us, and such relief might be on terms less favorable to us than those in our existing credit agreement. In addition, if we cannot satisfy these financial covenants, we would be prohibited under our credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying common stock dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to our assessment of our liquidity.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general terms, the credit agreement definition of Adjusted EBITDA, therein referred to as &#8220;Adjusted Consolidated EBITDA,&#8221; allows us to add back to consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> interest expense, income taxes, and depreciation and amortization and then add back to consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (1) all unusual or nonrecurring items reducing consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (of which only up to $10 million in a year may be cash expenditures), (2) any losses from discontinued operations, (3)&#160;non-ordinary course fees, costs and expenses incurred with respect to any litigation or settlement, (4)&#160;share-based compensation expense, (5) costs and expenses associated with changes in the fair value of marketable securities, (6) costs and expenses associated with the issuance or prepayment debt and acquisitions, and (7) any restructuring charges not in excess of 20% of Adjusted Consolidated EBITDA. We also subtract from consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> all unusual or nonrecurring items to the extent they increase consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the credit agreement, the Adjusted EBITDA calculation does not require us to deduct net income attributable to noncontrolling interests or&#160;gains on fair value adjustments of hedging and equity instruments, disposal of assets, and development activities. It also does not allow us to add back losses on fair value adjustments of hedging instruments or&#160;unusual or nonrecurring cash expenditures in excess of $10 million. These items and amounts, in addition to the items falling within the credit agreement&#8217;s &#8220;unusual or nonrecurring&#8221; classification, may occur in future periods, but can vary significantly from period to period and may not directly relate to, or be indicative of, our ongoing liquidity or operating performance. Accordingly, the Adjusted EBITDA calculation presented here includes adjustments for them.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States of America, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or cash flows from operating, investing, or financing activities. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2021 Form 10&#8209;K.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Adjusted EBITDA was as follows (in millions):</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Net Income to Adjusted EBITDA</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (gain) on disposal or impairment of assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs associated with the strategic alternatives review</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests in continuing operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt-related items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions from nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in assets and liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs associated with the strategic alternatives review</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information see the &#8220;Results of Operations&#8221; and &#8220;Segment Results of Operations&#8221; sections of this Item.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding recent accounting pronouncements, see Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included under Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_115"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary exposure to market risk is to changes in interest rates on our variable rate long-term debt. We use sensitivity analysis models to evaluate the impact of interest rate changes on our variable rate debt. As of March&#160;31, 2022, our primary variable rate debt outstanding related to $305.0 million in advances under our revolving credit facility and $235.3 million under our term loan facilities. Assuming outstanding balances were to remain the same, a 1% increase in interest rates would result in an incremental negative cash flow of approximately $4.9 million over the next 12 months, while a 1% decrease in interest rates would result in an incremental positive cash flow of approximately $1.8 million over the next 12 months.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the condensed consolidated financial statements included in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report, for additional information regarding our long-term debt. </span></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_118"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Controls and Procedures</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, an evaluation was carried out by our management, including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended. Based on our evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our Internal Control over Financial Reporting during the quarter ended March&#160;31, 2022 that have a material effect on our Internal Control over Financial Reporting.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_121"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_124"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Legal Proceedings </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide services in the highly regulated healthcare industry. In the ordinary course of our business, we are a party to various legal actions, proceedings, and claims as well as regulatory and other governmental audits and investigations. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These matters could potentially subject us to sanctions, damages, recoupments, fines, and other penalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these matters have been material to us in the past, and others in the future </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may, either individually or in the aggregate, be material and adverse to our business, financial position, results of operations, and liquidity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the False Claims Act (the &#8220;FCA&#8221;) allows private citizens, called &#8220;relators,&#8221; to institute civil proceedings on behalf of the United States alleging violations of the FCA. These lawsuits, also known as &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; actions, are common in the healthcare industry and can involve significant monetary damages, fines, attorneys&#8217; fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. It is possible that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or prevented by existing law or court order from discussing or disclosing the filing of such suits. Therefore, from time to time, we may be party to one or more undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases brought pursuant to the FCA.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2021, we filed suit in the district court of Dallas County, Texas against April K. Anthony, a former executive officer in our home health and hospice segment (&#8220;HH&amp;H&#8221;), for breach of her contractual noncompete, nonsolicitation, and nondisclosure obligations to us and for trade secret misappropriation. Ms. Anthony&#8217;s senior management agreement, dated October 7, 2019, provides, among other things, that she shall not (i) directly or indirectly engage in the provision of home health or hospice services in any state in which we are operating for a period one year following her departure, (ii) directly or indirectly induce or attempt to induce any of our employees to leave our employ or in any way interfere with the relationship between us and any employee for a period of two years following her departure, or (iii) disclose to any unauthorized person or directly or indirectly use for her own account any information, observations and data concerning our business and affairs. Ms. Anthony resigned from her position with HH&amp;H on June 18, 2021. In September 2021, we learned of evidence that Ms. Anthony during her tenure with us had engaged in, and was continuing to engage in, solicitation of certain HH&amp;H employees to join a competing home health and hospice venture. In this suit, we seek injunctions from the court ordering Ms. Anthony to comply with her senior management agreement, including its noncompete, nonsolicitation, and nondisclosure covenants, and to cease and desist all activities in furtherance of violations of those covenants. The trial is now scheduled for the docket beginning on May 23, 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to certain legal proceedings in which we are involved is included in Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Other Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the condensed consolidated financial statements contained in Part&#160;I, Item&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements (Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report and should be read in conjunction with the related disclosure previously reported in our Annual Report on Form&#160;10&#8209;K for the year ended December&#160;31, 2021 (the &#8220;2021 Form 10&#8209;K&#8221;).</span></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_127"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:34.8pt">Risk Factors</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes from the risk factors disclosed in Part I, Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the 2021 Form&#160;10-K. However, certain information in those risk factors has been updated by the discussion in the &#8220;Executive Overview&#8212;Key Challenges&#8221; section of Part I, Item 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report, which section is incorporated by reference herein.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_130"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our repurchases of equity securities during the three months ended March&#160;31, 2022:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:18.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.260%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.260%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.135%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares (or Units) Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price Paid per Share (or Unit) ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maximum Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under the Plans or Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, through January 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,053,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1, through February 28, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,053,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, through March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,053,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,634&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Except as noted in the following sentence, the number of shares reported in this column represents the shares tendered by employees as payments of the tax liabilities incident to the vesting of previously awarded shares of restricted stock and the exercise price and tax liability incident to the net settlement of an option exercise. In January, 1,202 shares were purchased pursuant to our Directors&#8217; Deferred Stock Investment Plan. This plan is a nonqualified deferral plan allowing non-employee directors to make advance elections to defer a fixed percentage of their director fees. The plan administrator acquires the shares in the open market which are then held in a rabbi trust. The plan also provides that dividends paid on the shares held for the accounts of the directors will be reinvested in shares of our common stock which will also be held in the trust. The directors&#8217; rights to all shares in the trust are nonforfeitable, but the shares are only released to the directors after departure from our board.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2013, we announced our board of directors authorized the repurchase of up to $200 million of our common stock. On February 14, 2014, our board approved an increase in this common stock repurchase authorization from $200 million to $250 million. On July 24, 2018, our board approved resetting the aggregate common stock repurchase authorization to $250 million. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. Subject to certain terms and conditions, including a maximum price per share and compliance with federal and state securities and other laws, the repurchases may be made from time to time in open market transactions, privately negotiated transactions, or other transactions, including trades under a plan established in accordance with Rule&#160;10b5-1 under the Securities Exchange Act of 1934, as amended.</span></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_133"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Exhibits</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the Exhibit Index immediately following the signature page of this report.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_136"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ENCOMPASS HEALTH CORPORATION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Douglas E. Coltharp</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Douglas E. Coltharp</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 3, 2022</span></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="ia58a0d4539bf462e8f4621edacd97f5a_139"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-bottom:7pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits required by Regulation S-K are set forth in the following list and are filed by attachment to this report unless otherwise noted.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:5.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.732%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000068/hls8kex31.htm">3.1.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000068/hls8kex31.htm">Amended and Restated Certificate of Incorporation of Encompass Health Corporation, effective as of January 1, 2018 (incorporated by reference to Exhibit 3.1 to Encompass Health&#8217;s Current Report on Form 8-K filed on October 25, 2017).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000134100406000665/healthsouthexhibit.txt">3.1.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000134100406000665/healthsouthexhibit.txt">Certificate of Designations of 6.50% Series A Convertible Perpetual Preferred Stock, as filed with the Secretary of State of the State of Delaware on March&#160;7, 2006 (incorporated by reference to Exhibit&#160;3.1 to Encompass Health&#8217;s Current Report on Form 8-K filed on March&#160;9, 2006).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000068/hls8kex32.htm">3.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000068/hls8kex32.htm">Amended and Restated Bylaws of Encompass Health Corporation, effective as of January 1, 2018 (incorporated by reference to Exhibit 3.2 to Encompass Health&#8217;s Current Report on Form 8-K filed on October 25, 2017).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000003/twelfthsupplementalindeture.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000003/twelfthsupplementalindeture.htm">Twelfth Supplemental Indenture, dated as of January 24, 2022, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee, relating to the 4.500% Notes due 2028, 4.750% Notes due 2030 and 4.625% Notes due 2031 (incorporated by reference to Exhibit 4.5 to the Encompass Health&#8217;s Current Report on Form 8-K filed on January 25, 2022).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000785161/000078516122000016/a2022proxystatement.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000785161/000078516122000016/a2022proxystatement.htm">Description of the Encompass Health Corporation Senior Management Bonus and Long-Term Incentive Plans (incorporated by reference to the section captioned &#8220;Executive Compensation &#8211; Compensation Discussion and Analysis &#8211; Elements of Executive Compensation&#8221; in Encompass Health&#8217;s Definitive Proxy Statement on Schedule 14A filed on April 4, 2022).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000785161/000078516122000016/a2022proxystatement.htm">10.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000785161/000078516122000016/a2022proxystatement.htm">Description of the annual compensation arrangement for non-employee directors of Encompass Health Corporation (incorporated by reference to the section captioned &#8220;Corporate Governance and Board Structure &#8211; Compensation of Directors&#8221; in Encompass Health&#8217;s Definitive Proxy Statement on Schedule 14A, filed on April 4, 2022).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q33122ex22.htm">22</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q33122ex22.htm">List of Subsidiary Guarantors.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q33122ex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q33122ex311.htm">Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q33122ex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q33122ex312.htm">Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q33122ex321.htm">32.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q33122ex321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q33122ex322.htm">32.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10q33122ex322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sections of the Encompass Health Corporation Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2022, formatted in XBRL (eXtensible Business Reporting Language), submitted in the following files:</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+  Management contract or compensatory plan or arrangement.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-22
<SEQUENCE>2
<FILENAME>ehc10q33122ex22.htm
<DESCRIPTION>EX-22
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if8d2bd991b7d438d8e292a8f18650c4d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 22</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">List of Subsidiary Guarantors</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following direct and indirect subsidiaries of Encompass Health Corporation guarantee each series of its senior unsecured notes.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.725%"><tr><td style="width:1.0%"></td><td style="width:81.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A&#38;B Home Health Solutions, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Abba Home Health, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Advanced Homecare Holdings, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Advanced Homecare Management, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AHM Action Home Health, LP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AHM Texas GP, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AHM Texas LP, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Apex Hospice LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Best Home Care LP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Home Health of Alabama, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Home Health of East Tennessee, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Home Health of the Gulf Coast, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of Central Mississippi, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of East Louisiana, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of Louisiana, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of North Mississippi, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of Northeast Alabama LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of Northeast Mississippi, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of South Alabama, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of Southwest Mississippi, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Hospice of the Gulf Coast, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Camellia Medical Systems, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareServices of the Treasure Coast, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth Health System, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Columbus, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Dothan, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Gainesville, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Greensboro, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Lexington, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of North Florida, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Panama City, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Richmond, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of South Carolina, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Tallahassee, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of the Bay Area, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Valley, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Virginia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Washington, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Western Carolina, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings of Winchester, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth HHA Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareSouth Hospice, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Continental Home Care, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Continental Medical Systems, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.725%"><tr><td style="width:1.0%"></td><td style="width:81.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Continental Rehabilitation Hospital of Arizona, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CS Health &#38; Wellness, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Day-By-Day Staff Relief, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DOSIK, INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DRC Health Systems, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Home Health of Alabama, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Home Health of Birmingham, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Home Health of Central Virginia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Home Health of Florida, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Home Health of Kentucky, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Home Health of New England, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Home Health of Ohio, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Home Health of the Northwest, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Home Health of the Southwest, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Hospice of Alabama, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Hospice of Pennsylvania, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Hospice of the Midwest, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Hospice of the Northwest, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Hospice of the Southwest, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Ventures Boise, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Ventures Bozeman, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Health Ventures Salida, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Home Health of Austin, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Home Health of Colorado, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Home Health of DFW, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Home Health of East Texas, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Home Health of New England, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Home Health of the Mid Atlantic, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Home Health of the Midwest, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Home Health of the Southeast, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Home Health of the West, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH Hospice of the West, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH of Fort Worth, LP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EH of West Texas, LP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EHHI Holdings, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Acquisition Holdings Subsidiary, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Acquisition Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Alabama Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Arizona Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Arkansas Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Boise Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Bryan Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health C Corp Sub Holdings, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health California Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Central Arkansas Holdings, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Charleston Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Colorado Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Dayton Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Deaconess Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.725%"><tr><td style="width:1.0%"></td><td style="width:81.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Fairlawn Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health GKBJH Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Gulfport Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Home Health Corporation</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Illinois Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Iowa City Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Iowa Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Johnson City Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Joint Ventures Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Jonesboro Holdings, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Kansas Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Kentucky Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Kingsport Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Littleton Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Louisiana Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Lubbock Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Martin County Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Maryland Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Massachusetts Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Midland Odessa Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Myrtle Beach Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Nevada Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health New Mexico Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Ohio Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Owned Hospitals Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Pennsylvania Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Properties, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Abilene, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Albuquerque, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Altamonte Springs, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Arlington, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Austin, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Bakersfield, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Bluffton, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Braintree, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Cardinal Hill, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Cincinnati, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of City View, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Colorado Springs, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Columbia, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Concord, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Cypress, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Dallas, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Desert Canyon, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Dothan, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of East Valley, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Erie, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Florence, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.725%"><tr><td style="width:1.0%"></td><td style="width:81.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Fort Smith, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Franklin, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Fredericksburg, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Gadsden, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Greenville, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Harmarville, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Henderson, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Humble, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Katy, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Lakeview, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Largo, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Las Vegas, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Libertyville, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Littleton, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Manati, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Mechanicsburg, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Miami, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Middletown, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Modesto, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Montgomery, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Murrieta, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of New England, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Nittany Valley, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of North Tampa, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Northern Kentucky, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Northern Virginia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Northwest Tucson, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Ocala, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Panama City, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Pearland, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Pensacola, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Petersburg, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Plano, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Reading, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Richardson, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Round Rock, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of San Antonio, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of San Juan, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sarasota, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Scottsdale, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Shelby County, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Shreveport, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sioux Falls, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Spring Hill, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of St. Augustine, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sugar Land, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Sunrise, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Tallahassee, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Texarkana, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.725%"><tr><td style="width:1.0%"></td><td style="width:81.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of the Mid-Cities, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of The Woodlands, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Toledo, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Toms River, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Treasure Coast, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Tustin, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Utah, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Vineland, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Waco, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of Western Massachusetts, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital of York, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital The Vintage, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Hospital Vision Park, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Rehabilitation Institute of Tucson, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health San Angelo Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Savannah Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Sea Pines Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Sewickley Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health South Carolina Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health South Dakota Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Southern Illinois Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Support Companies, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Texas Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Tucson Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Tulsa Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Tyler Holdings, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Utah Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health ValleyofTheSun Rehabilitation Hospital, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Virginia Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Walton Rehabilitation Hospital, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health West Tennessee Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health West Virginia Real Estate, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Westerville Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Winston-Salem Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Encompass Health Yuma Holdings, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Enhabit, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXCELLA ASSOCIATES, L.L.C.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXCELLA HEALTHCARE, INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXCELLA HOME HEALTH AGENCY, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXCELLA HOMECARE, INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Guardian Home Care, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Hallmark Homecare, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HealthCare Innovations of Oklahoma, L.L.C.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HEALTHCARE INNOVATIONS OF WESTERN OKLAHOMA, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HealthCare Innovations-Travertine Health Services, L.L.C.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HealthSouth Rehabilitation Hospital of Austin, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HealthSouth Rehabilitation Hospital of Forsyth County, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HealthSouth Rehabilitation Hospital of Fort Worth, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Home Health Care of Bogalusa, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.725%"><tr><td style="width:1.0%"></td><td style="width:81.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Home Health Care Systems, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Hospice Care of Mississippi, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Idaho Homecare Holdings, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Orion Homecare, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preferred Home Health, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Print Promotions Group, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Rebound, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Rehabilitation Hospital Corporation of America, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Rehabilitation Hospital of North Alabama, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Rehabilitation Hospital of Plano, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reliant Blocker Corp.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Saad Healthcare of St. Clair County LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Texas Senior Care, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TH of San Antonio LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WellCare, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Wellmark Healthcare Services of El Paso, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">West Mississippi Home Health Services, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Western Neuro Care, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ehc10q33122ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8f4a9a1347ac49d68b698bb8ac3e81de_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark J. Tarr, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Encompass Health Corporation&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARR</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark J. Tarr</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ehc10q33122ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i97a55f2a5ba243ae975c73157efc12a6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Douglas E. Coltharp, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Encompass Health Corporation&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OUGLAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E. C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OLTHARP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Douglas E. Coltharp</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ehc10q33122ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ibb0688525c314a22ac6e53aee01cf563_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Encompass Health Corporation on Form 10-Q for the period ended March&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Mark J. Tarr, President and Chief Executive Officer of Encompass Health Corporation, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge and belief&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Encompass Health Corporation.</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARR</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark J. Tarr</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement has been provided to Encompass Health Corporation and will be retained by Encompass Health Corporation and furnished to the Securities and Exchange Commission or its staff upon request.&#160;&#160;This written statement shall not, except to the extent required by the 2002 Act, be deemed filed by Encompass Health Corporation for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that Encompass Health Corporation specifically incorporates it by reference.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ehc10q33122ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i145cbec4fef3495590180a9e4f44e8cf_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Encompass Health Corporation on Form 10-Q for the period ended March&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Douglas E. Coltharp, Executive Vice President and Chief Financial Officer of Encompass Health Corporation, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge and belief&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Encompass Health Corporation.</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OUGLAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E. C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OLTHARP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Douglas E. Coltharp</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement has been provided to Encompass Health Corporation and will be retained by Encompass Health Corporation and furnished to the Securities and Exchange Commission or its staff upon request.&#160;&#160;This written statement shall not, except to the extent required by the 2002 Act, be deemed filed by Encompass Health Corporation for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that Encompass Health Corporation specifically incorporates it by reference.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ehc-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:69533f56-540a-48e1-b4ee-a7401038559f,g:2f1c880e-7b65-4846-aaa6-f9cb86c4b8d3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ehc="http://www.encompasshealth.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.encompasshealth.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ehc-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ehc-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ehc-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ehc-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.encompasshealth.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquityUnaudited" roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical" roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.encompasshealth.com/role/BasisofPresentation">
        <link:definition>2101101 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationPolicies" roleURI="http://www.encompasshealth.com/role/BasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationTables" roleURI="http://www.encompasshealth.com/role/BasisofPresentationTables">
        <link:definition>2303301 - Disclosure - Basis of Presentation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationTextualDetails" roleURI="http://www.encompasshealth.com/role/BasisofPresentationTextualDetails">
        <link:definition>2404401 - Disclosure - Basis of Presentation - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationNetOperatingRevenuesDetails" roleURI="http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails">
        <link:definition>2405402 - Disclosure - Basis of Presentation - Net Operating Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.encompasshealth.com/role/BusinessCombinations">
        <link:definition>2106102 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTables">
        <link:definition>2307302 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTextualDetails" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails">
        <link:definition>2408403 - Disclosure - Business Combinations - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails">
        <link:definition>2409404 - Disclosure - Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsNetCashPaidforAcquisitionsDetails" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails">
        <link:definition>2410405 - Disclosure - Business Combinations - Net Cash Paid for Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsProFormaResultsofOperationDetails" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails">
        <link:definition>2411406 - Disclosure - Business Combinations - Pro Forma Results of Operation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntities" roleURI="http://www.encompasshealth.com/role/VariableInterestEntities">
        <link:definition>2112103 - Disclosure - Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesTables" roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTables">
        <link:definition>2313303 - Disclosure - Variable Interest Entities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesTextualDetails" roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails">
        <link:definition>2414407 - Disclosure - Variable Interest Entities - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails" roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails">
        <link:definition>2415408 - Disclosure - Variable Interest Entities - Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt" roleURI="http://www.encompasshealth.com/role/LongtermDebt">
        <link:definition>2116104 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtTables" roleURI="http://www.encompasshealth.com/role/LongtermDebtTables">
        <link:definition>2317304 - Disclosure - Long-term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtLongtermDebtOutstandingDetails" roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails">
        <link:definition>2418409 - Disclosure - Long-term Debt - Long-term Debt Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtLongtermDebtOutstandingDetails_1" roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1">
        <link:definition>2418409 - Disclosure - Long-term Debt - Long-term Debt Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtTextualDetails" roleURI="http://www.encompasshealth.com/role/LongtermDebtTextualDetails">
        <link:definition>2419410 - Disclosure - Long-term Debt - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterests" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests">
        <link:definition>2120105 - Disclosure - Redeemable Noncontrolling Interests</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestsTables" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables">
        <link:definition>2321305 - Disclosure - Redeemable Noncontrolling Interests (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails">
        <link:definition>2422411 - Disclosure - Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails">
        <link:definition>2423412 - Disclosure - Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.encompasshealth.com/role/FairValueMeasurements">
        <link:definition>2124106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTables">
        <link:definition>2325306 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>2426413 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTextualDetails" roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails">
        <link:definition>2427414 - Disclosure - Fair Value Measurements - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails" roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails">
        <link:definition>2428415 - Disclosure - Fair Value Measurements - Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.encompasshealth.com/role/ShareBasedPayments">
        <link:definition>2129107 - Disclosure - Share-Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsDetails">
        <link:definition>2430416 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.encompasshealth.com/role/IncomeTaxes">
        <link:definition>2131108 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.encompasshealth.com/role/IncomeTaxesDetails">
        <link:definition>2432417 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperCommonShare" roleURI="http://www.encompasshealth.com/role/EarningsperCommonShare">
        <link:definition>2133109 - Disclosure - Earnings per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperCommonShareTables" roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareTables">
        <link:definition>2334307 - Disclosure - Earnings per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails" roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails">
        <link:definition>2435418 - Disclosure - Earnings per Common Share - Computation of Basic and Diluted Earnings Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails" roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails">
        <link:definition>2436419 - Disclosure - Earnings per Common Share - Reconciliation of Weighted Average Number of Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandOtherCommitments" roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitments">
        <link:definition>2137110 - Disclosure - Contingencies and Other Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.encompasshealth.com/role/SegmentReporting">
        <link:definition>2138111 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.encompasshealth.com/role/SegmentReportingTables">
        <link:definition>2339308 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTextualDetails" roleURI="http://www.encompasshealth.com/role/SegmentReportingTextualDetails">
        <link:definition>2440420 - Disclosure - Segment Reporting - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails" roleURI="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails">
        <link:definition>2441421 - Disclosure - Segment Reporting - Segment Reporting Information, Reconciliation of Net Operating Revenues to Segment Adjusted EBITDA (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails" roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails">
        <link:definition>2442422 - Disclosure - Segment Reporting - Reconciliation of Segment Assets and Investments In and Advances to Affiliates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails" roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails">
        <link:definition>2443423 - Disclosure - Segment Reporting - Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails" roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails">
        <link:definition>2444424 - Disclosure - Segment Reporting - Reconciliation of Revenue from Segments to Consolidated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ehc_BusinessCombinationNoncontrollingInterestFairValue" abstract="false" name="BusinessCombinationNoncontrollingInterestFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_HomeHealthandHospiceSegmentMember" abstract="true" name="HomeHealthandHospiceSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_SeniorNotes4.50Due2028Member" abstract="true" name="SeniorNotes4.50Due2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock" abstract="false" name="ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ehc_WorkersCompensationMember" abstract="true" name="WorkersCompensationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" abstract="false" name="IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_DebtInstrumentCovenantLeverageRatio" abstract="false" name="DebtInstrumentCovenantLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ehc_OtherThirdpartyPayorsMember" abstract="true" name="OtherThirdpartyPayorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_SaintAlphonsusMember" abstract="true" name="SaintAlphonsusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_ManagedCareMember" abstract="true" name="ManagedCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" abstract="false" name="NumberOfInpatientRehabilitationUnitsUnderManagementContracts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_SeniorNotes4625Due2031Member" abstract="true" name="SeniorNotes4625Due2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_InpatientMember" abstract="true" name="InpatientMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_OccupancyCost" abstract="false" name="OccupancyCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" abstract="false" name="Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" abstract="false" name="DebtInstrumentAmendmentAgreementAmountToBePaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_Numberofhospicelocations" abstract="false" name="Numberofhospicelocations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward" abstract="true" name="RedeemableNoncontrollingInterestEquityCarryingAmountRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_HomehealthMember" abstract="true" name="HomehealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NetIncomeLossAvailabletoCommonStockholders" abstract="false" name="NetIncomeLossAvailabletoCommonStockholders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_MedicareAdvantageMember" abstract="true" name="MedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_AdjustedEBITDA" abstract="false" name="AdjustedEBITDA" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_CostofServicesExcludingDepreciationandAmortization" abstract="false" name="CostofServicesExcludingDepreciationandAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" abstract="true" name="StatementOfComprehensiveIncomeAndIncomeStatementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_PatientsMember" abstract="true" name="PatientsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_RedeemableNoncontrollingInterestMember" abstract="true" name="RedeemableNoncontrollingInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_Numberofhomehealthlocations" abstract="false" name="Numberofhomehealthlocations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" abstract="false" name="DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_Numberofsolelyownedinpatientrehabilitationhospitals" abstract="false" name="Numberofsolelyownedinpatientrehabilitationhospitals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_Jointventureownershippercentage" abstract="false" name="Jointventureownershippercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_OtherIncomeSourceMember" abstract="true" name="OtherIncomeSourceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_SeniorNotes04.750Due2030Member" abstract="true" name="SeniorNotes04.750Due2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_SeniorNotes05.75Due2025Member" abstract="true" name="SeniorNotes05.75Due2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_SeniorNotes05.125Due2023Member" abstract="true" name="SeniorNotes05.125Due2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_OutpatientandotherMember" abstract="true" name="OutpatientandotherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_Numberofjointlyownedinpatientrehabilitationhospitals" abstract="false" name="Numberofjointlyownedinpatientrehabilitationhospitals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" abstract="false" name="Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_TermLoanFacilitiesMember" abstract="true" name="TermLoanFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_InpatientRehabilitationSegmentMember" abstract="true" name="InpatientRehabilitationSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" abstract="false" name="IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_HospiceMember" abstract="true" name="HospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NumberOfInpatientRehabilitationHospitals" abstract="false" name="NumberOfInpatientRehabilitationHospitals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock" abstract="false" name="ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ehc_VariableInterestEntityNumberofEntitiesConsolidated" abstract="false" name="VariableInterestEntityNumberofEntitiesConsolidated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ehc-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:69533f56-540a-48e1-b4ee-a7401038559f,g:2f1c880e-7b65-4846-aaa6-f9cb86c4b8d3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="ehc-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_df5b2c5e-c1ac-411a-981c-111d8142f1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c2b9b17c-a8d0-4505-8996-969c94d5b415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_df5b2c5e-c1ac-411a-981c-111d8142f1c2" xlink:to="loc_us-gaap_ProfitLoss_c2b9b17c-a8d0-4505-8996-969c94d5b415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_50d1b454-d250-4c02-ac3b-ad0a51a9ca6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_df5b2c5e-c1ac-411a-981c-111d8142f1c2" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_50d1b454-d250-4c02-ac3b-ad0a51a9ca6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_990c52ad-ecc8-4495-ad71-878344292353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_17410791-14d8-488f-8309-3428b26c42cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_990c52ad-ecc8-4495-ad71-878344292353" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_17410791-14d8-488f-8309-3428b26c42cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a71d8eec-8682-4606-94d8-2f300612034a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_990c52ad-ecc8-4495-ad71-878344292353" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a71d8eec-8682-4606-94d8-2f300612034a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e533ae1e-90a4-42a6-88d5-9ca74e0a80d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_a6e81893-42a0-488b-8512-4403f233e992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e533ae1e-90a4-42a6-88d5-9ca74e0a80d1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_a6e81893-42a0-488b-8512-4403f233e992" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b79a51ef-3395-4b31-9c6b-94add28b3d33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e533ae1e-90a4-42a6-88d5-9ca74e0a80d1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b79a51ef-3395-4b31-9c6b-94add28b3d33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fc17ae48-c2bf-440e-9ecd-1612d8882c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_a23a79f7-da43-4814-8c8c-d9eb313fc29a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_fc17ae48-c2bf-440e-9ecd-1612d8882c8b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_a23a79f7-da43-4814-8c8c-d9eb313fc29a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_e38ad5a3-d42f-4d7a-9181-551e6a0ba1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_fc17ae48-c2bf-440e-9ecd-1612d8882c8b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_e38ad5a3-d42f-4d7a-9181-551e6a0ba1b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_457dcc8b-cea0-4103-a4da-dd17ebb25731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_59f6ad2d-2f57-4b9c-a946-fd5a4b0b786a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_457dcc8b-cea0-4103-a4da-dd17ebb25731" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_59f6ad2d-2f57-4b9c-a946-fd5a4b0b786a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_aa62fb16-979a-41fd-9d14-30478ef3ef60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_457dcc8b-cea0-4103-a4da-dd17ebb25731" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_aa62fb16-979a-41fd-9d14-30478ef3ef60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_94c2ab91-b8e4-4f03-ad87-e02f4653a7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_457dcc8b-cea0-4103-a4da-dd17ebb25731" xlink:to="loc_us-gaap_CostsAndExpenses_94c2ab91-b8e4-4f03-ad87-e02f4653a7d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_dfdaa3d0-0ad5-4402-89ef-4883a2eeb6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_457dcc8b-cea0-4103-a4da-dd17ebb25731" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_dfdaa3d0-0ad5-4402-89ef-4883a2eeb6a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f786e701-1101-46a2-8793-90c9fc5a54e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_457dcc8b-cea0-4103-a4da-dd17ebb25731" xlink:to="loc_us-gaap_InterestExpense_f786e701-1101-46a2-8793-90c9fc5a54e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2c12aba7-15e9-4d5c-845b-553751bbea81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_457dcc8b-cea0-4103-a4da-dd17ebb25731" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2c12aba7-15e9-4d5c-845b-553751bbea81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_96ba7dae-ef1a-45b5-a1a4-3fe424932c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_8dddd615-c916-4e81-a00d-235aa154f9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_96ba7dae-ef1a-45b5-a1a4-3fe424932c85" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_8dddd615-c916-4e81-a00d-235aa154f9a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_17095ad8-9064-47a5-be61-ff6e085ed15f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_96ba7dae-ef1a-45b5-a1a4-3fe424932c85" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_17095ad8-9064-47a5-be61-ff6e085ed15f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_82ed1cb9-ab52-4200-93a4-844d8ef5067e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_26bea548-d7ec-4841-be7c-bad770c1716e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_82ed1cb9-ab52-4200-93a4-844d8ef5067e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_26bea548-d7ec-4841-be7c-bad770c1716e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7485c126-7e93-4821-9431-d32a1a110c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_82ed1cb9-ab52-4200-93a4-844d8ef5067e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7485c126-7e93-4821-9431-d32a1a110c7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_47234bbf-8765-4ded-a344-450cd3b947ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_ac33d9eb-af6d-4465-9ed6-f933611e8193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_47234bbf-8765-4ded-a344-450cd3b947ed" xlink:to="loc_us-gaap_LaborAndRelatedExpense_ac33d9eb-af6d-4465-9ed6-f933611e8193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_37799cc7-4da7-45f9-8688-9577791caa9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_47234bbf-8765-4ded-a344-450cd3b947ed" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_37799cc7-4da7-45f9-8688-9577791caa9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost_89e4bcfd-0875-4907-aab3-3359cd437875" xlink:href="ehc-20220331.xsd#ehc_OccupancyCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_47234bbf-8765-4ded-a344-450cd3b947ed" xlink:to="loc_ehc_OccupancyCost_89e4bcfd-0875-4907-aab3-3359cd437875" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_8346ba99-6d25-4365-97bf-96d3eb17ab76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_47234bbf-8765-4ded-a344-450cd3b947ed" xlink:to="loc_us-gaap_SuppliesExpense_8346ba99-6d25-4365-97bf-96d3eb17ab76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_09854b78-afee-4fec-b083-18212493e072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_47234bbf-8765-4ded-a344-450cd3b947ed" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_09854b78-afee-4fec-b083-18212493e072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_76aed72f-20d3-41b4-b0d2-670a6a3a7316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_47234bbf-8765-4ded-a344-450cd3b947ed" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_76aed72f-20d3-41b4-b0d2-670a6a3a7316" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="ehc-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_541484c9-1a7b-49c3-9dba-cfc79d097881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9aa6ac39-8c04-4e98-a11a-93cf38903954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_541484c9-1a7b-49c3-9dba-cfc79d097881" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9aa6ac39-8c04-4e98-a11a-93cf38903954" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_619cc7e7-e8a3-4af2-a4fa-1e6a68fc5f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_541484c9-1a7b-49c3-9dba-cfc79d097881" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_619cc7e7-e8a3-4af2-a4fa-1e6a68fc5f9a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="ehc-20220331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6ab7332a-12d7-47d8-ba96-a9f3cee15c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_ff42ff4d-611a-43fa-be08-06e9ace801e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6ab7332a-12d7-47d8-ba96-a9f3cee15c6c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_ff42ff4d-611a-43fa-be08-06e9ace801e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3e0ed69e-359b-4d2e-91cb-341499be44b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6ab7332a-12d7-47d8-ba96-a9f3cee15c6c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3e0ed69e-359b-4d2e-91cb-341499be44b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a48e888c-4126-433d-a954-021f4894d933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6ab7332a-12d7-47d8-ba96-a9f3cee15c6c" xlink:to="loc_us-gaap_Goodwill_a48e888c-4126-433d-a954-021f4894d933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d07d9086-fe8c-4483-8398-ef1c762a172c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6ab7332a-12d7-47d8-ba96-a9f3cee15c6c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d07d9086-fe8c-4483-8398-ef1c762a172c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9c681142-e758-4cd2-a950-6cd1667d21dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6ab7332a-12d7-47d8-ba96-a9f3cee15c6c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9c681142-e758-4cd2-a950-6cd1667d21dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8452d694-d029-4d8b-80d0-a93d2fc48e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6ab7332a-12d7-47d8-ba96-a9f3cee15c6c" xlink:to="loc_us-gaap_AssetsCurrent_8452d694-d029-4d8b-80d0-a93d2fc48e49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b8d79d58-53e1-43fc-ab90-429af252b263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fbfd1978-2162-4d25-8f10-500efa104fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b8d79d58-53e1-43fc-ab90-429af252b263" xlink:to="loc_us-gaap_StockholdersEquity_fbfd1978-2162-4d25-8f10-500efa104fe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_40d91edd-23a5-4d78-81aa-b48ddcc12910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b8d79d58-53e1-43fc-ab90-429af252b263" xlink:to="loc_us-gaap_MinorityInterest_40d91edd-23a5-4d78-81aa-b48ddcc12910" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e50a8b9d-4c88-4c42-99ee-97994a82f74f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_3ae6d460-81b7-4802-905c-6b2bbdc6dcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e50a8b9d-4c88-4c42-99ee-97994a82f74f" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_3ae6d460-81b7-4802-905c-6b2bbdc6dcdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_72fc7727-4502-485e-8b33-fea0e9210184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e50a8b9d-4c88-4c42-99ee-97994a82f74f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_72fc7727-4502-485e-8b33-fea0e9210184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_27f03b00-b389-43ce-ace5-ec0ef821f2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e50a8b9d-4c88-4c42-99ee-97994a82f74f" xlink:to="loc_us-gaap_AccountsPayableCurrent_27f03b00-b389-43ce-ace5-ec0ef821f2fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_cfbcbee4-bfa6-4c88-a556-bd970bdf4445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e50a8b9d-4c88-4c42-99ee-97994a82f74f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_cfbcbee4-bfa6-4c88-a556-bd970bdf4445" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_915b1824-b5f0-4acd-9d26-b698ebfa3b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4d5cd157-ade8-4f37-ae30-8acec26fdab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_915b1824-b5f0-4acd-9d26-b698ebfa3b88" xlink:to="loc_us-gaap_LiabilitiesCurrent_4d5cd157-ade8-4f37-ae30-8acec26fdab7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_bb4b85a1-15a7-4b9c-a65f-feddabab143a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_915b1824-b5f0-4acd-9d26-b698ebfa3b88" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_bb4b85a1-15a7-4b9c-a65f-feddabab143a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_79fad263-6435-4eaf-acf2-3833e8abe776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_915b1824-b5f0-4acd-9d26-b698ebfa3b88" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_79fad263-6435-4eaf-acf2-3833e8abe776" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_38a4de71-6489-421d-bafb-661d0dc483d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_915b1824-b5f0-4acd-9d26-b698ebfa3b88" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_38a4de71-6489-421d-bafb-661d0dc483d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d573c307-9a6f-48be-8640-c8e36cba57ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_915b1824-b5f0-4acd-9d26-b698ebfa3b88" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d573c307-9a6f-48be-8640-c8e36cba57ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d08c321f-72cd-4711-98ef-e81b9b2c7720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_91669aea-2d75-4105-b264-d1ef223a3a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d08c321f-72cd-4711-98ef-e81b9b2c7720" xlink:to="loc_us-gaap_CommitmentsAndContingencies_91669aea-2d75-4105-b264-d1ef223a3a45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_baaadb3b-270e-4e6b-b415-e2bac2a79117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d08c321f-72cd-4711-98ef-e81b9b2c7720" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_baaadb3b-270e-4e6b-b415-e2bac2a79117" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3217b31f-fc1c-4ea8-ac1c-6710393d6cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d08c321f-72cd-4711-98ef-e81b9b2c7720" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3217b31f-fc1c-4ea8-ac1c-6710393d6cf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0b97a055-6a5b-40c3-96b0-f9f38e8bb1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d08c321f-72cd-4711-98ef-e81b9b2c7720" xlink:to="loc_us-gaap_Liabilities_0b97a055-6a5b-40c3-96b0-f9f38e8bb1ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_60b503fe-8932-4aa3-878d-056bee30482d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_08c940c0-3b0f-4d3d-8607-702ced55a82e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_60b503fe-8932-4aa3-878d-056bee30482d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_08c940c0-3b0f-4d3d-8607-702ced55a82e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_f4ff5df5-7d52-447d-9afa-e162dd8ec682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_60b503fe-8932-4aa3-878d-056bee30482d" xlink:to="loc_us-gaap_RestrictedCashCurrent_f4ff5df5-7d52-447d-9afa-e162dd8ec682" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5839a9d2-7282-4bcd-8dd1-bc157ef3dc20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_60b503fe-8932-4aa3-878d-056bee30482d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5839a9d2-7282-4bcd-8dd1-bc157ef3dc20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_7ee0dd02-38f8-4357-b742-61eb0b607e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_60b503fe-8932-4aa3-878d-056bee30482d" xlink:to="loc_us-gaap_OtherAssetsCurrent_7ee0dd02-38f8-4357-b742-61eb0b607e06" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="ehc-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_772c99fa-0fa8-4c25-a8b2-d1e51329ff95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1070cec1-321c-48cd-85f8-25400f0f26b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_772c99fa-0fa8-4c25-a8b2-d1e51329ff95" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1070cec1-321c-48cd-85f8-25400f0f26b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_54f57485-5599-454b-86f8-86b14b851177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_772c99fa-0fa8-4c25-a8b2-d1e51329ff95" xlink:to="loc_us-gaap_RestrictedCashCurrent_54f57485-5599-454b-86f8-86b14b851177" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_6b51dde8-8287-41a4-a61f-eb6d3a743e84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_772c99fa-0fa8-4c25-a8b2-d1e51329ff95" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_6b51dde8-8287-41a4-a61f-eb6d3a743e84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4df440b4-03f4-4b79-a25c-c3bf59b9fe88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_aea5c15b-1336-473c-b6d1-8d40a2a74d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4df440b4-03f4-4b79-a25c-c3bf59b9fe88" xlink:to="loc_us-gaap_ProfitLoss_aea5c15b-1336-473c-b6d1-8d40a2a74d32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a0663d0d-2670-4f4b-a922-35fc19ff2ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4df440b4-03f4-4b79-a25c-c3bf59b9fe88" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a0663d0d-2670-4f4b-a922-35fc19ff2ab9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_76341f89-6d2d-4dc5-86c9-6a0f570be90a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bba16b18-febd-403d-99af-f1d01ddf545a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_76341f89-6d2d-4dc5-86c9-6a0f570be90a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bba16b18-febd-403d-99af-f1d01ddf545a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11543f32-c8f2-4256-bb52-fb293793d2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_76341f89-6d2d-4dc5-86c9-6a0f570be90a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11543f32-c8f2-4256-bb52-fb293793d2dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e669ebf1-f465-465a-bcfd-44c8f2407263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_76341f89-6d2d-4dc5-86c9-6a0f570be90a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e669ebf1-f465-465a-bcfd-44c8f2407263" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f164a4ee-135c-436e-b232-8eb354dc601c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_be93a7e5-c964-486c-a0cf-cb2a7342abe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f164a4ee-135c-436e-b232-8eb354dc601c" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_be93a7e5-c964-486c-a0cf-cb2a7342abe8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7d37eea4-dc80-4341-ae15-0c07c7ffde3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f164a4ee-135c-436e-b232-8eb354dc601c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7d37eea4-dc80-4341-ae15-0c07c7ffde3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_47bb4bdb-fece-45df-9eb2-a59b3d13f614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f070be0a-d1f5-40f0-bb47-349bd7a233a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_47bb4bdb-fece-45df-9eb2-a59b3d13f614" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f070be0a-d1f5-40f0-bb47-349bd7a233a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ffc6e4ef-c839-4ca3-b14e-c23157283d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_47bb4bdb-fece-45df-9eb2-a59b3d13f614" xlink:to="loc_us-gaap_ShareBasedCompensation_ffc6e4ef-c839-4ca3-b14e-c23157283d0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8cac97d0-4d21-44fe-82d7-dc85a68d559f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_47bb4bdb-fece-45df-9eb2-a59b3d13f614" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8cac97d0-4d21-44fe-82d7-dc85a68d559f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_19b71055-9421-4d57-bc5e-eb26a2dfe18d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_47bb4bdb-fece-45df-9eb2-a59b3d13f614" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_19b71055-9421-4d57-bc5e-eb26a2dfe18d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b8843dff-6a10-414a-893d-f250f29681d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_47bb4bdb-fece-45df-9eb2-a59b3d13f614" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b8843dff-6a10-414a-893d-f250f29681d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1d7e2fad-5e3f-4ebc-ad86-619a968421bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_47bb4bdb-fece-45df-9eb2-a59b3d13f614" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1d7e2fad-5e3f-4ebc-ad86-619a968421bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_68727953-9338-4239-ab69-e9c31729ff55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_47bb4bdb-fece-45df-9eb2-a59b3d13f614" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_68727953-9338-4239-ab69-e9c31729ff55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_fc90665b-042c-42c9-873f-57fa78be8270" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_47bb4bdb-fece-45df-9eb2-a59b3d13f614" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_fc90665b-042c-42c9-873f-57fa78be8270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_75f6f9ff-6d6a-498c-989c-cfd57e8969d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_47bb4bdb-fece-45df-9eb2-a59b3d13f614" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_75f6f9ff-6d6a-498c-989c-cfd57e8969d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e7928eb-17eb-4129-82f9-95f01309d184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_ab847019-2696-4497-b886-b69889d5e925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e7928eb-17eb-4129-82f9-95f01309d184" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_ab847019-2696-4497-b886-b69889d5e925" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2907d65c-7468-46a9-8f6d-1fde85ae8822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e7928eb-17eb-4129-82f9-95f01309d184" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2907d65c-7468-46a9-8f6d-1fde85ae8822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_57a7ea75-6a4a-4c34-aebe-c8273b024b97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e7928eb-17eb-4129-82f9-95f01309d184" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_57a7ea75-6a4a-4c34-aebe-c8273b024b97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts_2ad174fb-d079-4dce-9323-6be57ad67c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e7928eb-17eb-4129-82f9-95f01309d184" xlink:to="loc_us-gaap_PaymentsOfDebtRestructuringCosts_2ad174fb-d079-4dce-9323-6be57ad67c92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_b273df5c-e771-4faa-b60c-9c699801e551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e7928eb-17eb-4129-82f9-95f01309d184" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_b273df5c-e771-4faa-b60c-9c699801e551" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d2467796-b660-4944-bed5-d4298fd9ca8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e7928eb-17eb-4129-82f9-95f01309d184" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d2467796-b660-4944-bed5-d4298fd9ca8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_eace3581-252b-4170-9752-e28a5e0c00aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e7928eb-17eb-4129-82f9-95f01309d184" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_eace3581-252b-4170-9752-e28a5e0c00aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_41ba65dd-d9b5-44a7-9c39-6aebcc7a754e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e7928eb-17eb-4129-82f9-95f01309d184" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_41ba65dd-d9b5-44a7-9c39-6aebcc7a754e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_c5f2a7ed-856d-4c64-813a-7227ca556d95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e7928eb-17eb-4129-82f9-95f01309d184" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_c5f2a7ed-856d-4c64-813a-7227ca556d95" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_5ba68be7-284d-4736-8790-27b8a3ff7944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_65443fcc-5bd1-4dc3-b110-b01185467717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_5ba68be7-284d-4736-8790-27b8a3ff7944" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_65443fcc-5bd1-4dc3-b110-b01185467717" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_b357ef3e-60c8-4460-9a02-5f471187c32c" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_5ba68be7-284d-4736-8790-27b8a3ff7944" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_b357ef3e-60c8-4460-9a02-5f471187c32c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_a21756d7-5e55-429b-ae2a-7d872ced2c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_5ba68be7-284d-4736-8790-27b8a3ff7944" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_a21756d7-5e55-429b-ae2a-7d872ced2c15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0f4ed9aa-6f41-43e3-843b-2e359dcf1b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_b6b50452-1310-4650-82c2-f158d6eb6faa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0f4ed9aa-6f41-43e3-843b-2e359dcf1b42" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_b6b50452-1310-4650-82c2-f158d6eb6faa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5ed50244-778e-40b9-854a-45b378736769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0f4ed9aa-6f41-43e3-843b-2e359dcf1b42" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5ed50244-778e-40b9-854a-45b378736769" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll_b10f76db-c314-4d44-b018-0daecf6e71a7" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0f4ed9aa-6f41-43e3-843b-2e359dcf1b42" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll_b10f76db-c314-4d44-b018-0daecf6e71a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_16624e6c-511c-402c-ac1c-70dbb3f7187a" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0f4ed9aa-6f41-43e3-843b-2e359dcf1b42" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_16624e6c-511c-402c-ac1c-70dbb3f7187a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_aabe51c4-7b13-4ffc-8526-c5b35f1a28ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0f4ed9aa-6f41-43e3-843b-2e359dcf1b42" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_aabe51c4-7b13-4ffc-8526-c5b35f1a28ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_40aa1f80-7dff-4aca-8a5c-6ab9862ac4eb" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_34cef402-072d-4e21-9e12-876a6b96cac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_40aa1f80-7dff-4aca-8a5c-6ab9862ac4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_34cef402-072d-4e21-9e12-876a6b96cac5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_8b4e264c-31df-40cd-b954-db2a4cd650a2" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_40aa1f80-7dff-4aca-8a5c-6ab9862ac4eb" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_8b4e264c-31df-40cd-b954-db2a4cd650a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_acffea85-f519-4825-9d5c-6edb86212042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_40aa1f80-7dff-4aca-8a5c-6ab9862ac4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_acffea85-f519-4825-9d5c-6edb86212042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a872684d-421e-44a5-93fd-17c690be47aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_40aa1f80-7dff-4aca-8a5c-6ab9862ac4eb" xlink:to="loc_us-gaap_Goodwill_a872684d-421e-44a5-93fd-17c690be47aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_ddaf25e1-f261-4f45-a9ea-becaabce2ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_40aa1f80-7dff-4aca-8a5c-6ab9862ac4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_ddaf25e1-f261-4f45-a9ea-becaabce2ae6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#LongtermDebtLongtermDebtOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_a5133b2a-4820-4d95-8ae4-9f09c8a90317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4b1cca8d-bafb-444a-b4ee-101bcda2c37f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_a5133b2a-4820-4d95-8ae4-9f09c8a90317" xlink:to="loc_us-gaap_LongTermDebt_4b1cca8d-bafb-444a-b4ee-101bcda2c37f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_0d596979-0910-4c76-83a2-f789d4dead67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_a5133b2a-4820-4d95-8ae4-9f09c8a90317" xlink:to="loc_us-gaap_FinanceLeaseLiability_0d596979-0910-4c76-83a2-f789d4dead67" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1" xlink:type="simple" xlink:href="ehc-20220331.xsd#LongtermDebtLongtermDebtOutstandingDetails_1"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_50cb87f3-af9d-476a-bceb-9d6a3c7c57c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_43f5110d-c7ca-4eb1-8b73-3236352c3d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_50cb87f3-af9d-476a-bceb-9d6a3c7c57c0" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_43f5110d-c7ca-4eb1-8b73-3236352c3d78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_2a52961c-90ea-499a-b5f6-711f8252cf29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_50cb87f3-af9d-476a-bceb-9d6a3c7c57c0" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_2a52961c-90ea-499a-b5f6-711f8252cf29" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bddc4922-5606-44fc-94c5-fba87efc0401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_be2a0b56-5dd5-4e6a-a97f-cb78d80511ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bddc4922-5606-44fc-94c5-fba87efc0401" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_be2a0b56-5dd5-4e6a-a97f-cb78d80511ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_be3aec60-746e-4bd0-926b-454c036e0c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bddc4922-5606-44fc-94c5-fba87efc0401" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_be3aec60-746e-4bd0-926b-454c036e0c0e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_cf2d9dac-9d81-4693-a26b-1a763b357bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_4455e73d-6d12-46e9-a01e-d937ead0f512" xlink:href="ehc-20220331.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_cf2d9dac-9d81-4693-a26b-1a763b357bb2" xlink:to="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_4455e73d-6d12-46e9-a01e-d937ead0f512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c835e291-07f7-4989-b977-9b3c7cebc13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_cf2d9dac-9d81-4693-a26b-1a763b357bb2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c835e291-07f7-4989-b977-9b3c7cebc13b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NetIncomeLossAvailabletoCommonStockholders_b72cc7d4-ea76-4d68-bf27-572eb17600c6" xlink:href="ehc-20220331.xsd#ehc_NetIncomeLossAvailabletoCommonStockholders"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_6b6e5606-e6d0-459e-a22c-303a9bfc2901" xlink:href="ehc-20220331.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_NetIncomeLossAvailabletoCommonStockholders_b72cc7d4-ea76-4d68-bf27-572eb17600c6" xlink:to="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_6b6e5606-e6d0-459e-a22c-303a9bfc2901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_51025d20-fc79-4da7-956f-2a4701bd439d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_NetIncomeLossAvailabletoCommonStockholders_b72cc7d4-ea76-4d68-bf27-572eb17600c6" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_51025d20-fc79-4da7-956f-2a4701bd439d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_d309784b-ed93-4e0d-bfac-ca079ebd479e" xlink:href="ehc-20220331.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_52a4e0c4-3be0-439e-841b-481cb6270048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_d309784b-ed93-4e0d-bfac-ca079ebd479e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_52a4e0c4-3be0-439e-841b-481cb6270048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_ce15c9c3-e8c8-4af2-8804-f1e54b942af7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_d309784b-ed93-4e0d-bfac-ca079ebd479e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_ce15c9c3-e8c8-4af2-8804-f1e54b942af7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_a4fce5f9-fcd0-4fcf-bba9-dfd7d44b3eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_d309784b-ed93-4e0d-bfac-ca079ebd479e" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_a4fce5f9-fcd0-4fcf-bba9-dfd7d44b3eb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_49ec1c7d-8f3a-428e-85a9-8f29bec76c58" xlink:href="ehc-20220331.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_24e8d7f9-28be-4e8f-8031-f18ccd9e7f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_49ec1c7d-8f3a-428e-85a9-8f29bec76c58" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_24e8d7f9-28be-4e8f-8031-f18ccd9e7f8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_7dd85c09-4a1b-4285-ab49-8e587ca5156c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_49ec1c7d-8f3a-428e-85a9-8f29bec76c58" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_7dd85c09-4a1b-4285-ab49-8e587ca5156c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ef50b3f4-d79a-4d56-86d0-b74684bafdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9802d7f7-3f17-477c-944d-252680c81c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ef50b3f4-d79a-4d56-86d0-b74684bafdc9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9802d7f7-3f17-477c-944d-252680c81c31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_40b6beb6-5e57-4a6e-bd09-f4db0b2c5d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ef50b3f4-d79a-4d56-86d0-b74684bafdc9" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_40b6beb6-5e57-4a6e-bd09-f4db0b2c5d04" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d6a39967-b34d-4a20-b405-2a1865824e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CostofServicesExcludingDepreciationandAmortization_94ecb4db-4ad4-4db9-8ee5-187e9e2af89a" xlink:href="ehc-20220331.xsd#ehc_CostofServicesExcludingDepreciationandAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d6a39967-b34d-4a20-b405-2a1865824e8e" xlink:to="loc_ehc_CostofServicesExcludingDepreciationandAmortization_94ecb4db-4ad4-4db9-8ee5-187e9e2af89a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead_d594fa36-a9ed-4165-940e-838c9df0ed1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldOverhead"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d6a39967-b34d-4a20-b405-2a1865824e8e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead_d594fa36-a9ed-4165-940e-838c9df0ed1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_5e795f08-1cb3-40bb-8c59-e5fd90ae848e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d6a39967-b34d-4a20-b405-2a1865824e8e" xlink:to="loc_us-gaap_LaborAndRelatedExpense_5e795f08-1cb3-40bb-8c59-e5fd90ae848e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_1b1d3bfe-1630-43f7-95c8-ecd2b911bb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d6a39967-b34d-4a20-b405-2a1865824e8e" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_1b1d3bfe-1630-43f7-95c8-ecd2b911bb49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_b4605ab1-8cf8-48bc-b06b-27dcea09028d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d6a39967-b34d-4a20-b405-2a1865824e8e" xlink:to="loc_us-gaap_SuppliesExpense_b4605ab1-8cf8-48bc-b06b-27dcea09028d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost_4456a530-dca5-42a3-bec2-004d52036f6e" xlink:href="ehc-20220331.xsd#ehc_OccupancyCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d6a39967-b34d-4a20-b405-2a1865824e8e" xlink:to="loc_ehc_OccupancyCost_4456a530-dca5-42a3-bec2-004d52036f6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA_557c7168-afad-41ae-bbe8-82763c9be2ae" xlink:href="ehc-20220331.xsd#ehc_AdjustedEBITDA"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c99863a6-8cb2-46e1-978a-878896b62739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_AdjustedEBITDA_557c7168-afad-41ae-bbe8-82763c9be2ae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c99863a6-8cb2-46e1-978a-878896b62739" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ae5d4052-3962-461c-ae99-8aac563f7644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_AdjustedEBITDA_557c7168-afad-41ae-bbe8-82763c9be2ae" xlink:to="loc_us-gaap_CostsAndExpenses_ae5d4052-3962-461c-ae99-8aac563f7644" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_311658c9-ad88-4658-874e-a0869c4e72e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_AdjustedEBITDA_557c7168-afad-41ae-bbe8-82763c9be2ae" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_311658c9-ad88-4658-874e-a0869c4e72e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0cea7261-c794-45d9-b49e-e3dfb6838813" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_AdjustedEBITDA_557c7168-afad-41ae-bbe8-82763c9be2ae" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0cea7261-c794-45d9-b49e-e3dfb6838813" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_578f422e-fa1d-492c-a571-ed6fcb56a414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_AdjustedEBITDA_557c7168-afad-41ae-bbe8-82763c9be2ae" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_578f422e-fa1d-492c-a571-ed6fcb56a414" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3af58072-d5c4-4155-968c-38b6abcf3ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA_660ac259-64af-46ab-b9c4-daacb16f42c7" xlink:href="ehc-20220331.xsd#ehc_AdjustedEBITDA"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3af58072-d5c4-4155-968c-38b6abcf3ece" xlink:to="loc_ehc_AdjustedEBITDA_660ac259-64af-46ab-b9c4-daacb16f42c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d3685533-08cb-4409-a765-83532889877e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3af58072-d5c4-4155-968c-38b6abcf3ece" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d3685533-08cb-4409-a765-83532889877e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f54e0269-7018-4119-bbcd-aec43dd9839b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3af58072-d5c4-4155-968c-38b6abcf3ece" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f54e0269-7018-4119-bbcd-aec43dd9839b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_5790eda6-59c3-4e1d-812f-a9c2f4dbffb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3af58072-d5c4-4155-968c-38b6abcf3ece" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_5790eda6-59c3-4e1d-812f-a9c2f4dbffb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a1ee858b-4b6f-4c4b-bef4-f6f5f54904fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3af58072-d5c4-4155-968c-38b6abcf3ece" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a1ee858b-4b6f-4c4b-bef4-f6f5f54904fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_2bb06e09-2d63-4854-82ed-0d16871b28d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3af58072-d5c4-4155-968c-38b6abcf3ece" xlink:to="loc_us-gaap_InterestExpenseDebt_2bb06e09-2d63-4854-82ed-0d16871b28d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a428728b-0478-4199-bc90-777073c088cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3af58072-d5c4-4155-968c-38b6abcf3ece" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a428728b-0478-4199-bc90-777073c088cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesGainLoss_e013a55f-fe9f-401e-82c8-8ab4088406ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3af58072-d5c4-4155-968c-38b6abcf3ece" xlink:to="loc_us-gaap_MarketableSecuritiesGainLoss_e013a55f-fe9f-401e-82c8-8ab4088406ac" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ehc-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:69533f56-540a-48e1-b4ee-a7401038559f,g:2f1c880e-7b65-4846-aaa6-f9cb86c4b8d3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="ehc-20220331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" id="ie607038216b142bbae8cc2b348f0d19c_CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2d8a90e3-f357-450d-a4a3-8e47437c8076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cbb91f31-bbbc-463f-b894-22324db1ca0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d8a90e3-f357-450d-a4a3-8e47437c8076" xlink:to="loc_us-gaap_Assets_cbb91f31-bbbc-463f-b894-22324db1ca0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e3b66489-3add-418b-8353-dcd39e6cbab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d8a90e3-f357-450d-a4a3-8e47437c8076" xlink:to="loc_us-gaap_Liabilities_e3b66489-3add-418b-8353-dcd39e6cbab4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_06bee963-a6f8-4264-a250-db4fc0b9a794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2d8a90e3-f357-450d-a4a3-8e47437c8076" xlink:to="loc_us-gaap_StatementTable_06bee963-a6f8-4264-a250-db4fc0b9a794" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_2d894956-e64c-4890-af96-11f40063e94f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_06bee963-a6f8-4264-a250-db4fc0b9a794" xlink:to="loc_srt_ConsolidatedEntitiesAxis_2d894956-e64c-4890-af96-11f40063e94f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_2d894956-e64c-4890-af96-11f40063e94f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_2d894956-e64c-4890-af96-11f40063e94f" xlink:to="loc_srt_ConsolidatedEntitiesDomain_2d894956-e64c-4890-af96-11f40063e94f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_871b5580-9c75-4a54-b7d8-b758ea9b742b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_2d894956-e64c-4890-af96-11f40063e94f" xlink:to="loc_srt_ConsolidatedEntitiesDomain_871b5580-9c75-4a54-b7d8-b758ea9b742b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_0d35fb05-9bd7-4d40-b185-143fe3840907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_871b5580-9c75-4a54-b7d8-b758ea9b742b" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_0d35fb05-9bd7-4d40-b185-143fe3840907" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited" xlink:type="simple" xlink:href="ehc-20220331.xsd#CondensedConsolidatedStatementsofShareholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited" xlink:type="extended" id="i3fc2125ad8ed4884a7a58c0732e64d06_CondensedConsolidatedStatementsofShareholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9fe13496-8eb5-4065-836d-5aa67d4282f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9fe13496-8eb5-4065-836d-5aa67d4282f5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e9f7d28e-26ec-42da-a849-e10bf3394e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e9f7d28e-26ec-42da-a849-e10bf3394e6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e597bcf8-d703-4377-abe2-7d39f8def5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e597bcf8-d703-4377-abe2-7d39f8def5d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_05b9fd66-965a-4d16-90be-a6bef216e6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_05b9fd66-965a-4d16-90be-a6bef216e6b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_6d3bd4aa-ce88-4a2f-9818-b3f9a268682a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_6d3bd4aa-ce88-4a2f-9818-b3f9a268682a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_997a37ce-6edb-4282-a84a-02efda6fb55d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_997a37ce-6edb-4282-a84a-02efda6fb55d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_749ef675-8315-459f-8851-e2fb8c6f929b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_DividendsCommonStockCash_749ef675-8315-459f-8851-e2fb8c6f929b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_86d928a5-7d32-409c-901d-444399f9fc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_86d928a5-7d32-409c-901d-444399f9fc3a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_591a1b02-d6b2-4171-92f4-f9f90ef62953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_591a1b02-d6b2-4171-92f4-f9f90ef62953" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnersCapitalAccountContributions_6cd55bd9-e7ec-4cdd-9479-df736433ba48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnersCapitalAccountContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_PartnersCapitalAccountContributions_6cd55bd9-e7ec-4cdd-9479-df736433ba48" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_a686eb8b-ac70-4928-a8ea-3a4a4c3ae4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_a686eb8b-ac70-4928-a8ea-3a4a4c3ae4e3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_e335c53e-39cd-493f-ac05-70daa552f27a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_StockholdersEquityOther_e335c53e-39cd-493f-ac05-70daa552f27a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_06f978f5-98a0-4205-9a8f-1a05e088f3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0648ec82-6325-44d1-a658-63994df0eb19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a9cf911c-436d-46e3-8a43-eae4bd01d18a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9fe13496-8eb5-4065-836d-5aa67d4282f5" xlink:to="loc_us-gaap_StatementTable_a9cf911c-436d-46e3-8a43-eae4bd01d18a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_be189b38-b8d5-46c5-ba84-2876d21887f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a9cf911c-436d-46e3-8a43-eae4bd01d18a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_be189b38-b8d5-46c5-ba84-2876d21887f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_be189b38-b8d5-46c5-ba84-2876d21887f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_be189b38-b8d5-46c5-ba84-2876d21887f8" xlink:to="loc_us-gaap_EquityComponentDomain_be189b38-b8d5-46c5-ba84-2876d21887f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9b523902-fa34-4a67-a410-da84f420174c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_be189b38-b8d5-46c5-ba84-2876d21887f8" xlink:to="loc_us-gaap_EquityComponentDomain_9b523902-fa34-4a67-a410-da84f420174c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_798c21ea-ca0f-4a36-affa-4d8ef9a037af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b523902-fa34-4a67-a410-da84f420174c" xlink:to="loc_us-gaap_CommonStockMember_798c21ea-ca0f-4a36-affa-4d8ef9a037af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_87821a32-cea9-4447-ad72-ec859751c4db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b523902-fa34-4a67-a410-da84f420174c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_87821a32-cea9-4447-ad72-ec859751c4db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_289c4515-fc43-4ff1-9394-3825159319f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b523902-fa34-4a67-a410-da84f420174c" xlink:to="loc_us-gaap_RetainedEarningsMember_289c4515-fc43-4ff1-9394-3825159319f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_ca5363a2-12a5-4cca-be1d-01abe1235950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b523902-fa34-4a67-a410-da84f420174c" xlink:to="loc_us-gaap_TreasuryStockMember_ca5363a2-12a5-4cca-be1d-01abe1235950" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_2608882f-37aa-46eb-bc82-2a0d513c216f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b523902-fa34-4a67-a410-da84f420174c" xlink:to="loc_us-gaap_NoncontrollingInterestMember_2608882f-37aa-46eb-bc82-2a0d513c216f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#BasisofPresentationNetOperatingRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails" xlink:type="extended" id="ie2346cfd608941929cac0e65862d1776_BasisofPresentationNetOperatingRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_814a6f20-0a93-4da7-ac85-416f739185dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7cd6090c-fe17-4936-bfcb-7df930704981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_814a6f20-0a93-4da7-ac85-416f739185dd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7cd6090c-fe17-4936-bfcb-7df930704981" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3f8925e7-2f18-45d4-92cb-96a2ba2d9fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_814a6f20-0a93-4da7-ac85-416f739185dd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3f8925e7-2f18-45d4-92cb-96a2ba2d9fc7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c8102f42-b9d7-4800-8ef3-d7d018c11c3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3f8925e7-2f18-45d4-92cb-96a2ba2d9fc7" xlink:to="loc_srt_ProductOrServiceAxis_c8102f42-b9d7-4800-8ef3-d7d018c11c3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c8102f42-b9d7-4800-8ef3-d7d018c11c3d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c8102f42-b9d7-4800-8ef3-d7d018c11c3d" xlink:to="loc_srt_ProductsAndServicesDomain_c8102f42-b9d7-4800-8ef3-d7d018c11c3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c8102f42-b9d7-4800-8ef3-d7d018c11c3d" xlink:to="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareMember_f674c7d1-3e55-4fa2-84b0-bac6c18d58a6" xlink:href="ehc-20220331.xsd#ehc_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:to="loc_ehc_MedicareMember_f674c7d1-3e55-4fa2-84b0-bac6c18d58a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareAdvantageMember_2b78f19a-a101-44a7-9200-e7f6ea1d46f6" xlink:href="ehc-20220331.xsd#ehc_MedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:to="loc_ehc_MedicareAdvantageMember_2b78f19a-a101-44a7-9200-e7f6ea1d46f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ManagedCareMember_da60ab46-f784-4e86-9345-edc064722746" xlink:href="ehc-20220331.xsd#ehc_ManagedCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:to="loc_ehc_ManagedCareMember_da60ab46-f784-4e86-9345-edc064722746" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicaidMember_ea9c1cf1-ed4d-423b-8208-c8fa9413c4b9" xlink:href="ehc-20220331.xsd#ehc_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:to="loc_ehc_MedicaidMember_ea9c1cf1-ed4d-423b-8208-c8fa9413c4b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherThirdpartyPayorsMember_48b9e8df-6830-4b54-8b91-d3dd45d209de" xlink:href="ehc-20220331.xsd#ehc_OtherThirdpartyPayorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:to="loc_ehc_OtherThirdpartyPayorsMember_48b9e8df-6830-4b54-8b91-d3dd45d209de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WorkersCompensationMember_39c5b338-19a4-45d8-93c0-a111f736aa82" xlink:href="ehc-20220331.xsd#ehc_WorkersCompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:to="loc_ehc_WorkersCompensationMember_39c5b338-19a4-45d8-93c0-a111f736aa82" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PatientsMember_ab7100d3-3f3c-4ebc-961c-52dff2f21d03" xlink:href="ehc-20220331.xsd#ehc_PatientsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:to="loc_ehc_PatientsMember_ab7100d3-3f3c-4ebc-961c-52dff2f21d03" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherIncomeSourceMember_37b0bc6e-dd4b-4b2d-bbb7-fa18edf2425e" xlink:href="ehc-20220331.xsd#ehc_OtherIncomeSourceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:to="loc_ehc_OtherIncomeSourceMember_37b0bc6e-dd4b-4b2d-bbb7-fa18edf2425e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ffb0e814-7cfc-4f83-b16b-40f90f367680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3f8925e7-2f18-45d4-92cb-96a2ba2d9fc7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ffb0e814-7cfc-4f83-b16b-40f90f367680" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ffb0e814-7cfc-4f83-b16b-40f90f367680_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ffb0e814-7cfc-4f83-b16b-40f90f367680" xlink:to="loc_us-gaap_SegmentDomain_ffb0e814-7cfc-4f83-b16b-40f90f367680_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a47647ba-f10b-4635-b153-f54b0ffcd189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ffb0e814-7cfc-4f83-b16b-40f90f367680" xlink:to="loc_us-gaap_SegmentDomain_a47647ba-f10b-4635-b153-f54b0ffcd189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_f555a3b9-9fe4-4cd6-a834-61f40019154d" xlink:href="ehc-20220331.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a47647ba-f10b-4635-b153-f54b0ffcd189" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_f555a3b9-9fe4-4cd6-a834-61f40019154d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_588c4a00-b355-4134-b417-7d1ccdbc0d86" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a47647ba-f10b-4635-b153-f54b0ffcd189" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_588c4a00-b355-4134-b417-7d1ccdbc0d86" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#BusinessCombinationsTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails" xlink:type="extended" id="i1e5a384e96e1424d83dfe62110e2020e_BusinessCombinationsTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3ccc988e-5f1f-4380-b6d6-962e21a09bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6926a302-418e-42f6-85be-bd9ac4bdfb28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3ccc988e-5f1f-4380-b6d6-962e21a09bd2" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6926a302-418e-42f6-85be-bd9ac4bdfb28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_4b6a1375-292b-4d39-b410-f50ea4976e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3ccc988e-5f1f-4380-b6d6-962e21a09bd2" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_4b6a1375-292b-4d39-b410-f50ea4976e9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_97692354-ab45-40d7-b0ef-c074c0f57c32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3ccc988e-5f1f-4380-b6d6-962e21a09bd2" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_97692354-ab45-40d7-b0ef-c074c0f57c32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2ec081c-2e1d-4328-ae50-a549d18123e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3ccc988e-5f1f-4380-b6d6-962e21a09bd2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2ec081c-2e1d-4328-ae50-a549d18123e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b0a2c355-2663-4dc4-8a5e-e5e23f41584b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2ec081c-2e1d-4328-ae50-a549d18123e7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b0a2c355-2663-4dc4-8a5e-e5e23f41584b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b0a2c355-2663-4dc4-8a5e-e5e23f41584b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b0a2c355-2663-4dc4-8a5e-e5e23f41584b" xlink:to="loc_us-gaap_SegmentDomain_b0a2c355-2663-4dc4-8a5e-e5e23f41584b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_827ac23e-a28f-4220-bace-e3eef115b11a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b0a2c355-2663-4dc4-8a5e-e5e23f41584b" xlink:to="loc_us-gaap_SegmentDomain_827ac23e-a28f-4220-bace-e3eef115b11a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_738307ce-34a6-4f4f-bee3-d9c7457065e5" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_827ac23e-a28f-4220-bace-e3eef115b11a" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_738307ce-34a6-4f4f-bee3-d9c7457065e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e34b1e02-b3e8-46e5-aeb8-c2a22cd42715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2ec081c-2e1d-4328-ae50-a549d18123e7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e34b1e02-b3e8-46e5-aeb8-c2a22cd42715" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e34b1e02-b3e8-46e5-aeb8-c2a22cd42715_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e34b1e02-b3e8-46e5-aeb8-c2a22cd42715" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e34b1e02-b3e8-46e5-aeb8-c2a22cd42715_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4ef501e-6709-460a-a56b-0faea1e0c083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e34b1e02-b3e8-46e5-aeb8-c2a22cd42715" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4ef501e-6709-460a-a56b-0faea1e0c083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusMember_1bc3c595-4aa4-4701-8355-e53e49bd982b" xlink:href="ehc-20220331.xsd#ehc_SaintAlphonsusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4ef501e-6709-460a-a56b-0faea1e0c083" xlink:to="loc_ehc_SaintAlphonsusMember_1bc3c595-4aa4-4701-8355-e53e49bd982b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b1ffa708-6569-4806-854c-7e48b4f5dfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2ec081c-2e1d-4328-ae50-a549d18123e7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b1ffa708-6569-4806-854c-7e48b4f5dfe1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b1ffa708-6569-4806-854c-7e48b4f5dfe1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b1ffa708-6569-4806-854c-7e48b4f5dfe1" xlink:to="loc_us-gaap_RelatedPartyDomain_b1ffa708-6569-4806-854c-7e48b4f5dfe1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9f54cf34-8eb6-4a11-a2ec-aa6b302ac9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b1ffa708-6569-4806-854c-7e48b4f5dfe1" xlink:to="loc_us-gaap_RelatedPartyDomain_9f54cf34-8eb6-4a11-a2ec-aa6b302ac9a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_6873ce1f-aa03-4b60-b3fd-d5fe425fd905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9f54cf34-8eb6-4a11-a2ec-aa6b302ac9a0" xlink:to="loc_us-gaap_CorporateJointVentureMember_6873ce1f-aa03-4b60-b3fd-d5fe425fd905" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="extended" id="i98e120a28d374e9f9a8643bd8b90988d_BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_59008906-07d4-4e8f-ae5d-431b4a2592ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_59008906-07d4-4e8f-ae5d-431b4a2592ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_413eb5a3-0d5d-428d-89a1-a31853cc875a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_413eb5a3-0d5d-428d-89a1-a31853cc875a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_460881c2-8bd2-496e-abf9-814c9c69922a" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_460881c2-8bd2-496e-abf9-814c9c69922a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2ea54dc1-f3f1-4ddf-8800-371fa6578d24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2ea54dc1-f3f1-4ddf-8800-371fa6578d24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3e3329c1-3f3b-459f-a42d-3783f94a8ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_us-gaap_Goodwill_3e3329c1-3f3b-459f-a42d-3783f94a8ac2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_fc3926c5-1e0d-4487-9716-20c26c4d56a0" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_fc3926c5-1e0d-4487-9716-20c26c4d56a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_aa6585de-5fc7-4aed-8d91-4944dc485cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_aa6585de-5fc7-4aed-8d91-4944dc485cbf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_b41c8036-a567-4220-9128-d7fbb378c443" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_aa6585de-5fc7-4aed-8d91-4944dc485cbf" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_b41c8036-a567-4220-9128-d7fbb378c443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_b3bdad99-d829-41c6-962c-466ef5ba202d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_aa6585de-5fc7-4aed-8d91-4944dc485cbf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_b3bdad99-d829-41c6-962c-466ef5ba202d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll_ed7dd7ef-8358-4379-957c-c0550c466dd0" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_aa6585de-5fc7-4aed-8d91-4944dc485cbf" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll_ed7dd7ef-8358-4379-957c-c0550c466dd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_84b88783-4ddd-440a-8f77-8894f7a61d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_aa6585de-5fc7-4aed-8d91-4944dc485cbf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_84b88783-4ddd-440a-8f77-8894f7a61d5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_b03a0d6e-5263-4b95-a333-8102db6bd9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_aa6585de-5fc7-4aed-8d91-4944dc485cbf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_b03a0d6e-5263-4b95-a333-8102db6bd9b2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3c588f18-bfe9-41a3-b982-82d21f20e6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_aa6585de-5fc7-4aed-8d91-4944dc485cbf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3c588f18-bfe9-41a3-b982-82d21f20e6b4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_9d18dc87-50a1-4203-9b30-3e5c09f9d7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_9d18dc87-50a1-4203-9b30-3e5c09f9d7b7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_64954e7b-881e-4a37-82b4-d3d7467a17c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_64954e7b-881e-4a37-82b4-d3d7467a17c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_20dcab78-2d47-4ae1-8a37-0d7fbb9212f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_20dcab78-2d47-4ae1-8a37-0d7fbb9212f2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9581507c-54ec-4996-9472-1f38a13287c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9581507c-54ec-4996-9472-1f38a13287c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_013243d9-5b60-459b-900a-9dc976d97476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9581507c-54ec-4996-9472-1f38a13287c8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_013243d9-5b60-459b-900a-9dc976d97476" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_013243d9-5b60-459b-900a-9dc976d97476_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_013243d9-5b60-459b-900a-9dc976d97476" xlink:to="loc_us-gaap_SegmentDomain_013243d9-5b60-459b-900a-9dc976d97476_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c49310d3-0f57-4574-b32d-94f3435a1857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_013243d9-5b60-459b-900a-9dc976d97476" xlink:to="loc_us-gaap_SegmentDomain_c49310d3-0f57-4574-b32d-94f3435a1857" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_b4416660-95de-4191-b59f-cc93b2c8a842" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c49310d3-0f57-4574-b32d-94f3435a1857" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_b4416660-95de-4191-b59f-cc93b2c8a842" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f6d9f2a6-c3ea-4e22-8e25-25afefd9b352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9581507c-54ec-4996-9472-1f38a13287c8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f6d9f2a6-c3ea-4e22-8e25-25afefd9b352" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f6d9f2a6-c3ea-4e22-8e25-25afefd9b352_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f6d9f2a6-c3ea-4e22-8e25-25afefd9b352" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f6d9f2a6-c3ea-4e22-8e25-25afefd9b352_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c3c9864-6d22-4274-a5f3-072c34c7daa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f6d9f2a6-c3ea-4e22-8e25-25afefd9b352" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c3c9864-6d22-4274-a5f3-072c34c7daa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_6ea1b24c-4f42-48cc-a3d8-e6f226847485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c3c9864-6d22-4274-a5f3-072c34c7daa0" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_6ea1b24c-4f42-48cc-a3d8-e6f226847485" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_1646b08b-cf68-4f64-be77-81950bcfc853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c3c9864-6d22-4274-a5f3-072c34c7daa0" xlink:to="loc_us-gaap_TradeNamesMember_1646b08b-cf68-4f64-be77-81950bcfc853" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_36d483b6-8cc9-4bf9-88b7-9164871c17c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c3c9864-6d22-4274-a5f3-072c34c7daa0" xlink:to="loc_us-gaap_LicensingAgreementsMember_36d483b6-8cc9-4bf9-88b7-9164871c17c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_d8a6adfd-7b7a-48b6-bca6-3d69f9946bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c3c9864-6d22-4274-a5f3-072c34c7daa0" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_d8a6adfd-7b7a-48b6-bca6-3d69f9946bcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_092f6e70-453f-4386-a208-934ed1e9affa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9581507c-54ec-4996-9472-1f38a13287c8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_092f6e70-453f-4386-a208-934ed1e9affa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_092f6e70-453f-4386-a208-934ed1e9affa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_092f6e70-453f-4386-a208-934ed1e9affa" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_092f6e70-453f-4386-a208-934ed1e9affa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aaa1d315-2dca-473b-bd7a-a9c40dacefe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_092f6e70-453f-4386-a208-934ed1e9affa" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aaa1d315-2dca-473b-bd7a-a9c40dacefe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusMember_29f89b21-03f6-4c49-b5cf-3b90fc2d5966" xlink:href="ehc-20220331.xsd#ehc_SaintAlphonsusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aaa1d315-2dca-473b-bd7a-a9c40dacefe1" xlink:to="loc_ehc_SaintAlphonsusMember_29f89b21-03f6-4c49-b5cf-3b90fc2d5966" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#BusinessCombinationsNetCashPaidforAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails" xlink:type="extended" id="i786fa28831b6435e9c5dec5ac7128f40_BusinessCombinationsNetCashPaidforAcquisitionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4d54b720-e35e-45e5-95de-6eb09c192bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_f6089487-8242-4069-95c8-0893cecbe9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d54b720-e35e-45e5-95de-6eb09c192bdd" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_f6089487-8242-4069-95c8-0893cecbe9d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_762f9db4-960d-4525-a15f-b11a3cb376f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d54b720-e35e-45e5-95de-6eb09c192bdd" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_762f9db4-960d-4525-a15f-b11a3cb376f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_6c6645a5-4ff9-4090-8ce8-8fb6b512b954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d54b720-e35e-45e5-95de-6eb09c192bdd" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_6c6645a5-4ff9-4090-8ce8-8fb6b512b954" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue_87b97a04-38db-48b7-9d5e-aa011150eedb" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d54b720-e35e-45e5-95de-6eb09c192bdd" xlink:to="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue_87b97a04-38db-48b7-9d5e-aa011150eedb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ecc87365-5b13-4c7d-830d-b619f657f966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d54b720-e35e-45e5-95de-6eb09c192bdd" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ecc87365-5b13-4c7d-830d-b619f657f966" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c99b823e-57c3-4028-b9c1-dfb622f702e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d54b720-e35e-45e5-95de-6eb09c192bdd" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c99b823e-57c3-4028-b9c1-dfb622f702e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_594b15c8-d3b8-4434-b35d-9662a08b24ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c99b823e-57c3-4028-b9c1-dfb622f702e7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_594b15c8-d3b8-4434-b35d-9662a08b24ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_594b15c8-d3b8-4434-b35d-9662a08b24ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_594b15c8-d3b8-4434-b35d-9662a08b24ef" xlink:to="loc_us-gaap_SegmentDomain_594b15c8-d3b8-4434-b35d-9662a08b24ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_794b96d8-fbf8-4568-b12f-cf1b0cf266b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_594b15c8-d3b8-4434-b35d-9662a08b24ef" xlink:to="loc_us-gaap_SegmentDomain_794b96d8-fbf8-4568-b12f-cf1b0cf266b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_7de7ecad-4466-4104-b197-da267269f1e6" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_794b96d8-fbf8-4568-b12f-cf1b0cf266b2" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_7de7ecad-4466-4104-b197-da267269f1e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b2192370-3b7d-4f37-9c88-cd9986c5b0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c99b823e-57c3-4028-b9c1-dfb622f702e7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b2192370-3b7d-4f37-9c88-cd9986c5b0d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b2192370-3b7d-4f37-9c88-cd9986c5b0d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b2192370-3b7d-4f37-9c88-cd9986c5b0d0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b2192370-3b7d-4f37-9c88-cd9986c5b0d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6443f984-ee64-4754-b594-bdf4143b692a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b2192370-3b7d-4f37-9c88-cd9986c5b0d0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6443f984-ee64-4754-b594-bdf4143b692a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusMember_60ba6a22-f4cf-4c58-aaa8-b473f061019d" xlink:href="ehc-20220331.xsd#ehc_SaintAlphonsusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6443f984-ee64-4754-b594-bdf4143b692a" xlink:to="loc_ehc_SaintAlphonsusMember_60ba6a22-f4cf-4c58-aaa8-b473f061019d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#BusinessCombinationsProFormaResultsofOperationDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails" xlink:type="extended" id="i62a7a54f97554333b9fc330bdb93a0ce_BusinessCombinationsProFormaResultsofOperationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fb9bcc84-8ed5-4d8d-a681-a1f38b85e3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_dd219de4-12d6-4579-881a-a1386d14c6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb9bcc84-8ed5-4d8d-a681-a1f38b85e3d8" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_dd219de4-12d6-4579-881a-a1386d14c6b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_fbd5d221-dd5e-4d16-a7ae-5f70c3a73b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb9bcc84-8ed5-4d8d-a681-a1f38b85e3d8" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_fbd5d221-dd5e-4d16-a7ae-5f70c3a73b62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_c04ab89c-0f25-4ed9-8e42-36aa532acc42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb9bcc84-8ed5-4d8d-a681-a1f38b85e3d8" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_c04ab89c-0f25-4ed9-8e42-36aa532acc42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_80502d6c-a5da-4380-aeea-a585cb536304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb9bcc84-8ed5-4d8d-a681-a1f38b85e3d8" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_80502d6c-a5da-4380-aeea-a585cb536304" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_149efe38-c345-4807-81a3-e9132bb1aa51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb9bcc84-8ed5-4d8d-a681-a1f38b85e3d8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_149efe38-c345-4807-81a3-e9132bb1aa51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_40996f2b-fec3-47f4-92b6-65d14b57292a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_149efe38-c345-4807-81a3-e9132bb1aa51" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_40996f2b-fec3-47f4-92b6-65d14b57292a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_40996f2b-fec3-47f4-92b6-65d14b57292a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_40996f2b-fec3-47f4-92b6-65d14b57292a" xlink:to="loc_us-gaap_SegmentDomain_40996f2b-fec3-47f4-92b6-65d14b57292a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_699db501-d780-4fff-ad5d-642675d89f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_40996f2b-fec3-47f4-92b6-65d14b57292a" xlink:to="loc_us-gaap_SegmentDomain_699db501-d780-4fff-ad5d-642675d89f45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_99fdc5b2-acde-443e-b682-881d13c3fb36" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_699db501-d780-4fff-ad5d-642675d89f45" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_99fdc5b2-acde-443e-b682-881d13c3fb36" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#VariableInterestEntitiesTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails" xlink:type="extended" id="i8e0d5700c5c946919eda1cca8912959d_VariableInterestEntitiesTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_ec227dd5-a25c-434f-ae09-7d0a4c5f0812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated_9f51a234-7647-448f-b7a5-cec75b4335fa" xlink:href="ehc-20220331.xsd#ehc_VariableInterestEntityNumberofEntitiesConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ec227dd5-a25c-434f-ae09-7d0a4c5f0812" xlink:to="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated_9f51a234-7647-448f-b7a5-cec75b4335fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_231be058-9a70-4598-bf81-2596b151150e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ec227dd5-a25c-434f-ae09-7d0a4c5f0812" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_231be058-9a70-4598-bf81-2596b151150e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_22b5b66a-b0f0-4de4-9372-b56d6e99a1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ec227dd5-a25c-434f-ae09-7d0a4c5f0812" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_22b5b66a-b0f0-4de4-9372-b56d6e99a1db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_a1fbd8aa-100a-4523-a247-b8396d3b6081" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_22b5b66a-b0f0-4de4-9372-b56d6e99a1db" xlink:to="loc_srt_ConsolidatedEntitiesAxis_a1fbd8aa-100a-4523-a247-b8396d3b6081" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_a1fbd8aa-100a-4523-a247-b8396d3b6081_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_a1fbd8aa-100a-4523-a247-b8396d3b6081" xlink:to="loc_srt_ConsolidatedEntitiesDomain_a1fbd8aa-100a-4523-a247-b8396d3b6081_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_56b4804f-9809-4b54-b1d3-f9f6055debfa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_a1fbd8aa-100a-4523-a247-b8396d3b6081" xlink:to="loc_srt_ConsolidatedEntitiesDomain_56b4804f-9809-4b54-b1d3-f9f6055debfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_5f383ff0-8fdb-45c1-abb2-79f1a7737380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_56b4804f-9809-4b54-b1d3-f9f6055debfa" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_5f383ff0-8fdb-45c1-abb2-79f1a7737380" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_54f086f0-c62b-4239-8680-0c6d477cabc7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_22b5b66a-b0f0-4de4-9372-b56d6e99a1db" xlink:to="loc_srt_RangeAxis_54f086f0-c62b-4239-8680-0c6d477cabc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_54f086f0-c62b-4239-8680-0c6d477cabc7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_54f086f0-c62b-4239-8680-0c6d477cabc7" xlink:to="loc_srt_RangeMember_54f086f0-c62b-4239-8680-0c6d477cabc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a3fcc782-fe99-4698-8065-4389e3063aa1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_54f086f0-c62b-4239-8680-0c6d477cabc7" xlink:to="loc_srt_RangeMember_a3fcc782-fe99-4698-8065-4389e3063aa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6c71c734-a48c-443b-98ba-ada1385c9fbe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a3fcc782-fe99-4698-8065-4389e3063aa1" xlink:to="loc_srt_MinimumMember_6c71c734-a48c-443b-98ba-ada1385c9fbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_59cc7f1a-4ca1-4954-9d5c-0ea13ffe57dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a3fcc782-fe99-4698-8065-4389e3063aa1" xlink:to="loc_srt_MaximumMember_59cc7f1a-4ca1-4954-9d5c-0ea13ffe57dd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails" xlink:type="extended" id="i41c1ab241cfa4f9b936f52ffd600ac34_VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_c14f004d-2329-4263-891b-a9ddbbbe9e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3fa1aef6-978d-4ae0-b448-69bfa7e76a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c14f004d-2329-4263-891b-a9ddbbbe9e10" xlink:to="loc_us-gaap_AssetsAbstract_3fa1aef6-978d-4ae0-b448-69bfa7e76a6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_53ead133-810c-478f-b114-2c94b230e0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_3fa1aef6-978d-4ae0-b448-69bfa7e76a6a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_53ead133-810c-478f-b114-2c94b230e0a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_82c948db-e249-49ff-ac60-9a496a157edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_53ead133-810c-478f-b114-2c94b230e0a5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_82c948db-e249-49ff-ac60-9a496a157edd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_254a21f2-5090-4a75-80e9-d67596c64be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_53ead133-810c-478f-b114-2c94b230e0a5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_254a21f2-5090-4a75-80e9-d67596c64be3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_91f292c3-724d-43b8-9efc-939facdc225c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_53ead133-810c-478f-b114-2c94b230e0a5" xlink:to="loc_us-gaap_OtherAssetsCurrent_91f292c3-724d-43b8-9efc-939facdc225c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_747b610d-742f-45f8-813e-46bfefade795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_53ead133-810c-478f-b114-2c94b230e0a5" xlink:to="loc_us-gaap_AssetsCurrent_747b610d-742f-45f8-813e-46bfefade795" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3b4349f4-359c-4c98-9152-b49333f6c5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_3fa1aef6-978d-4ae0-b448-69bfa7e76a6a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3b4349f4-359c-4c98-9152-b49333f6c5e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_06cb0673-fae0-40ce-b645-9c9527c9dddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_3fa1aef6-978d-4ae0-b448-69bfa7e76a6a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_06cb0673-fae0-40ce-b645-9c9527c9dddb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6efeed47-c045-42b7-a5e8-c982c6dd2531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_3fa1aef6-978d-4ae0-b448-69bfa7e76a6a" xlink:to="loc_us-gaap_Goodwill_6efeed47-c045-42b7-a5e8-c982c6dd2531" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_632f0312-684c-42f8-b05a-e53d5624f954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_3fa1aef6-978d-4ae0-b448-69bfa7e76a6a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_632f0312-684c-42f8-b05a-e53d5624f954" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_58669b28-10e5-4c76-8d9f-618e447c3b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_3fa1aef6-978d-4ae0-b448-69bfa7e76a6a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_58669b28-10e5-4c76-8d9f-618e447c3b3a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5455ffb2-a84c-4856-be28-ed50a5ad3024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_3fa1aef6-978d-4ae0-b448-69bfa7e76a6a" xlink:to="loc_us-gaap_Assets_5455ffb2-a84c-4856-be28-ed50a5ad3024" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_ec0750fd-44ba-45c6-b1c8-2c8ffd93ef92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c14f004d-2329-4263-891b-a9ddbbbe9e10" xlink:to="loc_us-gaap_LiabilitiesAbstract_ec0750fd-44ba-45c6-b1c8-2c8ffd93ef92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_67200777-ffb9-491a-a4c3-9445036d2842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_ec0750fd-44ba-45c6-b1c8-2c8ffd93ef92" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_67200777-ffb9-491a-a4c3-9445036d2842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_5d2300c0-5fa7-4146-b5ba-d75fac2f69b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_67200777-ffb9-491a-a4c3-9445036d2842" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_5d2300c0-5fa7-4146-b5ba-d75fac2f69b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_aa8cc449-4dd7-4f70-af06-5dc82b30430d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_67200777-ffb9-491a-a4c3-9445036d2842" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_aa8cc449-4dd7-4f70-af06-5dc82b30430d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_bd2e9892-934a-4ddb-a044-28b4bccab1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_67200777-ffb9-491a-a4c3-9445036d2842" xlink:to="loc_us-gaap_AccountsPayableCurrent_bd2e9892-934a-4ddb-a044-28b4bccab1b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5d41acf4-8a8f-409d-839e-9151e497690d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_67200777-ffb9-491a-a4c3-9445036d2842" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5d41acf4-8a8f-409d-839e-9151e497690d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cc9975db-d0db-43aa-9aa0-fb30d45c509f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_67200777-ffb9-491a-a4c3-9445036d2842" xlink:to="loc_us-gaap_LiabilitiesCurrent_cc9975db-d0db-43aa-9aa0-fb30d45c509f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6525296f-33be-4e5e-ba49-787211923870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_ec0750fd-44ba-45c6-b1c8-2c8ffd93ef92" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6525296f-33be-4e5e-ba49-787211923870" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c2cc2678-2de5-4530-8f23-f177989e9663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_ec0750fd-44ba-45c6-b1c8-2c8ffd93ef92" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c2cc2678-2de5-4530-8f23-f177989e9663" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_baa152aa-3e7e-482d-ba10-ea27ef4c6b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_ec0750fd-44ba-45c6-b1c8-2c8ffd93ef92" xlink:to="loc_us-gaap_Liabilities_baa152aa-3e7e-482d-ba10-ea27ef4c6b23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf7699c5-7a91-458d-a104-25083c778fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c14f004d-2329-4263-891b-a9ddbbbe9e10" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf7699c5-7a91-458d-a104-25083c778fd1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_3551ef10-67a9-4501-865e-1ba1df90bb0b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf7699c5-7a91-458d-a104-25083c778fd1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_3551ef10-67a9-4501-865e-1ba1df90bb0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3551ef10-67a9-4501-865e-1ba1df90bb0b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_3551ef10-67a9-4501-865e-1ba1df90bb0b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3551ef10-67a9-4501-865e-1ba1df90bb0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_7aae4023-8c23-4a54-a380-1b0744e037a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_3551ef10-67a9-4501-865e-1ba1df90bb0b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_7aae4023-8c23-4a54-a380-1b0744e037a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ab7e7199-7c8f-4fb1-b1d6-b3b7de36d7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_7aae4023-8c23-4a54-a380-1b0744e037a7" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ab7e7199-7c8f-4fb1-b1d6-b3b7de36d7ba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#LongtermDebtLongtermDebtOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="extended" id="i1934e9af439b45398c30b576a85b0c1c_LongtermDebtLongtermDebtOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_77f3eb46-ef65-4cbe-b054-a1f0b0f50c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_42b25e32-9a34-48da-a8b9-9738a638a8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77f3eb46-ef65-4cbe-b054-a1f0b0f50c9b" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_42b25e32-9a34-48da-a8b9-9738a638a8fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f5c503b8-61ea-4c3d-b07b-f5df91cefd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_42b25e32-9a34-48da-a8b9-9738a638a8fa" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f5c503b8-61ea-4c3d-b07b-f5df91cefd5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_120f4a20-f91a-495e-8cbc-27362ed4299a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_42b25e32-9a34-48da-a8b9-9738a638a8fa" xlink:to="loc_us-gaap_LongTermDebt_120f4a20-f91a-495e-8cbc-27362ed4299a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_41ce152a-00c2-4d1e-91a5-4ed4a3d55fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_42b25e32-9a34-48da-a8b9-9738a638a8fa" xlink:to="loc_us-gaap_FinanceLeaseLiability_41ce152a-00c2-4d1e-91a5-4ed4a3d55fef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_9bf4788c-07e0-4272-914d-352fc3888d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_42b25e32-9a34-48da-a8b9-9738a638a8fa" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_9bf4788c-07e0-4272-914d-352fc3888d20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_df4eaeb6-22d2-4f68-8ffa-0a60fdaffb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_42b25e32-9a34-48da-a8b9-9738a638a8fa" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_df4eaeb6-22d2-4f68-8ffa-0a60fdaffb8a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_3e1ecf8e-4008-44ef-8246-ca4d49b817a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_42b25e32-9a34-48da-a8b9-9738a638a8fa" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_3e1ecf8e-4008-44ef-8246-ca4d49b817a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e5e65252-b4f0-4474-87bc-fd8c37c8ef51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77f3eb46-ef65-4cbe-b054-a1f0b0f50c9b" xlink:to="loc_us-gaap_DebtInstrumentTable_e5e65252-b4f0-4474-87bc-fd8c37c8ef51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ed806444-ba14-4646-996b-ec65fbd037e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e5e65252-b4f0-4474-87bc-fd8c37c8ef51" xlink:to="loc_us-gaap_CreditFacilityAxis_ed806444-ba14-4646-996b-ec65fbd037e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ed806444-ba14-4646-996b-ec65fbd037e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_ed806444-ba14-4646-996b-ec65fbd037e3" xlink:to="loc_us-gaap_CreditFacilityDomain_ed806444-ba14-4646-996b-ec65fbd037e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_81d64c66-eec2-427c-bee9-e42f8fd0fd30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_ed806444-ba14-4646-996b-ec65fbd037e3" xlink:to="loc_us-gaap_CreditFacilityDomain_81d64c66-eec2-427c-bee9-e42f8fd0fd30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_ad0d63f3-a061-4d82-9976-2673f4c1697c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_81d64c66-eec2-427c-bee9-e42f8fd0fd30" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_ad0d63f3-a061-4d82-9976-2673f4c1697c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fc0b760b-bfb1-436a-b58f-86dc25bfee8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e5e65252-b4f0-4474-87bc-fd8c37c8ef51" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fc0b760b-bfb1-436a-b58f-86dc25bfee8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fc0b760b-bfb1-436a-b58f-86dc25bfee8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fc0b760b-bfb1-436a-b58f-86dc25bfee8f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fc0b760b-bfb1-436a-b58f-86dc25bfee8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dae3d75e-90f0-442d-a716-053b4e09de4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fc0b760b-bfb1-436a-b58f-86dc25bfee8f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dae3d75e-90f0-442d-a716-053b4e09de4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_534c43df-075a-48b6-a5d6-0dd48198fa67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dae3d75e-90f0-442d-a716-053b4e09de4d" xlink:to="loc_us-gaap_LoansPayableMember_534c43df-075a-48b6-a5d6-0dd48198fa67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_8f945435-8ac4-4643-8672-33bae84cddee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dae3d75e-90f0-442d-a716-053b4e09de4d" xlink:to="loc_us-gaap_SeniorNotesMember_8f945435-8ac4-4643-8672-33bae84cddee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_a3a09642-3fa7-49c4-97fc-60812c8b110b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dae3d75e-90f0-442d-a716-053b4e09de4d" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_a3a09642-3fa7-49c4-97fc-60812c8b110b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5abb0c51-d322-4f83-bb24-98e3ccaf67af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e5e65252-b4f0-4474-87bc-fd8c37c8ef51" xlink:to="loc_us-gaap_DebtInstrumentAxis_5abb0c51-d322-4f83-bb24-98e3ccaf67af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5abb0c51-d322-4f83-bb24-98e3ccaf67af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5abb0c51-d322-4f83-bb24-98e3ccaf67af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5abb0c51-d322-4f83-bb24-98e3ccaf67af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e2bd9f5f-e5b2-4acf-9d98-a58ce22c7f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5abb0c51-d322-4f83-bb24-98e3ccaf67af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e2bd9f5f-e5b2-4acf-9d98-a58ce22c7f78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember_eb11ef42-2508-46c7-9583-6459b8546ad9" xlink:href="ehc-20220331.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e2bd9f5f-e5b2-4acf-9d98-a58ce22c7f78" xlink:to="loc_ehc_TermLoanFacilitiesMember_eb11ef42-2508-46c7-9583-6459b8546ad9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_c2577b7d-eb8c-4301-820f-1c98751e4916" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e2bd9f5f-e5b2-4acf-9d98-a58ce22c7f78" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_c2577b7d-eb8c-4301-820f-1c98751e4916" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_f2d78c18-ef67-4f81-afb8-8b49e99d4b40" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e2bd9f5f-e5b2-4acf-9d98-a58ce22c7f78" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_f2d78c18-ef67-4f81-afb8-8b49e99d4b40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_d49aa21c-e3c7-4213-aaff-70350f9c06e7" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e2bd9f5f-e5b2-4acf-9d98-a58ce22c7f78" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_d49aa21c-e3c7-4213-aaff-70350f9c06e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_b8c77a58-d4c1-49fd-aa75-62ae71fc834d" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e2bd9f5f-e5b2-4acf-9d98-a58ce22c7f78" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_b8c77a58-d4c1-49fd-aa75-62ae71fc834d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4625Due2031Member_85d62c64-506c-4e54-b135-92fe8ab7de76" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes4625Due2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e2bd9f5f-e5b2-4acf-9d98-a58ce22c7f78" xlink:to="loc_ehc_SeniorNotes4625Due2031Member_85d62c64-506c-4e54-b135-92fe8ab7de76" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtTextualDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#LongtermDebtTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtTextualDetails" xlink:type="extended" id="ia55287895c9d4c67979cb17eac921f78_LongtermDebtTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2017d3a6-36aa-4a64-87ac-61c9be096cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8f5abbf9-591b-4374-ab0c-2c91fa0ce0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2017d3a6-36aa-4a64-87ac-61c9be096cd5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8f5abbf9-591b-4374-ab0c-2c91fa0ce0b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatio_3916bc08-e93e-48a1-ae14-e3c4ea4d35e8" xlink:href="ehc-20220331.xsd#ehc_DebtInstrumentCovenantLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2017d3a6-36aa-4a64-87ac-61c9be096cd5" xlink:to="loc_ehc_DebtInstrumentCovenantLeverageRatio_3916bc08-e93e-48a1-ae14-e3c4ea4d35e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_a6ae0758-20f2-4f2a-acb3-38d971cb6908" xlink:href="ehc-20220331.xsd#ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2017d3a6-36aa-4a64-87ac-61c9be096cd5" xlink:to="loc_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_a6ae0758-20f2-4f2a-acb3-38d971cb6908" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_a1d6e825-a0db-4dbd-898c-13016a5d1102" xlink:href="ehc-20220331.xsd#ehc_DebtInstrumentAmendmentAgreementAmountToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2017d3a6-36aa-4a64-87ac-61c9be096cd5" xlink:to="loc_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_a1d6e825-a0db-4dbd-898c-13016a5d1102" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_ddfc64c1-9c83-4173-959e-976db7337fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2017d3a6-36aa-4a64-87ac-61c9be096cd5" xlink:to="loc_us-gaap_RepaymentsOfDebt_ddfc64c1-9c83-4173-959e-976db7337fe6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_4d9a4e78-24cd-4f70-a188-9ea8bc6294fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2017d3a6-36aa-4a64-87ac-61c9be096cd5" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_4d9a4e78-24cd-4f70-a188-9ea8bc6294fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0d4af75d-f528-4e37-ac2a-5c8397653f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2017d3a6-36aa-4a64-87ac-61c9be096cd5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0d4af75d-f528-4e37-ac2a-5c8397653f1c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2948535a-91d0-4932-b54f-483425a3706b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2017d3a6-36aa-4a64-87ac-61c9be096cd5" xlink:to="loc_us-gaap_DebtInstrumentTable_2948535a-91d0-4932-b54f-483425a3706b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6bf9a78d-fbed-4818-a115-cfa628ced5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2948535a-91d0-4932-b54f-483425a3706b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6bf9a78d-fbed-4818-a115-cfa628ced5e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6bf9a78d-fbed-4818-a115-cfa628ced5e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6bf9a78d-fbed-4818-a115-cfa628ced5e8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6bf9a78d-fbed-4818-a115-cfa628ced5e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7a4a386d-afe6-45da-82f5-0a822fbb26e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6bf9a78d-fbed-4818-a115-cfa628ced5e8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7a4a386d-afe6-45da-82f5-0a822fbb26e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_53e78b6d-b038-4f96-91b4-084e8e148105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7a4a386d-afe6-45da-82f5-0a822fbb26e0" xlink:to="loc_us-gaap_SeniorNotesMember_53e78b6d-b038-4f96-91b4-084e8e148105" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5cf9e2c3-0ef6-47d6-aea0-4bbe841394bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2948535a-91d0-4932-b54f-483425a3706b" xlink:to="loc_us-gaap_DebtInstrumentAxis_5cf9e2c3-0ef6-47d6-aea0-4bbe841394bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5cf9e2c3-0ef6-47d6-aea0-4bbe841394bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5cf9e2c3-0ef6-47d6-aea0-4bbe841394bd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5cf9e2c3-0ef6-47d6-aea0-4bbe841394bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5a1a6613-7c98-483f-8451-e6865dd9ff7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5cf9e2c3-0ef6-47d6-aea0-4bbe841394bd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5a1a6613-7c98-483f-8451-e6865dd9ff7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_c9e75ea8-8d4c-4272-bdb8-80374aeee8b1" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a1a6613-7c98-483f-8451-e6865dd9ff7b" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_c9e75ea8-8d4c-4272-bdb8-80374aeee8b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_39215e1a-a177-48b8-b283-bad9737177bd" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a1a6613-7c98-483f-8451-e6865dd9ff7b" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_39215e1a-a177-48b8-b283-bad9737177bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_7a9efb87-0d44-4e29-bac2-2ecb56392681" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a1a6613-7c98-483f-8451-e6865dd9ff7b" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_7a9efb87-0d44-4e29-bac2-2ecb56392681" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4625Due2031Member_af440400-7ec0-4cc8-ad53-42daccf59afd" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes4625Due2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a1a6613-7c98-483f-8451-e6865dd9ff7b" xlink:to="loc_ehc_SeniorNotes4625Due2031Member_af440400-7ec0-4cc8-ad53-42daccf59afd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_0ac2f5de-c33b-4dc6-beaf-f517f07e6020" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a1a6613-7c98-483f-8451-e6865dd9ff7b" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_0ac2f5de-c33b-4dc6-beaf-f517f07e6020" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" xlink:type="extended" id="ifc5de7d7ccb444d0808fcd24c0fbd909_RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_2d4069db-53ea-49f0-b297-cce0f4b76b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_3cee71cf-e89f-4567-be72-84f589943cd0" xlink:href="ehc-20220331.xsd#ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_2d4069db-53ea-49f0-b297-cce0f4b76b72" xlink:to="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_3cee71cf-e89f-4567-be72-84f589943cd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_edcac71a-3a4c-4ee0-a57d-db2986f0cd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_3cee71cf-e89f-4567-be72-84f589943cd0" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_edcac71a-3a4c-4ee0-a57d-db2986f0cd4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_6d1471c4-942c-4466-96e9-99eff1345b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_3cee71cf-e89f-4567-be72-84f589943cd0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_6d1471c4-942c-4466-96e9-99eff1345b17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_ec762bc2-6522-4566-8910-c3c3312e687d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_3cee71cf-e89f-4567-be72-84f589943cd0" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_ec762bc2-6522-4566-8910-c3c3312e687d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_dae8609e-757d-4589-9fa5-15cd428b4ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_dad40797-5df6-4abf-9566-9ae027cec37d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_2d4069db-53ea-49f0-b297-cce0f4b76b72" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_dad40797-5df6-4abf-9566-9ae027cec37d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9ff0080a-63e8-4330-a4f6-f2fe539fc718" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_dad40797-5df6-4abf-9566-9ae027cec37d" xlink:to="loc_dei_LegalEntityAxis_9ff0080a-63e8-4330-a4f6-f2fe539fc718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9ff0080a-63e8-4330-a4f6-f2fe539fc718_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9ff0080a-63e8-4330-a4f6-f2fe539fc718" xlink:to="loc_dei_EntityDomain_9ff0080a-63e8-4330-a4f6-f2fe539fc718_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ee0ce13e-4d2f-4228-b2a5-ef95b1a246af" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9ff0080a-63e8-4330-a4f6-f2fe539fc718" xlink:to="loc_dei_EntityDomain_ee0ce13e-4d2f-4228-b2a5-ef95b1a246af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestMember_e86aa71a-be96-47a9-985f-075e4f37bd09" xlink:href="ehc-20220331.xsd#ehc_RedeemableNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ee0ce13e-4d2f-4228-b2a5-ef95b1a246af" xlink:to="loc_ehc_RedeemableNoncontrollingInterestMember_e86aa71a-be96-47a9-985f-075e4f37bd09" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" id="i56c9f9559e79467caaf085a53fe44341_FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_06b558a5-4e80-4033-8e34-fe46f197da12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_42e2ce68-d521-4b91-b17b-ed49021f26fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_06b558a5-4e80-4033-8e34-fe46f197da12" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_42e2ce68-d521-4b91-b17b-ed49021f26fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_61b88b1d-a8be-42de-a857-061cbabf4539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_42e2ce68-d521-4b91-b17b-ed49021f26fd" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_61b88b1d-a8be-42de-a857-061cbabf4539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_a6733bc6-8308-4976-8112-f991d4da3220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_42e2ce68-d521-4b91-b17b-ed49021f26fd" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_a6733bc6-8308-4976-8112-f991d4da3220" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_92880bdb-e685-42a3-a7fa-5493267b9214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_42e2ce68-d521-4b91-b17b-ed49021f26fd" xlink:to="loc_us-gaap_OtherAssetsCurrent_92880bdb-e685-42a3-a7fa-5493267b9214" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1dd18f59-23ec-4878-b534-a302c92f714c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_42e2ce68-d521-4b91-b17b-ed49021f26fd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1dd18f59-23ec-4878-b534-a302c92f714c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3049e203-e848-461f-a8b8-08641d40f562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_06b558a5-4e80-4033-8e34-fe46f197da12" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3049e203-e848-461f-a8b8-08641d40f562" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ed391af1-8027-4af9-bb89-15d797eb5445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3049e203-e848-461f-a8b8-08641d40f562" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ed391af1-8027-4af9-bb89-15d797eb5445" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ed391af1-8027-4af9-bb89-15d797eb5445_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ed391af1-8027-4af9-bb89-15d797eb5445" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ed391af1-8027-4af9-bb89-15d797eb5445_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e835a09-4b82-4a16-b3bf-acc6095e9b12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ed391af1-8027-4af9-bb89-15d797eb5445" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e835a09-4b82-4a16-b3bf-acc6095e9b12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_fd11acb6-906e-4b9b-8bb5-cfe6ac844e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e835a09-4b82-4a16-b3bf-acc6095e9b12" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_fd11acb6-906e-4b9b-8bb5-cfe6ac844e5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_79bbbcf2-a9bd-4b5e-b3a6-90892822e310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3049e203-e848-461f-a8b8-08641d40f562" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_79bbbcf2-a9bd-4b5e-b3a6-90892822e310" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79bbbcf2-a9bd-4b5e-b3a6-90892822e310_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_79bbbcf2-a9bd-4b5e-b3a6-90892822e310" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79bbbcf2-a9bd-4b5e-b3a6-90892822e310_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ff56534-9c2a-419a-b0bc-61f937d041b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_79bbbcf2-a9bd-4b5e-b3a6-90892822e310" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ff56534-9c2a-419a-b0bc-61f937d041b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3bd1ab01-6c21-4770-b2e8-019fe8659049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ff56534-9c2a-419a-b0bc-61f937d041b7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3bd1ab01-6c21-4770-b2e8-019fe8659049" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2ed572d6-f15c-4c42-87ec-a2e9eb372a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ff56534-9c2a-419a-b0bc-61f937d041b7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2ed572d6-f15c-4c42-87ec-a2e9eb372a9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9b9770a1-4a3c-42f1-b4b8-9c9d25add88a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ff56534-9c2a-419a-b0bc-61f937d041b7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9b9770a1-4a3c-42f1-b4b8-9c9d25add88a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5c281dc3-4367-478c-921a-6ab420f12278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3049e203-e848-461f-a8b8-08641d40f562" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5c281dc3-4367-478c-921a-6ab420f12278" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5c281dc3-4367-478c-921a-6ab420f12278_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5c281dc3-4367-478c-921a-6ab420f12278" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5c281dc3-4367-478c-921a-6ab420f12278_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_34fd9006-18c1-4aae-a54d-8eae835b5d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5c281dc3-4367-478c-921a-6ab420f12278" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_34fd9006-18c1-4aae-a54d-8eae835b5d9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_12e5ad86-c92f-4c0d-8fd1-6e98c92a6ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_34fd9006-18c1-4aae-a54d-8eae835b5d9b" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_12e5ad86-c92f-4c0d-8fd1-6e98c92a6ae4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_2d075579-6c48-401e-997e-b1e2b5ba10c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_34fd9006-18c1-4aae-a54d-8eae835b5d9b" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_2d075579-6c48-401e-997e-b1e2b5ba10c6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#FairValueMeasurementsTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails" xlink:type="extended" id="i017a1617ec67488784234552748eb89f_FairValueMeasurementsTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55a9a382-dff8-40e3-b48c-f8b79dd77abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_4218fc3b-f29f-49af-bedc-ddbb82e2c260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55a9a382-dff8-40e3-b48c-f8b79dd77abc" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_4218fc3b-f29f-49af-bedc-ddbb82e2c260" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9b64cc6d-e11b-48ba-ac08-d3ef0d7153ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55a9a382-dff8-40e3-b48c-f8b79dd77abc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9b64cc6d-e11b-48ba-ac08-d3ef0d7153ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_34a89ade-6c7f-4df8-83e6-7caa16f008a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9b64cc6d-e11b-48ba-ac08-d3ef0d7153ca" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_34a89ade-6c7f-4df8-83e6-7caa16f008a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_34a89ade-6c7f-4df8-83e6-7caa16f008a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_34a89ade-6c7f-4df8-83e6-7caa16f008a0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_34a89ade-6c7f-4df8-83e6-7caa16f008a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ba0f814-ddf3-4f10-af7c-457cf6030f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_34a89ade-6c7f-4df8-83e6-7caa16f008a0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ba0f814-ddf3-4f10-af7c-457cf6030f12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_16110b92-5e19-4638-9662-b1218fb3d881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ba0f814-ddf3-4f10-af7c-457cf6030f12" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_16110b92-5e19-4638-9662-b1218fb3d881" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails" xlink:type="extended" id="i5409b012795f489c827b1a440c643701_FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6fe42168-8c88-4b04-8a56-570a88212ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2d8c4259-77e1-464c-81e8-2a36d7bf2dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6fe42168-8c88-4b04-8a56-570a88212ddb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2d8c4259-77e1-464c-81e8-2a36d7bf2dcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_730e6718-793d-46a5-887a-5f321286abdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6fe42168-8c88-4b04-8a56-570a88212ddb" xlink:to="loc_us-gaap_LongTermDebtFairValue_730e6718-793d-46a5-887a-5f321286abdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d79a41a5-96d7-407a-820c-7991a8fcec60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6fe42168-8c88-4b04-8a56-570a88212ddb" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d79a41a5-96d7-407a-820c-7991a8fcec60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f1aa0d11-d93f-4393-b41f-5e7171de764b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d79a41a5-96d7-407a-820c-7991a8fcec60" xlink:to="loc_us-gaap_CreditFacilityAxis_f1aa0d11-d93f-4393-b41f-5e7171de764b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f1aa0d11-d93f-4393-b41f-5e7171de764b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_f1aa0d11-d93f-4393-b41f-5e7171de764b" xlink:to="loc_us-gaap_CreditFacilityDomain_f1aa0d11-d93f-4393-b41f-5e7171de764b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_263a91fe-fde2-49f8-955e-09bd7f4a549e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_f1aa0d11-d93f-4393-b41f-5e7171de764b" xlink:to="loc_us-gaap_CreditFacilityDomain_263a91fe-fde2-49f8-955e-09bd7f4a549e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_d612e020-97a0-4209-b74a-1a4ff572a351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_263a91fe-fde2-49f8-955e-09bd7f4a549e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_d612e020-97a0-4209-b74a-1a4ff572a351" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_131b1e4e-8829-44ea-ade4-bd4586f8296d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_263a91fe-fde2-49f8-955e-09bd7f4a549e" xlink:to="loc_us-gaap_LetterOfCreditMember_131b1e4e-8829-44ea-ade4-bd4586f8296d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6cb17b48-4b08-4ce4-b9ed-72de20f0f5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d79a41a5-96d7-407a-820c-7991a8fcec60" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6cb17b48-4b08-4ce4-b9ed-72de20f0f5a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6cb17b48-4b08-4ce4-b9ed-72de20f0f5a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6cb17b48-4b08-4ce4-b9ed-72de20f0f5a3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6cb17b48-4b08-4ce4-b9ed-72de20f0f5a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_924cdaf9-843e-48dd-9fe4-c26f876be9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6cb17b48-4b08-4ce4-b9ed-72de20f0f5a3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_924cdaf9-843e-48dd-9fe4-c26f876be9b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_e87ff3c5-e5d3-43fa-9027-2c19ea6d4f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_924cdaf9-843e-48dd-9fe4-c26f876be9b7" xlink:to="loc_us-gaap_LoansPayableMember_e87ff3c5-e5d3-43fa-9027-2c19ea6d4f4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_0254acc6-4a32-41a1-b1ff-855699ca6c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_924cdaf9-843e-48dd-9fe4-c26f876be9b7" xlink:to="loc_us-gaap_SeniorNotesMember_0254acc6-4a32-41a1-b1ff-855699ca6c84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_f62ae144-8e57-4048-93c6-2dc45adbda84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_924cdaf9-843e-48dd-9fe4-c26f876be9b7" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_f62ae144-8e57-4048-93c6-2dc45adbda84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b7c72929-b225-4298-9947-a9fb3dbbab13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d79a41a5-96d7-407a-820c-7991a8fcec60" xlink:to="loc_us-gaap_DebtInstrumentAxis_b7c72929-b225-4298-9947-a9fb3dbbab13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b7c72929-b225-4298-9947-a9fb3dbbab13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b7c72929-b225-4298-9947-a9fb3dbbab13" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b7c72929-b225-4298-9947-a9fb3dbbab13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_058fe961-727d-4516-8ea1-a7089ba8bd73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b7c72929-b225-4298-9947-a9fb3dbbab13" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_058fe961-727d-4516-8ea1-a7089ba8bd73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember_16e8a4f4-6a76-4726-ac4a-0e65e69143a4" xlink:href="ehc-20220331.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_058fe961-727d-4516-8ea1-a7089ba8bd73" xlink:to="loc_ehc_TermLoanFacilitiesMember_16e8a4f4-6a76-4726-ac4a-0e65e69143a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_d9c709ec-f576-49ca-b29f-736fd53be686" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_058fe961-727d-4516-8ea1-a7089ba8bd73" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_d9c709ec-f576-49ca-b29f-736fd53be686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_aecf6ade-b11f-42d1-ba99-db2b14efd9d8" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_058fe961-727d-4516-8ea1-a7089ba8bd73" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_aecf6ade-b11f-42d1-ba99-db2b14efd9d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_efbf92b6-d978-4ad5-a5b2-6ad25927dc55" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_058fe961-727d-4516-8ea1-a7089ba8bd73" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_efbf92b6-d978-4ad5-a5b2-6ad25927dc55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_9f17a6ce-d661-44bc-b985-0e810e5bf36e" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_058fe961-727d-4516-8ea1-a7089ba8bd73" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_9f17a6ce-d661-44bc-b985-0e810e5bf36e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4625Due2031Member_88c09667-e787-43ef-96b2-c850232deb83" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes4625Due2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_058fe961-727d-4516-8ea1-a7089ba8bd73" xlink:to="loc_ehc_SeniorNotes4625Due2031Member_88c09667-e787-43ef-96b2-c850232deb83" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_07f0f105-83b1-4b42-98fa-2a1dbfd0c8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d79a41a5-96d7-407a-820c-7991a8fcec60" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_07f0f105-83b1-4b42-98fa-2a1dbfd0c8b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_07f0f105-83b1-4b42-98fa-2a1dbfd0c8b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_07f0f105-83b1-4b42-98fa-2a1dbfd0c8b3" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_07f0f105-83b1-4b42-98fa-2a1dbfd0c8b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c453ebe5-bc8a-49df-a17f-d5a7f03ddfe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_07f0f105-83b1-4b42-98fa-2a1dbfd0c8b3" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c453ebe5-bc8a-49df-a17f-d5a7f03ddfe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5c0e6d03-bd99-427f-b17a-27643145504e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c453ebe5-bc8a-49df-a17f-d5a7f03ddfe4" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5c0e6d03-bd99-427f-b17a-27643145504e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_fd976cbf-82f8-440e-a0c1-51227e597b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c453ebe5-bc8a-49df-a17f-d5a7f03ddfe4" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_fd976cbf-82f8-440e-a0c1-51227e597b20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5e7c6ff8-fea1-4f3c-89e7-ca1a31894d10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c453ebe5-bc8a-49df-a17f-d5a7f03ddfe4" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5e7c6ff8-fea1-4f3c-89e7-ca1a31894d10" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#ShareBasedPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsDetails" xlink:type="extended" id="i92e867fb09304c6baf79250bdcb24fee_ShareBasedPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_63c4b775-8856-46b2-b164-153a6338da31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4236381c-536e-4a38-a630-7d382a60e7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_63c4b775-8856-46b2-b164-153a6338da31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4236381c-536e-4a38-a630-7d382a60e7e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_93040e15-7d20-4f2e-8dc7-13ddb10cde17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_63c4b775-8856-46b2-b164-153a6338da31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_93040e15-7d20-4f2e-8dc7-13ddb10cde17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_68f37bea-7b17-45c9-9997-63952b262036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_63c4b775-8856-46b2-b164-153a6338da31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_68f37bea-7b17-45c9-9997-63952b262036" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53118213-e586-4dfa-9a06-9954ea6ee913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_63c4b775-8856-46b2-b164-153a6338da31" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53118213-e586-4dfa-9a06-9954ea6ee913" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d5391e4c-74e8-4481-adf3-539025331150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53118213-e586-4dfa-9a06-9954ea6ee913" xlink:to="loc_us-gaap_AwardTypeAxis_d5391e4c-74e8-4481-adf3-539025331150" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5391e4c-74e8-4481-adf3-539025331150_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d5391e4c-74e8-4481-adf3-539025331150" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5391e4c-74e8-4481-adf3-539025331150_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4783066-0ae9-4030-9299-4a13fc6284c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d5391e4c-74e8-4481-adf3-539025331150" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4783066-0ae9-4030-9299-4a13fc6284c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_7a0e24fc-1f2d-4815-89a7-fd94ea7436e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4783066-0ae9-4030-9299-4a13fc6284c8" xlink:to="loc_us-gaap_RestrictedStockMember_7a0e24fc-1f2d-4815-89a7-fd94ea7436e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_288df845-65d2-4e69-a015-59feadb4d088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4783066-0ae9-4030-9299-4a13fc6284c8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_288df845-65d2-4e69-a015-59feadb4d088" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_ad68bae9-a1dc-4c2f-ae0e-27f23007fbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53118213-e586-4dfa-9a06-9954ea6ee913" xlink:to="loc_us-gaap_VestingAxis_ad68bae9-a1dc-4c2f-ae0e-27f23007fbe9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_ad68bae9-a1dc-4c2f-ae0e-27f23007fbe9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_ad68bae9-a1dc-4c2f-ae0e-27f23007fbe9" xlink:to="loc_us-gaap_VestingDomain_ad68bae9-a1dc-4c2f-ae0e-27f23007fbe9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_79400a97-861a-4235-975c-4b8a564b963a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_ad68bae9-a1dc-4c2f-ae0e-27f23007fbe9" xlink:to="loc_us-gaap_VestingDomain_79400a97-861a-4235-975c-4b8a564b963a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_999d9fa1-82fe-4667-8dbe-49b51d58cc90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_79400a97-861a-4235-975c-4b8a564b963a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_999d9fa1-82fe-4667-8dbe-49b51d58cc90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ebddedf0-1dc1-49c3-bc89-a8a37f2453a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_79400a97-861a-4235-975c-4b8a564b963a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ebddedf0-1dc1-49c3-bc89-a8a37f2453a3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingTextualDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#SegmentReportingTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingTextualDetails" xlink:type="extended" id="ice4245ed161645efa1aed20c6f052653_SegmentReportingTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6da9baf8-fa83-4b96-8760-2b373e81424c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6da9baf8-fa83-4b96-8760-2b373e81424c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_40603b4b-a5e1-40ac-8aa0-c4cf078f908d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_40603b4b-a5e1-40ac-8aa0-c4cf078f908d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationHospitals_0e01271d-9e57-4d42-95a5-c8260fef23af" xlink:href="ehc-20220331.xsd#ehc_NumberOfInpatientRehabilitationHospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_ehc_NumberOfInpatientRehabilitationHospitals_0e01271d-9e57-4d42-95a5-c8260fef23af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_9dcaf3d1-f42b-4314-a918-8dd128ba2695" xlink:href="ehc-20220331.xsd#ehc_Numberofsolelyownedinpatientrehabilitationhospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_9dcaf3d1-f42b-4314-a918-8dd128ba2695" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Jointventureownershippercentage_aac04d12-ede8-457b-b91c-9dc5aeea39fd" xlink:href="ehc-20220331.xsd#ehc_Jointventureownershippercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_ehc_Jointventureownershippercentage_aac04d12-ede8-457b-b91c-9dc5aeea39fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_de43fc6b-da1b-4b35-9270-1bad402cdb17" xlink:href="ehc-20220331.xsd#ehc_Numberofjointlyownedinpatientrehabilitationhospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_de43fc6b-da1b-4b35-9270-1bad402cdb17" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_db08b216-8afe-4bae-b48c-6107cc9a6169" xlink:href="ehc-20220331.xsd#ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_db08b216-8afe-4bae-b48c-6107cc9a6169" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofhomehealthlocations_afc8159f-16ee-4c22-a1af-751156c412b3" xlink:href="ehc-20220331.xsd#ehc_Numberofhomehealthlocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_ehc_Numberofhomehealthlocations_afc8159f-16ee-4c22-a1af-751156c412b3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofhospicelocations_1f15080b-3c04-41f8-a8b7-8b0332ffe3f4" xlink:href="ehc-20220331.xsd#ehc_Numberofhospicelocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_ehc_Numberofhospicelocations_1f15080b-3c04-41f8-a8b7-8b0332ffe3f4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_866ac019-cc6c-42ea-9430-9ff90e7a8540" xlink:href="ehc-20220331.xsd#ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_866ac019-cc6c-42ea-9430-9ff90e7a8540" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_1fed72ab-1d9b-4332-a55d-2be25707af49" xlink:href="ehc-20220331.xsd#ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_1fed72ab-1d9b-4332-a55d-2be25707af49" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_21521d34-1f7e-45c9-97a8-d9295b948e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_21521d34-1f7e-45c9-97a8-d9295b948e00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7549340c-abc8-4031-8c39-a2e1d367c1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_21521d34-1f7e-45c9-97a8-d9295b948e00" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7549340c-abc8-4031-8c39-a2e1d367c1b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7549340c-abc8-4031-8c39-a2e1d367c1b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7549340c-abc8-4031-8c39-a2e1d367c1b9" xlink:to="loc_us-gaap_SegmentDomain_7549340c-abc8-4031-8c39-a2e1d367c1b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8a9e9df6-3552-493d-81b4-d8c15f10c6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7549340c-abc8-4031-8c39-a2e1d367c1b9" xlink:to="loc_us-gaap_SegmentDomain_8a9e9df6-3552-493d-81b4-d8c15f10c6f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_7f93685f-78ee-41ab-8527-b82450c2965e" xlink:href="ehc-20220331.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8a9e9df6-3552-493d-81b4-d8c15f10c6f6" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_7f93685f-78ee-41ab-8527-b82450c2965e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_1cbd2f86-ab39-4a15-9c53-fdf7e713240e" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8a9e9df6-3552-493d-81b4-d8c15f10c6f6" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_1cbd2f86-ab39-4a15-9c53-fdf7e713240e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a54968f7-60b9-4c60-82ab-d49e8b1b2e7b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_21521d34-1f7e-45c9-97a8-d9295b948e00" xlink:to="loc_srt_RangeAxis_a54968f7-60b9-4c60-82ab-d49e8b1b2e7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a54968f7-60b9-4c60-82ab-d49e8b1b2e7b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a54968f7-60b9-4c60-82ab-d49e8b1b2e7b" xlink:to="loc_srt_RangeMember_a54968f7-60b9-4c60-82ab-d49e8b1b2e7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9ea3a4eb-a3f1-49a8-b3bd-ae4b0ee2a185" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a54968f7-60b9-4c60-82ab-d49e8b1b2e7b" xlink:to="loc_srt_RangeMember_9ea3a4eb-a3f1-49a8-b3bd-ae4b0ee2a185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6fef6b22-2988-4c5e-9bb6-f125014c9961" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9ea3a4eb-a3f1-49a8-b3bd-ae4b0ee2a185" xlink:to="loc_srt_MinimumMember_6fef6b22-2988-4c5e-9bb6-f125014c9961" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_778e25a7-f82a-438b-903c-95fa9aa9605b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9ea3a4eb-a3f1-49a8-b3bd-ae4b0ee2a185" xlink:to="loc_srt_MaximumMember_778e25a7-f82a-438b-903c-95fa9aa9605b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails" xlink:type="extended" id="ia807fb27f9d04654b0b6f49215fdf30d_SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5305b7b0-876f-4ac8-9cbd-e4cb5d9608b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ed481b64-efb6-4840-b616-4e9a3c7c576a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5305b7b0-876f-4ac8-9cbd-e4cb5d9608b3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ed481b64-efb6-4840-b616-4e9a3c7c576a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_c78551d7-63d9-4647-8df0-66c0230c7c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5305b7b0-876f-4ac8-9cbd-e4cb5d9608b3" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_c78551d7-63d9-4647-8df0-66c0230c7c3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_6ffb71be-73d9-4e20-8c5a-a1cd5a3fa3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c78551d7-63d9-4647-8df0-66c0230c7c3e" xlink:to="loc_us-gaap_LaborAndRelatedExpense_6ffb71be-73d9-4e20-8c5a-a1cd5a3fa3a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_c988caca-2043-4b0a-8833-06468e92721e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c78551d7-63d9-4647-8df0-66c0230c7c3e" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_c988caca-2043-4b0a-8833-06468e92721e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_45d10417-7b9c-46ce-a8c0-822845b55f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c78551d7-63d9-4647-8df0-66c0230c7c3e" xlink:to="loc_us-gaap_SuppliesExpense_45d10417-7b9c-46ce-a8c0-822845b55f5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost_be15a116-3d02-4a4e-a186-d6c9a52071ff" xlink:href="ehc-20220331.xsd#ehc_OccupancyCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c78551d7-63d9-4647-8df0-66c0230c7c3e" xlink:to="loc_ehc_OccupancyCost_be15a116-3d02-4a4e-a186-d6c9a52071ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CostofServicesExcludingDepreciationandAmortization_7299d551-fa71-4c34-b0a5-7f0c8ccbe31e" xlink:href="ehc-20220331.xsd#ehc_CostofServicesExcludingDepreciationandAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c78551d7-63d9-4647-8df0-66c0230c7c3e" xlink:to="loc_ehc_CostofServicesExcludingDepreciationandAmortization_7299d551-fa71-4c34-b0a5-7f0c8ccbe31e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead_f511e19f-7ef3-4492-94ef-8afab4fb31c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldOverhead"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c78551d7-63d9-4647-8df0-66c0230c7c3e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead_f511e19f-7ef3-4492-94ef-8afab4fb31c9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6d365af4-61f4-4e35-a55b-65aa280eb028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c78551d7-63d9-4647-8df0-66c0230c7c3e" xlink:to="loc_us-gaap_CostsAndExpenses_6d365af4-61f4-4e35-a55b-65aa280eb028" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b95863ee-b337-473a-a261-1c6467a420d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5305b7b0-876f-4ac8-9cbd-e4cb5d9608b3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b95863ee-b337-473a-a261-1c6467a420d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5d6f50c7-8096-4f49-b546-cd30bd2f3f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5305b7b0-876f-4ac8-9cbd-e4cb5d9608b3" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5d6f50c7-8096-4f49-b546-cd30bd2f3f19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_845a8679-ce2c-4e5c-91d6-899737ee7566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5305b7b0-876f-4ac8-9cbd-e4cb5d9608b3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_845a8679-ce2c-4e5c-91d6-899737ee7566" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA_003edf79-0bfe-4d81-9b15-eb2673c2e84f" xlink:href="ehc-20220331.xsd#ehc_AdjustedEBITDA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5305b7b0-876f-4ac8-9cbd-e4cb5d9608b3" xlink:to="loc_ehc_AdjustedEBITDA_003edf79-0bfe-4d81-9b15-eb2673c2e84f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_63c3fa7e-a5dd-4699-9966-e8d5162383d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5305b7b0-876f-4ac8-9cbd-e4cb5d9608b3" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_63c3fa7e-a5dd-4699-9966-e8d5162383d4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_af023588-13d9-479b-b1eb-baeb60e48be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5305b7b0-876f-4ac8-9cbd-e4cb5d9608b3" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_af023588-13d9-479b-b1eb-baeb60e48be8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d009eb14-db71-4878-b577-64a12de8d5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_af023588-13d9-479b-b1eb-baeb60e48be8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d009eb14-db71-4878-b577-64a12de8d5de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d009eb14-db71-4878-b577-64a12de8d5de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d009eb14-db71-4878-b577-64a12de8d5de" xlink:to="loc_us-gaap_SegmentDomain_d009eb14-db71-4878-b577-64a12de8d5de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_239e87d2-59eb-4665-bcae-4ee1dd2ad0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d009eb14-db71-4878-b577-64a12de8d5de" xlink:to="loc_us-gaap_SegmentDomain_239e87d2-59eb-4665-bcae-4ee1dd2ad0a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_37baba82-28ed-4658-8983-6f37e7655f6c" xlink:href="ehc-20220331.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_239e87d2-59eb-4665-bcae-4ee1dd2ad0a5" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_37baba82-28ed-4658-8983-6f37e7655f6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_d749249e-f8fc-4b6f-8b5d-b6c72271fa75" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_239e87d2-59eb-4665-bcae-4ee1dd2ad0a5" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_d749249e-f8fc-4b6f-8b5d-b6c72271fa75" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails" xlink:type="extended" id="i8f1151d171e647bf925e6472b70a3216_SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_b186ef38-2d5d-479c-9d9b-81af080d6a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_007db165-15bf-4e55-8ae7-00375fe44e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_b186ef38-2d5d-479c-9d9b-81af080d6a0a" xlink:to="loc_us-gaap_Assets_007db165-15bf-4e55-8ae7-00375fe44e7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_948cf3b6-6c30-4754-8716-f1198bfe62f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_b186ef38-2d5d-479c-9d9b-81af080d6a0a" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_948cf3b6-6c30-4754-8716-f1198bfe62f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_38c0098b-bb3c-4f0f-a3f2-3b526463e6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_b186ef38-2d5d-479c-9d9b-81af080d6a0a" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_38c0098b-bb3c-4f0f-a3f2-3b526463e6e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ae207da4-7e11-406c-9711-05c07b85b980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_38c0098b-bb3c-4f0f-a3f2-3b526463e6e5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ae207da4-7e11-406c-9711-05c07b85b980" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ae207da4-7e11-406c-9711-05c07b85b980_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ae207da4-7e11-406c-9711-05c07b85b980" xlink:to="loc_us-gaap_SegmentDomain_ae207da4-7e11-406c-9711-05c07b85b980_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_857c89b1-4022-45a8-89ed-40d7e3934fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ae207da4-7e11-406c-9711-05c07b85b980" xlink:to="loc_us-gaap_SegmentDomain_857c89b1-4022-45a8-89ed-40d7e3934fd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_3d327f9f-9105-4152-b996-6146e369c8d5" xlink:href="ehc-20220331.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_857c89b1-4022-45a8-89ed-40d7e3934fd0" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_3d327f9f-9105-4152-b996-6146e369c8d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_b5f58122-a2ca-4c66-89f1-66118102aedc" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_857c89b1-4022-45a8-89ed-40d7e3934fd0" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_b5f58122-a2ca-4c66-89f1-66118102aedc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails" xlink:type="extended" id="i5ee1e10309a1434a909deccfb19f5647_SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA_914e4703-0bfd-44d0-a293-55c40c08fee4" xlink:href="ehc-20220331.xsd#ehc_AdjustedEBITDA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_ehc_AdjustedEBITDA_914e4703-0bfd-44d0-a293-55c40c08fee4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8bf07db5-d489-40c3-b440-6f3a5a8bda8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8bf07db5-d489-40c3-b440-6f3a5a8bda8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_27ccb06d-9bc0-4034-a7d4-d923bba960cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_27ccb06d-9bc0-4034-a7d4-d923bba960cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_8b05983f-0517-4fdb-b26f-c06b5a29323d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_8b05983f-0517-4fdb-b26f-c06b5a29323d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_24bac1b3-fc7e-4f82-8cd6-2650c981db15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_24bac1b3-fc7e-4f82-8cd6-2650c981db15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_35d91c10-d170-449f-b02b-4049195df45a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_us-gaap_InterestExpenseDebt_35d91c10-d170-449f-b02b-4049195df45a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_408ebd5f-ee98-46f7-9991-7a9478d24ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_408ebd5f-ee98-46f7-9991-7a9478d24ea3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesGainLoss_23f39721-0334-46f6-a85b-d845118cf8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_us-gaap_MarketableSecuritiesGainLoss_23f39721-0334-46f6-a85b-d845118cf8a8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2dc1f5d3-962c-4896-9aa9-e1314d197aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2dc1f5d3-962c-4896-9aa9-e1314d197aea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_a6b7e2de-3d23-4a61-817a-f581040f7c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_a6b7e2de-3d23-4a61-817a-f581040f7c4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9d482d0c-e311-49e1-b458-82f37e2edd24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_a6b7e2de-3d23-4a61-817a-f581040f7c4d" xlink:to="loc_srt_ConsolidationItemsAxis_9d482d0c-e311-49e1-b458-82f37e2edd24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_9d482d0c-e311-49e1-b458-82f37e2edd24_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_9d482d0c-e311-49e1-b458-82f37e2edd24" xlink:to="loc_srt_ConsolidationItemsDomain_9d482d0c-e311-49e1-b458-82f37e2edd24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8fe9e1ef-53cd-4539-bb0f-a3e5a2cca117" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_9d482d0c-e311-49e1-b458-82f37e2edd24" xlink:to="loc_srt_ConsolidationItemsDomain_8fe9e1ef-53cd-4539-bb0f-a3e5a2cca117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_569c6b69-9a29-439a-9739-8c8cffb3f89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_8fe9e1ef-53cd-4539-bb0f-a3e5a2cca117" xlink:to="loc_us-gaap_OperatingSegmentsMember_569c6b69-9a29-439a-9739-8c8cffb3f89c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_c19e6d12-10bb-4edf-96a7-6e820ca71bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_8fe9e1ef-53cd-4539-bb0f-a3e5a2cca117" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_c19e6d12-10bb-4edf-96a7-6e820ca71bfa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails" xlink:type="extended" id="i00cb114d2afb4e13b6849dd95352ae55_SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_92903713-3545-40fa-8c0a-40405c1fe7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_50516d6a-5b4d-44a6-99bb-ec923fb13005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_92903713-3545-40fa-8c0a-40405c1fe7c1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_50516d6a-5b4d-44a6-99bb-ec923fb13005" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_66bdcddd-7077-4a9e-849f-d1f98fd61757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_92903713-3545-40fa-8c0a-40405c1fe7c1" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_66bdcddd-7077-4a9e-849f-d1f98fd61757" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3c9acbf4-2cdb-4471-b688-82c8e550ee57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_66bdcddd-7077-4a9e-849f-d1f98fd61757" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3c9acbf4-2cdb-4471-b688-82c8e550ee57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3c9acbf4-2cdb-4471-b688-82c8e550ee57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3c9acbf4-2cdb-4471-b688-82c8e550ee57" xlink:to="loc_us-gaap_SegmentDomain_3c9acbf4-2cdb-4471-b688-82c8e550ee57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_eb712906-061e-4f83-a521-377eedcd11a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3c9acbf4-2cdb-4471-b688-82c8e550ee57" xlink:to="loc_us-gaap_SegmentDomain_eb712906-061e-4f83-a521-377eedcd11a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_2e995be6-22a0-4c85-9e6a-a5907edb7b2d" xlink:href="ehc-20220331.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_eb712906-061e-4f83-a521-377eedcd11a9" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_2e995be6-22a0-4c85-9e6a-a5907edb7b2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_575d2989-15d2-4fc5-88eb-2da0668d2d35" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_eb712906-061e-4f83-a521-377eedcd11a9" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_575d2989-15d2-4fc5-88eb-2da0668d2d35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_70d9dfa0-60e5-46cf-bc06-9d0d484e1bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_66bdcddd-7077-4a9e-849f-d1f98fd61757" xlink:to="loc_us-gaap_SubsegmentsAxis_70d9dfa0-60e5-46cf-bc06-9d0d484e1bb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_70d9dfa0-60e5-46cf-bc06-9d0d484e1bb7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_70d9dfa0-60e5-46cf-bc06-9d0d484e1bb7" xlink:to="loc_us-gaap_SubsegmentsDomain_70d9dfa0-60e5-46cf-bc06-9d0d484e1bb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_adcf4b98-738f-4eba-866a-1ebdcea6d8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_70d9dfa0-60e5-46cf-bc06-9d0d484e1bb7" xlink:to="loc_us-gaap_SubsegmentsDomain_adcf4b98-738f-4eba-866a-1ebdcea6d8ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientMember_d7f3b8ce-c35f-477a-8f13-9f1e36763338" xlink:href="ehc-20220331.xsd#ehc_InpatientMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_adcf4b98-738f-4eba-866a-1ebdcea6d8ef" xlink:to="loc_ehc_InpatientMember_d7f3b8ce-c35f-477a-8f13-9f1e36763338" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OutpatientandotherMember_0c9f71f8-7c0f-437e-9f81-bdd2778e9699" xlink:href="ehc-20220331.xsd#ehc_OutpatientandotherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_adcf4b98-738f-4eba-866a-1ebdcea6d8ef" xlink:to="loc_ehc_OutpatientandotherMember_0c9f71f8-7c0f-437e-9f81-bdd2778e9699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomehealthMember_218e2497-f8e5-47b7-8ff7-3056474433cc" xlink:href="ehc-20220331.xsd#ehc_HomehealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_adcf4b98-738f-4eba-866a-1ebdcea6d8ef" xlink:to="loc_ehc_HomehealthMember_218e2497-f8e5-47b7-8ff7-3056474433cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HospiceMember_deda02da-ab57-4fc9-930e-d27e4f9b2445" xlink:href="ehc-20220331.xsd#ehc_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_adcf4b98-738f-4eba-866a-1ebdcea6d8ef" xlink:to="loc_ehc_HospiceMember_deda02da-ab57-4fc9-930e-d27e4f9b2445" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ehc-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:69533f56-540a-48e1-b4ee-a7401038559f,g:2f1c880e-7b65-4846-aaa6-f9cb86c4b8d3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_LetterOfCreditMember_15b64c82-907f-4c01-a0a0-e1dc96bcf0d1_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ad5af2a-e042-4350-ab56-574c79a36fb5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_31741cef-cc04-4435-999e-b456d7d58f2f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Encompass Health</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_f205564e-7338-4471-b41a-1379e592536a_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes05.125Due2023Member_45e3bb94-ea3c-47fc-a404-5969943e8939_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes05.125Due2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.125% Senior Notes due 2023</link:label>
    <link:label id="lab_ehc_SeniorNotes05.125Due2023Member_label_en-US" xlink:label="lab_ehc_SeniorNotes05.125Due2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 05.125%, Due 2023 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes05.125Due2023Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes05.125Due2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 05.125%, Due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes05.125Due2023Member" xlink:to="lab_ehc_SeniorNotes05.125Due2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_e2296951-6c4d-42fc-acd0-2e3241bc152f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_b1a96232-29db-4f69-967a-cfcf574d4e32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_231705dd-7a40-4511-ad5c-cf7c25eaadc7_terseLabel_en-US" xlink:label="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of solely owned hospital based home health and hospice locations</link:label>
    <link:label id="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_label_en-US" xlink:label="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of solely owned hospital based home health and hospice locations</link:label>
    <link:label id="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_documentation_en-US" xlink:label="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of solely owned hospital based home health and hospice agencies the Company owns and operates as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" xlink:href="ehc-20220331.xsd#ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" xlink:to="lab_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_5f78c546-2885-415e-a972-bf84f4f41fe5_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_be12efea-2a1a-4113-8cfb-7250480b508d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow agent cost</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated_f73927c7-80b7-4fb0-b4d1-707faaabe6a8_terseLabel_en-US" xlink:label="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consolidated limited partnership-like entities</link:label>
    <link:label id="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated_label_en-US" xlink:label="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Number of Entities Consolidated</link:label>
    <link:label id="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated_documentation_en-US" xlink:label="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of facilities consolidated as variable interest entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:href="ehc-20220331.xsd#ehc_VariableInterestEntityNumberofEntitiesConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:to="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_1dfd9ffe-f8c8-4dd3-be14-581ba907a31f_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2b9f44d0-abbc-4acb-95d0-3fa79e1de54c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9512ebf6-50dc-453b-a25a-e94349e1903d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_10daafc4-f5b9-4057-8fd3-3ad3d64a12e2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock_6d4501d9-86c6-48c1-9469-93334b71dab3_terseLabel_en-US" xlink:label="lab_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense</link:label>
    <link:label id="lab_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock_label_en-US" xlink:label="lab_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense [Table Text Block]</link:label>
    <link:label id="lab_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock_documentation_en-US" xlink:label="lab_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of all significant reconciling items in the reconciliation segment adjusted EBITDA to income from continuing operations before income tax expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock" xlink:href="ehc-20220331.xsd#ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock" xlink:to="lab_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_5f193287-a512-4fa0-8a3b-73c4a86429ad_terseLabel_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use-assets</link:label>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-Of-Use Assets</link:label>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_aec9f082-d3f8-4821-99dc-63f417cd9e69_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15296c16-6041-403d-bed0-3f67e72ec57d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_d13e3eb6-b05a-4758-89f9-661cc6851e69_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedSalaries_c132b61a-b8e4-48a2-87c9-a59270912802_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedSalaries_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Salaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fad8b66c-9fc0-4b1f-a0b9-7126305d7307_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_78f754e1-711e-4028-b4cc-99fefe4866b0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_633480d9-0708-4104-a853-8b04acd59752_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1e65fbf3-bd3d-47c7-bade-c0fed0dcb7c7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OccupancyCost_e3a48644-9ecb-4183-ab51-9466767e230d_terseLabel_en-US" xlink:label="lab_ehc_OccupancyCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Occupancy costs</link:label>
    <link:label id="lab_ehc_OccupancyCost_label_en-US" xlink:label="lab_ehc_OccupancyCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Occupancy Cost</link:label>
    <link:label id="lab_ehc_OccupancyCost_documentation_en-US" xlink:label="lab_ehc_OccupancyCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts paid for rent associated with leased hospitals, including common area maintenance and similar charges.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost" xlink:href="ehc-20220331.xsd#ehc_OccupancyCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OccupancyCost" xlink:to="lab_ehc_OccupancyCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_d63815be-9f42-4d7c-bb6b-0110fb997afc_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, by Legal Entity [Table]</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, by Legal Entity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_820a5f81-80e2-470f-a623-95ee22478483_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_d2511759-cb16-4c4d-a2b7-043337abb777_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_58f9c092-7035-41ce-b3b4-51b87bb575c3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_704c72c2-98fc-4e61-b977-895cf195d9a9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_bbe40ceb-bf57-4bc0-8303-7c5913a19791_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_5940cceb-3b29-4552-8162-558b1522b660_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_label_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfAssetsAcquired" xlink:to="lab_us-gaap_FairValueOfAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_2853f187-df49-4df8-8279-7d53f6526314_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, pro forma information, earnings of acquiree since acquisition date, actual</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes4625Due2031Member_3da93c5b-df5d-41f9-a323-4299afbcc238_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes4625Due2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.625% Senior Notes due 2031</link:label>
    <link:label id="lab_ehc_SeniorNotes4625Due2031Member_label_en-US" xlink:label="lab_ehc_SeniorNotes4625Due2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.625%, Due 2031 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes4625Due2031Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes4625Due2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.625%, Due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4625Due2031Member" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes4625Due2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes4625Due2031Member" xlink:to="lab_ehc_SeniorNotes4625Due2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_2baadffe-8f7f-4f56-9673-cfc722acee27_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_09e26bbb-31eb-462a-bc0d-6f652a37ca2c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll_f576cd3f-8bf8-4f7c-a3e5-c1c98cc5a021_terseLabel_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll_label_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Payroll</link:label>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll_documentation_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Payroll</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" xlink:to="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_59068266-04e7-4667-a419-2f5ffad88a9e_terseLabel_en-US" xlink:label="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of solely owned inpatient rehabilitation hospitals</link:label>
    <link:label id="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_label_en-US" xlink:label="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of solely owned inpatient rehabilitation hospitals</link:label>
    <link:label id="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_documentation_en-US" xlink:label="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of solely owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofsolelyownedinpatientrehabilitationhospitals" xlink:href="ehc-20220331.xsd#ehc_Numberofsolelyownedinpatientrehabilitationhospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Numberofsolelyownedinpatientrehabilitationhospitals" xlink:to="lab_ehc_Numberofsolelyownedinpatientrehabilitationhospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SuppliesExpense_76957630-6650-4a16-846a-d87f36324b53_terseLabel_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_us-gaap_SuppliesExpense_label_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuppliesExpense" xlink:to="lab_us-gaap_SuppliesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4945c9e8-59a8-4426-8036-bec307e95577_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_051da4c3-384c-4ed3-87f4-ebc7855e650f_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_99ced8cc-bb3c-400f-8042-f30e722bb961_terseLabel_en-US" xlink:label="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement Of Comprehensive Income And Income Statement [Abstract]</link:label>
    <link:label id="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_label_en-US" xlink:label="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement Of Comprehensive Income And Income Statement [Abstract]</link:label>
    <link:label id="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_documentation_en-US" xlink:label="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement Of Comprehensive Income And Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:href="ehc-20220331.xsd#ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:to="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c481b9b5-79fa-4d27-bc1e-8729b052f1f7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_333040e0-4808-4e26-984e-a6c1bf83a752_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1ba45235-b528-43f0-bd01-bec139ae1e16_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_18836ced-7e71-4a48-aae0-96f980226401_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_9c7cc737-6ce1-4b9e-9254-490c714d21ac_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_78c31f71-6753-4621-8627-5cf467757e5e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_639f9806-9e12-4146-892b-4db7fa00003c_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment additions through finance leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_afe82fa7-ea6c-41bf-99c2-a65126f5ef8b_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cf041b31-d3b1-4964-baa1-78c5b623e142_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards issued (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SaintAlphonsusMember_50e174a3-20a8-4fad-ae13-022337d54441_terseLabel_en-US" xlink:label="lab_ehc_SaintAlphonsusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Saint Alphonsus</link:label>
    <link:label id="lab_ehc_SaintAlphonsusMember_label_en-US" xlink:label="lab_ehc_SaintAlphonsusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Saint Alphonsus [Member]</link:label>
    <link:label id="lab_ehc_SaintAlphonsusMember_documentation_en-US" xlink:label="lab_ehc_SaintAlphonsusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Saint Alphonsus [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusMember" xlink:href="ehc-20220331.xsd#ehc_SaintAlphonsusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SaintAlphonsusMember" xlink:to="lab_ehc_SaintAlphonsusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_6e0a04b8-9e93-4761-95d9-8d8643ad1e48_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions declared</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_2d4f7a1e-e3fa-4662-8dcb-39000c717836_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions declared</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_9c508a08-9c62-48f5-8a45-1bebf8a21316_terseLabel_en-US" xlink:label="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of jointly owned inpatient rehabilitation hospitals</link:label>
    <link:label id="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_label_en-US" xlink:label="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of jointly owned inpatient rehabilitation hospitals</link:label>
    <link:label id="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_documentation_en-US" xlink:label="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of jointly owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofjointlyownedinpatientrehabilitationhospitals" xlink:href="ehc-20220331.xsd#ehc_Numberofjointlyownedinpatientrehabilitationhospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Numberofjointlyownedinpatientrehabilitationhospitals" xlink:to="lab_ehc_Numberofjointlyownedinpatientrehabilitationhospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_f858651f-50b7-4f54-bdde-78d88b7c6b3d_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c80b765d-4745-48e3-aef5-926361251632_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Income (Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_89e8655a-6c5c-4201-9896-ca51506c9c0c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_02f91169-eada-410f-9889-b51d0c16062e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest in consolidated entities (percent)</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2d9b8679-066b-4a04-b41f-52d127de4ec4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesGainLoss_4764b99d-ce38-48bc-bb7a-b2b93ad8c30e_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair market value of equity securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_876992c5-96c6-42c0-9a41-a88c2a07f83f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_a1fc9bc7-4600-41eb-87ca-c2f70ba952c3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_19bb9626-1c3a-4b59-8ab5-c844d6969b7e_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease additions</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_1cedbcef-0d0e-4ac6-b837-131c0209479b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Actual and Pro Forma Results of Operations for Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Numberofhospicelocations_bb19161e-24a3-4863-83ac-4620dc9f8fe6_terseLabel_en-US" xlink:label="lab_ehc_Numberofhospicelocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of hospice locations</link:label>
    <link:label id="lab_ehc_Numberofhospicelocations_label_en-US" xlink:label="lab_ehc_Numberofhospicelocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of hospice locations</link:label>
    <link:label id="lab_ehc_Numberofhospicelocations_documentation_en-US" xlink:label="lab_ehc_Numberofhospicelocations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of hospice locations the Company owns and operates as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofhospicelocations" xlink:href="ehc-20220331.xsd#ehc_Numberofhospicelocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Numberofhospicelocations" xlink:to="lab_ehc_Numberofhospicelocations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_b34d9186-ad1b-4127-85da-c47c03b89cd3_negatedLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipt of treasury stock (shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_07b9f8a1-1b4d-4211-b25b-ba32b0dc758a_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and Other Commitments</link:label>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_label_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDisclosures" xlink:to="lab_us-gaap_LossContingencyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9e48d06c-7fe0-4f5b-bb79-2969dc98b5df_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_be98827e-a91c-4894-81eb-98342c6103be_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net and comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c46ad281-f13f-4741-b4ac-feace5490208_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_644f31c9-fca7-470c-b672-7552ea8e900d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_23b4a453-e978-4227-9036-207f8a9fcca5_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_28481219-a148-41b4-84b8-be503b470701_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Numberofhomehealthlocations_c3428335-78b8-462d-8fa0-719cdcd3f56d_terseLabel_en-US" xlink:label="lab_ehc_Numberofhomehealthlocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of home health locations</link:label>
    <link:label id="lab_ehc_Numberofhomehealthlocations_label_en-US" xlink:label="lab_ehc_Numberofhomehealthlocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of home health locations</link:label>
    <link:label id="lab_ehc_Numberofhomehealthlocations_documentation_en-US" xlink:label="lab_ehc_Numberofhomehealthlocations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of home health locations the Company owns and operates as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofhomehealthlocations" xlink:href="ehc-20220331.xsd#ehc_Numberofhomehealthlocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Numberofhomehealthlocations" xlink:to="lab_ehc_Numberofhomehealthlocations" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes05.75Due2025Member_0e85bf2b-da7d-4ba1-b531-c85e480e6e05_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes05.75Due2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% Senior Notes due 2025</link:label>
    <link:label id="lab_ehc_SeniorNotes05.75Due2025Member_label_en-US" xlink:label="lab_ehc_SeniorNotes05.75Due2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes; 05.75%; Due 2025 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes05.75Due2025Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes05.75Due2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes; 05.75%; Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes05.75Due2025Member" xlink:to="lab_ehc_SeniorNotes05.75Due2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_2f6cd891-1668-45a1-87ba-1badeebca28c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense and amortization of debt discounts and fees</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_1d7a1baa-11d2-4547-af85-511953684272_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Net Operating Revenues by Payor</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_6368575a-dc79-4416-a69c-1afdbf258e7b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_fd2aef3e-062b-4158-9e86-b784f288e63c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Encompass Health common shareholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_445a931b-b490-4cd2-9738-e7b55113920b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Encompass Health common shareholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_31e066f9-d427-408d-9540-745208800d45_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_MedicaidMember_7c690d8f-bf8d-490e-a859-8ae76b2c8133_terseLabel_en-US" xlink:label="lab_ehc_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_ehc_MedicaidMember_label_en-US" xlink:label="lab_ehc_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_ehc_MedicaidMember_documentation_en-US" xlink:label="lab_ehc_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicaidMember" xlink:href="ehc-20220331.xsd#ehc_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_MedicaidMember" xlink:to="lab_ehc_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_d13e9ef1-50b7-4fbc-9535-45fb4998be41_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipt of treasury stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_71a5394e-56a5-4ca7-b42f-ccfc93563b3d_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_037a5a3b-3b78-44b3-bcf5-a5f62fc641fb_negatedLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities assumed</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_b01f7a0a-2bfb-40d0-9813-c665ed90d801_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8a4cc826-09d7-437c-a63a-748b66aa6238_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_4996d979-1296-4a76-b11c-d6dd1917c201_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_9c8a9d32-4a2b-4a38-a064-9029af97101c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a26fa1ae-17c2-4d13-ba23-fb323de8ac67_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b685c9ce-723e-47d1-840a-43e7bab60ba4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_a4ca9d8a-d925-4c4b-b7a2-bd4a81bc8944_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_74f0438b-3756-4661-af48-3c6d6020b754_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes4.50Due2028Member_1d4c6d28-5d3d-49e5-89ed-8c466a2d7afa_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes4.50Due2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Notes due 2028</link:label>
    <link:label id="lab_ehc_SeniorNotes4.50Due2028Member_label_en-US" xlink:label="lab_ehc_SeniorNotes4.50Due2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.50%, Due 2028 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes4.50Due2028Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes4.50Due2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.50%, Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes4.50Due2028Member" xlink:to="lab_ehc_SeniorNotes4.50Due2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_1c2e9678-0042-4228-955c-12ee2cbb87fe_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes04.750Due2030Member_03c1d964-5b9b-4af9-bd91-65e7e1f9b470_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes04.750Due2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Notes due 2030</link:label>
    <link:label id="lab_ehc_SeniorNotes04.750Due2030Member_label_en-US" xlink:label="lab_ehc_SeniorNotes04.750Due2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 04.750%, Due 2030 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes04.750Due2030Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes04.750Due2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 04.750%, Due 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes04.750Due2030Member" xlink:to="lab_ehc_SeniorNotes04.750Due2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_11de4d88-70c6-42e1-ac87-84360a122d8b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_738d69bc-2bb7-46d9-a82a-c7d81089d32f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Condition</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_90726877-802f-4a10-9d65-0a4eaed9666f_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_db162fbe-c5ef-4f90-bd8f-b628f2b6aa49_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete agreements</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1c78449d-4bb1-4ff9-82b8-82b119e12bbf_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_10b6e018-2230-48bd-905e-c6c5974b677e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_9a97208a-85ae-46b3-a045-b7788e5b5e71_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3e84b84f-3ef6-4004-823b-d58c4bba9230_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromContributionsFromAffiliates_c8f6acfb-ccbc-4bac-8217-74016a1bce46_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_ProceedsFromContributionsFromAffiliates_label_en-US" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Contributions from Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_dd98ada2-4fc7-4563-88d3-0c395ad5251a_verboseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_eda06bbb-6303-499a-a246-c0897b98f8de_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_e69daff7-300b-445a-a130-f60ea786f31f_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_a28e653f-06ce-4ae3-94bb-8069068e45b5_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f6f25b16-2166-4318-a94b-f44ee2f948fa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net and comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ManagedCareMember_5ec23cf0-4c1c-442a-8faf-659d8c12f8d2_terseLabel_en-US" xlink:label="lab_ehc_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed care</link:label>
    <link:label id="lab_ehc_ManagedCareMember_label_en-US" xlink:label="lab_ehc_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care [Member]</link:label>
    <link:label id="lab_ehc_ManagedCareMember_documentation_en-US" xlink:label="lab_ehc_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ManagedCareMember" xlink:href="ehc-20220331.xsd#ehc_ManagedCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ManagedCareMember" xlink:to="lab_ehc_ManagedCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_HospiceMember_91db02ad-0ba5-4d79-8d5d-de191cc75de0_terseLabel_en-US" xlink:label="lab_ehc_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice</link:label>
    <link:label id="lab_ehc_HospiceMember_label_en-US" xlink:label="lab_ehc_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:label id="lab_ehc_HospiceMember_documentation_en-US" xlink:label="lab_ehc_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HospiceMember" xlink:href="ehc-20220331.xsd#ehc_HospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_HospiceMember" xlink:to="lab_ehc_HospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_bc77e02b-b98c-4adf-9893-b6e5bff8d097_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldOverhead_a026dc13-d3aa-48d9-b102-2606b75412a6_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldOverhead" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Support and overhead costs</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldOverhead_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldOverhead" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Overhead</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldOverhead"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldOverhead" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_670c8f8c-784b-46b7-8def-695b7dd2ce51_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2fa4dcfc-ade8-4ab8-b38c-fc9316fa76da_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition percentage of voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1392018c-ddce-4be2-ada4-25a55dcb9a31_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7cbc58bc-2b44-40e5-8d27-8d806f211905_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_4db9d8a0-bcda-4dba-9af7-809116fd9143_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_331c7a03-02f7-47ab-9b04-79e390cc2769_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d1871a2a-d0b0-40aa-8581-2580ecaea307_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_2a071182-8643-4750-aea1-ba594b61759c_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b257415f-87d0-493d-8c1f-52c819fb26a0_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_MedicareAdvantageMember_70c9e598-0d56-492f-a41d-20997879d1a2_terseLabel_en-US" xlink:label="lab_ehc_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:label id="lab_ehc_MedicareAdvantageMember_label_en-US" xlink:label="lab_ehc_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:label id="lab_ehc_MedicareAdvantageMember_documentation_en-US" xlink:label="lab_ehc_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareAdvantageMember" xlink:href="ehc-20220331.xsd#ehc_MedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_MedicareAdvantageMember" xlink:to="lab_ehc_MedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_87bfc82f-b21b-41b0-a365-1d56ff1f4a95_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_d0a45323-164f-45e8-9cd8-6ad388c63b80_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_dd222b82-957b-4a9f-bbdc-0d6cf1ba1ef6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_75b0ebd3-bfb9-4b65-965c-b27d17311648_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid on common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_InpatientMember_50a747ff-189a-4d36-8603-ff82085c5bc2_terseLabel_en-US" xlink:label="lab_ehc_InpatientMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient</link:label>
    <link:label id="lab_ehc_InpatientMember_label_en-US" xlink:label="lab_ehc_InpatientMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient [Member]</link:label>
    <link:label id="lab_ehc_InpatientMember_documentation_en-US" xlink:label="lab_ehc_InpatientMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientMember" xlink:href="ehc-20220331.xsd#ehc_InpatientMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_InpatientMember" xlink:to="lab_ehc_InpatientMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_78fa4811-2a1c-4c05-9126-0c991608ed27_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_7f9e5200-eb4c-44b3-a4e6-369e8b234841_periodStartLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_9d969a88-dc67-4f5a-9460-b536ccc45860_periodEndLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_332f0aec-3407-42ca-9e92-a0ed859ee077_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_e4e81f57-f23f-4b37-9d0a-5ecc1cdf66ab_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_cfebf61d-f899-48a5-a84c-88ad32c09d1f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatio_d24c228c-4c0a-4287-94cf-ecffdeb8b174_verboseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage ratio</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatio_label_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatio_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatio" xlink:href="ehc-20220331.xsd#ehc_DebtInstrumentCovenantLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentCovenantLeverageRatio" xlink:to="lab_ehc_DebtInstrumentCovenantLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_48007136-ed67-4bda-974e-01c3bf600791_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_69f66d6b-08f6-4e66-bb05-e1b83aa05492_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment agreement, amount to be paid</link:label>
    <link:label id="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_label_en-US" xlink:label="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Amendment Agreement, Amount To Be Paid</link:label>
    <link:label id="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Amendment Agreement, Amount To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" xlink:href="ehc-20220331.xsd#ehc_DebtInstrumentAmendmentAgreementAmountToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" xlink:to="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_a8108c28-5800-4dc1-8633-94a0c7dba380_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_156f5527-6e18-46b2-b771-89bffb07938c_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interests Activity</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e2d56c3c-ba61-41fa-a836-4fb42f768ab5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_77b840a5-b354-417b-a226-b76cb2384d16_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_a8162fbf-a928-4d53-b403-bad7c0f7e0ea_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_a6b8669d-0f2b-4a30-a9d8-49c937031f2c_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_1fe7080e-8dc9-4259-9664-fe2a6f104ac6_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3e491309-5a5f-4a83-8364-d93ec801ee28_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards, dilutive stock options, and restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_99bf69cd-e048-4505-975d-5ac685b5c8ba_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_ec9a371e-b773-4928-9642-9e6d10ac94d4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, pro forma net income</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_611ff6a9-59ce-44f4-8b60-9fbebdda87e2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted Numerator</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_f5c67c15-b5b7-493c-bbc7-d4a199d23ba6_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_HomehealthMember_f1a774b1-f962-481b-a6f9-0cbabbfc799b_terseLabel_en-US" xlink:label="lab_ehc_HomehealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home health</link:label>
    <link:label id="lab_ehc_HomehealthMember_label_en-US" xlink:label="lab_ehc_HomehealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home health [Member]</link:label>
    <link:label id="lab_ehc_HomehealthMember_documentation_en-US" xlink:label="lab_ehc_HomehealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomehealthMember" xlink:href="ehc-20220331.xsd#ehc_HomehealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_HomehealthMember" xlink:to="lab_ehc_HomehealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_e9455bbd-6859-474e-8f91-bc9f279d73f4_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_c4ecda5b-8b89-42f5-827e-446712967739_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_8dade5d6-dede-45db-bc3e-827f0b7b06fa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared on common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8e29035f-6708-49f9-9a26-9b42dda02b78_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_dbf3678a-7378-4727-a851-29c70fbeb5ee_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_4e9657be-d386-4c59-9856-0d2d2b1cbcc8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in assets and liabilities, net of acquisitions&#8212;</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_faaca433-8ca9-4464-80d8-ab8e03288d81_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_363b8366-89de-49ad-acf6-99d6962177eb_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c385dbda-eaa5-4d3e-9bbc-99884c5a3256_verboseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_e740cd97-d923-4c47-b93b-56ca7e3a44f1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_fc116c7f-848a-4ef2-b2ca-df97031949dc_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_11b869ed-fb38-4253-8830-090bca8b5c5b_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_9caa9b03-03ab-4439-bf6c-fdfb5f450a29_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_18030341-6309-4ff1-9ef2-f9f33cbd4ee7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_a58e6aaa-78cf-4394-8e85-123b0db0fc5d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c187b155-9fd6-49a7-8668-f116e87cf86e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OtherIncomeSourceMember_8a1fcc6d-88a4-4915-9089-0d1cf7513608_terseLabel_en-US" xlink:label="lab_ehc_OtherIncomeSourceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_ehc_OtherIncomeSourceMember_label_en-US" xlink:label="lab_ehc_OtherIncomeSourceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Source [Member]</link:label>
    <link:label id="lab_ehc_OtherIncomeSourceMember_documentation_en-US" xlink:label="lab_ehc_OtherIncomeSourceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Source [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherIncomeSourceMember" xlink:href="ehc-20220331.xsd#ehc_OtherIncomeSourceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OtherIncomeSourceMember" xlink:to="lab_ehc_OtherIncomeSourceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1fd5243b-f3e7-4151-9073-67206777d82c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6e2bb820-67e9-49ba-b084-634dba3f5139_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a18b2007-5a1b-47ab-8eb7-1c24b65ddeb8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f4771b49-2b4c-4023-b816-17c6d133edc7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in Excess of Par Value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_216ea2b9-0fec-4f0c-9d9c-2fafc769535a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9d34eecd-c2e0-4978-a569-b83a006a2699_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_bc975472-bb8a-4503-a815-20c76b017f76_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_f30b78c6-1b7c-4b3e-9e5c-128854e0615d_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_22bdabc5-b202-4217-82d2-43c5f9d35369_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_05f0a7e8-3222-48e5-82a7-104a88a071b9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtRestructuringCosts_564feadb-4551-4f71-9f58-1d0a14cb424d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt amendment costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtRestructuringCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:to="lab_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_85b52a26-1abe-454c-9d2a-dff142f082e5_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_CostofServicesExcludingDepreciationandAmortization_7479cfcf-47be-484f-8f63-ec79c62d5131_terseLabel_en-US" xlink:label="lab_ehc_CostofServicesExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of service (excluding depreciation and amortization)</link:label>
    <link:label id="lab_ehc_CostofServicesExcludingDepreciationandAmortization_label_en-US" xlink:label="lab_ehc_CostofServicesExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Services, Excluding Depreciation and Amortization</link:label>
    <link:label id="lab_ehc_CostofServicesExcludingDepreciationandAmortization_documentation_en-US" xlink:label="lab_ehc_CostofServicesExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate cost of services rendered during the reporting period, excluding depreciation and amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CostofServicesExcludingDepreciationandAmortization" xlink:href="ehc-20220331.xsd#ehc_CostofServicesExcludingDepreciationandAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_CostofServicesExcludingDepreciationandAmortization" xlink:to="lab_ehc_CostofServicesExcludingDepreciationandAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_a42d42e3-4ef0-4942-a1fe-201dd6865edb_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense (income)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_fb3161a8-ce9a-40db-8d30-8e09d2215bfa_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amounts and estimated fair values of financial instruments</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_bf027122-f517-4aaf-baca-107355a0571e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_56170fb9-eee5-41b4-9b33-d9e097ec7946_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fe9ca80c-2030-496c-9c2b-e0b3659806b7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_0be80622-3e23-4aa8-99d9-0be3eefad8f6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_faf5de8c-34fd-4865-a824-a9181183b567_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a2551d2c-7829-46a2-80fd-6c07d56d4e8b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestMember_f12b8578-53f5-4453-925f-baa1eefe8799_terseLabel_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestMember_label_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestMember_documentation_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestMember" xlink:href="ehc-20220331.xsd#ehc_RedeemableNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RedeemableNoncontrollingInterestMember" xlink:to="lab_ehc_RedeemableNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0c8bc216-efd3-4fba-917d-09a93fed9b41_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_574761ce-de97-43ac-9f63-4943eca07f36_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_9b5b4467-5fdc-493d-a8da-58942feceaab_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a7c3cf01-a75e-445a-9358-b93737ef69a6_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1df60c73-a8ff-4f97-a8c0-0ca853c98118_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_7f7608c8-c345-4933-a01f-5927020c8b4f_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_6e1e0df7-3efc-4770-a13c-20d4153031ee_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Encompass Health shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7585fc68-85b3-424f-9836-4efdbb5cc9ea_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock_ea9217bd-e0a2-41a5-b80f-30ffe97e5696_terseLabel_en-US" xlink:label="lab_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Noncontrolling Interests</link:label>
    <link:label id="lab_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock_label_en-US" xlink:label="lab_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Net Income Attributable to Noncontrolling Interests [Table Text Block]</link:label>
    <link:label id="lab_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock_documentation_en-US" xlink:label="lab_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Net Income Attributable to Noncontrolling Interests [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock" xlink:href="ehc-20220331.xsd#ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock" xlink:to="lab_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_23c29478-feb4-4c16-af4e-dd26900b4bb4_totalLabel_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_label_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Including Goodwill, Assets</link:label>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_documentation_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Including Goodwill, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" xlink:to="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ec002475-3f6e-48c1-ab1c-0c050c3e74d0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_64d3be19-6f3a-4d77-aa83-fa5b298b2df9_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on debt, including pre-payments</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_8b25d4b4-db5e-4741-851f-010a43a057fa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_62d4ed25-fd0f-4229-96ac-8d5f4de72581_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_4b9b7714-8358-4b7f-bbba-af12753f8304_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_79a37a0a-6029-43a5-a119-58c95559c8b1_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (shares)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOtherShares" xlink:to="lab_us-gaap_StockholdersEquityOtherShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_d3e52a4f-76b4-49d9-9f78-68b0158c22f2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_1a7f264f-82ac-4e6a-a234-a556b2199c41_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_2c99ddfa-4d96-4bcd-a357-bafa827840ba_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense and amortization of debt discounts and fees</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_4172b125-bc82-4323-a5da-49ed276ed95a_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OtherThirdpartyPayorsMember_29e2ec32-8c36-4091-994f-338d355e3bc2_terseLabel_en-US" xlink:label="lab_ehc_OtherThirdpartyPayorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other third-party payors</link:label>
    <link:label id="lab_ehc_OtherThirdpartyPayorsMember_label_en-US" xlink:label="lab_ehc_OtherThirdpartyPayorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Third-party Payors [Member]</link:label>
    <link:label id="lab_ehc_OtherThirdpartyPayorsMember_documentation_en-US" xlink:label="lab_ehc_OtherThirdpartyPayorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Third-party Payors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherThirdpartyPayorsMember" xlink:href="ehc-20220331.xsd#ehc_OtherThirdpartyPayorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OtherThirdpartyPayorsMember" xlink:to="lab_ehc_OtherThirdpartyPayorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_a6a37b5f-d24f-4f60-8501-9539ce2b4184_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_HomeHealthandHospiceSegmentMember_791e2901-5989-430e-8312-9dea6b8717ae_terseLabel_en-US" xlink:label="lab_ehc_HomeHealthandHospiceSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice</link:label>
    <link:label id="lab_ehc_HomeHealthandHospiceSegmentMember_label_en-US" xlink:label="lab_ehc_HomeHealthandHospiceSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice Segment [Member]</link:label>
    <link:label id="lab_ehc_HomeHealthandHospiceSegmentMember_documentation_en-US" xlink:label="lab_ehc_HomeHealthandHospiceSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_HomeHealthandHospiceSegmentMember" xlink:to="lab_ehc_HomeHealthandHospiceSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_2affbeef-23ce-4361-8fa0-576cac0a475d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_e91c8642-ba77-4308-b85e-36555bcf8f9e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets Acquired and Liabilities Assumed at the Acquisition Date</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_fb136d1f-9863-4b90-8485-49fa33eaf7a5_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_3cd55a02-026f-4c08-a5ba-723de16785a5_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_545fd287-d85a-41b8-8253-0d9b7b201144_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_30d9fcda-f9e7-4eed-b462-183074c9398b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ee003039-9035-4f20-bd86-9c1fe97aa71d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service and Performance Condition</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_92aaefcb-cbe4-467b-a8b7-b91ebfb0a331_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_7f637041-beb8-4838-bd40-c15fc87e27ac_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_43d1e0d9-5719-48f7-9d73-5269d1c2f577_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture</link:label>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_label_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateJointVentureMember" xlink:to="lab_us-gaap_CorporateJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7e0e5c7b-67fd-45bc-816e-c718e6d0cf07_verboseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_254aa488-8310-4cd9-aac9-6bb8969b1e70_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_51581136-5ad1-4897-9133-90414ab7a83e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income attributable to noncontrolling interests included in continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_332e023a-945c-4a49-85c0-3e224be80083_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_fef8b3f0-a91e-4fe1-9771-c43739a36eb4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OutpatientandotherMember_b22f793f-0877-4519-a385-c162f4ce8592_terseLabel_en-US" xlink:label="lab_ehc_OutpatientandotherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outpatient and other</link:label>
    <link:label id="lab_ehc_OutpatientandotherMember_label_en-US" xlink:label="lab_ehc_OutpatientandotherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outpatient and other [Member]</link:label>
    <link:label id="lab_ehc_OutpatientandotherMember_documentation_en-US" xlink:label="lab_ehc_OutpatientandotherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outpatient and other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OutpatientandotherMember" xlink:href="ehc-20220331.xsd#ehc_OutpatientandotherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OutpatientandotherMember" xlink:to="lab_ehc_OutpatientandotherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c7111585-886a-41c8-9913-9ae6964204b0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3fe3684c-0608-45bd-9ffa-f8668703bde0_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d113af74-bea4-4081-82c1-9a0119dd3ad8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00de6afb-58dc-4c03-9468-d49d2dafbf9c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d8276452-ca74-4bf7-8590-57f6acf997e8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_ceb9e859-07e4-48fe-a826-932076ca4123_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to nonredeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7263f3f9-f9d9-4132-8c62-468a199fe876_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2bed6ce0-2d5f-41c2-9d8f-66df39e31c1d_netLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a27a4761-d825-49f9-b3c7-818c91c98263_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_38f2fc8f-2a38-4c7c-a236-7a093c315d6e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_af0fa139-1e45-423e-8ddc-5cdf8297c07f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ab48ae7a-2e6d-41b0-96a4-abef2b172435_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_13c7c721-74a2-44b2-a909-92ead1e6bbeb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_941743d8-cac9-4a80-b66d-9859c76f65ea_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_66b55dad-b612-47ed-998a-fe0af8ef9f19_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_bf87a270-f2bb-4b63-91dc-3104dc4f5bad_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_c8412ee2-c3eb-458f-9158-3ed4f43e4791_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_83be1dc1-576e-4059-94bd-192c088d1a0c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_377a9477-3daf-43a9-b216-b19610d0adb5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_f53a61a6-611b-4f38-ac91-3ad7ca5751bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_a9d090cf-d163-4789-8721-64a6d2a7e16e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_834242a2-e5f8-404e-ac15-aa42c9ce7666_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Income allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_8e828ca9-32bf-4c6e-b710-62230b063e5b_totalLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total adjustments</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_3cd797b5-a199-4d33-927f-550558e8eca5_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_37bcb5d4-f379-4688-9c0a-8bd894ae33e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_4ad388fe-5927-4b5a-a55a-c149ec570ba6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Weighted Average Number of Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems_2ea69130-3b7d-4b73-a4db-6ac36743befa_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Asset Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Asset Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2c3c7c3f-38a4-4bed-b345-94a89daa4e61_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_34d11565-a97d-4d42-8480-ccf6951a76af_negatedLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_03f5278a-0be4-4d6f-9a2f-70576c8b7c17_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_8adf50f9-0a63-434f-bdb3-b44d84e8f51c_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, reduction in capacity under restricted payments builder basket</link:label>
    <link:label id="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_label_en-US" xlink:label="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Reduction In Capacity Under Restricted Payments Builder Basket</link:label>
    <link:label id="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Reduction In Capacity Under Restricted Payments Builder Basket</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" xlink:href="ehc-20220331.xsd#ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" xlink:to="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_c8065da6-96af-45ae-8061-a52ffcbdb7e5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_25480f6d-51da-4982-9b0e-6c2474c019df_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_05b396a0-77c7-4b85-8fca-b44dcb22b6da_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_9c038321-6db3-4b17-9a58-76ea1a09cd64_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other long-term assets at beginning of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_4b3ceba9-86e2-4286-a1f0-e4434d140132_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other long-term assets at end of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_3ff75cab-a754-4dd2-afb6-cfa24828e974_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_26ea5974-a057-4d76-8cba-4f5e633597e5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_18cc8b62-247d-43d4-b2ea-ab8b539780e7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_38e8945a-408a-427e-858d-9fd555ac7fcc_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d4ddb76c-5507-4385-8223-8ecdb5e5c4cd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_3ace7e5b-1b9e-4227-9776-aec1fcc12dc2_terseLabel_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of inpatient rehabilitation units under management contracts</link:label>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_label_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Inpatient Rehabilitation Units Under Management Contracts</link:label>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_documentation_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of inpatient rehabilitation units under management contracts with the Company as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" xlink:href="ehc-20220331.xsd#ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" xlink:to="lab_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_5e727026-6bf5-4051-bf73-e3018d3a4802_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_56dc4257-7ab0-4aa3-9765-ba68c7d7e3ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of Basic and Diluted Earnings Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_015896cd-64eb-405b-87fd-50e81fa67c3a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_4a77e90c-4550-43c1-8a49-3acad825ca5c_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7968a6d5-d08b-4430-851f-da8efbf12382_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_81fb8ef9-ab73-4929-8261-010a7826c5cb_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_dc412b0a-c780-4d3b-9695-b1c48dac9bdc_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_2270580f-52e6-4b3b-be35-ac58651c5f88_verboseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_746d883d-4d85-4b67-aa6a-1d0548acce2b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions paid to noncontrolling interests of consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NetIncomeLossAvailabletoCommonStockholders_7f6b799b-fcca-4830-9bce-85ebcf5c130b_totalLabel_en-US" xlink:label="lab_ehc_NetIncomeLossAvailabletoCommonStockholders" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_ehc_NetIncomeLossAvailabletoCommonStockholders_label_en-US" xlink:label="lab_ehc_NetIncomeLossAvailabletoCommonStockholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders</link:label>
    <link:label id="lab_ehc_NetIncomeLossAvailabletoCommonStockholders_documentation_en-US" xlink:label="lab_ehc_NetIncomeLossAvailabletoCommonStockholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income after adjustments for dividends on preferred stock (declared in the period), cumulative preferred stock (accumulated for the period), and/or income allocated to participating securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NetIncomeLossAvailabletoCommonStockholders" xlink:href="ehc-20220331.xsd#ehc_NetIncomeLossAvailabletoCommonStockholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NetIncomeLossAvailabletoCommonStockholders" xlink:to="lab_ehc_NetIncomeLossAvailabletoCommonStockholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_3eca3a4f-3173-4342-9e60-79e694acbb7d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains or losses related to non-financial assets and liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_label_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_32835baf-0a12-454c-833d-0d092466faa9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_38408d54-6255-4cba-8bb3-1ed1be3233cd_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts attributable to Encompass Health common shareholders:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f2cbed0c-bdbb-40f5-9b52-e1f3bb09559a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_0c8261c0-ea03-41a0-b414-a54f3f55b6d4_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_b29a81c4-1ddd-43c5-946c-8e65bbb9b4ee_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_a1ea73d2-1133-4936-b9e8-7d21ca087f08_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PartnersCapitalAccountContributions_3d31b8ea-fa14-4f28-8734-680bbec492e0_terseLabel_en-US" xlink:label="lab_us-gaap_PartnersCapitalAccountContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contributions from consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_PartnersCapitalAccountContributions_label_en-US" xlink:label="lab_us-gaap_PartnersCapitalAccountContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partners' Capital Account, Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnersCapitalAccountContributions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnersCapitalAccountContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnersCapitalAccountContributions" xlink:to="lab_us-gaap_PartnersCapitalAccountContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b71a23a0-65ac-4deb-b5ab-d26f402d4c26_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net and comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_69e8e9c5-7300-4507-8633-5eb8b0d78c91_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_cb0cac82-a3b2-402a-a373-5b8bc396383b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_705c0487-8293-43ee-9fbf-58f3b6746fb0_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_80d20567-6c39-4574-bbed-7659a59ef267_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f980d284-07b7-4165-985f-5898a7f292c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_b7a0168f-508b-4786-9d65-c87041901b9f_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances under revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a5d2caef-6917-455e-9c67-07a231aec455_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_37f8a777-132c-4aae-955e-5dce128a696c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17741381-9ea9-4739-be76-deb1b653a81c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_d65584da-47c6-4566-a1e2-b4ace4851a71_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_3c3b8c1d-c644-442f-8496-cbd19bd8ea23_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Encompass Health common shareholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_f3e06409-1f2a-429b-b311-e49f4d044534_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Encompass Health common shareholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_800c426c-8f1e-41e4-92f9-df49cbbbc52a_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0893bc88-b255-4e01-9261-d7a4e0a2d2aa_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9cb3903a-b362-4520-8cbb-417fb6a979a9_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_63ca6dcd-b5f9-4d33-b496-8a5801a856da_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_a2aedbfc-65a6-4cac-b17e-c0e055af0c8d_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_112eae2a-cd84-4508-84f7-7c945515ba8c_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_AdjustedEBITDA_784caa55-59c1-40ae-8974-b14f3ae362e2_totalLabel_en-US" xlink:label="lab_ehc_AdjustedEBITDA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Adjusted EBITDA</link:label>
    <link:label id="lab_ehc_AdjustedEBITDA_12ee73f7-b8a3-4e03-bc15-d390e797b6b7_verboseLabel_en-US" xlink:label="lab_ehc_AdjustedEBITDA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Segment Adjusted EBITDA</link:label>
    <link:label id="lab_ehc_AdjustedEBITDA_label_en-US" xlink:label="lab_ehc_AdjustedEBITDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted EBITDA</link:label>
    <link:label id="lab_ehc_AdjustedEBITDA_documentation_en-US" xlink:label="lab_ehc_AdjustedEBITDA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted earnings before interest, taxes, depreciation, and amortization as defined in the Company's credit agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA" xlink:href="ehc-20220331.xsd#ehc_AdjustedEBITDA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_AdjustedEBITDA" xlink:to="lab_ehc_AdjustedEBITDA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_6453b0fd-776c-4a26-a361-573584e0a5b2_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_f08beea8-4157-4075-86b9-780cbcdcfa24_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_fe60858b-a7e7-4e00-83fc-612d0c903442_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and advances to nonconsolidated affiliates</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_a85063d6-3ea1-4e62-8579-4c4f41a0c27f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9b15a9e7-7d2b-4694-8996-216e0081d86a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net and comprehensive income attributable to Encompass Health</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_ce342b29-68e2-4c72-8ad7-f46582a41269_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill expected to be tax-deductible amount</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2c8fa073-999c-4f94-913f-c6e082264e71_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_711cf981-09fb-4b69-9798-264150f387cb_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_43099cc7-ed16-4185-b963-86a57836da81_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e3770a69-818f-4cf0-bfd8-5b3302f17634_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance measurement period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_ec901385-fc78-4ab7-b0b6-8159b7003e80_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facilities</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_d89599c8-9436-45ff-bc54-74014c5214d7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net income of nonconsolidated affiliates</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_734e06f6-5c62-4e11-a9fe-93042f5dce16_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_539f1980-fbba-4465-b0f3-d2ccfa4538f9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_eef0072f-e9ab-4e69-a733-ae4d0f40caab_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating expenses</link:label>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_label_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost and Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_4c1c4179-1f82-4c02-84b0-17c48ae94730_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_1c939a55-0eae-4564-ae53-625c978ff2cb_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_7b9dbb6d-7013-4d63-8120-0c61e705c34e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_777f6be8-7ffa-4c7a-bea2-93ab6f662094_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_f90741e9-6eac-4064-a626-41dd3146069c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIE</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e1a48814-5f15-4ea1-bc3d-82999dc94554_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_d0ea414d-6978-429f-aaae-271cdc0d5ae6_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_36aaa6ff-a04d-44e3-a5cf-e12dcc520466_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_22797b2f-f976-47ec-a118-2bd5860ece66_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_b0be269e-c0c6-4ee8-8cfd-659d8311dae3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_11af0e43-d73f-44aa-a293-484e03afea2d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on revolving credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_InpatientRehabilitationSegmentMember_c2c6355f-fea7-49a2-ab59-81890639bc05_verboseLabel_en-US" xlink:label="lab_ehc_InpatientRehabilitationSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient Rehabilitation</link:label>
    <link:label id="lab_ehc_InpatientRehabilitationSegmentMember_label_en-US" xlink:label="lab_ehc_InpatientRehabilitationSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient Rehabilitation Segment [Member]</link:label>
    <link:label id="lab_ehc_InpatientRehabilitationSegmentMember_documentation_en-US" xlink:label="lab_ehc_InpatientRehabilitationSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inpatient Rehabilitation Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember" xlink:href="ehc-20220331.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_InpatientRehabilitationSegmentMember" xlink:to="lab_ehc_InpatientRehabilitationSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a18fbdfe-8cd3-46a8-a624-9ca00e7c3ba7_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ed119c76-2de4-430b-ba69-f4738d5a2c26_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_7fa363bd-03e9-4922-9fe7-ff19a7fd877e_terseLabel_en-US" xlink:label="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of jointly owned hospital based home health and hospice locations</link:label>
    <link:label id="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_label_en-US" xlink:label="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of jointly owned hospital based home health and hospice locations</link:label>
    <link:label id="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_documentation_en-US" xlink:label="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of jointly owned hospital based home health and hospice agencies the Company owns and operates as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" xlink:href="ehc-20220331.xsd#ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" xlink:to="lab_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_bc8a06b6-6b0b-4723-ba33-9dd135f4c871_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_cc8026c1-3947-4c98-a79e-feb30c32fc2c_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) gain on disposal or impairment of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_d3e0c0da-c752-40be-9b8b-25c1f281de43_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c97dec77-7cfe-413b-aba2-bf0312423dcd_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7105d789-c5d6-4ae9-824e-1ecaef8e2733_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_0d151c92-5cc2-4860-8af1-da0f66239118_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_37d80b20-a130-46fb-9553-0172fb259cb5_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_16e0ea41-de92-4df9-b2f1-8b662c1f2c00_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental schedule of noncash operating, investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_64a5cf4b-894f-4da1-aaf6-0c29c08f6c00_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_18220993-c2c0-4df2-92b6-e46e0b8a175e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_621a0a56-9acc-46dc-a3a1-cf71466e5b95_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_11baf63e-0cfc-42e0-bc60-4f009e934bed_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_572d50b2-7e63-4b1b-9e5d-0279a85fac6c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_975c73ac-f04c-419d-a864-b7d548780731_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, pro forma revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5d1ebfe9-66d2-4d93-92ea-4f2cb58ca212_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_411f17e6-631a-4c0d-8ab3-14639c0da388_terseLabel_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount [Roll Forward]</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_label_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount [Roll Forward]</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_documentation_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward" xlink:href="ehc-20220331.xsd#ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward" xlink:to="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_d60bc9d0-55a0-4499-9e5c-ee03687041d5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_fc8c2ab3-cc4b-4fad-b026-4f182485470a_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_62193170-cd8f-453c-8976-70eeb7588a0e_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_3fd39e19-0c1a-4eaa-bb4e-9ca0004fe90d_totalLabel_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt and finance lease obligations</link:label>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestLineItems_b1a6feaf-9d1e-427b-902d-1a613ff0c396_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestLineItems_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2df9da5c-5ecb-4575-9f98-a36c7ac05721_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a62e7210-6f3a-4f9e-af4a-09249dfd0b23_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_PatientsMember_6b41dbf4-0cbb-4065-8b5f-b2b16c8330e2_terseLabel_en-US" xlink:label="lab_ehc_PatientsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients</link:label>
    <link:label id="lab_ehc_PatientsMember_label_en-US" xlink:label="lab_ehc_PatientsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients [Member]</link:label>
    <link:label id="lab_ehc_PatientsMember_documentation_en-US" xlink:label="lab_ehc_PatientsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PatientsMember" xlink:href="ehc-20220331.xsd#ehc_PatientsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_PatientsMember" xlink:to="lab_ehc_PatientsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_TermLoanFacilitiesMember_15d7d2cd-d1bd-491b-abf1-5548c2a1373f_terseLabel_en-US" xlink:label="lab_ehc_TermLoanFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facilities</link:label>
    <link:label id="lab_ehc_TermLoanFacilitiesMember_label_en-US" xlink:label="lab_ehc_TermLoanFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facilities [Member]</link:label>
    <link:label id="lab_ehc_TermLoanFacilitiesMember_documentation_en-US" xlink:label="lab_ehc_TermLoanFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember" xlink:href="ehc-20220331.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_TermLoanFacilitiesMember" xlink:to="lab_ehc_TermLoanFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_098721b7-eb62-412a-8517-e6e38214f49e_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_5db1d64c-eb19-46dc-8726-1113b3f940fa_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net and comprehensive income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_85222bb3-39f1-4b21-ba7a-93dafdb08a82_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_6a0304de-3077-4850-9d28-431294c1af9a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_911bbab9-0760-4140-9c28-6bd9f2a36bd5_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_a7c11c01-76f9-4328-8f05-02ab088c3972_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1be70841-5ee8-4434-a3a9-ff72fa9a0fe3_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22d1ca81-64ea-4565-ad4a-e25d4bcf3e68_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_02b31ce7-ac0d-4846-843f-42511db0f23b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_e6c23313-4604-4970-82dd-ac8d383027de_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c96736fd-c751-4450-9b99-d5adce2f76b2_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3a7481af-a847-4fb1-b28a-c3205e7bef71_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9fdc9916-67a0-4518-92b9-3de1a1c45bc2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationHospitals_26343d07-830b-4309-a8d2-4afc35480233_terseLabel_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationHospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of inpatient rehabilitation hospitals operated</link:label>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationHospitals_label_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationHospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Inpatient Rehabilitation Hospitals</link:label>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationHospitals_documentation_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationHospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationHospitals" xlink:href="ehc-20220331.xsd#ehc_NumberOfInpatientRehabilitationHospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberOfInpatientRehabilitationHospitals" xlink:to="lab_ehc_NumberOfInpatientRehabilitationHospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_4dd29c6f-065e-43d3-8f66-07f450a42951_totalLabel_en-US" xlink:label="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_label_en-US" xlink:label="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss from Continuing Operations Attributable to Common Shareholders Diluted</link:label>
    <link:label id="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_documentation_en-US" xlink:label="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income loss from continuing operations attributable to common shareholders diluted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" xlink:href="ehc-20220331.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" xlink:to="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8d69a32f-f193-4c52-8715-f5b4fe0fa7dc_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_92537471-8aa9-4ddb-86ac-f0566726c1c5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c43f38e4-1927-4609-b752-a349fb06f8ba_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7b6756f9-f65b-4c8c-b21d-caa28a2af2c1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5a826323-9a52-45ce-9336-ceaf5e59415c_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0145b8ea-c1f8-4017-8642-27cb613f6208_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_b8ed6c63-2cdd-4c71-8451-f173e086c2af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_7c2b113d-cc85-463a-badc-0e0e02e46c40_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_80d808fe-7ad6-4435-8713-1fb9dd60ae00_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_WorkersCompensationMember_6e9a5e5f-de7f-44fc-b7bf-df72bf043281_terseLabel_en-US" xlink:label="lab_ehc_WorkersCompensationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers&#8217; compensation</link:label>
    <link:label id="lab_ehc_WorkersCompensationMember_label_en-US" xlink:label="lab_ehc_WorkersCompensationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers' Compensation [Member]</link:label>
    <link:label id="lab_ehc_WorkersCompensationMember_documentation_en-US" xlink:label="lab_ehc_WorkersCompensationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers' Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WorkersCompensationMember" xlink:href="ehc-20220331.xsd#ehc_WorkersCompensationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_WorkersCompensationMember" xlink:to="lab_ehc_WorkersCompensationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_fa572c60-5822-461d-af94-c4b291cd502f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_7c059553-2bab-4f5c-820b-8afc6a90edfa_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_59b74c3e-da5e-483d-af59-01261c45a70c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a148e1e8-b4ce-4337-8917-1472b053f1f4_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_a68a8eb7-c0ee-4ac0-ac46-70764ddd6f21_terseLabel_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_label_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Liability</link:label>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_documentation_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:to="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_d121055d-e3c6-4afc-8425-6ea369aed2dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_0b5217e9-0cad-4b10-94bc-b5482e224bdd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_45c93161-d59a-4abc-b3d9-6541005e5ab9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_53512eca-a5ea-48f9-a87f-94d16b62279b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_484a8328-c0c0-4989-96e8-0d3e3e39bd13_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_81b21055-95ed-4d77-b7b5-228f1d7172f8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f998dfa-5c34-405b-94c8-f63bf7847ae6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_e484da4e-f229-421f-9971-7faf98d1ab7d_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cb3f4232-2302-4c0a-9327-41a7928a23aa_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_e188a5e6-a9fc-4e9c-b162-b3560bf419d5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8c50b875-3272-4dc0-ba26-412c5f2b1c03_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6db3ebc8-56d8-4596-b454-9c22617d68a7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid on behalf of employees for shares withheld</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c88f959f-a84f-46ff-a259-8d6aa0f24be1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_382f507c-98b6-4ae8-a3f8-d14a08034880_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7f4b2276-dd03-40b0-ab85-7d3e5b4d9468_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_0495883a-73a8-4650-a6f1-ef1e23cbfad0_totalLabel_en-US" xlink:label="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_label_en-US" xlink:label="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss from Continuing Operations Attributable to Common Shareholders Basic</link:label>
    <link:label id="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_documentation_en-US" xlink:label="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from continuing operations attributable to HealthSouth common shareholders basic.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" xlink:href="ehc-20220331.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" xlink:to="lab_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_9f564014-6a85-428a-9fdc-ee49cd72c3e5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_c87f5f74-c4c8-42b2-9e39-62dd9ec5d820_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c8940a95-1ff8-4d9a-92d6-07ca2d5cbdcf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_5a1816d3-8be3-4876-a7f9-73b7160d8e98_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d25ba68a-b811-464a-9214-9d9e689f1965_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ed871784-8a2e-4099-ba01-3e7f59470bfc_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_MedicareMember_2da47795-1ac4-4629-9eb6-ac115fdfb2e7_terseLabel_en-US" xlink:label="lab_ehc_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_ehc_MedicareMember_label_en-US" xlink:label="lab_ehc_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_ehc_MedicareMember_documentation_en-US" xlink:label="lab_ehc_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareMember" xlink:href="ehc-20220331.xsd#ehc_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_MedicareMember" xlink:to="lab_ehc_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_fabae30e-c1b1-4b36-97a5-b388aac43f4c_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_ae0a1c02-4005-4492-9ed5-6c602d2706f1_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_64badff1-a119-4a36-b35b-879467133579_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_77660057-7891-4c7d-888d-929e7810cda7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue_a0ee32e3-857f-4c22-8bf6-017d2f6389bc_negatedTerseLabel_en-US" xlink:label="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of noncontrolling interest owned by joint venture partner</link:label>
    <link:label id="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Noncontrolling Interest, Fair Value</link:label>
    <link:label id="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue_documentation_en-US" xlink:label="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:to="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Jointventureownershippercentage_e9b6fe0c-3f70-483d-868c-615e2981750e_terseLabel_en-US" xlink:label="lab_ehc_Jointventureownershippercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture ownership percentage</link:label>
    <link:label id="lab_ehc_Jointventureownershippercentage_label_en-US" xlink:label="lab_ehc_Jointventureownershippercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture ownership percentage</link:label>
    <link:label id="lab_ehc_Jointventureownershippercentage_documentation_en-US" xlink:label="lab_ehc_Jointventureownershippercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture ownership percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Jointventureownershippercentage" xlink:href="ehc-20220331.xsd#ehc_Jointventureownershippercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Jointventureownershippercentage" xlink:to="lab_ehc_Jointventureownershippercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_d29f89e4-9658-4ae3-97d8-7c2343fdd686_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4eb53946-8f30-43e7-b871-6a2e0b321f33_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities&#8212;</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ehc-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:69533f56-540a-48e1-b4ee-a7401038559f,g:2f1c880e-7b65-4846-aaa6-f9cb86c4b8d3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CoverPage" xlink:type="simple" xlink:href="ehc-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_00105762-c219-4ee5-bfc6-09fefa9c1d1b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_DocumentType_00105762-c219-4ee5-bfc6-09fefa9c1d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_818e3a86-cf4e-4b8d-9a5a-d524079aa51f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_DocumentQuarterlyReport_818e3a86-cf4e-4b8d-9a5a-d524079aa51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e3e266d3-1440-454e-9f3b-1da81990186b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_DocumentPeriodEndDate_e3e266d3-1440-454e-9f3b-1da81990186b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_13694d94-a833-4d5a-aa5f-74df21cc1be0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_DocumentTransitionReport_13694d94-a833-4d5a-aa5f-74df21cc1be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3daa2a12-65c5-47a4-ba92-8882022066a2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_EntityFileNumber_3daa2a12-65c5-47a4-ba92-8882022066a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_31428882-7bc1-4b31-9854-b2491e02d5d6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_EntityRegistrantName_31428882-7bc1-4b31-9854-b2491e02d5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2d136f21-b24f-4e4f-a78a-c970d3b174da" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2d136f21-b24f-4e4f-a78a-c970d3b174da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c9da833b-3f21-41dd-ae44-49ad431631a2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_EntityTaxIdentificationNumber_c9da833b-3f21-41dd-ae44-49ad431631a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_182fdafd-e693-45b0-918f-ab8bbba35966" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_EntityAddressAddressLine1_182fdafd-e693-45b0-918f-ab8bbba35966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9589c84c-71a9-4ec0-9a6d-fa84750ea923" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_EntityAddressCityOrTown_9589c84c-71a9-4ec0-9a6d-fa84750ea923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1938331e-fdfa-45c0-b33f-f7f47c72f65b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_EntityAddressStateOrProvince_1938331e-fdfa-45c0-b33f-f7f47c72f65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2878d30e-19eb-49f7-8af5-48bcd3d1a95e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_EntityAddressPostalZipCode_2878d30e-19eb-49f7-8af5-48bcd3d1a95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5ae91e46-306c-472e-97ad-74dc7d1f02e1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_CityAreaCode_5ae91e46-306c-472e-97ad-74dc7d1f02e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e12f8933-86a4-4597-b984-40f027fb56cd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_LocalPhoneNumber_e12f8933-86a4-4597-b984-40f027fb56cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2f5ceb58-b0f7-43ec-8467-e6ac0c315d77" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_Security12bTitle_2f5ceb58-b0f7-43ec-8467-e6ac0c315d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e0842e81-b49d-4c4a-9d8a-a2120de46c7a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_TradingSymbol_e0842e81-b49d-4c4a-9d8a-a2120de46c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4c7f2a08-eaa1-4693-8715-6b854494315c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_SecurityExchangeName_4c7f2a08-eaa1-4693-8715-6b854494315c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_190bd1f2-86e4-4ecf-ae36-cd7460751ee5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_EntityCurrentReportingStatus_190bd1f2-86e4-4ecf-ae36-cd7460751ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c7a637da-30f6-468d-a9fe-f45cd8b10b28" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_EntityInteractiveDataCurrent_c7a637da-30f6-468d-a9fe-f45cd8b10b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_5f786a7e-bfe6-4df1-aa98-7065930be791" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_EntityFilerCategory_5f786a7e-bfe6-4df1-aa98-7065930be791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2b4fec41-69b7-44b3-8368-653a3a235690" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_EntitySmallBusiness_2b4fec41-69b7-44b3-8368-653a3a235690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a9cb6a83-997f-4a67-b54c-8c0d49d32f81" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_EntityEmergingGrowthCompany_a9cb6a83-997f-4a67-b54c-8c0d49d32f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6b66419e-6426-4013-b5a9-3149e42c8aeb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_EntityShellCompany_6b66419e-6426-4013-b5a9-3149e42c8aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_eef6a229-89ef-4286-9cd5-f577ab783da9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_eef6a229-89ef-4286-9cd5-f577ab783da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ed14b573-f9db-40f8-b811-d5f7c0abdf34" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_EntityCentralIndexKey_ed14b573-f9db-40f8-b811-d5f7c0abdf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_250d33cb-94c2-41ed-bc65-7ce9af219237" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_CurrentFiscalYearEndDate_250d33cb-94c2-41ed-bc65-7ce9af219237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_443baeb9-2395-4139-95df-f0e9952e7b05" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_DocumentFiscalYearFocus_443baeb9-2395-4139-95df-f0e9952e7b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_67f76a65-b2cb-4812-a5b2-cacb3849aca7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_DocumentFiscalPeriodFocus_67f76a65-b2cb-4812-a5b2-cacb3849aca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d7a29ea0-f547-4527-ab9e-f3db142758d3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2bbe241e-b10b-4119-89a1-640c9d9cca72" xlink:to="loc_dei_AmendmentFlag_d7a29ea0-f547-4527-ab9e-f3db142758d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="ehc-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:href="ehc-20220331.xsd#ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d45c2a63-b872-42ab-9cd4-447408cc13c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d45c2a63-b872-42ab-9cd4-447408cc13c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_b39a96ce-8c4d-42d4-a902-164ff47f4bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_b39a96ce-8c4d-42d4-a902-164ff47f4bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_ba06b8d9-7395-47ad-9dca-7d37e3862ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b39a96ce-8c4d-42d4-a902-164ff47f4bf7" xlink:to="loc_us-gaap_LaborAndRelatedExpense_ba06b8d9-7395-47ad-9dca-7d37e3862ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_2670c988-b28f-46d2-a734-7ec6f32bcda7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b39a96ce-8c4d-42d4-a902-164ff47f4bf7" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_2670c988-b28f-46d2-a734-7ec6f32bcda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost_92649757-5205-4084-8ad9-fbd01140f979" xlink:href="ehc-20220331.xsd#ehc_OccupancyCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b39a96ce-8c4d-42d4-a902-164ff47f4bf7" xlink:to="loc_ehc_OccupancyCost_92649757-5205-4084-8ad9-fbd01140f979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_51d854be-ac10-4395-a2c1-0a60ceff90e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b39a96ce-8c4d-42d4-a902-164ff47f4bf7" xlink:to="loc_us-gaap_SuppliesExpense_51d854be-ac10-4395-a2c1-0a60ceff90e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fb3b9ee6-b13c-44a3-b520-13608c19d26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b39a96ce-8c4d-42d4-a902-164ff47f4bf7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fb3b9ee6-b13c-44a3-b520-13608c19d26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7386d4f9-48ad-4876-83a5-b463e297d696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b39a96ce-8c4d-42d4-a902-164ff47f4bf7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7386d4f9-48ad-4876-83a5-b463e297d696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_090e7af7-805a-4a74-a6ed-2919ce2e583b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b39a96ce-8c4d-42d4-a902-164ff47f4bf7" xlink:to="loc_us-gaap_CostsAndExpenses_090e7af7-805a-4a74-a6ed-2919ce2e583b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_43c85e3b-d6bf-48a8-adbb-fdfdb1d0265f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_43c85e3b-d6bf-48a8-adbb-fdfdb1d0265f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9dbd7f1e-781e-44c5-b8e6-56780d40ec19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_InterestExpense_9dbd7f1e-781e-44c5-b8e6-56780d40ec19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_619cf3ad-32be-4858-9c98-87acbfcf2429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_619cf3ad-32be-4858-9c98-87acbfcf2429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fb6628f0-6411-462d-9e6e-ad18b6a4a0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fb6628f0-6411-462d-9e6e-ad18b6a4a0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f62fb3a9-48b9-4af9-a6b3-cf93d95519b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f62fb3a9-48b9-4af9-a6b3-cf93d95519b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b772b74a-bc49-431a-98b2-4a14187f0ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b772b74a-bc49-431a-98b2-4a14187f0ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_bb5701a1-0d2e-415f-8633-ea74a74713fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_bb5701a1-0d2e-415f-8633-ea74a74713fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_06ca4191-d743-4808-ab5c-602bf1656e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_06ca4191-d743-4808-ab5c-602bf1656e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_19b2be43-9b4b-4dfc-9ecc-072ddf72a004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_ProfitLoss_19b2be43-9b4b-4dfc-9ecc-072ddf72a004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3b566c95-adf8-4eab-bf0c-d4ea081325cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3b566c95-adf8-4eab-bf0c-d4ea081325cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c45a8dbd-048f-43fe-95a9-233ebbb2fe2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c45a8dbd-048f-43fe-95a9-233ebbb2fe2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_fba1a50e-18ca-4234-8f0c-560c86cabde5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_fba1a50e-18ca-4234-8f0c-560c86cabde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_62ac6038-56e0-426b-85d4-5d91b8df2ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_NetIncomeLoss_62ac6038-56e0-426b-85d4-5d91b8df2ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f323c4dc-4bbd-4ae5-b9da-035c32c62631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f323c4dc-4bbd-4ae5-b9da-035c32c62631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_41d82901-0eba-4217-b0e9-c19c32da4c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_41d82901-0eba-4217-b0e9-c19c32da4c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_87a2a938-8bd7-4cde-b7d7-a6fb9a26d20a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_41d82901-0eba-4217-b0e9-c19c32da4c6e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_87a2a938-8bd7-4cde-b7d7-a6fb9a26d20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2a73eb22-65dc-48d4-8a10-7a69e1af2223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_41d82901-0eba-4217-b0e9-c19c32da4c6e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2a73eb22-65dc-48d4-8a10-7a69e1af2223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_6b029e2d-64ea-4e48-867b-91d60282c9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_6b029e2d-64ea-4e48-867b-91d60282c9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_c2c84cf1-f601-40c3-8ab4-282b2a30d4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_6b029e2d-64ea-4e48-867b-91d60282c9f8" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_c2c84cf1-f601-40c3-8ab4-282b2a30d4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_20fdfb7c-31fe-4829-854c-26abc7699b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_c2c84cf1-f601-40c3-8ab4-282b2a30d4e0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_20fdfb7c-31fe-4829-854c-26abc7699b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_f70de9d4-41e5-4571-982c-288906d4294c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_c2c84cf1-f601-40c3-8ab4-282b2a30d4e0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_f70de9d4-41e5-4571-982c-288906d4294c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7246955a-33ef-4e59-970f-05d07af86092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_c2c84cf1-f601-40c3-8ab4-282b2a30d4e0" xlink:to="loc_us-gaap_EarningsPerShareBasic_7246955a-33ef-4e59-970f-05d07af86092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_44063a63-d3a0-4da2-bcb1-1f4169af0b93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_6b029e2d-64ea-4e48-867b-91d60282c9f8" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_44063a63-d3a0-4da2-bcb1-1f4169af0b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_8e6e615e-59a8-4062-967d-40366e34637f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_44063a63-d3a0-4da2-bcb1-1f4169af0b93" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_8e6e615e-59a8-4062-967d-40366e34637f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_59d275ff-c17e-42f9-88bc-a0dfb2cdfbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_44063a63-d3a0-4da2-bcb1-1f4169af0b93" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_59d275ff-c17e-42f9-88bc-a0dfb2cdfbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_564ec9f1-eaba-4a93-a219-806d0b2c190f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_44063a63-d3a0-4da2-bcb1-1f4169af0b93" xlink:to="loc_us-gaap_EarningsPerShareDiluted_564ec9f1-eaba-4a93-a219-806d0b2c190f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_9554d0e2-5ff0-45aa-9f03-f646ba185097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_aeba1b87-ea8e-481f-b8ad-79553bbe149c" xlink:to="loc_us-gaap_NetIncomeLossAbstract_9554d0e2-5ff0-45aa-9f03-f646ba185097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_d66f5b51-4e35-4128-858e-c10d0dddde78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_9554d0e2-5ff0-45aa-9f03-f646ba185097" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_d66f5b51-4e35-4128-858e-c10d0dddde78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_d6354f21-a9f0-4e25-a174-fedbf3c4847a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_9554d0e2-5ff0-45aa-9f03-f646ba185097" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_d6354f21-a9f0-4e25-a174-fedbf3c4847a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_86510806-8a87-4876-954f-16404e489c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_9554d0e2-5ff0-45aa-9f03-f646ba185097" xlink:to="loc_us-gaap_NetIncomeLoss_86510806-8a87-4876-954f-16404e489c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="ehc-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="ehc-20220331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fab2c6b0-2d1e-4865-b890-a1a6fde0918d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_48a17f7a-01b4-4c03-b5e9-4b2f665e993f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fab2c6b0-2d1e-4865-b890-a1a6fde0918d" xlink:to="loc_us-gaap_AssetsAbstract_48a17f7a-01b4-4c03-b5e9-4b2f665e993f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_48b69bb7-86d3-4ae5-8e59-1b8656941d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_48a17f7a-01b4-4c03-b5e9-4b2f665e993f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_48b69bb7-86d3-4ae5-8e59-1b8656941d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_adaf9702-033b-49dc-9cbe-e385f427519a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_48b69bb7-86d3-4ae5-8e59-1b8656941d19" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_adaf9702-033b-49dc-9cbe-e385f427519a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_88335ac3-d5f7-4fbc-b296-211779d06abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_48b69bb7-86d3-4ae5-8e59-1b8656941d19" xlink:to="loc_us-gaap_RestrictedCashCurrent_88335ac3-d5f7-4fbc-b296-211779d06abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7c53757f-02dc-4f6a-8154-7ad0b1405f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_48b69bb7-86d3-4ae5-8e59-1b8656941d19" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7c53757f-02dc-4f6a-8154-7ad0b1405f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_de1c2dce-98d7-4c70-b5f4-939e184027a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_48b69bb7-86d3-4ae5-8e59-1b8656941d19" xlink:to="loc_us-gaap_OtherAssetsCurrent_de1c2dce-98d7-4c70-b5f4-939e184027a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f69e66db-2a8d-4bbe-bef3-26bc276496c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_48b69bb7-86d3-4ae5-8e59-1b8656941d19" xlink:to="loc_us-gaap_AssetsCurrent_f69e66db-2a8d-4bbe-bef3-26bc276496c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_4b812949-d8e0-4144-aa99-03ee465ac447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_48a17f7a-01b4-4c03-b5e9-4b2f665e993f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_4b812949-d8e0-4144-aa99-03ee465ac447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d9f41d34-5f04-4462-9d87-7000c14e2bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_48a17f7a-01b4-4c03-b5e9-4b2f665e993f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d9f41d34-5f04-4462-9d87-7000c14e2bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7be4093a-dbce-4f9e-a876-93b3becd40a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_48a17f7a-01b4-4c03-b5e9-4b2f665e993f" xlink:to="loc_us-gaap_Goodwill_7be4093a-dbce-4f9e-a876-93b3becd40a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7d55a859-b6b9-413d-9517-2e605be9317e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_48a17f7a-01b4-4c03-b5e9-4b2f665e993f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7d55a859-b6b9-413d-9517-2e605be9317e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a01bb556-0751-41e1-b28a-2cd9636f2ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_48a17f7a-01b4-4c03-b5e9-4b2f665e993f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a01bb556-0751-41e1-b28a-2cd9636f2ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_38f4e934-6dd5-4776-9af3-97ae43f5bb31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_48a17f7a-01b4-4c03-b5e9-4b2f665e993f" xlink:to="loc_us-gaap_Assets_38f4e934-6dd5-4776-9af3-97ae43f5bb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8203befd-f02c-4921-bfcf-7ab7ea90168c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fab2c6b0-2d1e-4865-b890-a1a6fde0918d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8203befd-f02c-4921-bfcf-7ab7ea90168c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c0d90b53-5ccb-4a4e-8c5d-d9e428ffc42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8203befd-f02c-4921-bfcf-7ab7ea90168c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c0d90b53-5ccb-4a4e-8c5d-d9e428ffc42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_31f97ba8-846c-4fc5-9cf1-2019bb73b6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0d90b53-5ccb-4a4e-8c5d-d9e428ffc42d" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_31f97ba8-846c-4fc5-9cf1-2019bb73b6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ed476b3e-fbd7-4329-956b-e8ab706a95d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0d90b53-5ccb-4a4e-8c5d-d9e428ffc42d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ed476b3e-fbd7-4329-956b-e8ab706a95d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a4213944-45bf-479c-827c-f2dd9a56f61c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0d90b53-5ccb-4a4e-8c5d-d9e428ffc42d" xlink:to="loc_us-gaap_AccountsPayableCurrent_a4213944-45bf-479c-827c-f2dd9a56f61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_fd45d082-c6cb-453e-b113-ae776a05c7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0d90b53-5ccb-4a4e-8c5d-d9e428ffc42d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_fd45d082-c6cb-453e-b113-ae776a05c7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_04190189-63d4-41e5-925b-349093d7bf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0d90b53-5ccb-4a4e-8c5d-d9e428ffc42d" xlink:to="loc_us-gaap_LiabilitiesCurrent_04190189-63d4-41e5-925b-349093d7bf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_8befb599-52f3-4b3d-a5f1-ef4495df5556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8203befd-f02c-4921-bfcf-7ab7ea90168c" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_8befb599-52f3-4b3d-a5f1-ef4495df5556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9b7ae7fd-c8f8-42ca-8752-34a27b937b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8203befd-f02c-4921-bfcf-7ab7ea90168c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9b7ae7fd-c8f8-42ca-8752-34a27b937b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d6efbf36-0b22-4815-8adf-7f905bd8c7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8203befd-f02c-4921-bfcf-7ab7ea90168c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d6efbf36-0b22-4815-8adf-7f905bd8c7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_49bf9581-e6f1-43c7-aa6c-612766223cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8203befd-f02c-4921-bfcf-7ab7ea90168c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_49bf9581-e6f1-43c7-aa6c-612766223cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0218759a-fcda-4de2-9a95-7c0ac21c7ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8203befd-f02c-4921-bfcf-7ab7ea90168c" xlink:to="loc_us-gaap_Liabilities_0218759a-fcda-4de2-9a95-7c0ac21c7ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d63e01b7-6858-4cc9-b7ab-90a3cfc553e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8203befd-f02c-4921-bfcf-7ab7ea90168c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d63e01b7-6858-4cc9-b7ab-90a3cfc553e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_8897f795-ddac-434a-b7a5-ff6cb23fa2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8203befd-f02c-4921-bfcf-7ab7ea90168c" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_8897f795-ddac-434a-b7a5-ff6cb23fa2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_51dbb6f7-e6d5-4dd0-81ce-366daee6900f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8203befd-f02c-4921-bfcf-7ab7ea90168c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_51dbb6f7-e6d5-4dd0-81ce-366daee6900f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0c4429ab-5b78-4590-a313-c187c31609a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_51dbb6f7-e6d5-4dd0-81ce-366daee6900f" xlink:to="loc_us-gaap_StockholdersEquity_0c4429ab-5b78-4590-a313-c187c31609a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a6e22d3e-5833-4246-a214-631e126f26b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_51dbb6f7-e6d5-4dd0-81ce-366daee6900f" xlink:to="loc_us-gaap_MinorityInterest_a6e22d3e-5833-4246-a214-631e126f26b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_346215d7-cbac-4b58-b6f3-5d46123f40c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_51dbb6f7-e6d5-4dd0-81ce-366daee6900f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_346215d7-cbac-4b58-b6f3-5d46123f40c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_87b059c8-aa66-49d9-80bb-2e0082ef91d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8203befd-f02c-4921-bfcf-7ab7ea90168c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_87b059c8-aa66-49d9-80bb-2e0082ef91d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="ehc-20220331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f15f1b35-1da5-4a0d-bac2-538e72d5a30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_06bee963-a6f8-4264-a250-db4fc0b9a794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f15f1b35-1da5-4a0d-bac2-538e72d5a30c" xlink:to="loc_us-gaap_StatementTable_06bee963-a6f8-4264-a250-db4fc0b9a794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_2d894956-e64c-4890-af96-11f40063e94f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_06bee963-a6f8-4264-a250-db4fc0b9a794" xlink:to="loc_srt_ConsolidatedEntitiesAxis_2d894956-e64c-4890-af96-11f40063e94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_871b5580-9c75-4a54-b7d8-b758ea9b742b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_2d894956-e64c-4890-af96-11f40063e94f" xlink:to="loc_srt_ConsolidatedEntitiesDomain_871b5580-9c75-4a54-b7d8-b758ea9b742b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_0d35fb05-9bd7-4d40-b185-143fe3840907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_871b5580-9c75-4a54-b7d8-b758ea9b742b" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_0d35fb05-9bd7-4d40-b185-143fe3840907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2d8a90e3-f357-450d-a4a3-8e47437c8076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_06bee963-a6f8-4264-a250-db4fc0b9a794" xlink:to="loc_us-gaap_StatementLineItems_2d8a90e3-f357-450d-a4a3-8e47437c8076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cbb91f31-bbbc-463f-b894-22324db1ca0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d8a90e3-f357-450d-a4a3-8e47437c8076" xlink:to="loc_us-gaap_Assets_cbb91f31-bbbc-463f-b894-22324db1ca0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e3b66489-3add-418b-8353-dcd39e6cbab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d8a90e3-f357-450d-a4a3-8e47437c8076" xlink:to="loc_us-gaap_Liabilities_e3b66489-3add-418b-8353-dcd39e6cbab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited" xlink:type="simple" xlink:href="ehc-20220331.xsd#CondensedConsolidatedStatementsofShareholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3aa32314-cda9-4d57-958f-2e18c4123c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a9cf911c-436d-46e3-8a43-eae4bd01d18a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3aa32314-cda9-4d57-958f-2e18c4123c4b" xlink:to="loc_us-gaap_StatementTable_a9cf911c-436d-46e3-8a43-eae4bd01d18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_be189b38-b8d5-46c5-ba84-2876d21887f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a9cf911c-436d-46e3-8a43-eae4bd01d18a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_be189b38-b8d5-46c5-ba84-2876d21887f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9b523902-fa34-4a67-a410-da84f420174c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_be189b38-b8d5-46c5-ba84-2876d21887f8" xlink:to="loc_us-gaap_EquityComponentDomain_9b523902-fa34-4a67-a410-da84f420174c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_798c21ea-ca0f-4a36-affa-4d8ef9a037af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b523902-fa34-4a67-a410-da84f420174c" xlink:to="loc_us-gaap_CommonStockMember_798c21ea-ca0f-4a36-affa-4d8ef9a037af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_87821a32-cea9-4447-ad72-ec859751c4db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b523902-fa34-4a67-a410-da84f420174c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_87821a32-cea9-4447-ad72-ec859751c4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_289c4515-fc43-4ff1-9394-3825159319f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b523902-fa34-4a67-a410-da84f420174c" xlink:to="loc_us-gaap_RetainedEarningsMember_289c4515-fc43-4ff1-9394-3825159319f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_ca5363a2-12a5-4cca-be1d-01abe1235950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b523902-fa34-4a67-a410-da84f420174c" xlink:to="loc_us-gaap_TreasuryStockMember_ca5363a2-12a5-4cca-be1d-01abe1235950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_2608882f-37aa-46eb-bc82-2a0d513c216f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b523902-fa34-4a67-a410-da84f420174c" xlink:to="loc_us-gaap_NoncontrollingInterestMember_2608882f-37aa-46eb-bc82-2a0d513c216f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9fe13496-8eb5-4065-836d-5aa67d4282f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a9cf911c-436d-46e3-8a43-eae4bd01d18a" xlink:to="loc_us-gaap_StatementLineItems_9fe13496-8eb5-4065-836d-5aa67d4282f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9fe13496-8eb5-4065-836d-5aa67d4282f5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e9f7d28e-26ec-42da-a849-e10bf3394e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e9f7d28e-26ec-42da-a849-e10bf3394e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e597bcf8-d703-4377-abe2-7d39f8def5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e597bcf8-d703-4377-abe2-7d39f8def5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_05b9fd66-965a-4d16-90be-a6bef216e6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_05b9fd66-965a-4d16-90be-a6bef216e6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_6d3bd4aa-ce88-4a2f-9818-b3f9a268682a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_6d3bd4aa-ce88-4a2f-9818-b3f9a268682a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_997a37ce-6edb-4282-a84a-02efda6fb55d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_997a37ce-6edb-4282-a84a-02efda6fb55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_749ef675-8315-459f-8851-e2fb8c6f929b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_DividendsCommonStockCash_749ef675-8315-459f-8851-e2fb8c6f929b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_86d928a5-7d32-409c-901d-444399f9fc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_86d928a5-7d32-409c-901d-444399f9fc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_591a1b02-d6b2-4171-92f4-f9f90ef62953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_591a1b02-d6b2-4171-92f4-f9f90ef62953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnersCapitalAccountContributions_6cd55bd9-e7ec-4cdd-9479-df736433ba48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnersCapitalAccountContributions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_PartnersCapitalAccountContributions_6cd55bd9-e7ec-4cdd-9479-df736433ba48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_a686eb8b-ac70-4928-a8ea-3a4a4c3ae4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_a686eb8b-ac70-4928-a8ea-3a4a4c3ae4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_e335c53e-39cd-493f-ac05-70daa552f27a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_StockholdersEquityOther_e335c53e-39cd-493f-ac05-70daa552f27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_06f978f5-98a0-4205-9a8f-1a05e088f3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_06f978f5-98a0-4205-9a8f-1a05e088f3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0648ec82-6325-44d1-a658-63994df0eb19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b6140206-0d30-4336-bd4a-beb7da0d446f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0648ec82-6325-44d1-a658-63994df0eb19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical" xlink:type="simple" xlink:href="ehc-20220331.xsd#CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_02b347dc-c01f-42b7-8ae7-d20e4db177e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_14de97fd-bbef-4656-99a8-c507b105b576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_02b347dc-c01f-42b7-8ae7-d20e4db177e6" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_14de97fd-bbef-4656-99a8-c507b105b576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="ehc-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_aabb6bdb-1285-432a-892c-ce7a404b188a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_724c32a3-6a4c-422c-8ed6-281d38f66e31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aabb6bdb-1285-432a-892c-ce7a404b188a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_724c32a3-6a4c-422c-8ed6-281d38f66e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bfedc68e-d25f-4a43-b8a7-82cacaf42816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_724c32a3-6a4c-422c-8ed6-281d38f66e31" xlink:to="loc_us-gaap_ProfitLoss_bfedc68e-d25f-4a43-b8a7-82cacaf42816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e560c0d-1e56-45d5-88b0-bc670dfb7c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_724c32a3-6a4c-422c-8ed6-281d38f66e31" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e560c0d-1e56-45d5-88b0-bc670dfb7c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7c8e743c-86ea-4ba8-9c1b-ed79d5e9542e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e560c0d-1e56-45d5-88b0-bc670dfb7c36" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7c8e743c-86ea-4ba8-9c1b-ed79d5e9542e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a8a4f023-1432-4f02-a749-edbb67dc0849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e560c0d-1e56-45d5-88b0-bc670dfb7c36" xlink:to="loc_us-gaap_ShareBasedCompensation_a8a4f023-1432-4f02-a749-edbb67dc0849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_72fadc4d-60d7-44d6-ad89-5f5877f941d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e560c0d-1e56-45d5-88b0-bc670dfb7c36" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_72fadc4d-60d7-44d6-ad89-5f5877f941d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_55c3bb0b-ab8c-4d28-bac3-21cc1da00286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e560c0d-1e56-45d5-88b0-bc670dfb7c36" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_55c3bb0b-ab8c-4d28-bac3-21cc1da00286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_86ecee10-024a-42ff-8147-5a645d74836e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e560c0d-1e56-45d5-88b0-bc670dfb7c36" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_86ecee10-024a-42ff-8147-5a645d74836e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fd20cef9-d03a-4d09-bbb6-0d4ac6114314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_86ecee10-024a-42ff-8147-5a645d74836e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fd20cef9-d03a-4d09-bbb6-0d4ac6114314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d0fe1ab0-53e6-4ad5-9557-a3fc8c69cb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_86ecee10-024a-42ff-8147-5a645d74836e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d0fe1ab0-53e6-4ad5-9557-a3fc8c69cb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_38e31661-88ef-46d6-be5c-9ae5777d314d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_86ecee10-024a-42ff-8147-5a645d74836e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_38e31661-88ef-46d6-be5c-9ae5777d314d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e4a8a3d7-3fdf-4017-945e-8eeb0c941d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_86ecee10-024a-42ff-8147-5a645d74836e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e4a8a3d7-3fdf-4017-945e-8eeb0c941d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_5acc8fb5-fbd5-458c-a6f5-a7137fb1dca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e560c0d-1e56-45d5-88b0-bc670dfb7c36" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_5acc8fb5-fbd5-458c-a6f5-a7137fb1dca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_0b57189b-08ec-4126-bf8b-146bc42efbac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e560c0d-1e56-45d5-88b0-bc670dfb7c36" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_0b57189b-08ec-4126-bf8b-146bc42efbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a66fe47-0164-49eb-a1b6-3a5edb37f0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_724c32a3-6a4c-422c-8ed6-281d38f66e31" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a66fe47-0164-49eb-a1b6-3a5edb37f0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_da77f7fb-84a3-42d6-b7ef-271435e55a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aabb6bdb-1285-432a-892c-ce7a404b188a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_da77f7fb-84a3-42d6-b7ef-271435e55a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_18c12dfa-36b5-4290-aacb-36e2a1cfdf9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_da77f7fb-84a3-42d6-b7ef-271435e55a73" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_18c12dfa-36b5-4290-aacb-36e2a1cfdf9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_44638dec-8bea-4457-a8a5-fa77b73ce4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_da77f7fb-84a3-42d6-b7ef-271435e55a73" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_44638dec-8bea-4457-a8a5-fa77b73ce4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cc8e2395-e8bd-4c04-8c06-9024d6a9a824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_da77f7fb-84a3-42d6-b7ef-271435e55a73" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cc8e2395-e8bd-4c04-8c06-9024d6a9a824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b061b536-df95-4f68-95cd-1b6c3b16ead5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aabb6bdb-1285-432a-892c-ce7a404b188a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b061b536-df95-4f68-95cd-1b6c3b16ead5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_7404f363-e2cb-412f-bc40-0304db8689d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b061b536-df95-4f68-95cd-1b6c3b16ead5" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_7404f363-e2cb-412f-bc40-0304db8689d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_92741fde-b8be-4d24-bcc9-41bea6d46611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b061b536-df95-4f68-95cd-1b6c3b16ead5" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_92741fde-b8be-4d24-bcc9-41bea6d46611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_11238bf7-528b-4dcf-bb46-8acf7179aef6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b061b536-df95-4f68-95cd-1b6c3b16ead5" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_11238bf7-528b-4dcf-bb46-8acf7179aef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts_f070fa91-a03d-4859-905f-d3b893536bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b061b536-df95-4f68-95cd-1b6c3b16ead5" xlink:to="loc_us-gaap_PaymentsOfDebtRestructuringCosts_f070fa91-a03d-4859-905f-d3b893536bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b9b4c29d-061a-438d-a93d-93ea94fbd622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b061b536-df95-4f68-95cd-1b6c3b16ead5" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b9b4c29d-061a-438d-a93d-93ea94fbd622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_0ea42a00-16d2-492a-a1fc-630e224412cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b061b536-df95-4f68-95cd-1b6c3b16ead5" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_0ea42a00-16d2-492a-a1fc-630e224412cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_a5444f9f-41de-49a0-a354-0c776a160b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b061b536-df95-4f68-95cd-1b6c3b16ead5" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_a5444f9f-41de-49a0-a354-0c776a160b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_e4d044ed-1d04-4064-b83d-22331dd43597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b061b536-df95-4f68-95cd-1b6c3b16ead5" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_e4d044ed-1d04-4064-b83d-22331dd43597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_56781ff2-768f-4f1e-8e05-aea1b9f5fdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b061b536-df95-4f68-95cd-1b6c3b16ead5" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_56781ff2-768f-4f1e-8e05-aea1b9f5fdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eb1a2f48-a5f4-40dd-b23e-056e365121db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b061b536-df95-4f68-95cd-1b6c3b16ead5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eb1a2f48-a5f4-40dd-b23e-056e365121db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_49a4f1d8-b65e-4d99-b4fc-74d54fc8d485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aabb6bdb-1285-432a-892c-ce7a404b188a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_49a4f1d8-b65e-4d99-b4fc-74d54fc8d485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d50edb0c-bc85-42a9-b721-b33c2eed79ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aabb6bdb-1285-432a-892c-ce7a404b188a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d50edb0c-bc85-42a9-b721-b33c2eed79ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f990fa0-92c4-4f5c-af6c-1bcf9c13d300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aabb6bdb-1285-432a-892c-ce7a404b188a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f990fa0-92c4-4f5c-af6c-1bcf9c13d300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2356b995-d0b4-4966-b3da-66be6b55f953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aabb6bdb-1285-432a-892c-ce7a404b188a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2356b995-d0b4-4966-b3da-66be6b55f953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3a888ba-6258-4ecb-a342-6fb3b4f2a163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2356b995-d0b4-4966-b3da-66be6b55f953" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3a888ba-6258-4ecb-a342-6fb3b4f2a163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_7f2b3d0a-5583-4c58-85ee-6f6a65a6dcce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2356b995-d0b4-4966-b3da-66be6b55f953" xlink:to="loc_us-gaap_RestrictedCashCurrent_7f2b3d0a-5583-4c58-85ee-6f6a65a6dcce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_88d803ac-4028-41a8-8aba-f53e34cce99f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2356b995-d0b4-4966-b3da-66be6b55f953" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_88d803ac-4028-41a8-8aba-f53e34cce99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_57121520-9ad7-4d81-9f1b-4b7617e65de4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2356b995-d0b4-4966-b3da-66be6b55f953" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_57121520-9ad7-4d81-9f1b-4b7617e65de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_73990407-6d9b-4395-9a6b-ee309b682fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2356b995-d0b4-4966-b3da-66be6b55f953" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_73990407-6d9b-4395-9a6b-ee309b682fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_99b691c7-3155-4d37-9432-deaaf285ad9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2356b995-d0b4-4966-b3da-66be6b55f953" xlink:to="loc_us-gaap_RestrictedCashCurrent_99b691c7-3155-4d37-9432-deaaf285ad9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_6a33f0b7-0962-4525-b36f-1c6951f347e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2356b995-d0b4-4966-b3da-66be6b55f953" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_6a33f0b7-0962-4525-b36f-1c6951f347e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dad9e977-d45b-409a-bc8f-9fabd25c8d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2356b995-d0b4-4966-b3da-66be6b55f953" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dad9e977-d45b-409a-bc8f-9fabd25c8d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_911ce92f-8a93-47f8-b9a9-e62b513d12e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aabb6bdb-1285-432a-892c-ce7a404b188a" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_911ce92f-8a93-47f8-b9a9-e62b513d12e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_9778b9d6-7a0b-4b33-bb64-73abeac2c654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_911ce92f-8a93-47f8-b9a9-e62b513d12e1" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_9778b9d6-7a0b-4b33-bb64-73abeac2c654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_35d3b9c6-c10b-4e52-abfe-8ff0d6c7f157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_911ce92f-8a93-47f8-b9a9-e62b513d12e1" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_35d3b9c6-c10b-4e52-abfe-8ff0d6c7f157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentation" xlink:type="simple" xlink:href="ehc-20220331.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b7c3f92b-e6cb-4739-818e-3dd54a83a616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_de45b970-d3ae-4973-8973-0eb1b0a489d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b7c3f92b-e6cb-4739-818e-3dd54a83a616" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_de45b970-d3ae-4973-8973-0eb1b0a489d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="ehc-20220331.xsd#BasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d09d6d43-ce39-435d-9c71-d6343d8d288b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b52ec2de-4451-4744-a5f4-6ffc89207da3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d09d6d43-ce39-435d-9c71-d6343d8d288b" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b52ec2de-4451-4744-a5f4-6ffc89207da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentationTables" xlink:type="simple" xlink:href="ehc-20220331.xsd#BasisofPresentationTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a0e90d1-438b-49d6-a0ed-86d030a515b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_30161e03-ee71-4df2-90c9-c42aa1fb2075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a0e90d1-438b-49d6-a0ed-86d030a515b6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_30161e03-ee71-4df2-90c9-c42aa1fb2075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentationTextualDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#BasisofPresentationTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentationTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_389a191f-9d99-45d6-a3a0-ed1234ee5d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_abd5ac4b-f908-485a-a5af-b71157d8e7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_389a191f-9d99-45d6-a3a0-ed1234ee5d1f" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_abd5ac4b-f908-485a-a5af-b71157d8e7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7d99f0ba-51f6-45da-b780-f3bacf410a15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_389a191f-9d99-45d6-a3a0-ed1234ee5d1f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7d99f0ba-51f6-45da-b780-f3bacf410a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#BasisofPresentationNetOperatingRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e21a6570-ec81-4350-96d4-f4b45fdfbcfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3f8925e7-2f18-45d4-92cb-96a2ba2d9fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e21a6570-ec81-4350-96d4-f4b45fdfbcfa" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3f8925e7-2f18-45d4-92cb-96a2ba2d9fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c8102f42-b9d7-4800-8ef3-d7d018c11c3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3f8925e7-2f18-45d4-92cb-96a2ba2d9fc7" xlink:to="loc_srt_ProductOrServiceAxis_c8102f42-b9d7-4800-8ef3-d7d018c11c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c8102f42-b9d7-4800-8ef3-d7d018c11c3d" xlink:to="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareMember_f674c7d1-3e55-4fa2-84b0-bac6c18d58a6" xlink:href="ehc-20220331.xsd#ehc_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:to="loc_ehc_MedicareMember_f674c7d1-3e55-4fa2-84b0-bac6c18d58a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareAdvantageMember_2b78f19a-a101-44a7-9200-e7f6ea1d46f6" xlink:href="ehc-20220331.xsd#ehc_MedicareAdvantageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:to="loc_ehc_MedicareAdvantageMember_2b78f19a-a101-44a7-9200-e7f6ea1d46f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ManagedCareMember_da60ab46-f784-4e86-9345-edc064722746" xlink:href="ehc-20220331.xsd#ehc_ManagedCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:to="loc_ehc_ManagedCareMember_da60ab46-f784-4e86-9345-edc064722746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicaidMember_ea9c1cf1-ed4d-423b-8208-c8fa9413c4b9" xlink:href="ehc-20220331.xsd#ehc_MedicaidMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:to="loc_ehc_MedicaidMember_ea9c1cf1-ed4d-423b-8208-c8fa9413c4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherThirdpartyPayorsMember_48b9e8df-6830-4b54-8b91-d3dd45d209de" xlink:href="ehc-20220331.xsd#ehc_OtherThirdpartyPayorsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:to="loc_ehc_OtherThirdpartyPayorsMember_48b9e8df-6830-4b54-8b91-d3dd45d209de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WorkersCompensationMember_39c5b338-19a4-45d8-93c0-a111f736aa82" xlink:href="ehc-20220331.xsd#ehc_WorkersCompensationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:to="loc_ehc_WorkersCompensationMember_39c5b338-19a4-45d8-93c0-a111f736aa82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PatientsMember_ab7100d3-3f3c-4ebc-961c-52dff2f21d03" xlink:href="ehc-20220331.xsd#ehc_PatientsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:to="loc_ehc_PatientsMember_ab7100d3-3f3c-4ebc-961c-52dff2f21d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherIncomeSourceMember_37b0bc6e-dd4b-4b2d-bbb7-fa18edf2425e" xlink:href="ehc-20220331.xsd#ehc_OtherIncomeSourceMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5e94a1a-e234-43f8-ac79-b7f3f04eab87" xlink:to="loc_ehc_OtherIncomeSourceMember_37b0bc6e-dd4b-4b2d-bbb7-fa18edf2425e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ffb0e814-7cfc-4f83-b16b-40f90f367680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3f8925e7-2f18-45d4-92cb-96a2ba2d9fc7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ffb0e814-7cfc-4f83-b16b-40f90f367680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a47647ba-f10b-4635-b153-f54b0ffcd189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ffb0e814-7cfc-4f83-b16b-40f90f367680" xlink:to="loc_us-gaap_SegmentDomain_a47647ba-f10b-4635-b153-f54b0ffcd189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_f555a3b9-9fe4-4cd6-a834-61f40019154d" xlink:href="ehc-20220331.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a47647ba-f10b-4635-b153-f54b0ffcd189" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_f555a3b9-9fe4-4cd6-a834-61f40019154d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_588c4a00-b355-4134-b417-7d1ccdbc0d86" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a47647ba-f10b-4635-b153-f54b0ffcd189" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_588c4a00-b355-4134-b417-7d1ccdbc0d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_814a6f20-0a93-4da7-ac85-416f739185dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3f8925e7-2f18-45d4-92cb-96a2ba2d9fc7" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_814a6f20-0a93-4da7-ac85-416f739185dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7cd6090c-fe17-4936-bfcb-7df930704981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_814a6f20-0a93-4da7-ac85-416f739185dd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7cd6090c-fe17-4936-bfcb-7df930704981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinations" xlink:type="simple" xlink:href="ehc-20220331.xsd#BusinessCombinations"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c0fbf4d2-86e3-44ec-85be-a8e28c1760a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_638d22f2-4d2a-4ca0-b527-e1544a2f4817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c0fbf4d2-86e3-44ec-85be-a8e28c1760a9" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_638d22f2-4d2a-4ca0-b527-e1544a2f4817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="ehc-20220331.xsd#BusinessCombinationsTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e1c7abf1-f1f2-4d97-9d5f-ca1a76e6afbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_5c8729b8-781c-4701-a5eb-9c3fbe70dc02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e1c7abf1-f1f2-4d97-9d5f-ca1a76e6afbb" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_5c8729b8-781c-4701-a5eb-9c3fbe70dc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_d86219ea-e302-4979-aed8-eb8374806d26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e1c7abf1-f1f2-4d97-9d5f-ca1a76e6afbb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_d86219ea-e302-4979-aed8-eb8374806d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_137deab7-bde2-4b35-a432-5f49776895e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e1c7abf1-f1f2-4d97-9d5f-ca1a76e6afbb" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_137deab7-bde2-4b35-a432-5f49776895e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#BusinessCombinationsTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9a854c24-31db-4a47-861e-a97ff2d78c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2ec081c-2e1d-4328-ae50-a549d18123e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9a854c24-31db-4a47-861e-a97ff2d78c45" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2ec081c-2e1d-4328-ae50-a549d18123e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b0a2c355-2663-4dc4-8a5e-e5e23f41584b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2ec081c-2e1d-4328-ae50-a549d18123e7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b0a2c355-2663-4dc4-8a5e-e5e23f41584b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_827ac23e-a28f-4220-bace-e3eef115b11a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b0a2c355-2663-4dc4-8a5e-e5e23f41584b" xlink:to="loc_us-gaap_SegmentDomain_827ac23e-a28f-4220-bace-e3eef115b11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_738307ce-34a6-4f4f-bee3-d9c7457065e5" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_827ac23e-a28f-4220-bace-e3eef115b11a" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_738307ce-34a6-4f4f-bee3-d9c7457065e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e34b1e02-b3e8-46e5-aeb8-c2a22cd42715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2ec081c-2e1d-4328-ae50-a549d18123e7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e34b1e02-b3e8-46e5-aeb8-c2a22cd42715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4ef501e-6709-460a-a56b-0faea1e0c083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e34b1e02-b3e8-46e5-aeb8-c2a22cd42715" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4ef501e-6709-460a-a56b-0faea1e0c083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusMember_1bc3c595-4aa4-4701-8355-e53e49bd982b" xlink:href="ehc-20220331.xsd#ehc_SaintAlphonsusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d4ef501e-6709-460a-a56b-0faea1e0c083" xlink:to="loc_ehc_SaintAlphonsusMember_1bc3c595-4aa4-4701-8355-e53e49bd982b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b1ffa708-6569-4806-854c-7e48b4f5dfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2ec081c-2e1d-4328-ae50-a549d18123e7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b1ffa708-6569-4806-854c-7e48b4f5dfe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9f54cf34-8eb6-4a11-a2ec-aa6b302ac9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b1ffa708-6569-4806-854c-7e48b4f5dfe1" xlink:to="loc_us-gaap_RelatedPartyDomain_9f54cf34-8eb6-4a11-a2ec-aa6b302ac9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_6873ce1f-aa03-4b60-b3fd-d5fe425fd905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9f54cf34-8eb6-4a11-a2ec-aa6b302ac9a0" xlink:to="loc_us-gaap_CorporateJointVentureMember_6873ce1f-aa03-4b60-b3fd-d5fe425fd905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3ccc988e-5f1f-4380-b6d6-962e21a09bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2ec081c-2e1d-4328-ae50-a549d18123e7" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3ccc988e-5f1f-4380-b6d6-962e21a09bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6926a302-418e-42f6-85be-bd9ac4bdfb28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3ccc988e-5f1f-4380-b6d6-962e21a09bd2" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6926a302-418e-42f6-85be-bd9ac4bdfb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_4b6a1375-292b-4d39-b410-f50ea4976e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3ccc988e-5f1f-4380-b6d6-962e21a09bd2" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_4b6a1375-292b-4d39-b410-f50ea4976e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_97692354-ab45-40d7-b0ef-c074c0f57c32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3ccc988e-5f1f-4380-b6d6-962e21a09bd2" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_97692354-ab45-40d7-b0ef-c074c0f57c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a6ded943-b5ef-4c2a-91ec-97260f0f9438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9581507c-54ec-4996-9472-1f38a13287c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a6ded943-b5ef-4c2a-91ec-97260f0f9438" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9581507c-54ec-4996-9472-1f38a13287c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_013243d9-5b60-459b-900a-9dc976d97476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9581507c-54ec-4996-9472-1f38a13287c8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_013243d9-5b60-459b-900a-9dc976d97476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c49310d3-0f57-4574-b32d-94f3435a1857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_013243d9-5b60-459b-900a-9dc976d97476" xlink:to="loc_us-gaap_SegmentDomain_c49310d3-0f57-4574-b32d-94f3435a1857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_b4416660-95de-4191-b59f-cc93b2c8a842" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c49310d3-0f57-4574-b32d-94f3435a1857" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_b4416660-95de-4191-b59f-cc93b2c8a842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f6d9f2a6-c3ea-4e22-8e25-25afefd9b352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9581507c-54ec-4996-9472-1f38a13287c8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f6d9f2a6-c3ea-4e22-8e25-25afefd9b352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c3c9864-6d22-4274-a5f3-072c34c7daa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f6d9f2a6-c3ea-4e22-8e25-25afefd9b352" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c3c9864-6d22-4274-a5f3-072c34c7daa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_6ea1b24c-4f42-48cc-a3d8-e6f226847485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c3c9864-6d22-4274-a5f3-072c34c7daa0" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_6ea1b24c-4f42-48cc-a3d8-e6f226847485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_1646b08b-cf68-4f64-be77-81950bcfc853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c3c9864-6d22-4274-a5f3-072c34c7daa0" xlink:to="loc_us-gaap_TradeNamesMember_1646b08b-cf68-4f64-be77-81950bcfc853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_36d483b6-8cc9-4bf9-88b7-9164871c17c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c3c9864-6d22-4274-a5f3-072c34c7daa0" xlink:to="loc_us-gaap_LicensingAgreementsMember_36d483b6-8cc9-4bf9-88b7-9164871c17c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_d8a6adfd-7b7a-48b6-bca6-3d69f9946bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c3c9864-6d22-4274-a5f3-072c34c7daa0" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_d8a6adfd-7b7a-48b6-bca6-3d69f9946bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_092f6e70-453f-4386-a208-934ed1e9affa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9581507c-54ec-4996-9472-1f38a13287c8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_092f6e70-453f-4386-a208-934ed1e9affa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aaa1d315-2dca-473b-bd7a-a9c40dacefe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_092f6e70-453f-4386-a208-934ed1e9affa" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aaa1d315-2dca-473b-bd7a-a9c40dacefe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusMember_29f89b21-03f6-4c49-b5cf-3b90fc2d5966" xlink:href="ehc-20220331.xsd#ehc_SaintAlphonsusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aaa1d315-2dca-473b-bd7a-a9c40dacefe1" xlink:to="loc_ehc_SaintAlphonsusMember_29f89b21-03f6-4c49-b5cf-3b90fc2d5966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9581507c-54ec-4996-9472-1f38a13287c8" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_59008906-07d4-4e8f-ae5d-431b4a2592ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_59008906-07d4-4e8f-ae5d-431b4a2592ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_413eb5a3-0d5d-428d-89a1-a31853cc875a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_413eb5a3-0d5d-428d-89a1-a31853cc875a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_460881c2-8bd2-496e-abf9-814c9c69922a" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_460881c2-8bd2-496e-abf9-814c9c69922a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2ea54dc1-f3f1-4ddf-8800-371fa6578d24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2ea54dc1-f3f1-4ddf-8800-371fa6578d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3e3329c1-3f3b-459f-a42d-3783f94a8ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_us-gaap_Goodwill_3e3329c1-3f3b-459f-a42d-3783f94a8ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_fc3926c5-1e0d-4487-9716-20c26c4d56a0" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_fc3926c5-1e0d-4487-9716-20c26c4d56a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_aa6585de-5fc7-4aed-8d91-4944dc485cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_aa6585de-5fc7-4aed-8d91-4944dc485cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_b41c8036-a567-4220-9128-d7fbb378c443" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_aa6585de-5fc7-4aed-8d91-4944dc485cbf" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_b41c8036-a567-4220-9128-d7fbb378c443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_b3bdad99-d829-41c6-962c-466ef5ba202d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_aa6585de-5fc7-4aed-8d91-4944dc485cbf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_b3bdad99-d829-41c6-962c-466ef5ba202d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll_ed7dd7ef-8358-4379-957c-c0550c466dd0" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_aa6585de-5fc7-4aed-8d91-4944dc485cbf" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll_ed7dd7ef-8358-4379-957c-c0550c466dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_84b88783-4ddd-440a-8f77-8894f7a61d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_aa6585de-5fc7-4aed-8d91-4944dc485cbf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_84b88783-4ddd-440a-8f77-8894f7a61d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_b03a0d6e-5263-4b95-a333-8102db6bd9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_aa6585de-5fc7-4aed-8d91-4944dc485cbf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_b03a0d6e-5263-4b95-a333-8102db6bd9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3c588f18-bfe9-41a3-b982-82d21f20e6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_aa6585de-5fc7-4aed-8d91-4944dc485cbf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3c588f18-bfe9-41a3-b982-82d21f20e6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_9d18dc87-50a1-4203-9b30-3e5c09f9d7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_9d18dc87-50a1-4203-9b30-3e5c09f9d7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_64954e7b-881e-4a37-82b4-d3d7467a17c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_64954e7b-881e-4a37-82b4-d3d7467a17c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_20dcab78-2d47-4ae1-8a37-0d7fbb9212f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1751c1e7-839e-4f92-a207-92a889449af0" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_20dcab78-2d47-4ae1-8a37-0d7fbb9212f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#BusinessCombinationsNetCashPaidforAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_94da3c7f-9bc1-4ad6-9315-c6fd74d563c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c99b823e-57c3-4028-b9c1-dfb622f702e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_94da3c7f-9bc1-4ad6-9315-c6fd74d563c3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c99b823e-57c3-4028-b9c1-dfb622f702e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_594b15c8-d3b8-4434-b35d-9662a08b24ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c99b823e-57c3-4028-b9c1-dfb622f702e7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_594b15c8-d3b8-4434-b35d-9662a08b24ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_794b96d8-fbf8-4568-b12f-cf1b0cf266b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_594b15c8-d3b8-4434-b35d-9662a08b24ef" xlink:to="loc_us-gaap_SegmentDomain_794b96d8-fbf8-4568-b12f-cf1b0cf266b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_7de7ecad-4466-4104-b197-da267269f1e6" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_794b96d8-fbf8-4568-b12f-cf1b0cf266b2" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_7de7ecad-4466-4104-b197-da267269f1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b2192370-3b7d-4f37-9c88-cd9986c5b0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c99b823e-57c3-4028-b9c1-dfb622f702e7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b2192370-3b7d-4f37-9c88-cd9986c5b0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6443f984-ee64-4754-b594-bdf4143b692a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b2192370-3b7d-4f37-9c88-cd9986c5b0d0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6443f984-ee64-4754-b594-bdf4143b692a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SaintAlphonsusMember_60ba6a22-f4cf-4c58-aaa8-b473f061019d" xlink:href="ehc-20220331.xsd#ehc_SaintAlphonsusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6443f984-ee64-4754-b594-bdf4143b692a" xlink:to="loc_ehc_SaintAlphonsusMember_60ba6a22-f4cf-4c58-aaa8-b473f061019d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4d54b720-e35e-45e5-95de-6eb09c192bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c99b823e-57c3-4028-b9c1-dfb622f702e7" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_4d54b720-e35e-45e5-95de-6eb09c192bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_f6089487-8242-4069-95c8-0893cecbe9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d54b720-e35e-45e5-95de-6eb09c192bdd" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_f6089487-8242-4069-95c8-0893cecbe9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_762f9db4-960d-4525-a15f-b11a3cb376f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d54b720-e35e-45e5-95de-6eb09c192bdd" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_762f9db4-960d-4525-a15f-b11a3cb376f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_6c6645a5-4ff9-4090-8ce8-8fb6b512b954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d54b720-e35e-45e5-95de-6eb09c192bdd" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_6c6645a5-4ff9-4090-8ce8-8fb6b512b954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue_87b97a04-38db-48b7-9d5e-aa011150eedb" xlink:href="ehc-20220331.xsd#ehc_BusinessCombinationNoncontrollingInterestFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d54b720-e35e-45e5-95de-6eb09c192bdd" xlink:to="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue_87b97a04-38db-48b7-9d5e-aa011150eedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ecc87365-5b13-4c7d-830d-b619f657f966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4d54b720-e35e-45e5-95de-6eb09c192bdd" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ecc87365-5b13-4c7d-830d-b619f657f966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#BusinessCombinationsProFormaResultsofOperationDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6673622f-569c-4393-9ab7-0404b9850b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_149efe38-c345-4807-81a3-e9132bb1aa51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6673622f-569c-4393-9ab7-0404b9850b25" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_149efe38-c345-4807-81a3-e9132bb1aa51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_40996f2b-fec3-47f4-92b6-65d14b57292a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_149efe38-c345-4807-81a3-e9132bb1aa51" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_40996f2b-fec3-47f4-92b6-65d14b57292a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_699db501-d780-4fff-ad5d-642675d89f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_40996f2b-fec3-47f4-92b6-65d14b57292a" xlink:to="loc_us-gaap_SegmentDomain_699db501-d780-4fff-ad5d-642675d89f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_99fdc5b2-acde-443e-b682-881d13c3fb36" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_699db501-d780-4fff-ad5d-642675d89f45" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_99fdc5b2-acde-443e-b682-881d13c3fb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fb9bcc84-8ed5-4d8d-a681-a1f38b85e3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_149efe38-c345-4807-81a3-e9132bb1aa51" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_fb9bcc84-8ed5-4d8d-a681-a1f38b85e3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_dd219de4-12d6-4579-881a-a1386d14c6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb9bcc84-8ed5-4d8d-a681-a1f38b85e3d8" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_dd219de4-12d6-4579-881a-a1386d14c6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_fbd5d221-dd5e-4d16-a7ae-5f70c3a73b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb9bcc84-8ed5-4d8d-a681-a1f38b85e3d8" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_fbd5d221-dd5e-4d16-a7ae-5f70c3a73b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_c04ab89c-0f25-4ed9-8e42-36aa532acc42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb9bcc84-8ed5-4d8d-a681-a1f38b85e3d8" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_c04ab89c-0f25-4ed9-8e42-36aa532acc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_80502d6c-a5da-4380-aeea-a585cb536304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fb9bcc84-8ed5-4d8d-a681-a1f38b85e3d8" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_80502d6c-a5da-4380-aeea-a585cb536304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntities" xlink:type="simple" xlink:href="ehc-20220331.xsd#VariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4418c33e-2e51-48cb-ad3a-04733e5bf042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_cde2e185-3709-48ee-af3e-6eac6314355c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4418c33e-2e51-48cb-ad3a-04733e5bf042" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_cde2e185-3709-48ee-af3e-6eac6314355c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTables" xlink:type="simple" xlink:href="ehc-20220331.xsd#VariableInterestEntitiesTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72d70f3d-1879-4f08-965a-c617b2501bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_187b3000-2110-408c-bfa1-de7e392780cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72d70f3d-1879-4f08-965a-c617b2501bd1" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_187b3000-2110-408c-bfa1-de7e392780cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#VariableInterestEntitiesTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09834c47-cb7b-4548-abe6-79beb4b810ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_22b5b66a-b0f0-4de4-9372-b56d6e99a1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09834c47-cb7b-4548-abe6-79beb4b810ba" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_22b5b66a-b0f0-4de4-9372-b56d6e99a1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_a1fbd8aa-100a-4523-a247-b8396d3b6081" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_22b5b66a-b0f0-4de4-9372-b56d6e99a1db" xlink:to="loc_srt_ConsolidatedEntitiesAxis_a1fbd8aa-100a-4523-a247-b8396d3b6081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_56b4804f-9809-4b54-b1d3-f9f6055debfa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_a1fbd8aa-100a-4523-a247-b8396d3b6081" xlink:to="loc_srt_ConsolidatedEntitiesDomain_56b4804f-9809-4b54-b1d3-f9f6055debfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_5f383ff0-8fdb-45c1-abb2-79f1a7737380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_56b4804f-9809-4b54-b1d3-f9f6055debfa" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_5f383ff0-8fdb-45c1-abb2-79f1a7737380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_54f086f0-c62b-4239-8680-0c6d477cabc7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_22b5b66a-b0f0-4de4-9372-b56d6e99a1db" xlink:to="loc_srt_RangeAxis_54f086f0-c62b-4239-8680-0c6d477cabc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a3fcc782-fe99-4698-8065-4389e3063aa1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_54f086f0-c62b-4239-8680-0c6d477cabc7" xlink:to="loc_srt_RangeMember_a3fcc782-fe99-4698-8065-4389e3063aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6c71c734-a48c-443b-98ba-ada1385c9fbe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a3fcc782-fe99-4698-8065-4389e3063aa1" xlink:to="loc_srt_MinimumMember_6c71c734-a48c-443b-98ba-ada1385c9fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_59cc7f1a-4ca1-4954-9d5c-0ea13ffe57dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a3fcc782-fe99-4698-8065-4389e3063aa1" xlink:to="loc_srt_MaximumMember_59cc7f1a-4ca1-4954-9d5c-0ea13ffe57dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_ec227dd5-a25c-434f-ae09-7d0a4c5f0812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_22b5b66a-b0f0-4de4-9372-b56d6e99a1db" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_ec227dd5-a25c-434f-ae09-7d0a4c5f0812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated_9f51a234-7647-448f-b7a5-cec75b4335fa" xlink:href="ehc-20220331.xsd#ehc_VariableInterestEntityNumberofEntitiesConsolidated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ec227dd5-a25c-434f-ae09-7d0a4c5f0812" xlink:to="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated_9f51a234-7647-448f-b7a5-cec75b4335fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_231be058-9a70-4598-bf81-2596b151150e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ec227dd5-a25c-434f-ae09-7d0a4c5f0812" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_231be058-9a70-4598-bf81-2596b151150e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_699f2023-4011-4d11-abfb-c376c8417cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf7699c5-7a91-458d-a104-25083c778fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_699f2023-4011-4d11-abfb-c376c8417cc9" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf7699c5-7a91-458d-a104-25083c778fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_3551ef10-67a9-4501-865e-1ba1df90bb0b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf7699c5-7a91-458d-a104-25083c778fd1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_3551ef10-67a9-4501-865e-1ba1df90bb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_7aae4023-8c23-4a54-a380-1b0744e037a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_3551ef10-67a9-4501-865e-1ba1df90bb0b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_7aae4023-8c23-4a54-a380-1b0744e037a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ab7e7199-7c8f-4fb1-b1d6-b3b7de36d7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_7aae4023-8c23-4a54-a380-1b0744e037a7" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ab7e7199-7c8f-4fb1-b1d6-b3b7de36d7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_c14f004d-2329-4263-891b-a9ddbbbe9e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_cf7699c5-7a91-458d-a104-25083c778fd1" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_c14f004d-2329-4263-891b-a9ddbbbe9e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3fa1aef6-978d-4ae0-b448-69bfa7e76a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c14f004d-2329-4263-891b-a9ddbbbe9e10" xlink:to="loc_us-gaap_AssetsAbstract_3fa1aef6-978d-4ae0-b448-69bfa7e76a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_53ead133-810c-478f-b114-2c94b230e0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa1aef6-978d-4ae0-b448-69bfa7e76a6a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_53ead133-810c-478f-b114-2c94b230e0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_82c948db-e249-49ff-ac60-9a496a157edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_53ead133-810c-478f-b114-2c94b230e0a5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_82c948db-e249-49ff-ac60-9a496a157edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_254a21f2-5090-4a75-80e9-d67596c64be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_53ead133-810c-478f-b114-2c94b230e0a5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_254a21f2-5090-4a75-80e9-d67596c64be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_91f292c3-724d-43b8-9efc-939facdc225c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_53ead133-810c-478f-b114-2c94b230e0a5" xlink:to="loc_us-gaap_OtherAssetsCurrent_91f292c3-724d-43b8-9efc-939facdc225c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_747b610d-742f-45f8-813e-46bfefade795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_53ead133-810c-478f-b114-2c94b230e0a5" xlink:to="loc_us-gaap_AssetsCurrent_747b610d-742f-45f8-813e-46bfefade795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3b4349f4-359c-4c98-9152-b49333f6c5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa1aef6-978d-4ae0-b448-69bfa7e76a6a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3b4349f4-359c-4c98-9152-b49333f6c5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_06cb0673-fae0-40ce-b645-9c9527c9dddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa1aef6-978d-4ae0-b448-69bfa7e76a6a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_06cb0673-fae0-40ce-b645-9c9527c9dddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6efeed47-c045-42b7-a5e8-c982c6dd2531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa1aef6-978d-4ae0-b448-69bfa7e76a6a" xlink:to="loc_us-gaap_Goodwill_6efeed47-c045-42b7-a5e8-c982c6dd2531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_632f0312-684c-42f8-b05a-e53d5624f954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa1aef6-978d-4ae0-b448-69bfa7e76a6a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_632f0312-684c-42f8-b05a-e53d5624f954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_58669b28-10e5-4c76-8d9f-618e447c3b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa1aef6-978d-4ae0-b448-69bfa7e76a6a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_58669b28-10e5-4c76-8d9f-618e447c3b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5455ffb2-a84c-4856-be28-ed50a5ad3024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa1aef6-978d-4ae0-b448-69bfa7e76a6a" xlink:to="loc_us-gaap_Assets_5455ffb2-a84c-4856-be28-ed50a5ad3024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_ec0750fd-44ba-45c6-b1c8-2c8ffd93ef92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c14f004d-2329-4263-891b-a9ddbbbe9e10" xlink:to="loc_us-gaap_LiabilitiesAbstract_ec0750fd-44ba-45c6-b1c8-2c8ffd93ef92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_67200777-ffb9-491a-a4c3-9445036d2842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_ec0750fd-44ba-45c6-b1c8-2c8ffd93ef92" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_67200777-ffb9-491a-a4c3-9445036d2842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_5d2300c0-5fa7-4146-b5ba-d75fac2f69b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_67200777-ffb9-491a-a4c3-9445036d2842" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_5d2300c0-5fa7-4146-b5ba-d75fac2f69b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_aa8cc449-4dd7-4f70-af06-5dc82b30430d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_67200777-ffb9-491a-a4c3-9445036d2842" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_aa8cc449-4dd7-4f70-af06-5dc82b30430d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_bd2e9892-934a-4ddb-a044-28b4bccab1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_67200777-ffb9-491a-a4c3-9445036d2842" xlink:to="loc_us-gaap_AccountsPayableCurrent_bd2e9892-934a-4ddb-a044-28b4bccab1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5d41acf4-8a8f-409d-839e-9151e497690d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_67200777-ffb9-491a-a4c3-9445036d2842" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5d41acf4-8a8f-409d-839e-9151e497690d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cc9975db-d0db-43aa-9aa0-fb30d45c509f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_67200777-ffb9-491a-a4c3-9445036d2842" xlink:to="loc_us-gaap_LiabilitiesCurrent_cc9975db-d0db-43aa-9aa0-fb30d45c509f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6525296f-33be-4e5e-ba49-787211923870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_ec0750fd-44ba-45c6-b1c8-2c8ffd93ef92" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_6525296f-33be-4e5e-ba49-787211923870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c2cc2678-2de5-4530-8f23-f177989e9663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_ec0750fd-44ba-45c6-b1c8-2c8ffd93ef92" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c2cc2678-2de5-4530-8f23-f177989e9663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_baa152aa-3e7e-482d-ba10-ea27ef4c6b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_ec0750fd-44ba-45c6-b1c8-2c8ffd93ef92" xlink:to="loc_us-gaap_Liabilities_baa152aa-3e7e-482d-ba10-ea27ef4c6b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebt" xlink:type="simple" xlink:href="ehc-20220331.xsd#LongtermDebt"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4429fc6c-e641-4d82-83ac-30c395a420d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_6a51c983-0d44-420a-8b59-53736d44ec67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4429fc6c-e641-4d82-83ac-30c395a420d7" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_6a51c983-0d44-420a-8b59-53736d44ec67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="ehc-20220331.xsd#LongtermDebtTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_81fc8aea-e0ec-40ed-91ec-467877f370a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_3983f62e-03b9-484e-8da5-cbdf2c4b8154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_81fc8aea-e0ec-40ed-91ec-467877f370a8" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_3983f62e-03b9-484e-8da5-cbdf2c4b8154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#LongtermDebtLongtermDebtOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9c52cac8-55d4-4e20-a5ac-c6ec4e43e851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e5e65252-b4f0-4474-87bc-fd8c37c8ef51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9c52cac8-55d4-4e20-a5ac-c6ec4e43e851" xlink:to="loc_us-gaap_DebtInstrumentTable_e5e65252-b4f0-4474-87bc-fd8c37c8ef51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ed806444-ba14-4646-996b-ec65fbd037e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e5e65252-b4f0-4474-87bc-fd8c37c8ef51" xlink:to="loc_us-gaap_CreditFacilityAxis_ed806444-ba14-4646-996b-ec65fbd037e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_81d64c66-eec2-427c-bee9-e42f8fd0fd30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_ed806444-ba14-4646-996b-ec65fbd037e3" xlink:to="loc_us-gaap_CreditFacilityDomain_81d64c66-eec2-427c-bee9-e42f8fd0fd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_ad0d63f3-a061-4d82-9976-2673f4c1697c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_81d64c66-eec2-427c-bee9-e42f8fd0fd30" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_ad0d63f3-a061-4d82-9976-2673f4c1697c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fc0b760b-bfb1-436a-b58f-86dc25bfee8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e5e65252-b4f0-4474-87bc-fd8c37c8ef51" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fc0b760b-bfb1-436a-b58f-86dc25bfee8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dae3d75e-90f0-442d-a716-053b4e09de4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fc0b760b-bfb1-436a-b58f-86dc25bfee8f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dae3d75e-90f0-442d-a716-053b4e09de4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_534c43df-075a-48b6-a5d6-0dd48198fa67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dae3d75e-90f0-442d-a716-053b4e09de4d" xlink:to="loc_us-gaap_LoansPayableMember_534c43df-075a-48b6-a5d6-0dd48198fa67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_8f945435-8ac4-4643-8672-33bae84cddee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dae3d75e-90f0-442d-a716-053b4e09de4d" xlink:to="loc_us-gaap_SeniorNotesMember_8f945435-8ac4-4643-8672-33bae84cddee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_a3a09642-3fa7-49c4-97fc-60812c8b110b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dae3d75e-90f0-442d-a716-053b4e09de4d" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_a3a09642-3fa7-49c4-97fc-60812c8b110b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5abb0c51-d322-4f83-bb24-98e3ccaf67af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e5e65252-b4f0-4474-87bc-fd8c37c8ef51" xlink:to="loc_us-gaap_DebtInstrumentAxis_5abb0c51-d322-4f83-bb24-98e3ccaf67af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e2bd9f5f-e5b2-4acf-9d98-a58ce22c7f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5abb0c51-d322-4f83-bb24-98e3ccaf67af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e2bd9f5f-e5b2-4acf-9d98-a58ce22c7f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember_eb11ef42-2508-46c7-9583-6459b8546ad9" xlink:href="ehc-20220331.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e2bd9f5f-e5b2-4acf-9d98-a58ce22c7f78" xlink:to="loc_ehc_TermLoanFacilitiesMember_eb11ef42-2508-46c7-9583-6459b8546ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_c2577b7d-eb8c-4301-820f-1c98751e4916" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e2bd9f5f-e5b2-4acf-9d98-a58ce22c7f78" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_c2577b7d-eb8c-4301-820f-1c98751e4916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_f2d78c18-ef67-4f81-afb8-8b49e99d4b40" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e2bd9f5f-e5b2-4acf-9d98-a58ce22c7f78" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_f2d78c18-ef67-4f81-afb8-8b49e99d4b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_d49aa21c-e3c7-4213-aaff-70350f9c06e7" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e2bd9f5f-e5b2-4acf-9d98-a58ce22c7f78" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_d49aa21c-e3c7-4213-aaff-70350f9c06e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_b8c77a58-d4c1-49fd-aa75-62ae71fc834d" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e2bd9f5f-e5b2-4acf-9d98-a58ce22c7f78" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_b8c77a58-d4c1-49fd-aa75-62ae71fc834d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4625Due2031Member_85d62c64-506c-4e54-b135-92fe8ab7de76" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes4625Due2031Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e2bd9f5f-e5b2-4acf-9d98-a58ce22c7f78" xlink:to="loc_ehc_SeniorNotes4625Due2031Member_85d62c64-506c-4e54-b135-92fe8ab7de76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_77f3eb46-ef65-4cbe-b054-a1f0b0f50c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e5e65252-b4f0-4474-87bc-fd8c37c8ef51" xlink:to="loc_us-gaap_DebtInstrumentLineItems_77f3eb46-ef65-4cbe-b054-a1f0b0f50c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_42b25e32-9a34-48da-a8b9-9738a638a8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77f3eb46-ef65-4cbe-b054-a1f0b0f50c9b" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_42b25e32-9a34-48da-a8b9-9738a638a8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f5c503b8-61ea-4c3d-b07b-f5df91cefd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_42b25e32-9a34-48da-a8b9-9738a638a8fa" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f5c503b8-61ea-4c3d-b07b-f5df91cefd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_120f4a20-f91a-495e-8cbc-27362ed4299a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_42b25e32-9a34-48da-a8b9-9738a638a8fa" xlink:to="loc_us-gaap_LongTermDebt_120f4a20-f91a-495e-8cbc-27362ed4299a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_41ce152a-00c2-4d1e-91a5-4ed4a3d55fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_42b25e32-9a34-48da-a8b9-9738a638a8fa" xlink:to="loc_us-gaap_FinanceLeaseLiability_41ce152a-00c2-4d1e-91a5-4ed4a3d55fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_9bf4788c-07e0-4272-914d-352fc3888d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_42b25e32-9a34-48da-a8b9-9738a638a8fa" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_9bf4788c-07e0-4272-914d-352fc3888d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_df4eaeb6-22d2-4f68-8ffa-0a60fdaffb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_42b25e32-9a34-48da-a8b9-9738a638a8fa" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_df4eaeb6-22d2-4f68-8ffa-0a60fdaffb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_3e1ecf8e-4008-44ef-8246-ca4d49b817a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_42b25e32-9a34-48da-a8b9-9738a638a8fa" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_3e1ecf8e-4008-44ef-8246-ca4d49b817a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1" xlink:type="simple" xlink:href="ehc-20220331.xsd#LongtermDebtLongtermDebtOutstandingDetails_1"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtTextualDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#LongtermDebtTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ea98d4ff-90d8-4cca-aca1-c89f76c7f720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2948535a-91d0-4932-b54f-483425a3706b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ea98d4ff-90d8-4cca-aca1-c89f76c7f720" xlink:to="loc_us-gaap_DebtInstrumentTable_2948535a-91d0-4932-b54f-483425a3706b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6bf9a78d-fbed-4818-a115-cfa628ced5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2948535a-91d0-4932-b54f-483425a3706b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6bf9a78d-fbed-4818-a115-cfa628ced5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7a4a386d-afe6-45da-82f5-0a822fbb26e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6bf9a78d-fbed-4818-a115-cfa628ced5e8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7a4a386d-afe6-45da-82f5-0a822fbb26e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_53e78b6d-b038-4f96-91b4-084e8e148105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7a4a386d-afe6-45da-82f5-0a822fbb26e0" xlink:to="loc_us-gaap_SeniorNotesMember_53e78b6d-b038-4f96-91b4-084e8e148105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5cf9e2c3-0ef6-47d6-aea0-4bbe841394bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2948535a-91d0-4932-b54f-483425a3706b" xlink:to="loc_us-gaap_DebtInstrumentAxis_5cf9e2c3-0ef6-47d6-aea0-4bbe841394bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5a1a6613-7c98-483f-8451-e6865dd9ff7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5cf9e2c3-0ef6-47d6-aea0-4bbe841394bd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5a1a6613-7c98-483f-8451-e6865dd9ff7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_c9e75ea8-8d4c-4272-bdb8-80374aeee8b1" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a1a6613-7c98-483f-8451-e6865dd9ff7b" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_c9e75ea8-8d4c-4272-bdb8-80374aeee8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_39215e1a-a177-48b8-b283-bad9737177bd" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a1a6613-7c98-483f-8451-e6865dd9ff7b" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_39215e1a-a177-48b8-b283-bad9737177bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_7a9efb87-0d44-4e29-bac2-2ecb56392681" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a1a6613-7c98-483f-8451-e6865dd9ff7b" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_7a9efb87-0d44-4e29-bac2-2ecb56392681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4625Due2031Member_af440400-7ec0-4cc8-ad53-42daccf59afd" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes4625Due2031Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a1a6613-7c98-483f-8451-e6865dd9ff7b" xlink:to="loc_ehc_SeniorNotes4625Due2031Member_af440400-7ec0-4cc8-ad53-42daccf59afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_0ac2f5de-c33b-4dc6-beaf-f517f07e6020" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a1a6613-7c98-483f-8451-e6865dd9ff7b" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_0ac2f5de-c33b-4dc6-beaf-f517f07e6020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2017d3a6-36aa-4a64-87ac-61c9be096cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2948535a-91d0-4932-b54f-483425a3706b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2017d3a6-36aa-4a64-87ac-61c9be096cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8f5abbf9-591b-4374-ab0c-2c91fa0ce0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2017d3a6-36aa-4a64-87ac-61c9be096cd5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8f5abbf9-591b-4374-ab0c-2c91fa0ce0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatio_3916bc08-e93e-48a1-ae14-e3c4ea4d35e8" xlink:href="ehc-20220331.xsd#ehc_DebtInstrumentCovenantLeverageRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2017d3a6-36aa-4a64-87ac-61c9be096cd5" xlink:to="loc_ehc_DebtInstrumentCovenantLeverageRatio_3916bc08-e93e-48a1-ae14-e3c4ea4d35e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_a6ae0758-20f2-4f2a-acb3-38d971cb6908" xlink:href="ehc-20220331.xsd#ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2017d3a6-36aa-4a64-87ac-61c9be096cd5" xlink:to="loc_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_a6ae0758-20f2-4f2a-acb3-38d971cb6908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_a1d6e825-a0db-4dbd-898c-13016a5d1102" xlink:href="ehc-20220331.xsd#ehc_DebtInstrumentAmendmentAgreementAmountToBePaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2017d3a6-36aa-4a64-87ac-61c9be096cd5" xlink:to="loc_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_a1d6e825-a0db-4dbd-898c-13016a5d1102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_ddfc64c1-9c83-4173-959e-976db7337fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2017d3a6-36aa-4a64-87ac-61c9be096cd5" xlink:to="loc_us-gaap_RepaymentsOfDebt_ddfc64c1-9c83-4173-959e-976db7337fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_4d9a4e78-24cd-4f70-a188-9ea8bc6294fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2017d3a6-36aa-4a64-87ac-61c9be096cd5" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_4d9a4e78-24cd-4f70-a188-9ea8bc6294fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0d4af75d-f528-4e37-ac2a-5c8397653f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2017d3a6-36aa-4a64-87ac-61c9be096cd5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0d4af75d-f528-4e37-ac2a-5c8397653f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests" xlink:type="simple" xlink:href="ehc-20220331.xsd#RedeemableNoncontrollingInterests"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_cfd316db-ccc8-48e2-835e-9cc49ea1509b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock_cc56e377-7c34-4dbc-b3ac-627f1e636d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_cfd316db-ccc8-48e2-835e-9cc49ea1509b" xlink:to="loc_us-gaap_MinorityInterestDisclosureTextBlock_cc56e377-7c34-4dbc-b3ac-627f1e636d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables" xlink:type="simple" xlink:href="ehc-20220331.xsd#RedeemableNoncontrollingInterestsTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_59bd677b-0984-49a5-9010-3fc39518e51b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_513afad9-14c4-4abc-ab95-4d922940e92a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_59bd677b-0984-49a5-9010-3fc39518e51b" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_513afad9-14c4-4abc-ab95-4d922940e92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock_cb6d8a15-28cd-4d14-b892-74709e6e1772" xlink:href="ehc-20220331.xsd#ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_59bd677b-0984-49a5-9010-3fc39518e51b" xlink:to="loc_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock_cb6d8a15-28cd-4d14-b892-74709e6e1772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_41781599-2847-4dc2-a926-faddba2c3069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_dad40797-5df6-4abf-9566-9ae027cec37d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_41781599-2847-4dc2-a926-faddba2c3069" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_dad40797-5df6-4abf-9566-9ae027cec37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9ff0080a-63e8-4330-a4f6-f2fe539fc718" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_dad40797-5df6-4abf-9566-9ae027cec37d" xlink:to="loc_dei_LegalEntityAxis_9ff0080a-63e8-4330-a4f6-f2fe539fc718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ee0ce13e-4d2f-4228-b2a5-ef95b1a246af" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9ff0080a-63e8-4330-a4f6-f2fe539fc718" xlink:to="loc_dei_EntityDomain_ee0ce13e-4d2f-4228-b2a5-ef95b1a246af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestMember_e86aa71a-be96-47a9-985f-075e4f37bd09" xlink:href="ehc-20220331.xsd#ehc_RedeemableNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ee0ce13e-4d2f-4228-b2a5-ef95b1a246af" xlink:to="loc_ehc_RedeemableNoncontrollingInterestMember_e86aa71a-be96-47a9-985f-075e4f37bd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_2d4069db-53ea-49f0-b297-cce0f4b76b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_dad40797-5df6-4abf-9566-9ae027cec37d" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_2d4069db-53ea-49f0-b297-cce0f4b76b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_3cee71cf-e89f-4567-be72-84f589943cd0" xlink:href="ehc-20220331.xsd#ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_2d4069db-53ea-49f0-b297-cce0f4b76b72" xlink:to="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_3cee71cf-e89f-4567-be72-84f589943cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_edcac71a-3a4c-4ee0-a57d-db2986f0cd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_3cee71cf-e89f-4567-be72-84f589943cd0" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_edcac71a-3a4c-4ee0-a57d-db2986f0cd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_6d1471c4-942c-4466-96e9-99eff1345b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_3cee71cf-e89f-4567-be72-84f589943cd0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_6d1471c4-942c-4466-96e9-99eff1345b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_ec762bc2-6522-4566-8910-c3c3312e687d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_3cee71cf-e89f-4567-be72-84f589943cd0" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_ec762bc2-6522-4566-8910-c3c3312e687d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_dae8609e-757d-4589-9fa5-15cd428b4ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward_3cee71cf-e89f-4567-be72-84f589943cd0" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_dae8609e-757d-4589-9fa5-15cd428b4ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_063ef543-5a45-4169-b4c3-c1f66fb56ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_217ad063-bc08-4c02-b816-487f7939be7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_063ef543-5a45-4169-b4c3-c1f66fb56ca5" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_217ad063-bc08-4c02-b816-487f7939be7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_c59487dd-a623-4fd8-b2b1-f9cfb52943b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_063ef543-5a45-4169-b4c3-c1f66fb56ca5" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_c59487dd-a623-4fd8-b2b1-f9cfb52943b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1e2400a5-6fa6-4b10-9dbe-1e8303370bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_063ef543-5a45-4169-b4c3-c1f66fb56ca5" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1e2400a5-6fa6-4b10-9dbe-1e8303370bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ehc-20220331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4036093d-7111-48fa-84f5-7d71b6061304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_4ec7e15a-ed23-47a7-8bed-9f93ee3f27be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4036093d-7111-48fa-84f5-7d71b6061304" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_4ec7e15a-ed23-47a7-8bed-9f93ee3f27be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ehc-20220331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d7dd4bf1-e6ec-4c2c-8d37-bed9c7064bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_81bbde67-9bab-43e9-bbec-4b9da2fe8a21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d7dd4bf1-e6ec-4c2c-8d37-bed9c7064bdc" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_81bbde67-9bab-43e9-bbec-4b9da2fe8a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_65ded568-40ca-4611-824a-a9cf0c640b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d7dd4bf1-e6ec-4c2c-8d37-bed9c7064bdc" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_65ded568-40ca-4611-824a-a9cf0c640b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c05d8fea-a789-4898-8976-d934f6725d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3049e203-e848-461f-a8b8-08641d40f562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c05d8fea-a789-4898-8976-d934f6725d1b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3049e203-e848-461f-a8b8-08641d40f562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ed391af1-8027-4af9-bb89-15d797eb5445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3049e203-e848-461f-a8b8-08641d40f562" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ed391af1-8027-4af9-bb89-15d797eb5445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e835a09-4b82-4a16-b3bf-acc6095e9b12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ed391af1-8027-4af9-bb89-15d797eb5445" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e835a09-4b82-4a16-b3bf-acc6095e9b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_fd11acb6-906e-4b9b-8bb5-cfe6ac844e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e835a09-4b82-4a16-b3bf-acc6095e9b12" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_fd11acb6-906e-4b9b-8bb5-cfe6ac844e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_79bbbcf2-a9bd-4b5e-b3a6-90892822e310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3049e203-e848-461f-a8b8-08641d40f562" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_79bbbcf2-a9bd-4b5e-b3a6-90892822e310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ff56534-9c2a-419a-b0bc-61f937d041b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_79bbbcf2-a9bd-4b5e-b3a6-90892822e310" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ff56534-9c2a-419a-b0bc-61f937d041b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3bd1ab01-6c21-4770-b2e8-019fe8659049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ff56534-9c2a-419a-b0bc-61f937d041b7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3bd1ab01-6c21-4770-b2e8-019fe8659049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2ed572d6-f15c-4c42-87ec-a2e9eb372a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ff56534-9c2a-419a-b0bc-61f937d041b7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2ed572d6-f15c-4c42-87ec-a2e9eb372a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9b9770a1-4a3c-42f1-b4b8-9c9d25add88a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ff56534-9c2a-419a-b0bc-61f937d041b7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9b9770a1-4a3c-42f1-b4b8-9c9d25add88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5c281dc3-4367-478c-921a-6ab420f12278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3049e203-e848-461f-a8b8-08641d40f562" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5c281dc3-4367-478c-921a-6ab420f12278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_34fd9006-18c1-4aae-a54d-8eae835b5d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5c281dc3-4367-478c-921a-6ab420f12278" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_34fd9006-18c1-4aae-a54d-8eae835b5d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_12e5ad86-c92f-4c0d-8fd1-6e98c92a6ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_34fd9006-18c1-4aae-a54d-8eae835b5d9b" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_12e5ad86-c92f-4c0d-8fd1-6e98c92a6ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_2d075579-6c48-401e-997e-b1e2b5ba10c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_34fd9006-18c1-4aae-a54d-8eae835b5d9b" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_2d075579-6c48-401e-997e-b1e2b5ba10c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_06b558a5-4e80-4033-8e34-fe46f197da12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3049e203-e848-461f-a8b8-08641d40f562" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_06b558a5-4e80-4033-8e34-fe46f197da12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_42e2ce68-d521-4b91-b17b-ed49021f26fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_06b558a5-4e80-4033-8e34-fe46f197da12" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_42e2ce68-d521-4b91-b17b-ed49021f26fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_61b88b1d-a8be-42de-a857-061cbabf4539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_42e2ce68-d521-4b91-b17b-ed49021f26fd" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_61b88b1d-a8be-42de-a857-061cbabf4539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_a6733bc6-8308-4976-8112-f991d4da3220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_42e2ce68-d521-4b91-b17b-ed49021f26fd" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_a6733bc6-8308-4976-8112-f991d4da3220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_92880bdb-e685-42a3-a7fa-5493267b9214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_42e2ce68-d521-4b91-b17b-ed49021f26fd" xlink:to="loc_us-gaap_OtherAssetsCurrent_92880bdb-e685-42a3-a7fa-5493267b9214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1dd18f59-23ec-4878-b534-a302c92f714c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_42e2ce68-d521-4b91-b17b-ed49021f26fd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1dd18f59-23ec-4878-b534-a302c92f714c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#FairValueMeasurementsTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d7c8ff79-d891-4bea-a42d-d62cb3ce4205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9b64cc6d-e11b-48ba-ac08-d3ef0d7153ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d7c8ff79-d891-4bea-a42d-d62cb3ce4205" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9b64cc6d-e11b-48ba-ac08-d3ef0d7153ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_34a89ade-6c7f-4df8-83e6-7caa16f008a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9b64cc6d-e11b-48ba-ac08-d3ef0d7153ca" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_34a89ade-6c7f-4df8-83e6-7caa16f008a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ba0f814-ddf3-4f10-af7c-457cf6030f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_34a89ade-6c7f-4df8-83e6-7caa16f008a0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ba0f814-ddf3-4f10-af7c-457cf6030f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_16110b92-5e19-4638-9662-b1218fb3d881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ba0f814-ddf3-4f10-af7c-457cf6030f12" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_16110b92-5e19-4638-9662-b1218fb3d881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55a9a382-dff8-40e3-b48c-f8b79dd77abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9b64cc6d-e11b-48ba-ac08-d3ef0d7153ca" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55a9a382-dff8-40e3-b48c-f8b79dd77abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_4218fc3b-f29f-49af-bedc-ddbb82e2c260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55a9a382-dff8-40e3-b48c-f8b79dd77abc" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_4218fc3b-f29f-49af-bedc-ddbb82e2c260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3f57f3bc-eba4-408c-8e6d-bfc5e56e0c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d79a41a5-96d7-407a-820c-7991a8fcec60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3f57f3bc-eba4-408c-8e6d-bfc5e56e0c02" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d79a41a5-96d7-407a-820c-7991a8fcec60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f1aa0d11-d93f-4393-b41f-5e7171de764b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d79a41a5-96d7-407a-820c-7991a8fcec60" xlink:to="loc_us-gaap_CreditFacilityAxis_f1aa0d11-d93f-4393-b41f-5e7171de764b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_263a91fe-fde2-49f8-955e-09bd7f4a549e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_f1aa0d11-d93f-4393-b41f-5e7171de764b" xlink:to="loc_us-gaap_CreditFacilityDomain_263a91fe-fde2-49f8-955e-09bd7f4a549e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_d612e020-97a0-4209-b74a-1a4ff572a351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_263a91fe-fde2-49f8-955e-09bd7f4a549e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_d612e020-97a0-4209-b74a-1a4ff572a351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_131b1e4e-8829-44ea-ade4-bd4586f8296d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_263a91fe-fde2-49f8-955e-09bd7f4a549e" xlink:to="loc_us-gaap_LetterOfCreditMember_131b1e4e-8829-44ea-ade4-bd4586f8296d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6cb17b48-4b08-4ce4-b9ed-72de20f0f5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d79a41a5-96d7-407a-820c-7991a8fcec60" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6cb17b48-4b08-4ce4-b9ed-72de20f0f5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_924cdaf9-843e-48dd-9fe4-c26f876be9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6cb17b48-4b08-4ce4-b9ed-72de20f0f5a3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_924cdaf9-843e-48dd-9fe4-c26f876be9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_e87ff3c5-e5d3-43fa-9027-2c19ea6d4f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_924cdaf9-843e-48dd-9fe4-c26f876be9b7" xlink:to="loc_us-gaap_LoansPayableMember_e87ff3c5-e5d3-43fa-9027-2c19ea6d4f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_0254acc6-4a32-41a1-b1ff-855699ca6c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_924cdaf9-843e-48dd-9fe4-c26f876be9b7" xlink:to="loc_us-gaap_SeniorNotesMember_0254acc6-4a32-41a1-b1ff-855699ca6c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_f62ae144-8e57-4048-93c6-2dc45adbda84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_924cdaf9-843e-48dd-9fe4-c26f876be9b7" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_f62ae144-8e57-4048-93c6-2dc45adbda84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b7c72929-b225-4298-9947-a9fb3dbbab13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d79a41a5-96d7-407a-820c-7991a8fcec60" xlink:to="loc_us-gaap_DebtInstrumentAxis_b7c72929-b225-4298-9947-a9fb3dbbab13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_058fe961-727d-4516-8ea1-a7089ba8bd73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b7c72929-b225-4298-9947-a9fb3dbbab13" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_058fe961-727d-4516-8ea1-a7089ba8bd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember_16e8a4f4-6a76-4726-ac4a-0e65e69143a4" xlink:href="ehc-20220331.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_058fe961-727d-4516-8ea1-a7089ba8bd73" xlink:to="loc_ehc_TermLoanFacilitiesMember_16e8a4f4-6a76-4726-ac4a-0e65e69143a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_d9c709ec-f576-49ca-b29f-736fd53be686" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_058fe961-727d-4516-8ea1-a7089ba8bd73" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_d9c709ec-f576-49ca-b29f-736fd53be686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_aecf6ade-b11f-42d1-ba99-db2b14efd9d8" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_058fe961-727d-4516-8ea1-a7089ba8bd73" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_aecf6ade-b11f-42d1-ba99-db2b14efd9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_efbf92b6-d978-4ad5-a5b2-6ad25927dc55" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_058fe961-727d-4516-8ea1-a7089ba8bd73" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_efbf92b6-d978-4ad5-a5b2-6ad25927dc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_9f17a6ce-d661-44bc-b985-0e810e5bf36e" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_058fe961-727d-4516-8ea1-a7089ba8bd73" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_9f17a6ce-d661-44bc-b985-0e810e5bf36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4625Due2031Member_88c09667-e787-43ef-96b2-c850232deb83" xlink:href="ehc-20220331.xsd#ehc_SeniorNotes4625Due2031Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_058fe961-727d-4516-8ea1-a7089ba8bd73" xlink:to="loc_ehc_SeniorNotes4625Due2031Member_88c09667-e787-43ef-96b2-c850232deb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_07f0f105-83b1-4b42-98fa-2a1dbfd0c8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d79a41a5-96d7-407a-820c-7991a8fcec60" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_07f0f105-83b1-4b42-98fa-2a1dbfd0c8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c453ebe5-bc8a-49df-a17f-d5a7f03ddfe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_07f0f105-83b1-4b42-98fa-2a1dbfd0c8b3" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c453ebe5-bc8a-49df-a17f-d5a7f03ddfe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5c0e6d03-bd99-427f-b17a-27643145504e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c453ebe5-bc8a-49df-a17f-d5a7f03ddfe4" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5c0e6d03-bd99-427f-b17a-27643145504e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_fd976cbf-82f8-440e-a0c1-51227e597b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c453ebe5-bc8a-49df-a17f-d5a7f03ddfe4" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_fd976cbf-82f8-440e-a0c1-51227e597b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5e7c6ff8-fea1-4f3c-89e7-ca1a31894d10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c453ebe5-bc8a-49df-a17f-d5a7f03ddfe4" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5e7c6ff8-fea1-4f3c-89e7-ca1a31894d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6fe42168-8c88-4b04-8a56-570a88212ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d79a41a5-96d7-407a-820c-7991a8fcec60" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6fe42168-8c88-4b04-8a56-570a88212ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2d8c4259-77e1-464c-81e8-2a36d7bf2dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6fe42168-8c88-4b04-8a56-570a88212ddb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2d8c4259-77e1-464c-81e8-2a36d7bf2dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_730e6718-793d-46a5-887a-5f321286abdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6fe42168-8c88-4b04-8a56-570a88212ddb" xlink:to="loc_us-gaap_LongTermDebtFairValue_730e6718-793d-46a5-887a-5f321286abdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="ehc-20220331.xsd#ShareBasedPayments"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a397bb0-0ac4-4c8b-903c-a2992e72c49e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7b45d39f-85fe-47af-a2ab-50f4d92996ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a397bb0-0ac4-4c8b-903c-a2992e72c49e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7b45d39f-85fe-47af-a2ab-50f4d92996ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#ShareBasedPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c0682886-c043-4a19-bdc3-b0394dc96640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53118213-e586-4dfa-9a06-9954ea6ee913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c0682886-c043-4a19-bdc3-b0394dc96640" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53118213-e586-4dfa-9a06-9954ea6ee913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d5391e4c-74e8-4481-adf3-539025331150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53118213-e586-4dfa-9a06-9954ea6ee913" xlink:to="loc_us-gaap_AwardTypeAxis_d5391e4c-74e8-4481-adf3-539025331150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4783066-0ae9-4030-9299-4a13fc6284c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d5391e4c-74e8-4481-adf3-539025331150" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4783066-0ae9-4030-9299-4a13fc6284c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_7a0e24fc-1f2d-4815-89a7-fd94ea7436e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4783066-0ae9-4030-9299-4a13fc6284c8" xlink:to="loc_us-gaap_RestrictedStockMember_7a0e24fc-1f2d-4815-89a7-fd94ea7436e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_288df845-65d2-4e69-a015-59feadb4d088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4783066-0ae9-4030-9299-4a13fc6284c8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_288df845-65d2-4e69-a015-59feadb4d088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_ad68bae9-a1dc-4c2f-ae0e-27f23007fbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53118213-e586-4dfa-9a06-9954ea6ee913" xlink:to="loc_us-gaap_VestingAxis_ad68bae9-a1dc-4c2f-ae0e-27f23007fbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_79400a97-861a-4235-975c-4b8a564b963a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_ad68bae9-a1dc-4c2f-ae0e-27f23007fbe9" xlink:to="loc_us-gaap_VestingDomain_79400a97-861a-4235-975c-4b8a564b963a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_999d9fa1-82fe-4667-8dbe-49b51d58cc90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_79400a97-861a-4235-975c-4b8a564b963a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_999d9fa1-82fe-4667-8dbe-49b51d58cc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ebddedf0-1dc1-49c3-bc89-a8a37f2453a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_79400a97-861a-4235-975c-4b8a564b963a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ebddedf0-1dc1-49c3-bc89-a8a37f2453a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_63c4b775-8856-46b2-b164-153a6338da31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53118213-e586-4dfa-9a06-9954ea6ee913" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_63c4b775-8856-46b2-b164-153a6338da31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4236381c-536e-4a38-a630-7d382a60e7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_63c4b775-8856-46b2-b164-153a6338da31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4236381c-536e-4a38-a630-7d382a60e7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_93040e15-7d20-4f2e-8dc7-13ddb10cde17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_63c4b775-8856-46b2-b164-153a6338da31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_93040e15-7d20-4f2e-8dc7-13ddb10cde17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_68f37bea-7b17-45c9-9997-63952b262036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_63c4b775-8856-46b2-b164-153a6338da31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_68f37bea-7b17-45c9-9997-63952b262036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ehc-20220331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d1b1951c-dce6-4a61-8b96-47bab1483098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_771a4516-655a-42c7-af92-25e6f98ccb64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d1b1951c-dce6-4a61-8b96-47bab1483098" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_771a4516-655a-42c7-af92-25e6f98ccb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_aaddcfcc-271d-40b9-92fd-762b2c9a5aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dc86a559-57de-4dbb-a0e0-a25af02aa2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aaddcfcc-271d-40b9-92fd-762b2c9a5aa3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dc86a559-57de-4dbb-a0e0-a25af02aa2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShare" xlink:type="simple" xlink:href="ehc-20220331.xsd#EarningsperCommonShare"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a23cbd8b-13f5-47b8-a1f6-b497173da6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_14828504-2889-4134-85de-a9b534f1b420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a23cbd8b-13f5-47b8-a1f6-b497173da6ac" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_14828504-2889-4134-85de-a9b534f1b420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareTables" xlink:type="simple" xlink:href="ehc-20220331.xsd#EarningsperCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_280f7213-cba2-496a-8e10-6c435c048a61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fac0acb3-4716-4d34-a2df-593ef1a94172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_280f7213-cba2-496a-8e10-6c435c048a61" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fac0acb3-4716-4d34-a2df-593ef1a94172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_8070ae39-f0f7-451e-85c7-fda35ebc907b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_280f7213-cba2-496a-8e10-6c435c048a61" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_8070ae39-f0f7-451e-85c7-fda35ebc907b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_86b04b0a-f558-48db-bf51-542a0c350261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d6dd87-edca-4cb9-ae56-85d07b01939c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_86b04b0a-f558-48db-bf51-542a0c350261" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d6dd87-edca-4cb9-ae56-85d07b01939c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_00c7249b-ae24-4b0f-b1e7-1a406d96b296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d6dd87-edca-4cb9-ae56-85d07b01939c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_00c7249b-ae24-4b0f-b1e7-1a406d96b296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_f771aa1b-e27d-4b60-b838-f19ce66320ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d6dd87-edca-4cb9-ae56-85d07b01939c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_f771aa1b-e27d-4b60-b838-f19ce66320ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_c04e59c6-d933-47a6-9f86-c9e165cad729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d6dd87-edca-4cb9-ae56-85d07b01939c" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_c04e59c6-d933-47a6-9f86-c9e165cad729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_e549c507-d2b8-4ba5-86c2-d37e88ae9285" xlink:href="ehc-20220331.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d6dd87-edca-4cb9-ae56-85d07b01939c" xlink:to="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic_e549c507-d2b8-4ba5-86c2-d37e88ae9285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_4e062ea4-53b8-4e75-8291-734a58ef7ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d6dd87-edca-4cb9-ae56-85d07b01939c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_4e062ea4-53b8-4e75-8291-734a58ef7ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NetIncomeLossAvailabletoCommonStockholders_3c2aa204-6a39-4585-9626-375b1965ba63" xlink:href="ehc-20220331.xsd#ehc_NetIncomeLossAvailabletoCommonStockholders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_65d6dd87-edca-4cb9-ae56-85d07b01939c" xlink:to="loc_ehc_NetIncomeLossAvailabletoCommonStockholders_3c2aa204-6a39-4585-9626-375b1965ba63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_b786502c-3927-4f26-9cdb-74dc622f4f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_86b04b0a-f558-48db-bf51-542a0c350261" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_b786502c-3927-4f26-9cdb-74dc622f4f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8ac87856-b5cf-47d7-816b-f5234f1a9fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_b786502c-3927-4f26-9cdb-74dc622f4f9e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8ac87856-b5cf-47d7-816b-f5234f1a9fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_a9736675-e9b3-447c-aca5-136d08548f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_86b04b0a-f558-48db-bf51-542a0c350261" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_a9736675-e9b3-447c-aca5-136d08548f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5f011bf5-a1b9-473b-b404-e36853d11a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_a9736675-e9b3-447c-aca5-136d08548f1b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5f011bf5-a1b9-473b-b404-e36853d11a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_db7d98c9-73ed-4c11-b10c-9fdabeea4034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_a9736675-e9b3-447c-aca5-136d08548f1b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_db7d98c9-73ed-4c11-b10c-9fdabeea4034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_78412c36-a6b2-4cb8-b19d-fe3c9d01183c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_a9736675-e9b3-447c-aca5-136d08548f1b" xlink:to="loc_us-gaap_EarningsPerShareBasic_78412c36-a6b2-4cb8-b19d-fe3c9d01183c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_1d9da491-7b0e-4089-beaa-d457047f288f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_86b04b0a-f558-48db-bf51-542a0c350261" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_1d9da491-7b0e-4089-beaa-d457047f288f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_25f16156-1b5c-4657-92da-669ac517035d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_1d9da491-7b0e-4089-beaa-d457047f288f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_25f16156-1b5c-4657-92da-669ac517035d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_db778b5d-f2fe-4b5f-ae82-65fde289f23f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_1d9da491-7b0e-4089-beaa-d457047f288f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_db778b5d-f2fe-4b5f-ae82-65fde289f23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_06da52e8-e829-4220-b5f4-fbb866a17109" xlink:href="ehc-20220331.xsd#ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_1d9da491-7b0e-4089-beaa-d457047f288f" xlink:to="loc_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted_06da52e8-e829-4220-b5f4-fbb866a17109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6f08f072-4bfe-4b65-a23e-0d6a0faa2e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_1d9da491-7b0e-4089-beaa-d457047f288f" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6f08f072-4bfe-4b65-a23e-0d6a0faa2e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9dd0a40d-bb5f-4c42-85d4-6425d6dcaa65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_1d9da491-7b0e-4089-beaa-d457047f288f" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9dd0a40d-bb5f-4c42-85d4-6425d6dcaa65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_720cca78-0c62-4ad2-b840-ec72b2888540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_86b04b0a-f558-48db-bf51-542a0c350261" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_720cca78-0c62-4ad2-b840-ec72b2888540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8e51a60f-02ba-4d37-b7ea-36346f3c355b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_720cca78-0c62-4ad2-b840-ec72b2888540" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8e51a60f-02ba-4d37-b7ea-36346f3c355b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_7d8d28f4-1826-4f9e-87ab-60944f612c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_86b04b0a-f558-48db-bf51-542a0c350261" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_7d8d28f4-1826-4f9e-87ab-60944f612c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_103e16fd-6eb8-4c7b-bc75-e5292cdae9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_7d8d28f4-1826-4f9e-87ab-60944f612c4d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_103e16fd-6eb8-4c7b-bc75-e5292cdae9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_cd8c458f-3860-444d-a95e-e7b5a371966d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_7d8d28f4-1826-4f9e-87ab-60944f612c4d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_cd8c458f-3860-444d-a95e-e7b5a371966d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b7aa3a57-194f-48bb-a316-f88342d40fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_7d8d28f4-1826-4f9e-87ab-60944f612c4d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b7aa3a57-194f-48bb-a316-f88342d40fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_410cf525-fcc6-47d2-babf-48e71278c67e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4a046946-9d3c-4a1e-8f7e-f803e4eb313a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_410cf525-fcc6-47d2-babf-48e71278c67e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4a046946-9d3c-4a1e-8f7e-f803e4eb313a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c61bf0a1-1b46-4b1a-beb2-4cbd59b76ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_410cf525-fcc6-47d2-babf-48e71278c67e" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c61bf0a1-1b46-4b1a-beb2-4cbd59b76ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_517cca8a-ad24-422c-a196-ce70320e7b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_410cf525-fcc6-47d2-babf-48e71278c67e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_517cca8a-ad24-422c-a196-ce70320e7b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitments" xlink:type="simple" xlink:href="ehc-20220331.xsd#ContingenciesandOtherCommitments"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ContingenciesandOtherCommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6901b7bd-03b7-4f4b-bc3a-f2314f6263f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures_8624af4a-fc26-4a4d-bcca-77794a088dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6901b7bd-03b7-4f4b-bc3a-f2314f6263f3" xlink:to="loc_us-gaap_LossContingencyDisclosures_8624af4a-fc26-4a4d-bcca-77794a088dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReporting" xlink:type="simple" xlink:href="ehc-20220331.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_132a5d5f-6986-45a9-b412-6fae02e1cf67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_c3a961dc-6f10-43be-bbdb-174e44809d41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_132a5d5f-6986-45a9-b412-6fae02e1cf67" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_c3a961dc-6f10-43be-bbdb-174e44809d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="ehc-20220331.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5c22fd46-e0a8-45ff-b439-e74366828dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_21a82ad9-475e-49bc-9190-12674a25968f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5c22fd46-e0a8-45ff-b439-e74366828dfd" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_21a82ad9-475e-49bc-9190-12674a25968f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_e3b9943b-a557-4711-ba70-5781ed2d61b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5c22fd46-e0a8-45ff-b439-e74366828dfd" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_e3b9943b-a557-4711-ba70-5781ed2d61b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock_c6af665f-e4df-4840-9244-7e9634656965" xlink:href="ehc-20220331.xsd#ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5c22fd46-e0a8-45ff-b439-e74366828dfd" xlink:to="loc_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock_c6af665f-e4df-4840-9244-7e9634656965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_b5238b05-a9b0-4f41-b3e8-def943e9191f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5c22fd46-e0a8-45ff-b439-e74366828dfd" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_b5238b05-a9b0-4f41-b3e8-def943e9191f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingTextualDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#SegmentReportingTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_73c4d664-4f38-4242-ae25-88c1901bd281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_21521d34-1f7e-45c9-97a8-d9295b948e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_73c4d664-4f38-4242-ae25-88c1901bd281" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_21521d34-1f7e-45c9-97a8-d9295b948e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7549340c-abc8-4031-8c39-a2e1d367c1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_21521d34-1f7e-45c9-97a8-d9295b948e00" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7549340c-abc8-4031-8c39-a2e1d367c1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8a9e9df6-3552-493d-81b4-d8c15f10c6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7549340c-abc8-4031-8c39-a2e1d367c1b9" xlink:to="loc_us-gaap_SegmentDomain_8a9e9df6-3552-493d-81b4-d8c15f10c6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_7f93685f-78ee-41ab-8527-b82450c2965e" xlink:href="ehc-20220331.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8a9e9df6-3552-493d-81b4-d8c15f10c6f6" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_7f93685f-78ee-41ab-8527-b82450c2965e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_1cbd2f86-ab39-4a15-9c53-fdf7e713240e" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8a9e9df6-3552-493d-81b4-d8c15f10c6f6" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_1cbd2f86-ab39-4a15-9c53-fdf7e713240e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a54968f7-60b9-4c60-82ab-d49e8b1b2e7b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_21521d34-1f7e-45c9-97a8-d9295b948e00" xlink:to="loc_srt_RangeAxis_a54968f7-60b9-4c60-82ab-d49e8b1b2e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9ea3a4eb-a3f1-49a8-b3bd-ae4b0ee2a185" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a54968f7-60b9-4c60-82ab-d49e8b1b2e7b" xlink:to="loc_srt_RangeMember_9ea3a4eb-a3f1-49a8-b3bd-ae4b0ee2a185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6fef6b22-2988-4c5e-9bb6-f125014c9961" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9ea3a4eb-a3f1-49a8-b3bd-ae4b0ee2a185" xlink:to="loc_srt_MinimumMember_6fef6b22-2988-4c5e-9bb6-f125014c9961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_778e25a7-f82a-438b-903c-95fa9aa9605b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9ea3a4eb-a3f1-49a8-b3bd-ae4b0ee2a185" xlink:to="loc_srt_MaximumMember_778e25a7-f82a-438b-903c-95fa9aa9605b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_21521d34-1f7e-45c9-97a8-d9295b948e00" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6da9baf8-fa83-4b96-8760-2b373e81424c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6da9baf8-fa83-4b96-8760-2b373e81424c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_40603b4b-a5e1-40ac-8aa0-c4cf078f908d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_40603b4b-a5e1-40ac-8aa0-c4cf078f908d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationHospitals_0e01271d-9e57-4d42-95a5-c8260fef23af" xlink:href="ehc-20220331.xsd#ehc_NumberOfInpatientRehabilitationHospitals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_ehc_NumberOfInpatientRehabilitationHospitals_0e01271d-9e57-4d42-95a5-c8260fef23af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_9dcaf3d1-f42b-4314-a918-8dd128ba2695" xlink:href="ehc-20220331.xsd#ehc_Numberofsolelyownedinpatientrehabilitationhospitals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_ehc_Numberofsolelyownedinpatientrehabilitationhospitals_9dcaf3d1-f42b-4314-a918-8dd128ba2695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Jointventureownershippercentage_aac04d12-ede8-457b-b91c-9dc5aeea39fd" xlink:href="ehc-20220331.xsd#ehc_Jointventureownershippercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_ehc_Jointventureownershippercentage_aac04d12-ede8-457b-b91c-9dc5aeea39fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_de43fc6b-da1b-4b35-9270-1bad402cdb17" xlink:href="ehc-20220331.xsd#ehc_Numberofjointlyownedinpatientrehabilitationhospitals"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_ehc_Numberofjointlyownedinpatientrehabilitationhospitals_de43fc6b-da1b-4b35-9270-1bad402cdb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_db08b216-8afe-4bae-b48c-6107cc9a6169" xlink:href="ehc-20220331.xsd#ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts_db08b216-8afe-4bae-b48c-6107cc9a6169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofhomehealthlocations_afc8159f-16ee-4c22-a1af-751156c412b3" xlink:href="ehc-20220331.xsd#ehc_Numberofhomehealthlocations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_ehc_Numberofhomehealthlocations_afc8159f-16ee-4c22-a1af-751156c412b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofhospicelocations_1f15080b-3c04-41f8-a8b7-8b0332ffe3f4" xlink:href="ehc-20220331.xsd#ehc_Numberofhospicelocations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_ehc_Numberofhospicelocations_1f15080b-3c04-41f8-a8b7-8b0332ffe3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_866ac019-cc6c-42ea-9430-9ff90e7a8540" xlink:href="ehc-20220331.xsd#ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations_866ac019-cc6c-42ea-9430-9ff90e7a8540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_1fed72ab-1d9b-4332-a55d-2be25707af49" xlink:href="ehc-20220331.xsd#ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ef3155af-e0d0-4d36-b8fc-affc9549b8f3" xlink:to="loc_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations_1fed72ab-1d9b-4332-a55d-2be25707af49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d12adad7-34f0-49a9-80fc-dc0c7dff7785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_af023588-13d9-479b-b1eb-baeb60e48be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d12adad7-34f0-49a9-80fc-dc0c7dff7785" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_af023588-13d9-479b-b1eb-baeb60e48be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d009eb14-db71-4878-b577-64a12de8d5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_af023588-13d9-479b-b1eb-baeb60e48be8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d009eb14-db71-4878-b577-64a12de8d5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_239e87d2-59eb-4665-bcae-4ee1dd2ad0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d009eb14-db71-4878-b577-64a12de8d5de" xlink:to="loc_us-gaap_SegmentDomain_239e87d2-59eb-4665-bcae-4ee1dd2ad0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_37baba82-28ed-4658-8983-6f37e7655f6c" xlink:href="ehc-20220331.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_239e87d2-59eb-4665-bcae-4ee1dd2ad0a5" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_37baba82-28ed-4658-8983-6f37e7655f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_d749249e-f8fc-4b6f-8b5d-b6c72271fa75" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_239e87d2-59eb-4665-bcae-4ee1dd2ad0a5" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_d749249e-f8fc-4b6f-8b5d-b6c72271fa75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5305b7b0-876f-4ac8-9cbd-e4cb5d9608b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_af023588-13d9-479b-b1eb-baeb60e48be8" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_5305b7b0-876f-4ac8-9cbd-e4cb5d9608b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ed481b64-efb6-4840-b616-4e9a3c7c576a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5305b7b0-876f-4ac8-9cbd-e4cb5d9608b3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ed481b64-efb6-4840-b616-4e9a3c7c576a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_c78551d7-63d9-4647-8df0-66c0230c7c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5305b7b0-876f-4ac8-9cbd-e4cb5d9608b3" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_c78551d7-63d9-4647-8df0-66c0230c7c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_6ffb71be-73d9-4e20-8c5a-a1cd5a3fa3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c78551d7-63d9-4647-8df0-66c0230c7c3e" xlink:to="loc_us-gaap_LaborAndRelatedExpense_6ffb71be-73d9-4e20-8c5a-a1cd5a3fa3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_c988caca-2043-4b0a-8833-06468e92721e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c78551d7-63d9-4647-8df0-66c0230c7c3e" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_c988caca-2043-4b0a-8833-06468e92721e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_45d10417-7b9c-46ce-a8c0-822845b55f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c78551d7-63d9-4647-8df0-66c0230c7c3e" xlink:to="loc_us-gaap_SuppliesExpense_45d10417-7b9c-46ce-a8c0-822845b55f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost_be15a116-3d02-4a4e-a186-d6c9a52071ff" xlink:href="ehc-20220331.xsd#ehc_OccupancyCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c78551d7-63d9-4647-8df0-66c0230c7c3e" xlink:to="loc_ehc_OccupancyCost_be15a116-3d02-4a4e-a186-d6c9a52071ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CostofServicesExcludingDepreciationandAmortization_7299d551-fa71-4c34-b0a5-7f0c8ccbe31e" xlink:href="ehc-20220331.xsd#ehc_CostofServicesExcludingDepreciationandAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c78551d7-63d9-4647-8df0-66c0230c7c3e" xlink:to="loc_ehc_CostofServicesExcludingDepreciationandAmortization_7299d551-fa71-4c34-b0a5-7f0c8ccbe31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead_f511e19f-7ef3-4492-94ef-8afab4fb31c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldOverhead"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c78551d7-63d9-4647-8df0-66c0230c7c3e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldOverhead_f511e19f-7ef3-4492-94ef-8afab4fb31c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6d365af4-61f4-4e35-a55b-65aa280eb028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c78551d7-63d9-4647-8df0-66c0230c7c3e" xlink:to="loc_us-gaap_CostsAndExpenses_6d365af4-61f4-4e35-a55b-65aa280eb028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b95863ee-b337-473a-a261-1c6467a420d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5305b7b0-876f-4ac8-9cbd-e4cb5d9608b3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b95863ee-b337-473a-a261-1c6467a420d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5d6f50c7-8096-4f49-b546-cd30bd2f3f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5305b7b0-876f-4ac8-9cbd-e4cb5d9608b3" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5d6f50c7-8096-4f49-b546-cd30bd2f3f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_845a8679-ce2c-4e5c-91d6-899737ee7566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5305b7b0-876f-4ac8-9cbd-e4cb5d9608b3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_845a8679-ce2c-4e5c-91d6-899737ee7566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA_003edf79-0bfe-4d81-9b15-eb2673c2e84f" xlink:href="ehc-20220331.xsd#ehc_AdjustedEBITDA"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5305b7b0-876f-4ac8-9cbd-e4cb5d9608b3" xlink:to="loc_ehc_AdjustedEBITDA_003edf79-0bfe-4d81-9b15-eb2673c2e84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_63c3fa7e-a5dd-4699-9966-e8d5162383d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5305b7b0-876f-4ac8-9cbd-e4cb5d9608b3" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_63c3fa7e-a5dd-4699-9966-e8d5162383d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6f23f5d7-1696-4cbb-a105-2d8babf278f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_38c0098b-bb3c-4f0f-a3f2-3b526463e6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6f23f5d7-1696-4cbb-a105-2d8babf278f0" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_38c0098b-bb3c-4f0f-a3f2-3b526463e6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ae207da4-7e11-406c-9711-05c07b85b980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_38c0098b-bb3c-4f0f-a3f2-3b526463e6e5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ae207da4-7e11-406c-9711-05c07b85b980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_857c89b1-4022-45a8-89ed-40d7e3934fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ae207da4-7e11-406c-9711-05c07b85b980" xlink:to="loc_us-gaap_SegmentDomain_857c89b1-4022-45a8-89ed-40d7e3934fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_3d327f9f-9105-4152-b996-6146e369c8d5" xlink:href="ehc-20220331.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_857c89b1-4022-45a8-89ed-40d7e3934fd0" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_3d327f9f-9105-4152-b996-6146e369c8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_b5f58122-a2ca-4c66-89f1-66118102aedc" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_857c89b1-4022-45a8-89ed-40d7e3934fd0" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_b5f58122-a2ca-4c66-89f1-66118102aedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_b186ef38-2d5d-479c-9d9b-81af080d6a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_38c0098b-bb3c-4f0f-a3f2-3b526463e6e5" xlink:to="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_b186ef38-2d5d-479c-9d9b-81af080d6a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_007db165-15bf-4e55-8ae7-00375fe44e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_b186ef38-2d5d-479c-9d9b-81af080d6a0a" xlink:to="loc_us-gaap_Assets_007db165-15bf-4e55-8ae7-00375fe44e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_948cf3b6-6c30-4754-8716-f1198bfe62f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_b186ef38-2d5d-479c-9d9b-81af080d6a0a" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_948cf3b6-6c30-4754-8716-f1198bfe62f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6212cec7-813a-4d6e-b605-7608c91ade1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_a6b7e2de-3d23-4a61-817a-f581040f7c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6212cec7-813a-4d6e-b605-7608c91ade1b" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_a6b7e2de-3d23-4a61-817a-f581040f7c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9d482d0c-e311-49e1-b458-82f37e2edd24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_a6b7e2de-3d23-4a61-817a-f581040f7c4d" xlink:to="loc_srt_ConsolidationItemsAxis_9d482d0c-e311-49e1-b458-82f37e2edd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8fe9e1ef-53cd-4539-bb0f-a3e5a2cca117" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_9d482d0c-e311-49e1-b458-82f37e2edd24" xlink:to="loc_srt_ConsolidationItemsDomain_8fe9e1ef-53cd-4539-bb0f-a3e5a2cca117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_569c6b69-9a29-439a-9739-8c8cffb3f89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_8fe9e1ef-53cd-4539-bb0f-a3e5a2cca117" xlink:to="loc_us-gaap_OperatingSegmentsMember_569c6b69-9a29-439a-9739-8c8cffb3f89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_c19e6d12-10bb-4edf-96a7-6e820ca71bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_8fe9e1ef-53cd-4539-bb0f-a3e5a2cca117" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_c19e6d12-10bb-4edf-96a7-6e820ca71bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_a6b7e2de-3d23-4a61-817a-f581040f7c4d" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AdjustedEBITDA_914e4703-0bfd-44d0-a293-55c40c08fee4" xlink:href="ehc-20220331.xsd#ehc_AdjustedEBITDA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_ehc_AdjustedEBITDA_914e4703-0bfd-44d0-a293-55c40c08fee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8bf07db5-d489-40c3-b440-6f3a5a8bda8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8bf07db5-d489-40c3-b440-6f3a5a8bda8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_27ccb06d-9bc0-4034-a7d4-d923bba960cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_27ccb06d-9bc0-4034-a7d4-d923bba960cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_8b05983f-0517-4fdb-b26f-c06b5a29323d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_8b05983f-0517-4fdb-b26f-c06b5a29323d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_24bac1b3-fc7e-4f82-8cd6-2650c981db15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_24bac1b3-fc7e-4f82-8cd6-2650c981db15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_35d91c10-d170-449f-b02b-4049195df45a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_us-gaap_InterestExpenseDebt_35d91c10-d170-449f-b02b-4049195df45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_408ebd5f-ee98-46f7-9991-7a9478d24ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_408ebd5f-ee98-46f7-9991-7a9478d24ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesGainLoss_23f39721-0334-46f6-a85b-d845118cf8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_us-gaap_MarketableSecuritiesGainLoss_23f39721-0334-46f6-a85b-d845118cf8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2dc1f5d3-962c-4896-9aa9-e1314d197aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_987c4b2c-9e0f-4886-9572-71a4d38b3ace" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2dc1f5d3-962c-4896-9aa9-e1314d197aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="ehc-20220331.xsd#SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_96289ff1-a031-4e1c-aef8-4c3ba2c0be05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_66bdcddd-7077-4a9e-849f-d1f98fd61757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_96289ff1-a031-4e1c-aef8-4c3ba2c0be05" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_66bdcddd-7077-4a9e-849f-d1f98fd61757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3c9acbf4-2cdb-4471-b688-82c8e550ee57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_66bdcddd-7077-4a9e-849f-d1f98fd61757" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3c9acbf4-2cdb-4471-b688-82c8e550ee57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_eb712906-061e-4f83-a521-377eedcd11a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3c9acbf4-2cdb-4471-b688-82c8e550ee57" xlink:to="loc_us-gaap_SegmentDomain_eb712906-061e-4f83-a521-377eedcd11a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientRehabilitationSegmentMember_2e995be6-22a0-4c85-9e6a-a5907edb7b2d" xlink:href="ehc-20220331.xsd#ehc_InpatientRehabilitationSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_eb712906-061e-4f83-a521-377eedcd11a9" xlink:to="loc_ehc_InpatientRehabilitationSegmentMember_2e995be6-22a0-4c85-9e6a-a5907edb7b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_575d2989-15d2-4fc5-88eb-2da0668d2d35" xlink:href="ehc-20220331.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_eb712906-061e-4f83-a521-377eedcd11a9" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_575d2989-15d2-4fc5-88eb-2da0668d2d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_70d9dfa0-60e5-46cf-bc06-9d0d484e1bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_66bdcddd-7077-4a9e-849f-d1f98fd61757" xlink:to="loc_us-gaap_SubsegmentsAxis_70d9dfa0-60e5-46cf-bc06-9d0d484e1bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_adcf4b98-738f-4eba-866a-1ebdcea6d8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_70d9dfa0-60e5-46cf-bc06-9d0d484e1bb7" xlink:to="loc_us-gaap_SubsegmentsDomain_adcf4b98-738f-4eba-866a-1ebdcea6d8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InpatientMember_d7f3b8ce-c35f-477a-8f13-9f1e36763338" xlink:href="ehc-20220331.xsd#ehc_InpatientMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_adcf4b98-738f-4eba-866a-1ebdcea6d8ef" xlink:to="loc_ehc_InpatientMember_d7f3b8ce-c35f-477a-8f13-9f1e36763338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OutpatientandotherMember_0c9f71f8-7c0f-437e-9f81-bdd2778e9699" xlink:href="ehc-20220331.xsd#ehc_OutpatientandotherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_adcf4b98-738f-4eba-866a-1ebdcea6d8ef" xlink:to="loc_ehc_OutpatientandotherMember_0c9f71f8-7c0f-437e-9f81-bdd2778e9699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomehealthMember_218e2497-f8e5-47b7-8ff7-3056474433cc" xlink:href="ehc-20220331.xsd#ehc_HomehealthMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_adcf4b98-738f-4eba-866a-1ebdcea6d8ef" xlink:to="loc_ehc_HomehealthMember_218e2497-f8e5-47b7-8ff7-3056474433cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HospiceMember_deda02da-ab57-4fc9-930e-d27e4f9b2445" xlink:href="ehc-20220331.xsd#ehc_HospiceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_adcf4b98-738f-4eba-866a-1ebdcea6d8ef" xlink:to="loc_ehc_HospiceMember_deda02da-ab57-4fc9-930e-d27e4f9b2445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_92903713-3545-40fa-8c0a-40405c1fe7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_66bdcddd-7077-4a9e-849f-d1f98fd61757" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_92903713-3545-40fa-8c0a-40405c1fe7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_50516d6a-5b4d-44a6-99bb-ec923fb13005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_92903713-3545-40fa-8c0a-40405c1fe7c1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_50516d6a-5b4d-44a6-99bb-ec923fb13005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036264761656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 21, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-10315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Encompass Health Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">63-0860407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9001 Liberty Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Birmingham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">AL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">35242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">967-7116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EHC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,802,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000785161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036263657528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract', window );"><strong>Statement Of Comprehensive Income And Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 1,333.6<span></span>
</td>
<td class="nump">$ 1,230.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">776.0<span></span>
</td>
<td class="nump">687.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses</a></td>
<td class="nump">182.1<span></span>
</td>
<td class="nump">162.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_OccupancyCost', window );">Occupancy costs</a></td>
<td class="nump">20.9<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies</a></td>
<td class="nump">56.1<span></span>
</td>
<td class="nump">51.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">48.4<span></span>
</td>
<td class="nump">38.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">66.2<span></span>
</td>
<td class="nump">62.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,149.7<span></span>
</td>
<td class="nump">1,022.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense and amortization of debt discounts and fees</a></td>
<td class="nump">39.6<span></span>
</td>
<td class="nump">42.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income)</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net income of nonconsolidated affiliates</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income tax expense</a></td>
<td class="nump">141.3<span></span>
</td>
<td class="nump">167.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax expense</a></td>
<td class="nump">31.2<span></span>
</td>
<td class="nump">34.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">110.1<span></span>
</td>
<td class="nump">132.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net and comprehensive income</a></td>
<td class="nump">110.1<span></span>
</td>
<td class="nump">132.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Net and comprehensive income</a></td>
<td class="nump">110.1<span></span>
</td>
<td class="nump">132.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net and comprehensive income attributable to noncontrolling interests</a></td>
<td class="num">(22.6)<span></span>
</td>
<td class="num">(25.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Net and comprehensive income attributable to noncontrolling interests</a></td>
<td class="num">(22.6)<span></span>
</td>
<td class="num">(25.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Encompass Health</a></td>
<td class="nump">87.5<span></span>
</td>
<td class="nump">107.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net and comprehensive income attributable to Encompass Health</a></td>
<td class="nump">$ 87.5<span></span>
</td>
<td class="nump">$ 107.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">99.2<span></span>
</td>
<td class="nump">99.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">100.2<span></span>
</td>
<td class="nump">100.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per share attributable to Encompass Health common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">$ 0.88<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (in dollars per share)</a></td>
<td class="nump">0.88<span></span>
</td>
<td class="nump">1.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per share attributable to Encompass Health common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">0.87<span></span>
</td>
<td class="nump">1.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (in dollars per share)</a></td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Amounts attributable to Encompass Health common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Income from continuing operations</a></td>
<td class="nump">$ 87.5<span></span>
</td>
<td class="nump">$ 107.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Encompass Health</a></td>
<td class="nump">$ 87.5<span></span>
</td>
<td class="nump">$ 107.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_OccupancyCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts paid for rent associated with leased hospitals, including common area maintenance and similar charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_OccupancyCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Statement Of Comprehensive Income And Income Statement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036264783160">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 94.2<span></span>
</td>
<td class="nump">$ 54.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61.0<span></span>
</td>
<td class="nump">65.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">683.5<span></span>
</td>
<td class="nump">680.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">111.0<span></span>
</td>
<td class="nump">121.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">949.7<span></span>
</td>
<td class="nump">921.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,667.1<span></span>
</td>
<td class="nump">2,601.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">236.8<span></span>
</td>
<td class="nump">242.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,456.5<span></span>
</td>
<td class="nump">2,427.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">410.6<span></span>
</td>
<td class="nump">417.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">223.3<span></span>
</td>
<td class="nump">254.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,944.0<span></span>
</td>
<td class="nump">6,864.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42.8<span></span>
</td>
<td class="nump">42.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38.4<span></span>
</td>
<td class="nump">38.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">147.3<span></span>
</td>
<td class="nump">137.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">526.0<span></span>
</td>
<td class="nump">530.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">754.5<span></span>
</td>
<td class="nump">748.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,221.3<span></span>
</td>
<td class="nump">3,243.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">208.3<span></span>
</td>
<td class="nump">213.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">89.7<span></span>
</td>
<td class="nump">86.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">178.6<span></span>
</td>
<td class="nump">173.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,452.4<span></span>
</td>
<td class="nump">4,465.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43.2<span></span>
</td>
<td class="nump">42.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Encompass Health shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,973.5<span></span>
</td>
<td class="nump">1,911.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">474.9<span></span>
</td>
<td class="nump">445.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,448.4<span></span>
</td>
<td class="nump">2,357.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6,944.0<span></span>
</td>
<td class="nump">$ 6,864.9<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of March&#160;31, 2022 and December&#160;31, 2021 include total assets of variable interest entities of $228.0 million and $226.2 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of March&#160;31, 2022 and December&#160;31, 2021 include total liabilities of the variable interest entities of $40.8 million and $38.2 million, respectively. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036266356072">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6,944.0<span></span>
</td>
<td class="nump">$ 6,864.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,452.4<span></span>
</td>
<td class="nump">4,465.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">VIE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">228.0<span></span>
</td>
<td class="nump">226.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 40.8<span></span>
</td>
<td class="nump">$ 38.2<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of March&#160;31, 2022 and December&#160;31, 2021 include total assets of variable interest entities of $228.0 million and $226.2 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of March&#160;31, 2022 and December&#160;31, 2021 include total liabilities of the variable interest entities of $40.8 million and $38.2 million, respectively. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036263475592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Capital in Excess of Par Value</div></th>
<th class="th"><div>Accumulated Income (Deficit)</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Dec. 31, 2020</a></td>
<td class="nump">$ 1,970.0<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 2,326.6<span></span>
</td>
<td class="num">$ (242.3)<span></span>
</td>
<td class="num">$ (497.4)<span></span>
</td>
<td class="nump">$ 382.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">130.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock</a></td>
<td class="num">(15.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(27.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">(22.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountContributions', window );">Capital contributions from consolidated affiliates</a></td>
<td class="nump">5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Mar. 31, 2021</a></td>
<td class="nump">2,043.0<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">2,302.7<span></span>
</td>
<td class="num">(135.0)<span></span>
</td>
<td class="num">(513.7)<span></span>
</td>
<td class="nump">387.9<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Dec. 31, 2021</a></td>
<td class="nump">2,357.0<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">2,289.6<span></span>
</td>
<td class="nump">141.8<span></span>
</td>
<td class="num">(521.2)<span></span>
</td>
<td class="nump">445.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">108.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock</a></td>
<td class="num">(7.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(28.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">(24.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountContributions', window );">Capital contributions from consolidated affiliates</a></td>
<td class="nump">21.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">14.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Mar. 31, 2022</a></td>
<td class="nump">$ 2,448.4<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 2,301.1<span></span>
</td>
<td class="nump">$ 201.2<span></span>
</td>
<td class="num">$ (529.9)<span></span>
</td>
<td class="nump">$ 474.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total contributions made by each class of partners (i.e., general, limited and preferred partners).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 4.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOtherShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) in shares of stock classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOtherShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036268119912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared on common stock (in dollars per share)</a></td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036260961656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 110.1<span></span>
</td>
<td class="nump">$ 132.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities&#8212;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">66.2<span></span>
</td>
<td class="nump">62.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7.5<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Change in assets and liabilities, net of acquisitions&#8212;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">7.3<span></span>
</td>
<td class="num">(55.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">12.0<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedSalaries', window );">Accrued payroll</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in operating activities of discontinued operations</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">108.8<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">218.9<span></span>
</td>
<td class="nump">158.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(115.2)<span></span>
</td>
<td class="num">(98.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="num">(7.9)<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(123.1)<span></span>
</td>
<td class="num">(95.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Principal payments on debt, including pre-payments</a></td>
<td class="num">(103.9)<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowings on revolving credit facility</a></td>
<td class="nump">130.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Payments on revolving credit facility</a></td>
<td class="num">(25.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtRestructuringCosts', window );">Debt amendment costs</a></td>
<td class="num">(20.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid on behalf of employees for shares withheld</a></td>
<td class="num">(7.6)<span></span>
</td>
<td class="num">(15.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Contributions from consolidated affiliates</a></td>
<td class="nump">21.4<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid on common stock</a></td>
<td class="num">(28.5)<span></span>
</td>
<td class="num">(29.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distributions paid to noncontrolling interests of consolidated affiliates</a></td>
<td class="num">(21.3)<span></span>
</td>
<td class="num">(27.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="num">(6.0)<span></span>
</td>
<td class="num">(5.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(60.9)<span></span>
</td>
<td class="num">(77.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">34.9<span></span>
</td>
<td class="num">(14.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">120.3<span></span>
</td>
<td class="nump">310.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">155.2<span></span>
</td>
<td class="nump">296.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of Cash, Cash Equivalents, and Restricted Cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">54.8<span></span>
</td>
<td class="nump">224.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash at beginning of period</a></td>
<td class="nump">65.1<span></span>
</td>
<td class="nump">65.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash included in other long-term assets at beginning of period</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">21.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">120.3<span></span>
</td>
<td class="nump">310.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">94.2<span></span>
</td>
<td class="nump">223.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash at end of period</a></td>
<td class="nump">61.0<span></span>
</td>
<td class="nump">62.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash included in other long-term assets at end of period</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">155.2<span></span>
</td>
<td class="nump">296.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of noncash operating, investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Property and equipment additions through finance leases</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease additions</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">$ 17.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in accrued salaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036265115112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health Corporation, incorporated in Delaware in 1984, including its subsidiaries, is a leading provider of post-acute healthcare services, offering both facility-based and home-based patient services in 42 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. We manage our operations and disclose financial information using two reportable segments: (1) inpatient rehabilitation and (2) home health and hospice. See also Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2020, we announced a formal process to explore strategic alternatives for our home health and hospice business. As a result of this process, we expect to spin off our home health and hospice business to form an independent, publicly traded company on July 1, 2022, subject to customary conditions, including the effectiveness of a Form&#160;10 registration statement, regulatory approvals and receipt of a favorable IRS private letter ruling. On January 19, 2022, we announced the home health and hospice business would be rebranded and operate under the name Enhabit Home Health &amp; Hospice. The rebranding of agency locations began in mid-April 2022 and is expected to be largely completed by the effective date of the spin off.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Encompass Health Corporation and Subsidiaries should be read in conjunction with the consolidated financial statements and accompanying notes contained in Encompass Health&#8217;s Annual Report on Form&#160;10-K filed with the United States Securities and Exchange Commission on February&#160;25, 2022 (the &#8220;2021 Form 10&#8209;K&#8221;). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC applicable to interim financial information. Certain information and note disclosures included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been omitted in these interim statements, as allowed by such SEC rules and regulations. The condensed consolidated balance sheet as of December&#160;31, 2021 has been derived from audited financial statements, but it does not include all disclosures required by GAAP. However, we believe the disclosures are adequate to make the information presented not misleading.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited results of operations for the interim periods shown in these financial statements are not necessarily indicative of operating results for the entire year. In our opinion, the accompanying condensed consolidated financial statements recognize all adjustments of a normal recurring nature considered necessary to fairly state the financial position, results of operations, and cash flows for each interim period presented. Certain prior-year amounts have been reclassified to conform to the current year presentation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Operating Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by payor source and segment are as follows (in millions):</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:35.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2021 Form 10-K for our policy related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe any recently issued, but not yet effective, accounting standards will have a material effect on our condensed consolidated financial position, results of operations, or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036265234952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text">Business Combinations<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health and Hospice</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we acquired a 50% equity interest from Frontier Home Health and Hospice, LLC in a joint venture with Saint Alphonsus System (&#8220;Saint Alphonsus&#8221;) which operates home health and hospice locations in Boise, Idaho. The total purchase price was $15.9&#160;million and was funded on December 31, 2021. This acquisition was made to enhance our existing joint venture relationship with Saint Alphonsus and expand our footprint in this geographic area. This transaction was not material to our financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for this transaction under the acquisition method of accounting and reported the results of operations of the acquired locations from the date of acquisition. Assets acquired, liabilities assumed, and noncontrolling interests were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including: an income approach using primarily discounted cash flow techniques for the noncompete and license intangible assets; and an income approach utilizing the relief-from-royalty method for the trade name intangible asset. The aforementioned income methods utilize management&#8217;s estimates of future operating results and cash flows discounted using a weighted average cost of capital that reflects market participant assumptions. For all other assets and liabilities, the fair value was assumed to represent carrying value due to their short maturities. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. All goodwill recorded reflects our expectations of favorable growth opportunities in the home health and hospice markets based on positive demographic trends. At least $14.4 million of the goodwill recorded as a result of this transaction is deductible for federal income tax purposes.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values recorded were based upon a preliminary valuation. Estimates and assumptions used in such valuation are subject to change, which could be significant, within the measurement period (up to one year from the acquisition date). We expect to continue to obtain information to assist us in determining the fair value of the net assets acquired at the acquisition date during the measurement period.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use-assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreement (useful life of 5 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of 6 months)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses (useful lives of 10 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software (useful life of 3 years)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the cash paid for the acquisition during each period presented is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.683%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisition</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro Forma Results of Operations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above mentioned acquisition from the date of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisition been January&#160;1, 2021 (in millions): </span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.030%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health and Hospice</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2022-03/31/2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2021-03/31/2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisition had occurred as of the beginning of our 2021 reporting period. See Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2021 Form 10&#8209;K for information regarding acquisitions completed in 2021.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036265205880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entities</a></td>
<td class="text">Variable Interest Entities<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022 and December&#160;31, 2021, we consolidated ten limited partnership-like entities that are variable interest entities (&#8220;VIEs&#8221;) and of which we are the primary beneficiary. Our ownership percentages in these entities range from 50.0% to 90.0% as of March&#160;31, 2022. Through partnership and management agreements with or governing each of these entities, we manage all of these entities and handle all day-to-day operating decisions. Accordingly, we have the decision making power over the activities that most significantly impact the economic performance of our VIEs and an obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections, and creation and maintenance of medical records. The terms of the agreements governing each of our VIEs prohibit us from using the assets of each VIE to satisfy the obligations of other entities.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and classifications of the consolidated VIEs&#8217; assets and liabilities, which are included in our condensed consolidated balance sheet, are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036267318216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text">Long-term Debt<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term debt outstanding consists of the following (in&#160;millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"><tr><td style="width:1.0%"/><td style="width:59.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonds payable&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,264.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,286.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,243.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2021, we announced the commencement of a consent solicitation of holders of our 5.75% Senior Notes due 2025, 4.50% Senior Notes due 2028, 4.75% Senior Notes due 2030, and 4.625% Senior Notes due 2031 (collectively the &#8220;Senior Notes&#8221;) for the adoption of certain amendments to an indenture (the &#8220;Base Indenture&#8221;) dated as of December&#160;1,&#160;2009, as supplemented by each Senior Notes&#8217; respective supplemental indenture (together with the Base Indenture, the &#8220;Indenture&#8221;), which will provide us with greater flexibility in effecting the spin off discussed in Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Each Indenture contains restrictive covenants that, among other things, limit our ability and the ability of certain of our subsidiaries to make certain asset dispositions, investments, and distributions to holders of our capital stock. The amendments to the Indentures permit us, subject to the leverage ratio condition set forth below, to distribute to our equity holders in one or more transactions (a &#8220;Distribution&#8221;) some or all of the common stock of a subsidiary that holds substantially all of the assets of our home health and hospice business. We may make any such distribution so long as the Leverage Ratio (as defined in each Indenture) is no more than 3.5 to 1.0 on a pro forma basis after giving effect thereto. The amendments also reduce the capacity under our restricted payments builder basket under each existing Indenture by $200&#160;million and amends the definition of &#8220;Consolidated Net Income&#8221; to allow us to exclude from Consolidated Net Income (a component of the Leverage Ratio) any fees, expenses or charges related to any Distribution and the solicitation of consents from the holders of the Senior Notes. In December 2021 and January 2022, we received the requisite consents for the adoption of these amendments. Under the terms of the amendments, we agreed to pay the holders of the Senior Notes a total of $40.5&#160;million, excluding fees. We paid $20&#160;million of this amount in January 2022. The remaining payment is contingent upon the execution of a Distribution and will be paid at such time.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we redeemed the remaining $100&#160;million in outstanding principal amount of the 5.125% Senior Notes due 2023 (the &#8220;2023 Notes&#8221;) using capacity under our revolving credit facility. Pursuant to the terms of the 2023 Notes, this optional redemption was made at a price of par. As a result of this redemption, we recorded an aggregate $0.3&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the three months ended March 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036267309496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">Redeemable Noncontrolling Interests</a></td>
<td class="text">Redeemable Noncontrolling Interests<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the activity related to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the net income attributable to nonredeemable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the shareholders&#8217; equity section of the condensed consolidated balance sheets, and the net income attributable to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the mezzanine section of the condensed consolidated balance sheets, to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net and comprehensive income attributable to noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> presented in the condensed consolidated statements of comprehensive income (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to nonredeemable noncontrolling interests</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to redeemable noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036265230920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): </span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:32.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of March 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr></table></div><div style="margin-bottom:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).</span></div><div style="margin-bottom:10pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  As of March&#160;31, 2022, $4.8&#160;million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and $75.6&#160;million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other long-term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> assets in the condensed consolidated balance sheet. As of December&#160;31, 2021, $82.2&#160;million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other long-term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> assets in the condensed consolidated balance sheet.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are assets and liabilities that are not required to be measured at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. During the three months ended March&#160;31, 2022 and 2021, we did not record any material gains or losses related to these assets.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Fair Value Measurements,&#8221; to the consolidated financial statements accompanying the 2021 Form 10&#8209;K, the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our condensed consolidated balance sheets. The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial commitments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letters of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inputs within the fair value hierarchy. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Fair Value Measurements,&#8221; to the consolidated financial statements accompanying the 2021 Form 10&#8209;K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036265272312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payments</a></td>
<td class="text">Share-Based Payments<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, we issued a total of 0.6 million restricted stock awards to members of our management team and our board of directors. Approximately 0.2 million of these awards contain only a service condition, while the remainder contain both a service and a performance condition. For the awards that include a performance condition, the number of shares that will ultimately be granted to employees may vary based on the Company&#8217;s performance during the applicable two year performance measurement period. Additionally, we granted 0.1 million stock options to members of our management team. The fair value of these awards and options was determined using the policies described in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note&#160;14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2021 Form 10&#8209;K.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036345887384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $31.2 million for the three months ended March&#160;31, 2022 primarily resulted from the application of our estimated effective blended federal and state income tax rate. Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $34.5 million for the three months ended March 31, 2021 primarily resulted from the application of our estimated effective blended federal and state income tax rate offset by tax benefits resulting from share-based compensation windfalls.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036265266520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Common Share</a></td>
<td class="text">Earnings per Common Share<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income allocated to participating securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.87&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.07&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards, dilutive stock options, and restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Common Share</span>, to the consolidated financial statements accompanying the 2021 Form 10&#8209;K for additional information related to our common stock.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036265234952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Other Commitments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">Contingencies and Other Commitments</a></td>
<td class="text">Contingencies and Other Commitments<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The False Claims Act allows private citizens, called &#8220;relators,&#8221; to institute civil proceedings on behalf of the United States alleging violations of the False Claims Act. These lawsuits, also known as &#8220;whistleblower&#8221; or &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; actions, can involve significant monetary damages, fines, attorneys&#8217; fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases are sealed at the time of filing, which means knowledge of the information contained in the complaint typically is limited to the relator, the federal government, and the presiding court. The defendant in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action may remain unaware of the existence of a sealed complaint for years. While the complaint is under seal, the government reviews the merits of the case and may conduct a broad investigation and seek discovery from the defendant and other parties before deciding whether to intervene in the case and take the lead on litigating the claims. The court lifts the seal when the government makes its decision on whether to intervene. If the government decides not to intervene, the relator may elect to continue to pursue the lawsuit individually on behalf of the government. It is possible that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases brought pursuant to the False Claims Act.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the United States Department of Health and Human Services Office of Inspector General and the Centers for Medicare &amp; Medicaid Services relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, Encompass Health refunding amounts to Medicare or other federal healthcare programs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=2127197<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2127163<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036355074536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal financial reporting and management structure is focused on the major types of services provided by Encompass Health. We manage our operations using two operating segments which are also our reportable segments: (1)&#160;inpatient rehabilitation and (2)&#160;home health and hospice. These reportable operating segments are consistent with information used by our chief executive officer, who is our chief operating decision maker, to assess performance and allocate resources. The following is a brief description of our reportable segments:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Inpatient Rehabilitation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our national network of inpatient rehabilitation hospitals stretches across 35 states and Puerto Rico, with a concentration of hospitals in the eastern half of the United States and Texas. As of March&#160;31, 2022, we operate 147 inpatient rehabilitation hospitals. We are the sole owner of 93 of these hospitals. We retain 50.0% to 97.5% ownership in the remaining 54 jointly owned hospitals. In addition, we manage two inpatient rehabilitation units through management contracts. We provide specialized rehabilitative treatment on both an inpatient and outpatient basis. Our inpatient rehabilitation hospitals provide a higher level of rehabilitative care to </span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Home Health and Hospice </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- As of March&#160;31, 2022, we provide home health services in 252 locations and hospice services in 99 locations across 34 states with concentrations in the southern half of the United States. We are the sole owner of 335 of these locations. We retain 50.0% to 90.0% ownership in the remaining 16 jointly owned locations. Our home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. Hospice care focuses on the quality of life for patients who are experiencing an advanced, life limiting illness while treating the person and symptoms of the disease, rather than the disease itself. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of our reportable segments are the same as those described in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements accompanying the 2021 Form 10&#8209;K. All revenues for our services are generated through external customers. See Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues,&#8221; for the disaggregation of our revenues. No corporate overhead is allocated to either of our reportable segments. Our chief operating decision maker evaluates the performance of our segments and allocates resources to them based on adjusted earnings before interest, taxes, depreciation, and amortization (&#8220;Segment Adjusted EBITDA&#8221;).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected financial information for our reportable segments is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health and hospice:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service (excluding depreciation and amortization)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Support and overhead costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Adjusted EBITDA</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:51.477%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.219%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,199.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,745.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,944.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to nonconsolidated affiliates</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,143.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,864.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment reconciliations (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on disposal or impairment of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from continuing operations before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional detail regarding the revenues of our operating segments by service line follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inpatient rehabilitation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health and hospice:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total home health and hospice</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net operating revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036265035672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe any recently issued, but not yet effective, accounting standards will have a material effect on our condensed consolidated financial position, results of operations, or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036265219944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Concentration of Net Operating Revenues by Payor</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by payor source and segment are as follows (in millions):</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:35.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036264585304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Assets Acquired and Liabilities Assumed at the Acquisition Date</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use-assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreement (useful life of 5 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of 6 months)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses (useful lives of 10 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software (useful life of 3 years)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the cash paid for the acquisition during each period presented is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.683%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisition</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Summary of Actual and Pro Forma Results of Operations for Acquisitions</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above mentioned acquisition from the date of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisition been January&#160;1, 2021 (in millions): </span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.030%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health and Hospice</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2022-03/31/2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2021-03/31/2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036265075368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and classifications of the consolidated VIEs&#8217; assets and liabilities, which are included in our condensed consolidated balance sheet, are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036265247672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Outstanding Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term debt outstanding consists of the following (in&#160;millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"><tr><td style="width:1.0%"/><td style="width:59.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonds payable&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,264.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,286.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,243.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036266130312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestTableTextBlock', window );">Redeemable Noncontrolling Interests Activity</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the activity related to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock', window );">Reconciliation of Noncontrolling Interests</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the net income attributable to nonredeemable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the shareholders&#8217; equity section of the condensed consolidated balance sheets, and the net income attributable to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the mezzanine section of the condensed consolidated balance sheets, to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net and comprehensive income attributable to noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> presented in the condensed consolidated statements of comprehensive income (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to nonredeemable noncontrolling interests</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to redeemable noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of Net Income Attributable to Noncontrolling Interests [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036265084568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): </span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:32.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of March 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr></table></div><div style="margin-bottom:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).</span></div><div style="margin-bottom:10pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  As of March&#160;31, 2022, $4.8&#160;million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and $75.6&#160;million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other long-term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> assets in the condensed consolidated balance sheet. As of December&#160;31, 2021, $82.2&#160;million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other long-term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> assets in the condensed consolidated balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments</a></td>
<td class="text">The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial commitments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letters of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036265200248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Earnings Per Common Share</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income allocated to participating securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.87&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.07&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of Weighted Average Number of Shares Outstanding</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards, dilutive stock options, and restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036264586728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected financial information for our reportable segments is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health and hospice:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service (excluding depreciation and amortization)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Support and overhead costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Adjusted EBITDA</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Reconciliation of Assets from Segment to Consolidated</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:51.477%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.219%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inpatient Rehabilitation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health and Hospice</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,199.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,745.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,944.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to nonconsolidated affiliates</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,143.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,864.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to nonconsolidated affiliates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock', window );">Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment reconciliations (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on disposal or impairment of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from continuing operations before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Revenue from Segments to Consolidated</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional detail regarding the revenues of our operating segments by service line follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inpatient rehabilitation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health and hospice:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home health</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total home health and hospice</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net operating revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation segment adjusted EBITDA to income from continuing operations before income tax expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036265070168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation - Textual (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>segment </div>
<div>state</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036261026568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation - Net Operating Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 1,333.6<span></span>
</td>
<td class="nump">$ 1,230.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">1,059.3<span></span>
</td>
<td class="nump">959.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">274.3<span></span>
</td>
<td class="nump">270.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">907.3<span></span>
</td>
<td class="nump">838.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_MedicareMember', window );">Medicare | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">689.9<span></span>
</td>
<td class="nump">614.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_MedicareMember', window );">Medicare | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">217.4<span></span>
</td>
<td class="nump">223.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_MedicareAdvantageMember', window );">Medicare Advantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">190.5<span></span>
</td>
<td class="nump">186.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_MedicareAdvantageMember', window );">Medicare Advantage | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">156.0<span></span>
</td>
<td class="nump">158.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_MedicareAdvantageMember', window );">Medicare Advantage | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">34.5<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_ManagedCareMember', window );">Managed care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">150.3<span></span>
</td>
<td class="nump">126.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_ManagedCareMember', window );">Managed care | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">131.5<span></span>
</td>
<td class="nump">112.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_ManagedCareMember', window );">Managed care | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">18.8<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">45.2<span></span>
</td>
<td class="nump">42.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_MedicaidMember', window );">Medicaid | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">41.7<span></span>
</td>
<td class="nump">39.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_MedicaidMember', window );">Medicaid | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_OtherThirdpartyPayorsMember', window );">Other third-party payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">12.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_OtherThirdpartyPayorsMember', window );">Other third-party payors | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">12.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_OtherThirdpartyPayorsMember', window );">Other third-party payors | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_WorkersCompensationMember', window );">Workers&#8217; compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_WorkersCompensationMember', window );">Workers&#8217; compensation | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_WorkersCompensationMember', window );">Workers&#8217; compensation | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_PatientsMember', window );">Patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_PatientsMember', window );">Patients | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_PatientsMember', window );">Patients | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_OtherIncomeSourceMember', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">18.8<span></span>
</td>
<td class="nump">13.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_OtherIncomeSourceMember', window );">Other income | Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">18.8<span></span>
</td>
<td class="nump">13.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ehc_OtherIncomeSourceMember', window );">Other income | Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ehc_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ehc_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ehc_MedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ehc_MedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ehc_ManagedCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ehc_ManagedCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ehc_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ehc_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ehc_OtherThirdpartyPayorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ehc_OtherThirdpartyPayorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ehc_WorkersCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ehc_WorkersCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ehc_PatientsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ehc_PatientsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ehc_OtherIncomeSourceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ehc_OtherIncomeSourceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036266042632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations - Textual (Details) - Home Health and Hospice - Saint Alphonsus - Corporate Joint Venture<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Escrow agent cost</a></td>
<td class="nump">$ 15.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill expected to be tax-deductible amount</a></td>
<td class="nump">$ 14.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_SaintAlphonsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_SaintAlphonsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036263327192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations - Fair Value of Assets and Liabilities Assumed (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,456.5<span></span>
</td>
<td class="nump">$ 2,427.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Saint Alphonsus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable, net</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use-assets</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">28.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets', window );">Total assets acquired</a></td>
<td class="nump">32.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability', window );">Current operating lease liabilities</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll', window );">Accrued payroll</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other current liabilities</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Long-term operating lease liabilities</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Noncontrolling interests</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest', window );">Net assets acquired</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Noncompete agreements | Saint Alphonsus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Trade name | Saint Alphonsus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Licenses | Saint Alphonsus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Internal-use software | Saint Alphonsus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Payroll</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Including Goodwill, Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease obligation assumed in business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_SaintAlphonsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_SaintAlphonsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036263613672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Net Cash Paid for Acquisitions (Details) - Home Health and Hospice - Saint Alphonsus - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="nump">28.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of liabilities assumed</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_BusinessCombinationNoncontrollingInterestFairValue', window );">Fair value of noncontrolling interest owned by joint venture partner</a></td>
<td class="num">(15.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisition</a></td>
<td class="nump">$ 15.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_BusinessCombinationNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Noncontrolling Interest, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_BusinessCombinationNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_SaintAlphonsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_SaintAlphonsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036263554312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Pro Forma Results of Operation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Business acquisition, pro forma revenue</a></td>
<td class="nump">$ 1,333.6<span></span>
</td>
<td class="nump">$ 1,232.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Business acquisition, pro forma net income</a></td>
<td class="nump">87.5<span></span>
</td>
<td class="nump">$ 107.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, earnings of acquiree since acquisition date, actual</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036263285416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities - Textual (Details) - VIE - entity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_VariableInterestEntityNumberofEntitiesConsolidated', window );">Number of consolidated limited partnership-like entities</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Ownership interest in consolidated entities (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Ownership interest in consolidated entities (percent)</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_VariableInterestEntityNumberofEntitiesConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of facilities consolidated as variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_VariableInterestEntityNumberofEntitiesConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036260741960">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entities - Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 94.2<span></span>
</td>
<td class="nump">$ 54.8<span></span>
</td>
<td class="nump">$ 223.9<span></span>
</td>
<td class="nump">$ 224.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">683.5<span></span>
</td>
<td class="nump">680.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">111.0<span></span>
</td>
<td class="nump">121.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">949.7<span></span>
</td>
<td class="nump">921.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,667.1<span></span>
</td>
<td class="nump">2,601.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">236.8<span></span>
</td>
<td class="nump">242.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,456.5<span></span>
</td>
<td class="nump">2,427.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">410.6<span></span>
</td>
<td class="nump">417.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">223.3<span></span>
</td>
<td class="nump">254.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,944.0<span></span>
</td>
<td class="nump">6,864.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42.8<span></span>
</td>
<td class="nump">42.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38.4<span></span>
</td>
<td class="nump">38.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">147.3<span></span>
</td>
<td class="nump">137.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">526.0<span></span>
</td>
<td class="nump">530.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">754.5<span></span>
</td>
<td class="nump">748.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,221.3<span></span>
</td>
<td class="nump">3,243.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">208.3<span></span>
</td>
<td class="nump">213.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,452.4<span></span>
</td>
<td class="nump">4,465.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">VIE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34.7<span></span>
</td>
<td class="nump">36.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11.4<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46.7<span></span>
</td>
<td class="nump">44.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">115.6<span></span>
</td>
<td class="nump">116.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28.4<span></span>
</td>
<td class="nump">28.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31.2<span></span>
</td>
<td class="nump">31.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">228.0<span></span>
</td>
<td class="nump">226.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22.6<span></span>
</td>
<td class="nump">19.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30.9<span></span>
</td>
<td class="nump">27.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8.4<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 40.8<span></span>
</td>
<td class="nump">$ 38.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of March&#160;31, 2022 and December&#160;31, 2021 include total assets of variable interest entities of $228.0 million and $226.2 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of March&#160;31, 2022 and December&#160;31, 2021 include total liabilities of the variable interest entities of $40.8 million and $38.2 million, respectively. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036263372264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Long-term Debt Outstanding (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease obligations</a></td>
<td class="nump">$ 381.0<span></span>
</td>
<td class="nump">$ 386.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt and finance lease obligations</a></td>
<td class="nump">3,264.1<span></span>
</td>
<td class="nump">3,286.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less: Current portion</a></td>
<td class="num">(42.8)<span></span>
</td>
<td class="num">(42.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, net of current portion</a></td>
<td class="nump">3,221.3<span></span>
</td>
<td class="nump">3,243.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term loan facilities | Term loan facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 235.3<span></span>
</td>
<td class="nump">238.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.125% Senior Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">5.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">99.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 347.2<span></span>
</td>
<td class="nump">347.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 779.5<span></span>
</td>
<td class="nump">786.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% Senior Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 777.2<span></span>
</td>
<td class="nump">784.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.625% Senior Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 389.9<span></span>
</td>
<td class="nump">393.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Other notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">49.0<span></span>
</td>
<td class="nump">49.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Advances under revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 305.0<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_TermLoanFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_TermLoanFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4625Due2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4625Due2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036263667768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Textual (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantLeverageRatio', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket', window );">Debt instrument, reduction in capacity under restricted payments builder basket</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid', window );">Amendment agreement, amount to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% Senior Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.625% Senior Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.125% Senior Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Amendment Agreement, Amount To Be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentAmendmentAgreementAmountToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentCovenantLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentCovenantLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Reduction In Capacity Under Restricted Payments Builder Basket</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4625Due2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4625Due2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036263565112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward', window );"><strong>Redeemable Noncontrolling Interest, Equity, Carrying Amount [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at beginning of period</a></td>
<td class="nump">$ 42.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">(24.9)<span></span>
</td>
<td class="num">(22.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at end of period</a></td>
<td class="nump">43.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ehc_RedeemableNoncontrollingInterestMember', window );">Redeemable Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward', window );"><strong>Redeemable Noncontrolling Interest, Equity, Carrying Amount [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at beginning of period</a></td>
<td class="nump">42.2<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at end of period</a></td>
<td class="nump">$ 43.2<span></span>
</td>
<td class="nump">$ 31.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ehc_RedeemableNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ehc_RedeemableNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036264598152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest', window );">Net income attributable to nonredeemable noncontrolling interests</a></td>
<td class="nump">$ 20.7<span></span>
</td>
<td class="nump">$ 23.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Net income attributable to redeemable noncontrolling interests</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">$ 22.6<span></span>
</td>
<td class="nump">$ 25.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of net income (loss) attributable to nonredeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036263585640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">$ 111.0<span></span>
</td>
<td class="nump">$ 121.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">223.3<span></span>
</td>
<td class="nump">254.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">80.4<span></span>
</td>
<td class="nump">82.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">43.2<span></span>
</td>
<td class="nump">42.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">75.6<span></span>
</td>
<td class="nump">82.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">76.5<span></span>
</td>
<td class="nump">78.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">$ 43.2<span></span>
</td>
<td class="nump">$ 42.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036268164328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Textual (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Gains or losses related to non-financial assets and liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14172-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036260007304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 09, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term loan facilities | Term loan facilities | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 235.3<span></span>
</td>
<td class="nump">$ 238.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term loan facilities | Term loan facilities | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 236.3<span></span>
</td>
<td class="nump">239.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.125% Senior Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">5.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.125% Senior Notes due 2023 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">99.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.125% Senior Notes due 2023 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">100.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due 2025 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 347.2<span></span>
</td>
<td class="nump">347.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due 2025 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 356.1<span></span>
</td>
<td class="nump">357.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Notes due 2028 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 779.5<span></span>
</td>
<td class="nump">786.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Notes due 2028 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 790.9<span></span>
</td>
<td class="nump">823.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% Senior Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% Senior Notes due 2030 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 777.2<span></span>
</td>
<td class="nump">784.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% Senior Notes due 2030 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 768.0<span></span>
</td>
<td class="nump">824.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.625% Senior Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.625% Senior Notes due 2031 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 389.9<span></span>
</td>
<td class="nump">393.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.625% Senior Notes due 2031 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">374.4<span></span>
</td>
<td class="nump">407.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Other notes payable | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">49.0<span></span>
</td>
<td class="nump">49.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Other notes payable | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">49.0<span></span>
</td>
<td class="nump">49.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Advances under revolving credit facility | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">305.0<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Advances under revolving credit facility | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">305.0<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letters of credit | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letters of credit | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 37.2<span></span>
</td>
<td class="nump">$ 38.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_TermLoanFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_TermLoanFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4625Due2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4625Due2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036263781160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards issued (shares)</a></td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Service Condition</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards issued (shares)</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Service and Performance Condition</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Performance measurement period</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options granted (shares)</a></td>
<td class="nump">0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036265219944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax expense</a></td>
<td class="nump">$ 31.2<span></span>
</td>
<td class="nump">$ 34.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036263317304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Common Share - Computation of Basic and Diluted Earnings Per Common Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Basic Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">$ 110.1<span></span>
</td>
<td class="nump">$ 132.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less: Net income attributable to noncontrolling interests included in continuing operations</a></td>
<td class="num">(22.6)<span></span>
</td>
<td class="num">(25.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Less: Income allocated to participating securities</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic', window );">Income from continuing operations attributable to Encompass Health common shareholders</a></td>
<td class="nump">87.1<span></span>
</td>
<td class="nump">106.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NetIncomeLossAvailabletoCommonStockholders', window );">Net income attributable to Encompass Health common shareholders</a></td>
<td class="nump">$ 87.1<span></span>
</td>
<td class="nump">$ 106.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in shares)</a></td>
<td class="nump">99.2<span></span>
</td>
<td class="nump">99.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per share attributable to Encompass Health common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">$ 0.88<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (in dollars per share)</a></td>
<td class="nump">$ 0.88<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Diluted Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">$ 110.1<span></span>
</td>
<td class="nump">$ 132.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less: Net income attributable to noncontrolling interests included in continuing operations</a></td>
<td class="num">(22.6)<span></span>
</td>
<td class="num">(25.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted', window );">Income from continuing operations attributable to Encompass Health common shareholders</a></td>
<td class="nump">87.5<span></span>
</td>
<td class="nump">107.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Encompass Health common shareholders</a></td>
<td class="nump">$ 87.5<span></span>
</td>
<td class="nump">$ 107.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in shares)</a></td>
<td class="nump">100.2<span></span>
</td>
<td class="nump">100.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per share attributable to Encompass Health common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (in dollars per share)</a></td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (loss) from continuing operations attributable to HealthSouth common shareholders basic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income loss from continuing operations attributable to common shareholders diluted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NetIncomeLossAvailabletoCommonStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period), cumulative preferred stock (accumulated for the period), and/or income allocated to participating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NetIncomeLossAvailabletoCommonStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036264676008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Common Share - Reconciliation of Weighted Average Number of Shares Outstanding (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in shares)</a></td>
<td class="nump">99.2<span></span>
</td>
<td class="nump">99.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Restricted stock awards, dilutive stock options, and restricted stock units (in shares)</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in shares)</a></td>
<td class="nump">100.2<span></span>
</td>
<td class="nump">100.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036264716760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Textual (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>location </div>
<div>hospital </div>
<div>segment </div>
<div>state</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberOfInpatientRehabilitationHospitals', window );">Number of inpatient rehabilitation hospitals operated | hospital</a></td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Numberofsolelyownedinpatientrehabilitationhospitals', window );">Number of solely owned inpatient rehabilitation hospitals | hospital</a></td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Numberofjointlyownedinpatientrehabilitationhospitals', window );">Number of jointly owned inpatient rehabilitation hospitals | hospital</a></td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts', window );">Number of inpatient rehabilitation units under management contracts | hospital</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Jointventureownershippercentage', window );">Joint venture ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Jointventureownershippercentage', window );">Joint venture ownership percentage</a></td>
<td class="nump">97.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Numberofhomehealthlocations', window );">Number of home health locations | location</a></td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Numberofhospicelocations', window );">Number of hospice locations | location</a></td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations', window );">Number of solely owned hospital based home health and hospice locations | location</a></td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations', window );">Number of jointly owned hospital based home health and hospice locations | location</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Jointventureownershippercentage', window );">Joint venture ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_Jointventureownershippercentage', window );">Joint venture ownership percentage</a></td>
<td class="nump">90.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Jointventureownershippercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint venture ownership percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Jointventureownershippercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberOfInpatientRehabilitationHospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberOfInpatientRehabilitationHospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of inpatient rehabilitation units under management contracts with the Company as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Numberofhomehealthlocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of home health locations the Company owns and operates as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Numberofhomehealthlocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Numberofhospicelocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of hospice locations the Company owns and operates as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Numberofhospicelocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of jointly owned hospital based home health and hospice agencies the Company owns and operates as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Numberofjointlyownedinpatientrehabilitationhospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of jointly owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Numberofjointlyownedinpatientrehabilitationhospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of solely owned hospital based home health and hospice agencies the Company owns and operates as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Numberofsolelyownedinpatientrehabilitationhospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of solely owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Numberofsolelyownedinpatientrehabilitationhospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036260626840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Segment Reporting Information, Reconciliation of Net Operating Revenues to Segment Adjusted EBITDA (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 1,333.6<span></span>
</td>
<td class="nump">$ 1,230.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">776.0<span></span>
</td>
<td class="nump">687.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses</a></td>
<td class="nump">182.1<span></span>
</td>
<td class="nump">162.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies</a></td>
<td class="nump">56.1<span></span>
</td>
<td class="nump">51.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_OccupancyCost', window );">Occupancy costs</a></td>
<td class="nump">20.9<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,149.7<span></span>
</td>
<td class="nump">1,022.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income)</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net income of nonconsolidated affiliates</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Noncontrolling interests</a></td>
<td class="nump">22.6<span></span>
</td>
<td class="nump">25.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">1,059.3<span></span>
</td>
<td class="nump">959.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">587.4<span></span>
</td>
<td class="nump">501.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses</a></td>
<td class="nump">158.3<span></span>
</td>
<td class="nump">140.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies</a></td>
<td class="nump">49.8<span></span>
</td>
<td class="nump">45.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_OccupancyCost', window );">Occupancy costs</a></td>
<td class="nump">15.4<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_CostofServicesExcludingDepreciationandAmortization', window );">Cost of service (excluding depreciation and amortization)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldOverhead', window );">Support and overhead costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">810.9<span></span>
</td>
<td class="nump">702.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income)</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net income of nonconsolidated affiliates</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Noncontrolling interests</a></td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">25.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_AdjustedEBITDA', window );">Segment Adjusted EBITDA</a></td>
<td class="nump">226.2<span></span>
</td>
<td class="nump">234.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="nump">117.8<span></span>
</td>
<td class="nump">99.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">274.3<span></span>
</td>
<td class="nump">270.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_OccupancyCost', window );">Occupancy costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_CostofServicesExcludingDepreciationandAmortization', window );">Cost of service (excluding depreciation and amortization)</a></td>
<td class="nump">124.4<span></span>
</td>
<td class="nump">118.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldOverhead', window );">Support and overhead costs</a></td>
<td class="nump">99.2<span></span>
</td>
<td class="nump">101.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">223.6<span></span>
</td>
<td class="nump">219.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net income of nonconsolidated affiliates</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Noncontrolling interests</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_AdjustedEBITDA', window );">Segment Adjusted EBITDA</a></td>
<td class="nump">50.1<span></span>
</td>
<td class="nump">50.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_AdjustedEBITDA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted earnings before interest, taxes, depreciation, and amortization as defined in the Company's credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_AdjustedEBITDA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_CostofServicesExcludingDepreciationandAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of services rendered during the reporting period, excluding depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_CostofServicesExcludingDepreciationandAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_OccupancyCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts paid for rent associated with leased hospitals, including common area maintenance and similar charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_OccupancyCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldOverhead">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indirect cost incurred related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldOverhead</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036264775592">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Segment Assets and Investments In and Advances to Affiliates (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6,944.0<span></span>
</td>
<td class="nump">$ 6,864.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and advances to nonconsolidated affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,199.0<span></span>
</td>
<td class="nump">5,143.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and advances to nonconsolidated affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,745.0<span></span>
</td>
<td class="nump">1,721.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and advances to nonconsolidated affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of March&#160;31, 2022 and December&#160;31, 2021 include total assets of variable interest entities of $228.0 million and $226.2 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of March&#160;31, 2022 and December&#160;31, 2021 include total liabilities of the variable interest entities of $40.8 million and $38.2 million, respectively. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAssetReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036263327784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">$ (48.4)<span></span>
</td>
<td class="num">$ (38.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(66.2)<span></span>
</td>
<td class="num">(62.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">22.6<span></span>
</td>
<td class="nump">25.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income tax expense</a></td>
<td class="nump">141.3<span></span>
</td>
<td class="nump">167.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ehc_AdjustedEBITDA', window );">Total Segment Adjusted EBITDA</a></td>
<td class="nump">276.3<span></span>
</td>
<td class="nump">285.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(48.4)<span></span>
</td>
<td class="num">(38.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(66.2)<span></span>
</td>
<td class="num">(62.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">(Loss) gain on disposal or impairment of assets</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense and amortization of debt discounts and fees</a></td>
<td class="num">(39.6)<span></span>
</td>
<td class="num">(42.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">22.6<span></span>
</td>
<td class="nump">25.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLoss', window );">Change in fair market value of equity securities</a></td>
<td class="num">$ (2.5)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_AdjustedEBITDA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted earnings before interest, taxes, depreciation, and amortization as defined in the Company's credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_AdjustedEBITDA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140036261003944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Revenue from Segments to Consolidated (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 1,333.6<span></span>
</td>
<td class="nump">$ 1,230.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">1,059.3<span></span>
</td>
<td class="nump">959.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Inpatient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">1,036.2<span></span>
</td>
<td class="nump">942.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember', window );">Inpatient Rehabilitation | Outpatient and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">23.1<span></span>
</td>
<td class="nump">17.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">274.3<span></span>
</td>
<td class="nump">270.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Home health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">224.9<span></span>
</td>
<td class="nump">219.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice | Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 49.4<span></span>
</td>
<td class="nump">$ 50.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_InpatientRehabilitationSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ehc_InpatientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ehc_InpatientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ehc_OutpatientandotherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ehc_OutpatientandotherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ehc_HomehealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ehc_HomehealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ehc_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ehc_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>ehc-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:ehc="http://www.encompasshealth.com/20220331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ehc-20220331.xsd" xlink:type="simple"/>
    <context id="i3531353b480a49df89986d34e925eca7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i28ab1ceed8dd4ef4ada8933e4e54a5ff_I20220421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2022-04-21</instant>
        </period>
    </context>
    <context id="i91231db0dbac4520908543814857793e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if5385614e8bd4b7081a64d6cba8c9291_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i557a32613c404e579eedda986be748b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i027580bf78e446f9a1be1690bafd5055_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i05a3cf2b8383461c94f1b27d662f994c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i14493ec43a054a37a265fe545acfae34_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb8ac1140bb546ffbe29c3297dfca0ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5eaecfe3f96400b8f59e7967a61104c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd0a16468f25461eaa2eada251e33da7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0db82f105f774106945877e84af0cc3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i576c769a2bf3490093c90b7f2fd1d565_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i33aac6e817b84b2fbedbc7be7dd1d4e1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i70ffad11b2f64e0dafb9e8f6c59e3600_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia54089ca96194a95b6a9346ce2f33fc1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i74ec993229934505b223d7e527442ba7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2c072fe2fb1348d68775f83549979f34_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icf0cae1f6a4a43f293213bf2aea45abd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4efb9bf256844561b1d2a7fbb842421e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i288ad08f50a44c848d9ae9b15441d2dc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id2bafe8e3cac4147865d701ae99d921c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1beec8de6cfd45d8b5f89af034ba4093_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i78cf1e166e974c539ccf23447cde940b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b3a08ff093f420c99340aa4e1150824_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i36bea0bf3d9144caa0f8df9028b1dc79_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief9203a9500e4500971e238696312597_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f5b35fb51614954816b817c495b5d51_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c1ae97e068e4cff900ec3092c7f4f04_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i036534c3f4a5413e8de12b55fc657fe1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i622188ef7ebe41c680e18a9991186c28_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i117392f9d15f489cbe838f6b1ce3da6b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4cd1f1cb74084bb3b9abaf864a2e064b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i013c277808804f42827dd89d591b0f7c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i972509dbc5b6416a9dd899dc87ebd08b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia12ac2a64d1641ba80099f0e2982b794_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5d9c8cd1de2c4f13933b82337c8517f4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9121edbdc21a47948aa5552e7f4240fb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0c6a42e404cd4326b6c8697c3add3bf6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8aff770be2384e718613ee73e75c9d8c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i20db95e52d4340b89253015dadddfce8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i22e38d1a9d8c492983b5fe7bbc4a8114_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6ed9eb823c2440d48088c6f6ef06b87d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3d2de80a9ea142658a08aff95c64af19_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4a399017e33d42b2bf858dd4d6a9c0e1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i915084ab4bdd4e1689693609d0ef6b82_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7c8d685705124a67ba3a91dabc43a282_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6ef7afb70a7f4b27a6a3cefbe6320e01_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1745bec828ac49b1818f4f9a5135a42c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibcc4e89df88e43cfbef7da1f99240779_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i39f739399fa44a149e9c4093be040820_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i84bb98c1d43644a39513c7d343c7ffec_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i75ecf985b4164bff9fa7316be1a7474a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4d2d7e560f1441bca94bad9f8a814402_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibab4a62b6ba444c883fdc49380be38fb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i79fb50ea872e4a0ca7a8afe1c90123b2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4d5c49ba6ba94af8960ab5d485207093_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia0b8349513794a3294fb7992b1d132ab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iacc1a722e4414822b283443f547fa10b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2903b136be2a4ee89a98bcd8d1360b19_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iad23a50207a142ab9c646522e8434d32_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifc33a324f2c0445d95695eba2ca8ef8a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i599a045bbb1143038e76b94639d195fe_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i817f1c2f30674f89942c2d872a2ba105_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie4efd11aa331481487fdb712ec4c0ac2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7aafa9f641b84852af3d2fb5f01099e5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia19311f0969f4d318270fc2cc5ed5d0a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i816cdecfdda244c89818aaa109f9acec_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1b5fd3df85ec4c319b4bc0219d463e49_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9f172a6226384fecb27f5515fca37ab0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9457af3cee914d029434093eeae9c559_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i34d269849de54ca9aef661bdd4496c95_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibdc9747447a24dfdb2bc0d42c7649f61_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic5a3de3efd3d4a48ad46ff05596eb38e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i58a18ced43b9420abf4802064fa8951d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib164992f54584ed39d8de9248794b352_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i886e59e872c246ddb347cb38ec9a1160_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1416420c060b4050821f6eee0ac9a457_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7135e07b877d4f569de8504b4686a6ee_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibded32670d67459ca73c7300d578990b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id491747513c74175b42ca0a5e71438c0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:PatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i852f28e7df1d406994d8a3bd00d23115_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i16d0b325d18e4ddd9457d92019914f3a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id807874539934f0e9ed224fbc31c78b6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3313d74b1254472598b291ece765395d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i33b51c955001459e8173f274705cb785_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i293d6fb19adf46f18fb8ccfda949db85_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if99233a02a77455db55959da352fbfb2_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i29d56a10f17343bcaab0acd8dbcc3b4e_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i9b102d83166e4bc490cf1528eaade88d_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i629dd79718e44513b2d60bcae0d6f51a_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="ida96cd2b0e2746e39759c8c22c9bf7a5_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i6c4b218e644546e8963de5f7bb2c0e6c_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i53b09e480b6142de9d92527b0b5b9375_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i93824ec251c546cbb304b0de1adc1bc2_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="ica57130d0db94872b9b3a94cd9e7c39b_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i9bcefb1b301b491f9f6a61d393edcd39_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i6861efcf5c8e4791b4cf9947c83117e8_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i944fc8295c154979b4c5e2ae485eb03b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i090568ccb08b421a8703daa2d9b4d2c9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:SaintAlphonsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie1e6082c727c4be9853cda9efc66e5bd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0b4d6eb8f1624f5780188f869aa798da_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ice6f42f88a4d40f2bb746a1622dc9ab6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ice148ce40d284c87b5c5abf7edb0c698_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if2382ba129c3486f990cf1eea014c79c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5a79fe1564694ed59ea5acbff6dafa13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibff53e67228d4423a59336248f7e8a19_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idace690b6bd742fbb796490135ea208a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05147760daea434eab785f9bb77eed18_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i518ef403619b45068725459a3694675c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i40e9e244d5e64ca7bf0040d18e4fa154_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i54ff49d44cd5451da021a1dcfdd01a1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b70c8bc77434fcf8e8e9acd22c58c45_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6856f14b9e514819a81cb49c920770ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2cbef4d679154efc951e5c1786ca6bae_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idfab5bb13d1544f8b92a234bde75f0a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d86755ee8bc4045b33ab465c664b7a9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia263377add53435796d020a9fae4da89_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb23149d81b145d683c4131122e0613c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i135485ea2e124322b3cb9b6b28d207bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2432d02ccbce4152a2ebbc620946b0eb_I20211209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-09</instant>
        </period>
    </context>
    <context id="ib87798305a954bd68f594d703bee708a_I20211209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-09</instant>
        </period>
    </context>
    <context id="if3dee57d45ef4967a06bff2bb1519d67_I20211209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-09</instant>
        </period>
    </context>
    <context id="i9c40d9c98c634e8d9e33b00ff58b2939_I20211209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-09</instant>
        </period>
    </context>
    <context id="i37b439614a834d5fa4da55874df55dc4_I20211209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-09</instant>
        </period>
    </context>
    <context id="i825551a2736a4a0cbed667eb8cc2cca2_D20211201-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i368ed4d7ad354f0cab721ebb36d47844_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="id320e21f82b8400fadbbfe37b609516d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i39fdefb343d340ef94ee64a4ec92f2ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b46f0824cfc44a390637375c885461c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6ea604dd0d04859a2c8cc03396c69bb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i80c5200a89154eb89d8ae5eb77290c4e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifc945c722fc841aa95f6763fdd77a02c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i61423539f4b4453f9ea5b7bbc38883be_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icddbe6c9e899402ab0cd9e710f9d31ea_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idfc43ca1f96d45b5a0cf5b2d38ae5a60_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia8d214445f7041df915d431f92d7a70e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9a7dc7ae27134c52a55c357b78dd3cff_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8ac35e30b3384503867b9b29c33fcd12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39472c9a755a464e8a2cc3ca1799e165_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3e4ffea3ce24cf29b0a92241c3ecd15_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia606fb5d54a34f2fbc455e7223986acc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79fc6be415b54a58b5d2c217fab0f29b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i59d953168b134eaba7885b47f0cda8fd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if034be9bc98b47cf8c97bf47ab9ea038_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a7b858f19554add8379afca7b705865_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7b444a6f37fa4de1992c65a1698b0b20_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i64624582638a400485740c96311c1394_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if83c0d9db5394bde9d8b0c44800f9c9b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i91e7df9c82b3434983f969e537117392_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i831cf2390be0435eaadf768914370cbe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i248a1de457614c1c9d9c3795a5c5c6c2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1d4f1aa977184bbbbfe5144289d41e12_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i78e41d6d12974156b84238a2892182c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id07fee3147fe47a5868dde0e75b961bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i47572d62b06342fe93e19a7e55a4943a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i73e315035b554c8aa1875547b4630339_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3c9476be5bf24acb9f60b2167f82eb5e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02839eb8521947c8b4c9744e0ac23d7a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3fb81c7757df47a7872a6c2daef100ce_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1e88c315ef4c4d62ade591e994da366d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2dbc9fad2e274e4eb37fa988811ee2a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i94daa3156e1a45adbf33553663dd83fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibfcf9427557d461fbbebdf16a3b33843_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i74ea71ca5cf549bf8c8f2f8fc6a335b2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic05d7792773941d2b4f0ae2bfd35090b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e473304e17c4251a584a305f441fc45_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic402c5736b164f289ef558cc5bdc16b3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7c080a5046b140e19a17e88f98ac2e72_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib5708fcd82894c208dadd2fea50fa007_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc43445772fb4f7cafc73de38ead4bd0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab66f41dc66040f2856dd6db44d58787_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i41ff03c5cba2460d8cadd19e31f7ce2a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idedd404a57704848af9e8d99770a3e84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ccf6303eceb4c8882cde606d6046e98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib55408ef11da47b9a9ab25b915d6f44a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie932836488174026b6c0bb470e9937e1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1dcc02c84fae47a2a3f1e83d9186a6a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8628daca39564875a3d296261d4ddd8a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic22004d0542449c28c0dbfbf72a7738f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9905941e5e914330a739320a89ef96fa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i23319d48cfb542baa5100da894e4efd7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11f4eda008a3429e868ab8b5af645b77_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic01094ffa7604c71a90a6271b77d95ef_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if3198110221a45879053dbae18100b29_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idc081404cf0e4077909986bdf740a73b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3075bca9de3b4ee89c80a477c6851ee1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i53bdf1d6ecf041d7af98f062aa3d7212_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i96474acd4c0142dda31b7d96f99582f1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i79515ce75bf44070a97a38241f1e7d61_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4f992e9347194664b26f07fbc9a93d86_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iefcb7a67042b48cfb0c73139f067b3df_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia9f95cf921114fbfb5398dadad725123_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibabc6d389eb7499992b42a9d1f4b3120_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i407e8fe2e2364e5d91792421c5019898_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia036ff2cbdc34388aff7771c98304af2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie391de2d22ab44fda7310331622d23d1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i77fc9042b9d744ba9d2f6c315981cd86_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6c857df9e79e4435ab0c5961811291c6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4f9a417ef1c843ab8b66fc1f0fe8a378_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:InpatientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iee63741659464a8288af029c2e936705_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:InpatientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i77101558c6ed4f6da49ce1c65da87750_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:OutpatientandotherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iee418860b1b04eaabf4f28548bafff1c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:InpatientRehabilitationSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:OutpatientandotherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i06506ef5bc914c559c598b5f9589d0b3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib65ddfd24dd24997b9a0d223f2e38f80_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HomehealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4931e9bee9c14ae88ae967c8efd7c1da_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i00989e00d19949b0b76add02ac72e8dc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ehc:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="state">
        <measure>ehc:state</measure>
    </unit>
    <unit id="segment">
        <measure>ehc:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="entity">
        <measure>ehc:entity</measure>
    </unit>
    <unit id="hospital">
        <measure>ehc:hospital</measure>
    </unit>
    <unit id="location">
        <measure>ehc:location</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80L2ZyYWc6N2RiZWE3MTliMmQ5NGVhODlhMDk4ODQ3NjdlZDM1MDcvdGFibGU6NTI5NmM5NWE2MzljNDI1Yjg1MmEyNTI2MDIyYjlkYzkvdGFibGVyYW5nZTo1Mjk2Yzk1YTYzOWM0MjViODUyYTI1MjYwMjJiOWRjOV8zLTEtMS0xLTEyOTYwMQ_0d412d1e-7347-41a7-9ce5-3589c7aab45f">0000785161</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80L2ZyYWc6N2RiZWE3MTliMmQ5NGVhODlhMDk4ODQ3NjdlZDM1MDcvdGFibGU6NTI5NmM5NWE2MzljNDI1Yjg1MmEyNTI2MDIyYjlkYzkvdGFibGVyYW5nZTo1Mjk2Yzk1YTYzOWM0MjViODUyYTI1MjYwMjJiOWRjOV80LTEtMS0xLTEyOTYwMQ_e4344d6e-7d9d-4874-b8c9-2ff954692c4c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80L2ZyYWc6N2RiZWE3MTliMmQ5NGVhODlhMDk4ODQ3NjdlZDM1MDcvdGFibGU6NTI5NmM5NWE2MzljNDI1Yjg1MmEyNTI2MDIyYjlkYzkvdGFibGVyYW5nZTo1Mjk2Yzk1YTYzOWM0MjViODUyYTI1MjYwMjJiOWRjOV81LTEtMS0xLTEyOTYwMQ_895dc436-2077-4901-9fd6-6d997e02deca">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80L2ZyYWc6N2RiZWE3MTliMmQ5NGVhODlhMDk4ODQ3NjdlZDM1MDcvdGFibGU6NTI5NmM5NWE2MzljNDI1Yjg1MmEyNTI2MDIyYjlkYzkvdGFibGVyYW5nZTo1Mjk2Yzk1YTYzOWM0MjViODUyYTI1MjYwMjJiOWRjOV82LTEtMS0xLTEyOTYwMQ_978dc247-7c11-41dc-b9ef-8c977d44d53f">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80L2ZyYWc6N2RiZWE3MTliMmQ5NGVhODlhMDk4ODQ3NjdlZDM1MDcvdGFibGU6NTI5NmM5NWE2MzljNDI1Yjg1MmEyNTI2MDIyYjlkYzkvdGFibGVyYW5nZTo1Mjk2Yzk1YTYzOWM0MjViODUyYTI1MjYwMjJiOWRjOV83LTEtMS0xLTEyOTYwMQ_c96ccb0a-9d36-44a5-9ee3-e7b1d20cad46">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTgx_8a8662e9-b2a0-436c-b061-56adc95e8093">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6MmE3YWI3NDFkMDQ2NDQzNmFhZTFlOTkzMzljOTVjNTQvdGFibGVyYW5nZToyYTdhYjc0MWQwNDY0NDM2YWFlMWU5OTMzOWM5NWM1NF8wLTAtMS0xLTEyOTYwMQ_d7337f9d-78a7-4f52-898f-c9f167b8f17f">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xNTE_99e3a940-02ad-481b-b310-d2a9ed3ade96">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6MmNjNDUzM2VlMjY0NDI0NGFhYWM0OTkxODBlOTBhZGIvdGFibGVyYW5nZToyY2M0NTMzZWUyNjQ0MjQ0YWFhYzQ5OTE4MGU5MGFkYl8wLTAtMS0xLTEyOTYwMQ_65f5258f-7756-4ad6-982f-4cfd352736ff">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTgy_955c408d-739b-4a4a-aaad-cb8fbaa7b9c3">001-10315</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTg4_4436db63-6e4f-421b-af5c-a34f084608fc">Encompass Health Corporation</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6MmE4NDNhYmMzZTRjNGIyYmIwNDY2YjdiNTA4NDM5M2IvdGFibGVyYW5nZToyYTg0M2FiYzNlNGM0YjJiYjA0NjZiN2I1MDg0MzkzYl8wLTAtMS0xLTEyOTYwMQ_ec40fa6d-1b3f-46c6-85a3-4e2abd333f7a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6MmE4NDNhYmMzZTRjNGIyYmIwNDY2YjdiNTA4NDM5M2IvdGFibGVyYW5nZToyYTg0M2FiYzNlNGM0YjJiYjA0NjZiN2I1MDg0MzkzYl8wLTEtMS0xLTEyOTYwMQ_f90fc723-be22-409e-bba3-952dc7b728e5">63-0860407</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTg5_f935c5ac-7891-4ea6-a9aa-d946ed302661">9001 Liberty Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTc5_41cdf28e-1402-4bc7-8cc5-83676319f17c">Birmingham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTkw_46c315a4-176f-428f-b0f0-2a638d592cc2">AL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTgw_8388b9fd-172c-4ebc-b91f-070bbaedcd2f">35242</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTg0_da582875-1f42-48eb-a4a9-d43aa390c41c">205</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTg1_4945a640-e203-4bcd-9023-72fc48e80e59">967-7116</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6NThlMWQyOWJhZmRiNDVjNWExODFjZWU4MTY5NWZkYzcvdGFibGVyYW5nZTo1OGUxZDI5YmFmZGI0NWM1YTE4MWNlZTgxNjk1ZmRjN18xLTAtMS0xLTEyOTYwMQ_bee71ddc-612a-4c0a-b38f-07aa4e3b1b14">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6NThlMWQyOWJhZmRiNDVjNWExODFjZWU4MTY5NWZkYzcvdGFibGVyYW5nZTo1OGUxZDI5YmFmZGI0NWM1YTE4MWNlZTgxNjk1ZmRjN18xLTEtMS0xLTEyOTYwMQ_9d81e442-42af-4caa-bd93-958e22d73b24">EHC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6NThlMWQyOWJhZmRiNDVjNWExODFjZWU4MTY5NWZkYzcvdGFibGVyYW5nZTo1OGUxZDI5YmFmZGI0NWM1YTE4MWNlZTgxNjk1ZmRjN18xLTItMS0xLTEyOTYwMQ_8056410e-1447-48a0-acc8-6d50f238ae01">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTg2_31fe2786-5d94-4bd9-b819-a949dd52c029">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTg3_e6172e6d-d82b-4390-8e37-723fb0d5cfea">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6Y2I5ODZkYTMyNzJkNDQ0MjgxYzdhNjMxNWE5NmVmNjIvdGFibGVyYW5nZTpjYjk4NmRhMzI3MmQ0NDQyODFjN2E2MzE1YTk2ZWY2Ml8wLTAtMS0xLTEyOTYwMQ_6b5dcbd3-8361-4a8e-bb43-5e097710571b">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6Y2I5ODZkYTMyNzJkNDQ0MjgxYzdhNjMxNWE5NmVmNjIvdGFibGVyYW5nZTpjYjk4NmRhMzI3MmQ0NDQyODFjN2E2MzE1YTk2ZWY2Ml8xLTEtMS0xLTEyOTYwMQ_2a894111-af92-4e66-b294-76b5ac67d7c7">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGFibGU6Y2I5ODZkYTMyNzJkNDQ0MjgxYzdhNjMxNWE5NmVmNjIvdGFibGVyYW5nZTpjYjk4NmRhMzI3MmQ0NDQyODFjN2E2MzE1YTk2ZWY2Ml8xLTMtMS0xLTEyOTYwMQ_12694c60-8c26-4aad-b9cc-5fbd625f00dc">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTgz_0a6671af-cd88-47e3-93bd-57229ebc2011">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i28ab1ceed8dd4ef4ada8933e4e54a5ff_I20220421"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xL2ZyYWc6NmM2ODFjNWYxZTJkNDUzOWE1Mjk3NGU2ODFmNDYzYWMvdGV4dHJlZ2lvbjo2YzY4MWM1ZjFlMmQ0NTM5YTUyOTc0ZTY4MWY0NjNhY18xOTA4_15756c3c-6534-40e1-bae8-ec727f4a910b"
      unitRef="shares">99802649</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMy01LTEtMS0xMjk2MDE_1cc480da-cb14-4f4d-9ad4-1119fa22016e"
      unitRef="usd">1333600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMy03LTEtMS0xMjk2MDE_70a7235b-0201-4911-9461-7ac7c5d3b533"
      unitRef="usd">1230400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNS01LTEtMS0xMjk2MDE_242d3901-3d09-4d0e-95db-8371b6322109"
      unitRef="usd">776000000.0</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNS03LTEtMS0xMjk2MDE_95a0f1d2-8073-4b3e-9ec2-cb6c475bf12e"
      unitRef="usd">687200000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNi01LTEtMS0xMjk2MDE_a862fd7b-79d7-42ec-a413-f25b86080da4"
      unitRef="usd">182100000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNi03LTEtMS0xMjk2MDE_612aec22-271d-4397-a3b6-1e2004419ab4"
      unitRef="usd">162300000</us-gaap:OtherCostAndExpenseOperating>
    <ehc:OccupancyCost
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNy01LTEtMS0xMjk2MDE_12540313-c8ec-4f69-9dd7-afa4a5197581"
      unitRef="usd">20900000</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNy03LTEtMS0xMjk2MDE_cc44249b-df3a-4ef9-9619-5c1dcc335cfe"
      unitRef="usd">20200000</ehc:OccupancyCost>
    <us-gaap:SuppliesExpense
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfOC01LTEtMS0xMjk2MDE_e8b7f540-6277-488b-91ad-5c3dc12a9368"
      unitRef="usd">56100000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfOC03LTEtMS0xMjk2MDE_5c8ab23f-5e6c-4ace-8e7b-0a78aba36d13"
      unitRef="usd">51900000</us-gaap:SuppliesExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfOS01LTEtMS0xMjk2MDE_7e039b86-ab55-4a13-8fe8-547b817afb8f"
      unitRef="usd">48400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfOS03LTEtMS0xMjk2MDE_9b113b7b-04f6-464b-b587-302d7e94b02c"
      unitRef="usd">38600000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTAtNS0xLTEtMTI5NjAx_1020e3ad-20d2-4370-aecd-d08b2d7bb683"
      unitRef="usd">66200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTAtNy0xLTEtMTI5NjAx_7e2a729b-bf4e-4010-ac4a-3d0842100b77"
      unitRef="usd">62500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTMtNS0xLTEtMTI5NjAx_b635c72f-ce25-42ca-a013-1906567e84e3"
      unitRef="usd">1149700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTMtNy0xLTEtMTI5NjAx_37fd6ead-b185-4efe-a128-2c759249a354"
      unitRef="usd">1022700000</us-gaap:CostsAndExpenses>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTQtNS0xLTEtMTI5NjAx_54fd02dd-6e4e-4abd-be80-6de3ac877484"
      unitRef="usd">-300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTQtNy0xLTEtMTI5NjAx_7efcc42b-3c13-4ac6-bab8-663908281984"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpense
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTUtNS0xLTEtMTI5NjAx_8fbded54-eb41-4a85-a15a-2a21ca2f3265"
      unitRef="usd">39600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTUtNy0xLTEtMTI5NjAx_8c60e4cb-ed22-4218-9f7b-c5086d5b7982"
      unitRef="usd">42800000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTYtNS0xLTEtMTI5NjAx_c58708bf-f0b5-4a78-af98-573f16256783"
      unitRef="usd">-3600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTYtNy0xLTEtMTI5NjAx_0a15f2a8-fe8e-4238-ae85-2d1df5022e12"
      unitRef="usd">1400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTctNS0xLTEtMTI5NjAx_080b7711-2688-467e-922a-e342dd9b2c36"
      unitRef="usd">900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTctNy0xLTEtMTI5NjAx_cf67ca7d-d8fa-418b-9a64-2df6261f24d8"
      unitRef="usd">1000000.0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTgtNS0xLTEtMTI5NjAx_6c3738a3-4a3c-46b4-926b-aa7de7d17497"
      unitRef="usd">141300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTgtNy0xLTEtMTI5NjAx_82a2b056-e635-41fe-a508-c71bab9f1eae"
      unitRef="usd">167300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTktNS0xLTEtMTI5NjAx_b2cb674c-1330-4ed2-bece-3475266c25df"
      unitRef="usd">31200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMTktNy0xLTEtMTI5NjAx_13e847ea-0d05-470c-86d0-635f7c0f60e6"
      unitRef="usd">34500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjAtNS0xLTEtMTI5NjAx_bfc47e69-7c5a-4ee5-9d10-a81053e47d09"
      unitRef="usd">110100000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjAtNy0xLTEtMTI5NjAx_c337e573-d378-4f77-ac3c-62631bee4f38"
      unitRef="usd">132800000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjEtNS0xLTEtMTI5NjAx_7adb4485-93db-49ab-a662-80b88905ef1b"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjEtNy0xLTEtMTI5NjAx_e735989c-5bc6-48ee-977d-19a76281b848"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjItNS0xLTEtMTI5NjAx_1d1fffb1-53e9-4b62-a310-dc33a7c36760"
      unitRef="usd">110100000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjItNS0xLTEtMTI5NjAx_aa438da0-3dae-4574-91f7-a3488beed7ad"
      unitRef="usd">110100000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjItNy0xLTEtMTI5NjAx_21917c71-ce44-4b02-8afc-b68745c24ca0"
      unitRef="usd">132800000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjItNy0xLTEtMTI5NjAx_e4a44361-5fbf-4adc-805a-e4ffe0d73b44"
      unitRef="usd">132800000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjMtNS0xLTEtMTI5NjAx_59b575b3-d981-4df7-b8bd-01e739ab2830"
      unitRef="usd">22600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjMtNS0xLTEtMTI5NjAx_7a2c4a6a-1d73-467e-9572-e682e1234723"
      unitRef="usd">22600000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjMtNy0xLTEtMTI5NjAx_5a8aa03a-22d8-402e-93b7-ea61249110b1"
      unitRef="usd">25500000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjMtNy0xLTEtMTI5NjAx_a4dff9b7-c2f1-4b46-ab13-6b72ea1f3861"
      unitRef="usd">25500000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjQtNS0xLTEtMTI5NjAx_ed0fc66c-3993-46b4-8e43-429d81cbaed6"
      unitRef="usd">87500000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjQtNS0xLTEtMTI5NjAx_fbf15bbd-f3cb-470e-9ee9-940a5d71dad7"
      unitRef="usd">87500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjQtNy0xLTEtMTI5NjAx_1a72859a-384e-4027-94bc-fc9c67f2d30a"
      unitRef="usd">107300000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjQtNy0xLTEtMTI5NjAx_75451e88-30c5-4016-ae26-4bb241f3ebab"
      unitRef="usd">107300000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjktNS0xLTEtMTI5NjAx_332ee1ac-9e91-4d0e-873f-72d9af286329"
      unitRef="shares">99200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMjktNy0xLTEtMTI5NjAx_5ed23d5b-7a48-4815-9f10-fbf300ecbb03"
      unitRef="shares">99000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzAtNS0xLTEtMTI5NjAx_3c64b99c-8018-460e-bc5e-9ffd18b1a9c7"
      unitRef="shares">100200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzAtNy0xLTEtMTI5NjAx_85ca85b7-2dcc-468f-92fe-e19bc9b888b1"
      unitRef="shares">100200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzMtNS0xLTEtMTI5NjAx_65032a8d-dbbf-45ea-bcfa-19343724c254"
      unitRef="usdPerShare">0.88</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzMtNy0xLTEtMTI5NjAx_71647d60-55a2-47b2-ab17-de07ede1dd05"
      unitRef="usdPerShare">1.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzQtNS0xLTEtMTI5NjAx_a5ee8106-d931-46dc-b8c2-4ca160a574c4"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzQtNy0xLTEtMTI5NjAx_658bff30-5261-4dcf-8859-828d7840f5ab"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzUtNS0xLTEtMTI5NjAx_99930b2f-0388-410f-86e1-66bf31b97e36"
      unitRef="usdPerShare">0.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzUtNy0xLTEtMTI5NjAx_7e99a04e-3c17-413d-b238-6b51e7b143c3"
      unitRef="usdPerShare">1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzctNS0xLTEtMTI5NjAx_edd4849c-6e31-4ad5-bf81-d10911f45960"
      unitRef="usdPerShare">0.87</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzctNy0xLTEtMTI5NjAx_10cbf231-6366-4781-99f8-66546798bc0e"
      unitRef="usdPerShare">1.07</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzgtNS0xLTEtMTI5NjAx_4e9b2e40-a065-4d51-a111-07e113900cfe"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzgtNy0xLTEtMTI5NjAx_ff05c29d-a683-460b-804f-83b92d0e5515"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzktNS0xLTEtMTI5NjAx_d0e269c1-d349-47a8-aec1-4e10f8cecff1"
      unitRef="usdPerShare">0.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfMzktNy0xLTEtMTI5NjAx_896a436a-9920-47a8-b884-c9d9ece09c7c"
      unitRef="usdPerShare">1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNDItNS0xLTEtMTI5NjAx_3139e4ad-7f77-48a9-b395-4e06d6fd2fe0"
      unitRef="usd">87500000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNDItNy0xLTEtMTI5NjAx_7d24d382-7494-4f9f-8df9-c0c83aa337ef"
      unitRef="usd">107300000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNDMtNS0xLTEtMTI5NjAx_9c39c348-7509-40a7-ba6d-6e45ef78ee87"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNDMtNy0xLTEtMTI5NjAx_5016b20f-208d-4ee5-8f8c-0b2854ebc492"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNDQtNS0xLTEtMTI5NjAx_a7c4a5b7-20fe-4ec5-a49f-8d1a165c8fb1"
      unitRef="usd">87500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8xOS9mcmFnOjQ2MDc4ZjlkZDYyMzQwODhhYzJmYTFkZGM1NzRiNjRiL3RhYmxlOjNhMmNjYTViYmQ2MDQ1ZjA5YTgwZDQ4NWJmZTJjZjEzL3RhYmxlcmFuZ2U6M2EyY2NhNWJiZDYwNDVmMDlhODBkNDg1YmZlMmNmMTNfNDQtNy0xLTEtMTI5NjAx_75a1e431-3561-4cca-8891-79001c8c4767"
      unitRef="usd">107300000</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfNC0xLTEtMS0xMjk2MDE_25cf0e48-4dfd-43ef-a905-70bb4bb1c4a2"
      unitRef="usd">94200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfNC0zLTEtMS0xMjk2MDE_5ef4cbcc-adc1-4f1f-a268-f2e43e5b0d90"
      unitRef="usd">54800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfNS0xLTEtMS0xMjk2MDE_45dd6e83-e1cb-4f17-98da-96bf339c4985"
      unitRef="usd">61000000.0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfNS0zLTEtMS0xMjk2MDE_2f164129-a4ab-4403-afb6-e53333f34e61"
      unitRef="usd">65100000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfNi0xLTEtMS0xMjk2MDE_d10aa4d8-ebaa-49e4-a489-a39fdddb73b9"
      unitRef="usd">683500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfNi0zLTEtMS0xMjk2MDE_603efe03-f72a-4029-b7bc-9e1fc5442c58"
      unitRef="usd">680300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfNy0xLTEtMS0xMjk2MDE_24b1ed1b-b319-44c8-a1e6-a693663f9ffe"
      unitRef="usd">111000000.0</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfNy0zLTEtMS0xMjk2MDE_e365b3b4-ad8f-40b3-85a4-9a848229f267"
      unitRef="usd">121200000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfOC0xLTEtMS0xMjk2MDE_98f8696c-3be0-480a-a9d4-dce8d1622228"
      unitRef="usd">949700000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfOC0zLTEtMS0xMjk2MDE_314ad60a-214d-4206-92b6-089b8f95ecb3"
      unitRef="usd">921400000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfOS0xLTEtMS0xMjk2MDE_bc6a1a02-6589-4231-b5ca-9fbe360f47ad"
      unitRef="usd">2667100000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfOS0zLTEtMS0xMjk2MDE_24eb4f5d-e41d-4539-bae2-62a0b2259a52"
      unitRef="usd">2601600000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTAtMS0xLTEtMTI5NjAx_12efd679-d821-4bec-b397-58933a80d77d"
      unitRef="usd">236800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTAtMy0xLTEtMTI5NjAx_8f5fd09e-4af5-4b1d-bbaa-275732be0097"
      unitRef="usd">242000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTEtMS0xLTEtMTI5NjAx_3a3d3b24-5ded-4c91-a819-b4d7fcd7385f"
      unitRef="usd">2456500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTEtMy0xLTEtMTI5NjAx_3f195f29-92f3-452f-a042-0221e8b12154"
      unitRef="usd">2427900000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTItMS0xLTEtMTI5NjAx_495c6620-8436-4bed-99a8-f051590b4e2c"
      unitRef="usd">410600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTItMy0xLTEtMTI5NjAx_631e6500-c5b8-4ad7-aeee-a14a1c3093d0"
      unitRef="usd">417500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTQtMS0xLTEtMTI5NjAx_861d7b3b-0150-41fc-b7c7-7baafc736522"
      unitRef="usd">223300000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTQtMy0xLTEtMTI5NjAx_c815d6da-b808-4cde-8c06-59615f41bb79"
      unitRef="usd">254500000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTUtMS0xLTEtMTI5NjAx_7f8cccaa-f1ba-40bc-ad42-fcd4ee98eeb5"
      unitRef="usd">6944000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTUtMy0xLTEtMTI5NjAx_0f538598-45b6-4f09-a95f-5f81800fa896"
      unitRef="usd">6864900000</us-gaap:Assets>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTgtMS0xLTEtMTI5NjAx_033896b7-01dd-4c9c-87af-a6146c8a2c39"
      unitRef="usd">42800000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTgtMy0xLTEtMTI5NjAx_47f8b27e-dffb-42e9-bc3e-ac5fa3908651"
      unitRef="usd">42800000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTktMS0xLTEtMTI5NjAx_7394c8ad-3c2e-477b-bf3a-af579a630026"
      unitRef="usd">38400000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTktMy0xLTEtMTI5NjAx_bd3b9cf0-5d40-4de4-870b-4cd1ee008dac"
      unitRef="usd">38400000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjAtMS0xLTEtMTI5NjAx_827de33c-12b3-42e1-ad83-01c8410b4d7b"
      unitRef="usd">147300000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjAtMy0xLTEtMTI5NjAx_65d146ea-11b6-4959-b4ba-b14fcae04add"
      unitRef="usd">137600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjEtMS0xLTEtMTI5NjAx_017aeaa6-ff88-45e4-a4ec-959b596b3215"
      unitRef="usd">526000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjEtMy0xLTEtMTI5NjAx_d42fd917-eaa9-4d2d-80ca-073d29f444fa"
      unitRef="usd">530000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjItMS0xLTEtMTI5NjAx_70f59388-93ed-481e-b3a1-75e306f6bdda"
      unitRef="usd">754500000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjItMy0xLTEtMTI5NjAx_2290604b-e574-4699-8297-de594924d6c5"
      unitRef="usd">748800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjMtMS0xLTEtMTI5NjAx_afa52b39-88cd-4025-8f3e-5d5e252b016c"
      unitRef="usd">3221300000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjMtMy0xLTEtMTI5NjAx_1dc3cb3b-f773-4ce3-a801-36e30b0fb843"
      unitRef="usd">3243900000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjQtMS0xLTEtMTI5NjAx_1515784e-7a71-4f2b-bf6c-f991c8040e2c"
      unitRef="usd">208300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjQtMy0xLTEtMTI5NjAx_07cee54d-beff-41aa-abb5-2a50977fc9af"
      unitRef="usd">213100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjUtMS0xLTEtMTI5NjAx_3252cfee-0aa5-407a-939a-1bbd3b6e80d6"
      unitRef="usd">89700000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjUtMy0xLTEtMTI5NjAx_cf573116-ad60-4200-8f01-a6d36f50a0eb"
      unitRef="usd">86700000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjYtMS0xLTEtMTI5NjAx_668a520e-5ea1-4c51-a045-34cf49c5f886"
      unitRef="usd">178600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjYtMy0xLTEtMTI5NjAx_7480d374-27a1-4ff2-abb5-6a8b7f15b963"
      unitRef="usd">173200000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjctMS0xLTEtMTI5NjAx_2cb1ea28-7786-4c0c-a4a7-5bfc9b59bd7d"
      unitRef="usd">4452400000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjctMy0xLTEtMTI5NjAx_14071f8b-05d6-4fcc-89d3-c899f2583088"
      unitRef="usd">4465700000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjgtMS0xLTEtMTI5NjAx_91a86abc-3432-4742-b61f-f6ef7a2f9baa"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMjgtMy0xLTEtMTI5NjAx_49e4a846-7f1c-4a9a-9273-3b4f75f9f1e2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzAtMS0xLTEtMTI5NjAx_76243aca-7fc2-4eec-9573-664a24382c2e"
      unitRef="usd">43200000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzAtMy0xLTEtMTI5NjAx_24a3a4bd-7aad-49eb-a4f9-b17a38b32e75"
      unitRef="usd">42200000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:StockholdersEquity
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzItMS0xLTEtMTI5NjAx_03fe291a-ae8b-4fff-897d-002132e5e41c"
      unitRef="usd">1973500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzItMy0xLTEtMTI5NjAx_015413bc-8a5c-45a0-bf5e-106fadcbb73c"
      unitRef="usd">1911300000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzMtMS0xLTEtMTI5NjAx_fc2fedf2-d059-4e24-b5fc-0c02d43892ee"
      unitRef="usd">474900000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzMtMy0xLTEtMTI5NjAx_6c6c6d7e-e54a-42db-b8fd-31ffa781003d"
      unitRef="usd">445700000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzQtMS0xLTEtMTI5NjAx_324a4b36-89e6-4f13-bf1c-8efc662bfd5f"
      unitRef="usd">2448400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzQtMy0xLTEtMTI5NjAx_f02f1253-7df9-4393-a53b-46276311a712"
      unitRef="usd">2357000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzUtMS0xLTEtMTI5NjAx_376f026e-0a45-4eb7-8571-082b11d62254"
      unitRef="usd">6944000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzUtMy0xLTEtMTI5NjAx_b8465d0d-15b4-4e6b-8fca-465d4f86d90d"
      unitRef="usd">6864900000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Assets
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RleHRyZWdpb246ZWIxMjhmOWM2ZmJlNDE2ZDk3NTZjOWMyZTQ5NTU5YmVfMTAy_4a063b0b-baa6-4382-b2e6-f656101b3d98"
      unitRef="usd">228000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RleHRyZWdpb246ZWIxMjhmOWM2ZmJlNDE2ZDk3NTZjOWMyZTQ5NTU5YmVfMTA5_d46c722c-6214-44cc-bf36-aeec3eac4572"
      unitRef="usd">226200000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RleHRyZWdpb246ZWIxMjhmOWM2ZmJlNDE2ZDk3NTZjOWMyZTQ5NTU5YmVfMzA3_a644d747-94a2-4529-9240-da095d33f4b7"
      unitRef="usd">40800000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RleHRyZWdpb246ZWIxMjhmOWM2ZmJlNDE2ZDk3NTZjOWMyZTQ5NTU5YmVfMzE0_c5b38950-c29a-4bce-8144-6b67fc28b456"
      unitRef="usd">38200000</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i14493ec43a054a37a265fe545acfae34_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNC0xLTEtMS0xMjk2MDE_c03ef9fc-b1f3-4b44-9f0b-dfbea51f2baf"
      unitRef="shares">99500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i14493ec43a054a37a265fe545acfae34_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNC0zLTEtMS0xMjk2MDE_17501c0f-dee6-473d-8c4a-69f1f9e11819"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb8ac1140bb546ffbe29c3297dfca0ff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNC01LTEtMS0xMjk2MDE_a5324491-0ce6-4395-8ac2-6452b9320fbc"
      unitRef="usd">2289600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib5eaecfe3f96400b8f59e7967a61104c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNC03LTEtMS0xMjk2MDE_1bfcbee0-aee2-4fba-8ed7-52ad670f54cf"
      unitRef="usd">141800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd0a16468f25461eaa2eada251e33da7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNC0xMS0xLTEtMTI5NjAx_a0fb951f-304b-431d-9ee3-77c750d7c84c"
      unitRef="usd">-521200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0db82f105f774106945877e84af0cc3e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNC0xMy0xLTEtMTI5NjAx_867c455e-2a6c-4938-928d-c236f2974470"
      unitRef="usd">445700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNC0xNS0xLTEtMTI5NjAx_fc5acc5e-0ae8-45d7-bc7e-a0e5d31c0a83"
      unitRef="usd">2357000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i576c769a2bf3490093c90b7f2fd1d565_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNS03LTEtMS0xMjk2MDE_7b563fd7-70f6-4c07-8e6e-4cbe26fe70c9"
      unitRef="usd">87500000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i33aac6e817b84b2fbedbc7be7dd1d4e1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNS0xMy0xLTEtMTI5NjAx_5acd748e-312e-4862-99f4-aa33548c83bc"
      unitRef="usd">20700000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNS0xNS0xLTEtMTI5NjAx_3fb766e9-ab40-4c68-b8d0-31e080d808f2"
      unitRef="usd">108200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i70ffad11b2f64e0dafb9e8f6c59e3600_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNi0xLTEtMS0xMjk2MDE_62d94b28-710e-4479-958a-108b9e9c426f"
      unitRef="shares">100000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia54089ca96194a95b6a9346ce2f33fc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNi0xMS0xLTEtMTI5NjAx_69e17644-148f-4c52-a79a-626186ebba27"
      unitRef="usd">7600000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNi0xNS0xLTEtMTI5NjAx_83890d9c-904c-4b30-a59f-a26992bd7e0b"
      unitRef="usd">7600000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNy0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjo0MjQxNzI3NmI5NzA0NTcwYTU5NTE3MGIzMjVkMmYzY18yNA_65906638-f3d4-4986-8ae0-b084b1c21869"
      unitRef="usdPerShare">0.28</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i576c769a2bf3490093c90b7f2fd1d565_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNy03LTEtMS0xMjk2MDE_5efc94fe-4fae-4da7-9103-6d40de794a3d"
      unitRef="usd">28100000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfNy0xNS0xLTEtMTI5NjAx_648d6bd7-1326-43f5-b347-28aa319f26b9"
      unitRef="usd">28100000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i74ec993229934505b223d7e527442ba7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfOS01LTEtMS0xMjk2MDE_4cbcf6c8-c3ca-4660-81e0-bd3a26d1e036"
      unitRef="usd">7500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfOS0xNS0xLTEtMTI5NjAx_d0455003-431f-4bcb-b94b-11608500a883"
      unitRef="usd">7500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i33aac6e817b84b2fbedbc7be7dd1d4e1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTItMTMtMS0xLTEyOTYwMQ_c2c0f117-6a44-4589-9725-c6b5d70236bd"
      unitRef="usd">24900000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTItMTUtMS0xLTEyOTYwMQ_e1c1c8b6-a087-4548-9feb-09fa73d5c6fe"
      unitRef="usd">24900000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="i33aac6e817b84b2fbedbc7be7dd1d4e1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTMtMTMtMS0xLTEyOTYwMQ_a5ad3cd8-11cf-4962-9c46-78f4d131ebfc"
      unitRef="usd">21400000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTMtMTUtMS0xLTEyOTYwMQ_a766faf4-8d20-416d-8537-e4c03533840c"
      unitRef="usd">21400000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i70ffad11b2f64e0dafb9e8f6c59e3600_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTgtMS0xLTEtMTI5NjAx_eba57f50-c9d2-41f3-80e9-8bfbd6ab1ff2"
      unitRef="shares">400000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i74ec993229934505b223d7e527442ba7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTgtNS0xLTEtMTI5NjAx_65b63c67-eea6-4077-8fae-82aeb8d2869c"
      unitRef="usd">-4000000.0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ia54089ca96194a95b6a9346ce2f33fc1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTgtMTEtMS0xLTEyOTYwMQ_00163e03-d82b-4ee8-88c8-ee720a2e48c9"
      unitRef="usd">1100000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i33aac6e817b84b2fbedbc7be7dd1d4e1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTgtMTMtMS0xLTEyOTYwMQ_f85cc06a-d071-4133-9a7e-aaa610350096"
      unitRef="usd">-12000000.0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTgtMTUtMS0xLTEyOTYwMQ_4f14aacd-a36a-4219-b58d-bda372f5e958"
      unitRef="usd">-14900000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2c072fe2fb1348d68775f83549979f34_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTktMS0xLTEtMTI5NjAx_e6fdbf78-fcbe-41b2-9aae-f84aee4d09ab"
      unitRef="shares">99800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c072fe2fb1348d68775f83549979f34_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTktMy0xLTEtMTI5NjAx_2e0a8bc0-03bc-47c3-886e-cc9d568a8288"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf0cae1f6a4a43f293213bf2aea45abd_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTktNS0xLTEtMTI5NjAx_c4f0bda5-59e0-4d5f-9d77-a212cb3b9490"
      unitRef="usd">2301100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4efb9bf256844561b1d2a7fbb842421e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTktNy0xLTEtMTI5NjAx_aa68e3a4-bd73-4620-ac78-c25ca9795fa0"
      unitRef="usd">201200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i288ad08f50a44c848d9ae9b15441d2dc_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTktMTEtMS0xLTEyOTYwMQ_2de2c936-605c-4f45-94c7-77b3a66020a2"
      unitRef="usd">-529900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id2bafe8e3cac4147865d701ae99d921c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTktMTMtMS0xLTEyOTYwMQ_f8b8acb1-9af8-4605-ae82-92dcad10ac01"
      unitRef="usd">474900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOjk1M2U4Y2RiMWYyOTQwNTZhZDUzYTUwNmRmYTc5NjQxL3RhYmxlcmFuZ2U6OTUzZThjZGIxZjI5NDA1NmFkNTNhNTA2ZGZhNzk2NDFfMTktMTUtMS0xLTEyOTYwMQ_7dc0c14c-6b8b-43e0-a1bc-a219bdfb22f2"
      unitRef="usd">2448400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1beec8de6cfd45d8b5f89af034ba4093_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNC0xLTEtMS0xMjk2MDE_221b928c-9eda-4989-b5fd-1423bd8671ab"
      unitRef="shares">99400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1beec8de6cfd45d8b5f89af034ba4093_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNC0zLTEtMS0xMjk2MDE_fd6bb73f-9ad8-43ec-ae65-31ecfc57f002"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i78cf1e166e974c539ccf23447cde940b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNC01LTEtMS0xMjk2MDE_f8847068-9e97-4332-895c-d7b4ab145528"
      unitRef="usd">2326600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b3a08ff093f420c99340aa4e1150824_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNC03LTEtMS0xMjk2MDE_eaf17013-2e78-4b3e-a198-873cf4af64b5"
      unitRef="usd">-242300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36bea0bf3d9144caa0f8df9028b1dc79_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNC0xMS0xLTEtMTI5NjAx_c91f449a-c16c-461e-b9a1-b596b72f65c6"
      unitRef="usd">-497400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief9203a9500e4500971e238696312597_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNC0xMy0xLTEtMTI5NjAx_e215412e-5d2d-489b-b0dc-7503588dc136"
      unitRef="usd">382000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f5b35fb51614954816b817c495b5d51_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNC0xNS0xLTEtMTI5NjAx_80b4521c-fe1c-4e8a-90d5-a9bba33be37d"
      unitRef="usd">1970000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i8c1ae97e068e4cff900ec3092c7f4f04_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNS03LTEtMS0xMjk2MDE_145ef965-db1c-4106-bb29-18b18bfc4afa"
      unitRef="usd">107300000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i036534c3f4a5413e8de12b55fc657fe1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNS0xMy0xLTEtMTI5NjAx_d6ae9141-5731-47bd-a04d-1421e0780532"
      unitRef="usd">23100000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNS0xNS0xLTEtMTI5NjAx_69387bab-0574-4499-b892-83f4a0766f0d"
      unitRef="usd">130400000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i622188ef7ebe41c680e18a9991186c28_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNy0xLTEtMS0xMjk2MDE_36a08065-d0aa-47e8-aa20-a44a4a22c45a"
      unitRef="shares">200000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i117392f9d15f489cbe838f6b1ce3da6b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNy0xMS0xLTEtMTI5NjAx_99438676-da7a-403a-bec5-52e804e9e10f"
      unitRef="usd">15600000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfNy0xNS0xLTEtMTI5NjAx_a08f5813-4316-426a-89cd-3e33bba31560"
      unitRef="usd">15600000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfOC0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjpiMTkxNGRiZWI4OGU0MGVkYWIxNWMzYWI0N2M5MmZkOV8yNA_e5e2ff3c-fe27-4710-9164-b5268af4fe51"
      unitRef="usdPerShare">0.28</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i4cd1f1cb74084bb3b9abaf864a2e064b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfOC01LTEtMS0xMjk2MDE_3cdd459c-102d-4a29-89ee-254fa416e8bf"
      unitRef="usd">27800000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfOC0xNS0xLTEtMTI5NjAx_fffafd5b-17c4-4b56-8330-e16d0c362b70"
      unitRef="usd">27800000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4cd1f1cb74084bb3b9abaf864a2e064b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTAtNS0xLTEtMTI5NjAx_99384d6c-db7a-4aae-9ca9-c401e758ef05"
      unitRef="usd">2800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTAtMTUtMS0xLTEyOTYwMQ_aee534e4-6786-42c0-9f03-19cf2cfccaae"
      unitRef="usd">2800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i036534c3f4a5413e8de12b55fc657fe1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTMtMTMtMS0xLTEyOTYwMQ_2fc8018f-44b6-4234-ae91-2f4856c74e52"
      unitRef="usd">22400000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTMtMTUtMS0xLTEyOTYwMQ_5c33ec4e-f0a2-4595-bdd7-42eb39b44ba4"
      unitRef="usd">22400000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="i036534c3f4a5413e8de12b55fc657fe1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTQtMTMtMS0xLTEyOTYwMQ_ca04062f-f1ea-4ca7-9d0d-014891ad4e63"
      unitRef="usd">5800000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTQtMTUtMS0xLTEyOTYwMQ_bb428162-31be-4d6a-94be-cd531dbe27c2"
      unitRef="usd">5800000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i622188ef7ebe41c680e18a9991186c28_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTktMS0xLTEtMTI5NjAx_594a131f-d4b5-4fa6-a19b-a05653b0126e"
      unitRef="shares">400000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i4cd1f1cb74084bb3b9abaf864a2e064b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTktNS0xLTEtMTI5NjAx_a85d53d8-da43-457f-8eaf-e8cd0bda9b7e"
      unitRef="usd">-1100000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i117392f9d15f489cbe838f6b1ce3da6b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTktMTEtMS0xLTEyOTYwMQ_5dfb64ef-b3ef-404e-9664-3a80ab935fd8"
      unitRef="usd">700000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i036534c3f4a5413e8de12b55fc657fe1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTktMTMtMS0xLTEyOTYwMQ_21600dca-5b07-4178-9439-b44d80b66074"
      unitRef="usd">600000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMTktMTUtMS0xLTEyOTYwMQ_6d95df15-ae9a-4ae9-8e35-fbb0440ee0de"
      unitRef="usd">200000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i013c277808804f42827dd89d591b0f7c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMjAtMS0xLTEtMTI5NjAx_5676b82e-ef30-4317-8892-712e3979f1e7"
      unitRef="shares">99600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i013c277808804f42827dd89d591b0f7c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMjAtMy0xLTEtMTI5NjAx_3d026b78-8b07-44c0-8e33-83847eb59e41"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i972509dbc5b6416a9dd899dc87ebd08b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMjAtNS0xLTEtMTI5NjAx_d35d4a8e-71cc-4d1b-88f9-f8e47697d35f"
      unitRef="usd">2302700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia12ac2a64d1641ba80099f0e2982b794_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMjAtNy0xLTEtMTI5NjAx_6fb1b1f2-84da-4cf0-8618-7d40b8451cf4"
      unitRef="usd">-135000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d9c8cd1de2c4f13933b82337c8517f4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMjAtMTEtMS0xLTEyOTYwMQ_3511a324-8e8c-4f20-a91d-01e712337ba1"
      unitRef="usd">-513700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9121edbdc21a47948aa5552e7f4240fb_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMjAtMTMtMS0xLTEyOTYwMQ_b4306742-ece2-4263-b47a-6259e0970880"
      unitRef="usd">387900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0c6a42e404cd4326b6c8697c3add3bf6_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8zNy9mcmFnOmFhMDAxZTQ5MTlkZDQ0Zjg4ZGY0Y2E1NDQ5YzZiODZiL3RhYmxlOmU3NWQ0MzNiNzA2ZTRmZWM4N2FkZTU2ZDk4MTVjODZkL3RhYmxlcmFuZ2U6ZTc1ZDQzM2I3MDZlNGZlYzg3YWRlNTZkOTgxNWM4NmRfMjAtMTUtMS0xLTEyOTYwMQ_bc1a98a6-998c-41d3-b586-6c675134ac6f"
      unitRef="usd">2043000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNC0xLTEtMS0xMjk2MDE_0148d8e2-1efd-46fc-9bdd-9c501ffb7a86"
      unitRef="usd">110100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNC0zLTEtMS0xMjk2MDE_65b1e6c2-4589-41a4-9595-e3f512bd2853"
      unitRef="usd">132800000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfOC0xLTEtMS0xMjk2MDE_baa3fc1d-8630-4543-b819-48ef102a2fa6"
      unitRef="usd">66200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfOC0zLTEtMS0xMjk2MDE_9ecf6f1e-1d47-4e5f-a9c5-d353248c665c"
      unitRef="usd">62500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTItMS0xLTEtMTI5NjAx_4dc384e1-6179-432e-980e-192a72c7003e"
      unitRef="usd">7500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTItMy0xLTEtMTI5NjAx_aa583faa-5d01-4db3-ac01-c441976d175b"
      unitRef="usd">2800000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTMtMS0xLTEtMTI5NjAx_a36b2b5e-aa8b-4fdb-9ac8-d42a5f271809"
      unitRef="usd">2000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTMtMy0xLTEtMTI5NjAx_5f10ef50-d4e5-4437-b87e-752fe3bf90e2"
      unitRef="usd">8700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTUtMS0xLTEtMTI5NjAx_5167f50c-1a71-407f-a2fc-138cdbd009d8"
      unitRef="usd">-7900000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTUtMy0xLTEtMTI5NjAx_3ef6b382-962b-4600-8b76-9003117ced83"
      unitRef="usd">-2000000.0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTctMS0xLTEtMTI5NjAx_e700c1c8-39d5-4a63-af7c-c90709e33b3a"
      unitRef="usd">-7300000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTctMy0xLTEtMTI5NjAx_e8e21f30-bc18-48b1-8af7-e006dda9f74d"
      unitRef="usd">55100000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTgtMS0xLTEtMTI5NjAx_f29f25cd-c8db-4fac-ac0d-c1dc6dce382a"
      unitRef="usd">-12000000.0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMTgtMy0xLTEtMTI5NjAx_07bf286e-62db-402b-b14d-b0d540aac976"
      unitRef="usd">-1300000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjAtMS0xLTEtMTI5NjAx_00e95ba2-225f-4d6d-b4a1-cefda917fe82"
      unitRef="usd">5600000</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjAtMy0xLTEtMTI5NjAx_c60065d9-075a-4070-8377-6ed6e000fd47"
      unitRef="usd">5700000</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjItMS0xLTEtMTI5NjAx_617843c6-ca4a-4b79-9da8-e1b7223d8f95"
      unitRef="usd">400000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjItMy0xLTEtMTI5NjAx_fa1132da-d8e4-4b54-b0a5-1f3bf3422542"
      unitRef="usd">-2200000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjMtMS0xLTEtMTI5NjAx_8e31f82f-e336-4109-9c24-dc8798b87635"
      unitRef="usd">-100000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjMtMy0xLTEtMTI5NjAx_4c702eca-5190-4b26-b5a5-533cc1f25f7c"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjQtMS0xLTEtMTI5NjAx_a2126790-ba05-422d-92ca-a7a43b82d1c9"
      unitRef="usd">108800000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjQtMy0xLTEtMTI5NjAx_7cafe668-9f9a-42ad-9199-ed113596f88b"
      unitRef="usd">25700000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjUtMS0xLTEtMTI5NjAx_69b876a6-6f2e-4a1e-8e35-2db4c1fc3367"
      unitRef="usd">218900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjUtMy0xLTEtMTI5NjAx_e302520d-8d9d-4e81-b656-5cb1b37e1e4e"
      unitRef="usd">158500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjgtMS0xLTEtMTI5NjAx_5d3c049b-1b46-4856-a914-ad093f018f97"
      unitRef="usd">115200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMjgtMy0xLTEtMTI5NjAx_7b6cfd7a-efbd-45cc-9e1b-739183133a69"
      unitRef="usd">98800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMzItMS0xLTEtMTI5NjAx_3cc201d4-bf5d-4cba-b950-6a8cd5422cfc"
      unitRef="usd">7900000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMzItMy0xLTEtMTI5NjAx_159f5b23-451e-4431-95d4-cb0c35ee7977"
      unitRef="usd">-3200000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMzMtMS0xLTEtMTI5NjAx_3ce07b76-1cc7-4845-b14c-cca9fee1e0f6"
      unitRef="usd">-123100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfMzMtMy0xLTEtMTI5NjAx_9c7470a2-9d94-423e-8d60-ee8664d947c2"
      unitRef="usd">-95600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDAtMS0xLTEtMTI5NjAx_6f1c549d-1d2b-4812-bdf6-262601c12225"
      unitRef="usd">103900000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDAtMy0xLTEtMTI5NjAx_88772cd8-a5ee-4236-a9f1-f5d81ac69106"
      unitRef="usd">3600000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDEtMS0xLTEtMTI5NjAx_76032e4f-f236-49c1-a009-a0af6938b861"
      unitRef="usd">130000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDEtMy0xLTEtMTI5NjAx_cf21e471-06e3-463c-a6c6-4f5ca3148829"
      unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDItMS0xLTEtMTI5NjAx_aefbfff7-499e-4afc-9b83-4b81726e797f"
      unitRef="usd">25000000.0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDItMy0xLTEtMTI5NjAx_8218b00f-76b8-42d3-b8e0-bb2fd6704565"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:PaymentsOfDebtRestructuringCosts
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDQtMS0xLTEtMTI5NjAx_61faf674-27ea-4797-b3ec-93bd6128d6a1"
      unitRef="usd">20000000.0</us-gaap:PaymentsOfDebtRestructuringCosts>
    <us-gaap:PaymentsOfDebtRestructuringCosts
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDQtMy0xLTEtMTI5NjAx_9d7f3e3e-d652-4066-9611-09151cb5cba3"
      unitRef="usd">0</us-gaap:PaymentsOfDebtRestructuringCosts>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDUtMS0xLTEtMTI5NjAx_8cec6529-dff4-4b8c-8504-ed3e7edd0fe2"
      unitRef="usd">7600000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDUtMy0xLTEtMTI5NjAx_0e338ad0-e604-40b7-a86f-613c68aba1d3"
      unitRef="usd">15600000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDYtMS0xLTEtMTI5NjAx_73753b80-7dd3-4d6d-b60c-66d0e91e28a4"
      unitRef="usd">21400000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDYtMy0xLTEtMTI5NjAx_1dc6bc4d-02a9-4048-accb-d39e015c8dba"
      unitRef="usd">4500000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDctMS0xLTEtMTI5NjAx_4f32008e-c8ac-49f3-9d04-8b7001d0b6f0"
      unitRef="usd">28500000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDctMy0xLTEtMTI5NjAx_ca40c2b2-9639-4296-a113-d41bba19a04a"
      unitRef="usd">29100000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDgtMS0xLTEtMTI5NjAx_66b211f7-f963-4181-887a-28d5fb78a2c1"
      unitRef="usd">21300000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNDgtMy0xLTEtMTI5NjAx_de1734ac-9ff8-4769-b42d-872b588d5d88"
      unitRef="usd">27800000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTEtMS0xLTEtMTI5NjAx_86deeca5-cbe3-4a61-bb6c-2b37044e3cfa"
      unitRef="usd">-6000000.0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTEtMy0xLTEtMTI5NjAx_a41e5a17-7ad7-402c-a7d5-9992026a41cb"
      unitRef="usd">-5900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTItMS0xLTEtMTI5NjAx_6aeceda3-1741-4f16-913a-fe23f3408ee0"
      unitRef="usd">-60900000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTItMy0xLTEtMTI5NjAx_b9c1f812-3df6-4cf4-a307-9005b13873de"
      unitRef="usd">-77500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTMtMS0xLTEtMTI5NjAx_d0f196d0-eeb7-42f7-9716-361e517ad05f"
      unitRef="usd">34900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTMtMy0xLTEtMTI5NjAx_bb80869b-b5d2-4a64-a5be-b1342194a74f"
      unitRef="usd">-14600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTQtMS0xLTEtMTI5NjAx_6f8d27ad-3bb5-4310-bdbf-bfb84c69b6d5"
      unitRef="usd">120300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8f5b35fb51614954816b817c495b5d51_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTQtMy0xLTEtMTI5NjAx_092058c8-bcdc-4960-8e70-a16b2717f53c"
      unitRef="usd">310900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTUtMS0xLTEtMTI5NjAx_14e4e778-7879-41b2-b1a1-6d3b2f0c9325"
      unitRef="usd">155200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0c6a42e404cd4326b6c8697c3add3bf6_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTUtMy0xLTEtMTI5NjAx_4b9c5e6d-02f3-455c-969f-5e991c41f964"
      unitRef="usd">296300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTgtMS0xLTEtMTI5NjAx_ff1010e0-9438-4270-bc67-084c803e37cb"
      unitRef="usd">54800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8f5b35fb51614954816b817c495b5d51_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTgtMy0xLTEtMTI5NjAx_ca213391-cfbb-4c08-8d2d-03b8afbea00f"
      unitRef="usd">224000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTktMS0xLTEtMTI5NjAx_d6169312-30b3-468c-98dc-f238aaf3a6d8"
      unitRef="usd">65100000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i8f5b35fb51614954816b817c495b5d51_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNTktMy0xLTEtMTI5NjAx_bb55151a-2ade-4295-990c-fbac7a483765"
      unitRef="usd">65400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjAtMS0xLTEtMTI5NjAx_0a6ecd07-4a50-42ce-b12c-b921043e1d46"
      unitRef="usd">400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i8f5b35fb51614954816b817c495b5d51_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjAtMy0xLTEtMTI5NjAx_6e1e5b34-0e44-4e23-80d9-1f61d76d882d"
      unitRef="usd">21500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjEtMS0xLTEtMTI5NjAx_4f48908d-e165-4f7d-9597-69aabb84ab67"
      unitRef="usd">120300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8f5b35fb51614954816b817c495b5d51_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjEtMy0xLTEtMTI5NjAx_46d3b760-2093-4228-aa68-7cf4e5ba4365"
      unitRef="usd">310900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjMtMS0xLTEtMTI5NjAx_89d6142e-06c0-4043-9af9-3e78ef0c0620"
      unitRef="usd">94200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0c6a42e404cd4326b6c8697c3add3bf6_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjMtMy0xLTEtMTI5NjAx_8f434bba-85f9-43fb-8ef8-0c639e81cfd5"
      unitRef="usd">223900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjQtMS0xLTEtMTI5NjAx_5c34f575-bcf8-4fa2-8f7d-fb18a38adecb"
      unitRef="usd">61000000.0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i0c6a42e404cd4326b6c8697c3add3bf6_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjQtMy0xLTEtMTI5NjAx_bf9885c5-ed30-401e-a583-ec61830e0cf7"
      unitRef="usd">62200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjUtMS0xLTEtMTI5NjAx_5bbcbe3f-9c6d-4fe8-80de-eca63dae29ec"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i0c6a42e404cd4326b6c8697c3add3bf6_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjUtMy0xLTEtMTI5NjAx_74b51532-df4c-47e9-999b-9b9ffaefb1d2"
      unitRef="usd">10200000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjYtMS0xLTEtMTI5NjAx_82a55c81-dde7-4f9e-9aad-137799cdf807"
      unitRef="usd">155200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0c6a42e404cd4326b6c8697c3add3bf6_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjYtMy0xLTEtMTI5NjAx_77e4af01-1375-46bd-a2b9-67f0ad03bd44"
      unitRef="usd">296300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjktMS0xLTEtMTI5NjAx_4335cc31-13f3-4a64-9472-1064428267ab"
      unitRef="usd">200000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNjktMy0xLTEtMTI5NjAx_ef200405-d0c1-4e59-b0b7-8173437fce02"
      unitRef="usd">19700000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNzEtMS0xLTEtMTI5NjAx_8def29b5-5c02-45ae-9a29-0c03fa4da8e4"
      unitRef="usd">5900000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80MC9mcmFnOmJjMzM4YzVlOWYyODQ2MDJiOGY5MDA2NWMyYTgxZGEwL3RhYmxlOjhlZGUzZTI4MDI5MjRhZjk5MzI2MmY4NmI5MjYzZWY3L3RhYmxlcmFuZ2U6OGVkZTNlMjgwMjkyNGFmOTkzMjYyZjg2YjkyNjNlZjdfNzEtMy0xLTEtMTI5NjAx_ff003522-3bc0-4b68-97c6-15fb5f0d9da2"
      unitRef="usd">17400000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80Ni9mcmFnOjUyOTk3YWZjOWVhNTRhYTZiMjZiY2RkZmRlYWRmYzUxL3RleHRyZWdpb246NTI5OTdhZmM5ZWE1NGFhNmIyNmJjZGRmZGVhZGZjNTFfMjE1OQ_becb5e28-446b-4cbf-a9ba-f1840dee6bc2">Basis of Presentation&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Encompass Health Corporation, incorporated in Delaware in 1984, including its subsidiaries, is a leading provider of post-acute healthcare services, offering both facility-based and home-based patient services in 42 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. We manage our operations and disclose financial information using two reportable segments: (1) inpatient rehabilitation and (2) home health and hospice. See also Note 11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 9, 2020, we announced a formal process to explore strategic alternatives for our home health and hospice business. As a result of this process, we expect to spin off our home health and hospice business to form an independent, publicly traded company on July 1, 2022, subject to customary conditions, including the effectiveness of a Form&#160;10 registration statement, regulatory approvals and receipt of a favorable IRS private letter ruling. On January 19, 2022, we announced the home health and hospice business would be rebranded and operate under the name Enhabit Home Health &amp;amp; Hospice. The rebranding of agency locations began in mid-April 2022 and is expected to be largely completed by the effective date of the spin off.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of Encompass Health Corporation and Subsidiaries should be read in conjunction with the consolidated financial statements and accompanying notes contained in Encompass Health&#x2019;s Annual Report on Form&#160;10-K filed with the United States Securities and Exchange Commission on February&#160;25, 2022 (the &#x201c;2021 Form 10&#x2011;K&#x201d;). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC applicable to interim financial information. Certain information and note disclosures included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been omitted in these interim statements, as allowed by such SEC rules and regulations. The condensed consolidated balance sheet as of December&#160;31, 2021 has been derived from audited financial statements, but it does not include all disclosures required by GAAP. However, we believe the disclosures are adequate to make the information presented not misleading.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited results of operations for the interim periods shown in these financial statements are not necessarily indicative of operating results for the entire year. In our opinion, the accompanying condensed consolidated financial statements recognize all adjustments of a normal recurring nature considered necessary to fairly state the financial position, results of operations, and cash flows for each interim period presented. Certain prior-year amounts have been reclassified to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Operating Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; disaggregated by payor source and segment are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,230.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to the consolidated financial statements accompanying the 2021 Form 10-K for our policy related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe any recently issued, but not yet effective, accounting standards will have a material effect on our condensed consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80Ni9mcmFnOjUyOTk3YWZjOWVhNTRhYTZiMjZiY2RkZmRlYWRmYzUxL3RleHRyZWdpb246NTI5OTdhZmM5ZWE1NGFhNmIyNmJjZGRmZGVhZGZjNTFfMjQx_44f14cb9-7761-4cde-a1d2-04b2dc63b3f5"
      unitRef="state">42</us-gaap:NumberOfStatesInWhichEntityOperates>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80Ni9mcmFnOjUyOTk3YWZjOWVhNTRhYTZiMjZiY2RkZmRlYWRmYzUxL3RleHRyZWdpb246NTI5OTdhZmM5ZWE1NGFhNmIyNmJjZGRmZGVhZGZjNTFfNDM2_69c93ae5-d0df-4bc0-aca7-d84d85e3609f"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RleHRyZWdpb246NzdmNWFhMWVhZDY1NGIzOWE4NWNmM2IxMWVhYWEwNGZfMjc1_2378bfa6-1a8a-4701-970b-e83b348a19d3">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; disaggregated by payor source and segment are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;838.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,230.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8aff770be2384e718613ee73e75c9d8c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMy0xLTEtMS0xMjk2MDE_1ecaf57c-0854-4b0f-b11d-a56cb62d0c95"
      unitRef="usd">689900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20db95e52d4340b89253015dadddfce8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMy0zLTEtMS0xMjk2MDE_0e026599-9d54-4dba-b852-599eb8945cfd"
      unitRef="usd">614500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22e38d1a9d8c492983b5fe7bbc4a8114_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMy01LTEtMS0xMjk2MDE_8d34ea69-d98b-40da-8a42-48a0d892ab2f"
      unitRef="usd">217400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ed9eb823c2440d48088c6f6ef06b87d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMy03LTEtMS0xMjk2MDE_16716ed9-2535-43f9-b9bf-9c8362ec6051"
      unitRef="usd">223900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d2de80a9ea142658a08aff95c64af19_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMy05LTEtMS0xMjk2MDE_1558677d-b994-4f34-afa1-145e37e103de"
      unitRef="usd">907300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a399017e33d42b2bf858dd4d6a9c0e1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMy0xMS0xLTEtMTI5NjAx_0317eda1-abcc-467b-bac5-7688a08fb28f"
      unitRef="usd">838400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i915084ab4bdd4e1689693609d0ef6b82_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNC0xLTEtMS0xMjk2MDE_65a4bfdf-ef40-48ce-907b-b52dad768cb8"
      unitRef="usd">156000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c8d685705124a67ba3a91dabc43a282_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNC0zLTEtMS0xMjk2MDE_6f2e1329-3992-447e-9037-72d65f3fc18f"
      unitRef="usd">158400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ef7afb70a7f4b27a6a3cefbe6320e01_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNC01LTEtMS0xMjk2MDE_b9c2fea4-7df1-45df-994b-48b13a2a5a62"
      unitRef="usd">34500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1745bec828ac49b1818f4f9a5135a42c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNC03LTEtMS0xMjk2MDE_8293c6ab-12de-413a-b3a7-e9e78deb744f"
      unitRef="usd">28000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcc4e89df88e43cfbef7da1f99240779_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNC05LTEtMS0xMjk2MDE_ea160eab-34bc-45ab-8015-4c64f1c30b76"
      unitRef="usd">190500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39f739399fa44a149e9c4093be040820_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNC0xMS0xLTEtMTI5NjAx_9f152abd-f5ef-4076-87cd-1953bdb3e747"
      unitRef="usd">186400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84bb98c1d43644a39513c7d343c7ffec_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNS0xLTEtMS0xMjk2MDE_c4a5dc58-0a34-4605-b544-65ef3fa906b8"
      unitRef="usd">131500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75ecf985b4164bff9fa7316be1a7474a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNS0zLTEtMS0xMjk2MDE_8a55a073-52d1-461c-a207-1349fc00e9b2"
      unitRef="usd">112200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d2d7e560f1441bca94bad9f8a814402_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNS01LTEtMS0xMjk2MDE_72c24127-e06f-4d12-a059-6162ab68f94d"
      unitRef="usd">18800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibab4a62b6ba444c883fdc49380be38fb_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNS03LTEtMS0xMjk2MDE_8d6ded88-cc00-4c4b-a239-eb240f667586"
      unitRef="usd">14300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79fb50ea872e4a0ca7a8afe1c90123b2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNS05LTEtMS0xMjk2MDE_511900e2-c9f6-4084-ba6e-f4aac6db094d"
      unitRef="usd">150300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d5c49ba6ba94af8960ab5d485207093_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNS0xMS0xLTEtMTI5NjAx_0ac16664-385e-4728-8371-217e31068934"
      unitRef="usd">126500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0b8349513794a3294fb7992b1d132ab_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNi0xLTEtMS0xMjk2MDE_364c5879-d12f-4f07-839e-0503509e4bc2"
      unitRef="usd">41700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacc1a722e4414822b283443f547fa10b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNi0zLTEtMS0xMjk2MDE_a8433498-901e-4524-a51e-a2c6efa62422"
      unitRef="usd">39000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2903b136be2a4ee89a98bcd8d1360b19_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNi01LTEtMS0xMjk2MDE_527b1137-62a9-43c5-89d7-c47b9beee457"
      unitRef="usd">3500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad23a50207a142ab9c646522e8434d32_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNi03LTEtMS0xMjk2MDE_8e29d155-ec08-471d-b963-256d06f9a64a"
      unitRef="usd">3800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc33a324f2c0445d95695eba2ca8ef8a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNi05LTEtMS0xMjk2MDE_7e0d3864-05b3-4e14-a875-9d4fe6810bcf"
      unitRef="usd">45200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i599a045bbb1143038e76b94639d195fe_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNi0xMS0xLTEtMTI5NjAx_6da0b453-abc7-4361-b794-71dccbc363cd"
      unitRef="usd">42800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i817f1c2f30674f89942c2d872a2ba105_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNy0xLTEtMS0xMjk2MDE_498fa479-7168-4269-880d-76df03a46c2e"
      unitRef="usd">10100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4efd11aa331481487fdb712ec4c0ac2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNy0zLTEtMS0xMjk2MDE_eb5a1600-e9a7-42c8-a75d-4ec6e7094cad"
      unitRef="usd">12100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7aafa9f641b84852af3d2fb5f01099e5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNy01LTEtMS0xMjk2MDE_e64fc2ae-3af1-4d92-9c16-4044f1c1f857"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia19311f0969f4d318270fc2cc5ed5d0a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNy03LTEtMS0xMjk2MDE_8464ee59-8ae2-4ef1-934f-7e1033ea340f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i816cdecfdda244c89818aaa109f9acec_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNy05LTEtMS0xMjk2MDE_87a576ce-176b-4348-b759-503122e69830"
      unitRef="usd">10100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b5fd3df85ec4c319b4bc0219d463e49_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfNy0xMS0xLTEtMTI5NjAx_1b176ed5-c8e9-48ec-b04a-3f0571d439ab"
      unitRef="usd">12100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f172a6226384fecb27f5515fca37ab0_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOC0xLTEtMS0xMjk2MDE_8401ab54-1264-46f6-8d78-034c918fa179"
      unitRef="usd">6100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9457af3cee914d029434093eeae9c559_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOC0zLTEtMS0xMjk2MDE_b7b658f4-df31-4f62-98f6-9b1c8117604c"
      unitRef="usd">5700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34d269849de54ca9aef661bdd4496c95_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOC01LTEtMS0xMjk2MDE_e42aa293-e2f3-4e5b-aaec-6f691deab3c0"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibdc9747447a24dfdb2bc0d42c7649f61_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOC03LTEtMS0xMjk2MDE_30ee2f53-2ee1-46ae-ad09-b4a924c0f76f"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5a3de3efd3d4a48ad46ff05596eb38e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOC05LTEtMS0xMjk2MDE_4f21c7e4-c769-4f98-8295-7def791628fc"
      unitRef="usd">6200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58a18ced43b9420abf4802064fa8951d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOC0xMS0xLTEtMTI5NjAx_49217339-677a-4537-acb0-9e84c4b4c050"
      unitRef="usd">5800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib164992f54584ed39d8de9248794b352_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOS0xLTEtMS0xMjk2MDE_8308a4e9-b5bd-42a0-86ad-026a532139cf"
      unitRef="usd">5200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i886e59e872c246ddb347cb38ec9a1160_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOS0zLTEtMS0xMjk2MDE_10ffdb4b-0ccb-4359-91db-483d85cc4dd1"
      unitRef="usd">4900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1416420c060b4050821f6eee0ac9a457_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOS01LTEtMS0xMjk2MDE_ad77654b-11ab-4e05-b8a0-a6c39a6f0d4a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7135e07b877d4f569de8504b4686a6ee_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOS03LTEtMS0xMjk2MDE_56664834-acea-4b4b-abd0-05071c864b22"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibded32670d67459ca73c7300d578990b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOS05LTEtMS0xMjk2MDE_36dea482-7cc9-474d-9afb-784ab3850b2a"
      unitRef="usd">5200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id491747513c74175b42ca0a5e71438c0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfOS0xMS0xLTEtMTI5NjAx_19e6267c-51d4-45e2-be0b-7d6448caedb7"
      unitRef="usd">5100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i852f28e7df1d406994d8a3bd00d23115_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTAtMS0xLTEtMTI5NjAx_a19c4a03-de0f-463d-9fa1-a425ff615aed"
      unitRef="usd">18800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16d0b325d18e4ddd9457d92019914f3a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTAtMy0xLTEtMTI5NjAx_e753d049-1bd5-480c-8ab0-81ea36a3e860"
      unitRef="usd">13100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id807874539934f0e9ed224fbc31c78b6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTAtNS0xLTEtMTI5NjAx_7d739071-a7ef-455c-90f9-347ffb38377b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3313d74b1254472598b291ece765395d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTAtNy0xLTEtMTI5NjAx_3dde1d6f-594b-4254-9621-b17503d63c11"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33b51c955001459e8173f274705cb785_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTAtOS0xLTEtMTI5NjAx_03216d3b-5157-47fc-b3f8-778bd6c0b000"
      unitRef="usd">18800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i293d6fb19adf46f18fb8ccfda949db85_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTAtMTEtMS0xLTEyOTYwMQ_803e0c80-5f25-41bc-9080-dde1c1bdbfd1"
      unitRef="usd">13300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTEtMS0xLTEtMTI5NjAx_8ff287a1-5764-4f2e-b79b-2387e76a128c"
      unitRef="usd">1059300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTEtMy0xLTEtMTI5NjAx_1beb5c2e-ea8c-491a-a3a4-9b05b695d1e4"
      unitRef="usd">959900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTEtNS0xLTEtMTI5NjAx_9fb29f54-248c-49f3-ad0a-8e39bb077f5f"
      unitRef="usd">274300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTEtNy0xLTEtMTI5NjAx_f67b1b76-b2ea-4451-8ada-7f3254e35248"
      unitRef="usd">270500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTEtOS0xLTEtMTI5NjAx_df71c74e-0405-4e3e-abe8-21e282c1e2ee"
      unitRef="usd">1333600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV80OS9mcmFnOjc3ZjVhYTFlYWQ2NTRiMzlhODVjZjNiMTFlYWFhMDRmL3RhYmxlOjBhODVlNzYyYTY3ODQ4ZTZhMDRjYjQ3Y2ZmYTUwZTg0L3RhYmxlcmFuZ2U6MGE4NWU3NjJhNjc4NDhlNmEwNGNiNDdjZmZhNTBlODRfMTEtMTEtMS0xLTEyOTYwMQ_d1d24dc5-1072-469f-b2b6-1ff79f052ad3"
      unitRef="usd">1230400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81NS9mcmFnOjVmMzg0YWQ2ZTc3YjQ2MjhiNDRmM2U1MjFmNjViMjAwL3RleHRyZWdpb246NWYzODRhZDZlNzdiNDYyOGI0NGYzZTUyMWY2NWIyMDBfODQ2_5007f9b3-bead-42b9-b434-06f1b8470445">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe any recently issued, but not yet effective, accounting standards will have a material effect on our condensed consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RleHRyZWdpb246OWQ3MzQwYjJkZGYzNDljOWJjZWY5MjcxYjU5NDBkNWFfNjQ0OQ_b0de0bb4-af06-4aa5-8a88-b7c2c7544038">Business Combinations&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we acquired a 50% equity interest from Frontier Home Health and Hospice, LLC in a joint venture with Saint Alphonsus System (&#x201c;Saint Alphonsus&#x201d;) which operates home health and hospice locations in Boise, Idaho. The total purchase price was $15.9&#160;million and was funded on December 31, 2021. This acquisition was made to enhance our existing joint venture relationship with Saint Alphonsus and expand our footprint in this geographic area. This transaction was not material to our financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for this transaction under the acquisition method of accounting and reported the results of operations of the acquired locations from the date of acquisition. Assets acquired, liabilities assumed, and noncontrolling interests were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including: an income approach using primarily discounted cash flow techniques for the noncompete and license intangible assets; and an income approach utilizing the relief-from-royalty method for the trade name intangible asset. The aforementioned income methods utilize management&#x2019;s estimates of future operating results and cash flows discounted using a weighted average cost of capital that reflects market participant assumptions. For all other assets and liabilities, the fair value was assumed to represent carrying value due to their short maturities. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. All goodwill recorded reflects our expectations of favorable growth opportunities in the home health and hospice markets based on positive demographic trends. At least $14.4 million of the goodwill recorded as a result of this transaction is deductible for federal income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values recorded were based upon a preliminary valuation. Estimates and assumptions used in such valuation are subject to change, which could be significant, within the measurement period (up to one year from the acquisition date). We expect to continue to obtain information to assist us in determining the fair value of the net assets acquired at the acquisition date during the measurement period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preliminary fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use-assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreement (useful life of 5 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name (useful life of 6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses (useful lives of 10 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software (useful life of 3 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the cash paid for the acquisition during each period presented is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pro Forma Results of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the above mentioned acquisition from the date of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisition been January&#160;1, 2021 (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.030%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Operating Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Income Attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired entities only: Actual from acquisition date to March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2022-03/31/2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2021-03/31/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisition had occurred as of the beginning of our 2021 reporting period. See Note&#160;2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to the consolidated financial statements accompanying the 2021 Form 10&#x2011;K for information regarding acquisitions completed in 2021.&lt;/span&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="if99233a02a77455db55959da352fbfb2_I20220101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RleHRyZWdpb246OWQ3MzQwYjJkZGYzNDljOWJjZWY5MjcxYjU5NDBkNWFfMTA5OTUxMTYzODMwNQ_7bf0e388-ccd1-4413-9962-4c28c10afd91"
      unitRef="number">0.50</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i29d56a10f17343bcaab0acd8dbcc3b4e_D20220101-20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RleHRyZWdpb246OWQ3MzQwYjJkZGYzNDljOWJjZWY5MjcxYjU5NDBkNWFfMTA5OTUxMTYzODMyNA_f88f403f-23aa-4a7e-b8f1-46fe330d90a0"
      unitRef="usd">15900000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="if99233a02a77455db55959da352fbfb2_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RleHRyZWdpb246OWQ3MzQwYjJkZGYzNDljOWJjZWY5MjcxYjU5NDBkNWFfNDkyMw_cab5a35d-a165-427a-b500-ca5cbc4f7974"
      unitRef="usd">14400000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RleHRyZWdpb246OWQ3MzQwYjJkZGYzNDljOWJjZWY5MjcxYjU5NDBkNWFfNjQzNA_0047a85b-fd00-4058-b34a-b94cf7220269">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preliminary fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use-assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreement (useful life of 5 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name (useful life of 6 months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses (useful lives of 10 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software (useful life of 3 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMC0xLTEtMS0xMjk2MDE_1e051c75-e874-491f-b510-350bbd4f5a7e"
      unitRef="usd">700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMS0xLTEtMS0xMjk2MDE_b82ea2cc-015a-4f98-bc04-8f67adb0cfeb"
      unitRef="usd">1600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets
      contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfNC0xLTEtMS0xMjk2MDE_66a08d9e-386c-4faa-be57-66860afef97b"
      unitRef="usd">300000</ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i629dd79718e44513b2d60bcae0d6f51a_D20220101-20220101"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfNi0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjo2NjdkYTYwYjMwZTU0NDRhOWE4ODU5YWM2YjE1YTBhMl80MQ_9e96ce13-c59d-4685-af83-710f7730fb21">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ida96cd2b0e2746e39759c8c22c9bf7a5_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfNi0xLTEtMS0xMjk2MDE_c4c7e69b-f1bc-45b0-b5b4-26e8f892ece7"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i6c4b218e644546e8963de5f7bb2c0e6c_D20220101-20220101"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfNy0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjo4YjUyZDk2NzgwODU0N2ZmYjdiMTY1NDZlYzlkNTA4Y18zMQ_e564bba3-668b-4c18-8dd0-2c03ffe392aa">P6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i53b09e480b6142de9d92527b0b5b9375_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfNy0xLTEtMS0xMjk2MDE_5c0693aa-de3b-4c67-a912-05c667b8b418"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i93824ec251c546cbb304b0de1adc1bc2_D20220101-20220101"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfOS0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjpjM2NjYjBiNjFhMTI0YWFhYWQyMTE3NDZlZmM3MTBmN18zMA_a36772aa-88ba-4376-9d3f-642df4151ec1">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ica57130d0db94872b9b3a94cd9e7c39b_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfOS0xLTEtMS0xMjk2MDE_44f81791-6990-4057-8303-d8031d5febba"
      unitRef="usd">900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i9bcefb1b301b491f9f6a61d393edcd39_D20220101-20220101"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMTAtMC0xLTEtMTY1MTEwL3RleHRyZWdpb246OTQzY2FhMzJlMmY0NDk4OWE4ZTEwYTkwMDE5YjEyYmVfMTA5OTUxMTYyNzgzOQ_61938928-a99c-4ec0-a39f-85dbcbeb3a43">P3Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i6861efcf5c8e4791b4cf9947c83117e8_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMTAtMS0xLTEtMTYxNDE5_488da3a2-272a-4364-805b-cea6d0277038"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMTAtMS0xLTEtMTI5NjAx_efcac328-d292-46ad-82fb-7504449fbef4"
      unitRef="usd">28700000</us-gaap:Goodwill>
    <ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets
      contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMTItMS0xLTEtMTI5NjAx_50c0b976-05c0-46a8-89d0-d751b2549c41"
      unitRef="usd">32600000</ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets>
    <ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability
      contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMTQtMS0xLTEtMTI5NjAx_648d9134-eb8d-4027-a9e6-a431c0a86ea0"
      unitRef="usd">100000</ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMTUtMS0xLTEtMTI5NjAx_6c9a88a4-ae37-4fb2-9290-1255aa612c2f"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll
      contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMTYtMS0xLTEtMTI5NjAx_41f955d9-d3e9-4dad-b963-5bf27a4ce824"
      unitRef="usd">200000</ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMTctMS0xLTEtMTI5NjAx_856881b6-6516-43d7-9c61-b775647e2fae"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation
      contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMTgtMS0xLTEtMTI5NjAx_cc09a4b0-07e8-4789-98e6-ab0b66140f02"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMjAtMS0xLTEtMTI5NjAx_cdb751f9-5cca-4360-9a10-f08171401418"
      unitRef="usd">800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMjEtMS0xLTEtMTI5NjAx_7ae1bf4e-99ed-42bb-a528-2d390a7b7bb8"
      unitRef="usd">15900000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest
      contextRef="i9b102d83166e4bc490cf1528eaade88d_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOmJkNjgxOGE5NjVmYjQ1NDFhNzI4ODA4ZGE3MTBkYjNiL3RhYmxlcmFuZ2U6YmQ2ODE4YTk2NWZiNDU0MWE3Mjg4MDhkYTcxMGRiM2JfMjItMS0xLTEtMTI5NjAx_e90adc0c-ab51-4f38-821b-2036a80bac29"
      unitRef="usd">15900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RleHRyZWdpb246OWQ3MzQwYjJkZGYzNDljOWJjZWY5MjcxYjU5NDBkNWFfNjQ0MA_c16260db-d3cb-4b7d-a2c9-f31999706e57">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the cash paid for the acquisition during each period presented is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i944fc8295c154979b4c5e2ae485eb03b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfMi01LTEtMS0xMjk2MDE_85d5ccc2-8da6-4333-b79b-bfdddd71cd99"
      unitRef="usd">3900000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i090568ccb08b421a8703daa2d9b4d2c9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfMi03LTEtMS0xMjk2MDE_ca6abdfb-5a94-4850-9f18-60bc07e06942"
      unitRef="usd">0</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i944fc8295c154979b4c5e2ae485eb03b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfMy01LTEtMS0xMjk2MDE_060161f2-4f65-43f5-809d-0ba8be54d181"
      unitRef="usd">28700000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i090568ccb08b421a8703daa2d9b4d2c9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfMy03LTEtMS0xMjk2MDE_29a0f3b5-9957-4096-9b60-2b280af71dae"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i944fc8295c154979b4c5e2ae485eb03b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfNC01LTEtMS0xMjk2MDE_dea95930-c2f9-4cc8-b5ee-0a27f53946a0"
      unitRef="usd">800000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i090568ccb08b421a8703daa2d9b4d2c9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfNC03LTEtMS0xMjk2MDE_69c5a309-6f3e-4eb3-bd9f-6fd2e3af7f93"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <ehc:BusinessCombinationNoncontrollingInterestFairValue
      contextRef="i944fc8295c154979b4c5e2ae485eb03b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfNS01LTEtMS0xMjk2MDE_2574b252-4fe7-45c1-8913-f3b5f7aa381f"
      unitRef="usd">15900000</ehc:BusinessCombinationNoncontrollingInterestFairValue>
    <ehc:BusinessCombinationNoncontrollingInterestFairValue
      contextRef="i090568ccb08b421a8703daa2d9b4d2c9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfNS03LTEtMS0xMjk2MDE_74330eb9-1cd2-4555-8990-b93b6102ebdd"
      unitRef="usd">0</ehc:BusinessCombinationNoncontrollingInterestFairValue>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i944fc8295c154979b4c5e2ae485eb03b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfNy01LTEtMS0xMjk2MDE_c825d756-e1c6-463c-83bc-42681147e85d"
      unitRef="usd">15900000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i090568ccb08b421a8703daa2d9b4d2c9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjcyYTE0NmY3YTg2MjQxNTc4MThkMTU5ODU3N2RlZjY5L3RhYmxlcmFuZ2U6NzJhMTQ2ZjdhODYyNDE1NzgxOGQxNTk4NTc3ZGVmNjlfNy03LTEtMS0xMjk2MDE_b9f0b9f0-7846-4b4f-9cbe-9f063e6c729b"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RleHRyZWdpb246OWQ3MzQwYjJkZGYzNDljOWJjZWY5MjcxYjU5NDBkNWFfNjQ1OQ_5eff808d-2cc3-4884-a920-cd516f709ae9">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the above mentioned acquisition from the date of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisition been January&#160;1, 2021 (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.030%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Operating Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Income Attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired entities only: Actual from acquisition date to March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2022-03/31/2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2021-03/31/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjBlMTNhYWFiMjJjODQ1YWQ4NmY2ZDU3OWRkNWQyMWM5L3RhYmxlcmFuZ2U6MGUxM2FhYWIyMmM4NDVhZDg2ZjZkNTc5ZGQ1ZDIxYzlfNC0xLTEtMS0xMjk2MDE_846ca744-9b08-4a3a-92a4-a359cb52d837"
      unitRef="usd">1800000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjBlMTNhYWFiMjJjODQ1YWQ4NmY2ZDU3OWRkNWQyMWM5L3RhYmxlcmFuZ2U6MGUxM2FhYWIyMmM4NDVhZDg2ZjZkNTc5ZGQ1ZDIxYzlfNC0zLTEtMS0xMjk2MDE_cbf3c074-5871-4174-84d1-2b5b4d9fa411"
      unitRef="usd">200000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjBlMTNhYWFiMjJjODQ1YWQ4NmY2ZDU3OWRkNWQyMWM5L3RhYmxlcmFuZ2U6MGUxM2FhYWIyMmM4NDVhZDg2ZjZkNTc5ZGQ1ZDIxYzlfNS0xLTEtMS0xMjk2MDE_faedfe6c-5b47-4414-af36-2f3bfc67a389"
      unitRef="usd">1333600000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjBlMTNhYWFiMjJjODQ1YWQ4NmY2ZDU3OWRkNWQyMWM5L3RhYmxlcmFuZ2U6MGUxM2FhYWIyMmM4NDVhZDg2ZjZkNTc5ZGQ1ZDIxYzlfNS0zLTEtMS0xMjk2MDE_b8f9d7e1-a8dc-4e30-90b3-5cd915a86d49"
      unitRef="usd">87500000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjBlMTNhYWFiMjJjODQ1YWQ4NmY2ZDU3OWRkNWQyMWM5L3RhYmxlcmFuZ2U6MGUxM2FhYWIyMmM4NDVhZDg2ZjZkNTc5ZGQ1ZDIxYzlfNi0xLTEtMS0xMjk2MDE_6fcefac6-fa00-41a7-9362-7828ac181ec4"
      unitRef="usd">1232700000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV81OC9mcmFnOjlkNzM0MGIyZGRmMzQ5YzliY2VmOTI3MWI1OTQwZDVhL3RhYmxlOjBlMTNhYWFiMjJjODQ1YWQ4NmY2ZDU3OWRkNWQyMWM5L3RhYmxlcmFuZ2U6MGUxM2FhYWIyMmM4NDVhZDg2ZjZkNTc5ZGQ1ZDIxYzlfNi0zLTEtMS0xMjk2MDE_87e14345-9e85-42a4-85c2-aa3a6c28a70f"
      unitRef="usd">107500000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RleHRyZWdpb246NzhkMDgzZmIyMTQwNDE3Njk2ODVjZGI5NjM3YWJmNThfMTMzMA_e4ebc6d2-b6c1-4abf-a2cc-f12c2905f730">Variable Interest Entities&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022 and December&#160;31, 2021, we consolidated ten limited partnership-like entities that are variable interest entities (&#x201c;VIEs&#x201d;) and of which we are the primary beneficiary. Our ownership percentages in these entities range from 50.0% to 90.0% as of March&#160;31, 2022. Through partnership and management agreements with or governing each of these entities, we manage all of these entities and handle all day-to-day operating decisions. Accordingly, we have the decision making power over the activities that most significantly impact the economic performance of our VIEs and an obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections, and creation and maintenance of medical records. The terms of the agreements governing each of our VIEs prohibit us from using the assets of each VIE to satisfy the obligations of other entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and classifications of the consolidated VIEs&#x2019; assets and liabilities, which are included in our condensed consolidated balance sheet, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <ehc:VariableInterestEntityNumberofEntitiesConsolidated
      contextRef="ie1e6082c727c4be9853cda9efc66e5bd_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RleHRyZWdpb246NzhkMDgzZmIyMTQwNDE3Njk2ODVjZGI5NjM3YWJmNThfNjY_49ea043d-d4b5-452b-8c35-13caf1c41e9d"
      unitRef="entity">10</ehc:VariableInterestEntityNumberofEntitiesConsolidated>
    <ehc:VariableInterestEntityNumberofEntitiesConsolidated
      contextRef="i0b4d6eb8f1624f5780188f869aa798da_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RleHRyZWdpb246NzhkMDgzZmIyMTQwNDE3Njk2ODVjZGI5NjM3YWJmNThfNjY_5bee5a2a-fee3-4f1e-b649-e4b671a6a607"
      unitRef="entity">10</ehc:VariableInterestEntityNumberofEntitiesConsolidated>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="ice6f42f88a4d40f2bb746a1622dc9ab6_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RleHRyZWdpb246NzhkMDgzZmIyMTQwNDE3Njk2ODVjZGI5NjM3YWJmNThfMjcw_bb51f43c-52fd-4051-b8f7-0dc9cedfc96e"
      unitRef="number">0.500</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="ice148ce40d284c87b5c5abf7edb0c698_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RleHRyZWdpb246NzhkMDgzZmIyMTQwNDE3Njk2ODVjZGI5NjM3YWJmNThfMjc2_a4bea4a7-4833-4a50-8ea8-f95b52e702c0"
      unitRef="number">0.900</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RleHRyZWdpb246NzhkMDgzZmIyMTQwNDE3Njk2ODVjZGI5NjM3YWJmNThfMTMyNg_d6bbfd8f-b081-4000-91f3-7d9e4d236c7c">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and classifications of the consolidated VIEs&#x2019; assets and liabilities, which are included in our condensed consolidated balance sheet, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMy0xLTEtMS0xMjk2MDE_c5af0e4b-ae22-48dc-b99c-bb1b512f8821"
      unitRef="usd">600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMy0zLTEtMS0xMjk2MDE_5e2c8b0e-73f8-4c89-9413-98116df7b3ac"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfNC0xLTEtMS0xMjk2MDE_71812d4e-7b4f-41e7-883e-5c3bd39da94d"
      unitRef="usd">34700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfNC0zLTEtMS0xMjk2MDE_728f38ae-60dc-4170-887b-0060cea4bd95"
      unitRef="usd">36300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfNS0xLTEtMS0xMjk2MDE_81c47a36-a081-4ac8-8eac-bdeb378d0ed5"
      unitRef="usd">11400000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfNS0zLTEtMS0xMjk2MDE_f85a7b85-a482-4669-a0b8-e671759c3443"
      unitRef="usd">7700000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfNi0xLTEtMS0xMjk2MDE_f7cc5c14-628e-4dfc-baa7-323342ec84bb"
      unitRef="usd">46700000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfNi0zLTEtMS0xMjk2MDE_9c9fc240-3930-4d38-aed5-7276645dcf2c"
      unitRef="usd">44000000.0</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfNy0xLTEtMS0xMjk2MDE_17e36e86-99df-4b63-be7c-5d31b40ff995"
      unitRef="usd">115600000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfNy0zLTEtMS0xMjk2MDE_eeabdd0a-62c4-4a84-92fe-dddbe513bb65"
      unitRef="usd">116300000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfOC0xLTEtMS0xMjk2MDE_f870fb3e-a50e-4a34-b284-1aa1c6b1a8c4"
      unitRef="usd">3000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfOC0zLTEtMS0xMjk2MDE_2c099159-8f1d-409a-8b9c-d7345bb282d7"
      unitRef="usd">3200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfOS0xLTEtMS0xMjk2MDE_d6e2d5a9-3ad4-480c-b573-880726bd55ff"
      unitRef="usd">28400000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfOS0zLTEtMS0xMjk2MDE_e181aaf4-9f6c-499e-be63-a3526b7229ce"
      unitRef="usd">28300000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTAtMS0xLTEtMTI5NjAx_6c1a227d-0907-48a8-a772-58e1efcfce41"
      unitRef="usd">3100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTAtMy0xLTEtMTI5NjAx_167d476a-79ea-4c0b-8fa0-1eea2f8b930e"
      unitRef="usd">3300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTEtMS0xLTEtMTI5NjAx_928bdb57-c6cf-437f-995f-fc6df3f894b9"
      unitRef="usd">31200000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTEtMy0xLTEtMTI5NjAx_03e75314-7f0a-4645-9907-1baadeb4e040"
      unitRef="usd">31100000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTItMS0xLTEtMTI5NjAx_e16e1600-d1d0-4505-bfb2-09233739bdb2"
      unitRef="usd">228000000.0</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTItMy0xLTEtMTI5NjAx_112f0ed3-4aa4-40c5-bbd8-a4d402f3e5d2"
      unitRef="usd">226200000</us-gaap:Assets>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTUtMS0xLTEtMTI5NjAx_212ecd7c-576e-435f-8cdd-1fce769d2152"
      unitRef="usd">1000000.0</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTUtMy0xLTEtMTI5NjAx_ac53fb78-ea5b-4a65-9ec5-71f3e4e5ce87"
      unitRef="usd">1000000.0</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTYtMS0xLTEtMTI5NjAx_d3587324-c93e-43d4-b730-fbc04c5ce97e"
      unitRef="usd">1600000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTYtMy0xLTEtMTI5NjAx_3321f068-5493-4b3e-83b4-9de4a561ff0e"
      unitRef="usd">1500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTctMS0xLTEtMTI5NjAx_cf9cf6ef-a653-4d12-a011-7220c2962f34"
      unitRef="usd">5700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTctMy0xLTEtMTI5NjAx_44c35ba1-8c6f-412b-817f-0c8be84475bf"
      unitRef="usd">5900000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTgtMS0xLTEtMTI5NjAx_76323138-1977-4851-971e-2cbcbe88ea78"
      unitRef="usd">22600000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTgtMy0xLTEtMTI5NjAx_8439f1bf-2723-44c0-9f6b-4e0c6cbcb992"
      unitRef="usd">19400000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTktMS0xLTEtMTI5NjAx_6acafd13-c9cf-43d3-8b20-c49802c5f375"
      unitRef="usd">30900000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMTktMy0xLTEtMTI5NjAx_f4978ac5-ae09-4e83-bead-a091b19986b1"
      unitRef="usd">27800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMjAtMS0xLTEtMTI5NjAx_025c1400-283f-4b80-be2e-325798d61523"
      unitRef="usd">8400000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMjAtMy0xLTEtMTI5NjAx_f3536c22-47f5-404c-8d0c-b87b60fe823f"
      unitRef="usd">8600000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMjEtMS0xLTEtMTI5NjAx_59d5b669-755d-4874-b3dd-5645372ddc94"
      unitRef="usd">1500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMjEtMy0xLTEtMTI5NjAx_074aa2a9-3727-4991-a2f4-8aad21927095"
      unitRef="usd">1800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i027580bf78e446f9a1be1690bafd5055_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMjMtMS0xLTEtMTI5NjAx_524ca8c3-5de7-4cdd-ad28-76f8cbeefccb"
      unitRef="usd">40800000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i05a3cf2b8383461c94f1b27d662f994c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV82NC9mcmFnOjc4ZDA4M2ZiMjE0MDQxNzY5Njg1Y2RiOTYzN2FiZjU4L3RhYmxlOmM0M2ZjZWFmYWMxODQ5YzM5YzVlNjZjNmNmYmI1YmJiL3RhYmxlcmFuZ2U6YzQzZmNlYWZhYzE4NDljMzljNWU2NmM2Y2ZiYjViYmJfMjMtMy0xLTEtMTI5NjAx_50757705-f7ea-4344-a0ed-2662e1b342bc"
      unitRef="usd">38200000</us-gaap:Liabilities>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfNTUy_2eb0e67a-0177-4d54-a668-cf90e8afd3eb">Long-term Debt&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our long-term debt outstanding consists of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Agreement&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advances under revolving credit facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bonds payable&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.125% Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% Senior Notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,264.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,286.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,243.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 9, 2021, we announced the commencement of a consent solicitation of holders of our 5.75% Senior Notes due 2025, 4.50% Senior Notes due 2028, 4.75% Senior Notes due 2030, and 4.625% Senior Notes due 2031 (collectively the &#x201c;Senior Notes&#x201d;) for the adoption of certain amendments to an indenture (the &#x201c;Base Indenture&#x201d;) dated as of December&#160;1,&#160;2009, as supplemented by each Senior Notes&#x2019; respective supplemental indenture (together with the Base Indenture, the &#x201c;Indenture&#x201d;), which will provide us with greater flexibility in effecting the spin off discussed in Note 1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Each Indenture contains restrictive covenants that, among other things, limit our ability and the ability of certain of our subsidiaries to make certain asset dispositions, investments, and distributions to holders of our capital stock. The amendments to the Indentures permit us, subject to the leverage ratio condition set forth below, to distribute to our equity holders in one or more transactions (a &#x201c;Distribution&#x201d;) some or all of the common stock of a subsidiary that holds substantially all of the assets of our home health and hospice business. We may make any such distribution so long as the Leverage Ratio (as defined in each Indenture) is no more than 3.5 to 1.0 on a pro forma basis after giving effect thereto. The amendments also reduce the capacity under our restricted payments builder basket under each existing Indenture by $200&#160;million and amends the definition of &#x201c;Consolidated Net Income&#x201d; to allow us to exclude from Consolidated Net Income (a component of the Leverage Ratio) any fees, expenses or charges related to any Distribution and the solicitation of consents from the holders of the Senior Notes. In December 2021 and January 2022, we received the requisite consents for the adoption of these amendments. Under the terms of the amendments, we agreed to pay the holders of the Senior Notes a total of $40.5&#160;million, excluding fees. We paid $20&#160;million of this amount in January 2022. The remaining payment is contingent upon the execution of a Distribution and will be paid at such time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, we redeemed the remaining $100&#160;million in outstanding principal amount of the 5.125% Senior Notes due 2023 (the &#x201c;2023 Notes&#x201d;) using capacity under our revolving credit facility. Pursuant to the terms of the 2023 Notes, this optional redemption was made at a price of par. As a result of this redemption, we recorded an aggregate $0.3&#160;million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Loss on early extinguishment of debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfNTU1_b8902419-9738-4484-8982-13d65635b04f">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our long-term debt outstanding consists of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Agreement&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advances under revolving credit facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bonds payable&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.125% Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% Senior Notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,264.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,286.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,243.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermDebt
      contextRef="if2382ba129c3486f990cf1eea014c79c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMi0xLTEtMS0xMjk2MDE_0c2f0432-6dff-47a1-987a-dbee5878e615"
      unitRef="usd">305000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i5a79fe1564694ed59ea5acbff6dafa13_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMi0zLTEtMS0xMjk2MDE_e399d8d5-09f5-4110-bcd6-04068f2c3a52"
      unitRef="usd">200000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ibff53e67228d4423a59336248f7e8a19_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMy0xLTEtMS0xMjk2MDE_6a337378-73ec-47a0-9a2e-fce8c6a02fb5"
      unitRef="usd">235300000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="idace690b6bd742fbb796490135ea208a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMy0zLTEtMS0xMjk2MDE_fbaaae00-d0ad-461f-a960-de3f0c823205"
      unitRef="usd">238500000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i05147760daea434eab785f9bb77eed18_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfNS0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjpkN2VjOGQxMGY2NWI0YmZhYTc4YTI5NTJiYTcwNTM2Y180_fd1a326f-0c44-405c-9e4a-ab3d0f7bc918"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i05147760daea434eab785f9bb77eed18_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfNS0xLTEtMS0xMjk2MDE_49bc954c-b1f1-4d11-b459-56f7bc125bcd"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i518ef403619b45068725459a3694675c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfNS0zLTEtMS0xMjk2MDE_a96a536a-0113-498c-a0c3-81635f1fd428"
      unitRef="usd">99600000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i40e9e244d5e64ca7bf0040d18e4fa154_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfNi0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjphMDkwZDg1YTY2NGQ0MjNlYmRkNzQ0YjNmYTM2ZTg0MF80_3402c9c5-4882-4230-87d6-7b033034fd5a"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i40e9e244d5e64ca7bf0040d18e4fa154_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfNi0xLTEtMS0xMjk2MDE_3cab2d85-a11d-42fb-ab6e-9963db78ae69"
      unitRef="usd">347200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i54ff49d44cd5451da021a1dcfdd01a1c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfNi0zLTEtMS0xMjk2MDE_ad6f30c7-3aa2-43fe-8a81-06b28081d159"
      unitRef="usd">347000000.0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0b70c8bc77434fcf8e8e9acd22c58c45_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfNy0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjo1YTlmNDU2Mzk5ZjQ0YjIwYWE2ODgzZDg2MTNkYzQ5Nl80_48fd3f56-01a0-4362-accf-bdad2220338a"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i0b70c8bc77434fcf8e8e9acd22c58c45_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfNy0xLTEtMS0xMjk2MDE_77b3efe7-ff54-4425-9043-fef6ef651866"
      unitRef="usd">779500000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6856f14b9e514819a81cb49c920770ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfNy0zLTEtMS0xMjk2MDE_5750ef36-cee7-4f92-a7e9-7a8287fc6ab5"
      unitRef="usd">786800000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2cbef4d679154efc951e5c1786ca6bae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfOC0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjphMTM4YTI0M2I4NjI0OGI5OTRhYTRjMmIyN2M2MWZjNF80_99e2fb40-87d2-44e2-8cdc-cdf5f99a78bb"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i2cbef4d679154efc951e5c1786ca6bae_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfOC0xLTEtMS0xMjk2MDE_6ebb7f27-ca75-441f-bcf5-f51103e67e55"
      unitRef="usd">777200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="idfab5bb13d1544f8b92a234bde75f0a9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfOC0zLTEtMS0xMjk2MDE_36de1bb2-bb12-4a29-b2d6-7838b985556f"
      unitRef="usd">784700000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4d86755ee8bc4045b33ab465c664b7a9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfOS0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjphZjE2YzQxNTZiNGI0Yzk0YjBhMGE3YjI5YzU3YzliOF80_9857f756-60b0-4933-b8f3-f4afa1d4a010"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i4d86755ee8bc4045b33ab465c664b7a9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfOS0xLTEtMS0xMjk2MDE_f04b81de-4b2c-4051-ac10-6038ea6b643f"
      unitRef="usd">389900000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia263377add53435796d020a9fae4da89_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfOS0zLTEtMS0xMjk2MDE_88c5755b-94e0-4746-b71e-98a4b514d492"
      unitRef="usd">393700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="icb23149d81b145d683c4131122e0613c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTAtMS0xLTEtMTI5NjAx_a7157f32-d3ed-4e97-9656-6f05608b746f"
      unitRef="usd">49000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i135485ea2e124322b3cb9b6b28d207bc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTAtMy0xLTEtMTI5NjAx_4ced35f4-119e-4926-9362-34a79ada9eac"
      unitRef="usd">49600000</us-gaap:LongTermDebt>
    <us-gaap:FinanceLeaseLiability
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTEtMS0xLTEtMTI5NjAx_33e86cab-d803-458a-8489-a14b0af9a1da"
      unitRef="usd">381000000.0</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTEtMy0xLTEtMTI5NjAx_9dbe4275-600b-45f0-9df2-f23978d0f90c"
      unitRef="usd">386800000</us-gaap:FinanceLeaseLiability>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTItMS0xLTEtMTI5NjAx_bf807792-b7c0-441e-8cb7-25aec5307107"
      unitRef="usd">3264100000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTItMy0xLTEtMTI5NjAx_75f7430d-6694-4754-85ac-46c517888f6b"
      unitRef="usd">3286700000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTMtMS0xLTEtMTI5NjAx_cb78bfc6-1139-405d-9ad6-7ab8eabb6140"
      unitRef="usd">42800000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTMtMy0xLTEtMTI5NjAx_2db1acaa-f80f-428d-b9e2-6c7b233a264f"
      unitRef="usd">42800000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTQtMS0xLTEtMTI5NjAx_1c9a9d75-5b84-4441-8a92-5344e434d924"
      unitRef="usd">3221300000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RhYmxlOjkyOWE2YWMxZDUwMTQwZGU4NTExYzBlYTAwYjY5NWI3L3RhYmxlcmFuZ2U6OTI5YTZhYzFkNTAxNDBkZTg1MTFjMGVhMDBiNjk1YjdfMTQtMy0xLTEtMTI5NjAx_5afa447b-7dd6-4607-ab72-be77fab160aa"
      unitRef="usd">3243900000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2432d02ccbce4152a2ebbc620946b0eb_I20211209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfNDk0NzgwMjMyODkwNQ_0a2a0478-8dc4-405f-95de-f7dd2033c0f6"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib87798305a954bd68f594d703bee708a_I20211209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfNDk0NzgwMjMyODg4Mw_30e7fa58-8774-482d-a2fc-43b0b4a2942a"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if3dee57d45ef4967a06bff2bb1519d67_I20211209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfNDk0NzgwMjMyODg5MA_d9980e80-74dd-4386-b5fc-01897c24cd73"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9c40d9c98c634e8d9e33b00ff58b2939_I20211209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfNDk0NzgwMjMyODg5Nw_57a1335d-0965-426a-b1e1-0085e471262a"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i37b439614a834d5fa4da55874df55dc4_I20211209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfMTA5OTUxMTYzMDY2Nw_1a77c80e-9b88-43b0-a0d1-51b1074861c9"
      unitRef="number">3.5</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket
      contextRef="i37b439614a834d5fa4da55874df55dc4_I20211209"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfMTA5OTUxMTYzMDY4NQ_a4577b46-842d-4f3b-936c-2a7aa0e9caef"
      unitRef="usd">200000000</ehc:DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket>
    <ehc:DebtInstrumentAmendmentAgreementAmountToBePaid
      contextRef="i825551a2736a4a0cbed667eb8cc2cca2_D20211201-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfMTA5OTUxMTYzMDcxMw_4625e480-cba6-485b-a4dc-b5eff9a66174"
      unitRef="usd">40500000</ehc:DebtInstrumentAmendmentAgreementAmountToBePaid>
    <us-gaap:RepaymentsOfDebt
      contextRef="i368ed4d7ad354f0cab721ebb36d47844_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfMTA5OTUxMTYzMDc0MA_c567820e-fc35-4eaf-91dd-df80b17ca2fb"
      unitRef="usd">20000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i05147760daea434eab785f9bb77eed18_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfMTM2_d2e30d68-8d7f-4de6-b81a-5399131816fc"
      unitRef="usd">100000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i05147760daea434eab785f9bb77eed18_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfMTc4_987d3bf0-f14f-467d-9899-d829e1d70b6c"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id320e21f82b8400fadbbfe37b609516d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83Ni9mcmFnOmUwMjE3MDMyZDY1MDQyYmI4N2YyZDM5ZDIzNWRiZmQ5L3RleHRyZWdpb246ZTAyMTcwMzJkNjUwNDJiYjg3ZjJkMzlkMjM1ZGJmZDlfNDQ3_0234506f-352e-4a4e-ae5c-d2aa40260eb6"
      unitRef="usd">-300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RleHRyZWdpb246YmY2YzU4Yzc1ZDBkNGVlZmJmNTI4YWYyMDUzN2JkZTlfMzU4OQ_fc3cb7ee-ea8c-41fc-a6e3-5abda778c38f">Redeemable Noncontrolling Interests&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the activity related to our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributions declared&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the net income attributable to nonredeemable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as recorded in the shareholders&#x2019; equity section of the condensed consolidated balance sheets, and the net income attributable to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as recorded in the mezzanine section of the condensed consolidated balance sheets, to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net and comprehensive income attributable to noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; presented in the condensed consolidated statements of comprehensive income (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to nonredeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See also Note 6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:RedeemableNoncontrollingInterestTableTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RleHRyZWdpb246YmY2YzU4Yzc1ZDBkNGVlZmJmNTI4YWYyMDUzN2JkZTlfMzU4MA_32fca21a-8dc4-4ecd-96bd-378e9166fb8d">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the activity related to our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributions declared&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RedeemableNoncontrollingInterestTableTextBlock>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i39fdefb343d340ef94ee64a4ec92f2ae_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjUxN2YyOGRhMTUwYzQzOWE5ZmQ0YjViMzRmNDBiYWQ2L3RhYmxlcmFuZ2U6NTE3ZjI4ZGExNTBjNDM5YTlmZDRiNWIzNGY0MGJhZDZfMi0xLTEtMS0xMjk2MDE_35e02172-fc67-41fc-90c1-9f4af26d31ad"
      unitRef="usd">42200000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i5b46f0824cfc44a390637375c885461c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjUxN2YyOGRhMTUwYzQzOWE5ZmQ0YjViMzRmNDBiYWQ2L3RhYmxlcmFuZ2U6NTE3ZjI4ZGExNTBjNDM5YTlmZDRiNWIzNGY0MGJhZDZfMi0zLTEtMS0xMjk2MDE_5825905d-ab29-40b0-9542-3414b2cf9f6b"
      unitRef="usd">31600000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="if6ea604dd0d04859a2c8cc03396c69bb_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjUxN2YyOGRhMTUwYzQzOWE5ZmQ0YjViMzRmNDBiYWQ2L3RhYmxlcmFuZ2U6NTE3ZjI4ZGExNTBjNDM5YTlmZDRiNWIzNGY0MGJhZDZfMy0xLTEtMS0xMjk2MDE_92adb122-fb70-4ba6-b239-49479193c05e"
      unitRef="usd">1900000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i80c5200a89154eb89d8ae5eb77290c4e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjUxN2YyOGRhMTUwYzQzOWE5ZmQ0YjViMzRmNDBiYWQ2L3RhYmxlcmFuZ2U6NTE3ZjI4ZGExNTBjNDM5YTlmZDRiNWIzNGY0MGJhZDZfMy0zLTEtMS0xMjk2MDE_ced20bee-2e74-4fe9-8aca-da95db81f2cb"
      unitRef="usd">2400000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="if6ea604dd0d04859a2c8cc03396c69bb_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjUxN2YyOGRhMTUwYzQzOWE5ZmQ0YjViMzRmNDBiYWQ2L3RhYmxlcmFuZ2U6NTE3ZjI4ZGExNTBjNDM5YTlmZDRiNWIzNGY0MGJhZDZfNC0xLTEtMS0xMjk2MDE_e2dcf30e-6009-41fe-9358-e90eaf5e611e"
      unitRef="usd">900000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i80c5200a89154eb89d8ae5eb77290c4e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjUxN2YyOGRhMTUwYzQzOWE5ZmQ0YjViMzRmNDBiYWQ2L3RhYmxlcmFuZ2U6NTE3ZjI4ZGExNTBjNDM5YTlmZDRiNWIzNGY0MGJhZDZfNC0zLTEtMS0xMjk2MDE_86dd96f3-f2ae-4d93-add7-cb4971587e46"
      unitRef="usd">2300000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="ifc945c722fc841aa95f6763fdd77a02c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjUxN2YyOGRhMTUwYzQzOWE5ZmQ0YjViMzRmNDBiYWQ2L3RhYmxlcmFuZ2U6NTE3ZjI4ZGExNTBjNDM5YTlmZDRiNWIzNGY0MGJhZDZfMTEtMS0xLTEtMTI5NjAx_ae062584-4409-43d1-b261-4ccf9e3d264a"
      unitRef="usd">43200000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i61423539f4b4453f9ea5b7bbc38883be_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjUxN2YyOGRhMTUwYzQzOWE5ZmQ0YjViMzRmNDBiYWQ2L3RhYmxlcmFuZ2U6NTE3ZjI4ZGExNTBjNDM5YTlmZDRiNWIzNGY0MGJhZDZfMTEtMy0xLTEtMTI5NjAx_a90e193c-9d1e-4490-96a1-ca6bc6b7b153"
      unitRef="usd">31700000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <ehc:ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RleHRyZWdpb246YmY2YzU4Yzc1ZDBkNGVlZmJmNTI4YWYyMDUzN2JkZTlfMzU4NA_745680a8-21eb-4a15-ad19-bfb85787413f">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the net income attributable to nonredeemable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as recorded in the shareholders&#x2019; equity section of the condensed consolidated balance sheets, and the net income attributable to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as recorded in the mezzanine section of the condensed consolidated balance sheets, to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net and comprehensive income attributable to noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; presented in the condensed consolidated statements of comprehensive income (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to nonredeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ehc:ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjdhYTg1ZTQ3NThiNjQyMmJhN2QxNmU2NmNmZWI2ODlhL3RhYmxlcmFuZ2U6N2FhODVlNDc1OGI2NDIyYmE3ZDE2ZTY2Y2ZlYjY4OWFfMi0xLTEtMS0xMjk2MDE_55fb82a3-e3b8-4aae-afcc-4a80ed9eafb2"
      unitRef="usd">20700000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjdhYTg1ZTQ3NThiNjQyMmJhN2QxNmU2NmNmZWI2ODlhL3RhYmxlcmFuZ2U6N2FhODVlNDc1OGI2NDIyYmE3ZDE2ZTY2Y2ZlYjY4OWFfMi0zLTEtMS0xMjk2MDE_25b9c8c5-1286-40ab-a066-50a51ad3a446"
      unitRef="usd">23100000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjdhYTg1ZTQ3NThiNjQyMmJhN2QxNmU2NmNmZWI2ODlhL3RhYmxlcmFuZ2U6N2FhODVlNDc1OGI2NDIyYmE3ZDE2ZTY2Y2ZlYjY4OWFfMy0xLTEtMS0xMjk2MDE_70d31390-3992-4f22-9b54-3efae22f694f"
      unitRef="usd">1900000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjdhYTg1ZTQ3NThiNjQyMmJhN2QxNmU2NmNmZWI2ODlhL3RhYmxlcmFuZ2U6N2FhODVlNDc1OGI2NDIyYmE3ZDE2ZTY2Y2ZlYjY4OWFfMy0zLTEtMS0xMjk2MDE_96ef004e-d5f2-4063-92e5-2f3eb9d1305c"
      unitRef="usd">2400000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjdhYTg1ZTQ3NThiNjQyMmJhN2QxNmU2NmNmZWI2ODlhL3RhYmxlcmFuZ2U6N2FhODVlNDc1OGI2NDIyYmE3ZDE2ZTY2Y2ZlYjY4OWFfNC0xLTEtMS0xMjk2MDE_c05d8af1-a0b8-4afe-8917-f6bc11bda2d0"
      unitRef="usd">22600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV83OS9mcmFnOmJmNmM1OGM3NWQwZDRlZWZiZjUyOGFmMjA1MzdiZGU5L3RhYmxlOjdhYTg1ZTQ3NThiNjQyMmJhN2QxNmU2NmNmZWI2ODlhL3RhYmxlcmFuZ2U6N2FhODVlNDc1OGI2NDIyYmE3ZDE2ZTY2Y2ZlYjY4OWFfNC0zLTEtMS0xMjk2MDE_a5c6f7ed-f9ee-4dad-8170-9a3c239cea12"
      unitRef="usd">25500000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RleHRyZWdpb246YmUxYzA4YjVjMzNlNGI4NmE1MGNmOWZlNGRkMjUyMGRfMTQxMQ_9c1c207e-9258-4605-bf37-2ab26fb8ebf3">Fair Value Measurements&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Technique &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;  The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;  As of March&#160;31, 2022, $4.8&#160;million are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and $75.6&#160;million are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; assets in the condensed consolidated balance sheet. As of December&#160;31, 2021, $82.2&#160;million are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; assets in the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are assets and liabilities that are not required to be measured at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. During the three months ended March&#160;31, 2022 and 2021, we did not record any material gains or losses related to these assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Fair Value Measurements,&#x201d; to the consolidated financial statements accompanying the 2021 Form 10&#x2011;K, the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our condensed consolidated balance sheets. The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advances under revolving credit facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.125% Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;768.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% Senior Notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial commitments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letters of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;inputs within the fair value hierarchy. See Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Fair Value Measurements,&#x201d; to the consolidated financial statements accompanying the 2021 Form 10&#x2011;K.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RleHRyZWdpb246YmUxYzA4YjVjMzNlNGI4NmE1MGNmOWZlNGRkMjUyMGRfMTQyNQ_9f921633-2a4f-4c76-8a8b-cfec731cd97a">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Technique &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;  The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;  As of March&#160;31, 2022, $4.8&#160;million are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and $75.6&#160;million are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; assets in the condensed consolidated balance sheet. As of December&#160;31, 2021, $82.2&#160;million are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; assets in the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="icddbe6c9e899402ab0cd9e710f9d31ea_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfMy0xLTEtMS0xMjk2MDE_c8bd7a3a-6721-4790-b984-5566ead20c12"
      unitRef="usd">80400000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="idfc43ca1f96d45b5a0cf5b2d38ae5a60_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfMy0zLTEtMS0xMjk2MDE_281c6027-f6e3-4ce5-a033-71565b51a8db"
      unitRef="usd">3900000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ia8d214445f7041df915d431f92d7a70e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfMy01LTEtMS0xMjk2MDE_9fa7de5c-0d6a-4ece-8e11-50c82109979c"
      unitRef="usd">76500000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i9a7dc7ae27134c52a55c357b78dd3cff_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfMy03LTEtMS0xMjk2MDE_6eb5b97c-af4b-448e-bf7c-677ca1185966"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="icddbe6c9e899402ab0cd9e710f9d31ea_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfNS0xLTEtMS0xMjk2MDE_ce0d8ef1-074e-4026-9fb1-10ef9acbe8c7"
      unitRef="usd">43200000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="idfc43ca1f96d45b5a0cf5b2d38ae5a60_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfNS0zLTEtMS0xMjk2MDE_75535aea-1bb9-4f96-b5f3-38332c3b34d0"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="ia8d214445f7041df915d431f92d7a70e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfNS01LTEtMS0xMjk2MDE_865fa668-cb28-4235-8b9e-deef5e80a5ae"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i9a7dc7ae27134c52a55c357b78dd3cff_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfNS03LTEtMS0xMjk2MDE_77d03d24-2c34-4371-a2f2-172d1f6c0c26"
      unitRef="usd">43200000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i8ac35e30b3384503867b9b29c33fcd12_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfOC0xLTEtMS0xMjk2MDE_4ef067b9-8865-4839-9a5b-b724d58e0aec"
      unitRef="usd">82200000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i39472c9a755a464e8a2cc3ca1799e165_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfOC0zLTEtMS0xMjk2MDE_c105d734-81fb-4a96-aefc-8f0aad401adf"
      unitRef="usd">4100000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ie3e4ffea3ce24cf29b0a92241c3ecd15_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfOC01LTEtMS0xMjk2MDE_73a63044-8b01-46a6-bcd3-073ee795743e"
      unitRef="usd">78100000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ia606fb5d54a34f2fbc455e7223986acc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfOC03LTEtMS0xMjk2MDE_e312d507-6d17-41d4-9bff-cc5a10f78c1e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i8ac35e30b3384503867b9b29c33fcd12_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfMTAtMS0xLTEtMTI5NjAx_181ec135-e2b9-45a5-9e29-05b4c919c717"
      unitRef="usd">42200000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i39472c9a755a464e8a2cc3ca1799e165_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfMTAtMy0xLTEtMTI5NjAx_a8e05cdc-a796-4c79-b2a4-ab259902655f"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="ie3e4ffea3ce24cf29b0a92241c3ecd15_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfMTAtNS0xLTEtMTI5NjAx_2ac4f127-5e51-44d1-8e96-b80dfdddbce3"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="ia606fb5d54a34f2fbc455e7223986acc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmY4Yjg0MGFiNDBlYzQ0NzhhZGY5MDc2YjIwY2I1YjFmL3RhYmxlcmFuZ2U6ZjhiODQwYWI0MGVjNDQ3OGFkZjkwNzZiMjBjYjViMWZfMTAtNy0xLTEtMTI5NjAx_70de9cb3-cf5d-4591-bdb0-891aab7d74bf"
      unitRef="usd">42200000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i79fc6be415b54a58b5d2c217fab0f29b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RleHRyZWdpb246YmUxYzA4YjVjMzNlNGI4NmE1MGNmOWZlNGRkMjUyMGRfMTY0OTI2NzQ0NDMyOA_2670b7a5-24f2-44a8-9d59-be88e2f8a0a2"
      unitRef="usd">4800000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i59d953168b134eaba7885b47f0cda8fd_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RleHRyZWdpb246YmUxYzA4YjVjMzNlNGI4NmE1MGNmOWZlNGRkMjUyMGRfMTY0OTI2NzQ0NDM0Mg_93487c71-3cc4-43ca-a965-13185af72de5"
      unitRef="usd">75600000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="if034be9bc98b47cf8c97bf47ab9ea038_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RleHRyZWdpb246YmUxYzA4YjVjMzNlNGI4NmE1MGNmOWZlNGRkMjUyMGRfMTY0OTI2NzQ0NDM1Nw_aeeb5d4d-e5a8-4927-9186-ccc97d2eda1d"
      unitRef="usd">82200000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="i4a7b858f19554add8379afca7b705865_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RleHRyZWdpb246YmUxYzA4YjVjMzNlNGI4NmE1MGNmOWZlNGRkMjUyMGRfNjU5NzA2OTc2ODEwMQ_1e5e0869-e32d-451d-956d-9462bc5ec35b"
      unitRef="usd">0</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="i7b444a6f37fa4de1992c65a1698b0b20_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RleHRyZWdpb246YmUxYzA4YjVjMzNlNGI4NmE1MGNmOWZlNGRkMjUyMGRfNjU5NzA2OTc2ODEwMQ_5cc0b15f-602d-4fa7-a3ca-9051e8b91e15"
      unitRef="usd">0</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RleHRyZWdpb246YmUxYzA4YjVjMzNlNGI4NmE1MGNmOWZlNGRkMjUyMGRfMTQxNQ_af660af2-d529-49a8-bdae-95b5d1645f76">The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advances under revolving credit facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.125% Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;768.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% Senior Notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial commitments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letters of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:LongTermDebtFairValue
      contextRef="i64624582638a400485740c96311c1394_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMy0xLTEtMS0xMjk2MDE_20b04a74-1b45-4c5d-9911-122c5b4faa3c"
      unitRef="usd">305000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="if83c0d9db5394bde9d8b0c44800f9c9b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMy0zLTEtMS0xMjk2MDE_93bd5300-bc6d-4721-8822-1fd4b1df1fdd"
      unitRef="usd">305000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i91e7df9c82b3434983f969e537117392_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMy01LTEtMS0xMjk2MDE_8a46cbf3-71af-4451-8768-e4df5c8acb14"
      unitRef="usd">200000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i831cf2390be0435eaadf768914370cbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMy03LTEtMS0xMjk2MDE_04e3ddce-4785-4bc7-a4ab-636145ad960c"
      unitRef="usd">200000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i248a1de457614c1c9d9c3795a5c5c6c2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNC0xLTEtMS0xMjk2MDE_2b0c9041-36d5-4e40-aecb-497e32081986"
      unitRef="usd">235300000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i1d4f1aa977184bbbbfe5144289d41e12_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNC0zLTEtMS0xMjk2MDE_22f5e2b0-624b-4966-8755-7805234f03d0"
      unitRef="usd">236300000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i78e41d6d12974156b84238a2892182c6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNC01LTEtMS0xMjk2MDE_29f51405-46fe-403a-8525-b3f073e3c87b"
      unitRef="usd">238500000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="id07fee3147fe47a5868dde0e75b961bd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNC03LTEtMS0xMjk2MDE_63aecc51-0a26-474e-ac76-739359d27404"
      unitRef="usd">239600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i05147760daea434eab785f9bb77eed18_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNS0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjpmNzcxMWJkMzM1ZWM0MzdlODM1ZDVlNTQwYzdiMTBhNl80_50d97453-903f-43eb-bef6-feb4ec83b07d"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="i47572d62b06342fe93e19a7e55a4943a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNS0xLTEtMS0xMjk2MDE_885e091f-3bb6-467e-bc3b-56b5bfdb4d4a"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i73e315035b554c8aa1875547b4630339_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNS0zLTEtMS0xMjk2MDE_cd89a716-6143-45a2-a410-9d1ba4a98235"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i3c9476be5bf24acb9f60b2167f82eb5e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNS01LTEtMS0xMjk2MDE_35a04022-0afb-4629-bb25-575707729dc7"
      unitRef="usd">99600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i02839eb8521947c8b4c9744e0ac23d7a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNS03LTEtMS0xMjk2MDE_9fdc4185-1813-481a-a656-ef1419f1d190"
      unitRef="usd">100200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i40e9e244d5e64ca7bf0040d18e4fa154_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNi0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjowYmZjYWU3ZGU1MjQ0MTdlOTJlZGZlNzQ4MDA2NzRiNV80_1031dd48-4c14-4db9-a01c-871d0bcb46b5"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="i3fb81c7757df47a7872a6c2daef100ce_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNi0xLTEtMS0xMjk2MDE_b55691ec-3593-426a-86df-e1a910eb5a3f"
      unitRef="usd">347200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i1e88c315ef4c4d62ade591e994da366d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNi0zLTEtMS0xMjk2MDE_de846fe0-6b37-4cca-b043-d74c9b90b641"
      unitRef="usd">356100000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i2dbc9fad2e274e4eb37fa988811ee2a9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNi01LTEtMS0xMjk2MDE_12edb45e-eb41-4b14-b9f6-95360f73c5a7"
      unitRef="usd">347000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i94daa3156e1a45adbf33553663dd83fe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNi03LTEtMS0xMjk2MDE_e04c0456-cf84-40ed-8e57-97b25cee3584"
      unitRef="usd">357900000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0b70c8bc77434fcf8e8e9acd22c58c45_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNy0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjpjODliMWU2ZjAwZGQ0YWJjODU1MmQ1OTIwN2M5NGVlMF80_02450122-06a1-4536-a47b-d9ae39dc17fa"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="ibfcf9427557d461fbbebdf16a3b33843_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNy0xLTEtMS0xMjk2MDE_caa0048f-1966-4989-80ca-1417e3e74c10"
      unitRef="usd">779500000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i74ea71ca5cf549bf8c8f2f8fc6a335b2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNy0zLTEtMS0xMjk2MDE_44f97ce7-73cc-499b-9b10-f08539fd697a"
      unitRef="usd">790900000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ic05d7792773941d2b4f0ae2bfd35090b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNy01LTEtMS0xMjk2MDE_e04debe9-e026-4109-9e37-38c1b9609576"
      unitRef="usd">786800000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i4e473304e17c4251a584a305f441fc45_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfNy03LTEtMS0xMjk2MDE_26ff98eb-1df3-4c70-a8ee-e116685c2f8c"
      unitRef="usd">823000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2cbef4d679154efc951e5c1786ca6bae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOC0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjpmNjQ0ZTkxMjY2NmM0YTk4YjlhMzZjZmQyYjcxNmY0Nl80_67ccb168-7c99-4f1c-b885-746dc3651beb"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="ic402c5736b164f289ef558cc5bdc16b3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOC0xLTEtMS0xMjk2MDE_84c9e28f-d66d-4a6a-bb50-8566a402850a"
      unitRef="usd">777200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i7c080a5046b140e19a17e88f98ac2e72_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOC0zLTEtMS0xMjk2MDE_21ccbcba-0c9e-45f1-b224-1524fb4030a1"
      unitRef="usd">768000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ib5708fcd82894c208dadd2fea50fa007_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOC01LTEtMS0xMjk2MDE_4f15635f-9e33-42a7-a5bd-697b5d85b42a"
      unitRef="usd">784700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="icc43445772fb4f7cafc73de38ead4bd0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOC03LTEtMS0xMjk2MDE_d6c24f4b-5e11-4c3b-a41e-40ca40d457d1"
      unitRef="usd">824000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4d86755ee8bc4045b33ab465c664b7a9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOS0wLTEtMS0xMjk2MDEvdGV4dHJlZ2lvbjphNDBjNWJlYjY5N2U0MWI5YjU4MGFhMGMyNjdjNTJmMl80_65d38af5-bbb6-4c75-bcf9-30c61609545d"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="iab66f41dc66040f2856dd6db44d58787_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOS0xLTEtMS0xMjk2MDE_7bc42725-8ecc-4111-a038-42ebd62381f8"
      unitRef="usd">389900000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i41ff03c5cba2460d8cadd19e31f7ce2a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOS0zLTEtMS0xMjk2MDE_cbc81087-71b3-4cf2-9521-5be096924f71"
      unitRef="usd">374400000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="idedd404a57704848af9e8d99770a3e84_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOS01LTEtMS0xMjk2MDE_0ff1933c-e934-43d3-bff0-a800fe78ac04"
      unitRef="usd">393700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i0ccf6303eceb4c8882cde606d6046e98_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfOS03LTEtMS0xMjk2MDE_8f2dbe20-60cd-4487-87e2-6eadba9db6b0"
      unitRef="usd">407000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ib55408ef11da47b9a9ab25b915d6f44a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMTAtMS0xLTEtMTI5NjAx_985faeb4-ee82-466b-bb01-9c04300d6cb7"
      unitRef="usd">49000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ie932836488174026b6c0bb470e9937e1_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMTAtMy0xLTEtMTI5NjAx_946499ab-3aeb-49dc-9dc5-28cba6d1a3cc"
      unitRef="usd">49000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i1dcc02c84fae47a2a3f1e83d9186a6a2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMTAtNS0xLTEtMTI5NjAx_24d68923-44d9-4d87-84bc-43adddec6de2"
      unitRef="usd">49600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i8628daca39564875a3d296261d4ddd8a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMTAtNy0xLTEtMTI5NjAx_940a4100-078a-4488-855b-8c3759ecb4e8"
      unitRef="usd">49600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ic22004d0542449c28c0dbfbf72a7738f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMTItMS0xLTEtMTI5NjAx_9cf123b2-90c5-4024-9de6-7c9c3e44a3a6"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i9905941e5e914330a739320a89ef96fa_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMTItMy0xLTEtMTI5NjAx_ab192e24-2afc-4cf2-9880-de6ba81c7830"
      unitRef="usd">37200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i23319d48cfb542baa5100da894e4efd7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMTItNS0xLTEtMTI5NjAx_7fd49b15-0480-4e1e-9b37-20e4bac98a86"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i11f4eda008a3429e868ab8b5af645b77_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84Mi9mcmFnOmJlMWMwOGI1YzMzZTRiODZhNTBjZjlmZTRkZDI1MjBkL3RhYmxlOmZjMDE4YzVmNTg2MzRiNTg4MzFlMGE4ZDlkNDZiMzY3L3RhYmxlcmFuZ2U6ZmMwMThjNWY1ODYzNGI1ODgzMWUwYThkOWQ0NmIzNjdfMTItNy0xLTEtMTI5NjAx_9fb1dbda-4024-421a-a766-e92881d2fe56"
      unitRef="usd">38200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84NS9mcmFnOmE1NzQ5ZDcyYThjOTQzZjk4MzM2ODU2ZDcyMDRiNDQ2L3RleHRyZWdpb246YTU3NDlkNzJhOGM5NDNmOTgzMzY4NTZkNzIwNGI0NDZfMTI0Nw_ae93d47d-cdcd-4974-bb58-67246813de15">Share-Based Payments&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022, we issued a total of 0.6 million restricted stock awards to members of our management team and our board of directors. Approximately 0.2 million of these awards contain only a service condition, while the remainder contain both a service and a performance condition. For the awards that include a performance condition, the number of shares that will ultimately be granted to employees may vary based on the Company&#x2019;s performance during the applicable two year performance measurement period. Additionally, we granted 0.1 million stock options to members of our management team. The fair value of these awards and options was determined using the policies described in Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and Note&#160;14, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to the consolidated financial statements accompanying the 2021 Form 10&#x2011;K.&lt;/span&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic01094ffa7604c71a90a6271b77d95ef_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84NS9mcmFnOmE1NzQ5ZDcyYThjOTQzZjk4MzM2ODU2ZDcyMDRiNDQ2L3RleHRyZWdpb246YTU3NDlkNzJhOGM5NDNmOTgzMzY4NTZkNzIwNGI0NDZfNzk_82b58146-884c-4f1f-800a-5baa2bcf8a4b"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if3198110221a45879053dbae18100b29_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84NS9mcmFnOmE1NzQ5ZDcyYThjOTQzZjk4MzM2ODU2ZDcyMDRiNDQ2L3RleHRyZWdpb246YTU3NDlkNzJhOGM5NDNmOTgzMzY4NTZkNzIwNGI0NDZfMTgy_d4285833-edcd-4a8e-a637-4b66973dcc0e"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="idc081404cf0e4077909986bdf740a73b_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84NS9mcmFnOmE1NzQ5ZDcyYThjOTQzZjk4MzM2ODU2ZDcyMDRiNDQ2L3RleHRyZWdpb246YTU3NDlkNzJhOGM5NDNmOTgzMzY4NTZkNzIwNGI0NDZfMTI0Mw_0624671a-2455-40e1-b083-87b06ec28e2a">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i3075bca9de3b4ee89c80a477c6851ee1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84NS9mcmFnOmE1NzQ5ZDcyYThjOTQzZjk4MzM2ODU2ZDcyMDRiNDQ2L3RleHRyZWdpb246YTU3NDlkNzJhOGM5NDNmOTgzMzY4NTZkNzIwNGI0NDZfNTU3_3bcfc8f3-277d-4877-9958-0738cc3c429d"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84OC9mcmFnOjRiZGMxMTJhNjEzYTRkYzlhZGU3MzMxYjMyZjRjMjM0L3RleHRyZWdpb246NGJkYzExMmE2MTNhNGRjOWFkZTczMzFiMzJmNGMyMzRfNjg1_3410f6be-80af-44e8-bfd8-8a78d1a7fdfe">Income Taxes&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for income tax expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of $31.2 million for the three months ended March&#160;31, 2022 primarily resulted from the application of our estimated effective blended federal and state income tax rate. Our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for income tax expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of $34.5 million for the three months ended March 31, 2021 primarily resulted from the application of our estimated effective blended federal and state income tax rate offset by tax benefits resulting from share-based compensation windfalls.&lt;/span&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84OC9mcmFnOjRiZGMxMTJhNjEzYTRkYzlhZGU3MzMxYjMyZjRjMjM0L3RleHRyZWdpb246NGJkYzExMmE2MTNhNGRjOWFkZTczMzFiMzJmNGMyMzRfNTk_53a69111-d7c1-4267-9d03-0a87de76a529"
      unitRef="usd">31200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV84OC9mcmFnOjRiZGMxMTJhNjEzYTRkYzlhZGU3MzMxYjMyZjRjMjM0L3RleHRyZWdpb246NGJkYzExMmE2MTNhNGRjOWFkZTczMzFiMzJmNGMyMzRfNjY_25c1b012-0c19-4c06-bd62-a148d5aeb4ea"
      unitRef="usd">34500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RleHRyZWdpb246ZTMzNGRlZjI4ZTI2NDZiMDliMjE2NWQ2ZDQyMjNlMzVfNDk5_0a70fe03-3891-4c85-8504-e86bf318db86">Earnings per Common Share&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Income allocated to participating securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Encompass Health common shareholders:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Encompass Health common shareholders:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards, dilutive stock options, and restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note&#160;17, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings per Common Share&lt;/span&gt;, to the consolidated financial statements accompanying the 2021 Form 10&#x2011;K for additional information related to our common stock.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RleHRyZWdpb246ZTMzNGRlZjI4ZTI2NDZiMDliMjE2NWQ2ZDQyMjNlMzVfNTAz_d310ed3e-90a3-48ae-941b-de5f144272bd">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Income allocated to participating securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Encompass Health common shareholders:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Encompass Health common shareholders:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfNC0xLTEtMS0xMjk2MDE_bd9da633-9c5a-4996-92d6-a7b8c2c336f7"
      unitRef="usd">110100000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfNC0zLTEtMS0xMjk2MDE_a7d60cac-5805-472e-a2c0-9bc9ee344298"
      unitRef="usd">132800000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfNS0xLTEtMS0xMjk2MDE_7f13184c-0d84-45c3-ac02-078a5d1a1af4"
      unitRef="usd">22600000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfNS0zLTEtMS0xMjk2MDE_f5ded1bf-a731-4068-8dd5-e4d9cf40d4fc"
      unitRef="usd">25500000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfNi0xLTEtMS0xMjk2MDE_102ad7ba-003b-4f8f-9bb0-6068656cdd44"
      unitRef="usd">400000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfNi0zLTEtMS0xMjk2MDE_e73c3832-c1ca-4241-82b6-f58c04bf7787"
      unitRef="usd">500000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfOC0xLTEtMS0xMjk2MDE_cf4f09df-ab33-4d8c-9ba7-54752eeb88c3"
      unitRef="usd">87100000</ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic>
    <ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfOC0zLTEtMS0xMjk2MDE_876abaee-9fa8-454b-839a-f88baa92355d"
      unitRef="usd">106800000</ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfOS0xLTEtMS0xMjk2MDE_f8959763-0833-4d87-9ac7-65cdd512bf3e"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfOS0zLTEtMS0xMjk2MDE_87a98d98-95f6-4113-a271-fa18d3027310"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <ehc:NetIncomeLossAvailabletoCommonStockholders
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTEtMS0xLTEtMTI5NjAx_1615ecba-ecea-4fa4-97f4-28498eb4b00b"
      unitRef="usd">87100000</ehc:NetIncomeLossAvailabletoCommonStockholders>
    <ehc:NetIncomeLossAvailabletoCommonStockholders
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTEtMy0xLTEtMTI5NjAx_e7bb0b7c-7207-4924-9c8a-db906843f412"
      unitRef="usd">106800000</ehc:NetIncomeLossAvailabletoCommonStockholders>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTMtMS0xLTEtMTI5NjAx_fd312cbd-d41e-435c-9c29-55a31321f98c"
      unitRef="shares">99200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTMtMy0xLTEtMTI5NjAx_71401687-8ad0-4ed1-ba20-ffdcb4c6afc6"
      unitRef="shares">99000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTUtMS0xLTEtMTI5NjAx_528025eb-f1e0-4669-b223-176f68c4ab48"
      unitRef="usdPerShare">0.88</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTUtMy0xLTEtMTI5NjAx_89b8c877-8a78-4423-9d21-e8dc8693d63f"
      unitRef="usdPerShare">1.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTYtMS0xLTEtMTI5NjAx_5a25557e-4aca-4bbc-8b5d-9a14d4973151"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTYtMy0xLTEtMTI5NjAx_5a04d692-1c98-4219-adff-59e593b52a36"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTctMS0xLTEtMTI5NjAx_646cac16-ddd5-49ac-b529-8d24bbfd5542"
      unitRef="usdPerShare">0.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMTctMy0xLTEtMTI5NjAx_c15fdb43-bd21-44d7-b961-a6e1b3e2e52a"
      unitRef="usdPerShare">1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjEtMS0xLTEtMTI5NjAx_bd9da633-9c5a-4996-92d6-a7b8c2c336f7"
      unitRef="usd">110100000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjEtMy0xLTEtMTI5NjAx_a7d60cac-5805-472e-a2c0-9bc9ee344298"
      unitRef="usd">132800000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjItMS0xLTEtMTI5NjAx_7f13184c-0d84-45c3-ac02-078a5d1a1af4"
      unitRef="usd">22600000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjItMy0xLTEtMTI5NjAx_f5ded1bf-a731-4068-8dd5-e4d9cf40d4fc"
      unitRef="usd">25500000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjUtMS0xLTEtMTI5NjAx_4eaa03ed-0914-4ba5-be4f-e908c43611df"
      unitRef="usd">87500000</ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted>
    <ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjUtMy0xLTEtMTI5NjAx_c25575a1-ad1f-417c-a6da-5431ad623e4b"
      unitRef="usd">107300000</ehc:IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjYtMS0xLTEtMTI5NjAx_f8959763-0833-4d87-9ac7-65cdd512bf3e"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjYtMy0xLTEtMTI5NjAx_87a98d98-95f6-4113-a271-fa18d3027310"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjctMS0xLTEtMTI5NjAx_ae8c4988-e997-4ce5-881a-873f97f793c1"
      unitRef="usd">87500000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjctMy0xLTEtMTI5NjAx_29842694-9e1b-482c-a373-57004e767142"
      unitRef="usd">107300000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjktMS0xLTEtMTI5NjAx_d625537a-5f3d-4f88-824c-4f2d4ddc4215"
      unitRef="shares">100200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMjktMy0xLTEtMTI5NjAx_552b2bac-0450-4246-a322-5be18be1a44a"
      unitRef="shares">100200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMzEtMS0xLTEtMTI5NjAx_75cc2edb-67d4-49f9-8a05-ca340ad6aa5c"
      unitRef="usdPerShare">0.87</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMzEtMy0xLTEtMTI5NjAx_981c87cb-aba3-46af-97bb-0465220f5809"
      unitRef="usdPerShare">1.07</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMzItMS0xLTEtMTI5NjAx_1df8982c-264c-4fb4-a558-82d6530e9a70"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMzItMy0xLTEtMTI5NjAx_c0d1ed92-b6d8-453c-84e2-8cd079c0badd"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMzMtMS0xLTEtMTI5NjAx_7fc5d7cf-d5ac-41ec-a476-33ec6bac89b3"
      unitRef="usdPerShare">0.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjMyODE5MzM1NDBmNTRmMDQ4NmNlMDczYWEzNzExNmZlL3RhYmxlcmFuZ2U6MzI4MTkzMzU0MGY1NGYwNDg2Y2UwNzNhYTM3MTE2ZmVfMzMtMy0xLTEtMTI5NjAx_86aa6b58-a91f-4f1c-9c65-bbb83e5f064f"
      unitRef="usdPerShare">1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RleHRyZWdpb246ZTMzNGRlZjI4ZTI2NDZiMDliMjE2NWQ2ZDQyMjNlMzVfNDg4_47ca7853-b119-4fc2-a945-7d5c3f31a811">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards, dilutive stock options, and restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjU5YTdjNWUwZGQyMDRjZmM5YTk0MWNlMzk1NDMwM2FkL3RhYmxlcmFuZ2U6NTlhN2M1ZTBkZDIwNGNmYzlhOTQxY2UzOTU0MzAzYWRfMi0xLTEtMS0xMjk2MDE_fd312cbd-d41e-435c-9c29-55a31321f98c"
      unitRef="shares">99200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjU5YTdjNWUwZGQyMDRjZmM5YTk0MWNlMzk1NDMwM2FkL3RhYmxlcmFuZ2U6NTlhN2M1ZTBkZDIwNGNmYzlhOTQxY2UzOTU0MzAzYWRfMi0zLTEtMS0xMjk2MDE_71401687-8ad0-4ed1-ba20-ffdcb4c6afc6"
      unitRef="shares">99000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjU5YTdjNWUwZGQyMDRjZmM5YTk0MWNlMzk1NDMwM2FkL3RhYmxlcmFuZ2U6NTlhN2M1ZTBkZDIwNGNmYzlhOTQxY2UzOTU0MzAzYWRfNS0xLTEtMS0xMjk2MDE_619198d0-68a4-4f9f-b173-fe50c5c04a8f"
      unitRef="shares">1000000.0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjU5YTdjNWUwZGQyMDRjZmM5YTk0MWNlMzk1NDMwM2FkL3RhYmxlcmFuZ2U6NTlhN2M1ZTBkZDIwNGNmYzlhOTQxY2UzOTU0MzAzYWRfNS0zLTEtMS0xMjk2MDE_b46a9150-5dd0-4db6-b357-d96741b92c69"
      unitRef="shares">1200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjU5YTdjNWUwZGQyMDRjZmM5YTk0MWNlMzk1NDMwM2FkL3RhYmxlcmFuZ2U6NTlhN2M1ZTBkZDIwNGNmYzlhOTQxY2UzOTU0MzAzYWRfNi0xLTEtMS0xMjk2MDE_61432f07-086d-49b0-a75a-6fdbfeb7511e"
      unitRef="shares">100200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85MS9mcmFnOmUzMzRkZWYyOGUyNjQ2YjA5YjIxNjVkNmQ0MjIzZTM1L3RhYmxlOjU5YTdjNWUwZGQyMDRjZmM5YTk0MWNlMzk1NDMwM2FkL3RhYmxlcmFuZ2U6NTlhN2M1ZTBkZDIwNGNmYzlhOTQxY2UzOTU0MzAzYWRfNi0zLTEtMS0xMjk2MDE_98e9ac00-02f2-497e-95d3-2b505d4ca859"
      unitRef="shares">100200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:LossContingencyDisclosures
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85NC9mcmFnOjQ5ODcxZjVhNmZhMTRlYWRiMzcxNmVjMDhlOTZjNTM1L3RleHRyZWdpb246NDk4NzFmNWE2ZmExNGVhZGIzNzE2ZWMwOGU5NmM1MzVfMzY3MQ_02a6a036-1bb4-4d1b-8310-cb05c3babeee">Contingencies and Other Commitments&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Matters&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The False Claims Act allows private citizens, called &#x201c;relators,&#x201d; to institute civil proceedings on behalf of the United States alleging violations of the False Claims Act. These lawsuits, also known as &#x201c;whistleblower&#x201d; or &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; actions, can involve significant monetary damages, fines, attorneys&#x2019; fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; cases are sealed at the time of filing, which means knowledge of the information contained in the complaint typically is limited to the relator, the federal government, and the presiding court. The defendant in a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; action may remain unaware of the existence of a sealed complaint for years. While the complaint is under seal, the government reviews the merits of the case and may conduct a broad investigation and seek discovery from the defendant and other parties before deciding whether to intervene in the case and take the lead on litigating the claims. The court lifts the seal when the government makes its decision on whether to intervene. If the government decides not to intervene, the relator may elect to continue to pursue the lawsuit individually on behalf of the government. It is possible that &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; cases brought pursuant to the False Claims Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the United States Department of Health and Human Services Office of Inspector General and the Centers for Medicare &amp;amp; Medicaid Services relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, Encompass Health refunding amounts to Medicare or other federal healthcare programs.&lt;/span&gt;&lt;/div&gt;</us-gaap:LossContingencyDisclosures>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMzI2Mw_76478167-1e1d-46c3-b386-d168a0a9650f">Segment Reporting&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our internal financial reporting and management structure is focused on the major types of services provided by Encompass Health. We manage our operations using two operating segments which are also our reportable segments: (1)&#160;inpatient rehabilitation and (2)&#160;home health and hospice. These reportable operating segments are consistent with information used by our chief executive officer, who is our chief operating decision maker, to assess performance and allocate resources. The following is a brief description of our reportable segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Our national network of inpatient rehabilitation hospitals stretches across 35 states and Puerto Rico, with a concentration of hospitals in the eastern half of the United States and Texas. As of March&#160;31, 2022, we operate 147 inpatient rehabilitation hospitals. We are the sole owner of 93 of these hospitals. We retain 50.0% to 97.5% ownership in the remaining 54 jointly owned hospitals. In addition, we manage two inpatient rehabilitation units through management contracts. We provide specialized rehabilitative treatment on both an inpatient and outpatient basis. Our inpatient rehabilitation hospitals provide a higher level of rehabilitative care to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Home Health and Hospice &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- As of March&#160;31, 2022, we provide home health services in 252 locations and hospice services in 99 locations across 34 states with concentrations in the southern half of the United States. We are the sole owner of 335 of these locations. We retain 50.0% to 90.0% ownership in the remaining 16 jointly owned locations. Our home health services include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. Hospice care focuses on the quality of life for patients who are experiencing an advanced, life limiting illness while treating the person and symptoms of the disease, rather than the disease itself. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies of our reportable segments are the same as those described in Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to the consolidated financial statements accompanying the 2021 Form 10&#x2011;K. All revenues for our services are generated through external customers. See Note 1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Net Operating Revenues,&#x201d; for the disaggregation of our revenues. No corporate overhead is allocated to either of our reportable segments. Our chief operating decision maker evaluates the performance of our segments and allocates resources to them based on adjusted earnings before interest, taxes, depreciation, and amortization (&#x201c;Segment Adjusted EBITDA&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selected financial information for our reportable segments is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient rehabilitation:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Occupancy costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home health and hospice:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service (excluding depreciation and amortization)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Support and overhead costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense (income)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net income of nonconsolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment Adjusted EBITDA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Encompass Health Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,199.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,745.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,944.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in and advances to nonconsolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,864.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in and advances to nonconsolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment reconciliations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Segment Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) gain on disposal or impairment of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on early extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense and amortization of debt discounts and fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair market value of equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income from continuing operations before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional detail regarding the revenues of our operating segments by service line follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient rehabilitation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,036.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outpatient and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inpatient rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home health and hospice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total home health and hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,230.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMTg1_ecab0597-40a0-430f-bc72-8f48b1e2b220"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="i53bdf1d6ecf041d7af98f062aa3d7212_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfNjcy_f1a715af-7386-4575-a5eb-d27fc4acb16f"
      unitRef="state">35</us-gaap:NumberOfStatesInWhichEntityOperates>
    <ehc:NumberOfInpatientRehabilitationHospitals
      contextRef="i53bdf1d6ecf041d7af98f062aa3d7212_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfODA2_2d169de0-0bdf-4d1b-8b63-2d9eec65278c"
      unitRef="hospital">147</ehc:NumberOfInpatientRehabilitationHospitals>
    <ehc:Numberofsolelyownedinpatientrehabilitationhospitals
      contextRef="i53bdf1d6ecf041d7af98f062aa3d7212_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfODcw_18178a02-1aaf-47b5-b3db-87873b409db0"
      unitRef="hospital">93</ehc:Numberofsolelyownedinpatientrehabilitationhospitals>
    <ehc:Jointventureownershippercentage
      contextRef="i96474acd4c0142dda31b7d96f99582f1_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfOTAz_26e00931-b6f0-420d-ae4c-ec1e167053a9"
      unitRef="number">0.500</ehc:Jointventureownershippercentage>
    <ehc:Jointventureownershippercentage
      contextRef="i79515ce75bf44070a97a38241f1e7d61_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfOTA5_12e316bd-09fe-40e4-88f2-2a3d67d0b3bd"
      unitRef="number">0.975</ehc:Jointventureownershippercentage>
    <ehc:Numberofjointlyownedinpatientrehabilitationhospitals
      contextRef="i53bdf1d6ecf041d7af98f062aa3d7212_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfOTM5_0879f0de-566b-49a6-8719-c4f75e78c126"
      unitRef="hospital">54</ehc:Numberofjointlyownedinpatientrehabilitationhospitals>
    <ehc:NumberOfInpatientRehabilitationUnitsUnderManagementContracts
      contextRef="i53bdf1d6ecf041d7af98f062aa3d7212_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfOTkw_9a158385-628e-429d-8e8a-40e3edadfde8"
      unitRef="hospital">2</ehc:NumberOfInpatientRehabilitationUnitsUnderManagementContracts>
    <ehc:Numberofhomehealthlocations
      contextRef="i4f992e9347194664b26f07fbc9a93d86_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMTUxMQ_64b2fe6d-1e7c-494f-b4ea-62a6bb32a8ed"
      unitRef="location">252</ehc:Numberofhomehealthlocations>
    <ehc:Numberofhospicelocations
      contextRef="i4f992e9347194664b26f07fbc9a93d86_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMTU0OA_7f20bdac-1caf-41f7-b6a1-34b1def5d903"
      unitRef="location">99</ehc:Numberofhospicelocations>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="i4f992e9347194664b26f07fbc9a93d86_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMTU2OA_99d3b02e-f6ec-4986-b1ce-69d9bbb40bb3"
      unitRef="state">34</us-gaap:NumberOfStatesInWhichEntityOperates>
    <ehc:Numberofsolelyownedhospitalbasedhomehealthandhospicelocations
      contextRef="i4f992e9347194664b26f07fbc9a93d86_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMTgwMQ_bcea5c00-d038-4704-827f-639efe74e6c2"
      unitRef="location">335</ehc:Numberofsolelyownedhospitalbasedhomehealthandhospicelocations>
    <ehc:Jointventureownershippercentage
      contextRef="iefcb7a67042b48cfb0c73139f067b3df_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMTgzNA_c36a0ca7-ca63-4fa5-bd37-f701ed47d6da"
      unitRef="number">0.500</ehc:Jointventureownershippercentage>
    <ehc:Jointventureownershippercentage
      contextRef="ia9f95cf921114fbfb5398dadad725123_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMTg0MA_c902996d-0296-47b3-b8b7-0c4092868924"
      unitRef="number">0.900</ehc:Jointventureownershippercentage>
    <ehc:Numberofjointlyownedhospitalbasedhomehealthandhospicelocations
      contextRef="i4f992e9347194664b26f07fbc9a93d86_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMTg3MA_88342b99-825b-4035-97cb-f3fce8e94e37"
      unitRef="location">16</ehc:Numberofjointlyownedhospitalbasedhomehealthandhospicelocations>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMzI2Ng_669e2edd-6cae-4446-a7d8-f9f61ea37d21">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selected financial information for our reportable segments is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient rehabilitation:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Occupancy costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home health and hospice:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service (excluding depreciation and amortization)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Support and overhead costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense (income)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net income of nonconsolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment Adjusted EBITDA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMy0xLTEtMS0xMjk2MDE_20edfffb-ff31-4860-8c9d-6281cd93fcc0"
      unitRef="usd">1059300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMy0zLTEtMS0xMjk2MDE_d697a0a9-5da8-4ba8-b8c1-fb179eb7ae8d"
      unitRef="usd">959900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMy05LTEtMS0xMjk2MDE_73c2d8d7-c0f9-4e8c-b6a2-82eb76bdbc65"
      unitRef="usd">274300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMy0xMS0xLTEtMTI5NjAx_fdeb8ec9-16a6-48b1-959b-e6fecebf784f"
      unitRef="usd">270500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfNi0xLTEtMS0xMjk2MDE_2eeb1f91-d3e8-4097-b4c6-18acf656b9ab"
      unitRef="usd">587400000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfNi0zLTEtMS0xMjk2MDE_a55d8cd6-cd6b-40da-82f9-e2e4e8ba12d0"
      unitRef="usd">501900000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfNi05LTEtMS0xMjk2MDE_91c3bb7e-0307-45bf-9dd4-a0391f0f75b1"
      unitRef="usd">0</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfNi0xMS0xLTEtMTI5NjAx_38f14d66-9216-4b4b-a7e6-46c1d5af0fe9"
      unitRef="usd">0</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfNy0xLTEtMS0xMjk2MDE_3f948120-71a2-47b0-88f1-981ea5538429"
      unitRef="usd">158300000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfNy0zLTEtMS0xMjk2MDE_c2445f3b-637a-4fde-94ce-00aad89802ea"
      unitRef="usd">140000000.0</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfNy05LTEtMS0xMjk2MDE_eea575ec-eefb-4e52-bb51-be2614b6f6b5"
      unitRef="usd">0</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfNy0xMS0xLTEtMTI5NjAx_bdd11661-f16b-48ae-8bf3-e444bdd96dfb"
      unitRef="usd">0</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:SuppliesExpense
      contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfOC0xLTEtMS0xMjk2MDE_5c474aa5-3026-4b5b-9b05-cf94350d1858"
      unitRef="usd">49800000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfOC0zLTEtMS0xMjk2MDE_c15a4c60-ab71-43cf-9fa8-000ff5c8f5ff"
      unitRef="usd">45200000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfOC05LTEtMS0xMjk2MDE_2abafbf9-d88c-4ad1-aaf3-f713537d3c9b"
      unitRef="usd">0</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfOC0xMS0xLTEtMTI5NjAx_40dfb3dd-3cd8-40f7-9cc0-e3185897f7c5"
      unitRef="usd">0</us-gaap:SuppliesExpense>
    <ehc:OccupancyCost
      contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfOS0xLTEtMS0xMjk2MDE_e8c5238d-8a5c-423a-b6d5-b908de885607"
      unitRef="usd">15400000</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfOS0zLTEtMS0xMjk2MDE_4e79a4a5-9bf7-4a89-92af-9592d3cf73fa"
      unitRef="usd">15100000</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfOS05LTEtMS0xMjk2MDE_c0f5ac74-b9d5-42a2-a64c-0c09e3b8560a"
      unitRef="usd">0</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfOS0xMS0xLTEtMTI5NjAx_33ebf9e4-1a03-47e7-8edc-fad4e52009ce"
      unitRef="usd">0</ehc:OccupancyCost>
    <ehc:CostofServicesExcludingDepreciationandAmortization
      contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTEtMS0xLTEtMTI5NjAx_3e65273f-c108-44d1-8af1-a8117daa6ec6"
      unitRef="usd">0</ehc:CostofServicesExcludingDepreciationandAmortization>
    <ehc:CostofServicesExcludingDepreciationandAmortization
      contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTEtMy0xLTEtMTI5NjAx_133a0d06-6102-4c8e-a311-3da6ce436e82"
      unitRef="usd">0</ehc:CostofServicesExcludingDepreciationandAmortization>
    <ehc:CostofServicesExcludingDepreciationandAmortization
      contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTEtOS0xLTEtMTI5NjAx_29a8e5b2-8d4b-4f20-9386-f1b2ba1b63da"
      unitRef="usd">124400000</ehc:CostofServicesExcludingDepreciationandAmortization>
    <ehc:CostofServicesExcludingDepreciationandAmortization
      contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTEtMTEtMS0xLTEyOTYwMQ_8b643967-40db-47a1-889d-b52aa5fd8d2a"
      unitRef="usd">118100000</ehc:CostofServicesExcludingDepreciationandAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldOverhead
      contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTItMS0xLTEtMTI5NjAx_bc4c9c7b-7752-470d-ba75-e0ddc0e95753"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSoldOverhead>
    <us-gaap:CostOfGoodsAndServicesSoldOverhead
      contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTItMy0xLTEtMTI5NjAx_983eb8b8-f7d4-4d4b-8100-d4d898692454"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSoldOverhead>
    <us-gaap:CostOfGoodsAndServicesSoldOverhead
      contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTItOS0xLTEtMTI5NjAx_7318d079-a1df-472a-bc30-534d38b3975b"
      unitRef="usd">99200000</us-gaap:CostOfGoodsAndServicesSoldOverhead>
    <us-gaap:CostOfGoodsAndServicesSoldOverhead
      contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTItMTEtMS0xLTEyOTYwMQ_e19813b6-f059-4b30-82ad-344c6e2e5ce1"
      unitRef="usd">101400000</us-gaap:CostOfGoodsAndServicesSoldOverhead>
    <us-gaap:CostsAndExpenses
      contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTMtMS0xLTEtMTI5NjAx_812c3b05-c2a2-44dc-b3ce-095b9184982b"
      unitRef="usd">810900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTMtMy0xLTEtMTI5NjAx_e2b61197-55e3-4000-b812-3d333feac6e5"
      unitRef="usd">702200000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTMtOS0xLTEtMTI5NjAx_dd080b8c-4909-467c-a081-8d525839d6e6"
      unitRef="usd">223600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTMtMTEtMS0xLTEyOTYwMQ_b4e8ebc5-c8d4-4f07-889a-be7d68255202"
      unitRef="usd">219500000</us-gaap:CostsAndExpenses>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTQtMS0xLTEtMTI5NjAx_aeeb1aa3-2d73-47cb-b5fd-663738d32a18"
      unitRef="usd">-1100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTQtMy0xLTEtMTI5NjAx_0daf733a-d431-4f5e-ab80-f1dfa5df3f58"
      unitRef="usd">1500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTQtOS0xLTEtMTI5NjAx_36fe407d-7395-4888-af8e-5b1e9e9d7cd6"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTQtMTEtMS0xLTEyOTYwMQ_3ac6517f-e36c-4ad6-a0f1-8d7cc253ee36"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTUtMS0xLTEtMTI5NjAx_f6cae5d3-d558-4364-9bbb-fd622e7a16b0"
      unitRef="usd">900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTUtMy0xLTEtMTI5NjAx_4f3c8261-2abb-4601-a6d6-b7eff6f94402"
      unitRef="usd">800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTUtOS0xLTEtMTI5NjAx_ef373bac-b3ee-4414-bf61-39da47bf5306"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTUtMTEtMS0xLTEyOTYwMQ_10e5c72e-4605-4c13-9bb3-e0e9f15f6b2a"
      unitRef="usd">200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTYtMS0xLTEtMTI5NjAx_6fd37ee2-27b8-44bd-87d2-2399c27fee49"
      unitRef="usd">22000000.0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTYtMy0xLTEtMTI5NjAx_cbea3438-bb48-4ed6-a82a-863339296a6c"
      unitRef="usd">25100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTYtOS0xLTEtMTI5NjAx_927a745b-8b5b-4499-9187-c8c3ee701a41"
      unitRef="usd">600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTYtMTEtMS0xLTEyOTYwMQ_2327d641-820d-4dd9-ac2f-95d537a26f51"
      unitRef="usd">400000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <ehc:AdjustedEBITDA
      contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTctMS0xLTEtMTI5NjAx_ddc3e539-bc1c-433a-8495-e5e411935019"
      unitRef="usd">226200000</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTctMy0xLTEtMTI5NjAx_661948d6-b170-4b95-a369-393d5f09a313"
      unitRef="usd">234900000</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTctOS0xLTEtMTI5NjAx_d0f4e8ff-1f0c-4609-bd87-71904f6cd6e6"
      unitRef="usd">50100000</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTctMTEtMS0xLTEyOTYwMQ_570f8fb3-9fa2-4edb-a933-fb9653fbf774"
      unitRef="usd">50800000</ehc:AdjustedEBITDA>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTktMS0xLTEtMTI5NjAx_c4dcc116-33e7-460c-a91a-6d85e8fc34fe"
      unitRef="usd">117800000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTktMy0xLTEtMTI5NjAx_b46a92a7-2a32-4780-b859-5104e248534d"
      unitRef="usd">99800000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTktOS0xLTEtMTI5NjAx_dac50874-8d8e-4b81-9083-b07c5bd6403c"
      unitRef="usd">2300000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOjRkMWMyNzBjMmJjZTQxODI4NWJmNTc0OTVhYzU4ZGFjL3RhYmxlcmFuZ2U6NGQxYzI3MGMyYmNlNDE4Mjg1YmY1NzQ5NWFjNThkYWNfMTktMTEtMS0xLTEyOTYwMQ_504e59ba-1296-41e3-980e-09eb88d0c33c"
      unitRef="usd">900000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfNDk0NzgwMjMyODI3Mg_e1d7aee8-c937-49d4-8238-877a98b93d45">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inpatient Rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Home Health and Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Encompass Health Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,199.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,745.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,944.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in and advances to nonconsolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,721.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,864.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in and advances to nonconsolidated affiliates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets
      contextRef="i53bdf1d6ecf041d7af98f062aa3d7212_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfMi0xLTEtMS0xMzE5ODY_a894270d-2a4f-4055-9a47-5e34183bf127"
      unitRef="usd">5199000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i4f992e9347194664b26f07fbc9a93d86_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfMi0zLTEtMS0xMzE5ODY_733d6309-0002-4cbe-9ebf-c8b6e68d23a4"
      unitRef="usd">1745000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfMi01LTEtMS0xMzE5ODY_777e8c01-0fb5-4637-a255-0fddea49e4ef"
      unitRef="usd">6944000000</us-gaap:Assets>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i53bdf1d6ecf041d7af98f062aa3d7212_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfMy0xLTEtMS0xNDQ4MTc_ac10b872-ca3c-4160-b8f8-b4570fb40021"
      unitRef="usd">2200000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i4f992e9347194664b26f07fbc9a93d86_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfMy0zLTEtMS0xMzE5OTM_a4457891-a37f-490d-b2fa-42aadd5a5e8a"
      unitRef="usd">1600000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="if5385614e8bd4b7081a64d6cba8c9291_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfMy01LTEtMS0xMzE5OTM_867ac8c4-c3c4-4513-8d61-d45ca87f90e1"
      unitRef="usd">3800000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:Assets
      contextRef="ibabc6d389eb7499992b42a9d1f4b3120_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfNS0xLTEtMS0xMzIwMDE_86298b17-4282-42f5-901d-1e872877bcdc"
      unitRef="usd">5143000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i407e8fe2e2364e5d91792421c5019898_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfNS0zLTEtMS0xMzIwMDE_3ce7faf4-1fe9-4604-9fce-63ac95bdd9e9"
      unitRef="usd">1721900000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfNS01LTEtMS0xMzIwMDE_08256c54-4501-4646-acfd-1445fa4445a4"
      unitRef="usd">6864900000</us-gaap:Assets>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="ibabc6d389eb7499992b42a9d1f4b3120_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfNi0xLTEtMS0xNDQ4MTc_c948081e-323f-4893-a876-b18f2dd46bb5"
      unitRef="usd">2400000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i407e8fe2e2364e5d91792421c5019898_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfNi0zLTEtMS0xMzIwMDk_437b6fe4-dd29-466b-a217-c7a8fb02936e"
      unitRef="usd">1600000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i557a32613c404e579eedda986be748b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmRiOTAxNGZlMTdkZjQyZmE4ZTc4ZWIwNTZkZDAzOGMzL3RhYmxlcmFuZ2U6ZGI5MDE0ZmUxN2RmNDJmYThlNzhlYjA1NmRkMDM4YzNfNi01LTEtMS0xMzIwMDk_483ab810-8763-4e35-ac8e-78d6860a4efa"
      unitRef="usd">4000000.0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <ehc:ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMzI2Nw_ae311556-83a8-4368-a303-bf45fb7942a5">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment reconciliations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Segment Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) gain on disposal or impairment of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on early extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense and amortization of debt discounts and fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair market value of equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income from continuing operations before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ehc:ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock>
    <ehc:AdjustedEBITDA
      contextRef="ia036ff2cbdc34388aff7771c98304af2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMi0xLTEtMS0xMjk2MDE_726b92ab-2727-4a05-a293-887b6c1b6f34"
      unitRef="usd">276300000</ehc:AdjustedEBITDA>
    <ehc:AdjustedEBITDA
      contextRef="ie391de2d22ab44fda7310331622d23d1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMi0zLTEtMS0xMjk2MDE_bd817751-fec7-4af0-a6ba-3574fd6fa7bc"
      unitRef="usd">285700000</ehc:AdjustedEBITDA>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i77fc9042b9d744ba9d2f6c315981cd86_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMy0xLTEtMS0xMjk2MDE_4f1b2d63-3701-4c8d-b1be-621353224c7c"
      unitRef="usd">48400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6c857df9e79e4435ab0c5961811291c6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMy0zLTEtMS0xMjk2MDE_5862c172-dc66-4eb4-9c4c-87798f6fc7a3"
      unitRef="usd">38600000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i77fc9042b9d744ba9d2f6c315981cd86_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfNC0xLTEtMS0xMjk2MDE_942377fd-8eb9-49f7-8d73-d2a37b9515e1"
      unitRef="usd">66200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6c857df9e79e4435ab0c5961811291c6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfNC0zLTEtMS0xMjk2MDE_864a5805-c6fd-4331-bd09-a725ff6a21be"
      unitRef="usd">62500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i77fc9042b9d744ba9d2f6c315981cd86_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfNS0xLTEtMS0xMjk2MDE_25242d5b-b925-45d3-8660-81b9cd514608"
      unitRef="usd">-600000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i6c857df9e79e4435ab0c5961811291c6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfNS0zLTEtMS0xMjk2MDE_2502d3f4-00d7-4d76-87cc-bb5222e5f672"
      unitRef="usd">100000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i77fc9042b9d744ba9d2f6c315981cd86_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfOC0xLTEtMS0xMjk2MDE_2d67b365-d6e8-485a-b4e8-679f267e3e1e"
      unitRef="usd">-300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6c857df9e79e4435ab0c5961811291c6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfOC0zLTEtMS0xMjk2MDE_1f9408a9-4a0e-45c4-a13d-7c95903bc2b0"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i77fc9042b9d744ba9d2f6c315981cd86_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfOS0xLTEtMS0xMjk2MDE_f8120897-578d-4d7f-b4a7-6fa3fb8a4928"
      unitRef="usd">39600000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i6c857df9e79e4435ab0c5961811291c6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfOS0zLTEtMS0xMjk2MDE_0508165d-6db1-4bd6-b875-d8c8afd893d5"
      unitRef="usd">42800000</us-gaap:InterestExpenseDebt>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i77fc9042b9d744ba9d2f6c315981cd86_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMTEtMS0xLTEtMTI5NjAx_ed6c52bb-1f58-4149-af56-23dcbef7ac6b"
      unitRef="usd">22600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6c857df9e79e4435ab0c5961811291c6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMTEtMy0xLTEtMTI5NjAx_25735b6a-e93b-43ae-b76a-28d80c267db7"
      unitRef="usd">25500000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="i77fc9042b9d744ba9d2f6c315981cd86_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMTMtMS0xLTEtMTI5NjAx_568e5eda-0bf0-42d8-8838-2017275797cb"
      unitRef="usd">-2500000</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="i6c857df9e79e4435ab0c5961811291c6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMTMtMy0xLTEtMTI5NjAx_b9dc5d0b-231b-4cbd-b841-afb6c20da655"
      unitRef="usd">-100000</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMTctMS0xLTEtMTI5NjAx_d319af4d-05a6-4995-ae53-8084d337cfb5"
      unitRef="usd">141300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmIwZmY1ZmUzNGI4NTQwYmQ5MDZmOGVjZWY1ZTNjNDgzL3RhYmxlcmFuZ2U6YjBmZjVmZTM0Yjg1NDBiZDkwNmY4ZWNlZjVlM2M0ODNfMTctMy0xLTEtMTI5NjAx_49394571-52b7-45ca-95fe-c973f581e7d1"
      unitRef="usd">167300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RleHRyZWdpb246M2QzMzZkZGFmYTEyNGI2NmEzZmU4NTg4NGQzOTdiODJfMzI3Mw_fbb851cf-7425-4607-8902-52268f43f065">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional detail regarding the revenues of our operating segments by service line follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient rehabilitation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inpatient&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,036.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outpatient and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inpatient rehabilitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home health and hospice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total home health and hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,230.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f9a417ef1c843ab8b66fc1f0fe8a378_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfMy0xLTEtMS0xMjk2MDE_a5bef492-bc1b-4200-92a0-b9b779323b29"
      unitRef="usd">1036200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee63741659464a8288af029c2e936705_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfMy0zLTEtMS0xMjk2MDE_236e5b35-a709-441b-940b-88dfc16abeb8"
      unitRef="usd">942300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77101558c6ed4f6da49ce1c65da87750_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfNC0xLTEtMS0xMjk2MDE_6df06e70-00ae-4f67-946b-b7ab32876754"
      unitRef="usd">23100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee418860b1b04eaabf4f28548bafff1c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfNC0zLTEtMS0xMjk2MDE_44f39188-0b9b-4b7c-86b0-bc82feecd5b4"
      unitRef="usd">17600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfNS0xLTEtMS0xMjk2MDE_66bb1412-1757-4502-92e3-35af6a070f36"
      unitRef="usd">1059300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i948d5f7111ca493db4d39e499daa9e94_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfNS0zLTEtMS0xMjk2MDE_591d2c42-4242-4f3a-a910-feeaf86eb625"
      unitRef="usd">959900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06506ef5bc914c559c598b5f9589d0b3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfNy0xLTEtMS0xMjk2MDE_f7e71d05-03f0-498e-9147-dea7ed3d9284"
      unitRef="usd">224900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib65ddfd24dd24997b9a0d223f2e38f80_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfNy0zLTEtMS0xMjk2MDE_1ea3890e-d82f-4b45-9bbc-dc6dbbf305fe"
      unitRef="usd">219900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4931e9bee9c14ae88ae967c8efd7c1da_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfOC0xLTEtMS0xMjk2MDE_9da34d46-aac7-4f12-b654-eebfdc9c2e57"
      unitRef="usd">49400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00989e00d19949b0b76add02ac72e8dc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfOC0zLTEtMS0xMjk2MDE_19059f91-d445-49eb-851f-af451b194b1a"
      unitRef="usd">50600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id22debcdee444868b46cec08ef1f0b3b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfOS0xLTEtMS0xMjk2MDE_5288a572-1382-408e-a3b3-90fcf15336ff"
      unitRef="usd">274300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ce4ec3dba324584bcd7add41def2572_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfOS0zLTEtMS0xMjk2MDE_c3ff216d-ea7e-4ab5-8c9f-f52d4aa6c4ed"
      unitRef="usd">270500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3531353b480a49df89986d34e925eca7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfMTAtMS0xLTEtMTI5NjAx_37b5ac2f-4fde-4677-a7df-b8f9d7088712"
      unitRef="usd">1333600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91231db0dbac4520908543814857793e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV85Ny9mcmFnOjNkMzM2ZGRhZmExMjRiNjZhM2ZlODU4ODRkMzk3YjgyL3RhYmxlOmZiZmNjN2QzMDlmNDRjMmM5MTBiNzI4OTllMTQzYjgwL3RhYmxlcmFuZ2U6ZmJmY2M3ZDMwOWY0NGMyYzkxMGI3Mjg5OWUxNDNiODBfMTAtMy0xLTEtMTI5NjAx_1abb0d58-4b15-4423-a9ff-23cade1c5d0f"
      unitRef="usd">1230400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzUtMy0xLTEtMTI5NjAx_b8465d0d-15b4-4e6b-8fca-465d4f86d90d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzUtMy0xLTEtMTI5NjAx_b8465d0d-15b4-4e6b-8fca-465d4f86d90d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzUtMS0xLTEtMTI5NjAx_376f026e-0a45-4eb7-8571-082b11d62254"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzUtMS0xLTEtMTI5NjAx_376f026e-0a45-4eb7-8571-082b11d62254"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTUtMS0xLTEtMTI5NjAx_7f8cccaa-f1ba-40bc-ad42-fcd4ee98eeb5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTUtMS0xLTEtMTI5NjAx_7f8cccaa-f1ba-40bc-ad42-fcd4ee98eeb5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTUtMy0xLTEtMTI5NjAx_0f538598-45b6-4f09-a95f-5f81800fa896"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTUtMy0xLTEtMTI5NjAx_0f538598-45b6-4f09-a95f-5f81800fa896"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RleHRyZWdpb246ZWIxMjhmOWM2ZmJlNDE2ZDk3NTZjOWMyZTQ5NTU5YmVfMzUz_4d3515ba-93b0-4f03-8b82-aa0c4c4c406d" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RleHRyZWdpb246ZWIxMjhmOWM2ZmJlNDE2ZDk3NTZjOWMyZTQ5NTU5YmVfMzUz_4d3515ba-93b0-4f03-8b82-aa0c4c4c406d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Our consolidated assets as of March&#160;31, 2022 and December&#160;31, 2021 include total assets of variable interest entities of $228.0 million and $226.2 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of March&#160;31, 2022 and December&#160;31, 2021 include total liabilities of the variable interest entities of $40.8 million and $38.2 million, respectively. See Note 3, </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzUtMy0xLTEtMTI5NjAx_b8465d0d-15b4-4e6b-8fca-465d4f86d90d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RleHRyZWdpb246ZWIxMjhmOWM2ZmJlNDE2ZDk3NTZjOWMyZTQ5NTU5YmVfMzUz_4d3515ba-93b0-4f03-8b82-aa0c4c4c406d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMzUtMS0xLTEtMTI5NjAx_376f026e-0a45-4eb7-8571-082b11d62254"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RleHRyZWdpb246ZWIxMjhmOWM2ZmJlNDE2ZDk3NTZjOWMyZTQ5NTU5YmVfMzUz_4d3515ba-93b0-4f03-8b82-aa0c4c4c406d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTUtMS0xLTEtMTI5NjAx_7f8cccaa-f1ba-40bc-ad42-fcd4ee98eeb5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RleHRyZWdpb246ZWIxMjhmOWM2ZmJlNDE2ZDk3NTZjOWMyZTQ5NTU5YmVfMzUz_4d3515ba-93b0-4f03-8b82-aa0c4c4c406d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RhYmxlOmIwYWI0NTdjNGIwYTRhODE5ZjUyNDIwMmI3Yzc3NzE1L3RhYmxlcmFuZ2U6YjBhYjQ1N2M0YjBhNGE4MTlmNTI0MjAyYjdjNzc3MTVfMTUtMy0xLTEtMTI5NjAx_0f538598-45b6-4f09-a95f-5f81800fa896"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmE1OGEwZDQ1MzliZjQ2MmU4ZjQ2MjFlZGFjZDk3ZjVhL3NlYzphNThhMGQ0NTM5YmY0NjJlOGY0NjIxZWRhY2Q5N2Y1YV8yOC9mcmFnOmViMTI4ZjljNmZiZTQxNmQ5NzU2YzljMmU0OTU1OWJlL3RleHRyZWdpb246ZWIxMjhmOWM2ZmJlNDE2ZDk3NTZjOWMyZTQ5NTU5YmVfMzUz_4d3515ba-93b0-4f03-8b82-aa0c4c4c406d"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M\)ROA/;Z7IL9=YR:3O<=KS'3#F8RFPZ)W^]IRW :9/A1K[GJ3-#6>Q_)J4,
MS\@0[]'TH"9D2/TT9RW-69CF<EEN6+Y\0DM9^$,X<]Y+HN%\CYP7U!/"><MM
M'I[D<K-)A3]D<^=]XXD3,0\(=YCOD,*1;;]1D-:OD&Z*I57JL00:O#!%;:0M
M.,F-U2Z;>-:IKIJR!T5GG5+=Y=R1#!SD?,6A12T%JW78$,^DTN*?ZH&7+7:+
M8M*9T(:M!T6&XQZVQ+(E0;9_2 WQ?5[M-*9VR@+'\^%TGZH'!UK2P>V2M5*
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M#0!^7TFIMS?F!>UY]-F_4$L#!!0    ( $.*HU0$:6WXD@8  '0:   8
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MB([C.6 [\+#'&=FS.")9_AM8?S]2_A-<?4GQ,:("?0V&X,O#"ER]N0:YA.:
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MX392.U!B393)Z LUH>WZNCN@:4)KK Q2HX5M1:-06&] [VMC<'_P#H;A6KP
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MZQN/MT''I=)K98-V5GBU>-V;YJ_>C.D\'_B'5IMP\"Q(D[ES7^CE??6Z-R1
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MM>4&^E!V"A)XS/FH09M53+PS[E:8)RG^AA"T->LCKLT1, 4:'FD?13]\0!E
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M_O.&\>5@?"G&E_]W]/Z./GUJ'!7#4L9+J",?5)69:DNI12WXX,EN*.2:-K9
M3?&70U.!'$4!GONC=X08IOD01-A.=;G6KE]9T(W3F0ETM75:H\+"/_^QBA?Q
M>[K*'E25:D\-LNE0= ^V>)"M6X6-2DUAPIX.*)D?1W,\4?UX_LJ "ZNJ7L3
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MACS*2^[XZ;'1#\S0:FBC#[]5+PUPLJ2@W#J#60DY=_J22\,^<%4)=BVXK8R
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M#P!"%S).\B+B,M/7TZ=[H-,'8[^Y5*E*/.99X<X&:565)\?'+DY5+MW8E*K
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MF V$]5_J_4UE2OXZOC859FN^I#ZJ+"W ^XW!E-W<D(+NWR7G_P902P,$%
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M;"]W;W)K<VAE971S+W-H965T,C<N>&ULI5C;;N,V$/T5PET4-A#8NEFVTR1
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MH6D#WB^4LNL;,M#]&W#Q+U!+ P04    " !#BJ-4D2WP45,"   R!0  &0
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MU&3UILSZI$AWU;[&N[0HTK@ZW*I@K;(R0']^GZ;%\TEY@W9K[/)_4$L#!!0
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M-AL$O0!2G+%2V!NUO,15/&W'ERAA_"\L5[91 $EIK,I78%*0<UE]V>,J#QL
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M8_M%Z.9::A:H*M_9YPKM/>&GI;W*0;L ^WZA%&X63J#[<S#Y U!+ P04
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MI42QKP/4]VNNE%[=Z$/)^M1Z]C]02P,$%     @ 0XJC5/==*KI!!    !,
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M*%P.$>5Q2WFC^,H<#\RX4CPSETM@N#/6$_#YG&-;5S?:0'WH-?D/4$L#!!0
M   ( $.*HU2 ]B37* ,  .\*   9    >&PO=V]R:W-H965T<R]S:&5E=#,X
M+GAM;,662T_C,!" _XH5<0")S;,/0&VE/E@M!Q J8O>PVH.;3%N+Q"ZV2^'?
M[]A)T](F6;1"NY<V=N;QC6?&F=Y&R">U!-#D-4NYZCM+K5=7GJ?B)614N6(%
M'-_,A<RHQJ5<>&HE@296*4N]T/<[7D89=P8]NW<O!SVQUBGC<"^)6F<9E6\C
M2,6F[P3.=F/*%DMM-KQ!;T47\ #Z<74O<>655A*6 5=,<")AWG>&P=4XB(R"
ME?C.8*/VGHD)92;$DUG<)'W'-T200JR-"8I_+S"&-#66D..Y,.J4/HWB_O/6
M^E<;/ 8SHPK&(OW!$KWL.Q<.26!.UZF>BLTW* )J&WNQ2)7])9M"UG=(O%9:
M9(4R$F2,Y__TM3B(/06T4ZT0%@KAH4*K1B$J%.S)>3F9#6M"-1WTI-@0::31
MFGFP9V.U,1K&31H?M,2W#/7T8 H)8&',4B!W@L>":RE2%%J0&ZY!@M**?"$?
MD1J:A##]1DXGH"E+U1DJ/CY,R.G)&3DAC)-;ACJ"JYZGD=SX]^*"<I13AC64
M$;E%GTM%KGD"R7M]#R,NPPZW88_"1H.W5+HD"LY)Z(=A!<_XX^I! TY49B&R
M]J*_SL(YN7Y>X^F>DS&5\LV\&F9BS37Y.451@C6]H3+YU0#3*F%:%J95 S.B
M*>4Q$*K)#!:,<^-,S,D*)!-)5?)R>QUKS]P;+X-6Z.*QOE10M$N*=B/%'5YA
M#(\B,R!:LME:V_/1@O#W1\2V)5B%ECOI[J$%[F5)EN>Z?80?NJUJ^DY)WVFD
MGS"5,YMZQVLE3JD\+-P<L',$^"5L'2%62=5"=DO([D<3#3QI3G'W"* 5U:7X
MHO1_T>C_SU7?4,V7I9/+_]]:@;^[;OU/;J["8+>NN_("J9"* K=3G:!@[^L0
M_(LN++PTMV&%4&V)!^$N@O"3.K$P]*[)_&/*"JG0C6HP=Q^ (/JT7BQ,=>J:
ML0 ]EL**Z!Z >GNC0P9R82<J16)3__GGM-PMI[:AG54.]D=FFK,CR<Y,/@KB
MQQ(+79$4YFC2=[MXW\I\NLH76JSL@#(3&L<=^[C$B12D$<#W<R'T=F$<E#/N
MX#=02P,$%     @ 0XJC5.@(RUV+ @  _P8  !D   !X;"]W;W)K<VAE971S
M+W-H965T,SDN>&ULI55=3]LP%/TK5L0#2%O2)FW84!J)EDWCH1,J8GN8]N F
MMXV%8W?V+67_?M=.&DII$6(OB3_N.?><:^<FVVAS;RL 9(^U5'845(BKBRBR
M104UMZ%>@:*=A38U1YJ:9617!GCI0;6,XEXOC6HN5)!G?NW&Y)E>HQ0*;@RS
MZ[KFYN\8I-Z,@GZP79B)985N(<JS%5_"+>#=ZL;0+.I82E&#LD(K9F Q"B[[
M%Y/4Q?N 'P(V=F?,G).YUO=N<EV.@IX3!!(*= R<7@\P 2D=$<GXTW(&74H'
MW!UOV;]Z[^1ESBU,M/PI2JQ&P:> E;#@:XDSO?D&K9^AXRNTM/[)-FUL+V#%
MVJ*N6S IJ(5JWORQK<,.@'@. ^(6$.\#!D< 20M(O-%&F;=UQ9'GF=$;9EPT
ML;F!KXU'DQNAW"G>HJ%=03C,9U "W8NY!/9=JT(K-%I2T))=*P0#%BW[R&9
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M\9&@&&BQR_?92Z'-KCT_W0*-05H#<W\MA'X:V*U[]:EF_A]02P,$%     @
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MLJ)Z$GV,H,*%:!7=F/47[/,) DNC7/C"NO=-(BA;1Z;IP:R@D;K[BZ?^'K8
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M[1W,FX<SI7#9:_TUBM"@EI['+"[-6-.L.X<QT!$VTY$5S);E&@-K8#H,K(%
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MK"+U]5C'@U76^D &_C"T+1]XP;^(ME7VVOC,X)XJ6QU&V'6[(?:!5WPSKUA
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M40X']Z05W<JO-:RJ_ U>*TMZ\,N"7BS4+H#V-TK9@^$2]&]@^AM02P,$%
M  @ 0XJC5*;A!9;2!   *18  !D   !X;"]W;W)K<VAE971S+W-H965T-#4N
M>&ULS5AM3^,X$/XK5L4'D-@D=M^K4FEI.>U*QPHMXNZS2=S6VB3NV2YE__V-
MG31)D]3MPAXZ/D#LS$SFF1G/,WBZ$_*'6C.FT6L2I^JFL]9Z,_%]%:Y90I4G
M-BR%-TLA$ZIA*5>^VDA&(ZN4Q#X)@H&?4)YV9E.[]R!G4['5,4_9@T1JFR14
M_KQEL=C=='!GO_&=K];:;/BSZ8:NV"/33YL'"2N_L!+QA*6*BQ1)MKSI?,:3
M.1D:!2OQ%V<[57E&!LJS$#_,XFMTTPF,1RQFH38F*/QY87,6Q\82^/%/;K13
M?-,H5I_WUO^PX ',,U5L+N*_>:37-YU1!T5L2;>Q_BYV7U@.J&_LA2)6]C?:
MY;)!!X5;I462*X,'"4^SO_0U#T1% >RT*Y!<@=05>D<4NKE"UP+-/+.P%E33
MV52*'9)&&JR9!QL;JPUH>&K2^*@EO.6@IV=W5*8\72FT81+-19) :!_75#+T
MR2PW6TUMN,42W5+%0T33""UXO-4L0H7R0UWY<L$TY;&Z C-/CPMT>7&%+I"/
ME'FK$$_14\JUNJYLW/,XAB_!WD5U.?4UP#3.^F$.Z3:#1(Y ZJ)[D>JU0G=I
MQ*)#?1_"4\2([&-T2YP&[ZGT4!=?(Q(0TN+/_'QU['"G6Z2L:^UUC]C+\O!M
MFS!)M9 3A\E>8;)G3?:.F/R:AB)A:"E%@D(('D^WD%<$S4+:]+=F(3,YL"9-
MMWB981QX@/"E&IL6J2[Q1H74@;_]PM^^T]\_F5(3] VZ',\\IUI+_@S%^APS
MI 5*16IP2 %%!$!XJAF4F3:%%L9;* M38F<CS9P95C!\(L0;U)"V2?6]?CO2
M08%T< ;2/#\TCD5(S<D#B!LJ-0_Y!MP& (J%6\DU9ZT !DW7 J]7\[]5Z(C[
MP\+]X?L*JY&Y.Z.QH4JA+XS&>@UJMJ_81K$6<<1D*\1AP_O1T O&U9\:WJ8&
M#@;'*G-4 !ZY\R7 <PLWXBI'#/DJ 5^C%,H6VJFFK]>_#7WF5+^"):BA=4D<
M(!T72,=.I([3]U84XT:O.)7#IH8CAS@H23%PMM@%2P60[:GVBBLLBYW!RGKV
MS@X54 [T!<IAQ0[BHA!,64H#OYH3<LGWVU>M#(@;Q3L>>Z06G5RJ?R!U)#:D
MA$+.H!]6G1NLHV^J F=T2T+$76=TYZV=Q80P @*@LN)E>S0S\Z/JX?!&HWHT
MFU+8"X[56DF]V,V]B_8^\2ON]TZ>?J?(H>,E!V,W"5<:P"_XVC\KU$TI1ZA+
M+L4#]['.Y]9B=G)57TEQ^)T<UQJ'X5G34YO8\?$)ERR%3]#4QPY0N3>G)JA6
ML:,C%"Z9"KNIZN.FD-R1VAC2K^-L2N%@Z'7;<9*2MDCP?QP^<J]<_<<I<HBV
MY%3BYM3_8 #)OSAPIZ]%RI6^DEF)FUG/G#I(R8O$S8O[?O?[YH[\@X>5&S0&
MCY-BAX!*KB2]LQKX!TP?I.1!XN;!]TX?I)42A_60ME+B\$A$2THD[O\OWS]]
MY!]PGGZ7R*'C)>L2-^N^:?K(;9X*=5.J)=1^Y=(-QHF5O8M44&;;5&=W2\5N
M<=_YV=[RU?9O\62>W5J69K)+U'LJ5QR2$;,EF R\(4109O>2V4*+C;W:>Q9:
MB\0^KAF%TC8"\'XIA-XOS >*V^'9OU!+ P04    " !#BJ-40XPA7[L"   F
M!P  &0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6RM54USVC 0_2L:GYJ9
M%!OSD28#G@&23GM(RY!I<^CT(.P%:R)+KB3C]-]W)1G70$)ZZ 5;JWU/[^WB
MU:26ZDGG (8\%USH:9 ;4]Z$H4YS**CNR1($[FRD*JC!I=J&NE1 ,P<J>!A'
MT3@L*!-!,G&QI4HFLC*<"5@JHJNBH.KW'+BLIT$_V =6;)L;&PB324FW\ #F
M6[E4N I;EHP5(#23@BC83(-9_V8QMODNX3N#6G?>B76REO+)+CYGTR"R@H!#
M:BP#Q<<.%L"Y)4(9OQK.H#W2 KOO>_:/SCMZ65,-"\D?66;R:? A(!EL:,7-
M2M:?H/$SLGRIY-K]DKK)C0*25MK(H@&C@H()_Z3/31TZ .1Y&1 W@/@8,'P%
M,&@  V?4*W.V;JFAR43)FBB;C6SVQ=7&H=$-$[:+#T;A+D.<2>ZH$DQL-2E!
MD84L"BSM0TX5D/=D!:D4*>.,NHK+#7ET58&,S':@L,GD2U6L$8A;#J3)U\IH
M0T6&G.3=+1C*N+Y +NVWFP<3Y)YQCJQZ$AJT8<6$:2-Y[B7'KT@>D'LI3*[)
MG<@@.\2':+^M0;ROP3P^2WA/58\,^I<DCN+X!3V+?X?WS\@9M"T9.+[!6RU9
M8F5]+W[,UMHH_,O_/,,_;/F'CG_X"O^<:I:2>M]*VK0R]<UO.B2[?63[\,5+
MW?*G7;G3[-#8)=?7/:SCKEM"GS0Z2&I3#FR,6ANCLS96@"5AJ;6 7TGZ1&A-
M5:8O2<9X96=#$Y:E_?=B'-W@W#D"58(9_9;#T8GX_I&]T4D-^IT2'/@;M_[&
M9_W=6ANH\_\U:GPJ,HI..O56EC<3=D9. 6KK)K%&;94P_LMKH^VPG[D9=Q2?
MXR7@9_9?&G^#X'>U94(3#ANDC'I76&3EI[)?&%FZP;:6!L>D>\WQ(@-E$W!_
M(Z79+^P![=68_ %02P,$%     @ 0XJC5%19D,@4!   !Q,  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#<N>&ULO9AA;^,F&,>_"K(TZ29ML8WCICDED:YW
MF]K3.E7M;7LQ[06Q2<S.!@]PTY/VX?> 8Y,HL>/E+GW38&R>Y\<?^$.9;83\
MK#)*-7HI<J[F7J9U^=;W59+1@JB1*"F'-RLA"Z+A4:Y]54I*4MNHR'T<!%=^
M01CW%C-;]R 7,U'IG''Z()&JBH+(+S<T%YNY%WI-Q2-;9]I4^(M92=;TB>K?
MR@<)3WX;)64%Y8H)CB1=S;UWX=N;R#:P7_S.Z$;ME)'IRE*(S^;A+IU[@2&B
M.4VT"4'@YYF^IWEN(@''/]N@7IO3--PM-]%_MIV'SBR)HN]%_@=+=3;WKCV4
MTA6I<OTH-K=TVZ'8Q$M$KNQ?M-E^&W@HJ906Q;8Q$!2,U[_D92O$3H,Q[FB
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M:ZKX@&K<@7758EWU8MWQ$F2I!R0C2Y;#D)N1Z!%_TH:>7'ZDK]MDUY>7]_I
MWB@^+N^TQ9H.Q&*MT')/:-2NLP8Q!<2F\ACE]( R'$^.8X:!<ZI@J'XBISGH
MM>% ,H"Z'W:;=I=V&G7 [MAJ.!#V;\&X_H:TX0%M/.Z@Q8X6?^T<J#@#0ZK
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M(E6H?B/%Q!^<T*ALN@V;M)U!US'HOL)@C2],50<YG6-ZVKY %_:YYUSW/K;
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M?A]??5GUX-6#%FO;E<Z%QA[7#G/\;@%I#'!]*9!W_6 "N"^AR?]02P,$%
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M!)Y&',$4@ 8,B:+F'-P[C\+U.15N?OT9_P)02P,$%     @ 0XJC5)>*NQS
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M?8%YM_JKD=7QPX?C1QN?_@-02P,$%     @ 0XJC5*&7ZI3) 0  H!X  !H
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M*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>MM@LX1
M;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T>]G4!O1[V=0&]'O9U
M;T>]G4!O'VQV$^CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H7:/>-8'>->I=
M_Z?>*9_W,=U[;FM\_G]2G2_WQOOCK\O;R<%+N.(<X(?TRS=02P,$%     @
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M<F]P<R]A<' N>&UL4$L! A0#%     @ 0XJC5!?B3T_N    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 0XJC
M5)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " !#BJ-4^S<;;3,%  !K%0  &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 0XJC
M5*82+)&:!@  FQX  !@              ("!=@T  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( $.*HU0$:6WXD@8  '0:   8
M      " @484  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" !#BJ-4WTN$*U #  !2"0  &               @($.&P  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 0XJC5%P421C0!0  =!H  !@
M             ("!E!X  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( $.*HU0K&,W_8P(  &@%   8              " @9HD  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !#BJ-4CWW?A>H'  #4
M(@  &               @($S)P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ 0XJC5. %9LND"   JA0  !@              ("!4R\
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( $.*HU1 6Q"$
MU0@  %P6   8              " @2TX  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " !#BJ-4F<C9YJL%  #8#   &0
M@($X00  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( $.*
MHU2@HLCQ3@<  /\0   9              " @1I'  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ 0XJC5-%]HSY' P  # D  !D
M         ("!GTX  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " !#BJ-4'U7E_S$&  #T#P  &0              @($=4@  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( $.*HU2/!;_@A ,  .$'
M   9              " @858  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ 0XJC5)@"9-5^ @  *@8  !D              ("!0%P
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !#BJ-4X$QZ
M!. #  #)#   &0              @('U7@  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( $.*HU0;#5RMKP8  (@/   9
M  " @0QC  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M0XJC5($&CH\!"@  .AD  !D              ("!\FD  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " !#BJ-4#$&)KHT"  "3!0  &0
M            @($J=   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( $.*HU0W^-KTB@,  (H'   9              " @>YV  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 0XJC5($A=.(Q!0
M/0T  !D              ("!KWH  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " !#BJ-4G2-NB=X#  "&"   &0              @($7
M@   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( $.*HU27
MM?NO/P,  -L&   9              " @2R$  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ 0XJC5![&L"-< P  F0D  !D
M     ("!HH<  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $.*HU2<ABP4>@8  "8K   9              "
M@:2=  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 0XJC
M5 N$;-%W @  :@4  !D              ("!5:0  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " !#BJ-45B;K9- $  !W%@  &0
M        @($#IP  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( $.*HU22-9#@  ,  ! (   9              " @0JL  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 0XJC5+U->'#? @  2 @
M !D              ("!0:\  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " !#BJ-4@R/P,Z4"   H"   &0              @(%7L@
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( $.*HU0T\_7A
M'P<  )DA   9              " @3.U  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ 0XJC5!..R*FP!   P18  !D
M ("!B;P  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !#
MBJ-4]UTJND$$    $P  &0              @(%PP0  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( $.*HU2 ]B37* ,  .\*   9
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M970T,BYX;6Q02P$"% ,4    " !#BJ-4LD7V\-D"  "-"0  &0
M    @(%?V0  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M $.*HU3RO*KV-P(   \%   9              " @6_<  !X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ 0XJC5*;A!9;2!   *18  !D
M             ("!W=X  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " !#BJ-40XPA7[L"   F!P  &0              @('FXP  >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( $.*HU1469#(% 0
M  <3   9              " @=CF  !X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ 0XJC5*MH<?,Y!@  B1X  !D              ("!
M(^L  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !#BJ-4
M4T CR>T#   5#0  &0              @(&3\0  >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( $.*HU0!*"A$?@0  )P0   9
M      " @;?U  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ 0XJC5"&Q\YB( P  G0X  !D              ("!;/H  'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " !#BJ-4<92FFQP#   *$@
M#0              @ $K_@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( $.*
MHU27BKL<P    !,"   +              "  7(! 0!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( $.*HU0:D0U0)P0  #@B   /              "  5L" 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !#BJ-4H9?JE,D!  "@'@  &@
M            @ &O!@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " !#BJ-4*+1H$\,!  ")'@  $P              @ &P" $ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     .P [ !00  "D"@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>211</ContextCount>
  <ElementCount>227</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>55</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106102 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2112103 - Disclosure - Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/VariableInterestEntities</Role>
      <ShortName>Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2116104 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2120105 - Disclosure - Redeemable Noncontrolling Interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests</Role>
      <ShortName>Redeemable Noncontrolling Interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2124106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2129107 - Disclosure - Share-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ShareBasedPayments</Role>
      <ShortName>Share-Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2131108 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2133109 - Disclosure - Earnings per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EarningsperCommonShare</Role>
      <ShortName>Earnings per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2137110 - Disclosure - Contingencies and Other Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ContingenciesandOtherCommitments</Role>
      <ShortName>Contingencies and Other Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2138111 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BasisofPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Basis of Presentation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BasisofPresentationTables</Role>
      <ShortName>Basis of Presentation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/BasisofPresentation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2307302 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/BusinessCombinations</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Variable Interest Entities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/VariableInterestEntitiesTables</Role>
      <ShortName>Variable Interest Entities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/VariableInterestEntities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtTables</Role>
      <ShortName>Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/LongtermDebt</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2321305 - Disclosure - Redeemable Noncontrolling Interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables</Role>
      <ShortName>Redeemable Noncontrolling Interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2325306 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2334307 - Disclosure - Earnings per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EarningsperCommonShareTables</Role>
      <ShortName>Earnings per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/EarningsperCommonShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2339308 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/SegmentReporting</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Basis of Presentation - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BasisofPresentationTextualDetails</Role>
      <ShortName>Basis of Presentation - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Basis of Presentation - Net Operating Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails</Role>
      <ShortName>Basis of Presentation - Net Operating Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Business Combinations - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails</Role>
      <ShortName>Business Combinations - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails</Role>
      <ShortName>Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Business Combinations - Net Cash Paid for Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails</Role>
      <ShortName>Business Combinations - Net Cash Paid for Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Business Combinations - Pro Forma Results of Operation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails</Role>
      <ShortName>Business Combinations - Pro Forma Results of Operation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Variable Interest Entities - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails</Role>
      <ShortName>Variable Interest Entities - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Variable Interest Entities - Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails</Role>
      <ShortName>Variable Interest Entities - Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Long-term Debt - Long-term Debt Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails</Role>
      <ShortName>Long-term Debt - Long-term Debt Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Long-term Debt - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtTextualDetails</Role>
      <ShortName>Long-term Debt - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails</Role>
      <ShortName>Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails</Role>
      <ShortName>Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Fair Value Measurements - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails</Role>
      <ShortName>Fair Value Measurements - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Fair Value Measurements - Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/ShareBasedPayments</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/IncomeTaxes</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Earnings per Common Share - Computation of Basic and Diluted Earnings Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails</Role>
      <ShortName>Earnings per Common Share - Computation of Basic and Diluted Earnings Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Earnings per Common Share - Reconciliation of Weighted Average Number of Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails</Role>
      <ShortName>Earnings per Common Share - Reconciliation of Weighted Average Number of Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2440420 - Disclosure - Segment Reporting - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingTextualDetails</Role>
      <ShortName>Segment Reporting - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2441421 - Disclosure - Segment Reporting - Segment Reporting Information, Reconciliation of Net Operating Revenues to Segment Adjusted EBITDA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails</Role>
      <ShortName>Segment Reporting - Segment Reporting Information, Reconciliation of Net Operating Revenues to Segment Adjusted EBITDA (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Segment Reporting - Reconciliation of Segment Assets and Investments In and Advances to Affiliates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Segment Assets and Investments In and Advances to Affiliates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2443423 - Disclosure - Segment Reporting - Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ehc-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Segment Reporting - Reconciliation of Revenue from Segments to Consolidated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Revenue from Segments to Consolidated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ehc-20220331.htm">ehc-20220331.htm</File>
    <File>ehc-20220331.xsd</File>
    <File>ehc-20220331_cal.xml</File>
    <File>ehc-20220331_def.xml</File>
    <File>ehc-20220331_lab.xml</File>
    <File>ehc-20220331_pre.xml</File>
    <File>ehc10q33122ex22.htm</File>
    <File>ehc10q33122ex311.htm</File>
    <File>ehc10q33122ex312.htm</File>
    <File>ehc10q33122ex321.htm</File>
    <File>ehc10q33122ex322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="662">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>69
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ehc-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 20,
   "contextCount": 211,
   "dts": {
    "calculationLink": {
     "local": [
      "ehc-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ehc-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ehc-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ehc-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ehc-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ehc-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 392,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 26,
   "keyStandard": 201,
   "memberCustom": 22,
   "memberStandard": 33,
   "nsprefix": "ehc",
   "nsuri": "http://www.encompasshealth.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.encompasshealth.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112103 - Disclosure - Variable Interest Entities",
     "role": "http://www.encompasshealth.com/role/VariableInterestEntities",
     "shortName": "Variable Interest Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116104 - Disclosure - Long-term Debt",
     "role": "http://www.encompasshealth.com/role/LongtermDebt",
     "shortName": "Long-term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120105 - Disclosure - Redeemable Noncontrolling Interests",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests",
     "shortName": "Redeemable Noncontrolling Interests",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124106 - Disclosure - Fair Value Measurements",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129107 - Disclosure - Share-Based Payments",
     "role": "http://www.encompasshealth.com/role/ShareBasedPayments",
     "shortName": "Share-Based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131108 - Disclosure - Income Taxes",
     "role": "http://www.encompasshealth.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133109 - Disclosure - Earnings per Common Share",
     "role": "http://www.encompasshealth.com/role/EarningsperCommonShare",
     "shortName": "Earnings per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDisclosures",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137110 - Disclosure - Contingencies and Other Commitments",
     "role": "http://www.encompasshealth.com/role/ContingenciesandOtherCommitments",
     "shortName": "Contingencies and Other Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDisclosures",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138111 - Disclosure - Segment Reporting",
     "role": "http://www.encompasshealth.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation (Policies)",
     "role": "http://www.encompasshealth.com/role/BasisofPresentationPolicies",
     "shortName": "Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "role": "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Basis of Presentation (Tables)",
     "role": "http://www.encompasshealth.com/role/BasisofPresentationTables",
     "shortName": "Basis of Presentation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307302 - Disclosure - Business Combinations (Tables)",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsTables",
     "shortName": "Business Combinations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Variable Interest Entities (Tables)",
     "role": "http://www.encompasshealth.com/role/VariableInterestEntitiesTables",
     "shortName": "Variable Interest Entities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - Long-term Debt (Tables)",
     "role": "http://www.encompasshealth.com/role/LongtermDebtTables",
     "shortName": "Long-term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321305 - Disclosure - Redeemable Noncontrolling Interests (Tables)",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables",
     "shortName": "Redeemable Noncontrolling Interests (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325306 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334307 - Disclosure - Earnings per Common Share (Tables)",
     "role": "http://www.encompasshealth.com/role/EarningsperCommonShareTables",
     "shortName": "Earnings per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339308 - Disclosure - Segment Reporting (Tables)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "if5385614e8bd4b7081a64d6cba8c9291_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unitRef": "state",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Basis of Presentation - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/BasisofPresentationTextualDetails",
     "shortName": "Basis of Presentation - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Basis of Presentation - Net Operating Revenues (Details)",
     "role": "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails",
     "shortName": "Basis of Presentation - Net Operating Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3d2de80a9ea142658a08aff95c64af19_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "if5385614e8bd4b7081a64d6cba8c9291_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "if5385614e8bd4b7081a64d6cba8c9291_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredIncomeTaxLiabilitiesNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "if99233a02a77455db55959da352fbfb2_I20220101",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Business Combinations - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
     "shortName": "Business Combinations - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "if99233a02a77455db55959da352fbfb2_I20220101",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "if5385614e8bd4b7081a64d6cba8c9291_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
     "shortName": "Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i9b102d83166e4bc490cf1528eaade88d_I20220101",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i944fc8295c154979b4c5e2ae485eb03b_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueOfAssetsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Business Combinations - Net Cash Paid for Acquisitions (Details)",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
     "shortName": "Business Combinations - Net Cash Paid for Acquisitions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i944fc8295c154979b4c5e2ae485eb03b_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueOfAssetsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Business Combinations - Pro Forma Results of Operation (Details)",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
     "shortName": "Business Combinations - Pro Forma Results of Operation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "ie1e6082c727c4be9853cda9efc66e5bd_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ehc:VariableInterestEntityNumberofEntitiesConsolidated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "entity",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Variable Interest Entities - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails",
     "shortName": "Variable Interest Entities - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "ie1e6082c727c4be9853cda9efc66e5bd_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ehc:VariableInterestEntityNumberofEntitiesConsolidated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "entity",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "if5385614e8bd4b7081a64d6cba8c9291_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Variable Interest Entities - Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities (Details)",
     "role": "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails",
     "shortName": "Variable Interest Entities - Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i027580bf78e446f9a1be1690bafd5055_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "if5385614e8bd4b7081a64d6cba8c9291_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Long-term Debt - Long-term Debt Outstanding (Details)",
     "role": "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
     "shortName": "Long-term Debt - Long-term Debt Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "if5385614e8bd4b7081a64d6cba8c9291_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Long-term Debt - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/LongtermDebtTextualDetails",
     "shortName": "Long-term Debt - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i37b439614a834d5fa4da55874df55dc4_I20211209",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ehc:DebtInstrumentCovenantLeverageRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i557a32613c404e579eedda986be748b3_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails",
     "shortName": "Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i39fdefb343d340ef94ee64a4ec92f2ae_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails",
     "shortName": "Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "if5385614e8bd4b7081a64d6cba8c9291_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "if5385614e8bd4b7081a64d6cba8c9291_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis (Details)",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "icddbe6c9e899402ab0cd9e710f9d31ea_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueOptionChangesInFairValueGainLoss1",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i7b444a6f37fa4de1992c65a1698b0b20_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueOptionChangesInFairValueGainLoss1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Fair Value Measurements - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails",
     "shortName": "Fair Value Measurements - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueOptionChangesInFairValueGainLoss1",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i7b444a6f37fa4de1992c65a1698b0b20_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueOptionChangesInFairValueGainLoss1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i248a1de457614c1c9d9c3795a5c5c6c2_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Fair Value Measurements - Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments (Details)",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
     "shortName": "Fair Value Measurements - Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i248a1de457614c1c9d9c3795a5c5c6c2_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "ic01094ffa7604c71a90a6271b77d95ef_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Share-Based Payments (Details)",
     "role": "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails",
     "shortName": "Share-Based Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "ic01094ffa7604c71a90a6271b77d95ef_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Income Taxes (Details)",
     "role": "http://www.encompasshealth.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Earnings per Common Share - Computation of Basic and Diluted Earnings Per Common Share (Details)",
     "role": "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails",
     "shortName": "Earnings per Common Share - Computation of Basic and Diluted Earnings Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Earnings per Common Share - Reconciliation of Weighted Average Number of Shares Outstanding (Details)",
     "role": "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails",
     "shortName": "Earnings per Common Share - Reconciliation of Weighted Average Number of Shares Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440420 - Disclosure - Segment Reporting - Textual (Details)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingTextualDetails",
     "shortName": "Segment Reporting - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i53bdf1d6ecf041d7af98f062aa3d7212_I20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "state",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441421 - Disclosure - Segment Reporting - Segment Reporting Information, Reconciliation of Net Operating Revenues to Segment Adjusted EBITDA (Details)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails",
     "shortName": "Segment Reporting - Segment Reporting Information, Reconciliation of Net Operating Revenues to Segment Adjusted EBITDA (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i92a33f5a65e24aae9657b5cfae552611_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "if5385614e8bd4b7081a64d6cba8c9291_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Segment Reporting - Reconciliation of Segment Assets and Investments In and Advances to Affiliates (Details)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails",
     "shortName": "Segment Reporting - Reconciliation of Segment Assets and Investments In and Advances to Affiliates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "if5385614e8bd4b7081a64d6cba8c9291_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i1beec8de6cfd45d8b5f89af034ba4093_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)",
     "role": "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i1beec8de6cfd45d8b5f89af034ba4093_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443423 - Disclosure - Segment Reporting - Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense (Details)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails",
     "shortName": "Segment Reporting - Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "ia036ff2cbdc34388aff7771c98304af2_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ehc:AdjustedEBITDA",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Segment Reporting - Reconciliation of Revenue from Segments to Consolidated (Details)",
     "role": "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails",
     "shortName": "Segment Reporting - Reconciliation of Revenue from Segments to Consolidated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i4f9a417ef1c843ab8b66fc1f0fe8a378_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical)",
     "role": "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation",
     "role": "http://www.encompasshealth.com/role/BasisofPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106102 - Disclosure - Business Combinations",
     "role": "http://www.encompasshealth.com/role/BusinessCombinations",
     "shortName": "Business Combinations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20220331.htm",
      "contextRef": "i3531353b480a49df89986d34e925eca7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 55,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ehc_AdjustedEBITDA": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted earnings before interest, taxes, depreciation, and amortization as defined in the Company's credit agreement.",
        "label": "Adjusted EBITDA",
        "totalLabel": "Segment Adjusted EBITDA",
        "verboseLabel": "Total Segment Adjusted EBITDA"
       }
      }
     },
     "localname": "AdjustedEBITDA",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_BusinessCombinationNoncontrollingInterestFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Noncontrolling Interest, Fair Value",
        "label": "Business Combination, Noncontrolling Interest, Fair Value",
        "negatedTerseLabel": "Fair value of noncontrolling interest owned by joint venture partner"
       }
      }
     },
     "localname": "BusinessCombinationNoncontrollingInterestFairValue",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Payroll",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Payroll",
        "terseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedPayroll",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Including Goodwill, Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Including Goodwill, Assets",
        "totalLabel": "Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Liability",
        "terseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-Of-Use Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease, Right-Of-Use Assets",
        "terseLabel": "Operating lease right-of-use-assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_CostofServicesExcludingDepreciationandAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of services rendered during the reporting period, excluding depreciation and amortization.",
        "label": "Cost of Services, Excluding Depreciation and Amortization",
        "terseLabel": "Cost of service (excluding depreciation and amortization)"
       }
      }
     },
     "localname": "CostofServicesExcludingDepreciationandAmortization",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DebtInstrumentAmendmentAgreementAmountToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Amendment Agreement, Amount To Be Paid",
        "label": "Debt Instrument, Amendment Agreement, Amount To Be Paid",
        "terseLabel": "Amendment agreement, amount to be paid"
       }
      }
     },
     "localname": "DebtInstrumentAmendmentAgreementAmountToBePaid",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DebtInstrumentCovenantLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio",
        "label": "Debt Instrument, Covenant, Leverage Ratio",
        "verboseLabel": "Leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatio",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Reduction In Capacity Under Restricted Payments Builder Basket",
        "label": "Debt Instrument, Reduction In Capacity Under Restricted Payments Builder Basket",
        "terseLabel": "Debt instrument, reduction in capacity under restricted payments builder basket"
       }
      }
     },
     "localname": "DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_HomeHealthandHospiceSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health and Hospice Segment [Member]",
        "label": "Home Health and Hospice Segment [Member]",
        "terseLabel": "Home Health and Hospice"
       }
      }
     },
     "localname": "HomeHealthandHospiceSegmentMember",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_HomehealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home health [Member]",
        "label": "Home health [Member]",
        "terseLabel": "Home health"
       }
      }
     },
     "localname": "HomehealthMember",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_HospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice [Member]",
        "label": "Hospice [Member]",
        "terseLabel": "Hospice"
       }
      }
     },
     "localname": "HospiceMember",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails": {
       "order": 1.0,
       "parentTag": "ehc_NetIncomeLossAvailabletoCommonStockholders",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (loss) from continuing operations attributable to HealthSouth common shareholders basic.",
        "label": "Income Loss from Continuing Operations Attributable to Common Shareholders Basic",
        "totalLabel": "Income from continuing operations attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income loss from continuing operations attributable to common shareholders diluted.",
        "label": "Income Loss from Continuing Operations Attributable to Common Shareholders Diluted",
        "totalLabel": "Income from continuing operations attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_InpatientMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inpatient [Member]",
        "label": "Inpatient [Member]",
        "terseLabel": "Inpatient"
       }
      }
     },
     "localname": "InpatientMember",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_InpatientRehabilitationSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inpatient Rehabilitation Segment [Member]",
        "label": "Inpatient Rehabilitation Segment [Member]",
        "verboseLabel": "Inpatient Rehabilitation"
       }
      }
     },
     "localname": "InpatientRehabilitationSegmentMember",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_Jointventureownershippercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint venture ownership percentage",
        "label": "Joint venture ownership percentage",
        "terseLabel": "Joint venture ownership percentage"
       }
      }
     },
     "localname": "Jointventureownershippercentage",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_ManagedCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Managed Care [Member]",
        "label": "Managed Care [Member]",
        "terseLabel": "Managed care"
       }
      }
     },
     "localname": "ManagedCareMember",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_MedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid [Member]",
        "label": "Medicaid [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidMember",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_MedicareAdvantageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Advantage [Member]",
        "label": "Medicare Advantage [Member]",
        "terseLabel": "Medicare Advantage"
       }
      }
     },
     "localname": "MedicareAdvantageMember",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare [Member]",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_NetIncomeLossAvailabletoCommonStockholders": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net income after adjustments for dividends on preferred stock (declared in the period), cumulative preferred stock (accumulated for the period), and/or income allocated to participating securities.",
        "label": "Net Income (Loss) Available to Common Stockholders",
        "totalLabel": "Net income attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailabletoCommonStockholders",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_NumberOfInpatientRehabilitationHospitals": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of inpatient rehabilitation hospitals owned and operated as of the balance sheet date.",
        "label": "Number of Inpatient Rehabilitation Hospitals",
        "terseLabel": "Number of inpatient rehabilitation hospitals operated"
       }
      }
     },
     "localname": "NumberOfInpatientRehabilitationHospitals",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberOfInpatientRehabilitationUnitsUnderManagementContracts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of inpatient rehabilitation units under management contracts with the Company as of the balance sheet date.",
        "label": "Number of Inpatient Rehabilitation Units Under Management Contracts",
        "terseLabel": "Number of inpatient rehabilitation units under management contracts"
       }
      }
     },
     "localname": "NumberOfInpatientRehabilitationUnitsUnderManagementContracts",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_Numberofhomehealthlocations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of home health locations the Company owns and operates as of the balance sheet date.",
        "label": "Number of home health locations",
        "terseLabel": "Number of home health locations"
       }
      }
     },
     "localname": "Numberofhomehealthlocations",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_Numberofhospicelocations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of hospice locations the Company owns and operates as of the balance sheet date.",
        "label": "Number of hospice locations",
        "terseLabel": "Number of hospice locations"
       }
      }
     },
     "localname": "Numberofhospicelocations",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_Numberofjointlyownedhospitalbasedhomehealthandhospicelocations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of jointly owned hospital based home health and hospice agencies the Company owns and operates as of the balance sheet date.",
        "label": "Number of jointly owned hospital based home health and hospice locations",
        "terseLabel": "Number of jointly owned hospital based home health and hospice locations"
       }
      }
     },
     "localname": "Numberofjointlyownedhospitalbasedhomehealthandhospicelocations",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_Numberofjointlyownedinpatientrehabilitationhospitals": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of jointly owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.",
        "label": "Number of jointly owned inpatient rehabilitation hospitals",
        "terseLabel": "Number of jointly owned inpatient rehabilitation hospitals"
       }
      }
     },
     "localname": "Numberofjointlyownedinpatientrehabilitationhospitals",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_Numberofsolelyownedhospitalbasedhomehealthandhospicelocations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of solely owned hospital based home health and hospice agencies the Company owns and operates as of the balance sheet date.",
        "label": "Number of solely owned hospital based home health and hospice locations",
        "terseLabel": "Number of solely owned hospital based home health and hospice locations"
       }
      }
     },
     "localname": "Numberofsolelyownedhospitalbasedhomehealthandhospicelocations",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_Numberofsolelyownedinpatientrehabilitationhospitals": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of solely owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.",
        "label": "Number of solely owned inpatient rehabilitation hospitals",
        "terseLabel": "Number of solely owned inpatient rehabilitation hospitals"
       }
      }
     },
     "localname": "Numberofsolelyownedinpatientrehabilitationhospitals",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_OccupancyCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts paid for rent associated with leased hospitals, including common area maintenance and similar charges.",
        "label": "Occupancy Cost",
        "terseLabel": "Occupancy costs"
       }
      }
     },
     "localname": "OccupancyCost",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_OtherIncomeSourceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income Source [Member]",
        "label": "Other Income Source [Member]",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncomeSourceMember",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_OtherThirdpartyPayorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Third-party Payors [Member]",
        "label": "Other Third-party Payors [Member]",
        "terseLabel": "Other third-party payors"
       }
      }
     },
     "localname": "OtherThirdpartyPayorsMember",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_OutpatientandotherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outpatient and other [Member]",
        "label": "Outpatient and other [Member]",
        "terseLabel": "Outpatient and other"
       }
      }
     },
     "localname": "OutpatientandotherMember",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_PatientsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patients [Member]",
        "label": "Patients [Member]",
        "terseLabel": "Patients"
       }
      }
     },
     "localname": "PatientsMember",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation of Net Income Attributable to Noncontrolling Interests [Table Text Block]",
        "label": "Reconciliation of Net Income Attributable to Noncontrolling Interests [Table Text Block]",
        "terseLabel": "Reconciliation of Noncontrolling Interests"
       }
      }
     },
     "localname": "ReconciliationofNetIncomeAttributabletoNoncontrollingInterestsTableTextBlock",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation segment adjusted EBITDA to income from continuing operations before income tax expense.",
        "label": "Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense [Table Text Block]",
        "terseLabel": "Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense"
       }
      }
     },
     "localname": "ReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseTableTextBlock",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount [Roll Forward]",
        "terseLabel": "Redeemable Noncontrolling Interest, Equity, Carrying Amount [Roll Forward]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmountRollForward",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ehc_RedeemableNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest [Member]",
        "label": "Redeemable Noncontrolling Interest [Member]",
        "terseLabel": "Redeemable Noncontrolling Interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestMember",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SaintAlphonsusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Saint Alphonsus [Member]",
        "label": "Saint Alphonsus [Member]",
        "terseLabel": "Saint Alphonsus"
       }
      }
     },
     "localname": "SaintAlphonsusMember",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes04.750Due2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 04.750%, Due 2030 [Member]",
        "label": "Senior Notes, 04.750%, Due 2030 [Member]",
        "terseLabel": "4.75% Senior Notes due 2030"
       }
      }
     },
     "localname": "SeniorNotes04.750Due2030Member",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes05.125Due2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 05.125%, Due 2023 [Member]",
        "label": "Senior Notes, 05.125%, Due 2023 [Member]",
        "terseLabel": "5.125% Senior Notes due 2023"
       }
      }
     },
     "localname": "SeniorNotes05.125Due2023Member",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes05.75Due2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes; 05.75%; Due 2025 [Member]",
        "label": "Senior Notes; 05.75%; Due 2025 [Member]",
        "terseLabel": "5.75% Senior Notes due 2025"
       }
      }
     },
     "localname": "SeniorNotes05.75Due2025Member",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes4.50Due2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4.50%, Due 2028 [Member]",
        "label": "Senior Notes, 4.50%, Due 2028 [Member]",
        "terseLabel": "4.50% Senior Notes due 2028"
       }
      }
     },
     "localname": "SeniorNotes4.50Due2028Member",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes4625Due2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4.625%, Due 2031",
        "label": "Senior Notes, 4.625%, Due 2031 [Member]",
        "terseLabel": "4.625% Senior Notes due 2031"
       }
      }
     },
     "localname": "SeniorNotes4625Due2031Member",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statement Of Comprehensive Income And Income Statement [Abstract]",
        "label": "Statement Of Comprehensive Income And Income Statement [Abstract]",
        "terseLabel": "Statement Of Comprehensive Income And Income Statement [Abstract]"
       }
      }
     },
     "localname": "StatementOfComprehensiveIncomeAndIncomeStatementAbstract",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "xbrltype": "stringItemType"
    },
    "ehc_TermLoanFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Facilities [Member]",
        "label": "Term Loan Facilities [Member]",
        "terseLabel": "Term loan facilities"
       }
      }
     },
     "localname": "TermLoanFacilitiesMember",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_VariableInterestEntityNumberofEntitiesConsolidated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of facilities consolidated as variable interest entities.",
        "label": "Variable Interest Entity, Number of Entities Consolidated",
        "terseLabel": "Number of consolidated limited partnership-like entities"
       }
      }
     },
     "localname": "VariableInterestEntityNumberofEntitiesConsolidated",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_WorkersCompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Workers' Compensation [Member]",
        "label": "Workers' Compensation [Member]",
        "terseLabel": "Workers\u2019 compensation"
       }
      }
     },
     "localname": "WorkersCompensationMember",
     "nsuri": "http://www.encompasshealth.com/20220331",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r100",
      "r203",
      "r208",
      "r216",
      "r354",
      "r355",
      "r359",
      "r360",
      "r417",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r100",
      "r203",
      "r208",
      "r216",
      "r354",
      "r355",
      "r359",
      "r360",
      "r417",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r100",
      "r146",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r166",
      "r170",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r213",
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r100",
      "r146",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r166",
      "r170",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r213",
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r221",
      "r260",
      "r289",
      "r291",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r487",
      "r489",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r221",
      "r260",
      "r289",
      "r291",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r487",
      "r489",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r172",
      "r270",
      "r271",
      "r431",
      "r486",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r172",
      "r270",
      "r271",
      "r431",
      "r486",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r221",
      "r260",
      "r278",
      "r289",
      "r291",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r487",
      "r489",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r221",
      "r260",
      "r278",
      "r289",
      "r291",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r487",
      "r489",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r33",
      "r420"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r14",
      "r26",
      "r177",
      "r178"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "netLabel": "Accounts receivable",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Finite-lived intangible asset useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r302",
      "r303",
      "r304",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Capital in Excess of Par Value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities\u2014"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedLabel": "Receipt of treasury stock"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r292",
      "r294",
      "r305",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Total adjustments"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r96",
      "r154",
      "r161",
      "r168",
      "r181",
      "r203",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r214",
      "r216",
      "r217",
      "r354",
      "r359",
      "r393",
      "r418",
      "r420",
      "r448",
      "r469"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total assets",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r15",
      "r16",
      "r45",
      "r96",
      "r181",
      "r203",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r214",
      "r216",
      "r217",
      "r354",
      "r359",
      "r393",
      "r418",
      "r420"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r295",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r288",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r288",
      "r290",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Business acquisition percentage of voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Summary of Actual and Pro Forma Results of Operations for Acquisitions"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill expected to be tax-deductible amount"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r331",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Business acquisition, pro forma net income"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r331",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Business acquisition, pro forma revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.",
        "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Escrow agent cost"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "verboseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Business combination, pro forma information, earnings of acquiree since acquisition date, actual"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Business combination, pro forma information, revenue of acquiree since acquisition date, actual"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease obligation assumed in business combination.",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Total liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]",
        "terseLabel": "Liabilities assumed:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "verboseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r13",
      "r30",
      "r89"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r84",
      "r89",
      "r93"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r84",
      "r395"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of noncash operating, investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r9",
      "r84"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Net cash used in operating activities of discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r40",
      "r199",
      "r454",
      "r473"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividends declared on common stock (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r25",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (shares)",
        "periodStartLabel": "Balance at beginning of period (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r48",
      "r50",
      "r51",
      "r63",
      "r462",
      "r482"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Net and comprehensive income attributable to Encompass Health"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r48",
      "r50",
      "r62",
      "r352",
      "r353",
      "r369",
      "r461",
      "r481"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Less: Net and comprehensive income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r48",
      "r50",
      "r61",
      "r351",
      "r369",
      "r460",
      "r480"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Net and comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r188",
      "r192",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Internal-use software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.",
        "label": "Corporate Joint Venture [Member]",
        "terseLabel": "Corporate Joint Venture"
       }
      }
     },
     "localname": "CorporateJointVentureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldOverhead": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indirect cost incurred related to good produced and service rendered.",
        "label": "Cost, Overhead",
        "terseLabel": "Support and overhead costs"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldOverhead",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 2.0,
       "parentTag": "ehc_AdjustedEBITDA",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r453",
      "r474"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term and long-term debt and lease obligation.",
        "label": "Debt and Lease Obligation",
        "totalLabel": "Total debt and finance lease obligations"
       }
      }
     },
     "localname": "DebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r235",
      "r242",
      "r243",
      "r245",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r95",
      "r100",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r248",
      "r249",
      "r250",
      "r251",
      "r406",
      "r449",
      "r450",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r37",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument interest rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r38",
      "r95",
      "r100",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r248",
      "r249",
      "r250",
      "r251",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Redemption amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r38",
      "r95",
      "r100",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r244",
      "r248",
      "r249",
      "r250",
      "r251",
      "r262",
      "r263",
      "r264",
      "r265",
      "r403",
      "r404",
      "r406",
      "r407",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r87",
      "r97",
      "r314",
      "r319",
      "r320",
      "r321"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r87",
      "r149"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "negatedTerseLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Concentration of Net Operating Revenues by Payor"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedLabel": "Dividends declared"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r64",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r114",
      "r116",
      "r128",
      "r131",
      "r132",
      "r137",
      "r138",
      "r376",
      "r377",
      "r463",
      "r483"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Net income (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic earnings per share attributable to Encompass Health common shareholders:",
        "verboseLabel": "Basic earnings per share attributable to Encompass Health common shareholders:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r64",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r116",
      "r128",
      "r131",
      "r132",
      "r137",
      "r138",
      "r376",
      "r377",
      "r463",
      "r483"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Net income (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted earnings per share attributable to Encompass Health common shareholders:",
        "verboseLabel": "Diluted earnings per share attributable to Encompass Health common shareholders:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r133",
      "r135",
      "r136",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r52",
      "r53",
      "r54",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r140",
      "r182",
      "r261",
      "r267",
      "r302",
      "r303",
      "r304",
      "r315",
      "r316",
      "r375",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r490",
      "r491",
      "r492",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r233",
      "r248",
      "r249",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis [Abstract]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r378",
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r233",
      "r248",
      "r249",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r379",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r233",
      "r248",
      "r249",
      "r378",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r378",
      "r379",
      "r381",
      "r382",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r233",
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r233",
      "r279",
      "r280",
      "r285",
      "r287",
      "r379",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r233",
      "r248",
      "r249",
      "r279",
      "r280",
      "r285",
      "r287",
      "r379",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r233",
      "r248",
      "r249",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r379",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r233",
      "r248",
      "r249",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r384",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfAssetsAcquired": {
     "auth_ref": [
      "r90",
      "r91",
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of assets acquired in noncash investing or financing activities.",
        "label": "Fair Value of Assets Acquired",
        "terseLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "FairValueOfAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.",
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "terseLabel": "Gains or losses related to non-financial assets and liabilities"
       }
      }
     },
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r409",
      "r412"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "verboseLabel": "Finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r188",
      "r190",
      "r193",
      "r194",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r188",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "terseLabel": "(Loss) gain on disposal or impairment of assets"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r87",
      "r252",
      "r253"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on early extinguishment of debt",
        "terseLabel": "Loss on early extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "negatedTerseLabel": "General and administrative expenses",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r183",
      "r184",
      "r420",
      "r447"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r68",
      "r88",
      "r106",
      "r107",
      "r108",
      "r109",
      "r125",
      "r132",
      "r350"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r348",
      "r351"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails": {
       "order": 2.0,
       "parentTag": "ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Less: Net income attributable to noncontrolling interests included in continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r57",
      "r154",
      "r160",
      "r164",
      "r167",
      "r170",
      "r446",
      "r457",
      "r466",
      "r484"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income from continuing operations before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r96",
      "r104",
      "r154",
      "r160",
      "r164",
      "r167",
      "r170",
      "r181",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r210",
      "r212",
      "r214",
      "r216",
      "r217",
      "r351",
      "r377",
      "r393"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails": {
       "order": 1.0,
       "parentTag": "ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Income from continuing operations",
        "totalLabel": "Income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r55",
      "r64",
      "r104",
      "r106",
      "r107",
      "r108",
      "r109",
      "r116",
      "r128",
      "r131",
      "r377",
      "r455",
      "r458",
      "r463",
      "r476"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Continuing operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r55",
      "r64",
      "r104",
      "r106",
      "r107",
      "r108",
      "r109",
      "r116",
      "r128",
      "r131",
      "r132",
      "r377",
      "r463",
      "r476",
      "r479",
      "r483"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Continuing operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r10",
      "r11",
      "r324",
      "r477"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Loss from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r8",
      "r10",
      "r351"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails": {
       "order": 2.0,
       "parentTag": "ehc_NetIncomeLossAvailabletoCommonStockholders",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Loss from discontinued operations, net of tax, attributable to Encompass Health common shareholders",
        "verboseLabel": "Loss from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r59",
      "r64",
      "r120",
      "r128",
      "r131",
      "r463",
      "r477",
      "r479",
      "r483"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r120",
      "r128",
      "r131",
      "r370"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r58",
      "r87",
      "r151",
      "r180",
      "r456",
      "r475"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 4.0,
       "parentTag": "ehc_AdjustedEBITDA",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in net income of nonconsolidated affiliates"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r311",
      "r312",
      "r313",
      "r317",
      "r322",
      "r325",
      "r326",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r112",
      "r113",
      "r152",
      "r310",
      "r318",
      "r323",
      "r485"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Provision for income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedSalaries": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in accrued salaries.",
        "label": "Increase (Decrease) in Accrued Salaries",
        "terseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedSalaries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "verboseLabel": "Change in assets and liabilities, net of acquisitions\u2014"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r132"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Restricted stock awards, dilutive stock options, and restricted stock units (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r187",
      "r191"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r56",
      "r148",
      "r402",
      "r405",
      "r465"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense and amortization of debt discounts and fees"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r72",
      "r239",
      "r247",
      "r250",
      "r251"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedTerseLabel": "Interest expense and amortization of debt discounts and fees"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "verboseLabel": "Investments in and advances to nonconsolidated affiliates"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Labor and Related Expense",
        "terseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letters of credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r34",
      "r96",
      "r162",
      "r181",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r210",
      "r212",
      "r214",
      "r216",
      "r217",
      "r355",
      "r359",
      "r360",
      "r393",
      "r418",
      "r419"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r96",
      "r181",
      "r393",
      "r420",
      "r452",
      "r472"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r36",
      "r96",
      "r181",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r210",
      "r212",
      "r214",
      "r216",
      "r217",
      "r355",
      "r359",
      "r360",
      "r393",
      "r418",
      "r419",
      "r420"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licenses"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term loan facilities"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r24",
      "r232",
      "r246",
      "r248",
      "r249",
      "r450",
      "r470"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Total debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt and Lease Obligation [Abstract]",
        "verboseLabel": "Schedule of Outstanding Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "negatedTerseLabel": "Less: Current portion",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Carrying amounts and estimated fair values of financial instruments"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r38",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyDisclosures": {
     "auth_ref": [
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.",
        "label": "Contingencies Disclosure [Text Block]",
        "verboseLabel": "Contingencies and Other Commitments"
       }
      }
     },
     "localname": "LossContingencyDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Gain (Loss)",
        "terseLabel": "Change in fair market value of equity securities"
       }
      }
     },
     "localname": "MarketableSecuritiesGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Segment Reconciling Items"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r43",
      "r96",
      "r181",
      "r203",
      "r208",
      "r209",
      "r210",
      "r216",
      "r217",
      "r393",
      "r451",
      "r471"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Distributions declared",
        "negatedTerseLabel": "Distributions declared"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "Redeemable Noncontrolling Interests"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r84",
      "r85",
      "r88"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r11",
      "r47",
      "r49",
      "r54",
      "r60",
      "r88",
      "r96",
      "r104",
      "r106",
      "r107",
      "r108",
      "r109",
      "r112",
      "r113",
      "r125",
      "r154",
      "r160",
      "r164",
      "r167",
      "r170",
      "r181",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r210",
      "r212",
      "r214",
      "r216",
      "r217",
      "r377",
      "r393",
      "r459",
      "r478"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Encompass Health"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Amounts attributable to Encompass Health common shareholders:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r47",
      "r49",
      "r54",
      "r112",
      "r113",
      "r357",
      "r368"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 5.0,
       "parentTag": "ehc_AdjustedEBITDA",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Less: Net and comprehensive income attributable to noncontrolling interests",
        "terseLabel": "Net income attributable to noncontrolling interests",
        "totalLabel": "Net income attributable to noncontrolling interests",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of net income (loss) attributable to nonredeemable noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest",
        "terseLabel": "Net income attributable to nonredeemable noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNonredeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest",
        "terseLabel": "Net income attributable to redeemable noncontrolling interests",
        "verboseLabel": "Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "verboseLabel": "Basic Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r115",
      "r121",
      "r122",
      "r123",
      "r124",
      "r127",
      "r132"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Diluted Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {
     "auth_ref": [
      "r257",
      "r357",
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.",
        "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r90",
      "r91",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "negatedLabel": "Fair value of liabilities assumed"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Noncompete agreements"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r267",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Other notes payable"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states in which entity operates"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r408"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r12",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r44",
      "r420"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Other operating expenses"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r372",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r19",
      "r35",
      "r420"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Noncurrent Assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 3.0,
       "parentTag": "ehc_AdjustedEBITDA",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other expense (income)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PartnersCapitalAccountContributions": {
     "auth_ref": [
      "r266",
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total contributions made by each class of partners (i.e., general, limited and preferred partners).",
        "label": "Partners' Capital Account, Contributions",
        "terseLabel": "Capital contributions from consolidated affiliates"
       }
      }
     },
     "localname": "PartnersCapitalAccountContributions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r74",
      "r77"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtRestructuringCosts": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage.",
        "label": "Payments of Debt Restructuring Costs",
        "negatedLabel": "Debt amendment costs"
       }
      }
     },
     "localname": "PaymentsOfDebtRestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedTerseLabel": "Dividends paid on common stock"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid on behalf of employees for shares withheld"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "terseLabel": "Cash paid for acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r76",
      "r344",
      "r345",
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedLabel": "Distributions paid to noncontrolling interests of consolidated affiliates"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromContributionsFromAffiliates": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.",
        "label": "Proceeds from Contributions from Affiliates",
        "terseLabel": "Contributions from consolidated affiliates"
       }
      }
     },
     "localname": "ProceedsFromContributionsFromAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Borrowings on revolving credit facility"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r79",
      "r82"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r11",
      "r47",
      "r49",
      "r54",
      "r83",
      "r96",
      "r104",
      "r112",
      "r113",
      "r154",
      "r160",
      "r164",
      "r167",
      "r170",
      "r181",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r210",
      "r212",
      "r214",
      "r216",
      "r217",
      "r351",
      "r356",
      "r358",
      "r368",
      "r369",
      "r377",
      "r393",
      "r466"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net and comprehensive income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r46",
      "r195",
      "r410"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": {
     "auth_ref": [
      "r161",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table]",
        "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "auth_ref": [
      "r161",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Assets from Segment to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r160",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r159",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r159",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.",
        "label": "Redeemable Noncontrolling Interest, by Legal Entity [Table]",
        "terseLabel": "Redeemable Noncontrolling Interest, by Legal Entity [Table]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestByLegalEntityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "auth_ref": [
      "r255",
      "r256",
      "r258",
      "r259"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Redeemable noncontrolling interests"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityFairValue": {
     "auth_ref": [
      "r255",
      "r256",
      "r258",
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Fair Value",
        "terseLabel": "Redeemable noncontrolling interests"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Redeemable Noncontrolling Interest [Line Items]",
        "terseLabel": "Redeemable Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.",
        "label": "Redeemable Noncontrolling Interest [Table Text Block]",
        "terseLabel": "Redeemable Noncontrolling Interests Activity"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r286",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r286",
      "r414",
      "r416",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-term Lines of Credit",
        "negatedLabel": "Payments on revolving credit facility"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "negatedLabel": "Principal payments on debt, including pre-payments"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r13",
      "r20",
      "r93"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "periodEndLabel": "Restricted cash at end of period",
        "periodStartLabel": "Restricted cash at beginning of period",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r17",
      "r21",
      "r93",
      "r493"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "periodEndLabel": "Restricted cash included in other long-term assets at end of period",
        "periodStartLabel": "Restricted cash included in other long-term assets at beginning of period"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r182",
      "r302",
      "r303",
      "r304",
      "r315",
      "r316",
      "r375",
      "r490",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Income (Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r145",
      "r146",
      "r159",
      "r165",
      "r166",
      "r172",
      "r173",
      "r175",
      "r269",
      "r270",
      "r431"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 1.0,
       "parentTag": "ehc_AdjustedEBITDA",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net operating revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Advances under revolving credit facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r411",
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Property and equipment additions through finance leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r411",
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease additions"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "verboseLabel": "Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r38",
      "r100",
      "r248",
      "r250",
      "r262",
      "r263",
      "r264",
      "r265",
      "r403",
      "r404",
      "r407",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Earnings Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "verboseLabel": "Schedule of Assets Acquired and Liabilities Assumed at the Acquisition Date"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r154",
      "r157",
      "r163",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r154",
      "r157",
      "r163",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r295",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r354",
      "r355",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r361",
      "r362",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "terseLabel": "Schedule of Carrying Amounts and Classifications of VIE's Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of Weighted Average Number of Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r141",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r175",
      "r197",
      "r198",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingAssetReconcilingItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Asset Reconciling Item [Line Items]",
        "terseLabel": "Segment Reporting, Asset Reconciling Item [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingAssetReconcilingItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r141",
      "r143",
      "r144",
      "r154",
      "r158",
      "r164",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r174",
      "r175",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAdjustedEBITDAtoIncomefromContinuingOperationsBeforeIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingRevenueReconcilingItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsScheduleofCarryingAmountsandEstimatedFairValuesFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Performance measurement period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock awards issued (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Stock options granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r293",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Service Condition"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Service and Performance Condition"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedLabel": "Receipt of treasury stock (shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r7",
      "r141",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r175",
      "r186",
      "r196",
      "r197",
      "r198",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BasisofPresentationNetOperatingRevenuesDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionsDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails",
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofSegmentAssetsandInvestmentsInandAdvancestoAffiliatesDetails",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails",
      "http://www.encompasshealth.com/role/SegmentReportingTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r42",
      "r52",
      "r53",
      "r54",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r140",
      "r182",
      "r261",
      "r267",
      "r302",
      "r303",
      "r304",
      "r315",
      "r316",
      "r375",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r490",
      "r491",
      "r492",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Statement, Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r140",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r25",
      "r27",
      "r28",
      "r96",
      "r179",
      "r181",
      "r393",
      "r420"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "verboseLabel": "Encompass Health shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r53",
      "r96",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r181",
      "r182",
      "r267",
      "r302",
      "r303",
      "r304",
      "r315",
      "r316",
      "r348",
      "r349",
      "r367",
      "r375",
      "r393",
      "r396",
      "r397",
      "r401",
      "r491",
      "r492",
      "r503"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOtherShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of increase (decrease) in shares of stock classified as other.",
        "label": "Stockholders' Equity, Other Shares",
        "terseLabel": "Other (shares)"
       }
      }
     },
     "localname": "StockholdersEquityOtherShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/SegmentReportingReconciliationofRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SuppliesExpense": {
     "auth_ref": [
      "r464"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense associated with supplies that were used during the current accounting period.",
        "label": "Supplies Expense",
        "terseLabel": "Supplies"
       }
      }
     },
     "localname": "SuppliesExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/SegmentReportingSegmentReportingInformationReconciliationofNetOperatingRevenuestoSegmentAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade name"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r41",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofShareholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r126",
      "r129",
      "r130"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails": {
       "order": 3.0,
       "parentTag": "ehc_IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "negatedTerseLabel": "Less: Income allocated to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "terseLabel": "Ownership interest in consolidated entities (percent)"
       }
      }
     },
     "localname": "VariableInterestEntityOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r354",
      "r355",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "VIE"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesScheduleofCarryingAmountsandClassificationsofVIEsAssetsandLiabilitiesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r115",
      "r132"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Diluted weighted average common shares outstanding (in shares)",
        "verboseLabel": "Diluted weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails",
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r114",
      "r132"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Basic weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails",
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationofWeightedAverageNumberofSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareComputationofBasicandDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "verboseLabel": "Weighted average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.encompasshealth.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "65",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2793-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2814-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/subtopic&trid=2127163"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "http://asc.fasb.org/subtopic&trid=2127197"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(3)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13,16)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r497": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r498": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r499": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r500": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r501": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r502": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>70
<FILENAME>0000785161-22-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000785161-22-000021-xbrl.zip
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M>@ 1P24R04C/6!:4QL;C3"&C@^.(\\?3@5KC_5%D=]57!P\[/^GF-A^V?,_
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M8(W0F4",F!1U1%903!40 &&H6X!IC <5_/*COU9!<1L4P1BS8$+<82DNNM'
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M&DY?E.MUQO%#SY6\&A5%JK4;7R/:UZ$>CLJ%A(9_%7XDGR@.G@B9-;E3K,G
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M74RNR8=I@BV!+?S0'7^/6-T=E*,X^Z?-8#1LM'3QV0\;NWGY>07 RZ,%E*X
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M6,^J'!T=^;(^^=KV8[$9DX)6L2!-?IG*#I?&*FD]7Y<KRV,-M&JKF6^]6B6
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M)K>KJ/9NJ(H\Q[U.;:S=#"=%6I%;&+4IT 7#>#A,I:!CF>?"QQ=-@2T@'@.
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MZ:H3/Q$BN]*-R2R-VW6MOV\?$7-3:CJV.:4-Q5(_4T5(*TKMZY7058W!<45
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M)$&$W$$R=WKC.T! ?9^Q!?SJ5LO5L_A'QK31]O-1,1CU7;-N8DC__$CWSO<
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M[X\;Z:U5I:R<]>IN)L*66$4S\D3+P9WZ..QH5J"8:#BQ-#&7<CZW9>:@(@W
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MW=/3G1,R<I\XL@PK9# 6CC"M6(AK+Y6ZT>;T72' BIPGM68U;_M^&.TH%K^
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M0--0)DU\A+GB;TPTB+[73:L5'<BXW#96$QWT5*.#FO,I#P_IEV1>XXEK@W5
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MVN/<V/AC3+NK*Q^7A;,<0+9G!DQ%5T_I;%.JL59$[V2>&BB]/I1^7W(B7@<
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MBW+D,05"K 49Y1K^52DX16CTW&/K&X._AJ*\X(6/3N3#LQA%8X%:4*^152*
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M><N4=;AA$36#GNTE6>0UQ\0ZP1&A,B>D21+IH#3"C'M#=+)$F;67\N; TX0
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MHA@S2"IE$1=,(>L=1B;JG"T.U++ V5!N(N7O5A#_L>-.[(^;R/B+;0("W-\
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MNXU')_<]*[H=ZSI=^!;&PX*UU\L?YD; ZLT -1S DH5VS= :[+M8+BZ?]V]
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M%N6$HD%"DU%$E=UV+>Q]$B4F;XJ]L>U7BKLGD_EWGLOWN5/;Z>-H>FN#OE=
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M HL&\6 #<D8R)%RBRG(?->4K":=OV-<UCU>7^7O]U)2\J>G8T+#:T+!R8AL
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M @Y^FFFHYB2Y"82X-6YXLO4U!<_-TL_[3^GA;0#S*H!YO$@/L<1$DD013U(
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M@0_?W_0XG4:!TA"=#S%RSK74CDL?/=8QD83=-1SO2S;=EQB:4Y*PG:;*('X
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M[E<SLU9GJIE['X] ([.MS:WCO<U= IKY&+0JA^O@[RVQM_GV>^O3^\Y>[YT
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MC)P/$F&.I4[4,YNKG5.,5TK4/+=R@7F[%ZTNW'A,T*H@^!L$#8@4P:)4E.K
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M6 !L\J2=H98R[D)4(F%K*OKY\-B<HI],ADB<HP@6!E24I08YF@_H-(,%TD*
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M">A)<5D#G2OT2>?8V&G6'XTM?^*2%LY_7J:6&S#6"]]<WO_E=?^TG6'65OD
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M#Y$80[T4EDA0O-A17"[X9.?[:L&7MN#">^R(2$CBO.#)*F0S^358D*B=(9$
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M-D0!V\(8'BR3\M;-3BJ0+@"D4ZZ=$'4.'L!(.J9 <WF+'.8,!05F@S/824X
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M1QM0HA&R>2&K&,<4A0?XG.'E%9":Z\:B.)$<F$(]NC=2@_*4E&KJ;N"XP,L
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MX0%SB$>Y(Z3R16Q[F"[WSHE^P/[3HR>UV7]::8Y=F.,X%AZW74D4F.L@S5%
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MO,^S;G5XZW,Z:+\MMUS>_< ]6AC'8YU[18I+]F/F;!>>ZR(B&Y#R);6I=_5
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M[XN;*PD52>(X ?$\&:*!G "K=!@)1.2#X9QX5$FL[!INFE:N)AR[824W8'>
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M8^A?QUAWVA-93%@K3 8TK /"!-:>GCL8 _B<CV8GP4+^7DEJM7!V43IQ[&"
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MG[S%Y"E\6!Q9'V267Z4'Z*7<'SVTWSU^("KM9F</EF9\&N19[ZIT9URTT^S
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MJE;^V[!(,1N!=3$<=++L^WTX5'6@+B!TG@VPX&XQ -FL("89YCF6(TR[?98
MC*L\Z^HOH'U"=M-$*Y%<=ADJ(<#\+E:43."3*[ !JJ>D..M=*5(V,(6K.QGP
M'?S,ZNMCEOK1@"((.+P<QI9U(KO95<[Z;7C@ )HA .^+(> \('X_ZP\[I8*"
MP02=4;2S84>,<13K6U:UPJ?>!XW&!N#+=-5PK"T/R(.]@*8@&K:LS^T4% Q\
M B\%O37680!'H'3@?9CUMYL5NDHC-GFBY0 W ]^H3,3NHW$9\-ZXL-P9C$."
M%\I>GG4Z$EX.$"<KT@+-QI+D%NM#>WZD@*,2T-K[12/S2+)\W';XKP1\U248
MU1 YSA&,.]A?&NIG;@\]JXL*%D:K+[,^W#"NFPZ]P59!JSEJ6<]N6>^ ,D'_
MH(DX-:E"DM<9'9G+X3Z\I;QMIO?0C;G7!I,!F)HPM 'Z5LYZ5Z9XN1Y1L[1"
M'P<@C)</R6#N^?[4J( RS(97F@,$,(42J$@GE=>RK*QYWZQ;-S ^RQ</K#:\
MZ3^M3ZW992>+^1?!U0KD),MA)!#P)A6L"US 5ZBHTYX9%)4E0UA3\!?H'P#(
M!!3/N&6:K%4Z5<M8]1;X-6'ZNQRQ9JYW\'8LTSLBR,9%20.[LOQSZD5Z!8['
M >8 0.F[A$F\:<O<O,6(/@RSR*Q>-K#:,/= (?JXZGK WV"]X-F&03Y,3/7@
MO&23^,>8Z&')4D,-1U-?HZR;TH*WTE88WUZ2FL8-X$,86EAYR&1U:6(Q1%8$
M([5K,(NL/L>![$BF$;)<@1H<IF;(#,G,/!W!)4KJ 02%V+YOMLOBS?H1E7@8
M$CZXR?+O^+Y[2SS#.V<FJ)R4HZ53I<4!WX:D,1V4LBM@Y5Z;5K=A' AP4&ST
M$5P%G04C!MG>-8 7J@G ^\%<VUO6L5GG/=TT[6\(7Q=6!^97(@C?8#%XC;FZ
MDG66K]8SO;! )VA@'X.8QGPI$$H!!H=55R?X/34RLV(I4IP<>(A6<S#08 ]?
M5\!64NF^'*0:'LP493W=L7)$*D!-8-$@YL(? [A'S[N^?7JX4$6:SU7:8S#\
M<'T%,J;)QE@<2# 647#[?: Q;,RK9=+NP8J_&HV'5\$-:/B5PSJ]+"N=11*T
M^54*32^^XR$(,;,ZIO%D/+*3<7S,<(V,]IGM!-,+"A!J:N5,.F;U :G1%#'#
M9-; "%<DR+#68=8U P@Q Z^E!%9!&[FN&4"FQP!TX2!G8/SD,LER;2HA[ V[
M75,T':^LWJ__1I S!L7N@=,Q3*/&"1SM*00J\7:$>GFB&&"QP3@*K<*-/JH8
MW]2M20ZC 7>Q(:[X<B(G]-'PP_+IVMT!J";-BJS(H1:,WE6&3Z^<'C"-,"V]
M B=X_I7%J "+$2])L@QIJ%X9^JL2C(P!"F:Q+K;=S>!C0*]+ S*:22&5+6=7
M"U%9DALXR/BU9AT:\EM86-0['S"MWBN]/*GGK5=)%Y@7_C5>P*@E;V^6Z49A
MJ$DNM:/&*H!6:$H&%T ;#9_.*PNZ!<8'&O P1(;O7F5HD>OA0NF48YM^V(,E
M*HUJKC@0-IJC[!MAR& ^D5Q.N1RJ>3/OF=#JJ==4UK2^_BW(,.N-] J!UPR%
M'F[60\2&:SG:#D4_,Q"E25>Y$HIVJ@9&H6C>D?8 &XSF+[L +:Q,!=V)Q  W
M_(X>B)P98C+4N@]F3?:0*,,TF4:6/9Y62*;7R.SFH!;!.IUJ"Y> "2(MDK2/
M$J3;I-]N?"Q)Z=:8:P",CNK('WI$-2WL93.3*23'H8$;S,3T\S33@X1U:O7+
MI]EI2<8*?7P<H;73(>6+0=Q!SEB'(4DKVE(.4+4FG:$P[2N&'&V\ 6J,/BP4
ME8%AH$7L!CL#'>E8,-:5K3;=1G;-TDX%I,.>U@XP&0#Q6><:GP[# )QU3$R,
M;\@08ZV2X%>\G!59;T$AZ&4.*T(;--!%)EA_H(6X#::"T2JY3+L<504*"%J#
MQ8"5*V*\&+0T&P379D-%?:: V2P8: -6'RVEL8]C,98*+<$@C@!>0$ ^R=(5
MBYXHRSEZ&O?VHST/3]RJ.]MP5/GXWI9J&P7G4V7U5)X]'/?R.O@.EMB5@3SM
MJ"P_ 6O_3US[>B:J&S7X2KS.P34%DV#C5W;\^E]K.7SKZCSZ%RRVMVVPLR4N
M]1UT8?\^11:*"3/+Y14:S!.3;:3! :"BBWI!XU9_R&&0-&R5EV>E)IP1=\2!
M<GR,JAY[4F8OJ]0FVL/:3+K5%*@,IHJ_:E %FF?8C<:W*]SZF(; $HQ,"XS;
M!1>G[@TK75EH)4R&H^S34JX T#),0&\7:MB9OJ<BW\:E9,S?NW 196-N[(PQ
MI"E3[SH%-8&# Z#+AVE'H.(H9<WXR0$+VVD?7I< YRH6.)S1/,/NT1@YTV)@
MAFF9*IVW[4H[[O,,WNO1UG:=Q!' 30708&9^2LEWW->FD^CD,P^^I>%'TT94
M-=T3^PF;8\W93IKB3XR"B?:TC(_J!ETWTUJA;-'T%&@%B3-8LF!+C'I,\]I;
MU[]Y<=7_6VT,H=END97;*T /8+V@P87$8U@4X_T1.247^%BDST=ZXP65E=D+
M"NNFL<ZT!88K<FS.GTSZI?>6>JPS0L,!.OE^;.&^S7IBHL$_RF+8,?)V858[
MK(9:*,%W/V0RU"O_XAJ-8GE3+IY9G-^T=JN)+CC6"W&:KDH]'G*6J(%]WCLJ
M70^=3G:CZ2F:. C)MZ[MM09D)K;"IW-#1)QH:V.DISYXO;W5.CLV#IW$G0@$
M(2U,K[0.-%$=%V-]HH'N=X-O'\?X=EKBVS;E;^R +*UE87P 8'>/C,TUY0_3
M>@PM\A]6A]T4)=^H5+6.6-!+4\((8(E[;1$=E=M7Z)V[PCT4K56M#EKZP G.
M%C=-N-2>CPE9P9>B58$D:9I8H*(I01VEI%YX?2X'4X2B<NEM%VH5Z$-M7<].
M,4[:T@DU\U5Y,L;S ?KW*F?=\G*SEL$,'^C8ZBF[&<",?$^3[QC%9K@#?J)R
M-A35<BL95J(W(G&/*D]Q$9BK!;R]P%TKIFF(-30<$I9&/NS(Q>8:>J"O17=T
MEI?/+=E>23W-!4>SP,J0Y1A#EH_P0:8#Y2YNY76>9<TWAOFB:"!Q'KMR2WHG
MK'+O#)E489R@,.8I.AF.D/T*LS30HR6R9#AQ<^G]9);CYJT9)MV82;@(+$ 0
M24VCH8O&OVQ<O$?C\< =(^UGF*:J>K;[;2 )0 UZQ8R#0<D\1Q>,\8K-/ @[
M@0)9[5[FN*X'XSV-3MI-QR^<HH<Z<D%WK]HI,U$OI0\/!K:Z\ =N@>N-K>GM
MK\D>R3OLK7:6& 69#8NIP9S'J2;LY?%A+]$^A+TL4)DMC>92;$63OS>C(<:
MJ.$$XR:6F;?&M=9XU>XU*#Z.!_NH,AK,J!W7;=@^IL5WZ[V)@MCNT.$BU8/4
MF+_U-'^/5K!_-7PL<7X4U4TZ$ N8#=!GIEU\$U0J+<;Q;GA)]0J]7ZOC9;5B
MU^3C1LZQ2'2Y33VL,3NW8W:^+9V<,%.XY3BQ0M]-O)JE)."G"P&*VS5'3WO5
M!J>V4W3#M+>[<CD#".3(#-%Y7&1)JLV/L1TSV28'R;_*JZU.O;.J.87Q<H]M
MF?]CW?[K\L]4@&XM2?S+:F_F[%,I<K\"=\WZ^+)"8DA?1]NWPRG/^]B9W)4,
M)616:BJO;X[^7*5W))=YKW%O+A=FL[<4M'&DS<U"O*8Q>01P![WYJ!WCQC6+
MWN.+GE6&^8<ZLMT^PL[#^%E_0NM2O;5\F0^[?6U6:X\KW MTI=R)AL4"EE .
M;/LX!8/JHVZYT1+OH!49C#.,6(+[KR/KV$0=X&NLEU,1[&^//[[[A-]6XWAD
MW;13:%0Q!+M?CTX![9?:3:UM& S6@W'%:('$<G^!$1/#<7C[@A5:[OT7=[*F
MHW$D(TA#FFE_\1D;6<YXK_,$3#D,6)HY"F";38N9]I7MUGKGAA7&\,!>L*F0
M)XPST%1M^D88<[#R!&Z5PB7Z*(!5'CG 30:]X9WUT-ZUG%_&,0V3WE=-_6/8
MDY9GFSMU"X&#(P$O78-#& 08MLE(+3RIC(_ YK2LD_O/1UC>N)V#N\9C;/I.
M6:N5ZZ.*0[AU;ZD\=;.PQ[3D9(X.99H);/V'$XP#=O&&?_C5GT<:3\PV1F=D
M)G2\)LVIBK-/,UM!277&!CT9<F9>C;6LNVE4JO$F3,SM:0?!U)Y2>69';ZZ5
M?1@[,Z:?AH$M1F&;[9&&Y]_+G#X9CP7.SD>SU&;XOI'G>I/^)V_;G2UI2/_V
M3-0E+;N#X9/U]K8:3KU53OW>[(-4&SX53_RWO$H+XW%$#;3MQ3AAB;.'((]*
MM=B1.NXZA67:RP:H@S%<(,_Z&7Z,CO@N^Z[[C(<I0#JAQ_IX"3S$TQ_>JO#+
MF#=TNIO(.!/9>O?5HW&,*P[@;.#G#._4[_^S:NCIQ_?61VAL14(-#UA^3<FS
MQ\&GR #DP');T2^E*QOC&_$_XQ,O+V<_'_:%#M%6EM>J"*P)Y=71"YJ&7>M#
MG>+;L!A4E,9NT5]^G01=&$,>AK2M \PM+@<W&$AY 4H#^4AU7!57U2<)ILD4
M?S7LT+NSFSH^KV0YQ3@VQH1>EOL>^I"T<<H3/B+5[SH8W\*PDEEK:H;_Z$B=
M]E3,C7Z18;IX,9Z0T7L'VC[2QP=*&E3:?3<8<HYH]</L,S">Y:3:<#)';J]9
M1P?*FP'7=V;# 9@I^<0NP'NGOM=;,M!\TDU_5 >KRAT RTA*N?U0GMOJE*>0
M8'[ X!N5KVQ9OU7G$?2V1Z6'].@-!RE&Q>#^"'#IJY(U#O"865$>"DN&4\<7
M)J?A>KUA&8ZJCYLQ"V:\<PUM14I>V2Z&F+^7/#<'O:-*8LO#[G"5'.^++ Q'
M>8X-VEHP(-DZ(EJ!(57NU)JVJHJ8W,P>"[M-8"I[HC,P>]V]:>'0DY(OL4?T
ME"Q0>;<5_S(E!'.K_7$:<$OZ;D4A1!LR-[:5EBN,.M?0H&/!LX$T(<AE@%?:
M6P$L*S\&O&_LQYBU4O2*-1NE7$Y: D\O-TPG&#^UZ%D9]6?]IZ<%^-- 3^:)
M[+-\C&>_3PRXWX<PB!/WRH52I2HY[6DPA]Y^D#VM+ZLF__[[)W)Q^F&JV>BQ
M-'H)CT=@2)TPIZ1NVM*(6(:QS*DR1R9PC,MGF1,(B(Z&7%5+L)\!$]6;D :C
MY\8&)P%T&9[HF\ PNETFYNF150"&=5AN/K\IKY\V8*?N-<L_-4</)TKO6(?Z
MO,5O_YS2;G^6K?RDM5O+*D<$8\VUL(@2K$&J,0P.%PM.7;D^*N^9Z:*9X;*7
M@PQ!',=G'&,ZTW&]"SXKE<$ODQ-8KNV$91"R$UF K*SAI=OAI6<L[6%4+ J!
M*8QG_1<+=DKK@P['W"ZS/"XL8!9)GO+),91E.Q8S:F;:W9)4AEPQ#C2I5G7I
MYP5-<\6,:Z<D+7#-M1X"[7'!UTV=3Y_VG6+ )[:HNAI%Z%J?0"]FG3!3I/).
MBVTZ5+_T4]UY?9FTHYC)VG&$YV'*' +(J$L,AN=HK[?&S+<7_ST](4Z,QW:J
M9QCY-I%3T/I\V!]47&K2R2I(=\$5U8CO5L3WHTSR83H^%/E15K*,L8+DKS(^
M^T^9%UFO)SO;E>9)W$&MG6G;]>S<MR_+YJ+1JR.[FK1A%-F  34JLW/D YWG
M 2[3H?KZ%'&_6@Q+Z+JA UTVFG!OE'UM.)5A:-5A!"!$)2!/16P-,/TQ1F=5
M!@E ^-B1CZ&9>/V41WMRMJ^*NM//-PV8CKGCD[@\9!95)Z?Z:)(H2#"YLQ$F
M^.@"*P%XZB@\()%CX& /CU66H=' H<LXQ@H*CQ:>@&1JV"O/WW7&-S,8CD2?
MY$] *0AS@C$W)QDUW<,L)!T\<X/K0T<1EG=.3Q6:5F4736BKL?\KEWXU'^7Q
M&-0!1I54\R(6)F7R31EJAZHJ1R/<7+E5I=2DDMI 3%V\#S%U-3DO\7F<0@G$
M1)F=[%(H)OF12N_*.,AW)H-$*6^(0B8;3'%GLAM]<LDD3II*:8/R;DQ1W89$
MG^13F!0"D\(-]5$H WEE1ALDZ)/L$PHS>TX.UNEW3QTU-B>XC3U6G7[J,B&M
MN?.[<NJD]:VGHS!_B=GF-9O(F$PB3=!A _(W-!@P/FA5<?%%%8$,&4^(C3FJ
MSJ-C4'[JM.&B-*;B_WN1,C]BMJ"^%W-% U=&^-.1@B4B#I7/OCIV\&*EA?CD
MZRY<3C3NVDO::K/79$Q_LA$Z;M,?.WA8ZC-F?\A!NTR?2(<_ZL5)ZW< 9!+J
M-3D]UM?KH(SZ?_7 <^%C*V=.T>@,OQ.-CV%-F,>XP_J%?%7]\AIH3;_#1J_2
MGFZRONGU[ O]Q>2Y^GWFZXGR:]E& 9:9P\LWEU^W]%=5MN69[T*[%43>K5_;
M+>?6[^YZK..V:!P\Z+%W?Q>Y3]38:-7'+DE67<UC+T/3M@Y7WI-%ODJB;6,*
M[65/CQ<NW7*^[?NUE&VV&S",Z\R$<;V;#>-:(>OXLPSZ5C/TWP^89:)VW$M=
M)4^[P3:=(Z,/C I5DE6U;[?6#NZQ;:K'MPK6OHZ<\^32M06)K7>QC15%N=I\
MOG6"W/O[N_):M:TE0Y)C:VHU)D'8BI=#W,9& K_5(U+OD?AE$[4X;D6[0UQ:
M4<MIEM:J2VL/5,+CZ\+-$42SA1;/[R[&V_ ZS&@0ZUA<8]':J[D"*6N)_9+A
MVA')=FC+6U.REZ^-?1'>>_O[(+VPPPO$7QOZ]WN![ &Z/Y+P[P*ZZZ,F)N7Q
M(W!]R4#MBM@Z:^/Z\E6Q+V+[I'Q_%Q>(W2R0?</U1[+V[='P5#S(D;.[K,IK
MT894-:S[CO7A-^MCO\!Y![WL%]5!MUP0/ @T,O$%Q6.\[CLHC'8K:IA20Z5O
MI](MNUD?^P76.\BD/V?Y=YD796H-$][>*W1(XX&1:[LA3PVY;M;'(>'U#I+K
M/\M#60='IM?U?.PW66K(=+,^Z@"Y#9E>]'RD/3P;=6#LV6E<TPU[OG-]-/$@
M>P;0=VA0QVVY?LW!^A+3'VT@$KP\G>9!UT4VQ+-N5=OW+9Y7GZU[5$#O!L9J
MCS#@.8+)F]79K,Z]TE#_U$>#W^S24?7W.O\M%EVH2@!<L5Q4Z>+-YJC.B&-2
MLY@JM%.I7=9)V3*;L<44P9VDX;^O%8NO7LBKONR%4RG6ZY84JAY9ZA]4J+;)
MJK/J +OV'F35>;JQ6U-D,+=Y"34[F!<$6S^3$"2?H.94UK(;S!/&BC()QN$F
MO?#MEF^OG/!AY<=BUD/ZL/04=W_G>[>_]' :NW(ZD9W@==M/0+$S3HM[DE$<
M:*Z2-5)-[-:X_"ES;!56(##%1W;7;FN2P>QP2I,M)(.I"-?"H_9K9%=)%M,,
MWFW+TKHN6M;.IMQIL/8Q6.OX^PBV+T][UIFI65D<6>]^)!(ZM$ #?IT9E4.(
M>[L[D>9#HGV6;FO4KM__>%07Z[T+X1QYGM<*MA*XM<EMN6;5[=:J<[UMA0LV
M$9TK3U/41'36G&K6(@AI%Z-$QS0&RS3VBNF4VX\(*-P)J5[=?_+@^,EFR)HA
M6W7(Z@> M0#5'8_L_,0Z+,>"TEB6A,N>5.G!'9@*PV!+Y\L;CKM&@MRPY3:3
M5.]) L1[8(+LQA+9X2LW9(GLC-(T9]>R!=ODT,ZQ1>Z63BHUA\E6GZ3 W5+^
MZ6:2UM&;ZW*;YLC?[E]Y:,;F19(,X;7)R-)E? _,S'3M+9'CQH!99XX:([/F
M<[1^YM;&QMS]*P_-QOPT[/<[Z<'9E'[0F)2UGR-G;2+3S-&SAX0T.63JK=!J
MH22?J$X1TNBQ@MU^K:(/LB=SUM%[G$QTTUY:#')],'S1=7M()8SHM@+'&FMG
M=6LGVH.HWSV?(]=O C!KKAEKH6UWW"0]D?U<)JE)B:-U:3>#UOT\Q SX0;"E
M'9O&!EI]CMPMI:%OYFAU7\*67 F-YJRQYJQ?@YLKFP707%D_3Y6&?3"_PKIS
M9YU!>5,A@[.I6!>/\N\B$7".'!JWPD<EI;UG)';(";)G4VN[;C.U>SFU[D,]
M7T\VKPVSWRF]?O^9R0?M0,7UV7WZ=U845M:S),L[(U#\J/^':='6>:HS90G)
M!X_8?MI=V]]N M/K/D6ZUJG[>G^F:=^.;Y__\[C1/36+?JB1[CG%I&VR&%3V
MYL*V3:6 +!C0!,9F8$Z"*WF@(1%>W&RWUWV.J-N*FCFJ]QR]#%O^KTTT1$TU
M92VT[R,MOVW,MCGX7>G2EZ9ZZ<(RWW.;8/TTE#6V!_9SBEXZ+;HZ^C;3\]S3
MX_EARWGN"6K4XTZIQ_TW3M_];Y@.1E;:LWIR4)8"1WL4AFVF*A53*NVD\.MA
MFJ0O[5;\W%2ZL736T;5V,STUGA[[^>>G4;4[I6J?: ^R9J?@3HV"57G6A6'I
M#=+>$".1I@H]<JFR7%::>,!^C$W=Q^]/[ET);>H\=/OR*2MD;\L*V[OI#<)F
M>O=W>E\Z_CK^Z6>8V88R[!1EV'_K_,\\NTX+W"(&4K!A3K"[YH3G- G":C]'
M=$L9PIHY6ET!QZV@L<KKJ@YKH6+OV/78A=/R]YK;C]DVWC<^[CCV0Q-6->;6
M#DROMW[(5C.].S.]+YV';&<WUO2^7KG1O.;V$CT_;R+7:AWH\SY:[>N8:JWY
MI9A2_$=ZOSM3:$T?6 [TAYTG::RS9IJ:::K7-#4:=J<T[!W&=+W29X3+C[F-
M \0:J[FQF@]E>ANK>9^GM[&:&YW>[$'?;4K+HGAE392_Q0:#/.7# >,=:0VR
M,E1\D&>=#CK7T_*X\X$&BKON\V^J->;:&O.S5M!1,S_/KI#7.C;7V-&[?V5=
M0L4];\H&?TZ]>Y^YO:!QW^''?584UN^2=0;MY9IV119KQN65!V(CLB&^H>K;
MX\A^[8(!_O% FK^) :HW%D7A0Y.T;VZ(MFP$-\+2",N*'B'[L:<2=E]:'N R
M>BK)J=\">>E$#S_7L)VUT1#@K1/@?VIV5W&X*8[:9?E5VJL6QGPH1B+1W?+\
M%-75J7C&J=3?E:G4+0;_MW[!P KDKY,+/LIKV1O.9P^XNYOE1[CB_5MZ;2AQ
M)5M&0J#W'=8OY*OJE]?5H*<]W0=]T^O9%_J+ 2SZ?>;KUS>I&+1QX;9LO7@K
M>Z5\<_EU2W\U)_'FNR!H19%[Z]=VR[GUN[L>Z]"63[T'/?;N[WSO]I<^JK'^
MJH_='=&]W7;=I;Q:RRG-N%/Q*ITR<EFK7>O+=BZE=0;7M0LPG(44UAG+D[;E
M.4=/KH$.9WE,D<DU>$K-UXYKN^ZF>KQ*-N2]&CEG)_G=<V\ ;D.4+Q8JX+Q:
M996O745BW>7_X*V09VSD'JS8)W*?;V^'^A/KL#R5)FLVESVITD?M/B\9H!UQ
M/?C1EBJBUM6!T&2]G%L@3:W/O</SIPM!VA8_T1F>[ZC3=T@!18[WT*IM>RJQ
M3<3,P@+93C:4NBZ0/8#TO:/H%TDRA-<F(^C_XT)#=Y=[.5O*V5]7.6VX>;,^
MZH#.#35?P]4R[/<[Z8%2<=H0K8:)-^OCD !\[XCX!]F3.>N8&I2BF_;28H!N
MEFNY"3?+[I*O;174JJOL-N1\?GT\\)#_GJZ//<#VO2/G)[*?RR0U-87GBPP?
M)&/W6W;#R!K&?L?Z6!?5]WM][!RJUZ_!NW)E,[!UX2%/9&.6E:^VA#:7V0"L
MS(WNX3_ZH-0N:J@H>&A$UX;&:8^T6TV/.>[DLGRP/=PLRQU186L?2"Q39GC!
M-I2.:\H]6(.VU"F?AX4NFS1HLX&E_O_VWK2Y;61)%/TK%7W=-Z1[*9@ %Y'V
MW(Z0M],ZI]WV6.[I>9\FBF"11!L$V"A $L^O?YE9A86;1%*4"( 5,=-')L%"
M5>Z9E4OH^^&=;+ [P1(I&+9L=9IO)9^*"QF'D: /[+>,NFI$GL0YC'&(.LOG
MGEK3G?!@##N%?[I 7_@QZ+91&,&F7<&F(HX\5V4@X[Z8%XNI9'=>/($GPR1B
M(R^ )SU0BC+F\"6 2EKL3UB9^V[BPT<LW]#"3@9<8NOJ@$U".?- K:K73+ S
MR(3Z?^A_P[>P%3]T]2A)T+ZX>>#"\21,8@88F]!A1HGO,S>)(M@$'L,+AVK-
M&?P999_,(B&QM&1HL>\3^'-A5U[@^LE0J/6RL\$O$C^66/\)9/)#Q"R?(DWX
MB "]W%7[ \B(>T^2?:">!AQQ^#QFG@0LCD8>0"9&5 Q%+*(I +9!,&44Z$ ,
M-V@#L)F(0 I;\&"/KFKM39M>>&6HD%'89MX2W%J:IE4@>4UE[;Z%=:*S4'KX
MBS>1\"ETGI>'_KQHD&D>:>8_X0. 1A)O_LFFVMY?_F,0O?YEXPY?OB1X/0L6
MRGZ4A5?X[R3*#=6QN!A$@O^XX"/8[!ONW_&Y_.GUHJ !*;,(^4, ;0MY=A38
M*2$Z%&ZHZ/$-Z$X1X5.J%]#3:JE+(J&_ /,MS)5/S_!,FZ$5WZ#0]-PMMH=P
MSGV62,/YN3?YX)9(M)$&&"81[@KE74Q%K=.0BEK%8E$KPZI%+:KA<Q">^ O4
M+5JPH]3#^CR4]D IL&4U*>$6!!,VFU)ZP,5W@05W!])6JS OF %@4&=$8L('
MG@]P):DNQ1B%K\5N8%=HI.&G((H+BEBK4:UZ;]0/@)(S.?PED\.I-I:"A+:2
MY* 0KD%K6CO0?.FX>*%.Z=W:.J5EF?8B'+LCDZPMMZH_CPP3ZKTF\?1SEKY2
MTF1.Y XQG?GA7&BXY%NBWJAHD?@<7!M<8BI S$Q@_P)L+<U1BOD*-DB)<7U,
M5*L&(X DU/.(I7+!:[T".2K 7I(Y<JY /VF1\)&"7-@?:!8>T/("[/*8;'CE
M3.#F)-AP%_KZ4DZ\$7HM 3AMX!D\QCE'5#X;9/4C-GL%5)8JQ5KM\U-.TW-'
M9MU49U827894"TXO$>@06QE%2@PO2T M9;9A;Q6R.PR/HY48WGI *CA#2ZL(
MS9M4Y $;E2&F(\"CY+2#-+@5?@,V[$:)AR!OJ(")&&-81$2WGGMD1JX 2Q8S
M^*X6,_AJQ9U;9"H:1GV(41_F15QEAH[=:$1A,+!@-T44!XF$TTO@S/>;UT+<
MB+'G,OBYB )"E,0C>P!NM)'QJ<?>P.Y$)-BKOM5E@#$?^?9IP'K5M/K94EIZ
MK &>DCD%T?+Q7K@)T=J76Y1+XNXA>4+G*T@L+Z# L'HN>!P^E99'*UEG5QNS
MSBHJB;;*JRN_;;^'3-&2!(6#R^GN 5X)=!OGUQ<HB\'&+Y<;5EZ,%0PH-@X1
M92 J[GBDM86ZF$@%,IP!50<>( S4T^O04&7I49S0_C[,)K3G=AQ[)T9X(Z8?
M_,[O4S.GG++ET? W4.8%&,QI;__-L^D90.Q9N7O%8LBNTI Z05N6BZE+&8O2
MS@D F@_"6U%I7OR*_ASY66C/U(;ARD7%BT#60@#E@79JCNK3O+C$\4.P^,N%
M(';]J& >*)6TBKQ=V+\L+((I*"H5!- "-@5@*!;:Y),3-N-SLC*6R%50ALQ
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MOQ,OGC,O8(&(=?-@%HX8@,T- \HRX[$8,CX:>;X'?YZJPW/6M/K[R=E3]W@
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MJV?F*^^C5$RKU'(K@%(HE0HZ*1^G,S^<"U@0\_="#(-YRELY.6>E91E794_
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MOEUU"3";"XBM".32.L[8C>,32%D2%9VFY72.W)DJ7/%,3T"L:WQJST_?1[2
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M5K@, 03Z0>[^G7A*4."#GR)XB2<B!O_\9Q((IEY@T\[SO8'Q=B'20=<\Z]Y
M3RW/O5:)+I&0B4_QYS")6$!?P>E=>%W$W9C=>8"//P(OAM5_)60A."RV9B[+
M2V OAQ7@$6@V/3K\P3X+.#7B*A+>=)!$4DRQ_A8X14AK!P8I'<M?#?]*)"+@
MX[OK[Q^N*LCKWP&S<+8,54LG.CS)*+*&9T91.&43V K0:0JX9X( K?C& ^'A
MN5O 9.7>YYFW]^!F2!8 #%%EXJ:T0):,[!H%:PU%GX/YIR*65LE!>DR(%J3R
M1N". )#/J$<TPMR%7I^:-9#=BKQ1Q.JJ@/&&_^\GCW=ZO#EL=UK]P:C==40/
M_VN+(7>'_<M1A_^/;3L_E4/"KD_V_,T#G3KTXCGIP_=\AH0%FDR"ZG,K:4-]
M 9VMT#YG^A1(#GY^4%"'+I<3M!LF<.J&^M?(#^^DPK\.6(%!T""P !F &@?R
MD(Q4$-D%0+&A?XLT S0-"[,1=ST?7K"+7BT+T% 9A8._A(O^FDQ-'U>3@XRC
MQ(V3"'-RT708*R ".V'Y,?QU!YS*O2"&_P<32_R=P$-%B ,,1[ZX]P8*0.PK
M6"()@H[N[]V))VZ5K@OEPCZX#TAAB<1727U)A*PN[H6;I'8@[C0/,>**>I=@
M[\U\KDV].\%C9.I83&$9)(ZA)Z-DINP^V#>NFQX8$/5#Q.J'8Q' VCX;)!+
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M9.=*8N-[9=&I!&XM+*##A!IHDT)I$P)YHL859VF5E HQ!5U#^,*<.K+@B[B
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M[(QH!+O)S_WQ'@X8C 7:FH@0N]\"-D \3\D=>F@>D@H&JC2 - _ *5M \(\
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M/:=@)+Q/H@@;J<S05E!VPFJ#[1.S$YR^Z5M=>AQU]DT4-!;#KD5RJK$E756
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M@Q'N<$?D5B!V^SYWM:B?&JH'S8[L"QJXN:+[1F<"NJN@@?M]@KB<<$#C0(B
M!0M.)M+#RNG##:=G0!SX/XC]OQ,P4N QD7=L7O0!%;W1>SE#)R+"M11-I02^
M]9M-?.X \;G60>)SCEW!^%Q99B!\O?KVG5U?6^S+]U\_?F/7OW_Z\NWSU??K
M+[_O;6XZ[7J8FW;YS,W?P$'PE54F\&NYQBDHO?S_4Z0MM!FL<.NY2O"C#)_
M8_X<_:!$A> F@OOQ!(PP#"(-$QE'<PN$-#T<HJN$X3P7)+<4J<TT2*2'-E0#
M; :&/^1L!IIACCXP!O["1#*?X,C5%6]#V1D*H UEN_C<FY)M=2=\'_]7;RF,
M5% OQ.Q+-D;M$.B8%7F;RF[Q@ELA8V^LKI2MA]QEQW8Z3O]YM2W !M0=R!B)
MH/+!K@ICV#/H,X"U3 9_H0),*! +;TJ!,N13D*'P1R3@5S-]H8J6I@:2@L%,
M@+I4H<MC^MDWNG]DO'#<W,C(]#T<,LGH;<9E7#A,]ODHB=$8/2;>IGS>8,(C
M& /I>\ O"2&,;L-IEWP\QHA!+!IPQOR$U'IW")0I17JEF_-$;H^G9D9#AV&5
MTY$E0C1TT?O?B0=T/3\F;I\ABOOLZ+O*(CS^46'7($KYQ'T@AO=*JJ&K=U;(
MF_GT_DIGO8"_Z/OAG<2+DENZ<H$S_%L@,;CPC<A2:,B8#2/92--E@,Z\ $1>
MG-"O;CV_*%31NAZ("?='J:OV1X"1.16OD_A6,48[_M8+?5[(NX&=O[^RF))A
M/K^3B8=""$X3LA]!>(<-&M(]E2LF"6S#8CX])NJSU*=4HG/RKZ=3=9%%^G95
MO2K]1_<Q>*L%.AIL5 ]<=Q[$>*LB8E2YF7)(]0$P8!2(.>5/V9=OJ;$W+46"
MZHY'Y*4/*$]'C<_"+U(Z8G<3T#V)"Z: '"4HY8!ZL!XK1C7/!JF3AS>)2 +I
M[W,%#%9!C#>6(-6D1SU"T=DS-+&TA8R)"JIQY"%G\S%'#@;E2'=X[D1#6M\T
MJFM+"?320(P0=+5]E02(7]*^@,()KJ>8'B]<Q2UZ-Q2,$?>>)*<=]H!?HMD6
M,\I[5%W9, R4 /HPFI8%A5+W7JV:O80V1Y(A$J,P A5(2\3>E)0>_B\9@*!&
M43EF%B 0,"X^#6GC^AVP/T,IRY3B<@FK#:(P@0_9#$QL3)!(.0_E<@75\I>
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M[#,.?6<AP^74X*]SQ+)IQ..N?"SEF(9I&3TA"7).\2C@Z)K0V24:P\#C9YW
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M/IFLUK/<#G;<+ZJ1TZM69^.]Q;C0$,'^\8?Q)./DKS_R?97Y<@AQ>$Z2P^D
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MT^7 %>)MD6!94@A,HY3,HS1,&BA8<HC*M/%V.H#\)BR$5DIK4"9R!]2O0/^
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M?))F%W ^R)FV]8R:"9EM+6JN">\"2$S*VRQTLK&MA=W;4A[$MKH;_[;HOG5
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M']:F(O,NQ&L5F&",],X'D^@03-8%%U(4#B$%*4BE@SL^MTW%I>3"9066*0M
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M=>O7)"P6"A@F#&W_TD==RD,]T/N7T-,O+_$]G"]&?2XN2#.0=>C(&C2YWH1
M+"Q4Q09 +EW"I!J]Q]VQ'BK]L*UE?2!='3M?,>-P<&4!\UNW4 HGQQR85>B9
M5HH,,DTK*;*@4:&0L797FN(4TT_OQY]^IH^>T^R_=?V2+;Z<<VO#0X^5C-!:
MO>-^Q-RCW5NA+% L X+;X-@B*6$[M5]]\F&3#O96P;A'^;74)SE0"46MW,R2
M;! IZS49':58 EFM(+6]L_'A0]'C+=D"S=3816P]WR[>MPFM^F]Y"U =Y8BA
M9D, V4C>S!OPHB[*Q<RW:5VVW=,.9W?OIXD.@; =Q'AKO*O%3<6O,)S\ \XO
M\'<R^R\F\P-^^C:=8;XXQW&Y_.LGTRG.IC#*JPF5\Q9M\W^2QR-X@^EB,J%U
M/X7I<+K[I453./W=7QQ.:FM7&<:F0(PT 5W0UB6 PKT!HPIJK;08-$6VYZ#9
MZ\]^LO'9KT:7CZ9?H'=J<@W)5_N:VVB,GP]$]9QI8A#SJ#0C0=@B@LL@VMQ\
M]+J,O8?W]@#FRO0_E(D\=98-K5S'(%@4+C+,.I LBK3K*0</2*3'&TE_/%[?
MF"1\+#8TN*)9Q$#>5FQS^+]^^F.X'$:Z@)V6DTFMB-Y'D>ND2JRY'4A?&<>X
M%2F2HZ3)&FO"VFT1/DY&[L:#\0&4V. ^9KN W*58!V"=4C%9YE7M2EM'47DA
M)"LAB*PS*-EH_'5'H-\P]5JJM,'ERWR^P4)FJY'+07K/8XXU2XJ. PF*@2O
M3"U5L2X&*703DMW$\@WS:$_%-+CKN(+HR@XJ<A:^F,"DPL2T=^3 &K(;0'&9
M@BQ.Z#8=(C;"^4Z8/=33H!5-'])91*(5UZ$FV3+TNC9D%Z6>V9YQ;S5ME+P8
M^W#]KH/>%9V67]!=^\>^9KJQ^J=?K@1%?IW@?U_@**VFV*H@H CFN71,0PDL
M1A^8,-D%A]%HW:8J>@MPQ[JF.A)K;N-N3]IKX#ULBKE= KR<:WT_Q*95N%N
M/$Y!;N\*OHU /6OG2$12Z)4!'L@J\;4?N+ LJD@O5$J6!X,AMHY['II ]Y3P
M/@3^=%'*@7@SO=R75Z,XLA"0HF6!6ZPV;60^QMK<!"TDKS6:QM'=.] =T5_H
M2ZU;T&8OG32(L5YY=2Z__&V($WK(V9?:G_E\_O:X$&-,13((,1-*@R0&J* ]
MN<)2HA)MHEW;X?MN'_6LPP;AK8UOPTV\JX8\6X ]N+%T*]RCFTV]Z7V;+:Q7
MI1WJ++P5M"[T;M4X3*B]/+4(P"*/M6UD"<IEKD5L4TSQ !BVO5WU, C615<M
MB?5B]/%B-IU+8%5IKF(6$$G+-M5XH7,UV1=I Q>AH+<FT ;?ED8W03T,DZHG
M==Y&G#UUT=*FN@)-+J%)S,;);%D1)C&=M&3>86(@,6!43D)H4W!P!ZAOC2:[
MZ.) N\FJK4&(@5@+1%Y0M9T0^:V1/!"20,C20,[>P\%H<K1F$L>ER2ZZ:& W
M/X5S&"5\>X8X>UE_NXI\T:5,>I&38EK5P9K.)Q:D &8A:LF+D++14.G;$'W;
M7E@O>FIP5[P)UV6#PON1-76R;L=V'(^J'QUN08P]%-#@)+H#H=(E!\XM$[Y.
M  5 !D9GYA%J9"R:'-KTB#PT->YQA0[-C"YR;\"(>0;#*DUOOJLN#T,AD8X\
M;UG-6"";B1.DDLG2QN#I1W7<5L.,I V(#F^5]*6U34DC^XJ\@3<SQ_4UC>4:
M-)FY,\8%<K3J><D%LA <N?\"9301!$]MIE?= >JT"-&#X&_='@Y63+3W&-]M
M/K5Q:4^'P;Y<.!!6D"MIG?;>>2V5-D;2-QA]*)O]FEXG_/:;>&0,!%!>LEQ*
M91LJ\H#HH"L^NI"S<Q#;)!8^S$*;5Q\KM9Z=P>@]3E^,+G]>)TC5GB]BH*7P
M):G(BJS]. (4%C$GEG.,OB862MOXNNQ>C(\S/7,W3M[J[?>KR9:AQ+U=VQ"M
M3LEFAJ(.4_:Q#D+EGF6%A6<GC$J-(TK?9M)F+SP]J/8?4]*FTN #9"0[R-'K
MF4G$7J%EM2Q6V%J>#\WS$DXW:;,3:W9(VNRBO6/EVFT!\7O29B\*WB7I;@?M
M'(E(+@(O7FBR'(IBN@C.H+C$M'&I6*YJJ.BT"-1#TF9K_G11RJ$25:[NQ:L(
MD!6"QR"901&8MLJS8*TD;[]:IU%EOS[GH66*RDV #^-F<"_E;I.6LJ=F'E)3
ME^N-!6L3D%^FL^$'F-69V,M_.?UU.()1&L+YUX;^[?JZ[(WH8*U=^I7=>G<7
MS4/D0KI@BO8A>>FB *UYLEHY?F]WE[W!]66S7XF)_FTROOA(F"X?^W9&>.I3
MG\'< ;_B+MF"Y');VN>3)W<I<LT\&,N,X^"]%)(<[\8&_6[(^YW2MBI1?T./
MFS\SOR8'@/X"WN- 9I^T-($YAX(V'9V8%^B9!&6SBT7F=(AACG=A/.*)< CF
MW3WTK3?E-0@HU?FG[Y;S3[]V/G"*HW7",Q=4)E!@F/<.F"F*%NXMQ-R&41OA
M?&/DV5\E+4W3IU\VR639DM0%T(*0!:(NT]S5J;D\$>0@P)>$J768^PYT!P\7
M'H,[O:OIH03_GDTP#^EU2#5NM7 &BP#@60B6@R)G4(4:216%3&\GG,CHK&YC
M&MS$<O307F_J'O<J]@8;T75$2]=N&TQ-HW*;4!TG#+>OQNXDP![B/A05I%40
M1$%6,LK:9)T\<&.0D1N57=%@=*.$^L-1X)Y VB$8T$7*39JS?1J??Z(=[CJX
M91 F6R&12\Z"JT.:)0\L.@V,_.92C"/+VK0)C]T)Z_!6[/Z:N]% K2^QM_!D
M<$9NUJNRP+:*QRD1!6HD6UD&IC4"@XR:Q:R-MX5^:!LY,AO0G  #]A9R@\V@
M^DNSI;_TCO[-?,>SJ7;GTG/[F?Y(%4[ S)RD1?/"BP'5S(-=1W.RYN'>HF]0
M'[..:<GZ;5 U-1$WXSJ.D;B_WNXAPAY"/\ .L9J8(77*M?&+U[7+O\^9!?*]
M69*T:3D;,32J]#XD%>XQ%@_%A"ZR;L( &$U?PY>ZXUW.7W"EJ&08FERK-0JP
M4%L!R20"@LVZZ+OFD^RC_74LAS<,^M#2#<7O)>(&%N&54>&KZ>#2Z-JIIY9N
MDNDCH#;Q+(5Y8VP("6SR;:I5;D Y"97O)^ 60U0KE"4'Y^42RZ]7\(J5@$)K
MYM%46X>VN* (K<Q)&\@Q0R/]WP/L)-C0I_ ;V(77[^3FYUQTR<E /DN4LG9M
M#H0H:,<@U%2-&"&*-D["32PGZR+L*?8&!=#7$?T!'U;DWP974Q?A-F3'<1+V
MU=R=1-A3[ W.CEOQ<>,+!BO(_)W/A!6VENL)!H[[$,''[ ZQ2[2FPSV.PJ'8
MT$7:/<^_JY?NU8I=QLN&ER>7L.B!C%5FP=51;=(R2!H81VO0!J$5K)D-&R?>
MW?;YAS_]^Y'^N&?1]>@"5$Q7K%-N?A+2/+\@[U6NVKCDD!P/F%@Q%1D9IW4:
M;V%.V9*-BFB]W4*I=S_E!%3;HQA[?E^O(W-+8&8)## 56W/%HQ!U?&,F5P1"
M8#G**#26'++OK-^UAYR<>O<18H\V^QHP_9/A"UQ^%5DHL009+<O!>7(VLV%@
MHJ1=)DL32 +)F&[*O?&,T]+M?B+LT0I?YYPFSBV0*;YJL%6$ YO(?[&T9JUC
M8C%X0V>&%QQ-+,K>EUQ^_U-.2[W[BK''^3+KQ+/+$T.MNC%ZGWBPUC%TGKQ)
MA87\2B)>\H:.%9DQ>M7QW5U_QFDI=S\1WE2M:5.)NYB75!T#[@HO@AOF5:RS
MDK1DP1=@$D2.)?/D8QN/Z1Y@)QMDZ5,A#49-O1Y/YF+^FLY\^<7SX;2FD1+B
M501Y"ZA-@S =P#ZD0ML=E3T^K*9:9J9_!5CSJ)<%3\M=.&FC,*)A,7D@+R47
M!L(5E@W0*E3.I5&;LFW0/:!RVWY8U+M*&M"F"]--XF@S5RQF\GVT))21;"LF
MG=5*:&.X;I-3>J2]J&.13&]:WF,SZJ*B!E?-JS++-_B10&->".%VN.0X.YMB
MH2.^=H'1'!GP))BI_2'1!!<;30ON"/0$6=5250WVJ56Y[JNRS5N +MG:5ZA4
M%T,7E9@/Z%@" 4KXH'.CL3Q=4)X@IYHIZ=:86HL> 6_/8()D 6!^#5_VK.Z_
M_;/ZJ\O?$N]:17V0Z*TKD0?%=;(1B@O2\)A3E+H@#F[_V#W3D2X_]QFMA\RT
M1=/@R:1VFYL;7U]N//K)GS#)+[^6!JJDHW.U]--8IJO+'X753!@%5BF?B4!M
M\I?VQKYW,M>N"!93W:]T-ICGIKP[@]&BV]_T;_01L^F+T6N<#,=YH*6RRHO$
MC*H#V$!Y1K+ES&7E)5B.#MMDA1YJA8???P_,_!MI:@^1.BWR'7==Y_R/?R =
M8J/WBZ6(0=T=.0I#X"6G4THB\SDY)N@DC(*GC.*!O08;5O&=ZH>B0 /+=^>U
M;'XYK2_*103FR#%DVJ3 0@B.616,C-*2[=*F-WF_Z_A.Z</1H$$6ZJHSTZMR
M[[JFMRUL<5]@E!!>"L70>%M[X0$+P"VMQF@$BQ@:):_VMH1#=>0X-H&/HO*'
MTKAC 7]5692-"@)U8DYC#:9XP:!VXZ,?<VG(>12F38#B&HQCW0,>B0GCOC1R
MC$/^5D%\7<8HOSZ'T94[]VW6U/0.L<6JCG/9N =9NI[CA]+T8V%QT<XK;BWC
M@(%I3HYDD/5R X0JR4JO4YMY?H^'O??<<3YP\G91<),F*M/99)AFF-_.QNE?
MR^BT XY2E\1$D9F1D,CF">!8R8%.%J>5Q3:LVPCG 7H[S35]H^G*OFIJ$&KZ
MY</'\_$7Q#FDA:.UFD3E?2Y>&V9-EDRC#0PXH3.A(.2H,_=M^',KI.\<ZDE=
M#?:@9<1IOC]#MC[6M8'(=?RR+ R0(Y.N2,6Y*Q';3$R_ N+;]@QVU4:#.,D2
MRI+[VX!I:M!?@W,<2WQGY6Q6\AZ2;;</K#KU!\TY!,>\%<"T5(8%5T>RQ]H(
M5<=@59O95 =0\STF:QLM=Q'HX=RC^:9%^QKM?:]&J^R($$(.!41-MT&F:Y*[
MS[2)ZA"-R,:G%-I$B#J /+Q%L8<ZM_-D]M;%X>XSKT!]]^=X5<T4<\9<.*-7
M1=0R1%7S>.C5\:#H==%&->KWU@'D:=-F-UW<NMLT27!:A+07F7^U\&+?.;3W
M?&"/J4X=D*_E.R74)'+,P@I+_Z?7&3!+GFSA1EJC!O=\]KX]F*Y_^(M1&4\^
MP%(0R]L5+$H8 X4ASYQL5F59].3;0BF)S-9 WS1Z>;= MW=/HHOZ4KPJK\@=
M@/J0Y4.G YLA1*B)@. 5J^\?\\YR)J-R"KT@O;49HWLKI".XRGWSXT97HE[$
MW^!T6P&;3P*8OAC]\VR8SGX9S8:S+PNL.!UH;KF*.C(P=3@(A\0\ &=)I\*=
M+X'[-NUKMP!WPESI2R4]]SM8P7LQ^DB+GDOB;#'(<RZ#W\;3C_3E^73 L4Z,
M$IF%>:>M7&MW#!B6O+2\('D/4.XYV;H\[X28T$S,/3='6& <ERD)[?S+^,\1
MYN$*[N0:W+-+N"$G*"H+5K2,K%;%, C"DTF?A21'4]JP3<^$'1Y]D@1I)_R>
MNRW\WS$)\1-ANYA@!3N9G@T_?OPZ@0H@<4TH&.9Z+V9<9#&(Q BR 410H>0M
M>''/8TZ, WT*M>?F"RMZ_E>%N"T_,^IZBQ!9ACK:.5;?4#IRX2)DS67*<3W=
M]\[-H<NS3XP9S<7?8T.'+8Z[OY,RIG\G?W+R.XQ@<07Q;$PK@40V=([<1UE[
M6D"-$$7 Q31[*[A+*0#YG&%_2^-.#"=)GP.HXR:-;!^[SMGX RZB%_/?KQFX
M RC)"Q,*$Q:Q!K(E T&B<48(8Y,6<KT?R)V;RX9'G"0)]A?F31V[?G1,^U;"
MKYA$$89['IFB4X]I04XU^.B8CZ1 60JJLDV#Q-L^_V2UNX<8;ZK6]^Q0K$ZG
M6*.^7YD(HWP#N+>6[!T16$HV,2T16- U0:&0/XP.O-%\-]=B>Q G2I+V"KG)
MI-"W^=D!N2B8G83(1 [545*TO1F3F8PHC>,.BM[>HM@5Q8ERZ0 JV1#RVO\>
M\&MRS.U2>OIE^9>+-!@IC!19:2:*PV69#]&>Y2"#B4%[Y(VND;N#/5@=3.OX
M:6M%/92:ELOAO4\OIB2XZ71UIS!/VW D):4YB2PF7Q/U!/-)!082::'6)1';
MY+'=">L!9+:UX<0Z!WO338M$F 66U7W\%F#:EJE<A7.<K+8>U75C.,V^LFY.
M  \!0RZ6*6/J)$:5F1=1L^R3,$74._I&)<GM%7]/GMNA]-Y%Q#U?U]T2P5GB
M6^7QEZ"L-^2^^^K-"[*RO)&.SERI#4\R6+--K^-MGG4THW8758P;RK'G.0._
MD?'\V\IX_FUA/%\')U+,LGA+=%;SA'W#0C**E4SGFQ-*:KZ-DN]]T&/5<+\2
M[/$UGDYF@S<U\7Z1CTN[DO7%,<LC@4B6,U_=HJP#^BBB1!>WV:[I4Z]LU?3=
M^C9][;&G;KCM+N,>[]0O0:SF'FP!HXMIMKW*C]%9> \5K"MQ#_FU>&]7B<P(
M"C1&!JK4C%2B9%0Q,T =.:($X<WC4>,MIE7_6NPBMIZU]SM)ZL/%AR406[#8
M*"63P=>!M 99B-&R(J3A0J<0[%9][[;2W[5''^Y(W4OXXSXDUZ-=- <"GZ\
M<62825,K5(F&3"L?6> JL6 *!(!@N>GO\+SVZ$>HPITE=]1T^COLA#>8QJ,Z
M&FS^W;C\@;/+A-PW^ E'%SB=C9<?\"3_U\5TAOF7IR_>/7_27W9^6WSMDOT/
M*->UV@'PM<I,DG.5N;:&6!MMT8',/#*\%<\W0LIMH1Z@%,$H>IM<Y#45O)"C
MD3PY&O3*HD[19'K76HTN.40IPE+,O]*&M<H9^>=P=O:,1$T>V.27S^G\(M?J
MP^D4Z;_\#CX/,&ORX:QF6.C8T%YS%JV@KS" 2BX99]O48NX ]H%>VW7AU,WN
M#VU5UJ(7_G@ZFSX9Y5\^USHQG#Z)TSGN07+>&)%KK[U,)JG5M9RP<&9MXE)Q
M0J;:C%&X#=$)\J47X3<(?+^$.)X0KC=X#G5?7\ C\[1$)R(R-T>%DA:=## 0
M*1NRFLA^:G-7MAG/X0G1C[[&O0N[ 07FS9/K>K\N]]( &"1R3Q(D('WI6HS%
M@7FO%.-66X]!.BG:[ UWH3H1.O0F^!;]4"\^?CP?XG3%46VRX%HXYF)(M,Z$
M#'RJL0OIM8G&E/7[D+[LK^M 3D3U^XBWYS*45RE=?(11^E(7.H@H# @R2E3F
MDLXX34"$MRS;%,!([D39ID3MVH<^<IWM)Z2>BTCJ\\?E+4X^#5.ES]+,?(X?
M)Y@6+AR,ZNP<,F/^9_[MP,D0,JV:%7""Z:0TH]W$,%=X\BE%5.M;^$:5=G_R
M">B]L;@;S "MB%^5OXW'N0IBA?SM^#R_^H23,X0\*$8(%'46.!8Z6G20+&@L
MM3@!HBY1B=3&N+L?VR.G3",E]%@2<MNR!S8K:Z!H9@7]H5'5L=,F,OHA2,\Q
M<MFF/^ ZDA.BP,X"[K$^Y)JQ^<=X-%Y9F"]JF!-7!D@,QEN%R*)2CFFGR/V0
M5C"1R-YTH"7/;<:*W(WK!",!/2JB@=V_ /-R/)W6T-9BT,[O.#L;YQ>C3SB=
M+5ITF&R+(?XSSX-ENNC HM&6I:QX30A11;0Y0;:"=X*DZ5\M/7H1EVTZ</85
MYY/9;#*,%[.:?_)N3'RO.=\DT_.Y>&8X(=0#\FW 6Q=80DEN#YK$@LB6^1"<
M<HC.V#:)EIVAGB"GVJJK9[_G^L73@'.%N1 2'FM!;?:"A2@,PRBM4TFBU]NX
MJ=<_]81TO*?(&O@EJYF-[\9/$FU?$WP]&>>+-!M^PGI',IO/<E'D,Y$O;7(F
M:RO4"4#6,O39""N55[G-+/![H9T0,=JHHX&#LDN:(Q0RRXWW=1(:V>LN1!8%
MTA^ T7+4/C;JD?_8B\OV85)K13V.XK+,>< H-,NQ1GV\\V1Z.?(<-0B9ZSN3
M&\7'3Z6XK!,G.A67==%-\]JB;<!\V\5EG=1U9Y'1+K)N3@"I GJ7)3.$K39O
MKI/-@2PR1)&SA,QAJYSGAZCXO8K+^M-[%Q$?H[A,N0@1O&328S6MC"<7RBMF
M"WE1SAI3;-K">WD,Q66=5-&UN*R+' ]>7):=#E('9*66Z>M(AI4G8XI%FYR4
M3I!MO4U;QP=?7+:KAON5X%$3K-=3:%?)LG-'BE9W)4;W8GY?F#_!*-6TVB>E
MS/\93OM+I^X33;ODZ68R6TN5]D4(([)P JUVL01IZA<R.@Y*"GO#0>H36+^)
MT7,(E_#(EJ;#]*L/%X6W6)1GD@[*:C_7II9D1'M!EK7GV0)ODQ#<">;>8VL7
MP0G.78Z"MAIA8JF12,,\H&.<*V<*:HVNC;OU4 )"_7'AQAC:[A)ND*Q\[2W[
M^F*]O8C381["9(A3 CI.\Y\^&>5YW]=_X+SOZW00M$]%1<ML4IS6;S3S3M3J
M*A%\+&AE:6-C[P7[E%EU.'TVF<AY]4AX51:O2+V)6T4PQL_&H^GX?)AK7N\B
MGJ%\(H?&1Q:C(NNE\%++S213T4BKK4*+;3BX"]IC12/;$:ZYSAY'7!)0TD8.
MFCD4=2R")1$Z^HJ;Q%WT)@;?J-_:0XQ+MB=%I\!D%^4TCTMM ^;;#DQV4M>=
M :I=9-V^ZY5QR8=8\4C)ZE4_\Z'&57AVJ(+2)3?:*AYX8+(_O7<1\5$"DUG5
MHN+"@N"&:6$DBR&0V26T165#\GF;F-5C"$QV4D7GP&0'.1X\,!E-,5[4]N0R
M0>U 4A-XBF#6"N$%EX!YF^CS@P],[JKA?B7X( .3US*#9N-%&EA9UC(/1Q?T
M3Y>5:&0-/<4RGN#B=][!YV6B:OMX98\@#Q_&;"7AM>BF010HN.(!A%8: @\9
M4RI1A&*L=EM'-WO$VV_0<\TY_'4\N:R1?#T9E^%LE12[T8+_ZDL&[Y*.DHYN
M) ->>V]9,$XR)T!GY:."U"A!H\V">DRF#$*C=ES5S$#:'G7FM+$%Q8Q)FB?N
M"^(V4R(>6C+E,9AS1_YE%RDW"*C^#4>T^/,G]<+B ^FBEKC4;+]5W8&/I49\
M#<O:!SHCZW!@K7F]2P4Z.F,&W^;ZX!Y@WS:/6FBO@2-YM1Z2OC['N8;6"B.E
M2RERFUF(B=?FP9J!R[HVH50QUGY9J<U8W6W0?:=9$STVJ%#Z&PFWBN+5Z"V<
MXW05Q*LHZQ<OR&P;3JJ GIW!Y#U.Z=W@)GA5R%\7CI'5'UF4MK#$;31U"Y:J
MS;#>KDB_<["Y?AM4/56\TPJ8L(Y^^5QE=3&<GE6$K\ISC+.!U!&2B(J55+OO
M%B^93]DR:0U/P8L<19N;H'NA?6=<_QKLL?#IZ^7IH@#KTM$B2,KD()+@+ O'
M:_UX89'7$;9<!Q%,+MJTL=<V@/E.HSZTU*#HJGN)G^8>8S:%(0;/M"V.A1 $
M<Q"T\UEJA#9]%A]A1>9#(%U;#3>HZ_H=)O_".<*WF"XFI#*<KH[\@51%!5?Y
MH<BJ)&R6@3>19:^-$#X5#VT*N.Y"]9UHO>JM06^+Z]7Q6T0L:RL?\J#I^<,1
M3+[,I7/+ZR)S$L5DQ8*M-<\^D,P  D.AA,XB.,!6YVRS17UG]$-B38\38V_+
M<[E;N---62]@HT.9D:DL%=-@!?/" :LW7USS0G)OXS7OC_U8R6P/@=0'UORQ
MD^!J5_ZO*Z 5SR4XS]H(67N9>6*H:M9&0,&BKA5"LE8'2<QDZFQ#X*T&&VS&
M\%#2W%J38-RK,GJ>6'(3T3(_8!M,O<\2N@W-X0<+]:&I.Q6_AY@/10%?D/!@
M84:ES+11@<4XS^]$ S(E$&*KKF</4/5W#",ZE.:[2+=%7^O5KK?:YY;9.\:&
M9*,-9)')P+0*P((C;#Z1HU*B*CZTN8>Z!=!AY^#THZWUGG8]B+K!G??O=)Y-
MAG"^9IBMT"41T&8AF> Q,HVYD+D.CEGTDB=P(I8VKMW=N$Z #ST*_D'ESRVG
M?I0KQM/LFO'4+BMNZT<?+M=M-VFL9;!QGJ(@GUA"B9K<XVB]#CD'HXP$-.;>
M#+:M4?2=ES9_[*VU2T$&KIQ03!EM&%G,0+L>AQKYYR:)@BYM-1JOAWRS.X$>
M8W:1X4;8;(&9J&LJ%)"#&V@GP!2D*E$HSEN5QCW"V45],JV/,49=M-?@4%]W
M;J\LX2Z'UMJ84\Z9.>X<.;0!F:_7<5F4X$NVPIDV#8YWPWN\&%9+LC77W+'C
M4=L5%*D4(,6BF4R9[!_MR-.ROGI:R=.1QQ$;<?%1%&6VH$6GLLPNZFE>E;<-
MF&^[++.3NNXLS]M%ULT)@-$)VG0MXU;,<X\4 T.:4LXATAL@1*-1; ^]++,_
MO7<1\3'*,B6&8"):)B5PII,WC!QH()"!.\S119GO<2\?2UEF)U5T+<OL(L>#
MEV4:9[(,/C!!_Z>5)\.\Q\AD!FZMSS*KD^@7MZN&^Y5@BVW[(DZO[D^.YY +
M$<UR-'6F6V$QT;I#YEE[C2+&1E;>=2#?DEVWAPJ:#%&\A+,D_S: VEISZY".
M9-'MHZC;E;Z'E-MN"*N^'SD5'8-G3OG:5"V2]VSI !)(G$>PV6-YS&J_SYYK
MJO4NPFUEQ5UV+BTJ^H0L*4-0G",H12@6BD!EG55*^2X&V]%.[OV$O,D^VT%"
M/9MBKRYF2RQD2(SK-*XE)IY"<:+0VE+-NU(."8XGKR)GZ9S'8$/80FNW??YC
M5E\O,NOYI:L&X>+*:F7>"X]2!\>*K]N)BXXX51Q3O+9"T%JI]0+36RWHJY_[
MF/6VEXQZM(@66.8V^VH#0++*R3)G$$VMVDN!!<7)L)0.=0E1:KV=NW/E0Q^W
MIG:5SJTUC;?<D"]_7/^(,,7__+?_#U!+ P04    " !#BJ-4+471D,ZW   \
MJ0< %    &5H8RTR,#(R,#,S,5]L86(N>&ULU+UYD^.XE2_Z_WP*/#MF;G=$
MHIL@01+P+#>R-KLBREUUJ\KV?='Q0H$UDV.EE!:5U97^] \@*8G:*( "F9R[
MN"LS29YS?B!^/ #.\A__^_O#''Q3J[)8+O[S=^BGZ'= +<12%HN[__S=7[Z^
M@^1W__N__N5?_N/_@?#_OOK\ ;Q9BJ<'M5B#URO%UDJ"WXKU/?B;5.7?@5XM
M'\#?EJN_%]\8A/]5W?1Z^?B\*N[NUR".XOCPKZL_9#1-$IUF,,41@Y@H!#E6
M"K(<1RA*2)I2?7/WAU@C04BD8,ZSU%R&,\@8RZ"F@I-,8$YD4CUT7BS^_@?[
M/YR5"ACC%F7UXW_^[GZ]?OS#SS__]MMO/WWGJ_E/R]7=SW$4)3]OKOY=<_GW
MH^M_2ZJK$:7TY^JOVTO+XM2%YK'HY__[YP]?Q+UZ8+!8E&NV$%9 6?RAK'[Y
M82G8NL+\HE[@[!7V)[BY#-I?013#!/WTO92_^Z]_ :"&8[6<J\]* _O?OWQ^
M?U8D_=E>\?-"W=F1_:16Q5)^6;/5^@/C:FZTKYZV?GY4__F[LGAXG*O-[^Y7
M2I]^['RUVGNJU9):+5%FM?S].6$_7Z%^('W7Q[H&4*XR]Y=0.G9A^DLP=;\:
M?E##*]P2<[7*]0OU=B''>G>WHJY6?7B-0[T6RS6;C_!:[,2T5)[;7WPP_VK$
MV =UD&DEIZ'NEJKJ^UHMI*K9<N_1H)#_^3OSK]E3">\8>YQ]4.NU6GW4YL,G
MB_6?U0-7JQE*>88%B2&-<@VQB!!D$8N@0E+0C L=231;;]_KF5K OWS9J%#)
MN2SD=QX6KL_,U)4JET\KL?O&/<Q/?;C,-\M^Y<C/"_:@RD?6W& TM>Y K?Q_
MU3J68*F!J-3\CY]WYO3$<3X*.O,Q@+&XU J"7VL5_[^S "W%GC)SZQ0L5X<(
M+(43 KN)5AKE*_,U*WFE?W._P2)&/ZOYNMS\!MK?0//:UE[#[SL%_7PTNK>K
MC05L)2X,07/%SV)I?*''-=P;#>L[NINZ7KJ_&#6T1OCOP'(EU<IXN2<,.7I-
MW[%B]5<V?U)_5JQ\6BGK]);;7_ZI4"OSR/OG-\L'5BQF*9,ITS&#*L(QQ$D:
M0<:M5YMCD5.69)JG/CS@)7UJ!&'U!)6B-Z"M_PW8_05L;0"_UE:<GR4!QL>-
M7P9#?6#B.0DK6TCPR^U?+\/K34*]8 K*3GX:C$I;O< YY+-^#^E'=&:9\-ZL
M^!_4AV59SA*48R24AD)$&&+#9-"L>I59E*>9S&5*=*QGZZU'=G%*[3W=BZC.
M.)<AYXU1#A25=H"MUZN"/ZT9GRNP7H*W]M>/K"S!GQ2;K^_]R&D?4S?RZ8W4
MP.1B0:H5 S]8U7X$MP=8?6(K\WZ&XY>32 3ECWT)H_+#2>,.Y__IB_SF=[E:
MSUXO%^5R7DB[C'J[6!?K0I6WWXMRIN,H33.L8)XDQ$SSW&Z[(091DE.5TCA-
M,N;BKW0)F9I;TM83;!0%OUI5'7V/3DB[9WDHH :>[+TP<I[@+B!TS7-S?VN.
MFY\.YW>G@%&FN8N)F]GN=*W?I%?W8O9%+8KEZI?E6I51^A.*TS=/RN"4-$MM
MG*J$<XJA8HF .-<",FR^]2G-*,6)(C2A+E/_LJBI$4"EX;^"6FE0:0VD\9FM
MQFX$X !O-PV$!6U@,F@#=0-J7?_U!KQI(+N\O>&+G6P.EZJ3D9$PW),Y82R=
M2=8=GIIJS?661N,H:4C4X0&C4*F[(1M"];BCWUKIXZ-9>:V+Q=T'LRY3G^VY
MYD?]EU+=EJ5:SU0<&PY-$<P$EA#'EEF%C&"LDA@C+E!JUT[NFT"=TJ9&KEME
MP=QJ"ZI#7[C4\,G\P*S&I=\:JAMKMS55, 0'9MH=>)6B-^#S!CVC+*BT#;>\
M<@(EZ'*K6^*HRR\GXP^78VXW]:,4&R,@G^;JHW[U5!8+59:WXA]/15G8[U'Y
MZKGUTU?U??W*&//W&4>,9G$2PYA*#K'.**19SJ#00J<YEM@PC@_3]%%B:@2T
ML<&>OVRL &TS;@!_;O_"CXYZC9,;2PV-_M!NHB_PX->OU=:1-094U@3<G+X&
MS*"DUTN14;GP&J@.*?*J9_FO<7]YLM[<4INULYH_+W];*'F_+!^+-9O;6"CS
MPX.ZKS9NV:+^BU#S)N2JG,4)RJ-42IB;E2_$*4*0R508^LQ%G"K&I,A=E\!7
M:3(U#JV-L1.Y-@=4]H"-0:"R"%B30&U3=<K46 6V9KDO"*\;Q\MK[=%&9^A-
M^/]9 ^.^D!]M@$9:YU\W4.Q.+83=<5W?*_#:'D MJB>4U57+R@TU?V55\(V]
MAK.YC2P%Y;U2:V!W$7\*LX,09%PZ-ABN>_YH^P]!8&AO3X1YH/])T&?SDJIF
MFRW5.1$ISF!,2 HQ2A5D-(\AUP1K\W^15D[!*@?/G=K'[(N=Z^6Z$&;:M<[1
M/>--#L&[?,S3$Y*AO?2^:'B=[IRP_>H#G?8S1SO#.6%(^]CFU)_[K?\W[K)A
M>UXLJGG>\I4_J[D]&7J]+-?EC"L4*ZT8C!EB9MZB!!*A.<SC-,(DXFE$I,^J
MWUWTU*;VV](,Y&_5YW(-A-'0;RWO@;G;"GX8) =FA.U:O:7US=XZO5$<5)J'
M6Z+[HQ5T8>XA?M3EN#\LAXOP'D_P7WK_E:T*NWWS?F%FNBK7U:GU\\:OV9QA
MM\^U9SI/:)R+'!J2RB'6/((<2P3S*->,&0D9(Z[K;7_Q4R.OW1)!M*,MYL5#
M8?_[R%;KA5'COGB$\^+O"JC&)O?%6X\ANKR4'A;X@;ENHSS8:%\'MSS?@-UH
M;,-=VC8,"KK[,GE8\$=?&VLFBGD-]MX<, O;;YN1*C8CM7G_ ZUL^T/9L9SM
M\=#1UK#]#6XO7*]X2C_'^$WQK9!J(>W7[&&Y^+)>BK^_9N7]#$DMJ=8*:B((
MQ%(FT'C&&*8$<4:CG"5(S]J9;A?=MW.BG.;0Q>2]D%-HJRF02LS9RI6@+H+J
MYN=>!=0X3+]5\0;42H)*2_.3T3.<#WL)B: >ZUEAH_JGETP^]$8O7N_'"U(5
MLR]*/*T,[;S]+N[M"OP7\R+,8DXUQM)F7'$!,1,<TM3\F&B64X6D2K%P\2[/
M"9B:_[C1$6R4!%9+-QXX"V+W_ \!S=#[6WZH.$_X2Z:?F.BE$C_=+;_];&ZM
MYO@_L/TGK/]93>RS#QUE0E\R:3.1+U[G/X%KK\'F-JP>EZO*W[0;D^KU\FFQ
M7CV_7DHUHRF*%=<93"-IYG.:<,CBE$%%<8+-A*91XK3-Y2AO:M.[5AGLZ7P#
M*JT-S*#1'%C5W>>\"^Z7*2 PF@,S0@@@O6C" Y[>K.$B8S02\3"XS2D^MP7;
M5/^LQ/)N4?Q3R??2KBAUM9JI(OCJ4!7C2]\NY ?SZV9I:OYF5L7R]=/*IK>U
M_O!Q?6]+/T22,2TPU"FG$$=I#HDV:Y&$R41FF!D2\XK!&T'GJ5%=I100M;)@
MOM/VZNW\X*/=^QS@)<?P10X0=@:#ML5U%',3&+BR>ST+"5K&@<9LLU!KWH?6
M'V] 9?N@1Q!##=309Q?!]7[I0X^A!L+AM&0PT?['+%:5A=TEK11;ZB_JSF[1
MWLK_?BIMKN"K]U_?W*Z7=9JPQ?7UTBB\>"H6=TVXNHV[5'JY4O4U7]GWM]\?
MU:)45?3M+D@YDSB-D*209"*#F @$*;81Y4F28)XCR7CB>CHSFM93^Y3M&V[W
MN!O3P<9V4!MO$^:;=/JJ7N(. +!# -00;"XT(( &!??SB/%>H,MG1Y-\+0;^
M.H[U1OA$T[_@2^)^UC7)EV6D(S*CX-.<K8 L2C%?VB M^^*P^1R4A?DPZ4(P
M\P*M-@B95Z18JX<2%(LJ''2U_\Z5S0O'CE^XHO7"B=T+M]R]<+Q^X9H+U^:%
M4S6(@<[A1A_FCN.[\709[=1O='C;AX7C"_=WL$*Z?YT)@N4LU8@F,<DA2U$,
ML681)"SA,$\$9B3#,65..YKCJCTU%ZLKPQCZ9!B///J7W:-ICNFD=P]NS^T>
MG$FE_MA*I9[F:^+N($WS=1G)0YKB:^/E]XP_>AV.SXC*C.;YC ]PV_5Y >D]
M:YG8#:KZ2;\84.L-K!E3@NJ(Q% FFD!,8@0IE0)FB<8H%Y*JS*DZ5*>4R7D6
MU3G$?+FX@T;<0[]R)2?A=#LVN!JD@3_5-3ZU@C=@IV+ FB1="(2M17)2TK@U
M2+J,/:H]TGGQM35'OMRSE7IE$P]MMJE97]5) ZN5C?6HJLZ^>MY=\XD]5\NX
MW]A*5NNP&4ICF@F4P2S"".(HD9"K*O8JRU4>*Y'F7BE)P32;&L6TBV14:L,Z
M$[AM'&A;9VMFM"]L+ 25B<V>GV?)['##[D9K+S*80X>9C3N.5Y0_"83Y0#51
MKM7NA0JE! +U?/644 )Z?AAL&(Y]XL:+;3;NZ@JW$B4J43R#/$H9Q'E*(*&:
MPBQ#0F0D19Z^8:>TR1%XHYM7P6 W7!W9-!1:0S.D(U#^U.8"0%BZZI0X+@6Y
M&']$*TXW]:.*]PNQLJO2-ZK^[_O%K1"K)R6_L#E;F37L3* DYAEBD!.%S5*2
MQ9#D@D*6TCB/*(I)Y!4@=U'BU"BC40\\LF<C<^Y'&9?Q=:.-H*@-3!T;7<$/
M&VU_M">;&QPW&H>C%&=P@M+*9:FC4HLS"(?TXGYC/XJQR4+V_[_]QU/QC<TM
M<7U6Y7I5")O&;OYPNY#[OVA=67?E.U91S)]L<]--/L-GPY!OM59B/=-,$IYE
M E(M(H@YTI!%G,(<Q5D2I3)/HMRG]<FXZGN1WPB]579S6;;GLC!FWE3_"]3.
MVILJ&G2U!:.ZP(\O1WY9W,AWNJ_ P$S^NAIF^[_@;7N8=\;6?[3#?OB[O1MJ
M$,")+\,-V$*QR_FR8( :C7!?B9<9Q:"?G)%-&/7[]3+#<_@Q?"$M^J;@O2OF
MJD[>G^5$YRE6R'SHD((XB@GD6)C/(-5**TRRC$=^^7:[AT_-)6]RPJR"3>4/
MWQRZ%G#=WX!KX1B8H3V0Z)$$=VSRE1EOK0>.G-YV;,IQ+MN):_JYO)^55.K!
M[N39PY[E8FT7CH8!ME4W#&<8<9M.@+,L23"))(51'A&(480A(VD""8\P$S*E
M>>JUQO:4/[7IO5,?+/;TWU:3\3S5]1T/-[=P0)0'9HT6P/NJ;PLKW8!:^W:S
MUW"N6$_D@OI2OCJ,Z@SU!.C0F^G[F'ZL5\<%5SN37Y>W4E;EZMC\$RN,3_2:
M5=5QJT,/?G@P\EG5Y>W4%[7Z5@A5.U)-P(V]H)Z62&6IYCJ!7"828EN*CC.I
MH(BTDI$4/'<K^#Z6PE/CU:IV2W. *5K6^)'IX,/LQKY3&KR!Z?KVT_O7-Z>/
MGW<GBC>[U;6NZB*4:]"R*1QYCP5\4+8?7.E1/P]C#<'A]V0TN?YY(!^%>'ID
M"_%L7_R92IA9\6(,J1+<.-0D@8RG549LEF>YBI/(.55C[\E3H_2M<E7]9(^0
M^'V\NBGW*A0&YL8= *^="T@?V^\>M=\;AY$"ZV\?;/F5$CR:.5E]"*HB#*PL
MEZ*HBG/^5JSOZ]2;73^+\L8F"#:[L**NMV=F,0.VIOQ:+:KF%':3MRP>"IO8
M*,PDOPM6R_,DIAWA[OO7CQ:1?E+-=M#XZ0N&V4)X]?Q!W;%YO7%1A_/)+"$H
MY0I2C6.(92X@YQDW7T,4:4YISK13!;W^*DR-'5W6N?P95&8TI83[Q63V&*TP
M>PS7C<$$MAE\X0^^UW >P5&W&TZH,:D=A_,P^6XZ=#RI9PK,ZHXMBG]6']9=
MY6(;;[F0GXS$S4?WHWY7V$]989S434A5><O+]8J)]8S$$4LU09!$RK!G'FG(
MLCB!-%4JCG%.,'&JGQ)4JZD1:MNH&[!G5N4?M VSL=5;T\#.-O#KQCI/D@TS
MSFZ\._KH#>TFCS1P_BE#(8$.FV(41+-Q4Y)"@GF4PA3TX3VWF)L\2R.A6*L/
MQ3<ES6?%O.C%-A7S;\HF6"IY^TVMV)WZ2ZGTT_Q#H8U_'*<(Y2F%@J,,8MO=
MG<4\AQ%.DB1GG.>YW_;Q%<I,C=AK&^#<&F%/V1HKZAQ*\%3I#>9&<<^]XFO&
MRW$?>*11&'J/=Y/;OC<2.TNV>9L;8T!C#:C- 1^Z!L=_DS< JF$W<*]1:-S-
MV0#0'6V\AGCF%0GF36'$6M*F_R315$0TAGF4V/Z30D&>< Q3Q$G.>9JGPL]A
M/B-H:E19IU%ORIOZE"*Y"*FC;QH J*'=S1,8@5]K-4,ZCQ>0")]R?DK8^%GG
M'2:?3#SONKX?*WQ8+NZ^JM7#&\77QO]KSGZJ A<?^;RXJVM_S?((BSP6,:1$
M"XA5AB"G>0X)385&-)64>>4:NHF=&F-\V):DD$;O&[ P+I7M&]=,C\?ERO\4
MWG$ W!@E/*P#\\L.4:MR782Z.OK>J1N.9?S0"<HYCJ)'92 _. [YR//NOH<G
M[<*%'W5-?.^,*4WJY-=EN\59O2'/N<*14!QRG>80<Q%!DD0)S$5*4<(0S2GR
M.S[Q5V)JS'5<_;;YEE<51S>5<-?+O6:+?8]0>HR9ZR'*L",Q^#'*$(/0XR"E
M/XJ!CU)Z*#+R84I_J(Z/4ZYX5C_ZW :$;J1MEI^SE!J*M!R9\)A"G*8Q)"B+
M89H2CM(XYEGFE&1R4=+4B+"*@OYF-:TJ.=?SCS7*^A'=>73=V"P(9@-3UBYH
MO$57MY?@\J:DBU $Y9WSTD8EEXM&'S+(Y1N"M6?ZM%J^6ZX>V/N%MO^QOWK+
M5HMB<5=^7'U8EJ51H1:NOA3&VE9?\S>&O6[%^HG-9S%)$XU(#J7&AF6D)I#$
M.86Y-+_/TCA+$+ZR)U,01:=&4MNBJJ)=5/5QM025D:#8&7L#5&-NQ6>-J: L
MJDBOG;' ?E1NS&^LO5?W<PKS>KC1Y!0&?6"6/5U$UU@)*C/!^_9XO]V.]PI8
M6RMBWA_WEKW@337NM]WC'J)A4]!!&;I+4QAE7[HU4U#('?HQA97G'QO^12V*
MY>J7Y5J5.(O3-T\JCA+4[+DGDM%$I-Q\;%(),=(4LB1.((XI99H+$2?$-52\
M2]#4/A;X)Z/AOX):95#I#*3QUZS&[F'4G=!V$W5(P 8FVC9(-Z!&[@:\:="Z
M?+#A!YM[,'HH^$:*3>^&,4PLN0LD':'EG;>/%FGN8D0[\-SI^F!._NU"5NN(
M%DU[1M?Y/71"1'#*XZI.'RK=]QRH(8+E^N$VM%/4I<)+NSH.\#@X,"Y/Z3>]
MZG(3'W45*5>^7_SMOA#W=6ATW39 E;.8,R:U5I#H7$.LTPS2+$^@T"*/8_.B
MJM@K;LU!YM2<E5IENV0I*Z5M#;+?K-I U6D#RT9QOR6J"_INC!88TX%I; ?G
MEP,XFRR,CY?@]*8N#X""\I6+W%%)R@.(0V;RN?6ZKWV;Z&QMXXBJ...<&W05
MA\;'8)"+2,+,;L>Q)!<L]DHM.R-G:K2S_=SO?]C]*T>?P]7/7;H"K;'\(@^@
M>GL_9V 8Q,TYE/4B_LP9@\\Y+N<N?]GFBL>]M9LRLY_JNLHSG>:9D(F&A-N>
M13H7D"4JA0()2H1(F1FIEVBO>$GQJ9%6KWK5HX_VY;VAJ8[ABVSJNW;&8^<Z
MXVUB<5M_O-F6Y/XTZ5?E95HJAGQE_D<T51SFU7FQIHJNXS=26\6+ZOR/;*SH
M"O)0K16=Y?O[/O5B:ZE+ ^O\>?G;0LEB\6C4-?)6ZKX66&F_K:(R2VF4D3C+
M8(15#FVM(<@PHC#6J;9UZ0FCRM6%Z2%_:IY(:]>F,@)45H"M&6#?CETY&O</
M49]1NNQZ#(S]:+L[DX+=_3,^,/PC?8V_VO8,8-%W,)H+[5>YV=PT/U11&^M[
M!3B;5T69RGNEUE603J!:3%=@W_$E[?/4T3Z(5YC<_JY=\YB>?=Z>'A_GYIOW
M]KNMLZ=F>4;-&CJ)8):E$<0,99#@C$%)<IUD28QYZI61>?#\J7U>-NIY-G$[
M ,UM"^X**(:.36@T XUJ 3NUG;8Y;&^V QGC=F,[;>!1_[4SE_6<M+U;0];]
M(8U46W##O ._F+?BS=*6Z)MABE-!%8$I901B')N9'R49Y$HD4:YHFOJ5MAA"
MR:G11]VZU:H*?JTU]&T'.<1(.M+1"X_/P)SF,S3^M#8@=F&Y<0A%QR78 :$^
M8NDA985)0ZT/:8O%W2?C)A9K&_G:RN,J3R4X1BF2#(L$)@3;!'J90./,8:BX
MR$F:*N/HZ6N24OU5FAJ-'V=';C(BZVK59MGT]M7[KV]N;8;D^X58/J@Z<=)8
M9@Q_LN4H&Q2,J>"5TLN5VESXE7W?^%5ALEI[O )N7X1Q!W9@_C\>TZTYH+8'
M_& M^G$O!;8</P>V/\J#9L3V4.M%\V/[PW@I6_:*)_?(,]B4N_NH[3?(+/H-
M<13?5$TFYNM2_V-[V39JEE*A)!&V7G-B6#Z*M''?<0QU$JD\CCFGF?/1=U\E
MIL;K6P7!1PWV+-F0L[%E\\_=Q;[%1:\:M\L[R6.,QM ;#/\#!L(C96*$ 1DK
MG6*P@?'+N+@2T:YLC+Z/'B]3XTKC][(XKGV6?Q?1#V9DYY_NEXM-,TR!">*4
MIS"GFD$LXQQR@919=,241VFLD7;:2#KU\*E]82K]0*6@=Q?1(^"Z/P77PC$P
MQ7L@X=5%])S)O;N('CUPM"ZBYTQI=Q$]>TV_[8/7*R6+]3MFW=GU<[,_F"1)
MA",504QLJU 59Y 2K"#+!.*:),RS5>@I(5.;J+6.8*-DS^W:DW"Z+:ZO!6G@
MZ>N-CW_O] X PG8X/R5HW#[D':8>=0OONK9GA?,ZZ&GCV"+.<!HG*>1I;*9[
MHB/(I8&-*X$2RA12*)M]4RN^=*Y:OB? YRUNBQEP[[]'0=U#T A),K.BAKG*
M$<0,$\B8H4R::4J,CYGAR*N27W_(1CG'NAXP-Q;L#\/0QT5-?>$!,FY/VQRV
MLOF^B'%KE9\T[ZCZ^.FK^@:M\++9?:M2H*C(A<B3')H9:R8KIPK2.,40TTCD
MR*Q $/-*+3MX_M1F:TN]7IEDA_ YGA?W!V7HW25W/'H$L)RT.G  R[Z,D0-8
M3AIX',!R^K(KJT/^6;'R:56?K?ZR7*R4+6A=+.Z:,B8Y$0G2Y@.<Y6EB<T81
M)%F<PU1HG.5YFJO4*1C:4^[4)GQ;PYZ%(B\ [48! \ W,#7LBDC>@+:B S02
M\ 1GF+*2%V2_3)%)-T#.EIQTO+UG?(7M>/)1_Z6L4T4^\K59?]G.*&^_BWL;
M]O%NN:I[4:FJP/@F3>1YEB74+@4R2!6*(48X@X3&'&+)<\TB\W\2OU:I?369
M&EM]6ME@\_5S%7=N>W8_5F<&K.GU78+U_6KY='</=&U-W4G8<_71?]S<J&Z4
MT1B8_"H;X%)#8T5376ACAZW6L;&D:O'<V-*T0-A:$S#LX5I PT8[]-9FW""'
M:T$[BFVX^H']:/;/S#!/P>;;V(K%W?NU>M@T+6):D5BS'"J6"<.E7$-*10Q9
MEJ(XTZG2A/MP:;>XJ1'F)MBLI2VHU/6CQ L8N_%>..2&7O2= VT U\X-E* $
M=4'DJ"SD9OXAU3C>-5 &Q+E W;?&'UD_OU^4ZU457U%6S:V^&N[[^%AY)W\T
MCUB7[Q>?C/)+.1,Z,G24("@3CB"F&8:<,03-RC3E69PHA+W.RL92?&H<]UD9
MQ0MA(RK+]5+\'3!K5 F*LK0E 'XHK='ECX&S)T*]!8X[9!,<VZ%9V-IC9H0Q
M"+2-!BVK 7\&[>L:RT%E^@VHC0<MZT'=^F]M[ <- #>@AL#ZK34((R9S!!ZV
M<1,\0BD_K:2/P$/BG0@26GZ/0&'CN*]OYX_WYJ%/VWZJD4(Y9HEY6VP.GV82
M,H42&,5QDN0RQ1B[!P&?$#"UKTJE(]@JZ1$E>@J];I8/@<G0;+P/1Y^BXJ=P
M\8B,O1*?L:)>?7'R"V;M *$K4/74;>,%H78HO1=@VG5=S[V!8K%<5:QI*,.X
MB6^46-F]!YMD\::P;B-_JKCSZ_(78\ARL;9E>>QRHKGA3\NYD5;.,A6Q"',"
MJ:()Q'F&H&T/"XDD&4Z81 J3V4+=V3P-QWV$0*HYS0%:SX&V@L--@3WM@51B
MSKR[D 4;N%ABG3.DH$ILQ'"6Q6;,!(<)C2)[@I^3)-L,W%>/7:"7&[VO(WS\
M)C6$CKM+8X[(2)62]O0$&T5OP,:V.K]P?[#62W#F/M!8&'#S*C#F8;>Y0BDW
M[H988$B/MLY"/[]_Z;K_7IKOO6MY+BK2B+#(?("%H7!,= H)PRE$7'%-6(P2
ME/G6KO-18&K+DUT5M<:* <NH>0W4Y97.T/ /S<I31=Z_@MU0(_!")>Q\Q^.%
M:]CU0=^AB)W78T>O8M?'Z%-E['H]I]\B\NN*266KKFPV+31)298B#=.(Y[;C
M#89<2@5SLQHD/!<93Z3/P<VA@*E]:RK]@+W";P5P!)R;)W\-' -S?XU$I=L
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M&^\S3PGSZT1T7IC/I!RG*]%.3QNB:QV"NLZ=P?ZA6%?5POQHL -I-[(+@][
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MQ@7^.DS-.]Z88 ECUSZDL6(_A=.6K&^NJ,]=?5ML]A@QQPW*8<=AZ/W)08;
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MN+()C2.OST/ X1FE9]6D!Z??:>\5D+_ N>]F!(9(.G-$9M#CX$.9+WHP? :
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MN_!UF_J!4!N8!#H &X 3'# )R@Y=\D;E"0?##QG#Y9;KHGS-@HL7B[K@Z^X
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MTQSJ.-'0N*4YI#)B,%5"("%UEIGG>:P8+HN<&@DT'0TVG;<;?<%RJ["?E^.
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M% M05H#\Z)TK=NU(N_GTXX[?P#S5,F9;CZLRYRB?[,UF+-]JK425=W:AV4?
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MA$SH#%(J,YK%*,^54Z!1EY"I\<.>GG5W-<_3N$Y(NYDB%%"#;\SWP,B9$%Q
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M"./C\]Q\G+FMH*%2 5%,2(I5E"&_L+5# 5/[#N_TJ]H:&@U]ZTH? .C&)=?
M,C!M["/RI@N1'H6>3YL=N(KS@9"12S2?-O&X_O*9Z_I-Y _+Q9V9+P_V45_-
M(YIJ3G',)>,BA=R !7&,<DAB:?Z5B%0;MS!-,J]LE=-BIC:IK9;0JEF]OC?
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MN#:@!L>0(:W,T" I,Y*E2G*_)6VWP.DM:.LL1U6K9]N(6VT]&X=? -G-00T
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M CIOF@KCM;)#QG&>P&3@D,ZVQ/^_O'?M<1S'LD6_GU\A8(#I*B#8(Y&42,X
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MZ.+1YM2XIV5ILC,U^:TR-G"IXP.Y'^U$!G)@XNF)83#A!* 2E7)\VAV5= *
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M5V%)NG$,"QE>X^3T-GXEO'(LD:NO7^UP*^\S;9+5WK-_#R.J2#WI1VGC]\[
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M^/51Z^V?UJOG)TL<U;8Y(D**7&%@$&%."Y(")E,.J%"48:X1TF&5GCP:G=K
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M65(3E".WU6;70S++@4(LU80140CBM^%S&W;C[.94I=YC8]A-=[?A,C#7Q8+
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MFZ. =\S.<5[:EY^W]LL[M_1?71>R,\7[[W+Q[([/_[1:J=_GB\6,TSPMD"H
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MLMA;'"HRUHVU'Z-%1'!@ MN!5V\.NG5MR]ARES"FY)@7+I'EQ[K;'%F*S N
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M<IP\"/QQ=Q>C6CCNSN00X)[L:@[2R*TSQ]FMBWD[!T2D0L."N2+HTLX+6E-
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M#49_]<_A2K0<-?$Z"I^=)54N/-5OV'[:/NIU=;+<)!SG/*-9H1"@0B. *2D
M)X8!@@3)BE11S;Q.42XW,;7A6UJX2][FI:EA(_@,C'ZC^#9P!A[)%2Z-]E#T
MQ.W+OD<=T6>:&7547W;S>&1W/-EWN^;W>RF=*+Y;.:Q72_NC++EC\WFUF,N7
MZK]?]/?M&VOR?\\4S(6K;@0$S3* "^RF[0P#9F/Y@C*3L2)P0R;,@*DQPR]:
M6EL73@-G]536?=YYDQRZ$[HE$]@QOILNP\$]^+;*[Y?!O4LJPY/?ZO]U'B2E
M"U'OE?9#+_*^2* 1(^]\](/H=&^CYWO">'"SWLY^<8GZI2ZI5I1DA&) .=0
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M^:TQ^C@_,-E<]3MX*7#L9-00?_?R44/W8Y>.0_*3O_<;='^9+U?K^?9EER[
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MXDD)DYT[&@(WW[H;!#H^ZSQ*C"-#X/T2:DK+[]\^Q<5L@MQKB;ZFFH3,=-+
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M1= X?2%'1NAQ:NGBEOOQI4;?.$\7>5L/F4B?Z_5R&L_6$&?X?G'/*HO1."Z
M )0ER5:8PKQ5BD3MZB&#$ZH\U!6DI1$^A)]QFEIV;'^;@Z(;TWLAA1?353H7
M!.;O<O@-23$U?XK;!%H$P;+3BL3-/8-H$K-<QB*LL?C@M)BA /\PE2.UX.P$
MQP-JL O3_7:YH"VG<C<AIX5B4"([1!UK:7^B " EQIW,N3@)G+>)V;[3,%+S
MSM&P=:#T.[!K=\CH8A$<9-95--:F>E.>BV<:(;)(C@[+]"/W0DF3VARY#\S(
M2+U%1TS5' \'71A0XO;[#K$3BTD;\#EFQG5-&5,%6:B5\%(IC#'*@K)-/L7>
MI([4(W4T,+?593_73P\LVIVX+B1B,+7)L$_ M%2:^;I(C>7)DP<4\X-MV9H8
MZ^'P_./<;YU2S_V@^]HJGE@)R7+EB6CDQ(.-S)NLF<F!Q)J+A/Q0=Y^!K.U(
MO6;[L*1[Z:!OWW92E%1)Y\1T)*NOH8XD#1D85R8IF:RTJ@V<'B!JI%ZV/9JU
MO?33 =3^CG44-^9GY)+"AVTK[S?E5A><%]/9&7VMGC[,%JNS)6YN)RZEJ47V
M,A!H.(F5%IAP+'(,+(E 7&?0J5&*[C#TC]2$=S0 CZ#U+F*E7?G^!5;3-/$.
M) 3:-7S,CNF4D45'/X$M,8"T6?(VQ_][D3EN[=P82#H0S/LKM8,4JWN8VXKS
M=K,R"8X"/UFGC=8]R.=:)"0X<V #"BA2/C@;:W#,WD?HN&5Z_:)V$,5V@-N7
ML)P3V:NWN-SPLEE\M)MM^;L4H8U<!I2968U0AUK2PK0NLB"RY=++%$J;#( =
M"1RI__IHGD$+O74+QPMFDJR3[XI@Q1)0-$^*UE;4C/B($A3/^L'1YT.#<"_H
MM3*138"P$]@.T4H'$'L\W8#8W'"XX74B><DEND28*'65U@:CM3&QM!"3LR'$
M1A5">Q+:(PP/@LC>Z2&'ZZL[.#Z<-7"=T>)XQE"[Y@@T3!M71Y1+8M3[P&W6
M,NB'1N&<)@ED?X@V<R9/!=%6.NP K'>*<.*DMN2R %.J-EY&$UAPO#!N,G=0
MO.7AH3GA V_+X_:6: >RXV7?P3'F329N>BE:<ZMJ8["L@#.=0;*8HF"B:&$#
M%!Y#F[#X$<)ZM%QM?;QC--/%&>).?L/5,'[BT:(5!ID)X&EU6LF"=9E^4M:B
MTE:Y-JE%>Y/:EZ]W%%0.\?8.UEH'6^B>OL(U5DW(TIE26!*.7%M9R+7U,3'@
MY/'*1+\\. #W9![?WE ]F>5L!]5VFNP M/>(<6)HHZ%-13"$>K *0=5!HL0+
M^:Z<^!"!M[&8]Q#4E^\W)-B&T$ '_M_UQ+D+P9 #JS-'R6A%D& ,  N%*_*2
MM8T@O.&A3<NQ.\D9:49C'RDX!^GDB?A[DVQM,=%0Y(6J#G>0Y!\;DE<2//-,
M_T/7LHSQ(=K&]>@&@,#>?MQ>VNA@#]QGN[^>-'DY3??E9DH1,:Z,+@04"%6N
M* T#X30KF&-127O]X!#ST[AQ#[(PKE/7&JVGTFT79O-Z J:W1G#R'9@'VDPV
M[=P"\5/;??%ZGA"2:%/:M7\2;#,W;GAX'2[CP5RV#D>)3&[D5[8?)D)O[&:<
MR$WN+P>*_-Q")[_ #.8)?_^(N%X-/LSEGJ<WE_4N7!TYJ.5B"5_QS'^=SNFM
M4YB]7:RF&Z-T82,*4,1E(V<RU[9@O@Z*\H'3#@"V9.1!^#;G,[M0=^Q&4>=W
MK*_D5'G:UXH#HB9JIA.O'68Q,!UEL99^"JI-Z'^=CG']YL%1<7/G.$+H77@7
MY_1OIS!>82/:$*-CWF9UGGOOZ\T51;#6V*!%;M3%\$YRQH70,1J^$RS'"+L+
MS#R'U<=G\UQ_JRW(OL"L[J;/UL]AN?Q&GO;?8':&$\A0@N.2T=84F0XYL9 B
M,E3>E#J0380V0=1.Y/6 J:. <+.29G"==!#1OT.2S#21RU#YVHIKXKU2!I+:
M3 EFNL3$H@R622&<"YE;>E 38-U)SKB1]O! .E[F'0#G64J+,\+_.TQ(:R'.
M:EG9!2\N&>6,*XS+F@!>+# OC&8.,H]"<U-"&_P\1-6X$?7P,!I, QV@:=/X
M]9J()AE%(MJ1!;\I?G&<O("B65 !A==<NI83FZ[1,NX8EN&1<Z2T.\#+=>*+
M#6AMCDR"S[68%5G$HIBT,4EG=;"IS8G=_BAI-F*E@7TY6,8=7+*^7=8>TNMO
M;V<PW\PB(X_M\^:Z<)[/PU1\C;#"=[6RZ4WYZPHW[#XKA%$RK&>?SC:C\*[.
M_[@Y]D-'+V30@65?"_6%U@P@!'+\$+6EK5SK-@:J/6\]>%R#A(.=P: #RWDY
MC>\NOB<Y%+()2C-3>!U%6Q/)LG?,<<Z3T"AC;%-=]"!9/7AN@\!Q..%W@*1_
M6RSR']/9;.(B:AX4L!S)@=#D63+8W.BHJ"*FK#FTZ7!T04$/_MD@^#A(I!U
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M[%,]JYMX'UQQM&1R!I(=^8J51\-*L2E*54 V&@!_"+4[X7'P204GQ6-S)78
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MRAI=>Q33+[EHH56TX6:!Y7_M[C5[ 6#O[C7[:*/'[C661[ @)2LZU7$0QC,
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M@TGN(^U_<#B>1H7[8S6<8W6.'^J8U19%+8\EU'@7@P.NF?(YUJ; %/MDDB\
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M'5JVW56\R%8G:QEBDN3JN\0B8F!8,VQ+YB6K-J?%=U$S+F*.U?"#@#E W!U
MYAU^6<R^T/Y^G9F+=CF99ZN*8L#M-O0,P5DFK5-%)V&#:U/N^B!9/8'H$*TO
M6JF@ SQ=BW/IWVP664D\.LLCB[7ADE:U9;?QA7F;DS2Q(/I&-Y]W4#/N]=30
MF];1\NX0,]LUE0%5=@99V+1WUS(S<,(R;E34R$-&W2;=XFYZ1LXP/%K/CP#G
M *%W 1V87V0;78R(J$,852Z,.P-,^V@I8LC$0<[:B^ +-#I3ODU+7Y Y1,.W
M0'.4N#L S.\XGRZ6ORW6N-HRX$O01BO#/*2-!ZAH_3A9+_(!O4XY8YN&];=(
M&3EQ8GBX'"?L#M"R(7V+]TUBVO;GU>50&^#!:J)_DW(=B*?@2F)US*),/@JQ
M6POBO;'S"&$CIT@,CZ0A%=$!KJY[@>>ST2!&GHQ@64F*((I7+$9);'A4*4&Q
M#MKXR+=I&1<]0WO(1\JZ.[3\!I\N5A3*F$,QA:&)Q >DPD(.GC9@GU#*Y(IK
M=ZUW%T4]'0CNK^D'@7.@V$>>#54S%ZO3MCU4F%X:3"23B(4,9FUV2QMQ<BP8
MDH[5)D1OM(5\8]S%G1.@[GM^3T X5'.+@<4X,A2N.&/<_%E(\^(,ZYB)+2<4
M,#H77688ZV!%53N^2UY831-QFQ1[87< Q,-OZ>GL90!8#"C2KL#AMHR8+2-%
M9N>3\ S)8%8K*AB4Z)F/.F (64?-]\;&C9?TY'0,#HUC!-H/,O2?#3_GPV_Y
MR#H 2)$8[:;$AQ2* 93"'%>&EY"XO=EM[C%@W'K'N.F[+7%QG#C[@077A.]S
M3A3?<D(&SSF2!<LZU3FMA6*]VNS52D!74XW4S;/;1RW&[;>,6\74U&0<*=)^
MP*'M=E=4XN((R&0KD]7,<)MJI8QF42C#@BSHH8[A<'LZ&K?>,6[;HZ8VXRAQ
M=A?+OKYL[%)S##%J6W?$VLHI8FW^I1F(PB,OAJ?0YB3M'H)ZVG:&/@,Y3.H=
M@&>W6KSOB?,R2H-*L@!*,^TS,/ QL."4!ZMJ(7&;7FS[T=E3K'P@- ZJF3Q(
M3P,6(PQEQ"YZ5;V#-6[&.>8K@W9++3*NC<NMP#JU7F42HXNLF%R"2%BR.85=
M>XC&\6\I6V'E02LXF-HZ,XP3(7G1(#DKM7Q>!X/,)]HHI%-68M8RA/9F;_R[
MS!.!ZF#1=P";J\W&+RN/)YKP7>M*&><UERV+VF0#: \@!D!E8PJVN8FZDYSQ
MKS)/!*3CE='-WOA GX00BW;>)\9=;2<N'<E*Z,R4D24I[WV6;;*1!^A9T:Y(
M_+1[X$#J>3(-4RZZP>2B$3!:)F6NEX'6,U\*+2VPO&0H)?HQXX$^>O.,LW,.
MJ[PC)D=]J([@^Q-'K!.% E/QR#2OUX@:"_.28J\$.NL0O7"-1B<.V-&GV7E:
M=Y#<2UT_3#7KY$9=W,#UK/3X<2I:;_)U6=/Z\X"BK9709S ;IC#XQL.:M2EX
M@.:VA;\(P6=="@L\T_I*B99P L&2#\79>D[>T$D\3>&O#-H;98#<JTR.5B![
M%8TN9*^4E@:4X_84YT+]%O[N@X%="G_W$7@'H?F=]1XVE@!U4$*)F(ERX1D(
M85@J8*5/F VVR?<[N([JI,6_>ZEXESJJ?>3=(6:VUXX.-"AO,X."EFE##I&7
MQ9#G[*4L,4J+[=I%/HDZJKWTO%L=U3Y"[P ZMRLUC$+GHZWGWHKL;PF6EE74
MC'N-'@4)B;<)20XKBSEU%=5>^GVT+&8?87> EKL2K5,)6$?U\CK-1[ML&2"0
M%8X1O18JZ-BF6// \H63%O@>LS$=*>ONT'(E'\:  &N%8J[.)R5A4!BMC6!H
MO34YAU+<*7S@GLL7]M'TKN4+^XB]GT2R.[)H4T!G$#RC0"&='U;'7+-HN7(:
M$-''&\V3&J4EG[Z082\=[IR6O(] ^T'&[3Q:%:0P6'O'"^=J3;)G4=;2'\C!
M*4<?WMR,VJ0EG[Z280!<'"?.?F!Q5PZM@X E>K=M>XHR$!-),HDI&DM\6K^O
MQ3@P+?GTE0Q#F(PC1=H/.&[GT4+1FFO.F</$ZWD3Q8#9*+*"&5(J)D#9UV8<
ME)9\^E*&(6S&4>+L!Q9W57'Q.CO-9&1)J<ATKMW:$0HK1KC"'5I^\S"Z56'<
MZ4L9AG$SCA)I=P',Z\L46<F%RPHL4Q: :; U(QL2LR*%B#S8E-L<D1R3LW[2
MNOWA M_#I-X=>!Y,.O6EEJN7P$P=::O)YV80.=F2%$0!GI WFK3Y5'*%!X'$
MX4G!^^AGY#WM.E?/%U]P#B0Q_()+XN1=U1BY]<+&Q#W#H.KX$! ,4.A:?*@1
M=%:W;I/NW-AV>%5/P=)QJ&DAVU'3-F\S] [S6:JZ>35_#I\A3=??_CHG#;VC
M9;&<IKHDX-NFO?LO9R1W7/X"JW_@>@(6D#OC"2&E)FC)>F$;%5.>HD21H@W\
M_VOORYK;.I8TW^>_9$_MR\M$2+;LZPG;<DCJ[D=$+5D2NFE %R!UK?GUG04"
M7$"0Q'(*I^"8%UFF)""7K[(RLW(Y'$Y'$M/333@TX,ZAGZZLUQOZ):]^\WF!
M>/N3NF7TT_PM_A&F>1)X-NB$AK#:\I=C!N== BX9-T%GSIDX&'FO?6M/P=S0
M$!M4XAWX8!_PZ_I(W*ZHF.1<DJEMU#XYBDFYE>!U729J38Y62ENPC:>U34E/
M<=\P_M1)LNX *]O&]NO-(GT)2\P_A82WQV"BL@\*ZT8^E?)Z(39W#CP&%Y.A
MJ*><X^%J)W$]];ZW\-!/UT@'(/LY3&?+7^?+)2[?S][]5=<_WDR77RI_ZU/#
ML@K%Z@Q%"P<*I:7;FJYL38>(3HZ6A;>9O/XJ:7L!S%X2P(;5QM#-!VWJOLF+
MI)N])FGJIM'Y[)I^2I_V>1, 'U.C_/IG#EFJ?" ' U4L[_ZNNZK55++D=*]!
MJAEOY;#NZJLC3U-29(NX9HW&6+Q,UZGVZK?I;+Z@0&/SN;M6"J:D#1T,"S;5
MOHL<$\2ZIM (6S@::;)L,W=[#^+&35L-B)EMTS6T8CKO5GGUS!^]_G'?3SZK
M!6NX*/(53&H?L[$V O..,..#!L\X UGJSE'N4/-+M&.O27PE\/N3H[D,)60/
M7-5IY8%.3HA>TQGR@EQ*AEZT:1@]C,ZNK=LA2'H:2S93U\@9K@]([-19LBLU
MS<OO2%XM&09\<WV]F,:;Z\K9]?PEN_# P$>3'=T3(%P-?C)7$)T78)5E'@UR
M:_?)?PU)T[@9_P:0'%5IEWXKO_H7WJ3KZ;>Z3>OH_LCA:3CK37^:A,[C$RAN
M'=?>$V*5K54; H(7!LCDYAA$DLSXOZ%/\/;[KQ287[V;79/X;\L:<LB*66]!
MYUJ6'6(!KXT!'Y )FS!)VZ;9X7!:N_8-#D'4H;[!B6H;T3_(.)T\H'W5".!+
M8<RQ $8BQ8A2,@B*F"BBH):^),M?ZOQ<8OJWS_-O_YL^>@6V?ZKZ6[C][0IA
M.[YT7.BTUN]\&&&/C)-;JC?S99$EY+7>((L"2HA:ITW.#1:O(P]"F1=7R.P'
MDH??. Y"3E;9? #YC1X_O'PZ-NLIG G!\@ 1?>T?"AZ\TZM=;:B*M#&S?;9\
M[/=MXZ'A>"W.FXJT@Y>FU[CZ]?X%A8RG\3F"EG7DI2^,Y$;&-"5D145KXG84
M>2:GYM>#ZEN;!95GNI#:*JYSL_7NGS<DO!_"8O&=?GK[MON!_LI/\\6_PB)/
M9$*T/!5 Y^EL:V/I&%H!3A7MO%<RY7UJ\4\DHV_'Z$A@'& )A]32!9C(7>Q.
M,*>0ZC4@0VV5I$L'@K89,DG8F<)25FVVAAY#[3B /3N4#K2@)^OU:.Q^Q<5T
MGC]>A\7U( B^2T36(H:'R<A/\]>$,#&9*Y*P J\$,:SJ]620G!J/I7"IR&=J
M\VQ[ M'C. )CX_E<6NYBC/"3AVU,BSJ&\2=2QX_3Y2WS=1CCIV?R[?^8U]KG
MY023-2(F 4;7#9#5_7*>,T@RD4L@T+A&N;JA.!BGEGULL(^B_W[FQAYU=^5
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M%<Y#K4PL!9S6QOL43')MBHN?D#+N5=4 +J<)NP.TK$A?XWU5A;K^_8:=8D1
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MG:W4=I&7;<W6WMQ^Q[RLSFFX.Z</]/#@7QR?;!B:@O97^D#2:>T%.!.9BBQ
MT=K5I3P18M$<M!*!):F9N# OX'>\OHVR?YTOEV^^D417QW*^%G2M]/XROR(K
MM+R]6N[:PW4V.3L+F%, E2BL#ZA-=9#IH#+NI6\3A1U)<*=>P"%X>K+DZ0RJ
MZV+8V#V7/Y%D?YC/KJ>S&Q+G>S(A*Q4NZ6]<W>3ZS+N93'F]F$:R)RN!_#ZG
M#YA=$UWT#9\WHX$FC"4KE(_$O5!UZ$N=3(FV+AQF)M<AT+[-8V@;?L9%^%G
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M^F+^_/W-]?(ZS&IT^UB.T3JCF4@@O;"UQ)T\GY0C6)63$:*HTFC*Z%'D=OH
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M#J[3?N#Z,_GM58+O9Q_#%2XWK_V5N?J;7_[\&J:+*M<?OH3%9US2J63:.UF
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MR_#2XZ$Q,:><,UAF+:C@$5P-*#(OWI5LN-5MIML=1V]?#VE'H>FU4LT&BNO
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M")B\D"5RR1H]J5W\3O9!P3/ >O9#--E^O/_Z#^HO,2SQ__RO_P%02P,$%
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M*3%'50W+<*[L0!L-5E6LNOR>?G4:.EB)JIA4^$3=$ F&,I6XKICR<PEMX>:
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M*^JC:NH3+%Y0EIX0L'@LIV<HTKQ"Y>LZ_*WX#U\TK4SX*Q<$/.Q* -NS 3?
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MON082L(!EWTIS!!;8+48^!$Y$J^9,*%4)H-VR)Q:28^55*N0,[AMR"Y @W'
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M*.FS &YKL@_0"!A@S<6_<^\/:3Q@I 6D=),*J.%5:<&K[S-GA5</W)6[Y"A
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M&TBY=.I2[/.(B_J.8SX-+2F$9,JB1?V-QZ94PC&=PX!/2?PF+Y&&@J2"A>E
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MKUZ9E\#V_P502P$"% ,4    " !#BJ-4XJ>P*C_W 0!&.!D $
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M,#(R,#,S,5]L86(N>&UL4$L! A0#%     @ 0XJC5"?B\G%,?@  (LL% !0
M             ( !42\# &5H8RTR,#(R,#,S,5]P<F4N>&UL4$L! A0#%
M  @ 0XJC5/P\3?Z7#0  5T0! !,              ( !SZT# &5H8S$P<3,S
M,3(R97@R,BYH=&U02P$"% ,4    " !#BJ-4VFQYD*,(  !T-P  %
M        @ &7NP, 96AC,3!Q,S,Q,C)E>#,Q,2YH=&U02P$"% ,4    " !#
MBJ-4+04:R;4(  "1-P  %               @ %LQ , 96AC,3!Q,S,Q,C)E
M>#,Q,BYH=&U02P$"% ,4    " !#BJ-45D';QT8&  "_)@  %
M    @ %3S0, 96AC,3!Q,S,Q,C)E>#,R,2YH=&U02P$"% ,4    " !#BJ-4
M(\,,MUH&  !?)@  %               @ '+TP, 96AC,3!Q,S,Q,C)E>#,R
;,BYH=&U02P4&      L "P#- @  5]H#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
